pharmaceutics

MDPI

Review

Designing Formulation Strategies for Enhanced Stability of Therapeutic Peptides in Aqueous Solutions: A Review

Primawan Putra Nugrahadi [1], Wouter L. J. Hinrichs [2], Henderik W. Frijlink [2], Christian Schöneich [3] and Christina Avanti [1,*]

[1] Department of Pharmaceutics, Faculty of Pharmacy, University of Surabaya, Jalan Raya Kalirungkut, Surabaya 60293, Indonesia
[2] Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, 9701 BA Groningen, The Netherlands
[3] Department of Pharmaceutical Chemistry, School of Pharmacy, University of Kansas, 2095 Constant Avenue, Lawrence, KS 66047, USA
* Correspondence: c_avanti@staff.ubaya.ac.id; Tel.: +62-31-298-1100

Abstract: Over the past few decades, there has been a tremendous increase in the utilization of therapeutic peptides. Therapeutic peptides are usually administered via the parenteral route, requiring an aqueous formulation. Unfortunately, peptides are often unstable in aqueous solutions, affecting stability and bioactivity. Although a stable and dry formulation for reconstitution might be designed, from a pharmaco-economic and practical convenience point of view, a peptide formulation in an aqueous liquid form is preferred. Designing formulation strategies that optimize peptide stability may improve bioavailability and increase therapeutic efficacy. This literature review provides an overview of various degradation pathways and formulation strategies to stabilize therapeutic peptides in aqueous solutions. First, we introduce the major peptide stability issues in liquid formulations and the degradation mechanisms. Then, we present a variety of known strategies to inhibit or slow down peptide degradation. Overall, the most practical approaches to peptide stabilization are pH optimization and selecting the appropriate type of buffer. Other practical strategies to reduce peptide degradation rates in solution are the application of co-solvency, air exclusion, viscosity enhancement, PEGylation, and using polyol excipients.

Keywords: therapeutic peptides; stabilization formulations; aqueous solutions

Citation: Nugrahadi, P.P.; Hinrichs, W.L.J.; Frijlink, H.W.; Schöneich, C.; Avanti, C. Designing Formulation Strategies for Enhanced Stability of Therapeutic Peptides in Aqueous Solutions: A Review. *Pharmaceutics* **2023**, *15*, 935. https://doi.org/10.3390/pharmaceutics15030935

Academic Editors: Laura Zaccaro, Annarita Del Gatto and Galia Maayan

Received: 1 February 2023
Revised: 4 March 2023
Accepted: 9 March 2023
Published: 14 March 2023

1. Introduction

Advances in biotechnology have resulted in an increasing number of therapeutically active peptides entering the market. Since du Vigneaud [1] successfully synthesized oxytocin in 1953, there have been significant achievements in discovering peptides as active pharmaceutical ingredients in the following decades. Currently, over 80 peptides have been approved as therapeutic agents in the United States, Europe, and Japan, as shown in Figure 1 and Table 1. Additionally, more than 160 peptides are undergoing clinical trials, and more than 200 are in the preclinical stage [2]. This tendency is predicted to persist in the future. Table 2 shows peptide drug candidates currently in a clinical trial [3].

Peptides can control various physiological processes, functioning as growth factors, neurotransmitters, and endocrine or paracrine signals at other sites of action. In diverse disease areas, such as endocrinology, oncology, hematology, and urology, peptides are used as therapeutic agents [4]. Several antibiotics, antitumor agents, hormones, and neurotransmitters are peptides.

Peptides are different from proteins. Although both are composed of amino acids, peptides are smaller molecules comprised of two or more amino acids linked by peptide bonds, while proteins are long chains of amino acids that may have a much larger number of amino acids. Unlike proteins with a defined tertiary and quaternary structure [5],

peptides generally do not have a defined three-dimensional structure. Although peptides are mostly linear and usually do not have as much complexity in their structure as proteins, some can have a defined three-dimensional structure due to the presence of multiple disulfide bridges, hydrogen bonds, and hydrophobic interactions [6,7]. The hydrophobic sides of amino acids in peptides are buried inside their structure and tend to form aggregates. This is because hydrophobic, non-covalent interactions between non-polar or slightly polar molecules cause these side chains to avoid contact with water and interact instead. This tendency to aggregate can also be increased by changes in pH, temperature, ionic strength, and the presence of surfactants or other excipients [8]. Furthermore, their functionality in living organisms is different. While proteins usually act as structural and regulatory molecules [9], peptides regulate a broad spectrum of biological effects, including proteins [10,11]. Making a clear distinction between peptides and proteins based on the number of amino acids is challenging, and several definitions exist. First, the United States Food and Drug Administration defines peptides as short chains that contain less than 40 amino acid residues [12]. Malavolta [13] provides a similar definition, defining molecules containing 50 amino acid residues or more as proteins. Between them is a category called polypeptides that have 40–49 residues. Furthermore, Forbes [14] defines peptides as a short string of 2 to 50 amino acids, where oligopeptides contain between 10 and 20, and polypeptides contain more than 20 amino acids. Our review will focus on therapeutic peptides composed of fewer than 50 amino acids.



Figure 1. Increasing number of approved peptides in the United States, Europe, and Japan [3,4].

Table 1. Approved peptide drugs in the United States, Europe, and Japan from 2020.

Peptide	Year of Approval	Indications	Dosage Form	Administration Route
Setmelanotide	2020	Chronic weight management	Liq. Inj	Subcutaneous
64Cu-Dotatate	2020	Radiopharmaceutical	Liq. Inj	Intravenous
Vosoritide	2021	Pediatric bone growth	Powder for Inj	Subcutaneous
Difelikefalin	2021	Pruritus with chronic kidney disease	Liq, Inj	Intravenous
Melphalan flufenamide	2021	Relapsed or refractory multiple myeloma	Powder for Inj	Intravenous
Voclosporin	2021	Lupus nephritis	Capsule	Oral
Piflufolastat F 18	2021	Radiopharmaceutical	Liq. Inj	Intravenous
Pegcetacoplan	2021	Paroxysmal noctural hemoglobinuria	Liq. Inj	Subcutaneous
Dasiglucagon	2021	Hypoglycemia	Liq. Inj	Subcutaneous
Tirzepatide	2022	Type 2 diabetes	Liq. Inj	Subcutaneous
Terlipressin	2022	Hepatorenal syndrome	Powder for Inj	Intravenous

Table 2. Peptide drug candidates undergoing clinical development [3].

Peptide	Target Receptor	Indication(s) for Investigation	Clinical Trial Phase
TT-232	Somatostatin	Renal cell adenocarcinoma	I
BPI-3016	GLP-1	Type 2 diabetes	
NBI-6024	TCR	Type 1 diabetes	
Many more			
Angiotensin 1–7	AT 2	Miscellaneous Peripheral Blood Cell Abnormalities	II
		Prostate cancer	
Bombesin	Bombesin	Heart failure	
Cenderitide	NPRA and NPRB	Puberty; precocious	
Deslorelin	GnRH	Type 2 diabetes	
Gastric inhibitory polypeptide	GIPr	Migraine	
MK-3207	CGRP	Migraine disorders	
Olcegepant	CGRP	Type 1 diabetes	
Pancreatic polypeptide	Neuropeptide Y4	Metabolic disease; obesity	
Peptide YY (3–36)	Neuropeptide Y2	Acromegaly	
Somatoprim	Somatostatin	Benign nontoxic and toxic goiter; goiter; nodular	
Thyrotropin	TSH		
Albusomatropin	GHR	Growth hormone deficiency	III
Anamorelin	GHSRCCK-2	Cachexia; lung cancer non-small cell cancer	
G17DT	IR	Various forms of cancer	
Insulin peglispro	V1A	Type 1 and 2 diabetes	
Selepressin	GHR	Shock, septic	
Somapacitan	GLP-1	Adult growth hormone deficiency	
Taspoglutide	GIP and GLP-1	Type 2 diabetes	
Tirzepatide	NPR	Type 2 diabetes	
Ularitide	Somatostatin 2 and 5	Decompensated heart failure	
Vapreotide		Gastri varices; esophageal haemorrhage; portal	
	NPR-B	hypertension; esophageal varices	
Vosoritide	LHRH	Achondroplasia	
Zoptarelin doxorubicin		Endometrial cancer; prostate cancer	
Avexitide	GLP-1	Hypoglycemia	IV
Calcitonin gene-related peptide	CGRP-R	Migraine	
Corticorelin	CRF-1	Brain neoplasms; brain swelling	
Leptin	LEP-R	Obesity; lipodystrophy	
Thymalfasin	TLR	Liver cirrhosis, sepsis	

Therapeutic peptides have many challenges regarding their formulation and administration. Peptides are often sensitive to digestive enzymes and have a limited ability to permeate intestinal membranes, leading to poor bioavailability after oral administration [15]. Furthermore, peptides are prone to chemical and physical instability, which may cause them to degrade during preparation, manufacturing, and storage.

The poor oral bioavailability of peptides has encouraged the exploration of alternative non-invasive delivery methods of peptides, such as buccal [16,17], vaginal [18], ocular [19], percutaneous [20], rectal [21], nasal [22], transdermal [23], and pulmonary [24] routes. Although non-invasive delivery routes for peptides have been continuously developed, they have failed to produce satisfactory outcomes when a rapid onset is required. Consequently, the parenteral route remains the predominant method for administering therapeutic peptides. Intravenous injection is the most direct route for delivering peptides into the systemic circulation, providing immediate and complete bioavailability. Some peptides are administered intramuscularly, injected directly into a muscle, absorbed into the bloodstream, and distributed throughout the body. Both intramuscular and intravenous routes are not accessible to self-performed administration, and patients experience pain and discomfort after the injection. The subcutaneous route can show a peak level within 30 min [25]. This route can be employed and is more suitable for self-administration.

Due to their potential instability, most peptide drugs require storage and transportation at low temperatures, also referred to as the cold chain. The availability of therapeutic peptides is significantly impacted by this instability, especially in tropical and remote areas where a cold chain is unavailable [26,27]. An urgent strategy is required to address peptide instability, particularly in an aqueous solution for injection, which is favored compared to lyophilized powder. Despite lyophilization using appropriate stabilizing, and excipients

appearing to be an ideal approach in maintaining the integrity of peptides [28], it is unfortunately time-consuming and costly from an economic standpoint [29]. Furthermore, lyophilized products may be too expensive for developing countries. Reconstitution also poses a risk of contamination [30]. The volume and mass of freeze-dried products, including both vials used for lyophilized powder and its reconstitution liquid, are typically up to twice the size of those used for liquid formulations, resulting in more extensive packaging material, larger storage area, and higher transportation costs [29]. Finally, reconstituting the dried product may be inconvenient and difficult for patients. Therefore, liquid formulations are preferred if they are sufficiently stable.

Peptide stability in aqueous solutions is a critical aspect when developing parenteral formulations, as the potency of a peptide is often compromised due to chemical or physical degradation pathways [31]. Having a comprehensive understanding of the underlying instability mechanism of a particular peptide is crucial to optimizing its stability in the final formulation during the pharmaceutical development process [28]. The aim of this review is to explore different degradation pathways of peptides and to propose several rational strategies (excluding chemical modification of the peptide) for improving the stability of therapeutic peptides in aqueous solutions.

2. Instability of Peptide and the Possible Causes of Degradation

Peptides may be able to undergo several degradation pathways. Peptide degradation can occur through chemical and physical mechanisms. Chemical instability involves processes that alter the peptide by creating or breaking covalent bonds, leading to the formation of new chemical entities [32]. Oxidation, hydrolysis, β-elimination, deamidation, racemization, isomerization, and disulfide exchange are examples of chemical instability pathways [33,34]. Physical instability refers to structural changes in non-covalent interactions of the peptides and includes changes in secondary structure, adsorption, aggregation, and precipitation [28]. Table 3 shows various degradation pathways of peptides in an aqueous solution and influencing parameters.

Table 3. Degradation pathways of peptide in aqueous solution, critical parameters, and amino acid residue(s) involved.

Degradation Pathway	Critical Parameters	The Amino Acid Residue(s) Involved	References
Chemical Instability			
Hydrolysis	pH Temperature	Trp Ser Asn-Pro Asn-Tyr	[26,35–37]
Deamidation	pH Temperature	Asn Gln	[35,36,38–42]
β-elimination	Thermal stress pH	Cys-Cys	[35,37,43,44]
Oxidation	pH Temperature Oxygen	Trp Met Cys Tyr His	[36,37,39,44,45]
Light-induced oxidation	Light	Trp	[46–49]
Metal induced oxidation	Metal ions (copper, iron)	His Cys Arg Pro Met	[50,51]

Table 3. *Cont.*

Degradation Pathway	Critical Parameters	The Amino Acid Residue(s) Involved	References
Disulfide exchange	pH Oxygen Metal ions	Cys-Cys	[38,52]
Physical Instability			
Adsorption	Container	His Arg	[53]
Aggregation	Stress condition Concentration pH	Cys-Cys Tyr-Tyr	[39,40,42,43,54–60]

2.1. Hydrolytic Pathways

2.1.1. Chain Cleavage of the Peptide Backbone

Hydrolysis represents one of the main degradation pathways of peptides. Generally, hydrolysis is catalyzed by Bronsted acids and bases [61] and strongly depends on the pH. This pH dependency has been extensively investigated for the peptides gonadorelin and triptorelin. These peptides undergo acid-catalyzed hydrolysis at pH 1–3 through deamidation of the C-terminal amide. At pH 5–6, however, the peptide backbone can undergo hydrolysis at the N-terminal side of the serine (Ser) residue. This process is likely facilitated by the hydroxyl group on the Ser side chain, which acts as a nucleophile by attacking the adjacent amide bond. As a result of this reaction, a cyclic intermediate is formed, which ultimately leads to the fragmentation of the peptide [62,63]. At pH > 7, the primary degradation pathway of gonadorelin and triptorelin are base-catalyzed epimerization. The epimerization reaction most likely involves Ser via a carbanion intermediate. Gonadorelin and triptorelin have the capability to create hydrogen bridges in a relatively stable six-membered intermediate, which elucidates the reason for the Ser residue's relatively high rate of racemization in comparison to other amino acids. Apart from epimerization, the hydrolysis of gonadorelin and triptorelin under base-catalyzed conditions has also been detected [62,64,65]. Recombinant Glucagon-like Peptide-1 (r-GLP-1) has also been reported to undergo base-catalyzed racemization because of extreme pH exposure during purification that can impact its impurity profile and yield of bulk rGLP-1 [66]. The primary degradation route of recombinant human parathyroid hormone (rhPTH) occurs via cleavage at the aspartate (Asp) residue under acidic conditions. Conversely, when the pH is above 5, asparagine (Asn) deamidation is the primary degradation route [67]. The cholecystokinin peptide tends to undergo C-terminal and N-terminal cleavage as the primary degradation pathways when it is subjected to non-isothermal conditions [68].

Somatostatin and its analog octastatin have also been observed to undergo acid/base-catalyzed hydrolysis in aqueous formulations, with the rate of hydrolysis being influenced by the buffer species [69,70]. Octastatin, for example, experiences a higher degradation rate in a phosphate buffer than in a glutamate buffer solution, likely due to a catalytic effect of phosphate ions [69]. It appears that increasing phosphate concentration results in much faster degradation of octastatin. Conversely, increasing the concentration of glutamate in a buffer solution enhances the stability of the solution, as evidenced by hydrophobic and ionic interactions between glutamate and octastatin [67]. These findings underscore the significance of selecting appropriate buffer species and their concentrations when formulating peptides.

2.1.2. Deamidation of Asn and Gln Residues

Peptides containing glutamine (Gln) and Asn residues are susceptible to deamidation, leading to the formation of Glu and Asp, respectively, under physiological conditions. When the pH is lower than 3, Asn residues deamidation occurs primarily through the direct hydrolysis of the Asn amide side chain to generate Asp. Likewise, Gln residues undergo

acid-catalyzed direct hydrolysis to form Glu [32]. Asn deamidation mostly transpires via a cyclic imide intermediate that forms through an intramolecular reaction where the amino acid residue's nitrogen next to Asn attacks the carbonyl carbon on the side chain of the Asn residue. Thus, the rate of deamidation through this pathway depends on the carboxyl-side amino acid residue's nature [71–73]. Under similar conditions, the deamidation of Gln residues proceeds much slower than the deamidation of Asn, because the cyclization of Asn residues into a five-membered ring is kinetically more favorable than the formation of a six-membered ring intermediate in Gln deamidation [32].

Peptide chain flexibility strongly favors a high rate of Asn deamidation [74]. The amino acid sequence in the peptides can also affect the rate of deamidation [75]. Amino acid residues following Asn, such as threonine (Thr), Ser, and Asp, may substantially increase the reaction rate since they are very susceptible to dehydration, forming a cyclic imide intermediate [8].

At alkaline and neutral pH, adrenocorticotropic hormone (ACTH), was shown to degrade via deamidation of its single Asn residue [71,76]. Asn or Gln deamidation was also observed for salmon calcitonin (sCT) under acidic conditions [77]. Oxytocin provides another instance of a peptide that can be subjected to Asn [78] and Gln [79] side chain amides deamidation through hydrolysis. Additionally, oxytocin's C-terminal glycine (Gly)-NH has been reported to undergo deamidation at pH 2 [26].

2.1.3. Isomerization of Asp Residues

The Asp transformation into isoAsp follows the equivalent succinimide ring intermediate as reported for Asn deamidation [80,81] (see Figure 2). Moreover, racemization of L-succinimide into D-succinimide can produce D-Asp and D-isoAsp enantiomers [72,82]. The rate-limiting step for the isomerization of Asp and Asn deamidation reactions at physiological pH is the formation of the succinimide intermediate [83]. Isomerization of the Asp-hexapeptide into the isoAsp-hexapeptide through cyclic imide intermediate was also reported to be pH dependent [84].



Figure 2. Deamidation pathways of asparagine through (**a**) direct hydrolysis and (**b**) succinimide mediation [85]. Red lines show the proton transfer from water molecule to the leaving group (-NH_2).

2.2. Oxidative Pathways

Peptide oxidation is a reaction that increases the electronegative atom content in a peptide molecule [86], where oxygen or halogens are typically the electronegative heteroatoms [87]. Sulfur-containing residues such as Met and Cys are particularly susceptible to oxidation because sulfur atoms are highly reactive and can easily lose electrons, forming sulfur radicals when exposed to reactive oxygen species (ROS). Aromatic residues such as His, Trp, and Tyr are also prone to oxidation because the aromatic rings in these residues contain multiple carbon-carbon double bonds that are easily oxidized by various ROS (see Figure 3) [88].



Figure 3. Oxidation reactions of Met and His: (**a**) oxidation by hydrogen peroxide to methionine sulfoxide in an acidic solution and (**b**) conversion of histidine to 2-oxo-his, asparagine, and aspartate.

Oxidation can be induced by contaminating oxidants, trace amounts of catalytic redox-active metals, and light exposure. Moreover, peptide oxidation may be affected by pH, temperature, and buffer composition [8]. Deprotonation of the mercapto group of Cys [89] and the phenoxy group of Tyr accelerates oxidation of these residues [90]. Deprotonation of the imidazole side chain of His favors metal binding and, potentially, oxidation [91].

2.2.1. Autoxidation

Frequently, the oxidative degradation of pharmaceuticals is referred to as "autoxidation". However, the term "autoxidation" denotes "the spontaneous oxidation in an air of a substance not requiring catalysis" [92]. Hence, if peptides were to autoxidize, this would require the reaction of amino acids with molecular oxygen. In general, the reaction of "closed-shell" (i.e., non-radical) organic substances with oxygen is relatively slow [93], and it is unlikely that autoxidation contributes significantly to peptide oxidation except, perhaps, to the oxidation of the mercapto group of Cys under the condition that chain oxidation is possible. Conditions for the chain oxidation reaction of dithiols (i.e., dithiothreitol) have been defined by radiation chemical techniques [94].

2.2.2. Metal Induced Oxidation

Metal ion-catalyzed oxidation for peptides refers to the process by which metal ions can promote the oxidation of specific amino acid residues in peptides. This process usually requires the presence of a redox-active transition metal such as Fe^{2+} and Cu^{2+} that can undergo redox cycling reactions and produce ROS. In metal ion-catalyzed oxidation, metal ions act as catalysts, accelerating the conversion of hydrogen peroxide, superoxide anion radical, and hydroxyl radical. These hydroxyl radicals can then react with amino acid residues in peptides, causing degradation. Specifically, metal ion-catalyzed oxidation can cause oxidative damage to amino acid residues such as histidine (His), cysteine (Cys), and methionine (Met) [95]. Metal ion-catalyzed oxidation frequently implies a site-specific reaction catalyzed by transition metals complexed by metal-binding sites. Hence, metal ion-catalyzed oxidation frequently does not target the most solvent-accessible amino acids, but rather amino acids which are part of or are located close to metal ion-binding sites [96]. It was reported that the oxidation of hPTH (1–34) by ferrous ethylenediaminetetraacetic acid (EDTA)/H_2O_2, found that this system can cause oxidation of the methionine residue at position 8 (Met 8) and the histidine residue at position 9 (His 9) (1–34). The study found that the oxidation of Met 8 and His 9 in hPTH (1–34) resulted in the formation of sulfoxide and imidazole-5-aldehyde products, respectively. The oxidation of Met 8 was found to be highly selective, as this residue was oxidized much more rapidly than other methionine residues in the peptide. The oxidation of His 9 was also found to be highly selective, as other histidine residues in the peptide were not oxidized under these conditions. The study suggested that the oxidation of Met 8 and His 9 in hPTH (1–34) by ferrous EDTA/H_2O_2 may be relevant to the physiological and pathological roles of this peptide. For example, the oxidation of Met 8 may affect the biological activity of hPTH (1–34), as this residue is important for binding to the PTH receptor. The oxidation of His 9 may also affect the conformation of the peptide, as this residue is located near the N-terminus of the peptide and plays a role in stabilizing the peptide structure [97].

2.2.3. Light-Induced Oxidation

Light-induced oxidation usually affects peptides that contain aromatic amino acid residues such as Trp, Tyr, and Phe, or a disulfide bond [46]. The mechanisms of light-induced oxidation are complex and not completely understood. While much emphasis has been placed on the primary photophysics and photochemistry of Trp, Tyr, Phe, and cystine, secondary reactions can induce the formation of a large variety of products [47]. The photo-irradiation of Trp can lead to photoionization as well as the formation of singlet oxygen. Photoionization is associated with the release of an electron, which can react with suitable electron acceptors such as oxygen (to yield superoxide) or disulfides (to yield thiolate and thiyl radical) [48]. Similar mechanisms have been reported for Tyr and Phe, though photoionization may be a biphotonic rather than monophotonic process. The biphotonic process is initiated by two-photon absorption, whereas the monophotonic process involves a single photon. Oxytocin was reported to be sensitive to U.V. light at pH 4.0–5.0 and 7.0–8.0 [49]. Recently, a series of papers have focused on near U.V. and visible light-induced photo-oxidation of peptides promoted by ligand-to-charge-transfer (LMCT) pathways of iron-buffer complexes [98–100]. These processes yield multiple reactive species and peptide oxidation products at relatively low light doses.

2.2.4. Peroxide Oxidation

Peroxide can cause the oxidation of amino acid residues including Met [101], Cys [102], and His [103], as well as the formation of hydroperoxides on amino acids and polypeptides during oxidative stress, which can potentially lead to biological damage. Accidentally, peroxide may be present in formulations due to the inclusion of surfactants or other excipients. For example, some surfactants, such as polysorbate 20 and polysorbate 80, can produce peroxide [104]. Therefore, surfactants or co-solvents such as polyethylene glycol usually have certain specifications related to the levels of peroxides.

2.3. β-Elimination

A disulfide bond of a peptide can undergo β-elimination leading to C-S cleavage, resulting in perthiolate/perthiol and dehydroalanine. It is frequently observed when materials are subjected to high temperatures in conjunction with a high pH environment. Cys and Ser-containing peptides undergo β-elimination at alkaline pH [105,106]. Even at neutral pH, when cystine-containing peptides are heated at 100 °C, they initially form perthiol and then convert to free thiols [107]. sCT degrades through β-elimination at the disulfide bridge between the Cys residues at positions 1 and 7. It has also been reported that the insertion of an additional sulfur forms a trisulfide and tetrasulfide bridge because of a β-elimination reaction [108]. It has also been observed in oxytocin after exposure to heat stress at an alkaline pH [26]

2.4. Disulfide Exchange

Disulfide exchange reactions can occur in peptides, leading to disulfide scrambling and contributing to forming dimers and larger aggregates. An investigation on the degradation of sCT recognized dimeric products generated through disulfide exchange reactions. However, dimers linked to disulfides can go through further disulfide reactions, ultimately regenerating monomers of sCT [108]. In an acidic aqueous solution, disulfide interchange can continue through the formation of sulfonium ions [109]. When disulfide bonds are subjected to hydrolysis, sulfenic acid intermediates are formed, which can further react with other cysteine residues or with water to produce sulfonium ions. These ions can then undergo disulfide interchange reactions, leading to the formation of new disulfide bonds between cysteine residues. There have been several studies conducted on disulfide exchange reactions and the significance of disulfide bridges in maintaining peptide stability. Several investigations have highlighted the importance of disulfide bonds for peptide stability and the impact of disulfide exchange reactions on peptide conformation and function. By developing strategies to stabilize disulfide bonds and prevent disulfide exchange reactions, researchers can improve the stability and bioactivity of peptides for use as therapeutic agents [105,108–112].

2.5. Dimerization, Aggregation, and Precipitation

Apart from intermolecular disulfide bond formation, peptides can dimerize/oligomerize via a series of oxidative reactions [28,113,114]. Some of these processes may even lead to larger aggregates. In addition, stress conditions, such as freezing, heating, or agitation, may induce aggregation. Aggregates can form through covalent bonds; such as dityrosine, ester, disulfide, or amide linkages; or electrostatic interactions or non-covalent bonds that occur through hydrophobic interactions. However, during sample preparation, relatively weak non-covalent bonds may be disrupted again, leading to incorrect results [115].

The formation of aggregates on peptides is not limited to a single pathway [32]. Instead, multiple mechanisms can occur concurrently, leading to the formation of both soluble and insoluble aggregates [116]. Aggregation occurs when peptides interact with each other to form larger, multi-molecular species, which can have altered conformation, solubility, and biological activity. At higher concentrations, peptides are more likely to interact with each other due to increased intermolecular forces, resulting in faster aggregation. As aggregation proceeds, the peptides can become more insoluble and eventually precipitate out of solution [117]. In addition to precipitation, higher concentrations of peptides have been reported to form gel-like aggregates. Calcitonin, deterelix, leuprolide, and β-amyloid peptide are examples of peptides that are capable of forming gel-like aggregates under certain conditions [118]. Gel-like aggregates form because the structure shifts from an α-helix or β-turn structure to a β-sheet structure. As a result, they have strength, elasticity, and plasticity that can maintain their shape.

3. Strategies to Optimize Peptide Stability in Aqueous Formulations

Peptides are inherently unstable in aqueous solutions due to their susceptibility to degradation, aggregation, and other types of physical and chemical instability. To improve the stability of peptides in aqueous solutions, various strategies have been developed, including the use of buffers, organic solvents, specific metal ions, and air exclusion/oxygen removal (see Table 4). To optimize the utilization of formulation strategies for stable injectable peptide development, a deep understanding of peptide structure, physicochemical properties, and degradation pathways is required.

Table 4. Peptide therapeutic degradation pathways and possible stabilization strategies.

Peptide	Number of A.A.	Degradation Pathway	Stabilization Strategy	A.A. Residue(s) Involved	References
Thyrotropin-releasing hormones (T.R.H.)	3	Hydrolysis	pH 6.5	Glu	[119]
Ceftazidime	5	Hydrolysis	Pluronic® F68 pH 4.5–6.5	Glu	[120,121]
Eptifibatide	6	Hydrolysis Isomerization Deamidation Oxidation Dimerization	pH 5.7 Co-solvent 0.025 M citrate buffer	Asp Cys-Cys	[122]
Octreotide	8	Hydrolysis Disulfide exchange	Air exclusion Buffer pH close to 4	Tyr Trp	[69,123]
Oxytocin	9	Oxidation β-elimination Deamidation Hydrolysis Dimerization Light-induced oxidation	Antioxidant pH 4.5 Acetate/Citrate/ Aspartate buffer Divalent metal ions Protect from light PEGylation Cyclization	Tyr Cys Cys-Cys	[35,38,39,43–45,124]
Desmopressin	9	Oxidation Deamidation Disulfide exchange β-elimination Racemization	Surfactants Polyols Buffer Divalent metal ions Phosphate buffer (pH 4.5–5.5)	Asn Gln Cys Tyr	[32,52,125]
Leuprolide	10	Hydrolysis Isomerization β-elimination Oxidation Aggregation	pH 3–5 Acetate buffer Co-solvent (DMSO)	Ser Trp	[126]
Goserelin	10	Hydrolysis Debutylation Epimerization	pH 3–5 Acetate buffer Co-solvent	Ser	[62]
Gonadorelin	10	Hydrolysis Deamidation Epimerization	pH 3–5 Acetate buffer Co-solvent	Ser	[62,64]
Triptorelin	10	Hydrolysis Deamidation Epimerization	pH 3–5 Acetate buffer Co-solvent	Ser	[62,64]
Somatostatin and analogs	14	Hydrolysis Disulfide exchange	pH 4–5 Acetate buffer NaCl	Trp-Tyr Trp-Lys Cys-Cys	[69,123]
Liraglutide	30	Aggregation Oligomerization	pH > 6.9	-	[55,127]
Salmon Calcitonin	32	Deamidation Dimerization Aggregation Hydrolysis Disulfide exchange	pH 3–4 Citrate buffer Phosphate buffer	Asn Gln Cys-Cys Cys-Ser	[57,108,128]
Human Brain Natriuretic Peptide [hBNP(1–32)]	32	Aggregation Deamidation Oxidation	Sucrose Air exclusion	Met Asn	[129]
Human Parathyroid Hormone [hPTH(1–34)]	34	Oxidation Deamidation Aggregation Cleavage Asp residue	Sucrose Co-solvent Air exclusion	Asp Asn	[49,115]

Table 4. *Cont.*

Peptide	Number of A.A.	Degradation Pathway	Stabilization Strategy	A.A. Residue(s) Involved	References
Adenocortico-tropin hormone (ACTH)	39	Hydrolysis Deamidation	pH 3.0–5.0 Acetate buffer	Asn Met	[71,130]
Amyloid-β (Aβ) peptides	36–43	Metal-catalyzed oxidation Deamidation Dimerization Aggregation	Chelating agents Polyols	His Cys Arg Pro Met	[131–133]
Exenatide	39	Aggregation Oxidation Deamidation	pH 4.5 Polyols	Gly Met Asp Trp	[42]

Peptides differ from proteins in that they lack tertiary and quaternary structures due to their shorter length, and therefore, the side chains of amino acid residues are predominantly exposed to solvents and solutes. This exposes hydrophobic residues such as Trp, Tyr, and Phe to aqueous environments, leading to degradation. By analyzing a peptide's amino acid sequence, scientists can gain insight into its susceptibility to degradation via various pathways, including oxidation and deamidation, and identify potential enzymatic cleavage sites. Secondary structures, such as alpha-helices and beta-sheets, can also contribute to peptide aggregation and precipitation. To improve peptide stability, appropriate formulation strategies can be designed, such as substituting susceptible amino acids or utilizing stabilizing agents, based on an understanding of the amino acid sequence and degradation susceptibility. Figure 4 summarizes various strategies for enhancing peptide stability in aqueous formulations.



Figure 4. Known strategies that can be used individually or in combination to improve peptide stability in aqueous formulations.

3.1. Protection against Hydrolysis

3.1.1. pH Optimization

Maintaining the stability of peptides in aqueous solutions often requires controlling the pH. Using buffers is a common strategy to prevent degradation. To ensure patient comfort during injection, the acceptable pH range for intravenous administration is typically between 3 and 10.5, while for other routes of administration, the range may be narrower [134,135]. Hence, at the start of formulation development, it is essential to evaluate the pH-dependent degradation of a peptide in the pH range 3–10, adjusted with various types of buffers at different concentrations [136,137]. To minimize deamidation, formulations should preferably be in a pH range between 3 and 5 [76,138,139]. Oxytocin, for example, exhibits the highest stability at pH 4.5 [26].

The vast majority of organic compounds can go about as radical scavengers [139], particularly hydroxyl radical [140]. However, most organic compounds may not prevent more selective oxidants such as peroxyl radicals. Few buffers can tie directly to peptides, thereby increasing their conformational stability [38,141,142]. For instance, citric acid buffers have been reported to increase oxytocin stability. Even though citric acid reacts with oxytocin forming N-cytril oxytocin, it was observed that fewer degradation products were formed in the presence of divalent metal ions [39]. It was reported that the carboxylate group of aspartate buffer has the ability to neutralize the positive charge of the N-terminus of Cys [142], thereby facilitating interactions with Zn^{2+}, resulting in protection against dimerization of the disulfide bridge [38,142]. Octastatin, a somatostatin analog, was found to degrade greater in citrate or phosphate-containing buffers than in glutamate or aspartate buffers at pH 4.0 [69]. Additionally, octreotide has been reported to have better stability in acetate buffers at pH 4.0 [143].

3.1.2. The Use of Co-Solvents

Using co-solvents can improve peptide stability in an aqueous solution. An aqueous solution's dielectric constant can be decreased by adding organic solvent, resulting in a significantly lower rate of isomerization and deamidation [83]. The lower the dielectric constant of the solvent, the easier two differently charged (+, −) molecules contact each other. It is also possible that the reduced water content affects the rate of deamidation. E.g., peptide deamidation in an aqueous solution can be slowed down by the addition of glycerol [144,145], propylene glycol [138,146], or ethanol [147]. A formulation in an aqueous citrate buffer at pH 5.75 consisting of ethanol and propylene glycol increases the stability of eptifibatide [122].

3.1.3. Viscosity Enhancement

In liquid preparations, the rate of chemical reactions decreases as the solution viscosity increases. It has been reported that various compositions of a combination of glycerol and polyvinylpyrrolidone (PVP) can have an impact on the rate of deamidation of peptides. This study has proven that PVP at high concentrations can decrease the rate of Asn deamidation of a hexapeptide. However, it is still uncertain whether the decrease in deamidation rate was caused by a reduction in the dielectric constant of the solution by glycerol, increased viscosity, or a combination of both [144,148]. PVP without glycerol has also been successfully used to inhibit the rate of the Asn-hexapeptide deamidation in aqueous solutions. PVP can interact with the peptide through hydrogen bonding, electrostatic interactions, and hydrophobic interactions, and act as a physical barrier between the peptide and the water molecules [117,146,149]. Effects of stabilization increase with increasing concentration and molecular weight, hence the viscosity [144,150]. A polymeric surfactant, such as Pluronic® F68, may have a double effect as a polymeric surfactant and viscosity enhancer. Its surface acts as an interface protectant and has been used to improve ceftazidime stability in parenteral formulations [120]. Furthermore, high concentrations of Poloxamer 407 slowed down the deamidation rate of Asn residue in a model peptide Val-Tyr-Pro-Asn-Gly-Ala in an aqueous solution. The reduction of degradation rate was

ascribed to the formation of an aqueous gel-altering solution conformation of a peptide and to the salting-out effects of the Poloxamer 407 [125].

3.1.4. PEGylation

The covalent linkage of water-soluble polymers such as polyethylene glycol (P.E.G.) to peptides (PEGylation) can offer many advantages, including extended shelf life, improved water solubility, and stability under stressed conditions [124]. P.E.G. conjugation targeted site-specific amino acids, including lysine (Lys), Cys, arginine (Arg), and Tyr, which can increase the molecular size of the peptide. PEGylation has been reported to increase oxytocin stability at high temperatures [124], extending the biological activities of Human Pancreatic Polypeptide (hPP) [151] and minimizing side effects of antimicrobial peptides LyeTx I-b [152]. Although it is rare, it has been found that patients can develop allergic reactions to P.E.G. [153,154]. Therefore, PEGylated formula, although it has advantages, still needs further development.

3.2. Protection against Oxidation

The mechanisms of oxidation may vary depending on several factors, such as pH, the presence of oxygen, metal ions, and/or light, which can lead to damaging effects. Nevertheless, it is possible to mitigate such effects by adjusting the pH, eliminating oxygen from the solution, modifying the primary and secondary packaging to prevent light exposure, and employing antioxidants or metal chelators in the formulation. Waterman et al. have developed a comprehensive guideline for the use of excipients to enhance the oxidative stability of actives, which includes recommended concentrations [155].

3.2.1. Buffers

Buffer solutions can be used to help prevent peptide oxidation, particularly for peptides that contain Cys, Met, Trp, Tyr, and His side chains. The choice of buffer can have a significant impact on peptide stability, and several factors should be considered when selecting a buffer for a specific peptide. Cys and Met residues are generally the most susceptible to oxidation in peptides due to the presence of sulfur atoms in their side chains. Cysteine can be oxidized to cysteine sulfinic acid or cysteine sulfonic acid, while Methionine can form methionine sulfoxide or methionine sulfone. Cys, Tyr, and His can be more susceptible to oxidation at neutral and alkaline pH due to deprotonation of their side chains. In contrast, an acidic environment (pH < 5) may reduce the susceptibility to oxidation of Cys, Tyr, and His residues by protonating their side chains and decreasing their reactivity with reactive oxygen species [33]. Compared to Cys and His residues, however, oxidation of Met and Trp residues are less affected by pH. The oxidation of Met can be promoted at a very low, clinically irrelevant pH (below 2) [156].

3.2.2. Air Exclusion

Special handling is required during processing to minimize the exposure of peptide drugs to oxygen and other oxidizing agents that can cause damage. The manufacturing steps should be done by purging the container with an inert gas such as argon, helium, or nitrogen before adding and mixing the peptides. The filling steps must be performed using a pre-filled gas-tight container with inert gas. Additionally, it is crucial to handle the peptides gently and avoid agitation or shear stress, as these can cause structural damage and increase their susceptibility to oxidation [157]. The effect of temperature on oxygen solubility also needs to be considered during processing because dissolved oxygen concentrations at low temperatures is higher in an aqueous solution [158].

3.2.3. Antioxidants

Antioxidants protect peptides from oxidation during processing and storage by scavenging reactive oxygen species. The choice of the appropriate antioxidant will depend on several factors, such as the specific amino acid residues present in the peptide, the

formulation, and the intended use of the peptide. It is crucial to ensure that the selected antioxidant is compatible with the peptide and does not interfere with its activity or stability [33]. For instance, sodium bisulfite can be problematic for specific peptides because it is a nucleophile, meaning it can react with disulfide bonds, potentially leading to the formation of peptide aggregates and loss of activity [159]. Additionally, bisulfite can be oxidized to form the radical sulfite anion, which reacts with oxygen to generate peroxyl radicals—potent oxidizing agents that can damage peptides. Bisulfite can also react with amino acids containing thiol groups, such as cysteine, forming disulfides that can impact stability [160]. Similarly, adding ascorbic acid to peptide solutions contaminated with trace metal ions may not necessarily protect the peptide against oxidative modification. In some cases, it may accelerate the oxidation process, as shown by ascorbic acid's tendency to advance Met oxidation in small model peptides and form Met sulfoxide [161,162]. Met is a sulfur-containing amino acid that can act as a sacrificial antioxidant, rapidly oxidizing to form methionine sulfoxide in response to numerous reactive oxygen species [163].

3.2.4. Chelating Agents

Chelating agents protect peptides from oxidation by sequestering metal ions that can act as catalysts for the reaction. In pharmaceutical liquid formulations, various chelating agents are commonly used, including ethylenediaminetetraacetic acid (EDTA), diethylenetriaminepentaacetic acid (DTPA), desferal, ethylenediamine-di-o-hydroxyphenyl ace-tic acid (EDDHA), inositol hexaphosphate, tris(hydroxymethyl)aminomethane (TRIS), tartaric, and citric acid. EDTA is a versatile chelating agent that can bind to various metal ions, including copper, iron, and calcium. DTPA is particularly effective in binding to calcium and zinc ions. Desferal is used to treat iron overload, while EDDHA is used primarily for its ability to bind to iron ions in agricultural applications. Inositol hexaphosphate, a naturally occurring chelating agent, is particularly effective in binding to iron ions and has potential use in cancer treatment. TRIS is a buffering agent with some chelating properties, while tartaric acid is commonly used in the food industry to improve the stability and solubility of products. Citric acid is another chelating agent widely used in the food industry and pharmaceutical formulations, and is particularly effective in binding to calcium ions and other metal ions such as iron and copper. The choice of chelating agent will depend on the specific metal ions present in the formulation and the desired outcome [146].

However, adding specific chelating agents may accelerate the oxidation process of peptide molecules. Under certain conditions, chelating agents can bind to trace metal ions and form complexes with higher redox potential than metal ions alone, increasing the rate of oxidative reactions. In addition, some chelating agents may also generate free radicals during their interactions with metal ions, which can promote the oxidative degradation of peptides [33,164]. In an illustrative example, adding EDTA to a small peptide containing Met and His changed oxidation selectivity, targeting His instead of Met only [165]. It is also important to understand that EDTA/metal complexes are not always inert to oxidants. For example, [Fe(II)EDTA]2- reacts rapidly with hydrogen peroxide [166], ultimately generating both complexed and free hydroxyl radicals, which can attack all amino acids in a given peptide. Recently, triethylenetetramine was shown to be more effective than EDTA in protecting proteins (insulin and a monoclonal IgG) against Cu^{2+}-mediated oxidation [167]; however, it has not yet been tested for peptides.

3.2.5. Polyols

Polyols have been shown to protect therapeutic peptides from oxidation by scavenging reactive oxygen species (ROS). The hydroxyl groups in polyols can donate hydrogen atoms to ROS, inhibiting the ability to oxidize peptides. Some polyols commonly used to protect therapeutic peptides from oxidation are maltose, sucrose, trehalose, raffinose, and mannitol. For instance, mannitol has been shown to protect Met-containing peptides from iron-catalyzed oxidation [168], and sucrose has been shown to reduce the oxidation rate of both human brain natriuretic hormones (hBNP) and human parathyroid hormones

(hPTH) [129]. A high concentration of sucrose (as much as 1 M) has also been shown to increase the stability of hPTH and hBNP in liquid formulations. The sucrose stabilizing effect was predominately due to the retardation of aggregation, oxidation, and deamidation of the peptides [129]. Sucrose induced small conformation changes in the hPTH structure, preferentially excluding oxygen from the peptide surface and maintaining the native conformation of hBNP, leading to a more compact peptide structure [129].

3.3. Protection against Disulfide Exchange Reaction

It was found that formulating octreotide in 10 to 60 mM glycine with pharmaceutically acceptable salts and HCl to adjust the pH values in a range of 3.0 and 4.2 are effective in protecting the cleavage of its disulfide bridge [169]. Octastatin was also reported to be more stable in a glutamate buffer at pH 4.0 rather than in an acetate or citrate buffer [69]. The combination-specific buffers with divalent metal ions may protect peptide drugs against disulfide exchange. We have reported that combining zinc, calcium, and magnesium ions with dicarboxylic and tricarboxylic acids can improve the stability of oxytocin [39,141].

3.4. Inhibition of Aggregation, Dimerization, and Precipitation

Aggregation and dimerization of peptides can occur through the formation of covalent bonds such as disulfide bridges and dityrosine, or non-covalent interactions such as hydrophobic forces. These aggregates can exist in both soluble and insoluble forms. Optimizing the pH and ionic strength of the solution can stabilize peptide aggregation in aqueous solutions [170–174]. For instance, the use of citrate buffers and divalent metal ions have been shown to inhibit oxytocin dimerization mediated by cysteine.

Another strategy to minimize a peptide's aggregation is using extremolytes. Extremolytes are small organic molecules generated by extremophilic microorganisms that can safeguard biological macromolecules and cells from damage caused by external stresses including high temperatures and high salt concentrations [175]. Several studies have reported that extremolytes can stabilize peptides by creating solute hydrate clusters that are excluded from the peptide hydrate shell because of the repulsive interactions between the extremolytes and the peptide backbone. Water accumulation near the peptide area arranges the peptide into a more compact structure with a reduced surface area [176–180]. Some examples of extremolytes that have been shown to stabilize peptides in solution include polyol derivatives: ectoine and hydroxyectoine [181], trehalose [182], betaine [183], amino acids (e.g., proline), and mannosylglycerate [184]. Studies have shown that mannosylglycerate can stabilize β-amyloid peptides by inhibiting their aggregation [185].

Furthermore, sucrose, amino acids, and surfactants (polysorbate 20 and 80) [32] can be used with preferential exclusion to prevent dimerization. Polyethylene glycol (PEG) has been shown to reduce peptide aggregation by creating a steric barrier around the peptide molecule, preventing the close contact between peptide molecules that is required for aggregation [54,117,146,149,186–188]. The stabilizing effect increases with increasing concentration and molecular weight and, therefore, with increasing viscosity [83,144,150]. Peptide aggregation can also be reduced by dicarboxylic amino acids such as aspartic acid (Asp) and glutamic acid (Glu) through their ability to act as hydrogen bond donors and acceptors, enabling them to participate in intermolecular hydrogen bonding with other amino acid residues in the peptide, which in turn prevents the formation of insoluble aggregates [31,189]. Arg, Gly, and Lys have also been reported to prevent aggregation at neutral pH, since, at this condition, the positive charges of the amino groups electrostatically hinder the intermolecular interaction of a peptide [31,189–191]. Polysorbates can reduce agitation-induced aggregation of peptides, presumably due to a decreased exposure of peptide molecules to air/liquid interface [192,193]. However, some reports suggest that these surfactants are less effective in reducing thermally-induced aggregation [192–195].

3.5. Hydrophobic Ion-Pairing (HIP)

Hydrophobic ion-pairing (HIP) is a current strategy used to enhance the stability of therapeutic peptides in aqueous solutions. This technique involves the formation of ion pairs between a hydrophobic counterion and a positively charged amino acid residue in the peptide, typically His, Lys, or Arg. This interaction effectively shields the charged groups from the surrounding solvent, reducing their exposure to water and potential hydrolysis [196–198].

One advantage of the HIP strategy is that it does not involve chemical modification of the peptide, which can affect its biological activity, and may lead to undesirable side effects. In addition, HIP is a simple and effective approach that has been shown to enhance the stability of a wide range of therapeutic peptides, including glucagon-like peptide-1 (GLP-1) and somatostatin analogs [199,200].

Jörgensen et al. introduce biodegradable arginine-based steroid-surfactants as cationic green agents for hydrophobic ion-pairing, demonstrating their effectiveness in stabilizing model peptides under various stress conditions, such as high temperature and low pH. In addition, the study highlights the use of sustainable, biodegradable materials in designing the ion-pairing agents as an eco-friendlier approach to drug delivery [201].

4. Conclusions

Compared to proteins, peptides are generally more susceptible to degradation in aqueous solutions due to their smaller size and less complex structure. Unlike proteins, peptides do not have a well-defined 3D structure and are less flexible but more ordered, owing to fewer interactions and the potential to adopt multiple conformations. This exposes most amino acid residues' side chains to solvent, allowing maximum contact with solvents. Hydrophobic side groups of amino acids such as Trp, Tyr, and Phe in peptides are buried inside their structure and, therefore, not or less exposed to the aqueous environment. By understanding the peptide structure and degradation pathways, one can develop strategies for adequate stabilization.

To ensure the stability and efficacy of injectable peptides, unique formulations and preservation methods may be necessary. Designing a therapeutic peptide formulation begins with knowing the amino acid sequence to predict potential degradation pathways and characteristics of therapeutic peptides. pH plays a vital role in peptide stability, so selecting a buffer to maintain the desired pH is a common strategy to reduce degradation rates in an aqueous solution. Buffer solutions in pH between 3–5 diminish deamidation and oxidation and provide disulfide bridge protection against exchange reactions. Some peptides may require excipients such as amino acids, sugars, or buffer systems to reduce degradation. Co-solvents, air exclusion, viscosity enhancement, bivalent cations, PEGylation, and polyol excipients are practical strategies to enhance peptides' stability in solution. Additionally, aqueous injection peptides are often stored at low temperatures and protected from light to minimize degradation. Hydrophobic ion pairing (HIP) is an effective method for enhancing the stability of peptides in aqueous solutions. The technique involves introducing a hydrophobic counter-ion that forms a stable ion pair with the peptide's positively charged amino acid residues. Biodegradable materials such as arginine-based steroid-surfactants can be used as green cationic agents for HIP, offering a more sustainable approach to drug delivery. It is essential to assess the ideal formulation for preserving the stability of a particular peptide against degradation for every distinct stress it may encounter.

Existing strategies for improving peptide stability and delivery have limitations and challenges that need to be addressed. One limitation is that these methods may not work for all peptides, or may not be effective under certain stress conditions. Additionally, some excipients used for stabilizing peptides may have adverse effects, such as inducing immune responses or altering the pharmacokinetics of the peptide. Another challenge is the delivery of peptides to the target site. Peptides can be rapidly degraded in the bloodstream, limiting their bioavailability and therapeutic efficacy. Therefore, alternative delivery methods, such as oral, transdermal, or nanocarriers, have been explored to improve

peptide delivery. Improving peptide stability and delivery remains a critical challenge in peptide-based therapeutics. Therefore, future research should focus on developing innovative and effective strategies to overcome these limitations and challenges.

Future research directions include developing new strategies for improving peptide stability and delivery, such as using stabilizing agents specifically designed for a particular peptide, developing delivery systems that can protect peptides from degradation in the bloodstream, and improving the design of nanocarriers for more efficient peptide delivery. Furthermore, exploring new drug delivery routes, such as the oral route, may be necessary since oral administration of peptides is often more patient-friendly and cost-effective than injectable delivery. Another area of research is developing new formulations that can both withstand harsh conditions in the digestive system and effectively transport peptides to the target site.

Author Contributions: Conceptualization, C.A. and W.L.J.H.; methodology, C.A. and W.L.J.H.; literature research, P.P.N., C.A. and W.L.J.H.; writing—original draft preparation, P.P.N. and C.A.; writing—review and editing, W.L.J.H., H.W.F. and C.S.; supervision, C.A. and W.L.J.H. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. du Vigneaud, V.; Ressler, C.; Swan, J.M.; Roberts, C.W.; Katsoyannis, P.G. The Synthesis of Oxytocin[1]. *J. Am. Chem. Soc.* **1954**, *76*, 3115–3121. [CrossRef]
2. Zhang, Y.; Zhang, H.; Ghosh, D.; Williams, R.O. Just how prevalent are peptide therapeutic products? A critical review. *Int. J. Pharm.* **2020**, *587*, 119491. [CrossRef]
3. Wang, L.; Wang, N.; Zhang, W.; Cheng, X.; Yan, Z.; Shao, G.; Wang, X.; Wang, R.; Fu, C. Therapeutic peptides: Current applications and future directions. *Signal Transduct. Target. Ther.* **2022**, *7*, 48. [CrossRef]
4. Lau, J.L.; Dunn, M.K. Therapeutic peptides: Historical perspectives, current development trends, and future directions. *Bioorganic. Med. Chem.* **2018**, *26*, 2700–2707. [CrossRef] [PubMed]
5. Smith, A.D.; Datta, S.P.; Smith, G.H.; Campbell, P.N.; Bentley, R.; McKenzie, H.A.; Jakoby, W.B. Oxford dictionary of biochemistry and molecular biology. *Trends Biochem. Sci.* **1998**, *3*, 228.
6. Timmons, P.B.; Hewage, C.M. Biophysical study of the structure and dynamics of the antimicrobial peptide maximin [1]. *J. Pept. Sci.* **2022**, *28*, e3370. [CrossRef] [PubMed]
7. Rogne, P.; Fimland, G.; Nissen-Meyer, J.; Kristiansen, P.E. Three-dimensional structure of the two peptides that constitute the two-peptide bacteriocin lactociccin G. *Biochim. Biophys. Acta* **2008**, *1784*, 543–554. [CrossRef]
8. Ohtake, S.; Kita, Y.; Payne, R.; Manning, M.; Arakawa, T. Structural characteristics of short peptides in solution. *Protein Pept. Lett.* **2013**, *20*, 1308–1323. [CrossRef]
9. Bray, D. Protein molecules as computational elements in living cells. *Nature* **1995**, *376*, 307–312. [CrossRef]
10. Khavinson, V.K.; Popovich, I.G.; Linkova, N.S.; Mironova, E.S.; Ilina, A.R. Peptide Regulation of Gene Expression: A Systematic Review. *Molecules* **2021**, *26*, 7053. [CrossRef]
11. Vaudry, H.; Tonon, M.-C.; Vaudry, D. Editorial: Trends in Regulatory Peptides. *Front. Endocrinol.* **2018**, *9*, 125. [CrossRef]
12. F.D.A. ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin: Guidance. 2021. Available online: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/andas-certain-highly-purified-synthetic-peptide-drug-products-refer-listed-drugs-rdna-origin (accessed on 4 January 2023).
13. Malavolta, L.; Cabral, F.R. Peptides: Important tools for the treatment of central nervous system disorders. *Neuropeptides* **2011**, *45*, 309–316. [CrossRef]
14. Forbes, J.; Krishnamurthy, K. *Biochemistry, Peptide*; StatPearls: Tampa, Florida, 2022.
15. Papini, A.M. Peptide Chemistry Revolution. *Chem. Today* **2011**, *29*, 26–27.
16. Jin, L.; Boyd, B.J.; White, P.J.; Pennington, M.W.; Norton, R.S.; Nicolazzo, J.A. Buccal mucosal delivery of a potent peptide leads to therapeutically-relevant plasma concentrations for the treatment of autoimmune diseases. *J. Control. Release* **2015**, *199*, 37–44. [CrossRef] [PubMed]

17. Castro, P.M.; Baptista, P.; Madureira, A.R.; Sarmento, B.; Pintado, M.E. Combination of PLGA nanoparticles with mucoadhesive guar-gum films for buccal delivery of antihypertensive peptide. *Int. J. Pharm.* **2018**, *547*, 593–601. [CrossRef]
18. Marciello, M.; Rossi, S.; Caramella, C.; Remuñán-López, C. Freeze-dried cylinders carrying chitosan nanoparticles for vaginal peptide delivery. *Carbohydr. Polym.* **2017**, *170*, 43–51. [CrossRef] [PubMed]
19. Shankar, S.; Shah, S.G.; Yadav, S.; Chugh, A. Novel corneal targeting cell penetrating peptide as an efficient nanocarrier with an effective antimicrobial activity. *Eur. J. Pharm. Biopharm.* **2021**, *166*, 216–226. [CrossRef]
20. Fujiyama, T.; Oze, I.; Yagi, H.; Hashizume, H.; Matsuo, K.; Hino, R.; Kamo, R.; Imayama, S.; Hirakawa, S.; Ito, T.; et al. Induction of cytotoxic T cells as a novel independent survival factor in malignant melanoma with percutaneous peptide immunization. *J. Dermatol. Sci.* **2014**, *75*, 43–48. [CrossRef]
21. Chaudhuri, P.; Banerjee, G.B.; Mandal, A. Rectally administered misoprostol versus intravenous oxytocin infusion during cesarean delivery to reduce intraoperative and postoperative blood loss. *Int. J. Gynecol. Obstet.* **2010**, *109*, 25–29. [CrossRef]
22. Kim, Y.; Hwang, S.; Khalmuratova, R.; Kang, S.; Lee, M.; Song, Y.; Park, J.-W.; Yu, J.; Shin, H.-W.; Lee, Y. α-Helical cell-penetrating peptide-mediated nasal delivery of resveratrol for inhibition of epithelial-to-mesenchymal transition. *J. Control. Release* **2020**, *317*, 181–194. [CrossRef]
23. Dillon, C.; Hughes, H.; O'Reilly, N.J.; McLoughlin, P. Formulation and characterisation of dissolving microneedles for the transdermal delivery of therapeutic peptides. *Int. J. Pharm.* **2017**, *526*, 125–136. [CrossRef]
24. Andrade, F.; das Neves, J.; Gener, P.; Schwartz, S.; Ferreira, D.; Oliva, M.; Sarmento, B. Biological assessment of self-assembled polymeric micelles for pulmonary administration of insulin. *Nanomed. Nanotechnol. Biol. Med.* **2015**, *11*, 1621–1631. [CrossRef] [PubMed]
25. Satterwhite, J.; Heathman, M.; Miller, P.D.; Marín, F.; Glass, E.V.; Dobnig, H. Pharmacokinetics of Teriparatide (rhPTH[1–34]) and Calcium Pharmacodynamics in Postmenopausal Women with Osteoporosis. *Calcif. Tissue Int.* **2010**, *87*, 485–492. [CrossRef]
26. Hawe, A.; Poole, R.; Romeijn, S.; Kasper, P.; van der Heijden, R.; Jiskoot, W. Towards Heat-stable Oxytocin Formulations: Analysis of Degradation Kinetics and Identification of Degradation Products. *Pharm. Res.* **2009**, *26*, 1679–1688. [CrossRef]
27. WHO. Q1F Stability Guideline: Stability Testing of Active Pharmaceutical Ingredients and Finished Pharmaceutical products. 2018. Available online: https://bit.ly/3lhmy2R (accessed on 4 January 2023).
28. Hovgaard, L.; Frokjaer, S.; Van De Weert, M. *Pharmaceutical Formulation Development of Peptides and Proteins*, 2nd ed.; CRC Press: Boca Raton, FL, USA, 2012. [CrossRef]
29. FDA. Lyophilization of Parenteral. 2014. Available online: https://bit.ly/3HTG0Lx (accessed on 4 January 2023).
30. Curry, W.; Conway, S.; Goodfield, C.; Miller, K.; Mueller, R.L.; Polini, E. Reducing the Risk of Contamination of Sterile Parenteral Products via Ready-to-Use Closure Components. *AAPS PharmSciTech* **2010**, *11*, 1572–1579. [CrossRef]
31. Zapadka, K.L.; Becher, F.J.; Dos Santos, A.L.G.; Jackson, S.E. Factors affecting the physical stability (aggregation) of peptide therapeutics. *Interface Focus* **2017**, *7*, 20170030. [CrossRef]
32. Manning, M.C.; Chou, D.K.; Murphy, B.M.; Payne, R.W.; Katayama, D.S. Stability of Protein Pharmaceuticals: An Update. *Pharm. Res.* **2010**, *27*, 544–575. [CrossRef]
33. Li, S.; Schöneich, C.; Borchardt, R.T. Chemical instability of protein pharmaceuticals: Mechanisms of oxidation and strategies for stabilization. *Biotechnol. Bioeng.* **1995**, *48*, 490–500. [CrossRef]
34. Topp, E.M.; Zhang, L.; Zhao, H.; Payne, R.W.; Evans, G.J.; Manning, M.C. *Chemical Instability in Peptide and Protein Pharmaceuticals*; John Wiley & Sons, Inc.: Hoboken, NJ, USA, 2010; pp. 41–67. [CrossRef]
35. Wiśniewski, K.; Finnman, J.; Flipo, M.; Galyean, R.; Schteingart, C.D. On the mechanism of degradation of oxytocin and its analogues in aqueous solution. *Pept. Sci.* **2013**, *100*, 408–421. [CrossRef] [PubMed]
36. Pace, A.L.; Wong, R.L.; Zhang, Y.T.; Kao, Y.-H.; Wang, Y.J. Asparagine Deamidation Dependence on Buffer Type, pH, and Temperature. *J. Pharm. Sci.* **2013**, *102*, 1712–1723. [CrossRef] [PubMed]
37. Malm, M.; Madsen, I.; Kjellström, J. Development and stability of a heat-stable formulation of carbetocin for the prevention of postpartum haemorrhage for use in low and middle-income countries. *J. Pept. Sci.* **2018**, *24*, e3082. [CrossRef] [PubMed]
38. Avanti, C.; Oktaviani, N.A.; Hinrichs, W.L.; Frijlink, H.W.; Mulder, F.A. Aspartate buffer and divalent metal ions affect oxytocin in aqueous solution and protect it from degradation. *Int. J. Pharm.* **2013**, *444*, 139–145. [CrossRef] [PubMed]
39. Avanti, C.; Permentier, H.; Van Dam, A.; Poole, R.; Jiskoot, W.; Frijlink, H.W.; Hinrichs, W. A New Strategy to Stabilize Oxytocin in Aqueous Solutions: II. Suppression of Cysteine-Mediated Intermolecular Reactions by a Combination of Divalent Metal Ions and Citrate. *Mol. Pharm.* **2012**, *9*, 554–562. [CrossRef] [PubMed]
40. Zhu, H.J.; Liu, D.; Tran, V.P.; Wu, Z.; Jiang, K.; Zhu, H.; Zhang, J.; Gibbons, C.; Xue, B.; Shi, H.; et al. N-Linked Glycosylation Prevents Deamidation of Glycopeptide and Glycoprotein. *ACS Chem. Biol.* **2020**, *15*, 3197–3205. [CrossRef]
41. Hagen, N.; Bizimana, T.; Kayumba, P.C.; Khuluza, F.; Heide, L. Stability of Oxytocin Preparations in Malawi and Rwanda: Stabilizing Effect of Chlorobutanol. *Am. J. Trop. Med. Hyg.* **2020**, *103*, 2129–2141. [CrossRef]
42. Benet, A.; Halseth, T.; Kang, J.; Kim, A.; Ackermann, R.; Srinivasan, S.; Schwendeman, S.; Schwendeman, A. The Effects of pH and Excipients on Exenatide Stability in Solution. *Pharmaceutics* **2021**, *13*, 1263. [CrossRef]
43. Beard, R.; Stucki, A.; Schmitt, M.; Py, G.; Grundschober, C.; Gee, A.D.; Tate, E.W. Building bridges for highly selective, potent and stable oxytocin and vasopressin analogs. *Bioorg. Med. Chem.* **2018**, *26*, 3039–3045. [CrossRef]

44. Ghasemisarabbadieh, M.; Sigurdsson, S.J.; Dong, F.V.; Gizurarson, S.; Sveinbjörnsson, B.R. The effect of D-(+)-glucosamine, N-acetyl-D-glucosamine and tetraethylene glycol on the stability of oxytocin in aqueous solution. *Die. Pharm. Int. J. Pharm. Sci.* **2021**, *76*, 480–483. [CrossRef]
45. Ghasemisarabbadieh, M.; Gizurarson, S.; Sveinbjörnsson, B.R. The effect of trehalose, antioxidants, and acetate buffer concentration on oxytocin stability. *J. Pept. Sci.* **2021**, *27*, e3324. [CrossRef]
46. Neves-Petersen, M.T.; Klitgaard, S.; Pascher, T.; Skovsen, E.; Polivka, T.; Yartsev, A.; Sundström, V.; Petersen, S.B. Flash Photolysis of Cutinase: Identification and Decay Kinetics of Transient Intermediates Formed upon UV Excitation of Aromatic Residues. *Biophys. J.* **2009**, *97*, 211–226. [CrossRef]
47. Neves-Petersen, M.T.; Jonson, P.H.; Petersen, S.B. Amino acid neighbours and detailed conformational analysis of cysteines in proteins. *Protein Eng. Des. Sel.* **1999**, *12*, 535–548. [CrossRef] [PubMed]
48. Creed, D. The photophysics and photochemistry of the near-uv absorbing amino Acids-I. tryptophan and its simple derivatives. *Photochem. Photobiol.* **1984**, *39*, 537–562. [CrossRef]
49. Mozziconacci, O.; Schöneich, C. Photodegradation of Oxytocin and Thermal Stability of Photoproducts. *J. Pharm. Sci.* **2012**, *101*, 3331–3346. [CrossRef] [PubMed]
50. Schöneich, C.; Williams, T.D. Cu(II)-Catalyzed Oxidation of β-Amyloid Peptide Targets His^{13} and His^{14} over His^{6}: Detection of 2-Oxo-histidine by HPLC-MS/MS. *Chem. Res. Toxicol.* **2002**, *15*, 717–722. [CrossRef]
51. Csire, G.; Turi, I.; Sóvágó, I.; Kárpáti, E.; Kállay, C. Complex formation processes and metal ion catalyzed oxidation of model peptides related to the metal binding site of the human prion protein. *J. Inorg. Biochem.* **2020**, *203*, 110927. [CrossRef]
52. Law, S.L.; Huang, K.J.; Chou, V.H.Y. Stability of Desmopressin Loaded in Liposomes. *J. Liposome Res.* **2003**, *13*, 269–277. [CrossRef]
53. Hawe, A.; Fries, W. Formulation Development for Hydrophobic Therapeutic Proteins. *Pharm. Dev. Technol.* **2007**, *12*, 223–237. [CrossRef]
54. Ambrosio, E.; Podmore, A.; dos Santos, A.L.G.; Magarkar, A.; Bunker, A.; Caliceti, P.; Mastrotto, F.; van der Walle, C.F.; Salmaso, S. Control of Peptide Aggregation and Fibrillation by Physical PEGylation. *Biomacromolecules* **2018**, *19*, 3958–3969. [CrossRef]
55. Bothe, J.R.; Andrews, A.; Smith, K.J.; Joyce, L.A.; Krishnamachari, Y.; Kashi, S. Peptide Oligomerization Memory Effects and Their Impact on the Physical Stability of the GLP-1 Agonist Liraglutide. *Mol. Pharm.* **2019**, *16*, 2153–2161. [CrossRef]
56. Korang-Yeboah, M.; Ketcham, S.; Shih, M.; Ako-Adounvo, A.-M.; Zhang, J.; Bandaranayake, B.M.; Abbey-Berko, Y.; Faustino, P.; Ashraf, M. Effect of formulation and peptide folding on the fibrillar aggregation, gelation, and oxidation of a therapeutic peptide. *Int. J. Pharm.* **2021**, *604*, 120677. [CrossRef]
57. Rastogi, N.; Mitra, K.; Kumar, D.; Roy, R. Metal Ions as Cofactors for Aggregation of Therapeutic Peptide Salmon Calcitonin. *Inorg. Chem.* **2012**, *51*, 5642–5650. [CrossRef] [PubMed]
58. Liang, R.; Zhang, R.; Li, X.; Wang, A.; Chen, D.; Sun, K.; Liu, W.; Li, Y. Stability of exenatide in poly(d,l-lactide-co-glycolide) solutions: A simplified investigation on the peptide degradation by the polymer. *Eur. J. Pharm. Sci.* **2013**, *50*, 502–510. [CrossRef] [PubMed]
59. Høgstedt, U.B.; Østergaard, J.; Weiss, T.; Sjögren, H.; van de Weert, M. Manipulating Aggregation Behavior of the Uncharged Peptide Carbetocin. *J. Pharm. Sci.* **2018**, *107*, 838–847. [CrossRef]
60. Zhang, J.; Mao, X.; Xu, W. Fibril Nucleation Kinetics of a Pharmaceutical Peptide: The Role of Conformation Stability, Formulation Factors, and Temperature Effect. *Mol. Pharm.* **2018**, *15*, 5591–5601. [CrossRef] [PubMed]
61. Manning, M.C.; Patel, K.; Borchardt, R.T. Stability of Protein Pharmaceuticals. *Pharm. Res. J. Am Assoc. Pharm. Sci.* **1989**, *6*, 903–918. [CrossRef]
62. Hoitink, M.A.; Beijnen, J.H.; Boschma, M.U.S.; Bult, A.; Hop, E.; Nijholt, J.; Versluis, C.; Wiese, G.; Underberg, W.J.M. Identification of the Degradation Products of Gonadorelin and Three Analogues in Aqueous Solution. *Anal. Chem.* **1997**, *69*, 4972–4978. [CrossRef]
63. Strickley, R.G.; Brandl, M.; Chan, K.W.; Straub, K.; Gu, L. High-Performance Liquid Chromatographic (HPLC) and HPLC-Mass Spectrometric (MS) Analysis of the Degradation of the Luteinizing Hormone-Releasing Hormone (LH-RH) Antagonist RS-26306 in Aqueous Solution. *Pharm. Res.* **1990**, *7*, 530–536. [CrossRef]
64. Helm, V.J.; Müller, B.W. Stability of Gonadorelin and Triptorelin in Aqueous Solution. *Pharm. Res.* **1990**, *7*, 1253–1256. [CrossRef]
65. Hoitink, M.A.; Beijnen, J.H.; Bult, A.; van der Houwen, O.A.; Nijholt, J.; Underberg, W.J. Degradation Kinetics of Gonadorelin in Aqueous Solution. *J. Pharm. Sci.* **1996**, *85*, 1053–1059. [CrossRef]
66. Senderoff, R.I.; Kontor, K.M.; Kreilgaard, L.; Chang, J.J.; Patel, S.; Krakover, J.; Heffernan, J.K.; Snell, L.B.; Rosenberg, G.B. Consideration of Conformational Transitions And Racemization During Process Development of Recombinant Glucagon-Like Peptide-1. *J. Pharm. Sci.* **1998**, *87*, 183–189. [CrossRef] [PubMed]
67. Nabuchi, Y.; Fujiwara, E.; Kuboniwa, H.; Asoh, Y.; Ushio, H. The stability and degradation pathway of recombinant human par-athyroid hormone: Deamidation of asparaginyl residue and peptide bond cleavage at aspartyl and asparaginyl residues. *Pharm. Res.* **1997**, *14*, 1685–1690. [CrossRef] [PubMed]
68. Oliva, A.; Ashen, D.S.; Salmona, M.; Fariña, J.B.; Llabrés, M. Solid-state stability studies of cholecystokinin (CCK-4) peptide under nonisothermal conditions using thermal analysis, chromatography and mass spectrometry. *Eur. J. Pharm. Sci.* **2010**, *39*, 263–271. [CrossRef] [PubMed]
69. Jang, S.W.; Woo, B.H.; Lee, J.T.; Moon, S.C.; Lee, K.C.; Deluca, P.P. Stability of Octastatin, a Somatostatin Analog Cyclic Octapeptide, in Aqueous Solution. *Pharm. Dev. Technol.* **1997**, *2*, 409–414. [CrossRef] [PubMed]

70. Herrmann, J.; Bodmeier, R. Degradation Kinetics of Somatostatin in Aqueous Solution. *Drug Dev. Ind. Pharm.* **2003**, *29*, 1027–1033. [CrossRef] [PubMed]
71. Bhatt, N.P.; Patel, K.; Borchardt, R.T. Chemical Pathways of Peptide Degradation. I. Deamidation of Adrenocorticotropic Hormone. *Pharm. Res.* **1990**, *7*, 593–599. [CrossRef]
72. Geiger, T.; Clarke, S. Deamidation, isomerization, and racemization at asparaginyl and aspartyl residues in peptides. Succinimide-linked reactions that contribute to protein degradation. *J. Biol. Chem.* **1987**, *262*, 785–794. [CrossRef]
73. Reissner, K.J.; Aswad, D.W. Deamidation and isoaspartate formation in proteins: Unwanted alterations or surreptitious signals? *Cell. Mol. Life Sci.* **2003**, *60*, 1281–1295. [CrossRef]
74. Kato, K.; Nakayoshi, T.; Kurimoto, E.; Oda, A. Mechanisms of Deamidation of Asparagine Residues and Effects of Main-Chain Conformation on Activation Energy. *Int. J. Mol. Sci.* **2020**, *21*, 7035. [CrossRef]
75. Patel, K.; Borchardt, R.T. Chemical Pathways of Peptide Degradation. III. Effect of Primary Sequence on the Pathways of Deamidation of Asparaginyl Residues in Hexapeptides. *Pharm. Res.* **1990**, *7*, 787–793. [CrossRef]
76. Patel, K.; Borchardt, R.T. Chemical Pathways of Peptide Degradation. II. Kinetics of Deamidation of an Asparaginyl Residue in a Model Hexapeptide. *Pharm. Res.* **1990**, *7*, 703–711. [CrossRef]
77. Lee, K.C.; Lee, Y.J.; Song, H.M.; Chun, C.J.; De Luca, P.P. Degradation of Synthetic Salmon Calcitonin in Aqueous Solution. *Pharm. Res.* **1992**, *9*, 1521–1523. [CrossRef]
78. Lin, S.-Y.; Wang, S.-L. Advances in simultaneous DSC–FTIR microspectroscopy for rapid solid-state chemical stability studies: Some dipeptide drugs as examples. *Adv. Drug Deliv. Rev.* **2012**, *64*, 461–478. [CrossRef] [PubMed]
79. Lee, V.H.L. *Peptide and Protein Drug Delivery*; Marcel Dekker, Inc.: New York, NY, USA, 1991.
80. Robinson, N.E. Protein deamidation. *Proc. Natl. Acad. Sci. USA* **2002**, *99*, 5283–5288. [CrossRef]
81. Chu, G.C.; Chelius, D.; Xiao, G.; Khor, H.K.; Coulibaly, S.; Bondarenko, P.V. Accumulation of Succinimide in a Recombinant Monoclonal Antibody in Mildly Acidic Buffers Under Elevated Temperatures. *Pharm. Res.* **2007**, *24*, 1145–1156. [CrossRef] [PubMed]
82. Sargaeva, N.P.; Goloborodko, A.A.; O'Connor, P.B.; Moskovets, E.; Gorshkov, M.V. Sequence-specific predictive chromatography to assist mass spectrometric analysis of asparagine deamidation and aspartate isomerization in peptides. *Electrophoresis* **2011**, *32*, 1962–1969. [CrossRef]
83. Wakankar, A.A.; Borchardt, R.T. Formulation considerations for proteins susceptible to asparagine deamidation and aspartate isomerization. *J. Pharm. Sci.* **2006**, *95*, 2321–2336. [CrossRef]
84. Oliyai, C.; Borchardt, R.T. Chemical Pathways of Peptide Degradation. IV. Pathways, Kinetics, and Mechanism of Degradation of an Aspartyl Residue in a Model Hexapeptide. *Pharm. Res.* **1993**, *10*, 95–102. [CrossRef] [PubMed]
85. Catak, S.; Monard, G.; Aviyente, V.; Ruiz-López, M.F. Deamidation of asparagine residues: Direct hydrolysis versus succin-imide-mediated deamidation mechanisms. *J. Phys. Chem. A.* **2009**, *113*, 1111–1120. [CrossRef]
86. Solomons, T.W.G.; Fryhle, C. *Organic Chemistry*, 10th ed.; John Wiley & Sons, Inc.: Hoboken, NJ, USA, 2011.
87. Smith, M.B.; March, J. *March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure*, 6th ed.; Wiley: Hoboken, NJ, USA, 2007. [CrossRef]
88. Li, S.; Schöneich, C.; Borchardt, R.T. Chemical Pathways of Peptide Degradation. VIII. Oxidation of Methionine in Small Model Peptides by Prooxidant/Transition Metal Ion Systems: Influence of Selective Scavengers for Reactive Oxygen Intermediates. *Pharm. Res.* **1995**, *12*, 348–355. [CrossRef]
89. Nauser, T.; Koppenol, W.H.; Schöneich, C. Reversible Hydrogen Transfer Reactions in Thiyl Radicals from Cysteine and Related Molecules: Absolute Kinetics and Equilibrium Constants Determined by Pulse Radiolysis. *J. Phys. Chem. B* **2012**, *116*, 5329–5341. [CrossRef]
90. Liu, F.; Fang, Y.; Chen, Y.; Liu, J. Reactions of Deprotonated Tyrosine and Tryptophan with Electronically Excited Singlet Molecular Oxygen ($a^1\Delta_g$): A Guided-Ion-Beam Scattering, Statistical Modeling, and Trajectory Study. *J. Phys. Chem. B* **2012**, *116*, 6369–6379. [CrossRef] [PubMed]
91. Kállay, C.; Ősz, K.; Dávid, A.; Valastyán, Z.; Malandrinos, G.; Hadjiliadis, N.; Sóvágó, I. Zinc(ii) binding ability of tri-, tetra- and penta-peptides containing two or three histidyl residues. *Dalton Trans.* **2007**, *36*, 4040–4047. [CrossRef] [PubMed]
92. Miller, D.M.; Buettner, G.R.; Aust, S.D. Transition metals as catalysts of "autoxidation" reactions. *Free Radic. Biol. Med.* **1990**, *8*, 95–108. [CrossRef] [PubMed]
93. Merenyi, G.; Lind, J.; Jonsson, M. Autoxidation of closed-shell organics: An outer-sphere electron transfer. *J. Am. Chem. Soc.* **1993**, *115*, 4945–4946. [CrossRef]
94. Lal, M.; Rao, R.; Fang, X.; Schuchmann, H.-P.; von Sonntag, C. Radical-Induced Oxidation of Dithiothreitol in Acidic Oxygenated Aqueous Solution: A Chain Reaction. *J. Am. Chem. Soc.* **1997**, *119*, 5735–5739. [CrossRef]
95. Jomova, K.; Baros, S.; Valko, M. Redox active metal-induced oxidative stress in biological systems. *Transit. Met. Chem.* **2012**, *37*, 127–134. [CrossRef]
96. Stadtman, E.R. Metal ion-catalyzed oxidation of proteins: Biochemical mechanism and biological consequences. *Free. Radic. Biol. Med.* **1990**, *9*, 315–325. [CrossRef]
97. Mozziconacci, O.; Ji, J.A.; Wang, Y.J.; Schöneich, C. Metal-Catalyzed Oxidation of Protein Methionine Residues in Human Parathyroid Hormone (1-34): Formation of Homocysteine and a Novel Methionine-Dependent Hydrolysis Reaction. *Mol. Pharm.* **2013**, *10*, 739–755. [CrossRef]

98. Subelzu, N.; Schöneich, C. Near UV and Visible Light Induce Iron-Dependent Photodegradation Reactions in Pharmaceutical Buffers: Mechanistic and Product Studies. *Mol. Pharm.* **2020**, *17*, 4163–4179. [CrossRef]
99. Subelzu, N.; Schöneich, C. Pharmaceutical Excipients Enhance Iron-Dependent Photo-Degradation in Pharmaceutical Buffers by near UV and Visible Light: Tyrosine Modification by Reactions of the Antioxidant Methionine in Citrate Buffer. *Pharm. Res.* **2021**, *38*, 915–930. [CrossRef]
100. Zhang, Y.; Richards, D.S.; Grotemeyer, E.N.; Jackson, T.A.; Schöneich, C. Near-UV and Visible Light Degradation of Iron (III)-Containing Citrate Buffer: Formation of Carbon Dioxide Radical Anion via Fragmentation of a Sterically Hindered Alkoxyl Radical. *Mol. Pharm.* **2022**, *19*, 4026–4042. [CrossRef] [PubMed]
101. Sjöberg, B.; Foley, S.; Cardey, B.; Fromm, M.; Enescu, M. Methionine oxidation by hydrogen peroxide in peptides and proteins: A theoretical and Raman spectroscopy study. *J. Photochem. Photobiol. B Biol.* **2018**, *188*, 95–99. [CrossRef] [PubMed]
102. Peskin, A.V.; Cox, A.G.; Nagy, P.; Morgan, P.E.; Hampton, M.B.; Davies, M.J.; Winterbourn, C.C. Removal of amino acid, peptide and protein hydroperoxides by reaction with peroxiredoxins 2 and 3. *Biochem. J.* **2010**, *432*, 313–321. [CrossRef] [PubMed]
103. Khossravi, M.; Borchardt, R.T. Chemical pathways of peptide degradation: IX. Metal-catalyzed oxidation of histidine in model peptides. *Pharm. Res.* **1998**, *15*, 1096–1102. [CrossRef]
104. Kishore, R.S.K.; Kiese, S.; Fischer, S.; Pappenberger, A.; Grauschopf, U.; Mahler, H.-C. The Degradation of Polysorbates 20 and 80 and its Potential Impact on the Stability of Biotherapeutics. *Pharm. Res.* **2011**, *28*, 1194–1210. [CrossRef]
105. Galande, A.K.; Trent, J.O.; Spatola, A.F. Understanding base-assisted desulfurization using a variety of disulfide-bridged peptides. *Biopolymers* **2003**, *71*, 534–551. [CrossRef]
106. Cohen, S.L.; Price, C.; Vlasak, J. β-Elimination and Peptide Bond Hydrolysis: Two Distinct Mechanisms of Human IgG1 Hinge Fragmentation upon Storage. *J. Am. Chem. Soc.* **2007**, *129*, 6976–6977. [CrossRef]
107. Volkin, D.; Klibanov, A. Thermal destruction processes in proteins involving cystine residues. *J. Biol. Chem.* **1987**, *262*, 2945–2950. [CrossRef]
108. Windisch, V.; Deluccia, F.; Duhau, L.; Herman, F.; Mencel, J.J.; Tang, S.-Y.; Vuilhorgne, M. Degradation Pathways of Salmon Calcitonin in Aqueous Solution. *J. Pharm. Sci.* **1997**, *86*, 359–364. [CrossRef]
109. Benesch, R.E.; Benesch, R. The Mechanism of Disulfide Interchange in Acid Solution; Role of Sulfenium Ions. *J. Am. Chem. Soc.* **1958**, *80*, 1666–1669. [CrossRef]
110. Wakabayashi, K.; Nakagawa, H.; Tamura, A.; Koshiba, S.; Hoshijima, K.; Komada, M.; Ishikawa, T. Intramolecular Disulfide Bond Is a Critical Check Point Determining Degradative Fates of ATP-binding Cassette (ABC) Transporter ABCG2 Protein. *J. Biol. Chem.* **2007**, *282*, 27841–27846. [CrossRef]
111. Fázio, M.A.; Oliveira, V.X.; Bulet, P.; Miranda, M.T.M.; Daffre, S.; Miranda, A. Structure-activity relationship studies of gomesin: Importance of the disulfide bridges for conformation, bioactivities, and serum stability. *Pept. Sci. Orig. Res. Biomol.* **2006**, *84*, 205–218. [CrossRef]
112. Kourra, C.M.B.K.; Cramer, N. Converting disulfide bridges in native peptides to stable methylene thioacetals. *Chem. Sci.* **2016**, *7*, 7007–7012. [CrossRef] [PubMed]
113. Malencik, D.A.; Anderson, S.R. Dityrosine Formation in Calmodulin: Conditions for Intermolecular Crosslinking. *Biochemistry* **1994**, *33*, 13363–13372. [CrossRef] [PubMed]
114. Smith, I.C.P.; DesLauriers, R.; Saitô, H.; Walter, R.; Garrigou-Lagrange, C.; McGregor, H.; Sarantakis, D. Carbon-13 nmr studies of peptide hormones and their components. *Ann. N. Y. Acad. Sci.* **1973**, *222*, 597–627. [CrossRef] [PubMed]
115. Kamberi, M.; Chung, P.; Devas, R.; Li, L.; Li, Z.; Ma, X.; Fields, S.; Riley, C.M. Analysis of non-covalent aggregation of synthetic hPTH (1–34) by size-exclusion chromatography and the importance of suppression of non-specific interactions for a precise quantitation. *J. Chromatogr. B* **2004**, *810*, 151–155. [CrossRef]
116. Wang, W. Protein aggregation and its inhibition in biopharmaceutics. *Int. J. Pharm.* **2005**, *289*, 1–30. [CrossRef]
117. Powell, M.F.; Sanders, L.M.; Rogerson, A.; Si, V. Parenteral Peptide Formulations: Chemical and Physical Properties of Native Luteinizing Hormone-Releasing Hormone (LHRH) and Hydrophobic Analogues in Aqueous Solution. *Pharm. Res.* **1991**, *8*, 1258–1263. [CrossRef]
118. Tan, M.M.; Corley, C.A.; Stevenson, C.L. Effect of gelation on the chemical stability and conformation of leuprolide. *Pharm. Res.* **1998**, *15*, 1442–1448. [CrossRef]
119. Hashimoto, T.; Ohki, K.; Sakura, N. Hydrolytic Cleavage of Pyroglutamyl-Peptide Bond. I. The Susceptibility of Pyroglutamyl-Peptide Bond to Dilute Hydrochloric Acid. *Chem. Pharm. Bull.* **1995**, *43*, 2068–2074. [CrossRef]
120. Dos Santos, C.A.; Ribeiro, G.B.; Knirsch, M.C.; Junior, A.P.; Penna, T.C.V. Influence of Pluronic®F68 on Ceftazidime Biological Activity in Parenteral Solutions. *J. Pharm. Sci.* **2011**, *100*, 715–720. [CrossRef] [PubMed]
121. Hwang, J.M.; E Piccinini, T.; Lammel, C.J.; Hadley, W.K.; Brooks, G.F. Effect of storage temperature and pH on the stability of antimicrobial agents in MIC trays. *J. Clin. Microbiol.* **1986**, *23*, 959–961. [CrossRef]
122. Zhao, L.; Yalkowsky, S.H. Stabilization of eptifibatide by cosolvents. *Int. J. Pharm.* **2001**, *218*, 43–56. [CrossRef]
123. Krishnamoorthy, R.; Mitra, A.K. Kinetics and Mechanism of Degradation of a Cyclic Hexapeptide (Somatostatin Analogue) in Aqueous Solution. *Pharm. Res.* **1992**, *9*, 1314–1320. [CrossRef] [PubMed]
124. Collins, J.; Kempe, K.; Wilson, P.; Blindauer, C.A.; McIntosh, M.P.; Davis, T.P.; Whittaker, M.R.; Haddleton, D.M. Stability Enhancing N-Terminal PEGylation of Oxytocin Exploiting Different Polymer Architectures and Conjugation Approaches. *Biomacromolecules* **2016**, *17*, 2755–2766. [CrossRef]

125. Stratton, L.P.; Kelly, R.; Rowe, J.; Shively, J.E.; Smith, D.; Carpenter, J.F.; Manning, M.C. Controlling deamidation rates in a model peptide: Effects of temperature, peptide concentration, and additives. *J. Pharm. Sci.* **2001**, *90*, 2141–2148. [CrossRef]
126. Hall, S.; Tan, M.; Leonard, J.; Stevenson, C. Characterization and comparison of leuprolide degradation profiles in water and dimethyl sulfoxide. *J. Pept. Res.* **1999**, *53*, 432–441. [CrossRef]
127. Wang, Y.; Lomakin, A.; Kanai, S.; Alex, R.; Benedek, G.B. Transformation of Oligomers of Lipidated Peptide Induced by Change in pH. *Mol. Pharm.* **2015**, *12*, 411–419. [CrossRef] [PubMed]
128. Seyferth, S.; Lee, G. Structural studies of EDTA-induced fibrillation of salmon calcitonin. *Pharm. Res.* **2003**, *20*, 73–80. [CrossRef]
129. Kamberi, M.; Kim, Y.; Jun, B.; Riley, C. The effects of sucrose on stability of human brain natriuretic peptide [hBNP (1-32)] and human parathyroid hormone [hPTH (1-34)]. *J. Pept. Res.* **2005**, *66*, 348–356. [CrossRef]
130. Guan, Z.; Yates, N.A.; Bakhtiar, R. Detection and characterization of methionine oxidation in peptides by collision-induced dissociation and electron capture dissociation. *J. Am. Soc. Mass Spectrom.* **2003**, *14*, 605–613. [CrossRef]
131. Smith, D.P.; Ciccotosto, G.D.; Tew, D.J.; Fodero-Tavoletti, M.T.; Johanssen, T.; Masters, C.L.; Barnham, K.J.; Cappai, R. Concentration Dependent Cu^{2+} Induced Aggregation and Dityrosine Formation of the Alzheimer's Disease Amyloid-β Peptide. *Biochemistry* **2007**, *46*, 2881–2891. [CrossRef]
132. Inoue, K.; Nakagawa, A.; Hino, T.; Oka, H. Screening Assay for Metal-Catalyzed Oxidation Inhibitors Using Liquid Chromatography−Mass Spectrometry with an N-Terminal β-Amyloid Peptide. *Anal. Chem.* **2009**, *81*, 1819–1825. [CrossRef]
133. Dunkelberger, E.B.; Buchanan, L.E.; Marek, P.; Cao, P.; Raleigh, D.P.; Zanni, M.T. Deamidation Accelerates Amyloid Formation and Alters Amylin Fiber Structure. *J. Am. Chem. Soc.* **2012**, *134*, 12658–12667. [CrossRef]
134. Brazeau, G.A.; Cooper, B.; Svetic, K.A.; Smith, C.L.; Gupta, P. Current Perspectives on Pain upon Injection of Drugs. *J. Pharm. Sci.* **1998**, *87*, 667–677. [CrossRef] [PubMed]
135. Extemp.ie. Sterile Preparations—Parenterals. Available online: http://www.extemp.ie/general-methods/sterile-preparations/parenterals (accessed on 11 December 2021).
136. Jorgensen, L.; Hostrup, S.; Moeller, E.H.; Grohganz, H. Recent trends in stabilising peptides and proteins in pharmaceutical formulation—Considerations in the choice of excipients. *Expert Opin. Drug Deliv.* **2009**, *6*, 1219–1230. [CrossRef] [PubMed]
137. Cleland, J.L.; Powell, M.F.; Shire, S.J. The development of stable protein formulations: A close look at protein aggregation, deamidation, and oxidation. *Crit. Rev. Ther. Drug Carr. Syst.* **1993**, *10*, 307–377.
138. Wang, W.; Martin-Moe, S.; Pan, C.; Musza, L.; Wang, Y.J. Stabilization of a polypeptide in non-aqueous solvents. *Int. J. Pharm.* **2008**, *351*, 1–7. [CrossRef]
139. Good, N.E.; Winget, G.D.; Winter, W.; Connolly, T.N.; Izawa, S.; Singh, R.M.M. Hydrogen Ion Buffers for Biological Research *. *Biochemistry* **1966**, *5*, 467–477. [CrossRef]
140. Liu, F.; Lai, S.; Tong, H.; Lakey, P.S.J.; Shiraiwa, M.; Weller, M.G.; Pöschl, U.; Kampf, C.J. Release of free amino acids upon oxidation of peptides and proteins by hydroxyl radicals. *Anal. Bioanal. Chem.* **2017**, *409*, 2411–2420. [CrossRef]
141. Avanti, C.; Amorij, J.-P.; Setyaningsih, D.; Hawe, A.; Jiskoot, W.; Visser, J.; Kedrov, A.; Driessen, A.J.M.; Hinrichs, W.L.J.; Frijlink, H.W. A New Strategy to Stabilize Oxytocin in Aqueous Solutions: I. The Effects of Divalent Metal Ions and Citrate Buffer. *AAPS J.* **2011**, *13*, 284–290. [CrossRef] [PubMed]
142. Avanti, C.; Hinrichs, W.L.; Casini, A.; Eissens, A.C.; Van Dam, A.; Kedrov, A.; Driessen, A.J.; Frijlink, H.W.; Permentier, H.P. The Formation of Oxytocin Dimers is Suppressed by the Zinc-Aspartate-Oxytocin Complex. *J. Pharm. Sci.* **2013**, *102*, 1734–1741. [CrossRef]
143. Ryu, K.-W.; Na, D.-H. Stability of Octreotide Acetate in Aqueous Solutions and PLGA Films. *J. Korean Pharm. Sci.* **2009**, *39*, 353–357. [CrossRef]
144. Li, R.; D'Souza, A.J.; Schowen, R.L.; Borchardt, R.T.; Topp, E.M.; Laird, B.B. Effects of solution polarity and viscosity on peptide deamidation. *J. Pept. Res.* **2000**, *56*, 326–334. [CrossRef] [PubMed]
145. Ramm, I.; Sanchez-Fernandez, A.; Choi, J.; Lang, C.; Fransson, J.; Schagerlöf, H.; Wahlgren, M.; Nilsson, L. The Impact of Glycerol on an Affibody Conformation and Its Correlation to Chemical Degradation. *Pharmaceutics* **2021**, *13*, 1853. [CrossRef]
146. Parkins, D.A.; Lashmar, U.T. The formulation of biopharmaceutical products. *Pharm. Sci. Technol. Today* **2000**, *3*, 129–137. [CrossRef]
147. Brennan, T.V.; Clarke, S. Spontaneous degradation of polypeptides at aspartyl and asparaginyl residues: Effects of the solvent dielectric. *Protein Sci.* **1993**, *2*, 331–338. [CrossRef]
148. D'Souza, A.J.M.; Schowen, R.L.; Borchardt, R.T.; Salsbury, J.S.; Munson, E.J.; Topp, E.M. Reaction of a Peptide with Polyvinylpyrrolidone in the Solid State. *J. Pharm. Sci.* **2003**, *92*, 585–593. [CrossRef]
149. Hovgaard, L.; Frokjaer, S.; van de Weert, M. *Pharmaceutical Formulation Development of Peptides and Proteins*; Taylor & Francis: Milton Park, OX, USA, 1999. Available online: https://books.google.co.id/books?id=VVlLyQEACAAJ (accessed on 4 January 2023).
150. Li, R.; Topp, E.; Hageman, M. Effect of viscosity on the deamidation rate of a model Asn-hexapeptide. *J. Pept. Res.* **2002**, *59*, 211–220. [CrossRef]
151. Thieme, V.; Jolly, N.; Madsen, A.N.; Bellmann-Sickert, K.; Schwartz, T.W.; Holst, B.; Cox, H.M.; Beck-Sickinger, A.G. High molecular weight PEGylation of human pancreatic polypeptide at position 22 improves stability and reduces food intake in mice. *Br. J. Pharmacol.* **2016**, *173*, 3208–3221. [CrossRef] [PubMed]

152. Brito, J.C.M.; Carvalho, L.R.; de Souza, A.N.; Carneiro, G.; Magalhães, P.P.; Farias, L.M.; Guimarães, N.R.; Verly, R.M.; Resende, J.M.; de Lima, M.E. PEGylation of the antimicrobial peptide LyeTx I-b maintains structure-related biological properties and improves selectivity. *Front. Mol. Biosci.* **2022**, *9*, 1001508. [CrossRef] [PubMed]
153. Shrestha, P.; Stone, C.A. Allergy evaluation of messenger RNA vaccine reactions is crucial, with a specific role for polyethylene glycol testing. *Ann. Allergy Asthma Immunol.* **2022**, *129*, 22–23. [CrossRef] [PubMed]
154. Hatziantoniou, S.; Maltezou, H.C.; Tsakris, A.; Poland, G.A.; Anastassopoulou, C. Anaphylactic reactions to mRNA COVID-19 vaccines: A call for further study. *Vaccine* **2021**, *39*, 2605–2607. [CrossRef] [PubMed]
155. Waterman, K.C.; Adami, R.C.; Alsante, K.M.; Hong, J.; Landis, M.S.; Lombardo, F.; Roberts, C.J. Stabilization of Pharmaceuticals to Oxidative Degradation. *Pharm. Dev. Technol.* **2002**, *7*, 1–32. [CrossRef]
156. Chu, J.-W.; Brooks, B.R.; Trout, B.L. Oxidation of Methionine Residues in Aqueous Solutions: Free Methionine and Methionine in Granulocyte Colony-Stimulating Factor. *J. Am. Chem. Soc.* **2004**, *126*, 16601–16607. [CrossRef]
157. Landi, S.; Held, H.R. Effect of oxidation on the stability of tuberculin purified protein derivative (P.P.D.). *Dev. Biol. Stand.* **1986**, *58*, 545–552.
158. Rahimi, M.; Mobedi, H.; Behnamghader, A. Aqueous stability of leuprolide acetate: Effect of temperature, dissolved oxygen, pH and complexation with β-cyclodextrin. *Pharm. Dev. Technol.* **2016**, *21*, 108–115. [CrossRef]
159. Pagano, D.A.; Zeiger, E.; Stark, A.-A. Autoxidation and mutagenicity of sodium bisulfite. *Mutat. Res. Mol. Mech. Mutagen.* **1990**, *228*, 89–96. [CrossRef]
160. Ingold, K.U. Peroxy radicals. *Acc. Chem. Res.* **1969**, *2*, 1–9. [CrossRef]
161. Schöneich, C.; Zhao, F.; Wilson, G.S.; Borchardt, R.T. Iron-thiolate induced oxidation of methionine to methionine sulfoxide in small model peptides. Intramolecular catalysis by histidine. *Biochim. Biophys. Acta Gen. Subj.* **1993**, *1158*, 307–322. [CrossRef]
162. Li, S.; Schöneich, C.; Wilson, G.S.; Borchardt, R.T. Chemical Pathways of Peptide Degradation. V. Ascorbic Acid Promotes Rather than Inhibits the Oxidation of Methionine to Methionine Sulfoxide in Small Model Peptides. *Pharm. Res.* **1993**, *10*, 1572–1579. [CrossRef] [PubMed]
163. Levine, R.L.; Moskovitz, J.; Stadtman, E.R. Oxidation of Methionine in Proteins: Roles in Antioxidant Defense and Cellular Regulation. *IUBMB Life* **2000**, *50*, 301–307. [CrossRef] [PubMed]
164. Tsai, P.K.; Volkin, D.B.; Dabora, J.M.; Thompson, K.C.; Bruner, M.W.; Gress, J.O.; Matuszewska, B.; Keogan, M.; Bondi, J.V.; Middaugh, C.R. Formulation Design of Acidic Fibroblast Growth Factor. *Pharm. Res.* **1993**, *10*, 649–659. [CrossRef]
165. Zhao, F.; Yang, J.; Schöneich, C. Effects of Polyaminocarboxylate Metal Chelators on Iron-thiolate Induced Oxidation of Methionine- and Histidine-Containing Peptides. *Pharm. Res.* **1996**, *13*, 931–938. [CrossRef] [PubMed]
166. Rush, J.D.; Koppenol, W.H. Oxidizing intermediates in the reaction of ferrous EDTA with hydrogen peroxide. Reactions with organic molecules and ferrocytochrome c. *J. Biol. Chem.* **1986**, *261*, 6730–6733. [CrossRef]
167. Torosantucci, R.; Weinbuch, D.; Klem, R.; Jiskoot, W. Triethylenetetramine prevents insulin aggregation and fragmentation during copper catalyzed oxidation. *Eur. J. Pharm. Biopharm.* **2013**, *84*, 464–471. [CrossRef]
168. Li, S.; Patapoff, T.W.; Nguyen, T.H.; Borchardt, R.T. Inhibitory Effect of Sugars and Polyols on the Metal-Catalyzed Oxidation of Human Relaxin. *J. Pharm. Sci.* **1996**, *85*, 868–872. [CrossRef]
169. Obiols, B.P.; Farres, G.J.; Rodriguez, F.J.C.; Fernandez, S.P.; Cabado, J.B. Stable Pharmaceutical Formulation for Intravenous or In-Tramuscular Administration of Active Peptide Compound. 2003. Available online: https://patentimages.storage.googleapis.com/e9/8d/6c/1e6ec5ec4ba9b2/US6521599.pdf (accessed on 4 January 2023).
170. Zheng, K.; Middaugh, C.; Siahaan, T.J. Evaluation of the physical stability of the EC5 domain of E-cadherin: Effects of pH, temperature, ionic strength, and disulfide bonds. *J. Pharm. Sci.* **2009**, *98*, 63–73. [CrossRef]
171. Bursakov, S.; Carneiro, C.; Almendra, M.; Duarte, R.; Caldeira, J.; Moura, I.; Moura, J.J.G. Enzymatic Properties and Effect of Ionic Strength on Periplasmic Nitrate Reductase (NAP) fromDesulfovibrio desulfuricansATCC 27774. *Biochem. Biophys. Res. Commun.* **1997**, *239*, 816–822. [CrossRef]
172. Tyler-Cross, R.; Schirch, V. Effects of amino acid sequence, buffers, and ionic strength on the rate and mechanism of deami-dation of asparagine residues in small peptides. *J. Biol. Chem.* **1991**, *266*, 22549–22556. [CrossRef]
173. Campos-Ramírez, A.; Márquez, M.; Quintanar, L.; Rojas-Ochoa, L.F. Effect of ionic strength on the aggregation kinetics of the amidated amyloid beta peptide Aβ (1-40) in aqueous solutions. *Biophys. Chem.* **2017**, *228*, 98–107. [CrossRef]
174. Keyes, E.D.; Kauser, K.; Warner, K.S.; Roberts, A.G. Photosensitized Oxidative Dimerization at Tyrosine by a Water-Soluble 4-Amino-1, 8-naphthalimide. *Chembiochem* **2021**, *22*, 2703–2710. [CrossRef] [PubMed]
175. Lentzen, G.; Schwarz, T. Extremolytes: Natural compounds from extremophiles for versatile applications. *Appl. Microbiol. Biotechnol.* **2006**, *72*, 623–634. [CrossRef] [PubMed]
176. Galinski, E.A.; Stein, M.; Amendt, B.; Kinder, M. The Kosmotropic (Structure-Forming) Effect of Compensatory Solutes. *Comp. Biochem. Physiol. Part A Physiol.* **1997**, *117*, 357–365. [CrossRef]
177. Bolen, D.W.; Rose, G.D. Structure and Energetics of the Hydrogen-Bonded Backbone in Protein Folding. *Annu. Rev. Biochem.* **2008**, *77*, 339–362. [CrossRef]
178. Avanti, C.; Saluja, V.; Van Streun, E.L.P.; Frijlink, H.W.; Hinrichs, W. Stability of Lysozyme in Aqueous Extremolyte Solutions during Heat Shock and Accelerated Thermal Conditions. *PLoS ONE* **2014**, *9*, e86244. [CrossRef]
179. Panuszko, A.; Bruździak, P.; Kaczkowska, E.; Stangret, J. General Mechanism of Osmolytes' Influence on Protein Stability Irrespective of the Type of Osmolyte Cosolvent. *J. Phys. Chem. B* **2016**, *120*, 11159–11169. [CrossRef]

180. Maclagan, R.G.A.R.; Malardier-Jugroot, C.; Whitehead, M.A.; Lever, M. Theoretical Studies of the Interaction of Water with Compensatory and Noncompensatory Solutes for Proteins. *J. Phys. Chem. A* **2004**, *108*, 2514–2519. [CrossRef]
181. Kuhlmann, A.U.; Hoffmann, T.; Bursy, J.; Jebbar, M.; Bremer, E. Ectoine and hydroxyectoine as protectants against osmotic and cold stress: Uptake through the SigB-controlled betaine-choline-carnitine transporter-type carrier EctT from Virgibacillus pan-tothenticus. *J. Bacteriol.* **2011**, *193*, 4699–4708. [CrossRef]
182. Hédoux, A.; Paccou, L.; Guinet, Y. Relationship between β-relaxation and structural stability of lysozyme: Microscopic insight on thermostabilization mechanism by trehalose from Raman spectroscopy experiments. *J. Chem. Phys.* **2014**, *140*, 225102. [CrossRef]
183. Adamczak, B.; Kogut, M.; Czub, J. Effect of osmolytes on the thermal stability of proteins: Replica exchange simulations of Trp-cage in urea and betaine solutions. *Phys. Chem.* **2018**, *20*, 11174–11182. [CrossRef]
184. Pais, T.M.; Lamosa, P.; Matzapetakis, M.; Turner, D.L.; Santos, H. Mannosylglycerate stabilizes staphylococcal nuclease with restriction of slow β-sheet motions. *Protein Sci.* **2012**, *21*, 1126–1137. [CrossRef]
185. Ryu, J.; Kanapathipillai, M.; Lentzen, G.; Park, C.B. Inhibition of β-amyloid peptide aggregation and neurotoxicity by α-d-mannosylglycerate, a natural extremolyte. *Peptides* **2008**, *29*, 578–584. [CrossRef]
186. Ji, J.A.; Zhang, B.; Cheng, W.; Wang, Y.J. Methionine, tryptophan, and histidine oxidation in a model protein, PTH: Mechanisms and stabilization. *J. Pharm. Sci.* **2009**, *98*, 4485–4500. [CrossRef]
187. Drayton, M.; Alford, M.A.; Pletzer, D.; Haney, E.F.; Machado, Y.; Luo, H.D.; Overall, C.M.; Kizhakkedathu, J.N.; Hancock, R.E.; Straus, S.K. Enzymatically releasable polyethylene glycol—Host defense peptide conjugates with improved activity and biocompatibility. *J. Control. Release* **2021**, *339*, 220–231. [CrossRef]
188. Harrison, E.; Nicol, J.R.; Macias–Montero, M.; Burke, G.A.; Coulter, J.A.; Meenan, B.J.; Dixon, D. A comparison of gold nanoparticle surface co-functionalization approaches using Polyethylene Glycol (PEG) and the effect on stability, non-specific protein adsorption and internalization. *Mater. Sci. Eng. C* **2016**, *62*, 710–718. [CrossRef] [PubMed]
189. Arakawa, T.; Prestrelski, S.J.; Kenney, W.C.; Carpenter, J.F. Factors affecting short-term and long-term stabilities of proteins. *Adv. Drug Deliv. Rev.* **2001**, *46*, 307–326. [CrossRef] [PubMed]
190. Matsuoka, T.; Tomita, S.; Hamada, H.; Shiraki, K. Amidated amino acids are prominent additives for preventing heat-induced aggregation of lysozyme. *J. Biosci. Bioeng.* **2007**, *103*, 440–443. [CrossRef] [PubMed]
191. Quinn, R.; Andrade, J. Minimizing the Aggregation of Neutral Insulin Solutions. *J. Pharm. Sci.* **1983**, *72*, 1472–1473. [CrossRef]
192. Chou, D.K.; Krishnamurthy, R.; Randolph, T.W.; Carpenter, J.F.; Manning, M.C. Effects of Tween 20®and Tween 80®on the Stability of Albutropin During Agitation. *J. Pharm. Sci.* **2005**, *94*, 1368–1381. [CrossRef]
193. Lahlou, A.; Blanchet, B.; Carvalho, M.; Paul, M.; Astier, A. Mechanically-induced aggregation of the monoclonal antibody cetuximab. *Ann. Pharm. Fr.* **2009**, *67*, 340–352. [CrossRef]
194. Foster, T.; Dormish, J.J.; Narahari, U.; Meyer, J.D.; Vrkljan, M.; Henkin, J.; Porter, M.; Staack, H.; Carpenter, J.; Manning, M. Thermal stability of low molecular weight urokinase during heat treatment. III. Effect of salts, sugars and Tween 80. *Int. J. Pharm.* **1996**, *134*, 193–201. [CrossRef]
195. Vrkljan, M.; Foster, T.M.; Powers, M.E.; Henkin, J.; Porter, W.R.; Staack, H.; Carpenter, J.F.; Manning, M.C. Thermal Stability of Low Molecular Weight Urokinase During Heat Treatment. II. Effect of Polymeric Additives. *Pharm. Res.* **1994**, *11*, 1004–1008. [CrossRef]
196. Ristroph, K.D.; Prud'Homme, R.K. Hydrophobic ion pairing: Encapsulating small molecules, peptides, and proteins into nanocarriers. *Nanoscale Adv.* **2019**, *1*, 4207–4237. [CrossRef] [PubMed]
197. Sikora, K.; Jaśkiewicz, M.; Neubauer, D.; Migoń, D.; Kamysz, W. The Role of Counter-Ions in Peptides—An Overview. *Pharmaceuticals* **2020**, *13*, 442. [CrossRef] [PubMed]
198. Al Musaimi, O.; Lombardi, L.; Williams, D.R.; Albericio, F. Strategies for Improving Peptide Stability and Delivery. *Pharmaceuticals* **2022**, *15*, 1283. [CrossRef]
199. Ismail, R.; Phan, T.N.Q.; Laffleur, F.; Csóka, I.; Bernkop-Schnürch, A. Hydrophobic ion pairing of a GLP-1 analogue for incorporating into lipid nanocarriers designed for oral delivery. *Eur. J. Pharm. Biopharm.* **2020**, *152*, 10–17. [CrossRef]
200. Vaishya, R.D.; Mandal, A.; Gokulgandhi, M.; Patel, S.; Mitra, A.K. Reversible hydrophobic ion-paring complex strategy to minimize acylation of octreotide during long-term delivery from PLGA microparticles. *Int. J. Pharm.* **2015**, *489*, 237–245. [CrossRef]
201. Jörgensen, A.M.; Knoll, P.; Haddadzadegan, S.; Fabian, H.; Hupfauf, A.; Gust, R.; Jörgensen, R.G.; Bernkop-Schnürch, A. Biodegradable arginine based steroid-surfactants: Cationic green agents for hydrophobic ion-pairing. *Int. J. Pharm.* **2023**, *630*, 122438. [CrossRef]

pharmaceutics

Editorial Board

- Nanomedicine and Nanotechnology Section
- Pharmaceutical Technology, Manufacturing and Devices Section
- Physical Pharmacy and Formulation Section
- Biopharmaceutics Section
- Drug Delivery and Controlled Release Section
- Pharmacokinetics and Pharmacodynamics Section
- Gene and Cell Therapy Section
- Drug Targeting and Design Section
- Biologics and Biosimilars Section
- Clinical Pharmaceutics Section

Please note that the order in which the Editors appear on this page is alphabetical, and follows the structure of the editorial board presented on the MDPI website under information for editors: editorial board responsibilities.

Members

Search by first name, last name, affiliation, interest...

Prof. Dr. Patrick J. Sinko Website
Editor-in-Chief
Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854, USA
Interests: drug delivery; nanotechnology; biopharmaceutics; pharmacokinetics; absorption; permeability; AIDS; cancer
Special Issues, Collections and Topics in MDPI Journals

Prof. Dr. Donatella Paolino Website
Section Editor-in-Chief
Department of Experimental and Clinical Medicine, University Magna Graecia of Catanzaro, 88100 Catanzaro, Italy
Interests: nanomedicine; drug delivery; gene therapy; pharmaceutics; pharmaceutical education; topical delivery
Special Issues, Collections and Topics in MDPI Journals

Prof. Dr. Beom Soo Shin Website
Section Editor-in-Chief
School of Pharmacy, Sungkyunkwan University, Suwon, Gyeonggi-do 16419, Korea
Interests: pharmacokinetics; translational PKPD modeling; PBPK modeling; in vitro–in vivo correlation; pharmaceutical analysis; 3D printing
Special Issues, Collections and Topics in MDPI Journals

Prof. Dr. Thierry Vandamme Website
Section Editor-in-Chief
Laboratory for the Conception and Application of Bioactive Molecules, Faculty of Pharmacy, University of Strasbourg, 67400 Illkirch-Graffenstaden, France
Interests: microencapsulation; nanoemulsions; biopharmacy; formulation; pharmaceutical engineering
Special Issues, Collections and Topics in MDPI Journals

Prof. Dr. Ruggero Bettini Website
Associate Editor
Food and Drug Department, University of Parma, Parco Area delle Scienze 27/A, 43124 Parma, Italy
Interests: supercritial fluids; solid state chemistry; particle and crystal engineering; oral delivery; polymeric scaffolds; powders for transmucosal and pulmonary drug delivery; industrial pharmacy

Prof. Dr. Afzal R. Mohammed Website
Associate Editor
Aston Pharmacy School, School of Life and Health Sciences, Aston University, Aston Triangle, Birmingham B4 7ET, UK
Interests: freeze drying; fast disintegrating tablets; reformulation of medicines; microarray
Special Issues, Collections and Topics in MDPI Journals

Prof. Dr. Yvonne Perrie Website
Advisory Board Member
Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4 0RE, UK
Interests: particulate systems and formulations for drug delivery; vaccine adjuvanticity and diagnostics
Special Issues, Collections and Topics in MDPI journals

Dr. Remigius U. Agu Website
Editorial Board Member
Biopharmaceutics and Drug Delivery Laboratory, Dalhousie University, Halifax, NS, Canada
Interests: respiratory/nasal; transporters; toxicity screening; drug delivery
Special Issues, Collections and Topics in MDPI journals

Prof. Dr. Zeeshan Ahmad Website
Editorial Board Member
Leicester School of Pharmacy, De Montfort University, The Gateway, Leicester LE1 9BH, UK
Interests: nanotechnology; pharmaceutical engineering; fibers; nanoparticles; manufacturing; biomaterials; dosage forms
Special Issues, Collections and Topics in MDPI journals

Prof. Dr. Raid Alany Website1 Website2
Editorial Board Member
1. Faculty of Science, Engineering and Computing, Kingston University London; Penrhyn Road, Kingston upon Thames, London KT1 2EE, UK
2. Faculty of Medical and Health Sciences, The University of Auckland, Auckland CBD, Auckland 1010, New Zealand
Interests: ophthalmic drugs and delivery systems; veterinary pharmaceuticals
Special Issues, Collections and Topics in MDPI journals

Prof. Dr. Göran Alderborn Website
Editorial Board Member
Department of Pharmaceutical Biosciences, Uppsala University, 752 36 Uppsala, Sweden
Interests: formulation of tablets; formulation of inhalation powders; particle preparation and characterization; powder processing and characterization; stability of solid systems

Prof. Dr. António J. Almeida Website
Editorial Board Member
Faculdade de Farmácia, Universidade de Lisboa, 1649-004 Lisboa, Portugal
Interests: drug delivery; microparticles; nanoparticles; mucosal delivery; mucosal vaccines

Dr. David Andes ★ Website
Editorial Board Member
Department of Medicine and Medical Microbiology and Immunology, Head Division of Infectious Diseases, University of Wisconsin, 1685 Highland Ave, Madison, WI 53705-2281, USA
Interests: antimicrobial pharmacokinetics and pharmacodynamics; antimicrobial drug development; antimicrobial resistance

Prof. Dr. Anna Angela Barba Website
Editorial Board Member
Department of Pharmacy, University of Salerno, via Giovanni Paolo II, 132 , 84084 Fisciano, SA, Italy
Interests: drug delivery systems; sustainable process; process intensification; liposomes production; hydrogels
Special Issues, Collections and Topics in MDPI journals

Prof. Dr. Sophia G. Antimisiaris Website
Editorial Board Member
1. Laboratory of Pharmaceutical Technology, Department of Pharmacy, University of Patras, 26510 Rio-Patras, Greece
2. Institute for Chemical Engineering Sciences, Foundation for Research and Technology Hellas, FORTH/ICE-HT, Stadiou Street, 26504 Platani-Rio, Greece
Interests: targeted drug delivery; nanomedicines; liposome technology; lipid-based formulations
Special Issues, Collections and Topics in MDPI journals

Prof. Dr. Jessie Lai Sim Au
Editorial Board Member
Department of Pharmaceutical Sciences, College of Pharmacy, The University of Oklahoma Health Sciences Center, Oklahoma City OK 73117, USA
Interests: cancer treatments; Quantitative Systems Pharmacology; clinical drug development

Prof. Dr. Ildiko Badea Website
Editorial Board Member
College of Pharmacy and Nutrition, University of Saskatchewan, 107 Wiggins Road, Health Sciences Building, Room 3D01.5, Box 3D01-13, Saskatoon, SK S7N 5E5, Canada
Interests: nucleic acid delivery; nanodiamonds; cationic gemini lipids; self-assembling nanoparticles; small angle X-ray scattering; flow cytometry; radiopharmaceuticals
Special Issues, Collections and Topics in MDPI journals

Prof. Dr. Juan J. Badimon Website
Editorial Board Member
AtheroThrombosis Research Unit, Cardiovascular Institute, Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, NY 10029, USA
Interests: thrombosis platelet; antiplatelets and anticoagulants; cardiovascular disease; lipid and lipid-lowering agents; diabetes; SGLT2-inhibitors

Prof. Dr. Udo Bakowsky Website
Editorial Board Member
Department of Pharmaceutics and Biopharmaceutics, University of Marburg, Robert-Koch-Str. 4, 35037 Marburg, Germany
Interests: nanoscale drug delivery systems; photodynamic therapy; liposomes; gene therapy
Special Issues, Collections and Topics in MDPI journals

Prof. Dr. Ajay K. Banga Website
Editorial Board Member
Center for Drug Delivery and Research, Department of Pharmaceutical Sciences, College of Pharmacy, Mercer University, Atlanta, GA 30341, USA
Interests: transdermal delivery; topical delivery; iontophoresis; sonophoresis; laser assisted percutaneous delivery; microdermabrasion; microneedles

Prof. Dr. Arvind K. Bansal Website
Editorial Board Member
Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Sector 67, SAS Nagar (Mohali), Punjab 160 062, India
Interests: pre-formulation profiling; solid state characterization; polymorphism; amorphous systems; particle engineering; nano-crystalline dispersions; enhancement of oral bioavailability
Special Issues, Collections and Topics in MDPI journals

Dr. David Barlow Website
Editorial Board Member
Honorary Reader, Division of Pharmacy & Optometry, University of Manchester, Stopford Building, Oxford Road, Manchester M13 9PT, UK
Interests: molecular modelling; machine learning; cheminformatics; bioinformatics; medical informatics; protein & peptide therapeutics; structural studies of drug & gene delivery systems and their interactions with biological membranes

Prof. Dr. Antonello A. Barresi Website
Editorial Board Member
Coordinator of Pharmaceutical Technology lab, Department of Applied Science and Technology, Politecnico di Torino, 24 Corso Duca degli Abruzzi, 10129 Torino, Italy
Interests: freeze-drying; process monitoring; drug release; nanocarriers
Special Issues, Collections and Topics in MDPI journals

Prof. Dr. Abdul W. Basit Website
Editorial Board Member
Department of Pharmaceutics, UCL School of Pharmacy, University College London, 29/39 Brunswick Square, London WC1N 1AX, UK
Interests: biopharmaceutics; physiology of the gastrointestinal tract; formulation and modified release; oral drug delivery; colonic targeting; drug metabolism; drug absorption; gamma scintigraphy
Special Issues, Collections and Topics in MDPI journals

Dr. Elena V. Batrakova Website
Editorial Board Member
Center for Nanotechnology in Drug Delivery, Division of Pharmacoengineering & Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, MARSICO HALL, 125 Mason Farm Road, Chapel Hill, NC 27599-7362, USA
Interests: cell-mediated and exosome-mediated drug delivery systems; neurodegenerative disorders; Parkinson's disease; Lysosomal storage disorders, Batten disease

Prof. Dr. Luigi Battaglia Website
Editorial Board Member
Dipartimento di Scienza e Tecnologia del Farmaco, Università degli Studi di Torino, via Pietro Giuria 9, 10125 Torino, Italy
Interests: solid lipid nanoparticles (SLN); nanoemulsions; protein nano delivery systems

Prof. Dr. Richard A. Beers Website
Editorial Board Member
Department of Anesthesiology, SUNY Upstate Medical University, 750 East Adams Street, Syracuse, NY 13210, USA
Interests: anesthetics (inhaled and intravenous); opioids; anti-emetics; neuromuscular blocking agents; sympathomimetics; sympatholytics; parasympatholytics; cholinesterase inhibitors

Prof. Dr. Francine Behar-Cohen Website
Editorial Board Member
1. Eyevensys, 11 Rue Watt, 75013 Paris, France
2. Centre de Recherche des Cordeliers, INSERM, Université de Paris Cité, Sorbonne Université, From Physiopathology of Ocular Diseases to Clinical Development, 75006 Paris, France
3. Cochin Hospital, AP-HP, Assistance Publique Hôpitaux de Paris, 24 rue du Faubourg Saint Jacques, 75014 Paris, France
Interests: neuroprotection; diabetic retinopathy; retinal ischemia; glia; drug development
Special Issues, Collections and Topics in MDPI journals

Prof. Dr. Heather Benson Website
Editorial Board Member
School of Pharmacy and Biomedical Sciences, Curtin Health Innovation Research Institute, Curtin University, GPO Box U 1987, Perth, Western Australia 6845, Australia
Interests: topical and transdermal drug delivery; penetration enhancement; nanotechnology; skin permeation mechanisms
Special Issues, Collections and Topics in MDPI journals

Prof. Dr. Marival Bermejo Website
Editorial Board Member
Department Engineering Pharmacy Section, Miguel Hernandez University, San Juan de Alicante, 03550 Alicante, Spain
Interests: oral absorption; intestinal permeability methods; in vitro-in vivo correlations; PK modelling
Special Issues, Collections and Topics in MDPI journals

Pharmaceutics, Volume 15, Issue 3 (March 2023) – 316 articles

Cover Story (view full-size image (/files/uploaded/covers/pharmaceutics/big_cover-pharmaceutics-v15-i3.png)): The delivery of many drugs to the brain is limited by the blood–brain barrier (BBB). Nanoparticle (NP) technologies may be developed to provide targeted drug delivery with controlled release. Polymeric and lipid-based NPs have emerged as versatile and biocompatible materials that provide requisite protection for drugs and improve drug entry to the brain at the BBB. Intranasal drug delivery has been found to bypass the BBB. The details of the pharmacokinetic and pharmacodynamics of drugs associated with drug delivery via intranasal drug-loaded polymeric and lipid-based NPs are emerging from preclinical studies. A combinatory approach of nose-to-brain administration and drug-loaded polymeric and lipid-based NPs is a promising strategy for enhancing drug targeting to the brain.
View this paper (https://www.mdpi.com/1999-4923/15/3/746)

(https://www.mdpi.com/1999-4923/15/3/746)

Issues are regarded as officially published after their release is announced to the table of contents alert mailing list (/journal/pharmaceutics/toc-alert).

You may sign up for e-mail alerts (/journal/pharmaceutics/toc-alert) to receive table of contents of newly released issues.

- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader (http://www.adobe.com/) to open them.

Order results

Open Access Article (/1999-4923/15/3/1030/pdf?version=1679560575)

Block Copolymer Micelles Encapsulating Au(III) Bis(Dithiolene) Complexes as Promising Nanostructures with Antiplasmodial Activity (/1999-4923/15/3/1030)

by Joana F. Santos (https://sciprofiles.com/profile/2732388),
Raquel Azevedo (https://sciprofiles.com/profile/author/ZGtNMVVLZ1FxbEZZalVibE1EeUdyd3NSYjhCM3ZYL01YSTBjZU14SzFXQnRFbGhWNmRHN2hENDRsZEtRb0l1ZA==),
Miguel Prudêncio (https://sciprofiles.com/profile/786707), Fernanda Marques (https://sciprofiles.com/profile/880380),
Yann Le Gal (https://sciprofiles.com/profile/author/ekU3dU5LaVprWDVoeHR5cHBobGlrdlpoT1M5cExlb3lhNEpnOHBaL28xMD0=),
Dominique Lorcy (https://sciprofiles.com/profile/414773) and Célia Fernandes (https://sciprofiles.com/profile/1390134)
Pharmaceutics **2023**, *15*(3), 1030; https://doi.org/10.3390/pharmaceutics15031030 (https://doi.org/10.3390/pharmaceutics15031030) - 22 Mar 2023
Viewed by 935

Abstract Block copolymer micelles (BCMs) can be used to improve the solubility of lipophilic drugs and increase their circulation half-life. Hence, BCMs assembled from MePEG-*b*-PCL were evaluated as drug delivery systems of gold(III) bis(dithiolene) complexes (herein AuS and AuSe) to be employed **[...] Read more.**
(This article belongs to the Special Issue **Functional Polymers for Drug and Gene Delivery (/journal/pharmaceutics/special_issues/M1T86VV637)**)

► Show Figures


(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01030/article_deploy/html/images/pharmaceutics-15-01030-ag-550.jpg?1679560652) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01030/article_deploy/html/images/pharmaceutics-15-01030-g001-550.jpg?1679560652) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01030/article_deploy/html/images/pharmaceutics-15-01030-g002-550.jpg?1679560651) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01030/article_deploy/html/images/pharmaceutics-15-01030-g003-550.jpg?1679560641) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01030/article_deploy/html/images/pharmaceutics-15-01030-g004-550.jpg?1679560643) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01030/article_deploy/html/images/pharmaceutics-15-01030-g005-550.jpg?1679560647) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01030/article_deploy/html/images/pharmaceutics-15-01030-g006-550.jpg?1679560642) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01030/article_deploy/html/images/pharmaceutics-15-01030-g007-550.jpg?1679560649) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01030/article_deploy/html/images/pharmaceutics-15-01030-g008-550.jpg?1679560645)

Open Access Review (/1999-4923/15/3/1029/pdf?version=1679499042)

Apelin Is a Prototype of Novel Drugs for the Treatment of Acute Myocardial Infarction and Adverse Myocardial Remodeling (/1999-4923/15/3/1029)

by Sergey V. Popov (https://sciprofiles.com/profile/2743842), Leonid N. Maslov (https://sciprofiles.com/profile/2452761),
Alexandr V. Mukhomedzyanov (https://sciprofiles.com/profile/2924683), Boris K. Kurbatov (https://sciprofiles.com/profile/2356045),
Alexandr S. Gorbunov (https://sciprofiles.com/profile/author/Uk9RNTYwVTJ2MlJVL0p3bHBWNjg5dkVQOWE2b3dyankwMW5KVkZrNWdpMD0=),
Michail Kilin (https://sciprofiles.com/profile/author/bU1vVW03TjhNUXdkQmtxeHVsZVc5MnlaVUpPdElCSmhoaUdnczJvQlgwMD0=),
Viacheslav N. Azev (https://sciprofiles.com/profile/1776021),
Maria S. Khlestkina (https://sciprofiles.com/profile/author/VW00SVQ1TllvOUM3aEZCNVFvdHZ5emlDdlM2SURHTklxd3dZaW1rWHNQbz0=) and
Galina Z. Sufianova (https://sciprofiles.com/profile/author/aEl4R3JoMkxOVU5lM2FiMkRFak5DYWZuVXlpa3hvUjZzL0h5S0dlQ2JUYz0=)
Pharmaceutics **2023**, *15*(3), 1029; https://doi.org/10.3390/pharmaceutics15031029 (https://doi.org/10.3390/pharmaceutics15031029) - 22 Mar 2023
Cited by 1 (/1999-4923/15/3/1029#metrics) | Viewed by 1173

Abstract In-hospital mortality in patients with ST-segment elevation myocardial infarction (STEMI) is 5–6%. Consequently, it is necessary to develop fundamentally novel drugs capable of reducing mortality in patients with acute myocardial infarction. Apelins could be the prototype for such drugs. Chronic administration of apelins **[...] Read more.**
(This article belongs to the Section **Biologics and Biosimilars (/journal/pharmaceutics/sections/Biologics_Biosimilars)**)

► Show Figures


(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01029/article_deploy/html/images/pharmaceutics-15-01029-g001-550.jpg?1679499109) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01029/article_deploy/html/images/pharmaceutics-15-01029-g002-550.jpg?1679499110) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01029/article_deploy/html/images/pharmaceutics-15-01029-g003-550.jpg?1679499111)

Open Access Article (/1999-4923/15/3/1028/pdf?version=1679913100)

Antiviral Mechanisms of *N*-Phenyl Benzamides on Coxsackie Virus A9 (/1999-4923/15/3/1028)

by Mira Laajala (https://sciprofiles.com/profile/812006),
Kerttu Kalander (https://sciprofiles.com/profile/author/NzBLYm1VL0x2NkU4c1E2R2lvTlM3MG5DcEFSeHVHa3Yxa0hQVDN1UTBaST0=),
Sara Consalvi (https://sciprofiles.com/profile/833487), Olivier Sheik Amamuddy (https://sciprofiles.com/profile/948056),
Özlem Tastan Bishop (https://sciprofiles.com/profile/560256), Mariangela Biava (https://sciprofiles.com/profile/1863788),
Giovanna Poce (https://sciprofiles.com/profile/1033938) and Varpu Marjomäki (https://sciprofiles.com/profile/137891)
Pharmaceutics **2023**, *15*(3), 1028; https://doi.org/10.3390/pharmaceutics15031028 (https://doi.org/10.3390/pharmaceutics15031028) - 22 Mar 2023
Cited by 1 (/1999-4923/15/3/1028#metrics) | Viewed by 1033

Abstract Enteroviruses are one of the most abundant groups of viruses infecting humans, and yet there are no approved antivirals against them. To find effective antiviral compounds against enterovirus B group viruses, an in-house chemical library was screened. The most effective compounds against Coxsackieviruses **[...] Read more.**
(This article belongs to the Special Issue **Recent Advances in Antiviral Drug Development (/journal/pharmaceutics/special_issues/Antiviral)**)

► Show Figures


(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01028/article_deploy/html/images/pharmaceutics-15-01028-g001-550.jpg?1679913204) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01028/article_deploy/html/images/pharmaceutics-15-01028-g002-550.jpg?1679913208) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01028/article_deploy/html/images/pharmaceutics-15-01028-g003-550.jpg?1679913205) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01028/article_deploy/html/images/pharmaceutics-15-01028-g004-550.jpg?1679913197) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01028/article_deploy/html/images/pharmaceutics-15-01028-g005-550.jpg?1679913189) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01028/article_deploy/html/images/pharmaceutics-15-01028-g006-550.jpg?1679913187) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01028/article_deploy/html/images/pharmaceutics-15-01028-g007-550.jpg?1679913213) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01028/article_deploy/html/images/pharmaceutics-15-01028-g008-550.jpg?1679913203) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01028/article_deploy/html/images/pharmaceutics-15-01028-g009-550.jpg?1679913194) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01028/article_deploy/html/images/pharmaceutics-15-01028-g010-550.jpg?1679913195)

Open Access Article (/1999-4923/15/3/1027/pdf?version=1679490513)

Development and Characterization of Pullulan-Based Orodispersible Films of Iron (/1999-4923/15/3/1027)

by Maram Suresh Gupta (https://sciprofiles.com/profile/1143595),
Tegginamath Pramod Kumar (https://sciprofiles.com/profile/author/L09nT3plQTBPaHB0QkpKUlpjc2FnQzREME5vVmRZc2VPZi9DRVJNaDhuND0=),
Dinesh Reddy (https://sciprofiles.com/profile/author/ZGNrRzJ4bmVDZ0tjamMrM0tLRzlwVkFsWFovbm5VQkhJLzhYQ3NUZkt6az0=),
Kamla Pathak (https://sciprofiles.com/profile/1357811),
Devegowda Vishakante Gowda (https://sciprofiles.com/profile/author/QlBGUVdNZ1A4Y2JKNFZacDF1d0cvSnVTTUN0bVRnWXQ2MU5BS0NEbk1Edz0=),
A. V. Naresh Babu (https://sciprofiles.com/profile/author/aFJMdGNHQUFJWmdDRGtjeEo4c3RJbktHVkJKZHFxQVdnay9ucXJxMzRxaz0=),
Alhussain H. Aodah (https://sciprofiles.com/profile/1076995), El-Sayed Khafagy (https://sciprofiles.com/profile/884380),
Hadil Faris Alotaibi (https://sciprofiles.com/profile/2084240), Amr Selim Abu Lila (https://sciprofiles.com/profile/1226898),
Afrasim Moin (https://sciprofiles.com/profile/1240871) and Talib Hussin (https://sciprofiles.com/profile/1504170)
Pharmaceutics **2023**, *15*(3), 1027; https://doi.org/10.3390/pharmaceutics15031027 (https://doi.org/10.3390/pharmaceutics15031027) - 22 Mar 2023
Viewed by 1378

Abstract Iron deficiency is the principal cause of nutritional anemia and it constitutes a major health problem, especially during pregnancy. Despite the availability of various non-invasive traditional oral dosage forms such as tablets, capsules, and liquid preparations of iron, they are hard to consume **[...] Read more.**
(This article belongs to the Special Issue **Dosage Form Design for Oral Drug Delivery (/journal/pharmaceutics/special_issues/6T545O9NTQ)**)

► Show Figures


(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01027/article_deploy/html/images/pharmaceutics-15-01027-g001-550.jpg?1679490584) (https://pub.mdpi-

res.com/pharmaceutics/pharmaceutics-15-01027/article_deploy/html/images/pharmaceutics-15-01027-g002-550.jpg?1679490581) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01027/article_deploy/html/images/pharmaceutics-15-01027-g003-550.jpg?1679490589) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01027/article_deploy/html/images/pharmaceutics-15-01027-g004-550.jpg?1679490585) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01027/article_deploy/html/images/pharmaceutics-15-01027-g005-550.jpg?1679490576) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01027/article_deploy/html/images/pharmaceutics-15-01027-g006-550.jpg?1679490579) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01027/article_deploy/html/images/pharmaceutics-15-01027-g007-550.jpg?1679490587)

Open Access Article (/1999-4923/15/3/1026/pdf?version=1679492897)

Caveolin-Mediated Internalization of Fmoc-FF Nanogels in Breast Cancer Cell Lines (/1999-4923/15/3/1026)

by Giovanni Smaldone (https://sciprofiles.com/profile/766124), Elisabetta Rosa (https://sciprofiles.com/profile/2909876), Enrico Gallo (https://sciprofiles.com/profile/1165795), Carlo Diaferia (https://sciprofiles.com/profile/681061), Giancarlo Morelli (https://sciprofiles.com/profile/1176399), Mariano Stornaiuolo (https://sciprofiles.com/profile/323619) and Antonella Accardo (https://sciprofiles.com/profile/917598)

Pharmaceutics **2023**, *15*(3), 1026; https://doi.org/10.3390/pharmaceutics15031026 (https://doi.org/10.3390/pharmaceutics15031026) - 22 Mar 2023

Viewed by 948

Abstract Introduction: Hydrogel nanoparticles, also known as nanogels (NGs), have been recently proposed as alternative supramolecular vehicles for the delivery of biologically relevant molecules like anticancer drugs and contrast agents. The inner compartment of peptide based NGs can be opportunely modified according to the **[...] Read more.**

(This article belongs to the Special Issue **Nanotechnology-Based Drug Delivery Systems (/journal/pharmaceutics/special_issues/nano_drug_deliv)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01026/article_deploy/html/images/pharmaceutics-15-01026-ag-550.jpg?1679915549) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01026/article_deploy/html/images/pharmaceutics-15-01026-g001-550.jpg?1679492974) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01026/article_deploy/html/images/pharmaceutics-15-01026-g002-550.jpg?1679492968) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01026/article_deploy/html/images/pharmaceutics-15-01026-g003-550.jpg?1679492970) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01026/article_deploy/html/images/pharmaceutics-15-01026-g004-550.jpg?1679492972) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01026/article_deploy/html/images/pharmaceutics-15-01026-g005-550.jpg?1679492976) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01026/article_deploy/html/images/pharmaceutics-15-01026-g006-550.jpg?1679492966) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01026/article_deploy/html/images/pharmaceutics-15-01026-g007-550.jpg?1679492975)

Open Access Review (/1999-4923/15/3/1025/pdf?version=1679534381)

Nanotechnology in Cancer Diagnosis and Treatment (/1999-4923/15/3/1025)

by Noor Alrushaid (https://sciprofiles.com/profile/author/eFlkcXhqU1VBcTVlUFU4djFVUVNwMStaR2l5QytJMklocU1GTXZCQTRjUT0=), Firdos Alam Khan (https://sciprofiles.com/profile/396849), Ebtesam Abdullah Al-Suhaimi (https://sciprofiles.com/profile/313500) and Abdelhamid Elaissari (https://sciprofiles.com/profile/139943)

Pharmaceutics **2023**, *15*(3), 1025; https://doi.org/10.3390/pharmaceutics15031025 (https://doi.org/10.3390/pharmaceutics15031025) - 22 Mar 2023

Cited by 3 (/1999-4923/15/3/1025#metrics) | Viewed by 4489

Abstract Traditional cancer diagnosis has been aided by the application of nanoparticles (NPs), which have made the process easier and faster. NPs possess exceptional properties such as a larger surface area, higher volume proportion, and better targeting capabilities. Additionally, their low toxic effect on **[...] Read more.**

(This article belongs to the Special Issue **Study of Nanoparticles for Photodynamic Therapy and Imaging (/journal/pharmaceutics/special_issues/nanoparticles_PDT)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01025/article_deploy/html/images/pharmaceutics-15-01025-g001-550.jpg?1679534462) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01025/article_deploy/html/images/pharmaceutics-15-01025-g002-550.jpg?1679534464) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01025/article_deploy/html/images/pharmaceutics-15-01025-g003-550.jpg?1679534470) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01025/article_deploy/html/images/pharmaceutics-15-01025-g004-550.jpg?1679534463) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01025/article_deploy/html/images/pharmaceutics-15-01025-g005-550.jpg?1679534472) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01025/article_deploy/html/images/pharmaceutics-15-01025-g006-550.jpg?1679534465) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01025/article_deploy/html/images/pharmaceutics-15-01025-g007-550.jpg?1679534468) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01025/article_deploy/html/images/pharmaceutics-15-01025-g008-550.jpg?1679534469)

Open Access Review (/1999-4923/15/3/1024/pdf?version=1679485751)

The Potential Use of Exosomes in Anti-Cancer Effect Induced by Polarized Macrophages (/1999-4923/15/3/1024)

by Chizumi Abe (https://sciprofiles.com/profile/author/ZUdLK1F1L0Jvano3VVlrRk5UMFlHUXo2TnV2cXY1aE1FYytYNEY0Tm04dz0=), Maharshi Bhaswant (https://sciprofiles.com/profile/803963), Teruo Miyazawa (https://sciprofiles.com/profile/1737379) and Taiki Miyazawa (https://sciprofiles.com/profile/1754132)

Pharmaceutics **2023**, *15*(3), 1024; https://doi.org/10.3390/pharmaceutics15031024 (https://doi.org/10.3390/pharmaceutics15031024) - 22 Mar 2023

Cited by 1 (/1999-4923/15/3/1024#metrics) | Viewed by 1268

Abstract The rapid development of aberrant cells outgrowing their normal bounds, which can subsequently infect other body parts and spread to other organs—a process known as metastasis—is one of the significant characteristics of cancer. The main reason why cancer patients die is because of **[...] Read more.**

(This article belongs to the Special Issue **Nanomedicine to Enhance Innate and Adaptive Anticancer Immunity (/journal/pharmaceutics/special_issues/nanomedicine_anticancer_immunity)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01024/article_deploy/html/images/pharmaceutics-15-01024-g001-550.jpg?1679485816) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01024/article_deploy/html/images/pharmaceutics-15-01024-g002-550.jpg?1679485815)

Open Access Article (/1999-4923/15/3/1023/pdf?version=1679483114)

An Enhanced Dissolving Cyclosporin-A Inhalable Powder Efficiently Reduces SARS-CoV-2 Infection In Vitro (/1999-4923/15/3/1023)

by Davide D'Angelo (https://sciprofiles.com/profile/1922389), Eride Quarta (https://sciprofiles.com/profile/2765521), Stefania Glieca (https://sciprofiles.com/profile/2806231), Giada Varacca (https://sciprofiles.com/profile/author/dmpvT1VZT082Q3Awa1hFZk9WbzU5NEMvYm9yRW96MEx5QWl0Q3ZFNUxLTT0=), Lisa Flammini (https://sciprofiles.com/profile/1640777), Simona Bertoni (https://sciprofiles.com/profile/769272), Martina Brandolini (https://sciprofiles.com/profile/1574698), Vittorio Sambri (https://sciprofiles.com/profile/256694), Laura Grumiro (https://sciprofiles.com/profile/1771529), Giulia Gatti (https://sciprofiles.com/profile/author/TENWQVFUK2NOQ0RsdnZwWlBneDZXUlRieVV4NGVjV05DUjg5dlhQUFFzdz0=), Giorgio Dirani (https://sciprofiles.com/profile/author/VXJMUVFWdEx5K1J6ZWREUE93R1FsTEJlZVo3dWtuRitBVjFJaVl1cVl0TT0=), Francesca Taddei (https://sciprofiles.com/profile/1574697), Annalisa Bianchera (https://sciprofiles.com/profile/633552), Fabio Sonvico (https://sciprofiles.com/profile/220869), Ruggero Bettini (https://sciprofiles.com/profile/632604) and Francesca Buttini (https://sciprofiles.com/profile/1068499)

Pharmaceutics **2023**, *15*(3), 1023; https://doi.org/10.3390/pharmaceutics15031023 (https://doi.org/10.3390/pharmaceutics15031023) - 22 Mar 2023

Viewed by 907

Abstract This work illustrates the development of a dry inhalation powder of cyclosporine-A for the prevention of rejection after lung transplantation and for the treatment of COVID-19. The influence of excipients on the spray-dried powder's critical quality attributes was explored. The best-performing powder in **[...] Read more.**

(This article belongs to the Special Issue **Inhaled Treatment of Respiratory Infections (/journal/pharmaceutics/special_issues/inhaled_treatment)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01023/article_deploy/html/images/pharmaceutics-15-01023-g001-550.jpg?1679483202) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01023/article_deploy/html/images/pharmaceutics-15-01023-g002-550.jpg?1679483200) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01023/article_deploy/html/images/pharmaceutics-15-01023-g003-550.jpg?1679483199) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01023/article_deploy/html/images/pharmaceutics-15-01023-g004-550.jpg?1679483197) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01023/article_deploy/html/images/pharmaceutics-15-01023-g005-550.jpg?1679483196) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01023/article_deploy/html/images/pharmaceutics-15-01023-g006-550.jpg?1679483201) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01023/article_deploy/html/images/pharmaceutics-15-01023-g007-550.jpg?1679483204)

Open Access Article (/1999-4923/15/3/1022/pdf?version=1679480341)

MDPI (/) (/toggle_desktop_layout_cookie)

[Does Cytokine-Release Syndrome Induced by CAR T-Cell Treatment Have an Impact on the Pharmacokinetics of Meropenem and Piperacillin/Tazobactam in Patients with Hematological Malignancies? Findings from an Observational Case-Control Study (/1999-4923/15/3/1022)]

by Chun Liu (https://sciprofiles.com/profile/2853336), Pier Giorgio Cojutti (https://sciprofiles.com/profile/1918971),
Maddalena Giannella (https://sciprofiles.com/profile/author/K2Nnb0NYMWJQSkEvQXgwdFdmN3VMUDdHN3JxZGg4Yk03ZmJQZjRDUDV5WT0=),
Marcello Roberto (https://sciprofiles.com/profile/author/UklwUmc5Y0U5Q3F2VlhVWkNuNmdQL3FEZkw5Qk0yNFdMOW5ka0dBWnJlR3kvYldCekhxQzkwcGp2aE5MYXdjQw==)
,
Beatrice Casadei (https://sciprofiles.com/profile/author/a2xQYzdRMUI2NjlSMHlaci9sMHNpVjJYTzFtZ3ZYeTNVUy9XNWhYMXFDZz0=),
Gianluca Cristiano (https://sciprofiles.com/profile/author/NGRKd0ZuTEJnQXJoc3p4amxxVWtJWHcxQ2JITHY0MUtMUmxVRXlUQkcxYz0=),
Cristina Papayannidis (https://sciprofiles.com/profile/1093770),
Nicola Vianelli (https://sciprofiles.com/profile/author/Q0hCUVRDT2lzMmpwckZjcC83VmdGU3JaaUR4YzdnUkZmZkM5V2tLbkFtVT0=),
Pier Luigi Zinzani (https://sciprofiles.com/profile/1350496),
Pierluigi Viale (https://sciprofiles.com/profile/author/V0NCTzhiektodnZtSlRjZ0dXNEF3dkEyV3NpNUNoajdPQ3hCS3hFandhQT0=),
Francesca Bonifazi (https://sciprofiles.com/profile/1486697) and Federico Pea (https://sciprofiles.com/profile/773439)
Pharmaceutics **2023**, *15*(3), 1022; https://doi.org/10.3390/pharmaceutics15031022 (https://doi.org/10.3390/pharmaceutics15031022) - 22 Mar 2023

Abstract Chimeric antigen receptor (CAR) T-cell therapy is a promising approach for some relapse/refractory hematological B-cell malignancies; however, in most patients, cytokine release syndrome (CRS) may occur. CRS is associated with acute kidney injury (AKI) that may affect the pharmacokinetics of some beta-lactams. The [...] Read more.
(This article belongs to the Special Issue Dosing Strategies for Protecting the Vulnerable (/journal/pharmaceutics/special_issues/dosing_model))

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01022/article_deploy/html/images/pharmaceutics-15-01022-g001-550.jpg?1679480406) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01022/article_deploy/html/images/pharmaceutics-15-01022-g002-550.jpg?1679480407) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01022/article_deploy/html/images/pharmaceutics-15-01022-g003-550.jpg?1679480408)

Open Access Article (/1999-4923/15/3/1021/pdf?version=1679566556)

[Design, Synthesis, Characterization, and Evaluation of the Anti-HT-29 Colorectal Cell Line Activity of Novel 8-Oxyquinolinate-Platinum(II)-Loaded Nanostructured Lipid Carriers Targeted with Riboflavin (/1999-4923/15/3/1021)]

by Tugce Boztepe (https://sciprofiles.com/profile/2366062), Sebastián Scioli-Montoto (https://sciprofiles.com/profile/2333084),
Rocio C. Gambaro (https://sciprofiles.com/profile/author/TFdBaGRPcjFIWk1pOUdObTNUUklDU3pucEtXZ2k5R09uZ3ZSUW1UcUJOMD0=),
María Esperanza Ruiz (https://sciprofiles.com/profile/author/NVVRYXlTUTZqd3R6Yy9xaUx6NUpWQ3cwVmZmVEJRS0JaUVJRVXlhNkk2Zz0=),
Silvia Cabrera (https://sciprofiles.com/profile/1941441), José Alemán (https://sciprofiles.com/profile/1068654),
Germán A. Islan (https://sciprofiles.com/profile/author/UVFHZ3l0ZVpURndGRkh0cG9CMkhnQUdnT0Rlbm1kOTVnQXp0YlZYUkdtST0=),
Guillermo R. Castro (https://sciprofiles.com/profile/1396913) and Ignacio E. León (https://sciprofiles.com/profile/1792350)
Pharmaceutics **2023**, *15*(3), 1021; https://doi.org/10.3390/pharmaceutics15031021 (https://doi.org/10.3390/pharmaceutics15031021) - 22 Mar 2023

Abstract Colorectal cancer is occasionally called colon or rectal cancer, depending on where cancer begins to form, and is the second leading cause of cancer death among both men and women. The platinum-based [PtCl(8-O-quinolinate)(dmso)] (8-QO-Pt) compound has demonstrated encouraging anticancer activity. Three different systems [...] Read more.
(This article belongs to the Special Issue Recent Developments of Nanovaccine Candidates on Immunology (/journal/pharmaceutics/special_issues/Nanovaccine_immuno))

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01021/article_deploy/html/images/pharmaceutics-15-01021-g001-550.jpg?1679566630) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01021/article_deploy/html/images/pharmaceutics-15-01021-g002-550.jpg?1679566626) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01021/article_deploy/html/images/pharmaceutics-15-01021-g003-550.jpg?1679566636) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01021/article_deploy/html/images/pharmaceutics-15-01021-g004-550.jpg?1679566631) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01021/article_deploy/html/images/pharmaceutics-15-01021-g005-550.jpg?1679566633) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01021/article_deploy/html/images/pharmaceutics-15-01021-g006-550.jpg?1679566634)

Open Access Article (/1999-4923/15/3/1020/pdf?version=1679551686)

[Differential Preincubation Effects of Nicardipine on OATP1B1- and OATP1B3-Mediated Transport in the Presence and Absence of Protein: Implications in Assessing OATP1B1- and OATP1B3-Mediated Drug–Drug Interactions (/1999-4923/15/3/1020)]

by Ruhul Kayesh (https://sciprofiles.com/profile/author/VDBmY1p5RVlwR05qbURVbnN4QlhJWTF4RWg1MmVqOEU5RUVtdHVWVW4rRT0=),
Vishakha Tambe (https://sciprofiles.com/profile/2704083), Chao Xu (https://sciprofiles.com/profile/1568900) and
Wei Yue (https://sciprofiles.com/profile/364464)
Pharmaceutics **2023**, *15*(3), 1020; https://doi.org/10.3390/pharmaceutics15031020 (https://doi.org/10.3390/pharmaceutics15031020) - 22 Mar 2023

Abstract Impaired transport activity of hepatic OATP1B1 and OATP1B3 due to drug–drug interactions (DDIs) often leads to increased systemic exposure to substrate drugs (e.g., lipid-lowering statins). Since dyslipidemia and hypertension frequently coexist, statins are often concurrently used with antihypertensives, including calcium channel blockers (CCBs). [...] Read more.
(This article belongs to the Special Issue Role of Pharmacokinetics in Drug Development and Evaluation (/journal/pharmaceutics/special_issues/pharm_evalua))

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01020/article_deploy/html/images/pharmaceutics-15-01020-g001-550.jpg?1679551764) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01020/article_deploy/html/images/pharmaceutics-15-01020-g002-550.jpg?1679551766) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01020/article_deploy/html/images/pharmaceutics-15-01020-g003-550.jpg?1679551760)

Open Access Review (/1999-4923/15/3/1019/pdf?version=1679468880)

[Carbon Dots: Opportunities and Challenges in Cancer Therapy (/1999-4923/15/3/1019)]

by Tanima Bhattacharya (https://sciprofiles.com/profile/2770832), Gye Hwa Shin (https://sciprofiles.com/profile/1647467) and
Jun Tae Kim (https://sciprofiles.com/profile/1864736)
Pharmaceutics **2023**, *15*(3), 1019; https://doi.org/10.3390/pharmaceutics15031019 (https://doi.org/10.3390/pharmaceutics15031019) - 22 Mar 2023

Abstract Recently, carbon dots (CDs) have been actively studied and reported for their various properties. In particular, the specific characteristics of carbon dots have been considered as a possible technique for cancer diagnosis and therapy. This is also a cutting-edge technology that offers fresh [...] Read more.
(This article belongs to the Special Issue Multifunctional Nanoparticles for Cancer Therapy and Imaging (/journal/pharmaceutics/special_issues/30Z9ZI9L02))

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01019/article_deploy/html/images/pharmaceutics-15-01019-g001-550.jpg?1679468987) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01019/article_deploy/html/images/pharmaceutics-15-01019-g002-550.jpg?1679468985) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01019/article_deploy/html/images/pharmaceutics-15-01019-g003-550.jpg?1679468989) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01019/article_deploy/html/images/pharmaceutics-15-01019-g004-550.jpg?1679468988)

Open Access Article (/1999-4923/15/3/1018/pdf?version=1679464748)

[Bacterial Lectin FimH and Its Aggregation Hot-Spots: An Alternative Strategy against Uropathogenic *Escherichia coli* (/1999-4923/15/3/1018)]

by Georgia I. Nasi (https://sciprofiles.com/profile/1820890),
Konstantina I. Georgakopoulou (https://sciprofiles.com/profile/author/VFRJTHBvVGpabU04QXd2WnAwMUZxWkR1ZmpzTkRSQzFkdmRiSnlOY3czS2V1eWdHMzZwNEdSVDhES2F2
,
Marilena K. Theodoropoulou (https://sciprofiles.com/profile/author/VHVUOFpsclRhTmdJUkFPdGNNSmFjb0RkZXRMV0VncTA5elBNd0gvSWlRdz0=),
Nikos C. Papandreou (https://sciprofiles.com/profile/1486563), Evangelia D. Chrysina (https://sciprofiles.com/profile/249420),
Paraskevi L. Tsiolaki (https://sciprofiles.com/profile/619695) and Vassiliki A. Iconomidou (https://sciprofiles.com/profile/637650)
Pharmaceutics **2023**, *15*(3), 1018; https://doi.org/10.3390/pharmaceutics15031018 (https://doi.org/10.3390/pharmaceutics15031018) - 22 Mar 2023

Abstract Type I fimbriae are the main adhesive organelles of uropathogenic *Escherichia coli* (UPEC), consisting of four different subunits. Their component with the most important role in establishing bacterial infections is the FimH adhesin located at the fimbrial tip. This two-domain protein mediates adhesion [...] Read more.
(This article belongs to the Section Biologics and Biosimilars (/journal/pharmaceutics/sections/Biologics_Biosimilars))

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01018/article_deploy/html/images/pharmaceutics-15-01018-g001-550.jpg?1679464814) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01018/article_deploy/html/images/pharmaceutics-15-01018-g002-550.jpg?1679464815) (https://pub.mdpi-res.com

Back to TopTop

/pharmaceutics/pharmaceutics-15-01018/article_deploy/html/images/pharmaceutics-15-01018-g003-550.jpg?1679464817) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01018/article_deploy/html/images/pharmaceutics-15-01018-g004-550.jpg?1679464820) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01018/article_deploy/html/images/pharmaceutics-15-01018-g005-550.jpg?1679464818) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01018/article_deploy/html/images/pharmaceutics-15-01018-g006-550.jpg?1679464812)

Open Access Review (/1999-4923/15/3/1017/pdf?version=1679469030)

The Delivery and Activation of Growth Factors Using Nanomaterials for Bone Repair (/1999-4923/15/3/1017)

by Yiwei Li (https://sciprofiles.com/profile/2285507), Chun Xu (https://sciprofiles.com/profile/571896) and Chang Lei (https://sciprofiles.com/profile/1743295)
Pharmaceutics **2023**, *15*(3), 1017; https://doi.org/10.3390/pharmaceutics15031017 (https://doi.org/10.3390/pharmaceutics15031017) - 22 Mar 2023
Cited by 1 (/1999-4923/15/3/1017#metrics) | Viewed by 1456

Abstract Bone regeneration is a comprehensive process that involves different stages, and various growth factors (GFs) play crucial roles in the entire process. GFs are currently widely used in clinical settings to promote bone repair; however, the direct application of GFs is often limited **[...] Read more.**
(This article belongs to the Special Issue **Porous Nanomaterials for Tissue Engineering and Drug Delivery** (/journal/pharmaceutics/special_issues/porous_drug))

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01017/article_deploy/html/images/pharmaceutics-15-01017-g001-550.jpg?1679469105) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01017/article_deploy/html/images/pharmaceutics-15-01017-g002-550.jpg?1679469103) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01017/article_deploy/html/images/pharmaceutics-15-01017-g003-550.jpg?1679469107) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01017/article_deploy/html/images/pharmaceutics-15-01017-g004-550.jpg?1679469105) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01017/article_deploy/html/images/pharmaceutics-15-01017-g005-550.jpg?1679469098) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01017/article_deploy/html/images/pharmaceutics-15-01017-g006-550.jpg?1679469101)

Open Access Article (/1999-4923/15/3/1016/pdf?version=1679458915)

Design and Characterization of a Novel Venetoclax-Zanubrutinib Nano-Combination for Enhancing Leukemic Cell Uptake and Long-Acting Plasma Exposure (/1999-4923/15/3/1016)

by James Griffin (https://sciprofiles.com/profile/2435111), Yan Wu (https://sciprofiles.com/profile/3131562), Qingxin Mu (https://sciprofiles.com/profile/779055), Xinyan Li (https://sciprofiles.com/profile/2848058) and Rodney J. Y. Ho (https://sciprofiles.com/profile/1944386)
Pharmaceutics **2023**, *15*(3), 1016; https://doi.org/10.3390/pharmaceutics15031016 (https://doi.org/10.3390/pharmaceutics15031016) - 22 Mar 2023
Viewed by 1037

Abstract Leukemia remains incurable partly due to difficulties in reaching and maintaining therapeutic drug concentrations in the target tissues and cells. Next-generation drugs targeted to multiple cell checkpoints, including the orally active venetoclax (Bcl-2 target) and zanubrutinib (BTK target), are effective and have improved **[...] Read more.**
(This article belongs to the Special Issue **Polymer Nanoparticles for the Delivery of Anticancer Drugs, 2nd Edition** (/journal/pharmaceutics/special_issues/90SJC9DLBA))

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01016/article_deploy/html/images/pharmaceutics-15-01016-g001-550.jpg?1679458990) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01016/article_deploy/html/images/pharmaceutics-15-01016-g002-550.jpg?1679458988) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01016/article_deploy/html/images/pharmaceutics-15-01016-g003-550.jpg?1679458986)

Open Access Article (/1999-4923/15/3/1015/pdf?version=1679457325)

Sinonasal Stent Coated with Sustained-Release Varnish of Mometasone Furoate Inhibits Pro-Inflammatory Cytokine Release from Macrophages: An In Vitro Study (/1999-4923/15/3/1015)

by Alessandra Cataldo Russomando (https://sciprofiles.com/profile/1819427), Doron Steinberg (https://sciprofiles.com/profile/1502423), Irith Gati (https://sciprofiles.com/profile/author/QnFBcWFhbHhPWHF0VVlnQlZ5MTh3VG91b0Q5NFd4M2ZsMkM5TXJrQm54VT0=), Ronit Vogt Sionov (https://sciprofiles.com/profile/1666248), Ron Eliashar (https://sciprofiles.com/profile/1879021), Michael Friedman (https://sciprofiles.com/profile/author/Wk9JQ0tYd21DaElwUDRvY0gzQS9Eb1hJSVlXZHF1NGFMOWFTeTFWVWtlTT0=) and Menachem Gross (https://sciprofiles.com/profile/author/TE5ILzI5TnVYeWsyV0pPQVJlUGJnVDZ2V1ZTU3MrcWtXRkFwdGJpWkZOZz0=)
Pharmaceutics **2023**, *15*(3), 1015; https://doi.org/10.3390/pharmaceutics15031015 (https://doi.org/10.3390/pharmaceutics15031015) - 22 Mar 2023
Cited by 1 (/1999-4923/15/3/1015#metrics) | Viewed by 766

Abstract The aim of the study was to develop a sustained-release varnish (SRV) containing mometasone furoate (MMF) for sinonasal stents (SNS) to reduce mucosa inflammation in the sinonasal cavity. The SNS' segments coated with SRV-MMF or an SRV-placebo were incubated daily in a fresh **[...] Read more.**
(This article belongs to the Special Issue **Advances and Challenges in Nasal Formulation Developments** (/journal/pharmaceutics/special_issues/nasal_formulation))

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01015/article_deploy/html/images/pharmaceutics-15-01015-g001-550.jpg?1679457391) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01015/article_deploy/html/images/pharmaceutics-15-01015-g002-550.jpg?1679457395) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01015/article_deploy/html/images/pharmaceutics-15-01015-g003-550.jpg?1679457401) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01015/article_deploy/html/images/pharmaceutics-15-01015-g004-550.jpg?1679457399) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01015/article_deploy/html/images/pharmaceutics-15-01015-g005a-550.jpg?1679457396) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01015/article_deploy/html/images/pharmaceutics-15-01015-g005b-550.jpg?1679457403) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01015/article_deploy/html/images/pharmaceutics-15-01015-g006-550.jpg?1679457393)

Open Access Editorial (/1999-4923/15/3/1014/pdf?version=1679454383)

In Silico Pharmacology for Evidence-Based and Precision Medicine (/1999-4923/15/3/1014)

by Marios Spanakis (https://sciprofiles.com/profile/172494)
Pharmaceutics **2023**, *15*(3), 1014; https://doi.org/10.3390/pharmaceutics15031014 (https://doi.org/10.3390/pharmaceutics15031014) - 22 Mar 2023
Viewed by 971

Abstract Personalized/precision medicine (PM) originates from the application of molecular pharmacology in clinical practice, representing a new era in healthcare that aims to identify and predict optimum treatment outcomes for a patient or a cohort with similar genotype/phenotype characteristics [...] **Full article (/1999-4923/15/3/1014)**
(This article belongs to the Special Issue **In Silico Pharmacology for Evidence-Based and Precision Medicine** (/journal/pharmaceutics/special_issues/in_silico_pharmacology_precision_medicine))

Open Access Communication (/1999-4923/15/3/1013/pdf?version=1679453188)

Mesoporous Organosilica Nanoparticles with Tetrasulphide Bond to Enhance Plasmid DNA Delivery (/1999-4923/15/3/1013)

by Yue Zhang (https://sciprofiles.com/profile/author/aGhZdTM2SkNUT0JWaFNtZ0k4dlQyODNHRDYxdU1wMGwwaG5JMVNPeVZBWT0=), He Xian (https://sciprofiles.com/profile/author/NlJPUE9EMGV0RGdpWlIvT3hGOWQ5OWlYc251UTVBcFdZcjJiWWRtRDd5QT0=), Ekaterina Strounina (https://sciprofiles.com/profile/author/WUtxMmYrRktXOEgyZHpiMGg0enI4YzFjYnVlaXBLb3hhWG8rVjRWOGFOMD0=), Kimberley S. Gunther (https://sciprofiles.com/profile/author/aFpNcW4yeUFkcS9PbGFnOWNBSFNvc1IlNnRWcHJjUFBBalZPWkdRaStyRT0=), Matthew J. Sweet (https://sciprofiles.com/profile/1438566), Chen Chen (https://sciprofiles.com/profile/185155), Chengzhong Yu (https://sciprofiles.com/profile/2252295) and Yue Wang (https://sciprofiles.com/profile/2634279)
Pharmaceutics **2023**, *15*(3), 1013; https://doi.org/10.3390/pharmaceutics15031013 (https://doi.org/10.3390/pharmaceutics15031013) - 22 Mar 2023
Viewed by 1086

Abstract Cellular delivery of plasmid DNA (pDNA) specifically into dendritic cells (DCs) has provoked wide attention in various applications. However, delivery tools that achieve effective pDNA transfection in DCs are rare. Herein, we report that tetrasulphide bridged mesoporous organosilica nanoparticles (MONs) have enhanced pDNA **[...] Read more.**
(This article belongs to the Special Issue **Smart Drug Delivery Strategies Based on Porous Materials** (/journal/pharmaceutics/special_issues/porous_delivery))

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01013/article_deploy/html/images/pharmaceutics-15-01013-ag-550.jpg?1679453260) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01013/article_deploy/html/images/pharmaceutics-15-01013-g001-550.jpg?1679453254) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01013/article_deploy/html/images/pharmaceutics-15-01013-g002-550.jpg?1679453257) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01013/article_deploy/html/images/pharmaceutics-15-01013-g003-550.jpg?1679453254) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01013/article_deploy/html/images/pharmaceutics-15-01013-g004-550.jpg?1679453256) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01013/article_deploy/html/images/pharmaceutics-15-01013-g005-550.jpg?1679453259) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01013/article_deploy/html/images/pharmaceutics-15-01013-g006-550.jpg?1679453257)

Open Access Article (/1999-4923/15/3/1012/pdf?version=1679451905)

Intragastric Carbon Dioxide Release Prolongs the Gastric Residence Time of Postprandially Administered Caffeine (/1999-4923/15/3/1012)

Back to TopTop

by Stefan Senekowitsch (https://sciprofiles.com/profile/2070159), Constantin Foja (https://sciprofiles.com/profile/2595877), Tony Wildgrube (https://sciprofiles.com/profile/author/SDdlNWtxaHJ6N1FLU1FFTU0yR09NUWE3bmNMV0crQWNBN2VEWFRLRzJKbz0=), Philipp Schick (https://sciprofiles.com/profile/1479445), Christoph Rosenbaum (https://sciprofiles.com/profile/2160039), Julius Krause (https://sciprofiles.com/profile/2434449), Friederike Brokmann (https://sciprofiles.com/profile/3049542), Marie-Luise Kromrey (https://sciprofiles.com/profile/1915792), Stefan Engeli (https://sciprofiles.com/profile/author/TW1VV25iQkMvTkN4REdMZmJSYi9zT0VkSm56VThFZTZPNERiR3NZc09sYUxBNUFxZ2FPSXBlY1dEdS9UL3ZzWQ==), Werner Weitschies (https://sciprofiles.com/profile/540846) and Michael Grimm (https://sciprofiles.com/profile/1744175)

Pharmaceutics **2023**, *15*(3), 1012; https://doi.org/10.3390/pharmaceutics15031012 (https://doi.org/10.3390/pharmaceutics15031012) - 22 Mar 2023

Viewed by 1005

Abstract Sparkling water is said to increase gastric motility by the release of carbon dioxide, thereby potentially affecting the pharmacokinetics of orally administered drugs. The hypothesis of the present work was that the induction of gastric motility by intragastric release of carbon dioxide from **[...] Read more.**

(This article belongs to the Special Issue **Recent Advances in Oral Biopharmaceutics (/journal/pharmaceutics/special_issues/03197T2F2A)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01012/article_deploy/html/images/pharmaceutics-15-01012-ag-550.jpg?1679452010) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01012/article_deploy/html/images/pharmaceutics-15-01012-g001-550.jpg?1679451995) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01012/article_deploy/html/images/pharmaceutics-15-01012-g002-550.jpg?1679452002) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01012/article_deploy/html/images/pharmaceutics-15-01012-g003-550.jpg?1679451988) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01012/article_deploy/html/images/pharmaceutics-15-01012-g004-550.jpg?1679452008) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01012/article_deploy/html/images/pharmaceutics-15-01012-g005-550.jpg?1679451990) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01012/article_deploy/html/images/pharmaceutics-15-01012-g006a-550.jpg?1679451994) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01012/article_deploy/html/images/pharmaceutics-15-01012-g006b-550.jpg?1679451999) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01012/article_deploy/html/images/pharmaceutics-15-01012-g007-550.jpg?1679452001) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01012/article_deploy/html/images/pharmaceutics-15-01012-g008-550.jpg?1679452004) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01012/article_deploy/html/images/pharmaceutics-15-01012-g009-550.jpg?1679452010) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01012/article_deploy/html/images/pharmaceutics-15-01012-g010-550.jpg?1679451985) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01012/article_deploy/html/images/pharmaceutics-15-01012-g011-550.jpg?1679452005)

Open Access Article (/1999-4923/15/3/1011/pdf?version=1679405615)

pH-Dependent Behavior of Novel 5-FU Delivery System in Environmental Conditions Comparable to the Gastro-Intestinal Tract (/1999-4923/15/3/1011)

by Geza Lazar (https://sciprofiles.com/profile/1610034), Fran Nekvapil (https://sciprofiles.com/profile/410646), Branko Glamuzina (https://sciprofiles.com/profile/1680706), Tudor Tamaș (https://sciprofiles.com/profile/2936404), Lucian Barbu-Tudoran (https://sciprofiles.com/profile/832169), Maria Suciu (https://sciprofiles.com/profile/author/T2lwdFVyb1djSURFeWcxdXUzbnAyN3RVcjF5YWtOZi9nQlRNVEs1amU5MD0=) and Simona Cinta Pinzaru (https://sciprofiles.com/profile/814452)

Pharmaceutics **2023**, *15*(3), 1011; https://doi.org/10.3390/pharmaceutics15031011 (https://doi.org/10.3390/pharmaceutics15031011) - 21 Mar 2023

Cited by 1 (/1999-4923/15/3/1011#metrics) | Viewed by 913

Abstract A biogenic carrier for 5-fluorouracil (5-FU) loading and subsequent tableting as a new drug formulation for slow release has been proposed using the biomineral from blue crab carapace. Due to its highly ordered 3D porous nanoarchitecture, the biogenic carbonate carrier could achieve increased **[...] Read more.**

(This article belongs to the Special Issue **Innovative Drug Formulations Require Tailored Characterization Approaches (/journal/pharmaceutics/special_issues/drug_formulation)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01011/article_deploy/html/images/pharmaceutics-15-01011-g001-550.jpg?1679405694) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01011/article_deploy/html/images/pharmaceutics-15-01011-g002-550.jpg?1679405692) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01011/article_deploy/html/images/pharmaceutics-15-01011-g003-550.jpg?1679405690) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01011/article_deploy/html/images/pharmaceutics-15-01011-g004-550.jpg?1679405698) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01011/article_deploy/html/images/pharmaceutics-15-01011-g005-550.jpg?1679405691) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01011/article_deploy/html/images/pharmaceutics-15-01011-g006-550.jpg?1679405688) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01011/article_deploy/html/images/pharmaceutics-15-01011-g007-550.jpg?1679405696)

Open Access Article (/1999-4923/15/3/1010/pdf?version=1679399891)

Use of a Cellulase from *Trichoderma reesei* as an Adjuvant for *Enterococcus faecalis* Biofilm Disruption in Combination with Antibiotics as an Alternative Treatment in Secondary Endodontic Infection (/1999-4923/15/3/1010)

by Selene Velázquez-Moreno (https://sciprofiles.com/profile/2729818), Ana Maria González-Amaro (https://sciprofiles.com/profile/author/R09JTXBRWGZUckd5dW5pbThBS1hKK2owek1kY01TMkNpdmdFRy93YlRCUT0=), Antonio Aragón-Piña (https://sciprofiles.com/profile/2844873), Lluvia Itzel López-López (https://sciprofiles.com/profile/857739), Roberto Sánchez-Sánchez (https://sciprofiles.com/profile/2991028), Mario Alberto Pérez-Díaz (https://sciprofiles.com/profile/2506883), Ricardo Oliva Rodríguez (https://sciprofiles.com/profile/author/THJ4bklSYitwakt2N01MWGpNeEVlQWRqMld2NDhHNzBlUmFNbkUrczdsRT0=), Ana C. Lorenzo-Leal (https://sciprofiles.com/profile/2931064), Omar González-Ortega (https://sciprofiles.com/profile/269410), Fidel Martinez-Gutierrez (https://sciprofiles.com/profile/2553358) and Horacio Bach (https://sciprofiles.com/profile/31432)

Pharmaceutics **2023**, *15*(3), 1010; https://doi.org/10.3390/pharmaceutics15031010 (https://doi.org/10.3390/pharmaceutics15031010) - 21 Mar 2023

Viewed by 1286

Abstract Apical periodontitis is an inflammation leading to the injury and destruction of periradicular tissues. It is a sequence of events that starts from root canal infection, endodontic treatment, caries, or other dental interventions. *Enterococcus faecalis* is a ubiquitous oral pathogen that is challenging **[...] Read more.**

(This article belongs to the Special Issue **Drug Delivery and Pharmacokinetics in Oral Medicine and Dental Infection (/journal/pharmaceutics/special_issues/Oral)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01010/article_deploy/html/images/pharmaceutics-15-01010-g001-550.jpg?1679399967) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01010/article_deploy/html/images/pharmaceutics-15-01010-g002-550.jpg?1679399962) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01010/article_deploy/html/images/pharmaceutics-15-01010-g003-550.jpg?1679399961) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01010/article_deploy/html/images/pharmaceutics-15-01010-g004-550.jpg?1679399966) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01010/article_deploy/html/images/pharmaceutics-15-01010-g005-550.jpg?1679399971)

Open Access Article (/1999-4923/15/3/1009/pdf?version=1679465570)

DLin-MC3-Containing mRNA Lipid Nanoparticles Induce an Antibody Th2-Biased Immune Response Polarization in a Delivery Route-Dependent Manner in Mice (/1999-4923/15/3/1009)

by Altan Yavuz (https://sciprofiles.com/profile/2734262), Céline Coiffier (https://sciprofiles.com/profile/2805841), Cynthia Garapon (https://sciprofiles.com/profile/author/UVhMY1gvVmdpMGt0dUpDTHozYm5wblhreWFqQW04a2VoOEREKzk0cUM3Yz0=), Serra Gurcan (https://sciprofiles.com/profile/author/YnNRRTJ0WXRZeWtSaWd4QS9KNE40Sk1jZ1k0eVBwdkVZOWlhci9wOXd1WT0=), Claire Monge (https://sciprofiles.com/profile/1516653), Jean-Yves Exposito (https://sciprofiles.com/profile/author/YkJFakVWMVFiZitLVnpQMFd4Z0htTS9JeEd2OVBYbXFMMUhDbnh4b0pHdz0=), Danielle Campiol Arruda (https://sciprofiles.com/profile/2190038) and Bernard Verrier (https://sciprofiles.com/profile/200746)

Pharmaceutics **2023**, *15*(3), 1009; https://doi.org/10.3390/pharmaceutics15031009 (https://doi.org/10.3390/pharmaceutics15031009) - 21 Mar 2023

Viewed by 1662

Abstract mRNA-based vaccines have made a leap forward since the SARS-CoV-2 pandemic and are currently used to develop anti-infectious therapies. If the selection of a delivery system and an optimized mRNA sequence are two key factors to reach in vivo efficacy, the optimal administration **[...] Read more.**

(This article belongs to the Special Issue **State-of-Art in mRNA Therapeutics and Gene Delivery (/journal/pharmaceutics/special_issues/mRNA_Therap)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01009/article_deploy/html/images/pharmaceutics-15-01009-g001-550.jpg?1679465648) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01009/article_deploy/html/images/pharmaceutics-15-01009-g002-550.jpg?1679465651) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01009/article_deploy/html/images/pharmaceutics-15-01009-g003-550.jpg?1679465642) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01009/article_deploy/html/images/pharmaceutics-15-01009-g004-550.jpg?1679465652) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01009/article_deploy/html/images/pharmaceutics-15-01009-g005-550.jpg?1679465646)

Open Access Review (/1999-4923/15/3/1008/pdf?version=1679387442)

Drug Delivery Strategies for Avobenzone: A Case Study of Photostabilization (/1999-4923/15/3/1008)

by Amol D. Gholap (https://sciprofiles.com/profile/2524216), Sadikali F. Sayyad (https://sciprofiles.com/profile/2751426), Navnath T. Hatvate (https://sciprofiles.com/profile/2656312), Vilas V. Dhumal (https://sciprofiles.com/profile/author/VEpuZ2wrQ0FiMVJISDlCL0IwNndweTA2T2RyUS82bGQ3STZrM09jamxCVT0=), Sagar R. Pardeshi (https://sciprofiles.com/profile/2222290), Vivek P. Chavda (https://sciprofiles.com/profile/1665236) and Lalitkumar K. Vora (https://sciprofiles.com/profile/1548814)

Pharmaceutics **2023**, *15*(3), 1008; https://doi.org/10.3390/pharmaceutics15031008 (https://doi.org/10.3390/pharmaceutics15031008) - 21 Mar 2023

Cited by 5 (/1999-4923/15/3/1008#metrics) | Viewed by 3076

Abstract Several developments and research methods are ongoing in drug technology and chemistry research to elicit effectiveness regarding the therapeutic activity of drugs along with photoprotection for their molecular integrity. The detrimental effect of UV light induces damaged cells and DNA, which leads to **[...] Read more.**

(This article belongs to the Special Issue **Formulation of Photosensitive Drugs (/journal/pharmaceutics/special_issues/photosensitive_drug)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01008/article_deploy/html/images/pharmaceutics-15-01008-ag-550.jpg?1679387542) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01008/article_deploy/html/images/pharmaceutics-15-01008-g001-550.jpg?1679387511) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01008/article_deploy/html/images/pharmaceutics-15-01008-g002-550.jpg?1679387508) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01008/article_deploy/html/images/pharmaceutics-15-01008-g003-550.jpg?1679387523) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01008/article_deploy/html/images/pharmaceutics-15-01008-g004-550.jpg?1679387521) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01008/article_deploy/html/images/pharmaceutics-15-01008-g005-550.jpg?1679387514) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01008/article_deploy/html/images/pharmaceutics-15-01008-g006-550.jpg?1679387513) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01008/article_deploy/html/images/pharmaceutics-15-01008-g007-550.jpg?1679387525) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01008/article_deploy/html/images/pharmaceutics-15-01008-g008-550.jpg?1679387517)

Open Access Article (/1999-4923/15/3/1007/pdf?version=1679585443)

Derivatives of Amaryllidaceae Alkaloid Ambelline as Selective Inhibitors of Hepatic Stage of *Plasmodium berghei* Infection In Vitro (/1999-4923/15/3/1007)

by Kateřina Hradiská Breiterová (https://sciprofiles.com/profile/1285750), Aneta Ritomská (https://sciprofiles.com/profile/2764372), Diana Fontinha (https://sciprofiles.com/profile/1174125), Jana Křoustková (https://sciprofiles.com/profile/author/NWwyQTBDY1lJemg1MFBYbWtFTktodko3T3NmRnJ6QVhqUlVFYmFlRzBnMD0=), Daniela Suchánková (https://sciprofiles.com/profile/2358965), Anna Hošťálková (https://sciprofiles.com/profile/466201), Marcela Šafratová (https://sciprofiles.com/profile/1200332), Eliška Kohelová (https://sciprofiles.com/profile/author/R0pqVEN4bENDTXc3SE5qZHlYbnhhVVFVdnorVXlvTWpNc1NGZWZSTnFYWT0=), Rozálie Peřinová (https://sciprofiles.com/profile/author/ZVZycnhoS1dtWHJNeDZHR1laaXJwRC9wT09ncmQwZGVrQ2JrekIXNU9zOD0=), Rudolf Vrabec (https://sciprofiles.com/profile/author/S0lTRTBKUkRLV0ZYQ2RUcll5SUZqQTFFaXUyTjljbUJoWUphbVBhWXB4az0=), Denise Francisco (https://sciprofiles.com/profile/author/cFBSWUFVejNDTEFGQlFIKzZBbW96WVd5dWg5OWtYdDBPQiszRmN5QkJwZz0=), Miguel Prudêncio (https://sciprofiles.com/profile/786707) and Lucie Cahlíková (https://sciprofiles.com/profile/390161)

Pharmaceutics **2023**, *15*(3), 1007; https://doi.org/10.3390/pharmaceutics15031007 (https://doi.org/10.3390/pharmaceutics15031007) - 21 Mar 2023

Viewed by 791

Abstract The incidence rate of malaria and the ensuing mortality prompts the development of novel antimalarial drugs. In this work, the activity of twenty-eight Amaryllidaceae alkaloids (**1–28**) belonging to seven different structural types was assessed, as well as twenty semisynthetic derivatives of **[...] Read more.**

(This article belongs to the Special Issue **Development of Novel Pharmaceuticals for the Treatment of Parasitic Diseases (/journal/pharmaceutics/special_issues/Parasitic_Disease)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01007/article_deploy/html/images/pharmaceutics-15-01007-ag-550.jpg?1679585537) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01007/article_deploy/html/images/pharmaceutics-15-01007-g001-550.jpg?1679585523) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01007/article_deploy/html/images/pharmaceutics-15-01007-g002-550.jpg?1679585531) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01007/article_deploy/html/images/pharmaceutics-15-01007-g003-550.jpg?1679585516) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01007/article_deploy/html/images/pharmaceutics-15-01007-g004-550.jpg?1679585537) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01007/article_deploy/html/images/pharmaceutics-15-01007-g005-550.jpg?1679585534) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01007/article_deploy/html/images/pharmaceutics-15-01007-g006-550.jpg?1679585514) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01007/article_deploy/html/images/pharmaceutics-15-01007-g007-550.jpg?1679585528) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01007/article_deploy/html/images/pharmaceutics-15-01007-g008-550.jpg?1679585525)

Open Access Review (/1999-4923/15/3/1006/pdf?version=1679379903)

The Exosome-Mediated PI3K/Akt/mTOR Signaling Pathway in Neurological Diseases (/1999-4923/15/3/1006)

by Amin Iranpanah (https://sciprofiles.com/profile/2621548), Leila Kooshki (https://sciprofiles.com/profile/author/MVpMQkcxS205ckZWcG9yWUZ2TVVYcFYxNXdnQzhsVkNCMVArQzFpRGhsbzc0=), Seyed Zachariah Moradi (https://sciprofiles.com/profile/1264006), Luciano Saso (https://sciprofiles.com/profile/420194), Sajad Fakhri (https://sciprofiles.com/profile/714906) and Haroon Khan (https://sciprofiles.com/profile/1056383)

Pharmaceutics **2023**, *15*(3), 1006; https://doi.org/10.3390/pharmaceutics15031006 (https://doi.org/10.3390/pharmaceutics15031006) - 21 Mar 2023

Cited by 2 (/1999-4923/15/3/1006#metrics) | Viewed by 1706

Abstract As major public health concerns associated with a rapidly growing aging population, neurodegenerative diseases (NDDs) and neurological diseases are important causes of disability and mortality. Neurological diseases affect millions of people worldwide. Recent studies have indicated that apoptosis, inflammation, and oxidative stress are **[...] Read more.**

(This article belongs to the Special Issue **Bioengineering and Nanotechnology to Create Advanced Therapeutics for Neurological Disorders and Neurosensory Pathologies (/journal/pharmaceutics/special_issues/neurology)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01006/article_deploy/html/images/pharmaceutics-15-01006-g001-550.jpg?1679379978) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01006/article_deploy/html/images/pharmaceutics-15-01006-g002-550.jpg?1679379976)

Open Access Article (/1999-4923/15/3/1005/pdf?version=1679378468)

Conjugation of Short Oligopeptides to a Second-Generation Polyamidoamine Dendrimer Shows Antibacterial Activity (/1999-4923/15/3/1005)

by Namyoung Kang (https://sciprofiles.com/profile/author/RXFxTVpoNVNCQmxHS1BraFFBdlIkUkI1Z0JVWnpJazVRNnZuMXprZVdFST0=), Le Thi Thuy (https://sciprofiles.com/profile/author/WVRlZkRhNjNkRXZsai9iTXM5ZnFESVpQUmM1dUZ0K3RiTDY3RjVQWG1BTT0=), Viet Dongquoc (https://sciprofiles.com/profile/author/d2pEeUhnNHBMcmRTQzlJZ2ZySEI4ekJlSmxEYXFoZG1CZzFiVWFwdEFlUT0=) and Joon Sig Choi (https://sciprofiles.com/profile/244280)

Pharmaceutics **2023**, *15*(3), 1005; https://doi.org/10.3390/pharmaceutics15031005 (https://doi.org/10.3390/pharmaceutics15031005) - 21 Mar 2023

Viewed by 806

Abstract The growing evolution of bacterial resistance to antibiotics represents a global issue that not only impacts healthcare systems but also political and economic processes. This necessitates the development of novel antibacterial agents. Antimicrobial peptides have shown promise in this regard. Thus, in this **[...] Read more.**

(This article belongs to the Special Issue **Applications of Dendrimers in Biomedicine (/journal/pharmaceutics/special_issues/ODKZLDI71Z)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01005/article_deploy/html/images/pharmaceutics-15-01005-ag-550.jpg?1679378555) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01005/article_deploy/html/images/pharmaceutics-15-01005-g001-550.jpg?1679378552) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01005/article_deploy/html/images/pharmaceutics-15-01005-g002a-550.jpg?1679378550) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01005/article_deploy/html/images/pharmaceutics-15-01005-g002b-550.jpg?1679378555) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01005/article_deploy/html/images/pharmaceutics-15-01005-g003-550.jpg?1679378538) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01005/article_deploy/html/images/pharmaceutics-15-01005-g004-550.jpg?1679378553) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01005/article_deploy/html/images/pharmaceutics-15-01005-g005-550.jpg?1679378546) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01005/article_deploy/html/images/pharmaceutics-15-01005-g006-550.jpg?1679378551) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01005/article_deploy/html/images/pharmaceutics-15-01005-g007-550.jpg?1679378542) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01005/article_deploy/html/images/pharmaceutics-15-01005-g008-550.jpg?1679378547)

Open Access Article (/1999-4923/15/3/1004/pdf?version=1679380632)

Gene Electrotransfer Efficiency in 2D and 3D Cancer Cell Models Using Different Electroporation Protocols: A Comparative Study (/1999-4923/15/3/1004)

by Alexia de Caro (https://sciprofiles.com/profile/author/RHUvNHcvK3ZndG9xUnNOOFV3M3duU3ZYaFFHZEd2N1JlbHVuYkRiWHM4VT0=), Elisabeth Bellard (https://sciprofiles.com/profile/author/Sk5Nc0F6THpSendEZmYrV21QLzZ3RTNCSllwSUM0SlJsaDBweVdTVUs1VT0=), Jelena Kolosnjaj-Tabi (https://sciprofiles.com/profile/429097), Muriel Golzio (https://sciprofiles.com/profile/40655) and Marie-Pierre Rols (https://sciprofiles.com/profile/851408)

Pharmaceutics **2023**, *15*(3), 1004; https://doi.org/10.3390/pharmaceutics15031004 (https://doi.org/10.3390/pharmaceutics15031004) - 21 Mar 2023
Viewed by 985

Abstract Electroporation, a method relying on a pulsed electric field to induce transient cell membrane permeabilization, can be used as a non-viral method to transfer genes in vitro and in vivo. Such transfer holds great promise for cancer treatment, as it can induce or **[...] Read more.**

(This article belongs to the Special Issue **Plasmid DNA for Gene Therapy and DNA Vaccine Applications (/journal/pharmaceutics/special_issues/dna_gene_vaccine)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01004/article_deploy/html/images/pharmaceutics-15-01004-g001-550.jpg?1679380734) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01004/article_deploy/html/images/pharmaceutics-15-01004-g002-550.jpg?1679380746) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01004/article_deploy/html/images/pharmaceutics-15-01004-g003-550.jpg?1679380727) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01004/article_deploy/html/images/pharmaceutics-15-01004-g004-550.jpg?1679380724) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01004/article_deploy/html/images/pharmaceutics-15-01004-g005-550.jpg?1679380730) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01004/article_deploy/html/images/pharmaceutics-15-01004-g006-550.jpg?1679380733) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01004/article_deploy/html/images/pharmaceutics-15-01004-g007-550.jpg?1679380740) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01004/article_deploy/html/images/pharmaceutics-15-01004-g008-550.jpg?1679380743) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01004/article_deploy/html/images/pharmaceutics-15-01004-g009-550.jpg?1679380737)

Open Access Article (/1999-4923/15/3/999/pdf?version=1679880195)

Nanoemulsions Based on Sunflower and Rosehip Oils: The Impact of Natural and Synthetic Stabilizers on Skin Penetration and an Ex Vivo Wound Healing Model (/1999-4923/15/3/999)

by Cynthia Nara Pereira Oliveira (https://sciprofiles.com/profile/author/WEFHUXdrYUNYT202S05VSy9xTkV2VzQ5bGppRFM4OGhES2JCUG9Yc0Uybz0=), Marcel Nani Leite (https://sciprofiles.com/profile/2828073), Natália Aparecida de Paula (https://sciprofiles.com/profile/author/WGJFV0ZXUDRLeHFycWVCcFVmVFlwcjFhWGJFYUJHMkRFK05wdDQyZGh5bz0=), Yugo Araújo Martins (https://sciprofiles.com/profile/author/L3FFT25aMXBvdHVEdTlSMWxXR2JiY2ZEeXlkSmpHWkpJKytlWVdsL3V1Yz0=), Sonia Aparecida Figueiredo (https://sciprofiles.com/profile/author/UThERHN0Rk9vSjVueFR0c1VURjlvcVEzdVBQekIyMk1MVzNJTCtkcGxQUVdVZm1kU3Jhb1MwREoxN3EzckxVZg==), Marco Andrey Cipriani Frade (https://sciprofiles.com/profile/712669) and Renata Fonseca Vianna Lopez (https://sciprofiles.com/profile/205870)

Pharmaceutics **2023**, *15*(3), 999; https://doi.org/10.3390/pharmaceutics15030999 (https://doi.org/10.3390/pharmaceutics15030999) - 20 Mar 2023
Cited by 1 (/1999-4923/15/3/999#metrics) | Viewed by 1163

Abstract Vegetable oils offer excellent biological properties, but their high lipophilicity limits their bioavailability. This work aimed to develop nanoemulsions based on sunflower and rosehip oils and to evaluate their wound-healing activity. The influence of phospholipids of plant origin on nanoemulsions' characteristics was investigated. **[...] Read more.**

(This article belongs to the Special Issue **Drugs in Dermatology: Topical Agent, Cosmetics, Dermatological Drug Delivery, Natural Product in Dermatology (/journal/pharmaceutics/special_issues/dermatology_drug)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00999/article_deploy/html/images/pharmaceutics-15-00999-g001-550.jpg?1679880279) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00999/article_deploy/html/images/pharmaceutics-15-00999-g002-550.jpg?1679880264) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00999/article_deploy/html/images/pharmaceutics-15-00999-g003-550.jpg?1679880275) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00999/article_deploy/html/images/pharmaceutics-15-00999-g004-550.jpg?1679880281) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00999/article_deploy/html/images/pharmaceutics-15-00999-g005-550.jpg?1679880269) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00999/article_deploy/html/images/pharmaceutics-15-00999-g006-550.jpg?1679880273) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00999/article_deploy/html/images/pharmaceutics-15-00999-g007-550.jpg?1679880288) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00999/article_deploy/html/images/pharmaceutics-15-00999-g008-550.jpg?1679880284) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00999/article_deploy/html/images/pharmaceutics-15-00999-g009-550.jpg?1679880267) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00999/article_deploy/html/images/pharmaceutics-15-00999-g010-550.jpg?1679880285)

Open Access Review (/1999-4923/15/3/998/pdf?version=1679305128)

Nanosystems, Drug Molecule Functionalization and Intranasal Delivery: An Update on the Most Promising Strategies for Increasing the Therapeutic Efficacy of Antidepressant and Anxiolytic Drugs (/1999-4923/15/3/998)

by Jéssica L. Antunes (https://sciprofiles.com/profile/2412764), Joana Amado (https://sciprofiles.com/profile/2466371), Francisco Veiga (https://sciprofiles.com/profile/author/WExjUjcwL3N2TDdqKzl4aGRTUHBDUT09), Ana Cláudia Paiva-Santos (https://sciprofiles.com/profile/713309) and Patrícia C. Pires (https://sciprofiles.com/profile/1819045)

Pharmaceutics **2023**, *15*(3), 998; https://doi.org/10.3390/pharmaceutics15030998 (https://doi.org/10.3390/pharmaceutics15030998) - 20 Mar 2023
Cited by 1 (/1999-4923/15/3/998#metrics) | Viewed by 1392

Abstract Depression and anxiety are high incidence and debilitating psychiatric disorders, usually treated by antidepressant or anxiolytic drug administration, respectively. Nevertheless, treatment is usually given through the oral route, but the low permeability of the blood–brain barrier reduces the amount of drug that will **[...] Read more.**

(This article belongs to the Special Issue **Strategies to Enhance Drug Permeability across Biological Barriers (/journal/pharmaceutics/special_issues/drug_permeability_across_barrier)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00998/article_deploy/html/images/pharmaceutics-15-00998-ag-550.jpg?1679305214) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00998/article_deploy/html/images/pharmaceutics-15-00998-g001-550.jpg?1679305199) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00998/article_deploy/html/images/pharmaceutics-15-00998-g002-550.jpg?1679305211) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00998/article_deploy/html/images/pharmaceutics-15-00998-g003-550.jpg?1679305213) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00998/article_deploy/html/images/pharmaceutics-15-00998-g004-550.jpg?1679305205) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00998/article_deploy/html/images/pharmaceutics-15-00998-g005-550.jpg?1679305201) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00998/article_deploy/html/images/pharmaceutics-15-00998-g006-550.jpg?1679305203) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00998/article_deploy/html/images/pharmaceutics-15-00998-g007-550.jpg?1679305209) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00998/article_deploy/html/images/pharmaceutics-15-00998-g008-550.jpg?1679305207)

Open Access Article (/1999-4923/15/3/997/pdf?version=1679302393)

Targeting Glioblastoma-Associated Macrophages for Photodynamic Therapy Using AGuIX®-Design Nanoparticles (/1999-4923/15/3/997)

by Lucie Lerouge (https://sciprofiles.com/profile/2777413), Mickaël Gries (https://sciprofiles.com/profile/author/eHpQTnZDMjBWOUxEUkM5OUlYdUw4Y3pPVVBEYzNhbm0xVTlmV3VoUkhSMD0=), Alicia Chateau (https://sciprofiles.com/profile/author/dCtmV2cybnJCY1daTU5uRjZQNWZqdHM4eUp6bzJ3a3JQNGtMQTdDSEorND0=), Joël Daouk (https://sciprofiles.com/profile/1278397), François Lux (https://sciprofiles.com/profile/2049002), Paul Rocchi (https://sciprofiles.com/profile/author/OWFaZnBzbzRGNDQyTUZHSm1qM2d4MTVnVEZLKzUvbVBuRTBlWHJxTUlvTT0=), Jessica Cedervall (https://sciprofiles.com/profile/author/NExweVBZM3NhbjRhcmtNT20xWExPWkd6OUtUd0VzL3hqcm5vKys0NWc0Zz0=), Anna-Karin Olsson (https://sciprofiles.com/profile/1837615), Olivier Tillement (https://sciprofiles.com/profile/author/Z0wvZ21BVDVYdmNYTG5hZFdlQmZpUnRnMWNQOXlreUxobkNHSzdxZmtsRT0=), Céline Frochot (https://sciprofiles.com/profile/453906), Samir Acherar (https://sciprofiles.com/profile/466663), Noémie Thomas (https://sciprofiles.com/profile/857042) and Muriel Barberi-Heyob (https://sciprofiles.com/profile/2775721)

Pharmaceutics **2023**, *15*(3), 997; https://doi.org/10.3390/pharmaceutics15030997 (https://doi.org/10.3390/pharmaceutics15030997) - 20 Mar 2023
Cited by 3 (/1999-4923/15/3/997#metrics) | Viewed by 1383

Abstract Glioblastoma (GBM) is the most difficult brain cancer to treat, and photodynamic therapy (PDT) is emerging as a complementary approach to improve tumor eradication. Neuropilin-1 (NRP-1) protein expression plays a critical role in GBM progression and immune response. Moreover, various clinical databases highlight **[...] Read more.**

(This article belongs to the Special Issue **Advances in Cancer Nanotechnology for Photodynamic and Photothermal Therapy (/journal/pharmaceutics/special_issues/XWXN8534AC)**)

Back to TopTop

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00997/article_deploy/html/images/pharmaceutics-15-00997-g001-550.jpg?1679302479) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00997/article_deploy/html/images/pharmaceutics-15-00997-g002-550.jpg?1679302489) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00997/article_deploy/html/images/pharmaceutics-15-00997-g003-550.jpg?1679302481) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00997/article_deploy/html/images/pharmaceutics-15-00997-g004-550.jpg?1679302495) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00997/article_deploy/html/images/pharmaceutics-15-00997-g005-550.jpg?1679302491) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00997/article_deploy/html/images/pharmaceutics-15-00997-g006-550.jpg?1679302494) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00997/article_deploy/html/images/pharmaceutics-15-00997-g007-550.jpg?1679302497) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00997/article_deploy/html/images/pharmaceutics-15-00997-g008-550.jpg?1679302483) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00997/article_deploy/html/images/pharmaceutics-15-00997-g009-550.jpg?1679302486) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00997/article_deploy/html/images/pharmaceutics-15-00997-g010-550.jpg?1679302492)

Open Access Article (/1999-4923/15/3/996/pdf?version=1679305030)

Scalable Production and In Vitro Efficacy of Inhaled Erlotinib Nanoemulsion for Enhanced Efficacy in Non-Small Cell Lung Cancer (NSCLC) (/1999-4923/15/3/996)

by Gautam Chauhan (https://sciprofiles.com/profile/author/ZVpxbWgrY01GeHB2Um55ODg1SDd2a1VlWmdVaEhOa3BKS1NMWmU4cDJSST0=), Xuechun Wang (https://sciprofiles.com/profile/2825469), Carol Yousry (https://sciprofiles.com/profile/1776784) and Vivek Gupta (https://sciprofiles.com/profile/813148)

Pharmaceutics **2023**, *15*(3), 996; https://doi.org/10.3390/pharmaceutics15030996 (https://doi.org/10.3390/pharmaceutics15030996) - 20 Mar 2023

Cited by 1 (/1999-4923/15/3/996#metrics) | Viewed by 1519

Abstract Non-small cell lung cancer (NSCLC) is a global concern as one of the leading causes of cancer deaths. The treatment options for NSCLC are limited to systemic chemotherapy, administered either orally or intravenously, with no local chemotherapies to target NSCLC. In this study, **[...] Read more.**

(This article belongs to the Special Issue **Inhalable Formulations for Pulmonary Delivery to Treat Non-small Cell Lung Cancer (NSCLC): Development and In-Vitro Efficacy (/journal/pharmaceutics/special_issues/Inhalable_NSCLC)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00996/article_deploy/html/images/pharmaceutics-15-00996-g001-550.jpg?1679305123) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00996/article_deploy/html/images/pharmaceutics-15-00996-g002-550.jpg?1679305113) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00996/article_deploy/html/images/pharmaceutics-15-00996-g003-550.jpg?1679305121) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00996/article_deploy/html/images/pharmaceutics-15-00996-g004-550.jpg?1679305107) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00996/article_deploy/html/images/pharmaceutics-15-00996-g005-550.jpg?1679305119) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00996/article_deploy/html/images/pharmaceutics-15-00996-g006-550.jpg?1679305105) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00996/article_deploy/html/images/pharmaceutics-15-00996-g007-550.jpg?1679305109) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00996/article_deploy/html/images/pharmaceutics-15-00996-g008-550.jpg?1679305116) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00996/article_deploy/html/images/pharmaceutics-15-00996-g009-550.jpg?1679305110) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00996/article_deploy/html/images/pharmaceutics-15-00996-g010-550.jpg?1679305112)

Open Access Article (/1999-4923/15/3/995/pdf?version=1679300525)

Quality by Design-Based Development of Solid Self-Emulsifying Drug Delivery System (SEDDS) as a Potential Carrier for Oral Delivery of Lysozyme (/1999-4923/15/3/995)

by Merima Šahinović (https://sciprofiles.com/profile/1311883), Alharith Hassan (https://sciprofiles.com/profile/2915304), Katalin Kristó (https://sciprofiles.com/profile/1310050), Géza Regdon, Jr. (https://sciprofiles.com/profile/404864), Edina Vranić (https://sciprofiles.com/profile/1284494) and Tamás Sovány (https://sciprofiles.com/profile/425685)

Pharmaceutics **2023**, *15*(3), 995; https://doi.org/10.3390/pharmaceutics15030995 (https://doi.org/10.3390/pharmaceutics15030995) - 20 Mar 2023

Viewed by 1655

Abstract For many years, researchers have been making efforts to find a manufacturing technique, as well as a drug delivery system, that will allow for oral delivery of biopharmaceuticals to their target site of action without impairing their biological activity. Due to the positive **[...] Read more.**

(This article belongs to the Special Issue **Understanding Pharmaceutical Quality by Design (/journal/pharmaceutics/special_issues/quality_design)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00995/article_deploy/html/images/pharmaceutics-15-00995-g001-550.jpg?1679300601) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00995/article_deploy/html/images/pharmaceutics-15-00995-g002-550.jpg?1679300595) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00995/article_deploy/html/images/pharmaceutics-15-00995-g003-550.jpg?1679300593) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00995/article_deploy/html/images/pharmaceutics-15-00995-g004-550.jpg?1679300596) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00995/article_deploy/html/images/pharmaceutics-15-00995-g005-550.jpg?1679300600) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00995/article_deploy/html/images/pharmaceutics-15-00995-g006-550.jpg?1679300603) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00995/article_deploy/html/images/pharmaceutics-15-00995-g007-550.jpg?1679300604)

Open Access Correction (/1999-4923/15/3/994/pdf?version=1679298460)

Correction: Mansour et al. Dual-Enhanced Pluronic Nanoformulated Methotrexate-Based Treatment Approach for Breast Cancer: Development and Evaluation of In Vitro and In Vivo Efficiency. *Pharmaceutics* 2022, *14*, 2668 (/1999-4923/15/3/994)

by Amira Mansour (https://sciprofiles.com/profile/2534298), Mohamed Y. Mahmoud (https://sciprofiles.com/profile/author/TWNNTVRWR2ZWY1BuL1FobzNYVnFDNTlwbnF2Mk01SEo1bDgzUUM5cFlVYz0=), Alaa F. Bakr (https://sciprofiles.com/profile/author/VGJkV0ora0gzKzB6TTFxWnNtT3ZDcXJhd0JTMUtuL0hvaFhRcmVGMEcxTT0=), **Monira G. Ghoniem**, Fatima A. Adam (https://sciprofiles.com/profile/1914024) and Ibrahim M. El-Sherbiny (https://sciprofiles.com/profile/1124542)

Pharmaceutics **2023**, *15*(3), 994; https://doi.org/10.3390/pharmaceutics15030994 (https://doi.org/10.3390/pharmaceutics15030994) - 20 Mar 2023

Viewed by 496

Abstract In the original publication [...] **Full article (/1999-4923/15/3/994)**

Open Access Article (/1999-4923/15/3/993/pdf?version=1679297055)

Does Green Exfoliation of Graphene Produce More Biocompatible Structures? (/1999-4923/15/3/993)

by Eirini Papanikolaou (https://sciprofiles.com/profile/2488215), Yannis V. Simos (https://sciprofiles.com/profile/546697), Konstantinos Spyrou (https://sciprofiles.com/profile/941469), Michaela Patila (https://sciprofiles.com/profile/150794), Christina Alatzoglou (https://sciprofiles.com/profile/2649972), Konstantinos Tsamis (https://sciprofiles.com/profile/1651490), Patra Vezyraki (https://sciprofiles.com/profile/2786051), Haralambos Stamatis (https://sciprofiles.com/profile/467004), Dimitrios P. Gournis (https://sciprofiles.com/profile/716862), Dimitrios Peschos (https://sciprofiles.com/profile/author/em5lYkJHOTdQeEo4VVloTVlEaFUvdz09) and Evangelia Dounousi (https://sciprofiles.com/profile/1442716)

Pharmaceutics **2023**, *15*(3), 993; https://doi.org/10.3390/pharmaceutics15030993 (https://doi.org/10.3390/pharmaceutics15030993) - 20 Mar 2023

Viewed by 793

Abstract Graphene has been studied thoroughly for its use in biomedical applications over the last decades. A crucial factor for a material to be used in such applications is its biocompatibility. Various factors affect the biocompatibility and toxicity of graphene structures, including lateral size, **[...] Read more.**

(This article belongs to the Section **Nanomedicine and Nanotechnology (/journal/pharmaceutics/sections/Nanomedicine_and_Nanotechnology)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00993/article_deploy/html/images/pharmaceutics-15-00993-g001-550.jpg?1679297132) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00993/article_deploy/html/images/pharmaceutics-15-00993-g002-550.jpg?1679297134) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00993/article_deploy/html/images/pharmaceutics-15-00993-g003-550.jpg?1679297136) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00993/article_deploy/html/images/pharmaceutics-15-00993-g004-550.jpg?1679297129) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00993/article_deploy/html/images/pharmaceutics-15-00993-g005-550.jpg?1679297133) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00993/article_deploy/html/images/pharmaceutics-15-00993-g006-550.jpg?1679297132) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00993/article_deploy/html/images/pharmaceutics-15-00993-g007-550.jpg?1679297131) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00993/article_deploy/html/images/pharmaceutics-15-00993-g008-550.jpg?1679297138) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00993/article_deploy/html/images/pharmaceutics-15-00993-g009-550.jpg?1679297130) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00993/article_deploy/html/images/pharmaceutics-15-00993-

g010-550.jpg?1679297128)

Open Access Article (/1999-4923/15/3/992/pdf?version=1679289188)

The Bioactivity of Xylene, Pyridine, and Pyrazole Aza Macrocycles against Three Representative *Leishmania* Species (/1999-4923/15/3/992)

by Álvaro Martín-Montes (https://sciprofiles.com/profile/2846023), Álvaro Martínez-Camarena (https://sciprofiles.com/profile/655227), Alberto Lopera (https://sciprofiles.com/profile/author/bTdoV1hMZDFDemowcFhJM2tlZ3VWUjVhT1NkOE8xemx1QTJEUHhrYmxTST0=), Irene Bonastre-Sabater (https://sciprofiles.com/profile/author/Q01oTGlRL0lOWEhPYmY4U2dQSUNwdz09), M. Paz Clares (https://sciprofiles.com/profile/3077394), Begoña Verdejo (https://sciprofiles.com/profile/133498), Enrique García-España (https://sciprofiles.com/profile/655190) and Clotilde Marín (https://sciprofiles.com/profile/517241)

Pharmaceutics **2023**, *15*(3), 992; https://doi.org/10.3390/pharmaceutics15030992 (https://doi.org/10.3390/pharmaceutics15030992) - 20 Mar 2023
Viewed by 806

Abstract Due to the urgent need for finding effective and free of secondary effect treatments for every clinical form of Leishmaniasis, a series of synthetic xylene, pyridine and, pyrazole azamacrocycles were tested against three *Leishmania* species. A total of 14 compounds were tested against **[...] Read more.**
(This article belongs to the Special Issue **Tropical Protozoan Disease Treatment Drugs (/journal/pharmaceutics/special_issues/32P7Y91SQC)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00992/article_deploy/html/images/pharmaceutics-15-00992-ag-550.jpg?1679289286) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00992/article_deploy/html/images/pharmaceutics-15-00992-g001-550.jpg?1679289264) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00992/article_deploy/html/images/pharmaceutics-15-00992-g002-550.jpg?1679289275) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00992/article_deploy/html/images/pharmaceutics-15-00992-g003-550.jpg?1679289276) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00992/article_deploy/html/images/pharmaceutics-15-00992-g004-550.jpg?1679289273) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00992/article_deploy/html/images/pharmaceutics-15-00992-g005-550.jpg?1679289268) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00992/article_deploy/html/images/pharmaceutics-15-00992-g006-550.jpg?1679289280) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00992/article_deploy/html/images/pharmaceutics-15-00992-g007-550.jpg?1679289283) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00992/article_deploy/html/images/pharmaceutics-15-00992-g008-550.jpg?1679289266) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00992/article_deploy/html/images/pharmaceutics-15-00992-g009-550.jpg?1679289270) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00992/article_deploy/html/images/pharmaceutics-15-00992-g010-550.jpg?1679289286) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00992/article_deploy/html/images/pharmaceutics-15-00992-g011-550.jpg?1679289269) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00992/article_deploy/html/images/pharmaceutics-15-00992-g012-550.jpg?1679289272) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00992/article_deploy/html/images/pharmaceutics-15-00992-sch001-550.jpg?1679289284)

Open Access Article (/1999-4923/15/3/1003/pdf?version=1679329439)

Basic Properties of Adipose-Derived Mesenchymal Stem Cells of Rheumatoid Arthritis and Osteoarthritis Patients (/1999-4923/15/3/1003)

by Ewa Kuca-Warnawin (https://sciprofiles.com/profile/880310), Weronika Kurowska (https://sciprofiles.com/profile/1322665), Magdalena Plebańczyk (https://sciprofiles.com/profile/author/RDhrYnJyUnFRYXpoemZObUpyeVVFZm9rZllqOGR4c0ZsYnFGQm41OW9uM1dMelhDOTM5c0FiVkR1OHB3VWdyYg==, Anna Wajda (https://sciprofiles.com/profile/3153677), Anna Kornatka (https://sciprofiles.com/profile/author/MytvUU5FVE82QVl6ZHZZT1M3OXp3OGNMc0hQWjRLcG1YaWs1RXFlZktkND0=), Tomasz Burakowski (https://sciprofiles.com/profile/author/TkJXd1NhdUFST0dPSVBFN2ozR0prQT09), Iwona Janicka (https://sciprofiles.com/profile/author/bjlKdW1qWW9ocjBSTW8yT21BSnZHd3JqMVVWMTFBaE1vdTM4dFNEYUFOR1RtZWx0cytuZ24rOUdQZTB6ZEZxbg==, Piotr Syrówka (https://sciprofiles.com/profile/author/SmhnQUVScTFjcjhqbUNNVHZNUUErVzlGVFlwSFg5ekZtV0xJUVVydERMcz0=) and Urszula Skalska (https://sciprofiles.com/profile/author/M3dhbEV2emJBSS9lVXRiajV6RW4wZHovZCtrQkhDVWhzUFU0QU0rLzJDZz0=)

Pharmaceutics **2023**, *15*(3), 1003; https://doi.org/10.3390/pharmaceutics15031003 (https://doi.org/10.3390/pharmaceutics15031003) - 20 Mar 2023
Cited by 1 (/1999-4923/15/3/1003#metrics) | Viewed by 1203

Abstract Rheumatoid arthritis (RA) and osteoarthritis (OA) are destructive joint diseases, the development of which are associated with the expansion of pathogenic T lymphocytes. Mesenchymal stem cells may be an attractive therapeutic option for patients with RA or OA due to the regenerative and **[...] Read more.**
(This article belongs to the Special Issue **Stromal, Stem, Signaling Cells: The Multiple Roles and Applications of Mesenchymal Cells, 2nd Edition (/journal/pharmaceutics/special_issues/1S4BYOVRQ2)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01003/article_deploy/html/images/pharmaceutics-15-01003-g001-550.jpg?1679913505) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01003/article_deploy/html/images/pharmaceutics-15-01003-g002-550.jpg?1679913518) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01003/article_deploy/html/images/pharmaceutics-15-01003-g003-550.jpg?1679913512) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01003/article_deploy/html/images/pharmaceutics-15-01003-g004-550.jpg?1679913511) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01003/article_deploy/html/images/pharmaceutics-15-01003-g005-550.jpg?1679913500) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01003/article_deploy/html/images/pharmaceutics-15-01003-g006-550.jpg?1679913514) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01003/article_deploy/html/images/pharmaceutics-15-01003-g007-550.jpg?1679913509) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01003/article_deploy/html/images/pharmaceutics-15-01003-g008-550.jpg?1679913503) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01003/article_deploy/html/images/pharmaceutics-15-01003-g009-550.jpg?1679913507) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01003/article_deploy/html/images/pharmaceutics-15-01003-g010-550.jpg?1679913516)

Open Access Review (/1999-4923/15/3/1002/pdf?version=1679575703)

Understanding the Mechanisms and Treatment of Heart Failure: Quantitative Systems Pharmacology Models with a Focus on SGLT2 Inhibitors and Sex-Specific Differences (/1999-4923/15/3/1002)

by Jean François Ndiaye (https://sciprofiles.com/profile/2742984), Fahima Nekka (https://sciprofiles.com/profile/author/UWFzZ2lZT2dMdWFjVzl5UGtuZHgxMWZST0lwdUlBV0Fab08vVU1KQStNVT0=) and Morgan Craig (https://sciprofiles.com/profile/945359)

Pharmaceutics **2023**, *15*(3), 1002; https://doi.org/10.3390/pharmaceutics15031002 (https://doi.org/10.3390/pharmaceutics15031002) - 20 Mar 2023
Cited by 1 (/1999-4923/15/3/1002#metrics) | Viewed by 1671

Abstract Heart failure (HF), which is a major clinical and public health challenge, commonly develops when the myocardial muscle is unable to pump an adequate amount of blood at typical cardiac pressures to fulfill the body's metabolic needs, and compensatory mechanisms are compromised or **[...] Read more.**
(This article belongs to the Special Issue **The Role of Pharmacometrics in Drug Discovery and Development Process (Volume II) (/journal/pharmaceutics/special_issues/pharmacometrics_volume_II)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01002/article_deploy/html/images/pharmaceutics-15-01002-g001-550.jpg?1679575773) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01002/article_deploy/html/images/pharmaceutics-15-01002-g002-550.jpg?1679575775)

Open Access Article (/1999-4923/15/3/1001/pdf?version=1679312827)

Development and Characterization of Folic Acid-Conjugated Amodiaquine-Loaded Nanoparticles–Efficacy in Cancer Treatment (/1999-4923/15/3/1001)

by Vineela Parvathaneni (https://sciprofiles.com/profile/982045), Snehal K. Shukla (https://sciprofiles.com/profile/829552) and Vivek Gupta (https://sciprofiles.com/profile/813148)

Pharmaceutics **2023**, *15*(3), 1001; https://doi.org/10.3390/pharmaceutics15031001 (https://doi.org/10.3390/pharmaceutics15031001) - 20 Mar 2023
Cited by 2 (/1999-4923/15/3/1001#metrics) | Viewed by 1454

Abstract The objective of this study was to construct amodiaquine-loaded, folic acid-conjugated polymeric nanoparticles (FA-AQ NPs) to treat cancer that could be scaled to commercial production. In this study, folic acid (FA) was conjugated with a PLGA polymer followed by the formulation of drug-loaded **[...] Read more.**
(This article belongs to the Special Issue **Development of Novel Tumor-Targeting Nanoparticles (/journal/pharmaceutics/special_issues/nanoparticles_tumor)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01001/article_deploy/html/images/pharmaceutics-15-01001-g001-550.jpg?1679312910) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01001/article_deploy/html/images/pharmaceutics-15-01001-g002-550.jpg?1679312905) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01001/article_deploy/html/images/pharmaceutics-15-01001-g003-550.jpg?1679312902) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01001/article_deploy/html/images/pharmaceutics-15-01001-g004-550.jpg?1679312912) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01001/article_deploy/html/images/pharmaceutics-15-01001-g005-550.jpg?1679312917) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01001

Back to TopTop

/article_deploy/html/images/pharmaceutics-15-01001-g006-550.jpg?1679312915) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01001/article_deploy/html/images/pharmaceutics-15-01001-g007-550.jpg?1679312909) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01001/article_deploy/html/images/pharmaceutics-15-01001-g008-550.jpg?1679312919) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01001/article_deploy/html/images/pharmaceutics-15-01001-g009-550.jpg?1679312906)

Open Access Article (/1999-4923/15/3/1000/pdf?version=1679451802)

Coating of SPIONs with a Cysteine-Decorated Copolyester: A Possible Novel Nanoplatform for Enzymatic Release (/1999-4923/15/3/1000)

by Jeovandro Maria Beltrame (https://sciprofiles.com/profile/2749446), Brena Beatriz Pereira Ribeiro (https://sciprofiles.com/profile/2846966), Camila Guindani (https://sciprofiles.com/profile/author/UmlKNkR1bkYyNFQwQ0xpeTZXQkwrV3MvYmpFajlEVEVneTExNDZuZU1scz0=), Graziâni Candiotto (https://sciprofiles.com/profile/2791727), Karina Bettega Felipe (https://sciprofiles.com/profile/2847187), Rodrigo Lucas (https://sciprofiles.com/profile/author/OHdGTzRBQVl6VmplcjdLcWRlNU15bGpMKzhyVEpLcnlJTGQyaCt2MHpBQT0=), Alexandre D'Agostini Zottis (https://sciprofiles.com/profile/author/S2lxOWtVTFNGcG5ERlNjVnZtWTVsZz09), Eduardo Isoppo (https://sciprofiles.com/profile/author/d2xnOEJrR3c0eEs5Tk9lWmF5VVBzM1kxbXNVc2FlVExBd1l1ZlNzbDNhOD0=), Claudia Sayer (https://sciprofiles.com/profile/133330) and Pedro Henrique Hermes de Araújo (https://sciprofiles.com/profile/2448456)

Pharmaceutics **2023**, *15*(3), 1000; https://doi.org/10.3390/pharmaceutics15031000 (https://doi.org/10.3390/pharmaceutics15031000) - 20 Mar 2023

Cited by 2 (/1999-4923/15/3/1000#metrics) | Viewed by 983

Abstract Superparamagnetic iron oxide nanoparticles (SPIONs) have their use approved for the diagnosis/treatment of malignant tumors and can be metabolized by the organism. To prevent embolism caused by these nanoparticles, they need to be coated with biocompatible and non-cytotoxic materials. Here, we synthesized an **[...] Read more.**
(This article belongs to the Special Issue **Polymers Enhancing Bioavailability in Drug Delivery, 2nd Edition (/journal/pharmaceutics/special_issues/0JC3F78273)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01000/article_deploy/html/images/pharmaceutics-15-01000-g001-550.jpg?1679451877) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01000/article_deploy/html/images/pharmaceutics-15-01000-g002-550.jpg?1679451880) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01000/article_deploy/html/images/pharmaceutics-15-01000-g003-550.jpg?1679451876) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-01000/article_deploy/html/images/pharmaceutics-15-01000-sch001-550.jpg?1679451875)

Open Access Article (/1999-4923/15/3/991/pdf?version=1679219466)

Antibacterial, Anti-Biofilm and Pro-Migratory Effects of Double Layered Hydrogels Packaged with Lactoferrin-DsiRNA-Silver Nanoparticles for Chronic Wound Therapy (/1999-4923/15/3/991)

by Mohammad Aqil M. Fathil (https://sciprofiles.com/profile/author/TlhyNzA2bnBPem0xYXJQWi8yUkRiS2l0MzRONVViRC9Nb29EcU1FZ2JTcz0=) and Haliza Katas (https://sciprofiles.com/profile/1418666)

Pharmaceutics **2023**, *15*(3), 991; https://doi.org/10.3390/pharmaceutics15030991 (https://doi.org/10.3390/pharmaceutics15030991) - 19 Mar 2023

Cited by 3 (/1999-4923/15/3/991#metrics) | Viewed by 1413

Abstract Antimicrobial resistance and biofilm formation in diabetic foot infections worsened during the COVID-19 pandemic, resulting in more severe infections and increased amputations. Therefore, this study aimed to develop a dressing that could effectively aid in the wound healing process and prevent bacterial infections **[...] Read more.**
(This article belongs to the Special Issue **Lactoferrin in Biomedical Applications (/journal/pharmaceutics/special_issues/Lactoferrin)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00991/article_deploy/html/images/pharmaceutics-15-00991-g001-550.jpg?1679219569) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00991/article_deploy/html/images/pharmaceutics-15-00991-g002-550.jpg?1679219574) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00991/article_deploy/html/images/pharmaceutics-15-00991-g003-550.jpg?1679219560) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00991/article_deploy/html/images/pharmaceutics-15-00991-g004-550.jpg?1679219566) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00991/article_deploy/html/images/pharmaceutics-15-00991-g005a-550.jpg?1679219576) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00991/article_deploy/html/images/pharmaceutics-15-00991-g005b-550.jpg?1679219573) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00991/article_deploy/html/images/pharmaceutics-15-00991-g006-550.jpg?1679219543) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00991/article_deploy/html/images/pharmaceutics-15-00991-g007-550.jpg?1679219547) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00991/article_deploy/html/images/pharmaceutics-15-00991-g008-550.jpg?1679219577) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00991/article_deploy/html/images/pharmaceutics-15-00991-g009-550.jpg?1679219548) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00991/article_deploy/html/images/pharmaceutics-15-00991-g010-550.jpg?1679219556) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00991/article_deploy/html/images/pharmaceutics-15-00991-g011-550.jpg?1679219578) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00991/article_deploy/html/images/pharmaceutics-15-00991-g012a-550.jpg?1679219565) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00991/article_deploy/html/images/pharmaceutics-15-00991-g012b-550.jpg?1679219553) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00991/article_deploy/html/images/pharmaceutics-15-00991-g013-550.jpg?1679219538)

Open Access Review (/1999-4923/15/3/990/pdf?version=1679218911)

A Review on Dry Eye Disease Treatment: Recent Progress, Diagnostics, and Future Perspectives (/1999-4923/15/3/990)

by Himangsu Mondal (https://sciprofiles.com/profile/2697534), Ho-Joong Kim (https://sciprofiles.com/profile/322749), Nijaya Mohanto (https://sciprofiles.com/profile/author/UStOeXRDdVNsVnhuRmZDeUJlVCt3TnU5M1Z5YjlFbDlIZncvbURTcFFwVT0=) and Jun-Pil Jee (https://sciprofiles.com/profile/309831)

Pharmaceutics **2023**, *15*(3), 990; https://doi.org/10.3390/pharmaceutics15030990 (https://doi.org/10.3390/pharmaceutics15030990) - 19 Mar 2023

Cited by 1 (/1999-4923/15/3/990#metrics) | Viewed by 2223

Abstract Dry eye disease is a multifactorial disorder of the eye and tear film with potential damage to the ocular surface. Various treatment approaches for this disorder aim to alleviate disease symptoms and restore the normal ophthalmic environment. The most widely used dosage form **[...] Read more.**
(This article belongs to the Special Issue **Local Drug Delivery System (/journal/pharmaceutics/special_issues/Local_Drug_Delivery)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00990/article_deploy/html/images/pharmaceutics-15-00990-g001-550.jpg?1679218999) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00990/article_deploy/html/images/pharmaceutics-15-00990-g002-550.jpg?1679219003) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00990/article_deploy/html/images/pharmaceutics-15-00990-g003-550.jpg?1679218992) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00990/article_deploy/html/images/pharmaceutics-15-00990-g004-550.jpg?1679218993) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00990/article_deploy/html/images/pharmaceutics-15-00990-g005-550.jpg?1679218994) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00990/article_deploy/html/images/pharmaceutics-15-00990-g006-550.jpg?1679219002) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00990/article_deploy/html/images/pharmaceutics-15-00990-g007-550.jpg?1679218995) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00990/article_deploy/html/images/pharmaceutics-15-00990-g008-550.jpg?1679219006) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00990/article_deploy/html/images/pharmaceutics-15-00990-g009-550.jpg?1679219001)

Open Access Article (/1999-4923/15/3/989/pdf?version=1679296278)

***Blautia coccoides* JCM1395^T Achieved Intratumoral Growth with Minimal Inflammation: Evidence for Live Bacterial Therapeutic Potential by an Optimized Sample Preparation and Colony PCR Method (/1999-4923/15/3/989)**

by Shoko Nomura (https://sciprofiles.com/profile/1558891), Erike W. Sukowati (https://sciprofiles.com/profile/2795961), Yuko Shigeno (https://sciprofiles.com/profile/author/ZDNkQStnTkxnYWl4NDdtNCtrM3JlTzFXNVp1ZHFFQ0dFbTdGWUpTZnNuWT0=), Maiko Takahashi (https://sciprofiles.com/profile/author/MERhUHZETjBKM3RCZGlmaW9vcU02VCtMQ1N1MUVud1NqcDl4SmhWSTY3ST0=), Akari Kato (https://sciprofiles.com/profile/author/dlVyMnpEU2JYNjlxR1VWNEN3ODNqKzZYSUJPN3QyOVl6YWdSc1VldUozcz0=), Yoshimi Benno (https://sciprofiles.com/profile/author/dEVUODJRRzF3MC9GSFZ0RXNYem5Bb3RRZTNOTzJCNFEwSW10eVNSNmFrbz0=), Fumiyoshi Yamashita (https://sciprofiles.com/profile/author/VnA2cU1GOGtiSGJlakVTS2VQeFM0RDZSQlpVMktYc2N5dEEySE43ZjJyQnBhT3JMcTdMR1ZtM05NQVBhMEd3Vw==) and Hidefumi Mukai (https://sciprofiles.com/profile/1225610)

Pharmaceutics **2023**, *15*(3), 989; https://doi.org/10.3390/pharmaceutics15030989 (https://doi.org/10.3390/pharmaceutics15030989) - 19 Mar 2023

Cited by 1 (/1999-4923/15/3/989#metrics) | Viewed by 1706

Abstract We demonstrate that *Blautia coccoides* JCM1395^T has the potential to be used for tumor-targeted live bacterial therapeutics. Prior to studying its in vivo biodistribution, a sample preparation method for reliable quantitative analysis of bacteria in biological tissues was required. Gram-positive bacteria have **[...] Read more.**
(This article belongs to the Special Issue **Novel Cell and Bioinspired Drug Delivery Systems (/journal/pharmaceutics/special_issues/cell_bioinspired_dds)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00989/article_deploy/html/images/pharmaceutics-15-00989-g001-550.jpg?1679296351) (https://pub.mdpi-

Back to TopTop

res.com/pharmaceutics/pharmaceutics-15-00989/article_deploy/html/images/pharmaceutics-15-00989-g002a-550.jpg?1679296354) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00989/article_deploy/html/images/pharmaceutics-15-00989-g002b-550.jpg?1679296350) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00989/article_deploy/html/images/pharmaceutics-15-00989-g003-550.jpg?1679296348) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00989/article_deploy/html/images/pharmaceutics-15-00989-g004-550.jpg?1679296358)

Open Access Article (/1999-4923/15/3/988/pdf?version=1679214906)

Efficient Delivery of Gemcitabine by Estrogen Receptor-Targeted PEGylated Liposome and Its Anti-Lung Cancer Activity In Vivo and In Vitro (/1999-4923/15/3/988)

by Huan Tang (https://sciprofiles.com/profile/author/SzlOTERtU2RyTzFVMnBpV2NPaGJTTTd1K3NVZkl5MU1DUFpYb0lrWlhrST0=), Zheng Zhang (https://sciprofiles.com/profile/author/WDRoR0dyUVRWZTVsamhRRTZnekdESWZ5elVKYmZlWk5nWVhTZmQxZE5QVT0=), Ming Zhu (https://sciprofiles.com/profile/author/S3ZOQU5EbGVSMS9JcXZTSlNZdWdFclhGVSsvZ2tvcFZsRTUwQkYvM0dITT0=), Yizhuo Xie (https://sciprofiles.com/profile/author/b0tWaWFBaDc1Y2kxZ2JNQ0VTUERub1lpWjdBWGYzcHoyZDlrUkM2R0VmOD0=), Zhe Lv (https://sciprofiles.com/profile/author/SmdQTDQxNTVEaFBoQTNWdVRCMlMydXlwN2tadEZremI3c2hLNmpON2NUMD0=), Rui Liu (https://sciprofiles.com/profile/author/UHBTRzdiUzI3Q3dpakhEOGc5K1RBVlZvUjZiS2xNMzFrRjc4K1BuR09yRT0=), Yujia Shen (https://sciprofiles.com/profile/author/Q1p3MS96R3hpcWFRQ2xqQlQzZFdZNzJickxzWTNiMGFGaXhTR1d6UE1RND0=) and Jin Pei (https://sciprofiles.com/profile/1585564)

Pharmaceutics **2023**, *15*(3), 988; https://doi.org/10.3390/pharmaceutics15030988 (https://doi.org/10.3390/pharmaceutics15030988) - 19 Mar 2023

Cited by 2 (/1999-4923/15/3/988#metrics) | Viewed by 943

Abstract Lung cancer is one of the main causes of cancer-related deaths. At present, the main treatment method for lung cancer is chemotherapy. Gemcitabine (GEM) is widely applied in lung cancer treatment, but its lack of targeting ability and serious side effects limit its **[...] Read more.**

(This article belongs to the Special Issue **Targeted Drug Delivery to Improve Cancer Therapy** (/journal/pharmaceutics/special_issues/target_cancer))

► **Show Figures**

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00988/article_deploy/html/images/pharmaceutics-15-00988-ag-550.jpg?1679215017) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00988/article_deploy/html/images/pharmaceutics-15-00988-g001-550.jpg?1679215004) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00988/article_deploy/html/images/pharmaceutics-15-00988-g002-550.jpg?1679215006) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00988/article_deploy/html/images/pharmaceutics-15-00988-g003-550.jpg?1679215000) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00988/article_deploy/html/images/pharmaceutics-15-00988-g004-550.jpg?1679215012) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00988/article_deploy/html/images/pharmaceutics-15-00988-g005-550.jpg?1679215008) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00988/article_deploy/html/images/pharmaceutics-15-00988-g006-550.jpg?1679215011) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00988/article_deploy/html/images/pharmaceutics-15-00988-g007-550.jpg?1679215003) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00988/article_deploy/html/images/pharmaceutics-15-00988-g008-550.jpg?1679215015) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00988/article_deploy/html/images/pharmaceutics-15-00988-g009-550.jpg?1679215016)

Open Access Review (/1999-4923/15/3/987/pdf?version=1679210431)

Prospects of Using Protein Engineering for Selective Drug Delivery into a Specific Compartment of Target Cells (/1999-4923/15/3/987)

by Andrey A. Rosenkranz (https://sciprofiles.com/profile/2786934) and Tatiana A. Slastnikova (https://sciprofiles.com/profile/author/Tm50MEwrYjcyNEhyL1R6TEZCN2ZZTnJqbGJoZHhsbFBmbk1xckgyWUVzUT0=)

Pharmaceutics **2023**, *15*(3), 987; https://doi.org/10.3390/pharmaceutics15030987 (https://doi.org/10.3390/pharmaceutics15030987) - 19 Mar 2023

Viewed by 1288

Abstract A large number of proteins are successfully used to treat various diseases. These include natural polypeptide hormones, their synthetic analogues, antibodies, antibody mimetics, enzymes, and other drugs based on them. Many of them are demanded in clinical settings and commercially successful, mainly for **[...] Read more.**

(This article belongs to the Special Issue **Editorial Board Members' Collection Series: Targeted Delivery of Anticancer Agents Engaging Cell Specific Mechanisms** (/journal/pharmaceutics/special_issues/TR941Y9BE4))

► **Show Figures**

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00987/article_deploy/html/images/pharmaceutics-15-00987-g001-550.jpg?1679210504) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00987/article_deploy/html/images/pharmaceutics-15-00987-g002-550.jpg?1679210500) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00987/article_deploy/html/images/pharmaceutics-15-00987-g003-550.jpg?1679210502) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00987/article_deploy/html/images/pharmaceutics-15-00987-g004-550.jpg?1679210507) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00987/article_deploy/html/images/pharmaceutics-15-00987-g005-550.jpg?1679210509)

Open Access Review (/1999-4923/15/3/986/pdf?version=1679382744)

Nanofibrous Scaffolds for Diabetic Wound Healing (/1999-4923/15/3/986)

by Anna Yusuf Aliyu (https://sciprofiles.com/profile/author/Y0NSSFRBMFRoZDVGdXYwQU1LQlNydz09) and Oluwatoyin A. Adeleke (https://sciprofiles.com/profile/746130)

Pharmaceutics **2023**, *15*(3), 986; https://doi.org/10.3390/pharmaceutics15030986 (https://doi.org/10.3390/pharmaceutics15030986) - 19 Mar 2023

Cited by 2 (/1999-4923/15/3/986#metrics) | Viewed by 1498

Abstract Chronic wounds are one of the secondary health complications that develop in individuals who have poorly managed diabetes mellitus. This is often associated with delays in the wound healing process, resulting from long-term uncontrolled blood glucose levels. As such, an appropriate therapeutic approach **[...] Read more.**

(This article belongs to the Special Issue **Nanofibrous Scaffolds: Promising Wound Dressing Materials** (/journal/pharmaceutics/special_issues/nano_wound))

► **Show Figures**

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00986/article_deploy/html/images/pharmaceutics-15-00986-g001-550.jpg?1679382813)

Open Access Article (/1999-4923/15/3/985/pdf?version=1679134475)

Auranofin Targeting the NDM-1 Beta-Lactamase: Computational Insights into the Electronic Configuration and Quasi-Tetrahedral Coordination of Gold Ions (/1999-4923/15/3/985)

by Iogann Tolbatov (https://sciprofiles.com/profile/1897260) and Alessandro Marrone (https://sciprofiles.com/profile/210279)

Pharmaceutics **2023**, *15*(3), 985; https://doi.org/10.3390/pharmaceutics15030985 (https://doi.org/10.3390/pharmaceutics15030985) - 18 Mar 2023

Cited by 2 (/1999-4923/15/3/985#metrics) | Viewed by 845

Abstract Recently, the well-characterized metallodrug auranofin has been demonstrated to restore the penicillin and cephalosporin sensitivity in resistant bacterial strains via the inhibition of the NDM-1 beta-lactamase, which is operated via the Zn/Au substitution in its bimetallic core. The resulting unusual tetrahedral coordination of **[...] Read more.**

(This article belongs to the Special Issue **Metallodrugs: Investigation of the Mechanism of Action and Advanced Delivery Systems at Molecular Level** (/journal/pharmaceutics/special_issues/D81HYY6DB2))

► **Show Figures**

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00985/article_deploy/html/images/pharmaceutics-15-00985-ag-550.jpg?1679134552) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00985/article_deploy/html/images/pharmaceutics-15-00985-g001-550.jpg?1679134547) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00985/article_deploy/html/images/pharmaceutics-15-00985-g002-550.jpg?1679134552) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00985/article_deploy/html/images/pharmaceutics-15-00985-g003-550.jpg?1679134548) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00985/article_deploy/html/images/pharmaceutics-15-00985-g004-550.jpg?1679134551)

Open Access Review (/1999-4923/15/3/984/pdf?version=1679147136)

The CRISPR/Cas9 System Delivered by Extracellular Vesicles (/1999-4923/15/3/984)

by Xinglong Zhu (https://sciprofiles.com/profile/author/RU1FWmxwc1R3R2NPdG96dm5lM1VTL2R5NlltKzU1dmhqY2pQeXhvVkw4WT0=), Mengyu Gao (https://sciprofiles.com/profile/author/U2VuQnJZZjVQSlp0WDY3c1plSUluNVpWYkdtNTZVaVVpcTdNVS9kYVROQT0=), Yongfeng Yang (https://sciprofiles.com/profile/author/RjZqNkpsSFdmRG9tZ2twRXZwSnlXUzhMRDQwQmN5Z0s0Zm5VcnhZVHdiVT0=), Weimin Li (https://sciprofiles.com/profile/1801344), Ji Bao (https://sciprofiles.com/profile/2209959) and Yi Li (https://sciprofiles.com/profile/2682834)

Pharmaceutics **2023**, *15*(3), 984; https://doi.org/10.3390/pharmaceutics15030984 (https://doi.org/10.3390/pharmaceutics15030984) - 18 Mar 2023

Cited by 6 (/1999-4923/15/3/984#metrics) | Viewed by 1868

Abstract Clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated protein (Cas) systems can precisely manipulate DNA sequences to change the characteristics of cells and organs, which has potential in the mechanistic research on genes and the treatment of diseases. However, clinical applications are restricted by **[...] Read more.**

(This article belongs to the Special Issue **Advances of Membrane Vesicles in Drug Delivery Systems** (/journal/pharmaceutics/special_issues/Vesicles))

► **Show Figures**

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00984/article_deploy/html/images/pharmaceutics-15-00984-g001-550.jpg?1679147216)

Open Access Review (/1999-4923/15/3/983/pdf?version=1679133304)

In Vitro Dissolution and Permeability Testing of Inhalation Products: Challenges and Advances (/1999-4923/15/3/983)

by Ali Nokhodchi (https://sciprofiles.com/profile/2686215), Salonee Chavan (https://sciprofiles.com/profile/author/TW9rS3NMMlVvc2NWYnVkYUlTd245SldWdjJEVFhzTlROd1VHQkpWL2FVTT0=) and Taravat Ghafourian (https://sciprofiles.com/profile/1322715)

Pharmaceutics **2023**, *15*(3), 983; https://doi.org/10.3390/pharmaceutics15030983 (https://doi.org/10.3390/pharmaceutics15030983) - 18 Mar 2023
Cited by 3 (/1999-4923/15/3/983#metrics) | Viewed by 2535

Abstract In vitro dissolution and permeability testing aid the simulation of the in vivo behavior of inhalation drug products. Although the regulatory bodies have specific guidelines for the dissolution of orally administered dosage forms (e.g., tablets and capsules), this is not the case for **[...] Read more.**
(This article belongs to the Special Issue **Development and Evaluation of Inhalable Dry Powder Formulations (/journal/pharmaceutics/special_issues/Inhal_formula)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00983/article_deploy/html/images/pharmaceutics-15-00983-g001-550.jpg?1679133370) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00983/article_deploy/html/images/pharmaceutics-15-00983-g002-550.jpg?1679133378) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00983/article_deploy/html/images/pharmaceutics-15-00983-g003-550.jpg?1679133376) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00983/article_deploy/html/images/pharmaceutics-15-00983-g004-550.jpg?1679133383) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00983/article_deploy/html/images/pharmaceutics-15-00983-g005-550.jpg?1679133373) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00983/article_deploy/html/images/pharmaceutics-15-00983-g006-550.jpg?1679133374) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00983/article_deploy/html/images/pharmaceutics-15-00983-g007-550.jpg?1679133371) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00983/article_deploy/html/images/pharmaceutics-15-00983-g008-550.jpg?1679133369) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00983/article_deploy/html/images/pharmaceutics-15-00983-g009-550.jpg?1679133379) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00983/article_deploy/html/images/pharmaceutics-15-00983-g010-550.jpg?1679133381) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00983/article_deploy/html/images/pharmaceutics-15-00983-g011-550.jpg?1679133372)

Open Access Review (/1999-4923/15/3/982/pdf?version=1679131888)

Applications of Stimuli-Responsive Hydrogels in Bone and Cartilage Regeneration (/1999-4923/15/3/982)

by Xiaoqi Ni (https://sciprofiles.com/profile/author/TUYwbDVqYmltbVErRmlUS1NlZ1F4MnlpUStqVnFSK1hJRlZVQmY5bWYwaz0=), Xin Xing (https://sciprofiles.com/profile/2522506), Yunfan Deng (https://sciprofiles.com/profile/author/NTJld3ZkSUVna0xHc2p4QTVDNldYWUQwK3ZkcWxUMElEcnV1ZFVqNXZ3VT0=) and Zhi Li (https://sciprofiles.com/profile/1682943)

Pharmaceutics **2023**, *15*(3), 982; https://doi.org/10.3390/pharmaceutics15030982 (https://doi.org/10.3390/pharmaceutics15030982) - 18 Mar 2023
Cited by 2 (/1999-4923/15/3/982#metrics) | Viewed by 1147

Abstract Bone and cartilage regeneration is an area of tremendous interest and need in health care. Tissue engineering is a potential strategy for repairing and regenerating bone and cartilage defects. Hydrogels are among the most attractive biomaterials in bone and cartilage tissue engineering, mainly **[...] Read more.**
(This article belongs to the Special Issue **Frontiers in Hydrogel-Based Drug Delivery Systems (/journal/pharmaceutics/special_issues/hydrogel_system)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00982/article_deploy/html/images/pharmaceutics-15-00982-g001-550.jpg?1679131970) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00982/article_deploy/html/images/pharmaceutics-15-00982-g002-550.jpg?1679131975) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00982/article_deploy/html/images/pharmaceutics-15-00982-g003-550.jpg?1679131968) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00982/article_deploy/html/images/pharmaceutics-15-00982-g004-550.jpg?1679131964) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00982/article_deploy/html/images/pharmaceutics-15-00982-g005-550.jpg?1679131959) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00982/article_deploy/html/images/pharmaceutics-15-00982-g006-550.jpg?1679131972) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00982/article_deploy/html/images/pharmaceutics-15-00982-g007-550.jpg?1679131962) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00982/article_deploy/html/images/pharmaceutics-15-00982-g008-550.jpg?1679131977) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00982/article_deploy/html/images/pharmaceutics-15-00982-g009-550.jpg?1679131967) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00982/article_deploy/html/images/pharmaceutics-15-00982-g010-550.jpg?1679131978)

Open Access Article (/1999-4923/15/3/981/pdf?version=1679133653)

Design of Innovative Biocompatible Cellulose Nanostructures for the Delivery and Sustained Release of Curcumin (/1999-4923/15/3/981)

by Francisca Casanova (https://sciprofiles.com/profile/2300591), Carla F. Pereira (https://sciprofiles.com/profile/2038502), Alessandra B. Ribeiro (https://sciprofiles.com/profile/1021974), Eduardo M. Costa (https://sciprofiles.com/profile/89330), Ricardo Freixo (https://sciprofiles.com/profile/2806113), Pedro M. Castro (https://sciprofiles.com/profile/author/R2dzUjJseDRLM2lETU56RDlSdUZLUT09), João C. Fernandes (https://sciprofiles.com/profile/2196046), Manuela Pintado (https://sciprofiles.com/profile/456608) and Óscar L. Ramos (https://sciprofiles.com/profile/2238150)

Pharmaceutics **2023**, *15*(3), 981; https://doi.org/10.3390/pharmaceutics15030981 (https://doi.org/10.3390/pharmaceutics15030981) - 18 Mar 2023
Cited by 1 (/1999-4923/15/3/981#metrics) | Viewed by 1241

Abstract Poor aqueous solubility, stability and bioavailability of interesting bioactive compounds is a challenge in the development of bioactive formulations. Cellulose nanostructures are promising and sustainable carriers with unique features that may be used in enabling delivery strategies. In this work, cellulose nanocrystals (CNC) **[...] Read more.**
(This article belongs to the Special Issue **Frontiers in the Application of Nanomaterials in Drug Delivery (/journal/pharmaceutics/special_issues/Nanomaterials_Delivery)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00981/article_deploy/html/images/pharmaceutics-15-00981-ag-550.jpg?1679133754) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00981/article_deploy/html/images/pharmaceutics-15-00981-g001-550.jpg?1679133741) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00981/article_deploy/html/images/pharmaceutics-15-00981-g002-550.jpg?1679133745) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00981/article_deploy/html/images/pharmaceutics-15-00981-g003-550.jpg?1679133742) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00981/article_deploy/html/images/pharmaceutics-15-00981-g004-550.jpg?1679133743) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00981/article_deploy/html/images/pharmaceutics-15-00981-g005-550.jpg?1679133749) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00981/article_deploy/html/images/pharmaceutics-15-00981-g006-550.jpg?1679133746) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00981/article_deploy/html/images/pharmaceutics-15-00981-g007-550.jpg?1679133748) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00981/article_deploy/html/images/pharmaceutics-15-00981-g008-550.jpg?1679133741) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00981/article_deploy/html/images/pharmaceutics-15-00981-g009-550.jpg?1679133753)

Open Access Article (/1999-4923/15/3/980/pdf?version=1679129525)

Physicochemical Characterization and Evaluation of Gastrointestinal In Vitro Behavior of Alginate-Based Microbeads with Encapsulated Grape Pomace Extracts (/1999-4923/15/3/980)

by Josipa Martinović (https://sciprofiles.com/profile/author/c0NCbW5OSTYyd2k2RmtVUjhxbitFTmgvSXNQbHMxOHRRYXIxQ2pSdWdqWT0=), Jasmina Lukinac (https://sciprofiles.com/profile/444184), Marko Jukić (https://sciprofiles.com/profile/529157), Rita Ambrus (https://sciprofiles.com/profile/161462), Mirela Planinić (https://sciprofiles.com/profile/1571782), Gordana Šelo (https://sciprofiles.com/profile/1266283), Ana-Marija Klarić (https://sciprofiles.com/profile/author/S1INVlFCaXdDS2dweG51MlltZ0Fybk9VQi9QOFdPR0dKTDJUQmZHMGU4UT0=), Gabriela Perković (https://sciprofiles.com/profile/author/SE5EVXpTd0hlZUlVMnhSL0NNVytEVzhlcTFDZE1CKzQzQ0dDTmlISlBEND0=) and Ana Bucić-Kojić (https://sciprofiles.com/profile/1208596)

Pharmaceutics **2023**, *15*(3), 980; https://doi.org/10.3390/pharmaceutics15030980 (https://doi.org/10.3390/pharmaceutics15030980) - 18 Mar 2023
Cited by 1 (/1999-4923/15/3/980#metrics) | Viewed by 1218

Abstract Grape pomace is a byproduct of wineries and a rich source of phenolic compounds that can exert multiple pharmacological effects when consumed and enter the intestine where they can then be absorbed. Phenolic compounds are susceptible to degradation and interaction with other food **[...] Read more.**
(This article belongs to the Section **Drug Delivery and Controlled Release (/journal/pharmaceutics/sections/Drug_Delivery_and_Control_Release)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00980/article_deploy/html/images/pharmaceutics-15-00980-ag-550.jpg?1679541743) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00980/article_deploy/html/images/pharmaceutics-15-00980-g001-550.jpg?1679129594) (https://pub.mdpi-res.com

Back to TopTop

/pharmaceutics/pharmaceutics-15-00980/article_deploy/html/images/pharmaceutics-15-00980-g002-550.jpg?1679129606) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00980/article_deploy/html/images/pharmaceutics-15-00980-g003-550.jpg?1679129603) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00980/article_deploy/html/images/pharmaceutics-15-00980-g004-550.jpg?1679129605) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00980/article_deploy/html/images/pharmaceutics-15-00980-g005-550.jpg?1679129598) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00980/article_deploy/html/images/pharmaceutics-15-00980-g006-550.jpg?1679129600) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00980/article_deploy/html/images/pharmaceutics-15-00980-g007-550.jpg?1679129596)

Open Access Article (/1999-4923/15/3/979/pdf?version=1679272853)

Phenotyping Indices of CYP450 and P-Glycoprotein in Human Volunteers and in Patients Treated with Painkillers or Psychotropic Drugs (/1999-4923/15/3/979)

by Léa Darnaud (https://sciprofiles.com/profile/2560915), Clément Delage (https://sciprofiles.com/profile/1758289), Youssef Daali (https://sciprofiles.com/profile/781576), Anne-Priscille Trouvin (https://sciprofiles.com/profile/913107), Serge Perrot (https://sciprofiles.com/profile/1702765), Nihel Khoudour (https://sciprofiles.com/profile/1450317), Nadia Merise (https://sciprofiles.com/profile/author/bm9KelFqTkRGZnNnQjJsajY3KzNBdDdNTmNCYkNySitiUVArVXlUK1NZUT0=), Laurence Labat (https://sciprofiles.com/profile/2816783), Bruno Etain (https://sciprofiles.com/profile/514642), Frank Bellivier (https://sciprofiles.com/profile/author/eS95MEVmRmlvbGtTM0VSR2tFYlVMc045V0pzeWF0WWY4L0U5ZmFNL2FXZz0=), Célia Lloret-Linares (https://sciprofiles.com/profile/author/RlUvVlY5amdJdk53VmJoR0xKYWt3aTkzYUJaR01QblNjemxCVlpDMWwvST0=), Vanessa Bloch (https://sciprofiles.com/profile/1926887), Emmanuel Curis (https://sciprofiles.com/profile/221481) and Xavier Declèves (https://sciprofiles.com/profile/966765)

Pharmaceutics **2023**, *15*(3), 979; https://doi.org/10.3390/pharmaceutics15030979 (https://doi.org/10.3390/pharmaceutics15030979) - 18 Mar 2023
Viewed by 772

Abstract Drug-metabolizing enzymes and drug transporters are key determinants of drug pharmacokinetics and response. The cocktail-based cytochrome P450 (CYP) and drug transporter phenotyping approach consists in the administration of multiple CYP or transporter-specific probe drugs to determine their activities simultaneously. Several drug cocktails have **[...] Read more.**
(This article belongs to the Section **Pharmacokinetics and Pharmacodynamics (/journal/pharmaceutics/sections/Pharmacokinetics_and_Pharmacodynamics)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00979/article_deploy/html/images/pharmaceutics-15-00979-g001-550.jpg?1679272933) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00979/article_deploy/html/images/pharmaceutics-15-00979-g0A1-550.jpg?1679272927) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00979/article_deploy/html/images/pharmaceutics-15-00979-g0A2-550.jpg?1679272929)

Open Access Article (/1999-4923/15/3/978/pdf?version=1679124579)

Analysis of NSAIDs in Rat Plasma Using 3D-Printed Sorbents by LC-MS/MS: An Approach to Pre-Clinical Pharmacokinetic Studies (/1999-4923/15/3/978)

by Daya Raju Adye (https://sciprofiles.com/profile/2761862), Sachin B. Jorvekar (https://sciprofiles.com/profile/author/NmR0aXRwMXpwZm4vT2xjanZucjE2MUxBbXRqV1IyZFFTRFBGTHNJTlAwUT0=), Upadhyayula Suryanarayana Murty (https://sciprofiles.com/profile/author/RG4wSHlhbHlDMTFSWGFGL1VWNzlNUDMzN2t5ZzFQMTdzbEFlS1VVZUR2ST0=), Subham Banerjee (https://sciprofiles.com/profile/1076621) and Roshan M. Borkar (https://sciprofiles.com/profile/2473724)

Pharmaceutics **2023**, *15*(3), 978; https://doi.org/10.3390/pharmaceutics15030978 (https://doi.org/10.3390/pharmaceutics15030978) - 18 Mar 2023
Cited by 1 (/1999-4923/15/3/978#metrics) | Viewed by 1008

Abstract Analytical sample preparation techniques are essential for assessing chemicals in various biological matrices. The development of extraction techniques is a modern trend in the bioanalytical sciences. We fabricated customized filaments using hot-melt extrusion techniques followed by fused filament fabrication-mediated 3D printing technology to **[...] Read more.**
(This article belongs to the Special Issue **Printed Pharmaceuticals in Future Healthcare (/journal/pharmaceutics/special_issues/printed_pharmaceuticals_future_healthcare)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00978/article_deploy/html/images/pharmaceutics-15-00978-g001-550.jpg?1679124655) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00978/article_deploy/html/images/pharmaceutics-15-00978-g002-550.jpg?1679124656) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00978/article_deploy/html/images/pharmaceutics-15-00978-g003-550.jpg?1679124668) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00978/article_deploy/html/images/pharmaceutics-15-00978-g004-550.jpg?1679124648) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00978/article_deploy/html/images/pharmaceutics-15-00978-g005-550.jpg?1679124653) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00978/article_deploy/html/images/pharmaceutics-15-00978-g006a-550.jpg?1679124648) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00978/article_deploy/html/images/pharmaceutics-15-00978-g006b-550.jpg?1679124657) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00978/article_deploy/html/images/pharmaceutics-15-00978-g007a-550.jpg?1679124661) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00978/article_deploy/html/images/pharmaceutics-15-00978-g007b-550.jpg?1679124649) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00978/article_deploy/html/images/pharmaceutics-15-00978-g008a-550.jpg?1679124660) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00978/article_deploy/html/images/pharmaceutics-15-00978-g008b-550.jpg?1679124665) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00978/article_deploy/html/images/pharmaceutics-15-00978-g009-550.jpg?1679124661)

Open Access Article (/1999-4923/15/3/977/pdf?version=1679115549)

pH-Responsive Poly(ethylene glycol)-*b*-poly(2-vinylpyridine) Micelles for the Triggered Release of Therapeutics (/1999-4923/15/3/977)

by Kyle Brewer (https://sciprofiles.com/profile/author/S2kzRTJwN09DZlN4OHFCVERuS2luNTR0Q2pyOXlmdlNYWGhWOHgwRUdzZz0=), Fengxiang Bai (https://sciprofiles.com/profile/author/b2hwbFZNc0taQ2R5bGI2V0plR3Y3d2RIa09jbThBUmQwa1FlYWxZMWZYaHJUNmlNSndXQjg2VkR6ZnFnTmU1Mg==) and Anton Blencowe (https://sciprofiles.com/profile/374125)

Pharmaceutics **2023**, *15*(3), 977; https://doi.org/10.3390/pharmaceutics15030977 (https://doi.org/10.3390/pharmaceutics15030977) - 18 Mar 2023
Cited by 1 (/1999-4923/15/3/977#metrics) | Viewed by 1148

Abstract The use of pH-responsive polymeric micelles is a promising approach to afford the targeted, pH-mediated delivery of hydrophobic drugs within the low-pH tumour milieu and intracellular organelles of cancer cells. However, even for a common pH-responsive polymeric micelle system—e.g., those utilising poly(ethylene glycol)- **[...] Read more.**
(This article belongs to the Special Issue **Self-Assembled Amphiphilic Copolymers in Drug Delivery (/journal/pharmaceutics/special_issues/assembled_polymer)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00977/article_deploy/html/images/pharmaceutics-15-00977-ag-550.jpg?1679115618) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00977/article_deploy/html/images/pharmaceutics-15-00977-g001-550.jpg?1679115614) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00977/article_deploy/html/images/pharmaceutics-15-00977-g002-550.jpg?1679115613) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00977/article_deploy/html/images/pharmaceutics-15-00977-g003-550.jpg?1679115615) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00977/article_deploy/html/images/pharmaceutics-15-00977-sch001-550.jpg?1679115609)

Open Access Review (/1999-4923/15/3/976/pdf?version=1679387791)

Polymeric Micellar Systems—A Special Emphasis on "Smart" Drug Delivery (/1999-4923/15/3/976)

by Irina Negut (https://sciprofiles.com/profile/509227) and Bogdan Bita (https://sciprofiles.com/profile/1716353)

Pharmaceutics **2023**, *15*(3), 976; https://doi.org/10.3390/pharmaceutics15030976 (https://doi.org/10.3390/pharmaceutics15030976) - 17 Mar 2023
Cited by 3 (/1999-4923/15/3/976#metrics) | Viewed by 1638

Abstract Concurrent developments in anticancer nanotechnological treatments have been observed as the burden of cancer increases every year. The 21st century has seen a transformation in the study of medicine thanks to the advancement in the field of material science and nanomedicine. Improved drug **[...] Read more.**
(This article belongs to the Special Issue **Self-Assembled Amphiphilic Copolymers in Drug Delivery (/journal/pharmaceutics/special_issues/assembled_polymer)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00976/article_deploy/html/images/pharmaceutics-15-00976-g001-550.jpg?1679387875) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00976/article_deploy/html/images/pharmaceutics-15-00976-g002-550.jpg?1679387879) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00976/article_deploy/html/images/pharmaceutics-15-00976-g003-550.jpg?1679387863) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00976/article_deploy/html/images/pharmaceutics-15-00976-g004-550.jpg?1679387867) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00976/article_deploy/html/images/pharmaceutics-15-00976-g005-550.jpg?1679387865) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00976/article_deploy/html/images/pharmaceutics-15-00976-g006-550.jpg?1679387869) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00976/article_deploy/html/images/pharmaceutics-15-00976-g007-550.jpg?1679387871) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00976/article_deploy/html/images

/pharmaceutics-15-00976-g008-550.jpg?1679387874) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00976/article_deploy/html/images/pharmaceutics-15-00976-g009-550.jpg?1679387876) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00976/article_deploy/html/images/pharmaceutics-15-00976-g010-550.jpg?1679387872)

(/toggle_desktop_layout_cookie)

Open Access Article (/1999-4923/15/3/975/pdf?version=1679048587)

New Smart Bioactive and Biomimetic Chitosan-Based Hydrogels for Wounds Care Management (/1999-4923/15/3/975)

by Simona-Maria Tatarusanu (https://sciprofiles.com/profile/2346697), Alexandru Sava (https://sciprofiles.com/profile/1644812), Bianca-Stefania Profire (https://sciprofiles.com/profile/2746023), Tudor Pinteala (https://sciprofiles.com/profile/author/dGxyQ3F0ZXBkRUR4d2x0NTFxUHdTMDE5OG9QTVl0N1krTDU1bWdpL0NuRT0=), Alexandra Jitareanu (https://sciprofiles.com/profile/1841443), Andreea-Teodora Iacob (https://sciprofiles.com/profile/442719), Florentina Lupascu (https://sciprofiles.com/profile/1573830), Natalia Simionescu (https://sciprofiles.com/profile/1525682), Irina Rosca (https://sciprofiles.com/profile/439755) and Lenuta Profire (https://sciprofiles.com/profile/44326)

Pharmaceutics **2023**, *15*(3), 975; https://doi.org/10.3390/pharmaceutics15030975 (https://doi.org/10.3390/pharmaceutics15030975) - 17 Mar 2023

Abstract Wound management represents a continuous challenge for health systems worldwide, considering the growing incidence of wound-related comorbidities, such as diabetes, high blood pressure, obesity, and autoimmune diseases. In this context, hydrogels are considered viable options since they mimic the skin structure and promote [...] **Read more.**

(This article belongs to the Special Issue **Carbohydrate-Based Carriers for Drug Delivery (/journal/pharmaceutics/special_issues/C4VV1368VZ)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00975/article_deploy/html/images/pharmaceutics-15-00975-g001-550.jpg?1679048671) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00975/article_deploy/html/images/pharmaceutics-15-00975-g002-550.jpg?1679048660) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00975/article_deploy/html/images/pharmaceutics-15-00975-g003-550.jpg?1679048654) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00975/article_deploy/html/images/pharmaceutics-15-00975-g004-550.jpg?1679048665) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00975/article_deploy/html/images/pharmaceutics-15-00975-g005-550.jpg?1679048670) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00975/article_deploy/html/images/pharmaceutics-15-00975-g006-550.jpg?1679048661) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00975/article_deploy/html/images/pharmaceutics-15-00975-g007-550.jpg?1679048657) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00975/article_deploy/html/images/pharmaceutics-15-00975-g008-550.jpg?1679048658) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00975/article_deploy/html/images/pharmaceutics-15-00975-g009-550.jpg?1679048676) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00975/article_deploy/html/images/pharmaceutics-15-00975-g010-550.jpg?1679048673) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00975/article_deploy/html/images/pharmaceutics-15-00975-g011-550.jpg?1679048655) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00975/article_deploy/html/images/pharmaceutics-15-00975-g012-550.jpg?1679048659)

Open Access Article (/1999-4923/15/3/974/pdf?version=1679044161)

Plant-Derived Extracellular Vesicles as a Delivery Platform for RNA-Based Vaccine: Feasibility Study of an Oral and Intranasal SARS-CoV-2 Vaccine (/1999-4923/15/3/974)

by Margherita A. C. Pomatto (https://sciprofiles.com/profile/2777567), Chiara Gai (https://sciprofiles.com/profile/author/dFc2ZDdVU1pwT29DNWl4NjJUSk5mYVJmRXFZUE50WmhwdzhsRkUremJoST0=), Federica Negro (https://sciprofiles.com/profile/author/Tm53Z1pJOG15SGhDRXlDRXQwczF0TjhiYmFaVl9KQzRiOGRSSkdFeTdqcz0=), Lucia Massari (https://sciprofiles.com/profile/author/QUZLODJ5VUxyT2xRcUdmSzdFeUNYYjZKeWxFUE9xY3F1bzhUc3RoN1ZWRT0=), Maria Chiara Deregibus (https://sciprofiles.com/profile/1849108), Cristina Grange (https://sciprofiles.com/profile/722075), Francesco Giuseppe De Rosa (https://sciprofiles.com/profile/1450348) and Giovanni Camussi (https://sciprofiles.com/profile/683994)

Pharmaceutics **2023**, *15*(3), 974; https://doi.org/10.3390/pharmaceutics15030974 (https://doi.org/10.3390/pharmaceutics15030974) - 17 Mar 2023

Abstract Plant-derived extracellular vesicles (EVs) may represent a platform for the delivery of RNA-based vaccines, exploiting their natural membrane envelope to protect and deliver nucleic acids. Here, EVs extracted from orange (*Citrus sinensis*) juice (oEVs) were investigated as carriers for oral and **[...] Read more.**

(This article belongs to the Special Issue **Advances of Membrane Vesicles in Drug Delivery Systems (/journal/pharmaceutics/special_issues/Vesicles)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00974/article_deploy/html/images/pharmaceutics-15-00974-ag-550.jpg?1679044251) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00974/article_deploy/html/images/pharmaceutics-15-00974-g001-550.jpg?1679044242) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00974/article_deploy/html/images/pharmaceutics-15-00974-g002-550.jpg?1679044246) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00974/article_deploy/html/images/pharmaceutics-15-00974-g003-550.jpg?1679044244) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00974/article_deploy/html/images/pharmaceutics-15-00974-g004-550.jpg?1679044241) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00974/article_deploy/html/images/pharmaceutics-15-00974-g005-550.jpg?1679044238) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00974/article_deploy/html/images/pharmaceutics-15-00974-g006-550.jpg?1679044236) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00974/article_deploy/html/images/pharmaceutics-15-00974-g007-550.jpg?1679044234)

Open Access Article (/1999-4923/15/3/973/pdf?version=1679041257)

A Novel Preparation Technique for Human Nasal Respiratory Mucosa to Disclose Its Glycosylation Pattern for Bioadhesive Drug Delivery (/1999-4923/15/3/973)

by Julia Clara Gausterer (https://sciprofiles.com/profile/2710578), Michael Schlager (https://sciprofiles.com/profile/author/Y1oyblJGNk4rQzFCQ2hGT3lBV1BwdGlwTl9TZnlwR0ZmbjFqUHVveIF2bz0=), Navid Ahmadi (https://sciprofiles.com/profile/author/YTRJb05jeWpmZUMrRm1Td1RCSW5XUG5oQ1pJUEU4alg3QVg3dUYrRjQyVT0=), Michael Nieratschker (https://sciprofiles.com/profile/author/T0ZCMTNXcC9VbmF3VnBHVlN5UFlIdjNxRjVhN0E4TXJ1cmNiT2lmREZ2Y2tkQ2lDdFJuM0ZEM3VoZ2NPa21sVQ==), Valerie Dahm (https://sciprofiles.com/profile/883988), Michael Wirth (https://sciprofiles.com/profile/author/bkpvMTY1YVJETTlRczhkaGZvWkprN2JmektHNktiZEoxYk8rcVd6RzZpND0=), Christoph Arnoldner (https://sciprofiles.com/profile/868397), Clemens Honeder (https://sciprofiles.com/profile/author/UXRyR2k0TGZ0SG9CbE9hRndCRXUwVnpEdmQ4UFdNNnVHZE9Zem1QeGtDdzJNOWxBSHAwTlJ5OW5maG5PV2tGRg==) and Franz Gabor (https://sciprofiles.com/profile/2710568)

Pharmaceutics **2023**, *15*(3), 973; https://doi.org/10.3390/pharmaceutics15030973 (https://doi.org/10.3390/pharmaceutics15030973) - 17 Mar 2023

Abstract To shed some light on glycotargeting as a potential strategy for nasal drug delivery, a reliable preparation method for human nasal mucosa samples and a tool to investigate the carbohydrate building blocks of the glycocalyx of the respiratory epithelium are required. Applying a **[...] Read more.**

(This article belongs to the Section **Drug Targeting and Design (/journal/pharmaceutics/sections/Drug_Targeting_Design)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00973/article_deploy/html/images/pharmaceutics-15-00973-ag-550.jpg?1679041362) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00973/article_deploy/html/images/pharmaceutics-15-00973-g001-550.jpg?1679041345) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00973/article_deploy/html/images/pharmaceutics-15-00973-g002-550.jpg?1679041342) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00973/article_deploy/html/images/pharmaceutics-15-00973-g003-550.jpg?1679041351) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00973/article_deploy/html/images/pharmaceutics-15-00973-g004-550.jpg?1679041348) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00973/article_deploy/html/images/pharmaceutics-15-00973-g005-550.jpg?1679041344) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00973/article_deploy/html/images/pharmaceutics-15-00973-g006-550.jpg?1679041354)

Open Access Article (/1999-4923/15/3/972/pdf?version=1679040644)

Therapeutic Drug Monitoring of Vedolizumab in Inflammatory Bowel Disease Patients during Maintenance Treatment—TUMMY Study (/1999-4923/15/3/972)

by Merve Sivridaş (https://sciprofiles.com/profile/2749077), Rob H. Creemers (https://sciprofiles.com/profile/author/aStuNytDUFRGY2lHOGUvb0JTdkIVdkpWNUpEZWU2UjJ6NlVJUUh5U3pHND0=), Dennis R. Wong (https://sciprofiles.com/profile/author/YktmNUVNUURBQTVFeXhsQUFhYzJpVG1Rc28rbUt2SkczZE03SW44Znl5Zz0=), Paul J. Boekema (https://sciprofiles.com/profile/author/VlAwdnF3Yi9XYngzWHVyT0VGd1FSOVhDMzJVVG4reXpNYnYyVXVZY2o5WT0=), Tessa E. H. Römkens (https://sciprofiles.com/profile/author/ejg2ZG93dVhQRk5kV1pZc0wrdzJ2MlZvYUY4VW4ySkoxSGEvelRlM2Rsaz0=), Lennard P. L. Gilissen (https://sciprofiles.com/profile/author/eW03UlImUnAwaGs4TEZRcFM1Sy91SS9Cc0ZwMXo0Uk9lK3g5bzEvZ2NYdXB1a2NKUmNCZnFUMFQ1azZhdEwvUw==)

Back to TopTop

Adriaan A. van Bodegraven (https://sciprofiles.com/profile/1640931), Floris C. Loeff (https://sciprofiles.com/profile/author/eDBHUUhhekIrSy9BVy9WUG1HeTBLT2NHYXNCQXMrZ1hvZS91ZW9YUHFObz0=), Theo Rispens (https://sciprofiles.com/profile/1571127) and Luc J. J. Derijks (https://sciprofiles.com/profile/2779773)
Pharmaceutics **2023**, *15*(3), 972; https://doi.org/10.3390/pharmaceutics15030972 (https://doi.org/10.3390/pharmaceutics15030972) - 17 Mar 2023
Viewed by 1059

Abstract There are limited data on therapeutic drug monitoring (TDM) in inflammatory bowel disease (IBD) patients treated with vedolizumab (VDZ). Although an exposure–response relation has been demonstrated in the post-induction phase, this relationship is more uncertain in the maintenance phase of treatment. The aim **[...] Read more.**
(This article belongs to the Special Issue **Personalisation the Management of Inflammatory Diseases** (/journal/pharmaceutics/special_issues/O427TF423K))

► **Show Figures**

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00972/article_deploy/html/images/pharmaceutics-15-00972-g001-550.jpg?1679040714) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00972/article_deploy/html/images/pharmaceutics-15-00972-g002-550.jpg?1679040717) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00972/article_deploy/html/images/pharmaceutics-15-00972-g003-550.jpg?1679040716) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00972/article_deploy/html/images/pharmaceutics-15-00972-g004-550.jpg?1679040720) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00972/article_deploy/html/images/pharmaceutics-15-00972-g005-550.jpg?1679040719)

Open Access Review (/1999-4923/15/3/971/pdf?version=1679040371)

Advances in Radionuclides and Radiolabelled Peptides for Cancer Therapeutics (/1999-4923/15/3/971)

by Kushal Chakraborty (https://sciprofiles.com/profile/2840752), Jagannath Mondal (https://sciprofiles.com/profile/2471063), Jeong Man An (https://sciprofiles.com/profile/author/cFRScHNGaGhTVGJsQmFROW5RK2lab3dPUVF5VTNaenhmL0Z2L2U5Yzl6dz0=), Jooho Park (https://sciprofiles.com/profile/1207240) and Yong-Kyu Lee (https://sciprofiles.com/profile/645689)
Pharmaceutics **2023**, *15*(3), 971; https://doi.org/10.3390/pharmaceutics15030971 (https://doi.org/10.3390/pharmaceutics15030971) - 17 Mar 2023
Cited by 2 (/1999-4923/15/3/971#metrics) | Viewed by 1751

Abstract Radiopharmaceutical therapy, which can detect and treat tumours simultaneously, was introduced more than 80 years ago, and it has changed medical strategies with respect to cancer. Many radioactive radionuclides have been developed, and functional, molecularly modified radiolabelled peptides have been used to produce **[...] Read more.**
(This article belongs to the Special Issue **Peptide-Drug Conjugates for Targeted Anti-Cancer Therapy: From Design to Application** (/journal/pharmaceutics/special_issues/Conjugates))

► **Show Figures**

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00971/article_deploy/html/images/pharmaceutics-15-00971-g001-550.jpg?1679040444) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00971/article_deploy/html/images/pharmaceutics-15-00971-g002-550.jpg?1679040455) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00971/article_deploy/html/images/pharmaceutics-15-00971-g003-550.jpg?1679040458) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00971/article_deploy/html/images/pharmaceutics-15-00971-g004-550.jpg?1679040450) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00971/article_deploy/html/images/pharmaceutics-15-00971-g005-550.jpg?1679040456) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00971/article_deploy/html/images/pharmaceutics-15-00971-g006-550.jpg?1679040446) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00971/article_deploy/html/images/pharmaceutics-15-00971-g007-550.jpg?1679040453) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00971/article_deploy/html/images/pharmaceutics-15-00971-g008-550.jpg?1679040449) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00971/article_deploy/html/images/pharmaceutics-15-00971-sch001-550.jpg?1679040442)

Open Access Review (/1999-4923/15/3/970/pdf?version=1679039315)

Antimicrobial Nano-Zinc Oxide Biocomposites for Wound Healing Applications: A Review (/1999-4923/15/3/970)

by Paolo Pino (https://sciprofiles.com/profile/1745348), Francesca Bosco (https://sciprofiles.com/profile/766164), Chiara Mollea (https://sciprofiles.com/profile/2278419) and Barbara Onida (https://sciprofiles.com/profile/592386)
Pharmaceutics **2023**, *15*(3), 970; https://doi.org/10.3390/pharmaceutics15030970 (https://doi.org/10.3390/pharmaceutics15030970) - 17 Mar 2023
Cited by 15 (/1999-4923/15/3/970#metrics) | Viewed by 2426

Abstract Chronic wounds are a major concern for global health, affecting millions of individuals worldwide. As their occurrence is correlated with age and age-related comorbidities, their incidence in the population is set to increase in the forthcoming years. This burden is further worsened by **[...] Read more.**
(This article belongs to the Special Issue **Nanotechnology-Based Pharmaceutical Treatments** (/journal/pharmaceutics/special_issues/3P640V73Q6))

► **Show Figures**

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00970/article_deploy/html/images/pharmaceutics-15-00970-g001-550.jpg?1679039396) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00970/article_deploy/html/images/pharmaceutics-15-00970-g002-550.jpg?1679039391) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00970/article_deploy/html/images/pharmaceutics-15-00970-g003-550.jpg?1679039395) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00970/article_deploy/html/images/pharmaceutics-15-00970-g004-550.jpg?1679039393) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00970/article_deploy/html/images/pharmaceutics-15-00970-g005-550.jpg?1679039392)

Open Access Review (/1999-4923/15/3/969/pdf?version=1679036802)

Pharmacologic Management of Monogenic and Very Early Onset Inflammatory Bowel Diseases (/1999-4923/15/3/969)

by Anne E. Levine (https://sciprofiles.com/profile/author/ZFRoWWlJQmliV2ZRY3NET0gwb1BtZUhoUCtCc2Rxakp6K0Rrb3oxTXpWQUtxQ2dBQStEeHhrZDJWSUxrUzdQVQ==), Dominique Mark (https://sciprofiles.com/profile/2807698), Laila Smith (https://sciprofiles.com/profile/2807619), Henggi B. Zheng (https://sciprofiles.com/profile/2810101) and David L. Suskind (https://sciprofiles.com/profile/1330267)
Pharmaceutics **2023**, *15*(3), 969; https://doi.org/10.3390/pharmaceutics15030969 (https://doi.org/10.3390/pharmaceutics15030969) - 17 Mar 2023
Cited by 1 (/1999-4923/15/3/969#metrics) | Viewed by 1447

Abstract Inflammatory bowel disease (IBD) is treated with a variety of immunomodulating and immunosuppressive therapies; however, for the majority of cases, these therapies are not targeted for specific disease phenotypes. Monogenic IBD with causative genetic defect is the exception and represents a disease cohort **[...] Read more.**
(This article belongs to the Special Issue **Novel Therapeutic Approaches in Rare Genetic Diseases** (/journal/pharmaceutics/special_issues/KU394Z5EBL))

Open Access Article (/1999-4923/15/3/968/pdf?version=1679036273)

Effects of Dendrimer-microRNA Nanoformulations against Glioblastoma Stem Cells (/1999-4923/15/3/968)

by Nadezhda Knauer (https://sciprofiles.com/profile/592647), Mariya Meschaninova (https://sciprofiles.com/profile/1049818), Sajjad Muhammad (https://sciprofiles.com/profile/925245), Daniel Hänggi (https://sciprofiles.com/profile/1233282), Jean-Pierre Majoral (https://sciprofiles.com/profile/468332), Ulf Dietrich Kahlert (https://sciprofiles.com/profile/767508), Vladimir Kozlov (https://sciprofiles.com/profile/author/RDY2SXlJaVpxeHpGcXl3ZnpSdkFMZUhobWNGcmY0dklyU0UyS2dTMVI1OD0=) and Evgeny K. Apartsin (https://sciprofiles.com/profile/326428)
Pharmaceutics **2023**, *15*(3), 968; https://doi.org/10.3390/pharmaceutics15030968 (https://doi.org/10.3390/pharmaceutics15030968) - 17 Mar 2023
Cited by 3 (/1999-4923/15/3/968#metrics) | Viewed by 960

Abstract Glioblastoma is a rapidly progressing tumor quite resistant to conventional treatment. These features are currently assigned to a self-sustaining population of glioblastoma stem cells. Anti-tumor stem cell therapy calls for a new means of treatment. In particular, microRNA-based treatment is a solution, which **[...] Read more.**
(This article belongs to the Special Issue **Recent Trends in Oligonucleotide Based Therapies** (/journal/pharmaceutics/special_issues/rt_olibt))

► **Show Figures**

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00968/article_deploy/html/images/pharmaceutics-15-00968-g001-550.jpg?1679036360) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00968/article_deploy/html/images/pharmaceutics-15-00968-g002-550.jpg?1679036374) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00968/article_deploy/html/images/pharmaceutics-15-00968-g003-550.jpg?1679036368) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00968/article_deploy/html/images/pharmaceutics-15-00968-g004-550.jpg?1679036361) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00968/article_deploy/html/images/pharmaceutics-15-00968-g005-550.jpg?1679036371) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00968/article_deploy/html/images/pharmaceutics-15-00968-g006-550.jpg?1679036371) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00968/article_deploy/html/images/pharmaceutics-15-00968-g007-550.jpg?1679036370) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00968/article_deploy/html/images/pharmaceutics-15-00968-g008-550.jpg?1679036363) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00968/article_deploy/html/images/pharmaceutics-15-00968-g009-550.jpg?1679036365) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00968/article_deploy/html/images/pharmaceutics-15-00968-g010-550.jpg?1679036366) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00968/article_deploy/html/images/pharmaceutics-15-00968-g011-550.jpg?1679036355) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00968/article_deploy/html/images/pharmaceutics-15-00968-g012-550.jpg?1679036364) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00968/article_deploy/html/images/pharmaceutics-15-00968-

g013-550.jpg?1679036357) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00968/article_deploy/html/images/pharmaceutics-15-00968-g014-550.jpg?1679036355)

Open Access Article (/1999-4923/15/3/967/pdf?version=1679033864)

Dose-Effect Determination of a Neuroprotector Fraction Standardized in Coumarins of *Tagetes lucida* and Bioavailability (/1999-4923/15/3/967)

by Anislada Santibáñez (https://sciprofiles.com/profile/2055134), Maribel Herrera-Ruiz (https://sciprofiles.com/profile/39324), Manasés González-Cortazar (https://sciprofiles.com/profile/280125), Pilar Nicasio-Torres (https://sciprofiles.com/profile/2516637), Ashutosh Sharma (https://sciprofiles.com/profile/521109) and Enrique Jiménez-Ferrer (https://sciprofiles.com/profile/56545)

Pharmaceutics **2023**, *15*(3), 967; https://doi.org/10.3390/pharmaceutics15030967 (https://doi.org/10.3390/pharmaceutics15030967) - 17 Mar 2023

Viewed by 982

Abstract Neurodegeneration has been associated with chronic inflammation states in the brain. For this reason, attention has been directed to drugs indicated as anti-inflammatory as possible therapies for the treatment of said conditions. *Tagetes lucida* has been widely used as a folk remedy in **[...] Read more.**

(This article belongs to the Special Issue **New Insights on Drug Design, Delivery and Targeting in Neurodegeneration (/journal/pharmaceutics/special_issues/drug_neurodegeneration)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00967/article_deploy/html/images/pharmaceutics-15-00967-g001-550.jpg?1679033733) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00967/article_deploy/html/images/pharmaceutics-15-00967-g002-550.jpg?1679033741) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00967/article_deploy/html/images/pharmaceutics-15-00967-g003-550.jpg?1679033731) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00967/article_deploy/html/images/pharmaceutics-15-00967-g004-550.jpg?1679033737) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00967/article_deploy/html/images/pharmaceutics-15-00967-g005-550.jpg?1679033740) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00967/article_deploy/html/images/pharmaceutics-15-00967-g006-550.jpg?1679033730) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00967/article_deploy/html/images/pharmaceutics-15-00967-g007-550.jpg?1679033738) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00967/article_deploy/html/images/pharmaceutics-15-00967-g008-550.jpg?1679033736)

Open Access Article (/1999-4923/15/3/966/pdf?version=1678969541)

Radiothermal Emission of Nanoparticles with a Complex Shape as a Tool for the Quality Control of Pharmaceuticals Containing Biologically Active Nanoparticles (/1999-4923/15/3/966)

by Anton V. Syroeshkin (https://sciprofiles.com/profile/1569552), Gleb V. Petrov (https://sciprofiles.com/profile/author/YkdNNnF2b01XK1F1UGkrYi9HelBQNmFlVllGRkVtZHd0ZUcrRTNVNTFVOD0=), Viktor V. Taranov (https://sciprofiles.com/profile/2841606), Tatiana V. Pleteneva (https://sciprofiles.com/profile/2767979), Alena M. Koldina (https://sciprofiles.com/profile/2548902), Ivan A. Gaydashev (https://sciprofiles.com/profile/author/elY4K2ZLMUJFQ1dLM2srRWd1blpzMUFCYmNtK2RhV2RTRjF1QXVFMHpJMD0=), Ekaterina S. Kolyabina (https://sciprofiles.com/profile/author/UCtTOUJPblRvS3ljYkx2SDBtclFDV2hmRzBYcC9LNmJqKzBnKzhjc2p4bz0=), Daria A. Galkina (https://sciprofiles.com/profile/author/RzAyVHNoNXJqL0JRYU96SzZtaUNzNWlRTE44MFY3dklOY1dWQ2VPOTV6Zz0=), Ekaterina V. Sorokina (https://sciprofiles.com/profile/author/WEZldXhoZjBWRUNKbU5LRVluMzY4TFExU09HcTlqYUg1d0JCcXVtYUNEQT0=), Elena V. Uspenskaya (https://sciprofiles.com/profile/1395395), Ilaha V. Kazimova (https://sciprofiles.com/profile/author/Vnk3b2FkdWZPdzZUL2kwS0Y1QlJYMjBGOHNLOVVRQXYrR3pMNU54dnlTND0=), Mariya A. Morozova (https://sciprofiles.com/profile/author/QTR3RGNJekU3OHZrcFEvS01FR3F0S1hpY3ZOKzRXYTZZZ1pxdnF4U0dybz0=), Varvara V. Lebedeva (https://sciprofiles.com/profile/1918849), Stanislav A. Cherepushkin (https://sciprofiles.com/profile/1624259), Irina V. Tarabrina (https://sciprofiles.com/profile/2839229), Sergey A. Syroeshkin (https://sciprofiles.com/profile/author/RTFJamY0WnVlMjZSYjBoWXdPSGxvNmZlWWdLUnBmT1daRVNBc2dhMCs4TT0=), Alexander V. Tertyshnikov (https://sciprofiles.com/profile/author/UzdGR1V6eGFsZFRpT0hNRU44VDN2Zz09) and Tatiana V. Grebennikova (https://sciprofiles.com/profile/1651992)

Pharmaceutics **2023**, *15*(3), 966; https://doi.org/10.3390/pharmaceutics15030966 (https://doi.org/10.3390/pharmaceutics15030966) - 16 Mar 2023

Viewed by 1139

Abstract It has recently been shown that the titer of the SARS-CoV-2 virus decreases in a cell culture when the cell suspension is irradiated with electromagnetic waves at a frequency of 95 GHz. We assumed that a frequency range in the gigahertz and sub-terahertz **[...] Read more.**

(This article belongs to the Special Issue **New Properties of Supramolecular Complexes and Drug Nanoparticles (/journal/pharmaceutics/special_issues/Sup_drug)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00966/article_deploy/html/images/pharmaceutics-15-00966-g001-550.jpg?1678969611) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00966/article_deploy/html/images/pharmaceutics-15-00966-g002-550.jpg?1678969606) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00966/article_deploy/html/images/pharmaceutics-15-00966-g003-550.jpg?1678969615) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00966/article_deploy/html/images/pharmaceutics-15-00966-g004-550.jpg?1678969607) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00966/article_deploy/html/images/pharmaceutics-15-00966-g005-550.jpg?1678969616) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00966/article_deploy/html/images/pharmaceutics-15-00966-g006-550.jpg?1678969613)

Open Access Article (/1999-4923/15/3/965/pdf?version=1678967163)

SGLT2 Inhibitor—Dapagliflozin Attenuates Diabetes-Induced Renal Injury by Regulating Inflammation through a CYP4A/20-HETE Signaling Mechanism (/1999-4923/15/3/965)

by Batoul Dia (https://sciprofiles.com/profile/1432870), Sahar Alkhansa (https://sciprofiles.com/profile/2836270), Rachel Njeim (https://sciprofiles.com/profile/2395741), Sarah Al Moussawi (https://sciprofiles.com/profile/2971631), Theresa Farhat (https://sciprofiles.com/profile/author/Unp3RUxScWsxcDlXU3FWMTZRcExwdz09), Antony Haddad (https://sciprofiles.com/profile/2370080), Mansour E. Riachi (https://sciprofiles.com/profile/2736382), Rashad Nawfal (https://sciprofiles.com/profile/2182690), William S. Azar (https://sciprofiles.com/profile/author/SUFWaEZHQ2F3V2NzU1orWEZ3TlVkbE9mcEg2S25wS3Vra29VOUF1TlFaYz0=) and Assaad A. Eid (https://sciprofiles.com/profile/748962)

Pharmaceutics **2023**, *15*(3), 965; https://doi.org/10.3390/pharmaceutics15030965 (https://doi.org/10.3390/pharmaceutics15030965) - 16 Mar 2023

Cited by 1 (/1999-4923/15/3/965#metrics) | Viewed by 1217

Abstract Diabetic kidney disease (DKD) is a serious complication of diabetes, affecting millions of people worldwide. Inflammation and oxidative stress are key contributors to the development and progression of DKD, making them potential targets for therapeutic interventions. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have emerged **[...] Read more.**

(This article belongs to the Special Issue **Targeted Therapies in Cardiovascular and Kidney Diseases (/journal/pharmaceutics/special_issues/4P5CO9N3NU)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00965/article_deploy/html/images/pharmaceutics-15-00965-g001-550.jpg?1678967246) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00965/article_deploy/html/images/pharmaceutics-15-00965-g002-550.jpg?1678967260) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00965/article_deploy/html/images/pharmaceutics-15-00965-g003-550.jpg?1678967255) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00965/article_deploy/html/images/pharmaceutics-15-00965-g004-550.jpg?1678967253) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00965/article_deploy/html/images/pharmaceutics-15-00965-g005-550.jpg?1678967251) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00965/article_deploy/html/images/pharmaceutics-15-00965-g006-550.jpg?1678967257) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00965/article_deploy/html/images/pharmaceutics-15-00965-g007-550.jpg?1678967248)

Open Access Article (/1999-4923/15/3/964/pdf?version=1679358810)

Comparative HPLC–DAD–ESI-QTOF/MS/MS Analysis of Bioactive Phenolic Compounds Content in the Methanolic Extracts from Flowering Herbs of *Monarda* Species and Their Free Radical Scavenging and Antimicrobial Activities (/1999-4923/15/3/964)

by Małgorzata Kozyra (https://sciprofiles.com/profile/274569), Anna Biernasiuk (https://sciprofiles.com/profile/189765), Magdalena Wiktor (https://sciprofiles.com/profile/author/dTRQNUtHY2hnV3RyZFZOWk0yQ2QyM0QyU2dPcmtmL0U2Z3dFUExiNkt2UT0=), Wirginia Kukula-Koch (https://sciprofiles.com/profile/43614) and Anna Malm (https://sciprofiles.com/profile/1508776)

Pharmaceutics **2023**, *15*(3), 964; https://doi.org/10.3390/pharmaceutics15030964 (https://doi.org/10.3390/pharmaceutics15030964) - 16 Mar 2023

Viewed by 853

Abstract Comparative analysis of flavonoids and phenolic acids composition, in plants of six species of *Monarda* from family Lamiaceae was carried out. The 70% (*v/v*) methanolic extracts of flowering herbs of *Monarda citriodora* Cerv. ex Lag., *Monarda bradburiana* L.C. Beck, *Monarda didyma* **[...] Read more.**

(This article belongs to the Special Issue **Pharmaceutical Applications of Plant Extracts (/journal/pharmaceutics/special_issues/plant_extracts_pharma)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00964/article_deploy/html/images/pharmaceutics-15-00964-g001-550.jpg?1679358880) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00964/article_deploy/html/images/pharmaceutics-15-00964-g002-550.jpg?1679358885) (https://pub.mdpi-res.com

Back to TopTop

/pharmaceutics/pharmaceutics-15-00964/article_deploy/html/images/pharmaceutics-15-00964-g003-550.jpg?1679358877)

Open Access Review (/1999-4923/15/3/963/pdf?version=1678970473)

Quercetin and Its Nano-Formulations for Brain Tumor Therapy—Current Developments and Future Perspectives for Paediatric Studies (/1999-4923/15/3/963)

by Aida Loshaj Shala (https://sciprofiles.com/profile/1686655), Ilaria Arduino (https://sciprofiles.com/profile/1887080), Mimoza Basholli Salihu (https://sciprofiles.com/profile/2177495) and Nunzio Denora (https://sciprofiles.com/profile/344219)

Pharmaceutics **2023**, *15*(3), 963; https://doi.org/10.3390/pharmaceutics15030963 (https://doi.org/10.3390/pharmaceutics15030963) - 16 Mar 2023

Cited by 2 (/1999-4923/15/3/963#metrics) | Viewed by 1715

Abstract The development of efficient treatments for tumors affecting the central nervous system (CNS) remains an open challenge. Particularly, gliomas are the most malignant and lethal form of brain tumors in adults, causing death in patients just over 6 months after diagnosis without treatment. **[...] Read more.**

(This article belongs to the Special Issue **Advances in Age Related Drug Delivery (/journal/pharmaceutics/special_issues/age_drug_delivery)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00963/article_deploy/html/images/pharmaceutics-15-00963-g001-550.jpg?1678970548) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00963/article_deploy/html/images/pharmaceutics-15-00963-g002-550.jpg?1678970548) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00963/article_deploy/html/images/pharmaceutics-15-00963-g003-550.jpg?1678970544) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00963/article_deploy/html/images/pharmaceutics-15-00963-g004-550.jpg?1678970546) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00963/article_deploy/html/images/pharmaceutics-15-00963-g005-550.jpg?1678970547) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00963/article_deploy/html/images/pharmaceutics-15-00963-g006-550.jpg?1678970541) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00963/article_deploy/html/images/pharmaceutics-15-00963-g007-550.jpg?1678970539) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00963/article_deploy/html/images/pharmaceutics-15-00963-g008-550.jpg?1678970542)

Open Access Article (/1999-4923/15/3/962/pdf?version=1678960986)

A Comparative Study of Cancer Cells Susceptibility to Silver Nanoparticles Produced by Electron Beam (/1999-4923/15/3/962)

by Evgenii V. Plotnikov (https://sciprofiles.com/profile/38452), Maria S. Tretyakova (https://sciprofiles.com/profile/author/VFhUd2F3bVRZTEpjK2M4MjBEM2NiVzE5a2ozdUxRRlFRdnFPODdHYXBSOD0=), Diana Garibo-Ruiz (https://sciprofiles.com/profile/1529993), Ana G. Rodríguez-Hernández (https://sciprofiles.com/profile/2454733), Alexey N. Pestryakov (https://sciprofiles.com/profile/1453339), Yanis Toledano-Magaña (https://sciprofiles.com/profile/1170010) and Nina Bogdanchikova (https://sciprofiles.com/profile/2644154)

Pharmaceutics **2023**, *15*(3), 962; https://doi.org/10.3390/pharmaceutics15030962 (https://doi.org/10.3390/pharmaceutics15030962) - 16 Mar 2023

Viewed by 1381

Abstract Introduction: Silver nanoparticles (AgNPs) have a wide range of bioactivity, which is highly dependent on particle size, shape, stabilizer, and production method. Here, we present the results of studies of AgNPs cytotoxic properties obtained by irradiation treatment of silver nitrate solution and various **[...] Read more.**

(This article belongs to the Special Issue **Antitumor Activity of Silver Nanoparticles and Its Implications on Global Health (/journal/pharmaceutics/special_issues/V6NR0657OE)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00962/article_deploy/html/images/pharmaceutics-15-00962-g001-550.jpg?1678961058) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00962/article_deploy/html/images/pharmaceutics-15-00962-g002-550.jpg?1678961054) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00962/article_deploy/html/images/pharmaceutics-15-00962-g003-550.jpg?1678961051) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00962/article_deploy/html/images/pharmaceutics-15-00962-g004-550.jpg?1678961066) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00962/article_deploy/html/images/pharmaceutics-15-00962-g005-550.jpg?1678961053) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00962/article_deploy/html/images/pharmaceutics-15-00962-g006-550.jpg?1678961070) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00962/article_deploy/html/images/pharmaceutics-15-00962-g007-550.jpg?1678961072) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00962/article_deploy/html/images/pharmaceutics-15-00962-g008-550.jpg?1678961061)

Open Access Article (/1999-4923/15/3/961/pdf?version=1678955203)

A New Strategy for Nucleic Acid Delivery and Protein Expression Using Biocompatible Nanohydrogels of Predefined Sizes (/1999-4923/15/3/961)

by Lakshmanan Eswaran (https://sciprofiles.com/profile/author/UGhrdDJGMFBnc1Vhd1lINUtJRjV2MHRPL0NnTVZLRlRqOTlpWitTdUpXND0=), Gila Kazimirsky (https://sciprofiles.com/profile/author/S3hOVndreXBOSE5vcFlEam03Q2ZzZzNrSHV2RTR4eU1tMVZOVmMxcUtkTT0=), Ronen Yehuda (https://sciprofiles.com/profile/2838335) and Gerardo Byk (https://sciprofiles.com/profile/23564)

Pharmaceutics **2023**, *15*(3), 961; https://doi.org/10.3390/pharmaceutics15030961 (https://doi.org/10.3390/pharmaceutics15030961) - 16 Mar 2023

Viewed by 843

Abstract We have developed new formulations of nanohydrogels (NHGs) complexed with DNA devoid of cell toxicity, which, together with their tuned sizes, makes them of great interest for delivering DNA/RNA for foreign protein expression. Transfection results demonstrate that, unlike classical lipo/polyplexes, the new NHGs **[...] Read more.**

(This article belongs to the Special Issue **Sustainable Materials and Technologies for Drug Delivery and Tissue Engineering (/journal/pharmaceutics/special_issues/Sustainable_Materials_Drug_Delivery_Tissue_Engineering)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00961/article_deploy/html/images/pharmaceutics-15-00961-g001-550.jpg?1678955275) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00961/article_deploy/html/images/pharmaceutics-15-00961-g002-550.jpg?1678955297) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00961/article_deploy/html/images/pharmaceutics-15-00961-g003-550.jpg?1678955279) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00961/article_deploy/html/images/pharmaceutics-15-00961-g004-550.jpg?1678955286) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00961/article_deploy/html/images/pharmaceutics-15-00961-g005-550.jpg?1678955293) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00961/article_deploy/html/images/pharmaceutics-15-00961-g006-550.jpg?1678955301) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00961/article_deploy/html/images/pharmaceutics-15-00961-g007-550.jpg?1678955298) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00961/article_deploy/html/images/pharmaceutics-15-00961-g008-550.jpg?1678955304) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00961/article_deploy/html/images/pharmaceutics-15-00961-g009-550.jpg?1678955303) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00961/article_deploy/html/images/pharmaceutics-15-00961-g010-550.jpg?1678955311) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00961/article_deploy/html/images/pharmaceutics-15-00961-g011-550.jpg?1678955287) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00961/article_deploy/html/images/pharmaceutics-15-00961-g012-550.jpg?1678955295) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00961/article_deploy/html/images/pharmaceutics-15-00961-g013-550.jpg?1678955313) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00961/article_deploy/html/images/pharmaceutics-15-00961-g014-550.jpg?1678955290) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00961/article_deploy/html/images/pharmaceutics-15-00961-g015-550.jpg?1678955316) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00961/article_deploy/html/images/pharmaceutics-15-00961-g016-550.jpg?1678955309) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00961/article_deploy/html/images/pharmaceutics-15-00961-g017-550.jpg?1678955308) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00961/article_deploy/html/images/pharmaceutics-15-00961-g018-550.jpg?1678955282) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00961/article_deploy/html/images/pharmaceutics-15-00961-g019-550.jpg?1678955315)

Open Access Article (/1999-4923/15/3/960/pdf?version=1678957268)

Catheters with Dual-Antimicrobial Properties by Gamma Radiation-Induced Grafting (/1999-4923/15/3/960)

by Lorena Duarte-Peña (https://sciprofiles.com/profile/1835992), Héctor Magaña (https://sciprofiles.com/profile/1012009) and Emilio Bucio (https://sciprofiles.com/profile/137152)

Pharmaceutics **2023**, *15*(3), 960; https://doi.org/10.3390/pharmaceutics15030960 (https://doi.org/10.3390/pharmaceutics15030960) - 16 Mar 2023

Viewed by 863

Abstract Dual antimicrobial materials that have a combination of antimicrobial and antifouling properties were developed. They were developed through modification using gamma radiation of poly (vinyl chloride) (PVC) catheters with 4-vinyl pyridine (4VP) and subsequent functionalization with 1,3-propane sultone (PS). These materials were characterized **[...] Read more.**

(This article belongs to the Special Issue **Polymers Enhancing Bioavailability in Drug Delivery, 2nd Edition (/journal/pharmaceutics/special_issues/0JC3F78273)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00960/article_deploy/html/images/pharmaceutics-15-00960-g001-550.jpg?1678957344) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00960/article_deploy/html/images/pharmaceutics-15-00960-g002-550.jpg?1678957347) (https://pub.mdpi-res.com

/pharmaceutics/pharmaceutics-15-00960/article_deploy/html/images/pharmaceutics-15-00960-g003-550.jpg?1678957341) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00960/article_deploy/html/images/pharmaceutics-15-00960-g004-550.jpg?1678957344) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00960/article_deploy/html/images/pharmaceutics-15-00960-g005-550.jpg?1678957340) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00960/article_deploy/html/images/pharmaceutics-15-00960-g006-550.jpg?1678957343) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00960/article_deploy/html/images/pharmaceutics-15-00960-g007-550.jpg?1678957337) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00960/article_deploy/html/images/pharmaceutics-15-00960-g008-550.jpg?1678957338) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00960/article_deploy/html/images/pharmaceutics-15-00960-g009-550.jpg?1678957337) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00960/article_deploy/html/images/pharmaceutics-15-00960-g010-550.jpg?1678957342)

Open Access Article .(/1999-4923/15/3/959/pdf?version=1678962959)

A New Productive Approach and Formulative Optimization for Curcumin Nanoliposomal Delivery Systems (/1999-4923/15/3/959)

by Raffaella De Piano (https://sciprofiles.com/profile/author/bDQwRC9pWlUzWTFlZ1M5MUxYVWYyVFpKSjArcVl1MmQ3VlRRR3lpc1MyYz0=), Diego Caccavo (https://sciprofiles.com/profile/2193897), Gaetano Lamberti (https://sciprofiles.com/profile/127980), Katrien Remaut (https://sciprofiles.com/profile/521899), Hanne Seynaeve (https://sciprofiles.com/profile/author/dXBrTk5GZkNuVWgwN0lmdERqeHpoZEdSejZOb0t2blVmMzl5aUVoVnJOZz0=) and Anna Angela Barba (https://sciprofiles.com/profile/553183)

Pharmaceutics **2023**, *15*(3), 959; https://doi.org/10.3390/pharmaceutics15030959 (https://doi.org/10.3390/pharmaceutics15030959) - 16 Mar 2023

Cited by 1 (/1999-4923/15/3/959#metrics) | Viewed by 1181

Abstract The use of natural resources and the enhancing of technologies are outlining the strategies of modern scientific-technological research for sustainable health products manufacturing. In this context, the novel simil-microfluidic technology, a mild production methodology, is exploited to produce liposomal curcumin as potential powerful **[...] Read more.**

(This article belongs to the Special Issue **Enhancement for Strategies in Liposomal and Niosomal Preparations: Formulative and Technological Innovations** (/journal/pharmaceutics/special_issues/liposomal_niosomal))

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00959/article_deploy/html/images/pharmaceutics-15-00959-ag-550.jpg?1679021225) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00959/article_deploy/html/images/pharmaceutics-15-00959-g001-550.jpg?1679021219) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00959/article_deploy/html/images/pharmaceutics-15-00959-g002-550.jpg?1679021223) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00959/article_deploy/html/images/pharmaceutics-15-00959-g003-550.jpg?1679021213) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00959/article_deploy/html/images/pharmaceutics-15-00959-g004-550.jpg?1679021214) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00959/article_deploy/html/images/pharmaceutics-15-00959-g005-550.jpg?1679021222) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00959/article_deploy/html/images/pharmaceutics-15-00959-g006-550.jpg?1679021225) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00959/article_deploy/html/images/pharmaceutics-15-00959-g007-550.jpg?1679021211) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00959/article_deploy/html/images/pharmaceutics-15-00959-g008-550.jpg?1679021217) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00959/article_deploy/html/images/pharmaceutics-15-00959-g009-550.jpg?1679021221) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00959/article_deploy/html/images/pharmaceutics-15-00959-g010-550.jpg?1679021218)

Open Access Review .(/1999-4923/15/3/958/pdf?version=1678946582)

The Hedgehog Pathway as a Therapeutic Target in Chronic Myeloid Leukemia (/1999-4923/15/3/958)

by Andrew Wu (https://sciprofiles.com/profile/author/ZE5qWFFzaHhCemkvazJaSkdvcGlBZz09), Kelly A. Turner (https://sciprofiles.com/profile/author/Q1NUeEU1S2pkWldkWEdzSVhZczdaaHdPd0F0Z1hDcUtrYlh6YlpWTkh1RT0=), Adrian Woolfson (https://sciprofiles.com/profile/author/Y2xORGhyWEpOTVA1cmQyaXZpTUlyLzdKMEJXc2YzYmtxTzcvVExydVoyWT0=) and Xiaoyan Jiang (https://sciprofiles.com/profile/591589)

Pharmaceutics **2023**, *15*(3), 958; https://doi.org/10.3390/pharmaceutics15030958 (https://doi.org/10.3390/pharmaceutics15030958) - 16 Mar 2023

Cited by 1 (/1999-4923/15/3/958#metrics) | Viewed by 1266

Abstract Despite the development of therapeutic agents that selectively target cancer cells, relapse driven by acquired drug resistance and resulting treatment failure remains a significant issue. The highly conserved Hedgehog (HH) signaling pathway performs multiple roles in both development and tissue homeostasis, and its **[...] Read more.**

(This article belongs to the Special Issue **Targeting Drug Resistance and Metastatic Pathways for Cancer Therapy** (/journal/pharmaceutics/special_issues/drug_resistance_cancer))

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00958/article_deploy/html/images/pharmaceutics-15-00958-g001-550.jpg?1678946649) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00958/article_deploy/html/images/pharmaceutics-15-00958-g002-550.jpg?1678946651)

Open Access Article .(/1999-4923/15/3/957/pdf?version=1678942195)

Pharmaceutical Oral Formulation of Methionine as a Pediatric Treatment in Inherited Metabolic Disease (/1999-4923/15/3/957)

by Benjamin Querin (https://sciprofiles.com/profile/author/OEJTb09qNzBCeTJ6UUZnMXFOK1VlQVdTRUNZM3puNHdkV1VkQTU5alA5MD0=), Arnaud Schweitzer-Chaput (https://sciprofiles.com/profile/author/Z0VtWXF6T2dvMUJjSHZGTnB0WkV0YU12UnJ3eDNVSHVHdmdnZ2o3RVRLTT0=), Salvatore Cisternino (https://sciprofiles.com/profile/381994), Sylvain Auvity (https://sciprofiles.com/profile/2500150), Anne-Sophie Fauqueur (https://sciprofiles.com/profile/author/TU55Vlg1RlNlbGRhWUhBbVp1UEpyTkJzNXdlcElkZjM3Y1R6czNta3FRYz0=), Abdel Negbane (https://sciprofiles.com/profile/2821816), Alice Hadchouel (https://sciprofiles.com/profile/author/UlcxaFITd2l0NVJSUi9QWVFYNDJ0T1hZM2xkb01KbG9SVXQ3cnFiVWVScz0=), Joël Schlatter (https://sciprofiles.com/profile/205599) and Camille Cotteret (https://sciprofiles.com/profile/author/RjI2bEV2dXZ2VFRXaUUvZThrelR0QXRML3h6TG1YSzFmZGR5RE8xbSt2cz0=)

Pharmaceutics **2023**, *15*(3), 957; https://doi.org/10.3390/pharmaceutics15030957 (https://doi.org/10.3390/pharmaceutics15030957) - 16 Mar 2023

Viewed by 1366

Abstract L-Methionine (Met) is an essential alpha-amino acid playing a key role in several metabolic pathways. Rare inherited metabolic diseases such as mutations affecting the MARS1 gene encoding methionine tRNA synthetase (MetRS) can cause severe lung and liver disease before the age of two **[...] Read more.**

(This article belongs to the Special Issue **Recent Advances in Physicochemical Stability of Drugs** (/journal/pharmaceutics/special_issues/recent_advances_in_psd))

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00957/article_deploy/html/images/pharmaceutics-15-00957-ag-550.jpg?1678942279) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00957/article_deploy/html/images/pharmaceutics-15-00957-g001-550.jpg?1678942279) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00957/article_deploy/html/images/pharmaceutics-15-00957-g002-550.jpg?1678942275) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00957/article_deploy/html/images/pharmaceutics-15-00957-g003-550.jpg?1678942278) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00957/article_deploy/html/images/pharmaceutics-15-00957-g004-550.jpg?1678942276) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00957/article_deploy/html/images/pharmaceutics-15-00957-g005-550.jpg?1678942276) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00957/article_deploy/html/images/pharmaceutics-15-00957-g006-550.jpg?1678942273)

Open Access Article .(/1999-4923/15/3/956/pdf?version=1678892044)

Photodynamic Inhibition of Herpes Simplex Virus 1 Infection by Tricationic Amphiphilic Porphyrin with a Long Alkyl Chain (/1999-4923/15/3/956)

by Igor Jurak (https://sciprofiles.com/profile/292933), Maja Cokarić Brdovčak (https://sciprofiles.com/profile/2564583), Lara Djaković (https://sciprofiles.com/profile/author/MEM5MWw1ejJiZXI2cDF3NmJPOU11azBzQ2ZoZFlwQ3RBcUJSZTNScDF4Zz0=), Ivana Bertović (https://sciprofiles.com/profile/author/MzkxSnRHbGo2OFJQMEs5OWI4TGVTRG8xejkxL1hKaUNjSTBGZll0c2ttdz0=), Klaudia Knežević (https://sciprofiles.com/profile/author/WVkyS2JXWU1VdEZYZE5OU2hlVG14U1YvTDRFU1hOczV4WUc5RitiekRFND0=), Martin Lončarić (https://sciprofiles.com/profile/author/WHI3VjlwZWNRUWRMdjVmSDlQSGY0SHk2WUxzUDQranljODZBMVpUTk1MST0=), Antonija Jurak Begonja (https://sciprofiles.com/profile/author/aVRRYWRnSUJTVVk5WjNmR0s3Y1o5c0J6eE1jS0k0SlFTUXN0NmRna1p6QT0=) and Nela Malatesti (https://sciprofiles.com/profile/1122710)

Pharmaceutics **2023**, *15*(3), 956; https://doi.org/10.3390/pharmaceutics15030956 (https://doi.org/10.3390/pharmaceutics15030956) - 15 Mar 2023

Viewed by 1049

Abstract Photodynamic therapy (PDT) is broadly used to treat different tumors, and it is a rapidly developing approach to inactivating or inhibiting the replication of fungi, bacteria, and viruses. Herpes simplex virus 1 (HSV-1) is an important human pathogen and a frequently used model **[...] Read more.**

(This article belongs to the Special Issue **Antimicrobial Sonodynamic and Photodynamic Therapies** (/journal/pharmaceutics/special_issues/antimicrobial_therapies))

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00956/article_deploy/html/images/pharmaceutics-15-00956-g001-550.jpg?1678892115) (https://pub.mdpi-

res.com/pharmaceutics/pharmaceutics-15-00956/article_deploy/html/images/pharmaceutics-15-00956-g002-550.jpg?1678892123) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00956/article_deploy/html/images/pharmaceutics-15-00956-g003-550.jpg?1678892126) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00956/article_deploy/html/images/pharmaceutics-15-00956-g004-550.jpg?1678892115) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00956/article_deploy/html/images/pharmaceutics-15-00956-g005-550.jpg?1678892116) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00956/article_deploy/html/images/pharmaceutics-15-00956-g006-550.jpg?1678892127) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00956/article_deploy/html/images/pharmaceutics-15-00956-g007-550.jpg?1678892111) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00956/article_deploy/html/images/pharmaceutics-15-00956-g008-550.jpg?1678892110)

Open Access Article (/1999-4923/15/3/955/pdf?version=1678875178)

Development of Dipeptide *N*–acetyl–L–cysteine Loaded Nanostructured Carriers Based on Inorganic Layered Hydroxides (/1999-4923/15/3/955)

by Denise Eulálio (https://sciprofiles.com/profile/2663276), Mariana Pires Figueiredo (https://sciprofiles.com/profile/author/ckZPZHpqSDkwNG5HM24xeWVObGF5dFZadkUvYWZwQUtWblpmUDBod2UzYz0=), Christine Taviot-Gueho (https://sciprofiles.com/profile/author/ODBCTzI5NE0yeHRKcDJrazFHMC9STG5xc3RQTnhOV3FUczZBUlRKeDlYdz0=), Fabrice Leroux (https://sciprofiles.com/profile/2465582), Cristina Helena dos Reis Serra (https://sciprofiles.com/profile/author/cnp3ZmJjQ1plWm42ZlE5dmNPaHlQQT09), Dalva Lúcia Araújo de Faria (https://sciprofiles.com/profile/author/cnR3bG5uSkR3VHloZlp2TERhakhKdTByaGNDa2pkeWJiUjNTOFlVem52VT0=) and Vera Regina Leopoldo Constantino (https://sciprofiles.com/profile/681816)

Pharmaceutics **2023**, *15*(3), 955; https://doi.org/10.3390/pharmaceutics15030955 (https://doi.org/10.3390/pharmaceutics15030955) - 15 Mar 2023
Viewed by 1163

Abstract *N*–acetyl–L–cysteine (NAC), a derivative of the L–cysteine amino acid, presents antioxidant and mucolytic properties of pharmaceutical interest. This work reports the preparation of organic-inorganic nanophases aiming for the development of drug delivery systems based on NAC intercalation into layered double hydroxides (LDH) **[...] Read more.**
(This article belongs to the Special Issue **Inorganic Biomaterials for Drug Delivery** (/journal/pharmaceutics/special_issues/VJBX2086AU))

► Show Figures
(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00955/article_deploy/html/images/pharmaceutics-15-00955-g001-550.jpg?1678875256) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00955/article_deploy/html/images/pharmaceutics-15-00955-g002-550.jpg?1678875260) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00955/article_deploy/html/images/pharmaceutics-15-00955-g003-550.jpg?1678875264) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00955/article_deploy/html/images/pharmaceutics-15-00955-g004-550.jpg?1678875255) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00955/article_deploy/html/images/pharmaceutics-15-00955-g005-550.jpg?1678875253) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00955/article_deploy/html/images/pharmaceutics-15-00955-g006-550.jpg?1678875250) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00955/article_deploy/html/images/pharmaceutics-15-00955-g007-550.jpg?1678875244) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00955/article_deploy/html/images/pharmaceutics-15-00955-g008-550.jpg?1678875251) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00955/article_deploy/html/images/pharmaceutics-15-00955-g009-550.jpg?1678875258) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00955/article_deploy/html/images/pharmaceutics-15-00955-g010-550.jpg?1678875263) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00955/article_deploy/html/images/pharmaceutics-15-00955-g011-550.jpg?1678875262) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00955/article_deploy/html/images/pharmaceutics-15-00955-g012-550.jpg?1678875267) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00955/article_deploy/html/images/pharmaceutics-15-00955-g013-550.jpg?1678875260)

Open Access Article (/1999-4923/15/3/954/pdf?version=1678870817)

Travoprost Liquid Nanocrystals: An Innovative Armamentarium for Effective Glaucoma Therapy (/1999-4923/15/3/954)

by Mohamed A. El-Gendy (https://sciprofiles.com/profile/author/NDgwVlowUi82RjdKR1JDeUg0TEVncmk0NUhPRG53MWFEOVNlMUZDK3cvMD0=), Mai Mansour (https://sciprofiles.com/profile/1771911), Mona I. A. El-Assal (https://sciprofiles.com/profile/206341), Rania A. H. Ishak (https://sciprofiles.com/profile/773844) and Nahed D. Mortada (https://sciprofiles.com/profile/2709695)

Pharmaceutics **2023**, *15*(3), 954; https://doi.org/10.3390/pharmaceutics15030954 (https://doi.org/10.3390/pharmaceutics15030954) - 15 Mar 2023
Cited by 1 (/1999-4923/15/3/954#metrics) | Viewed by 1001

Abstract To date, the ophthalmic application of liquid crystalline nanostructures (LCNs) has not been thoroughly reconnoitered, yet they have been extensively used. LCNs are primarily made up of glyceryl monooleate (GMO) or phytantriol as a lipid, a stabilizing agent, and a penetration enhancer (PE). **[...] Read more.**
(This article belongs to the Topic **New Challenges in Ocular Drug Delivery (/topics/ocular_drug_delivery)**)

► Show Figures
(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00954/article_deploy/html/images/pharmaceutics-15-00954-ag-550.jpg?1679018162) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00954/article_deploy/html/images/pharmaceutics-15-00954-g001-550.jpg?1678870884) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00954/article_deploy/html/images/pharmaceutics-15-00954-g002-550.jpg?1678870891) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00954/article_deploy/html/images/pharmaceutics-15-00954-g003-550.jpg?1678870899) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00954/article_deploy/html/images/pharmaceutics-15-00954-g004-550.jpg?1678870898) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00954/article_deploy/html/images/pharmaceutics-15-00954-g005-550.jpg?1678870889) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00954/article_deploy/html/images/pharmaceutics-15-00954-g006-550.jpg?1678870892) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00954/article_deploy/html/images/pharmaceutics-15-00954-g007-550.jpg?1678870894) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00954/article_deploy/html/images/pharmaceutics-15-00954-g008-550.jpg?1678870886) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00954/article_deploy/html/images/pharmaceutics-15-00954-g009a-550.jpg?1678870901) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00954/article_deploy/html/images/pharmaceutics-15-00954-g009b-550.jpg?1678870904)

Open Access Article (/1999-4923/15/3/953/pdf?version=1678872733)

Clinically Expired Platelet Concentrates as a Source of Extracellular Vesicles for Targeted Anti-Cancer Drug Delivery (/1999-4923/15/3/953)

by Ana Meliciano (https://sciprofiles.com/profile/2740891), Daniela Salvador (https://sciprofiles.com/profile/2781093), Pedro Mendonça (https://sciprofiles.com/profile/2225000), Ana Filipa Louro (https://sciprofiles.com/profile/author/SysxNXFKNUI5b3U2eXhwNXNyeEI5aHR6b2FjMXBFMFYyc2JZblVqeE1jOD0=) and Margarida Serra (https://sciprofiles.com/profile/1897251)

Pharmaceutics **2023**, *15*(3), 953; https://doi.org/10.3390/pharmaceutics15030953 (https://doi.org/10.3390/pharmaceutics15030953) - 15 Mar 2023
Cited by 1 (/1999-4923/15/3/953#metrics) | Viewed by 1035

Abstract The short shelf life of platelet concentrates (PC) of up to 5–7 days leads to higher wastage due to expiry. To address this massive financial burden on the healthcare system, alternative applications for expired PC have emerged in recent years. Engineered nanocarriers functionalized **[...] Read more.**
(This article belongs to the Special Issue **Recent Advances in Exosomes as Drug Carriers** (/journal/pharmaceutics/special_issues/5PT3I500J7))

► Show Figures
(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00953/article_deploy/html/images/pharmaceutics-15-00953-g001-550.jpg?1678872803) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00953/article_deploy/html/images/pharmaceutics-15-00953-g002-550.jpg?1678872802) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00953/article_deploy/html/images/pharmaceutics-15-00953-g003-550.jpg?1678872804) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00953/article_deploy/html/images/pharmaceutics-15-00953-g004-550.jpg?1678872802) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00953/article_deploy/html/images/pharmaceutics-15-00953-g005-550.jpg?1678872805) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00953/article_deploy/html/images/pharmaceutics-15-00953-g006-550.jpg?1678872806)

Open Access Article (/1999-4923/15/3/952/pdf?version=1678865481)

The Development of Cell-Penetrating Peptides for Efficient and Selective In Vivo Expression of mRNA in Spleen Tissue (/1999-4923/15/3/952)

by Ly Porosk (https://sciprofiles.com/profile/2286496), Heleri Heike Härk (https://sciprofiles.com/profile/2781959), Piret Arukuusk (https://sciprofiles.com/profile/author/MHRpd3JXNEtmTG5FMnUyUlU1amptaWNlQTNzLyttWE12TmhHQ1hzcTRVQT0=), Uku Haljasorg (https://sciprofiles.com/profile/2744104), Pärt Peterson (https://sciprofiles.com/profile/2744082) and Kaido Kurrikoff (https://sciprofiles.com/profile/470124)

Pharmaceutics **2023**, *15*(3), 952; https://doi.org/10.3390/pharmaceutics15030952 (https://doi.org/10.3390/pharmaceutics15030952) - 15 Mar 2023
Cited by 2 (/1999-4923/15/3/952#metrics) | Viewed by 1421

Abstract mRNA-based therapeutics are presently one of the nucleic acid-based therapeutics with a high potential for extraordinary success as preventive vaccines. Current applications with mRNA therapeutics rely on lipid nanoparticle (LNP) mediated delivery of nucleic acids. In order to achieve the transition from preventive **[...] Read more.**

(This article belongs to the Special Issue **The Delivery of RNA-Based Therapeutics: New Strategies in Cancer and Gene Therapy (/journal/pharmaceutics/special_issues/36BUGK3ER)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00952/article_deploy/html/images/pharmaceutics-15-00952-g001-550.jpg?1678865554) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00952/article_deploy/html/images/pharmaceutics-15-00952-g002-550.jpg?1678865551) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00952/article_deploy/html/images/pharmaceutics-15-00952-g003-550.jpg?1678865547) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00952/article_deploy/html/images/pharmaceutics-15-00952-g004-550.jpg?1678865545)

Open Access Article **(/1999-4923/15/3/951/pdf?version=1678863154)**

Nanostructured Lipid Carriers Aimed to the Ocular Delivery of Mangiferin: In Vitro Evidence (/1999-4923/15/3/951)

by **Debora Santonocito (https://sciprofiles.com/profile/2009998)**, **Ignazio Barbagallo (https://sciprofiles.com/profile/466008)**, **Alfio Distefano (https://sciprofiles.com/profile/author/eHRPdFlBdUJMTEFpMXNSSmZHZzdSN05qajQ2aFVISW9GMDVDeEM5MVk0RT0=)**, **Giuseppe Sferrazzo (https://sciprofiles.com/profile/703928)**, **Maria Vivero-Lopez (https://sciprofiles.com/profile/1512967)**, **Maria Grazia Sarpietro (https://sciprofiles.com/profile/21420)** and **Carmelo Puglia (https://sciprofiles.com/profile/358593)**

Pharmaceutics **2023**, *15*(3), 951; **https://doi.org/10.3390/pharmaceutics15030951 (https://doi.org/10.3390/pharmaceutics15030951)** - 15 Mar 2023

Viewed by 972

Abstract Although mangiferin (MGN) is a natural antioxidant that could be a good candidate for the treatment of ocular diseases, its use in ophthalmology is strongly compromised due to its high lipophilicity. Its encapsulation in nanostructured lipid carriers (NLC) seems to be an interesting **[...] Read more.**

(This article belongs to the Special Issue **Nanotechnology and Natural Products: Plant Bioactive Compounds for Drug Delivery (Volume II) (/journal/pharmaceutics/special_issues/1G3T5446B3)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00951/article_deploy/html/images/pharmaceutics-15-00951-g001-550.jpg?1678863254) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00951/article_deploy/html/images/pharmaceutics-15-00951-g002-550.jpg?1678863242) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00951/article_deploy/html/images/pharmaceutics-15-00951-g003a-550.jpg?1678863235) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00951/article_deploy/html/images/pharmaceutics-15-00951-g003b-550.jpg?1678863256) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00951/article_deploy/html/images/pharmaceutics-15-00951-g004-550.jpg?1678863248) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00951/article_deploy/html/images/pharmaceutics-15-00951-g005-550.jpg?1678863240) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00951/article_deploy/html/images/pharmaceutics-15-00951-g006-550.jpg?1678863236) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00951/article_deploy/html/images/pharmaceutics-15-00951-g007-550.jpg?1678863253) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00951/article_deploy/html/images/pharmaceutics-15-00951-g008-550.jpg?1678863251)

Open Access Article **(/1999-4923/15/3/950/pdf?version=1678860904)**

The Development of Super-Saturated Rebamipide Eye Drops for Enhanced Solubility, Stability, Patient Compliance, and Bioavailability (/1999-4923/15/3/950)

by **Dong-Jin Jang (https://sciprofiles.com/profile/2811617)**, **Jun Hak Lee (https://sciprofiles.com/profile/2426488)**, **Da Hun Kim (https://sciprofiles.com/profile/author/cUI3aFBvcEEreG5ENWx5UGxoUUZqei9UVnNSSVk5a1kzRE1qZGtRdk1NRT0=)**, **Jin-Woo Kim (https://sciprofiles.com/profile/2121327)**, **Tae-Sung Koo (https://sciprofiles.com/profile/1478472)** and **Kwan Hyung Cho (https://sciprofiles.com/profile/232530)**

Pharmaceutics **2023**, *15*(3), 950; **https://doi.org/10.3390/pharmaceutics15030950 (https://doi.org/10.3390/pharmaceutics15030950)** - 15 Mar 2023

Viewed by 1239

Abstract The present study aimed to develop clear aqueous rebamipide (REB) eye drops to enhance solubility, stability, patient compliance, and bioavailability. For the preparation of a super-saturated 1.5% REB solution, the pH-modification method using NaOH and a hydrophilic polymer was employed. Low-viscosity hydroxypropyl methylcellulose **[...] Read more.**

(This article belongs to the Section **Biopharmaceutics (/journal/pharmaceutics/sections/Biopharmaceutics)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00950/article_deploy/html/images/pharmaceutics-15-00950-ag-550.jpg?1678860987) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00950/article_deploy/html/images/pharmaceutics-15-00950-g001-550.jpg?1678860982) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00950/article_deploy/html/images/pharmaceutics-15-00950-g002-550.jpg?1678860985) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00950/article_deploy/html/images/pharmaceutics-15-00950-g003-550.jpg?1678860984) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00950/article_deploy/html/images/pharmaceutics-15-00950-g004-550.jpg?1678860987) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00950/article_deploy/html/images/pharmaceutics-15-00950-g005-550.jpg?1678860978) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00950/article_deploy/html/images/pharmaceutics-15-00950-g006-550.jpg?1678860986) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00950/article_deploy/html/images/pharmaceutics-15-00950-g007-550.jpg?1678860981) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00950/article_deploy/html/images/pharmaceutics-15-00950-g008-550.jpg?1678860981) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00950/article_deploy/html/images/pharmaceutics-15-00950-g009-550.jpg?1678860983)

Open Access Article **(/1999-4923/15/3/949/pdf?version=1678858696)**

Nutmeg Essential Oil, Red Clover, and Liquorice Extracts Microencapsulation Method Selection for the Release of Active Compounds from Gel Tablets of Different Bases (/1999-4923/15/3/949)

by **Jurga Andreja Kazlauskaite (https://sciprofiles.com/profile/1469797)**, **Inga Matulyte (https://sciprofiles.com/profile/821038)**, **Mindaugas Marksa (https://sciprofiles.com/profile/3149361)** and **Jurga Bernatoniene (https://sciprofiles.com/profile/414631)**

Pharmaceutics **2023**, *15*(3), 949; **https://doi.org/10.3390/pharmaceutics15030949 (https://doi.org/10.3390/pharmaceutics15030949)** - 15 Mar 2023

Cited by 2 (/1999-4923/15/3/949#metrics) | Viewed by 1053

Abstract The current study presents the most suitable method for encapsulating nutmeg essential oil with liquorice and red clover. Two widely used methods, spray-drying and freeze-drying, were employed to find the most suitable for essential oil volatile compounds' protection. Results showed that freeze-dried capsules **[...] Read more.**

(This article belongs to the Special Issue **Essential Oils in Pharmaceutical Products (Volume II) (/journal/pharmaceutics/special_issues/G1PHTVMMDJ)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00949/article_deploy/html/images/pharmaceutics-15-00949-g001-550.jpg?1678858766) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00949/article_deploy/html/images/pharmaceutics-15-00949-g002-550.jpg?1678858765) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00949/article_deploy/html/images/pharmaceutics-15-00949-g003-550.jpg?1678858762) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00949/article_deploy/html/images/pharmaceutics-15-00949-g004-550.jpg?1678858769) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00949/article_deploy/html/images/pharmaceutics-15-00949-g005-550.jpg?1678858763) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00949/article_deploy/html/images/pharmaceutics-15-00949-g006-550.jpg?1678858767) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00949/article_deploy/html/images/pharmaceutics-15-00949-g007-550.jpg?1678858768)

Open Access Review **(/1999-4923/15/3/948/pdf?version=1678856950)**

Potential Role of Vaginal Microbiota in Ovarian Cancer Carcinogenesis, Progression and Treatment (/1999-4923/15/3/948)

by **Xiumiao Zhao (https://sciprofiles.com/profile/author/Q2FEOGNFVEQyK0l4dlgvYk1oQ2Y4MnVERmx4VjFZWDZrVUdrTE5EakJWQT0=)**, **Zhaoxia Liu (https://sciprofiles.com/profile/937447)** and **Tingtao Chen (https://sciprofiles.com/profile/1070564)**

Pharmaceutics **2023**, *15*(3), 948; **https://doi.org/10.3390/pharmaceutics15030948 (https://doi.org/10.3390/pharmaceutics15030948)** - 15 Mar 2023

Cited by 1 (/1999-4923/15/3/948#metrics) | Viewed by 1788

Abstract Ovarian cancer represents one of the most challenging gynecologic cancers which still has numerous unknowns on the underlying pathogenesis. In addition to the verified contributors such as genomic predisposition and medical history in the carcinogenesis, emerging evidence points out the potential role of **[...] Read more.**

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00948/article_deploy/html/images/pharmaceutics-15-00948-g001-550.jpg?1678857036) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00948/article_deploy/html/images/pharmaceutics-15-00948-g002-550.jpg?1678857038) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00948/article_deploy/html/images/pharmaceutics-15-00948-g003-550.jpg?1678857040)

Open Access Review **(/1999-4923/15/3/947/pdf?version=1678852406)**

Application of DNA Replicons in Gene Therapy and Vaccine Development (/1999-4923/15/3/947)

by **Kenneth Lundstrom (https://sciprofiles.com/profile/11276)**

Back to TopTop

Pharmaceutics **2023**, *15*(3), 947; **https://doi.org/10.3390/pharmaceutics15030947 (https://doi.org/10.3390/pharmaceutics15030947)** - 15 Mar 2023
Cited by 2 (/1999-4923/15/3/947#metrics) | Viewed by 1292

Abstract DNA-based gene therapy and vaccine development has received plenty of attention lately. DNA replicons based on self-replicating RNA viruses such as alphaviruses and flaviviruses have been of particular interest due to the amplification of RNA transcripts leading to enhanced transgene expression in transfected **[...] Read more.**
(This article belongs to the Special Issue **Plasmid DNA for Gene Therapy and DNA Vaccine Applications (/journal/pharmaceutics/special_issues/dna_gene_vaccine)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00947/article_deploy/html/images/pharmaceutics-15-00947-g001-550.jpg?1678852469) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00947/article_deploy/html/images/pharmaceutics-15-00947-g002-550.jpg?1678852469)

Open Access Review **(/1999-4923/15/3/946/pdf?version=1678851741)**

Nontoxic Fluorescent Nanoprobes for Multiplexed Detection and 3D Imaging of Tumor Markers in Breast Cancer (/1999-4923/15/3/946)

by **Pavel Sokolov (https://sciprofiles.com/profile/author/L0xleWljYVJpbzQ1azI5Q01oSkFLb0hTWU8rYUJjWnk3Ri9QWUJ1bUcwaz0=)**, **Galina Nifontova (https://sciprofiles.com/profile/1884715)**, **Pavel Samokhvalov (https://sciprofiles.com/profile/1340560)**, **Alexander Karaulov (https://sciprofiles.com/profile/917416)**, **Alyona Sukhanova (https://sciprofiles.com/profile/835850)** and **Igor Nabiev (https://sciprofiles.com/profile/836843)**

Pharmaceutics **2023**, *15*(3), 946; **https://doi.org/10.3390/pharmaceutics15030946 (https://doi.org/10.3390/pharmaceutics15030946)** - 15 Mar 2023
Cited by 1 (/1999-4923/15/3/946#metrics) | Viewed by 1430

Abstract Multiplexed fluorescent immunohistochemical analysis of breast cancer (BC) markers and high-resolution 3D immunofluorescence imaging of the tumor and its microenvironment not only facilitate making the disease prognosis and selecting effective anticancer therapy (including photodynamic therapy), but also provides information on signaling and metabolic **[...] Read more.**
(This article belongs to the Special Issue **Study of Nanoparticles for Photodynamic Therapy and Imaging (/journal/pharmaceutics/special_issues/nanoparticles_PDT)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00946/article_deploy/html/images/pharmaceutics-15-00946-ag-550.jpg?1678851824) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00946/article_deploy/html/images/pharmaceutics-15-00946-g001-550.jpg?1678851820) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00946/article_deploy/html/images/pharmaceutics-15-00946-g002-550.jpg?1678851813) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00946/article_deploy/html/images/pharmaceutics-15-00946-g003-550.jpg?1678851817) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00946/article_deploy/html/images/pharmaceutics-15-00946-g004-550.jpg?1678851818) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00946/article_deploy/html/images/pharmaceutics-15-00946-g005-550.jpg?1678851824) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00946/article_deploy/html/images/pharmaceutics-15-00946-g006-550.jpg?1678851822) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00946/article_deploy/html/images/pharmaceutics-15-00946-g007-550.jpg?1678851814)

Open Access Article **(/1999-4923/15/3/945/pdf?version=1678807159)**

In Vivo and In Vitro Antidiabetic Efficacy of Aqueous and Methanolic Extracts of Orthosiphon Stamineus Benth (/1999-4923/15/3/945)

by **Najlaa Bassalat (https://sciprofiles.com/profile/2045898)**, **Sleman Kadan (https://sciprofiles.com/profile/837201)**, **Sarit Melamed (https://sciprofiles.com/profile/author/TWYyR3BQY01PYVhVam52cFhsdndqc20wN2YyeXJhajN2RHRYMzR1d01DMD0=)**, **Tamar Yaron (https://sciprofiles.com/profile/author/K1Ezc1pnSkllYVo4N3pGanVySXlaTDFLUHdxN1pPYm0yK0xjMCtCRU8wZz0=)**, **Zipora Tietel (https://sciprofiles.com/profile/1499081)**, **Dina Karam (https://sciprofiles.com/profile/author/NGFtb3dUTnVwU2dSNTRuNC9hOG9sNUw0eE9jNVlQbnlpNHNVWnI2MzE5UT0=)**, **Asmaa Kmail (https://sciprofiles.com/profile/author/d2JUUUNLeHpyN3RuS1Z0TjQ2U0lmMUg0MGlHVzZMY0ZkR2ZtVEYySVpKND0=)**, **Mahmud Masalha (https://sciprofiles.com/profile/author/QXBVaHRqRmM5bktoS1VaL1ZXRFZweTZWUUQveEtBQW4rakVpWjJCYWEyZz0=)** and **Hilal Zaid (https://sciprofiles.com/profile/836811)**

Pharmaceutics **2023**, *15*(3), 945; **https://doi.org/10.3390/pharmaceutics15030945 (https://doi.org/10.3390/pharmaceutics15030945)** - 14 Mar 2023
Cited by 1 (/1999-4923/15/3/945#metrics) | Viewed by 943

Abstract *Orthosiphon stamineus* is a popular folk herb used to treat diabetes and some other disorders. Previous studies have shown that *O. stamineus* extracts were able to balance blood glucose levels in diabetic rat animal models. However, the antidiabetic mechanism of *O. stamineus* is **[...] Read more.**
(This article belongs to the Special Issue **The Role of Natural Products on Diabetes Mellitus Treatment (/journal/pharmaceutics/special_issues/diabetes_mellitus_treatment)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00945/article_deploy/html/images/pharmaceutics-15-00945-g001-550.jpg?1678807246) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00945/article_deploy/html/images/pharmaceutics-15-00945-g002-550.jpg?1678807244) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00945/article_deploy/html/images/pharmaceutics-15-00945-g003-550.jpg?1678807233) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00945/article_deploy/html/images/pharmaceutics-15-00945-g004-550.jpg?1678807231) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00945/article_deploy/html/images/pharmaceutics-15-00945-g005a-550.jpg?1678807238) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00945/article_deploy/html/images/pharmaceutics-15-00945-g005b-550.jpg?1678807226)

Open Access Article **(/1999-4923/15/3/944/pdf?version=1678798574)**

A Novel Fibromodulin Antagonist Peptide RP4 Exerts Antitumor Effects on Colorectal Cancer (/1999-4923/15/3/944)

by **Ting Deng (https://sciprofiles.com/profile/author/aGRnYmd1aXl5RWpPNFRNclBBTlVuK25XbTZvNXEwcXdkR3JZODdYc0FFST0=)**, **Yibo Hou (https://sciprofiles.com/profile/2829169)**, **Gaoyang Lin (https://sciprofiles.com/profile/author/R0crME1FbE8yNWozZnNNQ1dCOGVuai9SclRpRHNGNFEvaldONk83TUZtND0=)**, **Chunyan Feng (https://sciprofiles.com/profile/author/WUJjZzAxaHdQais5OVhEV09LTGQxMmZZakV0V2tTYzRLSGRFejA2U0dlND0=)**, **Kewei Liu (https://sciprofiles.com/profile/author/NkxhdFNzQ1ZlUWw0amZLb2hKejQ1SVhrc29PVnVxZ0xXVHJoSzUyRFV5VT0=)**, **Wenke Chen (https://sciprofiles.com/profile/author/OXYzdWowcUNQcmNlUUhkREJlRXJaYndGd0RRcFBCT3Q5QzJBWWRjdUVCMD0=)**, **Wei Wei (https://sciprofiles.com/profile/author/U3NzbDFFZlUvODhxNVkvVGlMb0JZeTR2ZXFKVVVsbmp4U2FyNi96d1g2bz0=)**, **Laiqiang Huang (https://sciprofiles.com/profile/1012942)** and **Xiaoyong Dai (https://sciprofiles.com/profile/author/NmRFTTZQaTB4bUZjOEhhNUI1RzBmeE1LdmNWREN4eGhiUTJuQXZhWElLdz0=)**

Pharmaceutics **2023**, *15*(3), 944; **https://doi.org/10.3390/pharmaceutics15030944 (https://doi.org/10.3390/pharmaceutics15030944)** - 14 Mar 2023
Cited by 1 (/1999-4923/15/3/944#metrics) | Viewed by 1177

Abstract Colorectal cancer (CRC) is the leading cause of cancer-related deaths worldwide. Fibromodulin (FMOD) is the main proteoglycan that contributes to extracellular matrix (ECM) remodeling by binding to matrix molecules, thereby playing an essential role in tumor growth and metastasis. There are still no **[...] Read more.**
(This article belongs to the Special Issue **Recent Progress in Reactive Oxygen Species-Related Therapy for Disease Treatment (/journal/pharmaceutics/special_issues/D00R8YA626)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00944/article_deploy/html/images/pharmaceutics-15-00944-g001-550.jpg?1678798655) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00944/article_deploy/html/images/pharmaceutics-15-00944-g002-550.jpg?1678798647) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00944/article_deploy/html/images/pharmaceutics-15-00944-g003-550.jpg?1678798652) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00944/article_deploy/html/images/pharmaceutics-15-00944-g004-550.jpg?1678798659) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00944/article_deploy/html/images/pharmaceutics-15-00944-g005-550.jpg?1678798643) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00944/article_deploy/html/images/pharmaceutics-15-00944-g006-550.jpg?1678798662) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00944/article_deploy/html/images/pharmaceutics-15-00944-g007-550.jpg?1678798665) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00944/article_deploy/html/images/pharmaceutics-15-00944-g008-550.jpg?1678798657)

Open Access Article **(/1999-4923/15/3/943/pdf?version=1678798633)**

Immunogenic Cell Death Photothermally Mediated by Erythrocyte Membrane-Coated Magnetofluorescent Nanocarriers Improves Survival in Sarcoma Model (/1999-4923/15/3/943)

by **Ailton Antonio Sousa-Junior (https://sciprofiles.com/profile/1750250)**, **Francyelli Mello-Andrade (https://sciprofiles.com/profile/3021452)**, **João Victor Ribeiro Rocha (https://sciprofiles.com/profile/author/dDBkSUEwS3hISHVHaE1URlFQWThyMExsTVlHTHAycVZHYjdRb3hGbHh5VT0=)**, **Tácio Gonçalves Hayasaki (https://sciprofiles.com/profile/2685724)**, **Juliana Santana de Curcio (https://sciprofiles.com/profile/author/UlJoeC8wV0dlVGVFLzBrc01NUTgzd1NCQzRqZlNlR2t4czFhZmJGanNrRT0=)**, **Lívia do Carmo Silva (https://sciprofiles.com/profile/3021719)**, **Ricardo Costa de Santana (https://sciprofiles.com/profile/2687672)**, **Eliana Martins Lima (https://sciprofiles.com/profile/1626632)**, **Cléver Gomes Cardoso (https://sciprofiles.com/profile/2835330)**, **Elisângela de Paula Silveira-Lacerda (https://sciprofiles.com/profile/2122230)**, **Sebastião Antonio Mendanha (https://sciprofiles.com/profile/812075)** and **Andris Figueiroa Bakuzis (https://sciprofiles.com/profile/2521761)**

Pharmaceutics **2023**, *15*(3), 943; **https://doi.org/10.3390/pharmaceutics15030943 (https://doi.org/10.3390/pharmaceutics15030943)** - 14 Mar 2023

Abstract Inducing immunogenic cell death (ICD) during cancer therapy is a major challenge that might significantly improve patient survival. The purpose of this study was to develop a theranostic nanocarrier, capable both of conveying a cytotoxic thermal dose when mediating photothermal therapy (PTT) after **[...] Read more.**
(This article belongs to the Special Issue **Nanocarriers for Cancer Therapy and Diagnosis, 2nd Edition (/journal/pharmaceutics/special_issues/NP-3UXG0193)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00943/article_deploy/html/images/pharmaceutics-15-00943-ag-550.jpg?1678798714) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00943/article_deploy/html/images/pharmaceutics-15-00943-g001-550.jpg?1678798709) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00943/article_deploy/html/images/pharmaceutics-15-00943-g002-550.jpg?1678798704) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00943/article_deploy/html/images/pharmaceutics-15-00943-g003-550.jpg?1678798701) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00943/article_deploy/html/images/pharmaceutics-15-00943-g004-550.jpg?1678798712) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00943/article_deploy/html/images/pharmaceutics-15-00943-g005-550.jpg?1678798713)

Open Access Article (/1999-4923/15/3/942/pdf?version=1678791270)

Physiologically Based Pharmacokinetic Modelling to Predict Pharmacokinetics of Enavogliflozin, a Sodium-Dependent Glucose Transporter 2 Inhibitor, in Humans (/1999-4923/15/3/942)

by **Min-Soo Kim (https://sciprofiles.com/profile/959697)**, **Yoo-Kyung Song (https://sciprofiles.com/profile/1062553)**, **Ji-Soo Choi (https://sciprofiles.com/profile/author/UnhzSjdOcno3elFyU1ZPeG5OSUN1U05kdlNsemV1dEdlcHV0clJ4K3FBRT0=)**, **Hye Young Ji (https://sciprofiles.com/profile/author/Y3Nyazk1c0s1czEwSCt2QnZrT3pib3hCaC8wWnQ0aTFFQXdPNEJDd3IrYz0=)**, **Eunsuk Yang (https://sciprofiles.com/profile/author/WElCRlZNeElyMXp5RU1mNEdLRFMvRXpkWFJub01saThLMmlOTHlBaEVEbz0=)**, **Joon Seok Park (https://sciprofiles.com/profile/author/ZUZlaW5peE5lN2tGNTZMSmd0TkJqaDJHdTNRVFphUUNtQUFRd3JDd0NUaz0=)**, **Hyung Sik Kim (https://sciprofiles.com/profile/380647)**, **Min-Joo Kim (https://sciprofiles.com/profile/author/b3ZPUnJwZnNPYmJBYmh2a0N2ZlhOTXhQcytCSFExcVk1cCtlOWtmcUVkST0=)**, **In-Kyung Cho (https://sciprofiles.com/profile/author/alkyUWhWV3pmVjdVWHFlL00wNm5Mdz09)**, **Suk-Jae Chung (https://sciprofiles.com/profile/643505)**, **Yoon-Jee Chae (https://sciprofiles.com/profile/1412322)** and **Kyeong-Ryoon Lee (https://sciprofiles.com/profile/1410156)**

Pharmaceutics **2023**, *15*(3), 942; **https://doi.org/10.3390/pharmaceutics15030942 (https://doi.org/10.3390/pharmaceutics15030942)** - 14 Mar 2023
Cited by 1 (/1999-4923/15/3/942#metrics) | Viewed by 1412

Abstract Enavogliflozin is a sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor approved for clinical use in South Korea. As SGLT2 inhibitors are a treatment option for patients with diabetes, enavogliflozin is expected to be prescribed in various populations. Physiologically based pharmacokinetic (PBPK) modelling can rationally **[...] Read more.**
(This article belongs to the Special Issue **Advances in Pharmacokinetics, Pharmacodynamics and Drug Interactions (/journal/pharmaceutics/special_issues/pharmacokinetics_drug)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00942/article_deploy/html/images/pharmaceutics-15-00942-g001-550.jpg?1678791363) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00942/article_deploy/html/images/pharmaceutics-15-00942-g002-550.jpg?1678791361) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00942/article_deploy/html/images/pharmaceutics-15-00942-g003-550.jpg?1678791354) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00942/article_deploy/html/images/pharmaceutics-15-00942-g004-550.jpg?1678791350) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00942/article_deploy/html/images/pharmaceutics-15-00942-g005-550.jpg?1678791352) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00942/article_deploy/html/images/pharmaceutics-15-00942-g006-550.jpg?1678791357)

Open Access Review (/1999-4923/15/3/941/pdf?version=1678790559)

Platinum-Nucleos(t)ide Compounds as Possible Antimetabolites for Antitumor/Antiviral Therapy: Properties and Perspectives (/1999-4923/15/3/941)

by **Federica De Castro (https://sciprofiles.com/profile/506828)**, **Erika Stefàno (https://sciprofiles.com/profile/1582294)**, **Erik De Luca (https://sciprofiles.com/profile/2748997)**, **Michele Benedetti (https://sciprofiles.com/profile/399709)** and **Francesco Paolo Fanizzi (https://sciprofiles.com/profile/22972)**

Pharmaceutics **2023**, *15*(3), 941; **https://doi.org/10.3390/pharmaceutics15030941 (https://doi.org/10.3390/pharmaceutics15030941)** - 14 Mar 2023
Cited by 1 (/1999-4923/15/3/941#metrics) | Viewed by 1273

Abstract Nucleoside analogues (NAs) are a family of compounds which include a variety of purine and pyrimidine derivatives, widely used as anticancer and antiviral agents. For their ability to compete with physiological nucleosides, NAs act as antimetabolites exerting their activity by interfering with the **[...] Read more.**
(This article belongs to the Special Issue **Novel Metal-Based Drugs for Anticancer and Antiviral Applications (/journal/pharmaceutics/special_issues/Metal_Anticancer)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00941/article_deploy/html/images/pharmaceutics-15-00941-g001-550.jpg?1678790638) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00941/article_deploy/html/images/pharmaceutics-15-00941-g002-550.jpg?1678790632) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00941/article_deploy/html/images/pharmaceutics-15-00941-g003-550.jpg?1678790637) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00941/article_deploy/html/images/pharmaceutics-15-00941-g004-550.jpg?1678790640) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00941/article_deploy/html/images/pharmaceutics-15-00941-g005-550.jpg?1678790639) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00941/article_deploy/html/images/pharmaceutics-15-00941-g006-550.jpg?1678790630) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00941/article_deploy/html/images/pharmaceutics-15-00941-g007-550.jpg?1678790640) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00941/article_deploy/html/images/pharmaceutics-15-00941-g008-550.jpg?1678790627) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00941/article_deploy/html/images/pharmaceutics-15-00941-g009-550.jpg?1678790630) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00941/article_deploy/html/images/pharmaceutics-15-00941-g010-550.jpg?1678790628) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00941/article_deploy/html/images/pharmaceutics-15-00941-g011-550.jpg?1678790629) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00941/article_deploy/html/images/pharmaceutics-15-00941-g012-550.jpg?1678790635) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00941/article_deploy/html/images/pharmaceutics-15-00941-g013-550.jpg?1678790634)

Open Access Article (/1999-4923/15/3/940/pdf?version=1678788811)

Size-Controllable Nanosystem with Double Responsive for Deep Photodynamic Therapy (/1999-4923/15/3/940)

by **Shuang-Shuang Wan (https://sciprofiles.com/profile/2726688)**, **Jun Tao (https://sciprofiles.com/profile/author/dTh6UHMrUlhsdnBYS1VZcHNPcEpoMHA1em90VHJScjFQM0l2bDNTSWt3VT0=)**, **Qian Wu (https://sciprofiles.com/profile/author/aGZ2WWw2aWl2Q0lwQzA5akdFK2R3TGtlWGlUN1U1YzE1aGlCSkkwckN1VT0=)**, **Wu-Rui Liu (https://sciprofiles.com/profile/author/bFNidnlIRTgyVXBKSjI1eFNMQ1dFcWo1Vml2Qi9GV3lyVzhLNUlCY0JPQT0=)**, **Xian-Guang Ding (https://sciprofiles.com/profile/2728166)** and **Xian-Zheng Zhang (https://sciprofiles.com/profile/195708)**

Pharmaceutics **2023**, *15*(3), 940; **https://doi.org/10.3390/pharmaceutics15030940 (https://doi.org/10.3390/pharmaceutics15030940)** - 14 Mar 2023
Viewed by 974

Abstract Photodynamic therapy (PDT) is a promising strategy for cancer treatment. However, a poor tissue penetration of activation light and low target specificity seriously hindered the clinical application of PDT. Here, we designed and constructed a size-controllable nanosystem (UPH) with inside-out responsive for deep **[...] Read more.**

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00940/article_deploy/html/images/pharmaceutics-15-00940-g001-550.jpg?1678788892) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00940/article_deploy/html/images/pharmaceutics-15-00940-g002-550.jpg?1678788888) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00940/article_deploy/html/images/pharmaceutics-15-00940-g003-550.jpg?1678788894) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00940/article_deploy/html/images/pharmaceutics-15-00940-g004-550.jpg?1678788898) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00940/article_deploy/html/images/pharmaceutics-15-00940-sch001-550.jpg?1678788895)

Open Access Article (/1999-4923/15/3/939/pdf?version=1678786514)

Antibacterial Activity and Cytocompatibility of Electrospun PLGA Scaffolds Surface-Modified by Pulsed DC Magnetron Co-Sputtering of Copper and Titanium (/1999-4923/15/3/939)

by **Arsalan D. Badaraev (https://sciprofiles.com/profile/author/blBQcTE3Mkd3OHpJQm5CdlV2WThkdz09)**, **Marat I. Lerner (https://sciprofiles.com/profile/2651929)**, **Olga V. Bakina (https://sciprofiles.com/profile/3139930)**, **Dmitrii V. Sidelev (https://sciprofiles.com/profile/1566150)**, **Tuan-Hoang Tran (https://sciprofiles.com/profile/2578417)**, **Maksim G. Krinitcyn (https://sciprofiles.com/profile/294157)**, **Anna B. Malashicheva (https://sciprofiles.com/profile/630585)**, **Elena G. Cherempey (https://sciprofiles.com/profile/author/NHA1OEFMcVV3Wk4rYndhdWpwWW8zYk1MYm1iMTkwelhaYlU5Q1B0Ni8yWT0=)**, **Galina B. Slepchenko (https://sciprofiles.com/profile/author/c2dRWEJ4RzlwQ29mQWt1TTBwY1JGZz09)**, **Anna I. Kozelskaya (https://sciprofiles.com/profile/1334064)**, **Sven Rutkowski (https://sciprofiles.com/profile/1993636)** and **Sergei I. Tverdokhlebov (https://sciprofiles.com/profile/489806)**

Back to TopTop

Pharmaceutics **2023**, *15*(3), 939; **https://doi.org/10.3390/pharmaceutics15030939 (https://doi.org/10.3390/pharmaceutics15030939)** - 14 Mar 2023
Cited by 1 (/1999-4923/15/3/939#metrics) | Viewed by 1041

Abstract Biocompatible poly(lactide-co-glycolide) scaffolds fabricated via electrospinning are having promising properties as implants for the regeneration of fast-growing tissues, which are able to degrade in the body. The hereby-presented research work investigates the surface modification of these scaffolds in order to improve antibacterial properties **[...] Read more.**

(This article belongs to the Special Issue **Fiber-Based Scaffolds as Drug Carriers: Recent Advances (/journal/pharmaceutics/special_issues/0GQ0VY3PU0)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00939/article_deploy/html/images/pharmaceutics-15-00939-ag-550.jpg?1678786604) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00939/article_deploy/html/images/pharmaceutics-15-00939-g001-550.jpg?1678786593) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00939/article_deploy/html/images/pharmaceutics-15-00939-g002-550.jpg?1678786599) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00939/article_deploy/html/images/pharmaceutics-15-00939-g003-550.jpg?1678786595) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00939/article_deploy/html/images/pharmaceutics-15-00939-g004-550.jpg?1678786603) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00939/article_deploy/html/images/pharmaceutics-15-00939-g005-550.jpg?1678786601)

Open Access Feature Paper Article (/1999-4923/15/3/938/pdf?version=1678785833)

Prognostic and Predictive Value of *LIV1* Expression in Early Breast Cancer and by Molecular Subtype (/1999-4923/15/3/938)

by **Alexandre de Nonneville (https://sciprofiles.com/profile/657825)**, **Pascal Finetti (https://sciprofiles.com/profile/346619)**, **Laurys Boudin (https://sciprofiles.com/profile/2026999)**, **Emilie Denicolaï (https://sciprofiles.com/profile/author/cXlxNG40NktXNWRzWEFIdEZOM0ZiS1JSOWZRWHkvUVQyNnpvNU40RXZsRT0=)**, **Daniel Birnbaum (https://sciprofiles.com/profile/2976192)**, **Emilie Mamessier (https://sciprofiles.com/profile/723193)** and **François Bertucci (https://sciprofiles.com/profile/347862)**

Pharmaceutics **2023**, *15*(3), 938; **https://doi.org/10.3390/pharmaceutics15030938 (https://doi.org/10.3390/pharmaceutics15030938)** - 14 Mar 2023
Viewed by 1214

Abstract Background: LIV1 is a transmembrane protein that may become a new therapeutic target through the development of antibody–drug conjugates (ADCs). Few studies are available regarding the assessment of *LIV1* expression in clinical breast cancer (BC) samples. Methods: We analyzed *LIV1* mRNA expression in **[...] Read more.**

(This article belongs to the Special Issue **Peptide-Drug Conjugates for Targeted Anti-Cancer Therapy: From Design to Application (/journal/pharmaceutics/special_issues/Conjugates_)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00938/article_deploy/html/images/pharmaceutics-15-00938-g001-550.jpg?1678785911) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00938/article_deploy/html/images/pharmaceutics-15-00938-g002-550.jpg?1678785908) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00938/article_deploy/html/images/pharmaceutics-15-00938-g003-550.jpg?1678785914)

Open Access Review (/1999-4923/15/3/937/pdf?version=1678796415)

Exploiting Nanomedicine for Cancer Polychemotherapy: Recent Advances and Clinical Applications (/1999-4923/15/3/937)

by **Elena Boggio (https://sciprofiles.com/profile/363687)**, **Casimiro Luca Gigliotti (https://sciprofiles.com/profile/691301)**, **Ian Stoppa (https://sciprofiles.com/profile/2306996)**, **Deepika Pantham (https://sciprofiles.com/profile/2783019)**, **Sara Sacchetti (https://sciprofiles.com/profile/author/azFGQU9LMGtEU2dDTjVTdW8xZTlEZlNpREErdWdWS3BXeHZlbWZtbi84cz0=)**, **Roberta Rolla (https://sciprofiles.com/profile/1266042)**, **Margherita Grattarola (https://sciprofiles.com/profile/2780679)**, **Chiara Monge (https://sciprofiles.com/profile/author/eitpaVo2M0k0ZEZVM1JOWVdqdnFIbnFCcDV6UlV4TWN4d0dMZ0ZsMU8rRT0=)**, **Stefania Pizzimenti (https://sciprofiles.com/profile/543512)**, **Umberto Dianzani (https://sciprofiles.com/profile/572852)**, **Chiara Dianzani (https://sciprofiles.com/profile/672012)** and **Luigi Battaglia (https://sciprofiles.com/profile/357643)**

Pharmaceutics **2023**, *15*(3), 937; **https://doi.org/10.3390/pharmaceutics15030937 (https://doi.org/10.3390/pharmaceutics15030937)** - 14 Mar 2023
Cited by 1 (/1999-4923/15/3/937#metrics) | Viewed by 1306

Abstract The most important limitations of chemotherapeutic agents are severe side effects and the development of multi-drug resistance. Recently, the clinical successes achieved with immunotherapy have revolutionized the treatment of several advanced-stage malignancies, but most patients do not respond and many of them develop **[...] Read more.**

(This article belongs to the Special Issue **Nanocarriers for Cancer Therapy and Diagnosis, 2nd Edition (/journal/pharmaceutics/special_issues/MP30XG0Y93)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00937/article_deploy/html/images/pharmaceutics-15-00937-g001-550.jpg?1678796489) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00937/article_deploy/html/images/pharmaceutics-15-00937-g002-550.jpg?1678796491) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00937/article_deploy/html/images/pharmaceutics-15-00937-g003-550.jpg?1678796488) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00937/article_deploy/html/images/pharmaceutics-15-00937-g004-550.jpg?1678796490)

Open Access Article (/1999-4923/15/3/936/pdf?version=1678782800)

Development and Characterization of Quercetin-Loaded Delivery Systems for Increasing Its Bioavailability in Cervical Cancer Cells (/1999-4923/15/3/936)

by **Miguel Ferreira (https://sciprofiles.com/profile/2209443)**, **Diana Gomes (https://sciprofiles.com/profile/2262953)**, **Miguel Neto (https://sciprofiles.com/profile/2836875)**, **Luís A. Passarinha (https://sciprofiles.com/profile/78298)**, **Diana Costa (https://sciprofiles.com/profile/1132776)** and **Ângela Sousa (https://sciprofiles.com/profile/686120)**

Pharmaceutics **2023**, *15*(3), 936; **https://doi.org/10.3390/pharmaceutics15030936 (https://doi.org/10.3390/pharmaceutics15030936)** - 14 Mar 2023
Cited by 4 (/1999-4923/15/3/936#metrics) | Viewed by 1318

Abstract Quercetin is a natural flavonoid with high anticancer activity, especially for related-HPV cancers such as cervical cancer. However, quercetin exhibits a reduced aqueous solubility and stability, resulting in a low bioavailability that limits its therapeutic use. In this study, chitosan/sulfonyl-ether-β-cyclodextrin (SBE-β-CD)-conjugated delivery systems **[...] Read more.**

(This article belongs to the Special Issue **Novel Insights in Delivery Systems: Phytochemicals and Biopharmaceuticals (/journal/pharmaceutics/special_issues/Ph_Bio)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00936/article_deploy/html/images/pharmaceutics-15-00936-ag-550.jpg?1678844887) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00936/article_deploy/html/images/pharmaceutics-15-00936-g001-550.jpg?1678782898) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00936/article_deploy/html/images/pharmaceutics-15-00936-g002-550.jpg?1678782892) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00936/article_deploy/html/images/pharmaceutics-15-00936-g003-550.jpg?1678782904) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00936/article_deploy/html/images/pharmaceutics-15-00936-g004-550.jpg?1678782894) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00936/article_deploy/html/images/pharmaceutics-15-00936-g005-550.jpg?1678782901) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00936/article_deploy/html/images/pharmaceutics-15-00936-g006-550.jpg?1678782908)

Open Access Review (/1999-4923/15/3/935/pdf?version=1678779555)

Designing Formulation Strategies for Enhanced Stability of Therapeutic Peptides in Aqueous Solutions: A Review (/1999-4923/15/3/935)

by **Primawan Putra Nugrahadi (https://sciprofiles.com/profile/2780452)**, **Wouter L. J. Hinrichs (https://sciprofiles.com/profile/275524)**, **Henderik W. Frijlink (https://sciprofiles.com/profile/805271)**, **Christian Schönelch (https://sciprofiles.com/profile/853188)** and **Christina Avanti (https://sciprofiles.com/profile/415894)**

Pharmaceutics **2023**, *15*(3), 935; **https://doi.org/10.3390/pharmaceutics15030935 (https://doi.org/10.3390/pharmaceutics15030935)** - 14 Mar 2023
Cited by 1 (/1999-4923/15/3/935#metrics) | Viewed by 1922

Abstract Over the past few decades, there has been a tremendous increase in the utilization of therapeutic peptides. Therapeutic peptides are usually administered via the parenteral route, requiring an aqueous formulation. Unfortunately, peptides are often unstable in aqueous solutions, affecting stability and bioactivity. Although **[...] Read more.**

(This article belongs to the Topic **Peptoids and Peptide Based Drugs (/topics/J8M4JV4G5Q)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00935/article_deploy/html/images/pharmaceutics-15-00935-g001-550.jpg?1678779631) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00935/article_deploy/html/images/pharmaceutics-15-00935-g002-550.jpg?1678779629) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00935/article_deploy/html/images/pharmaceutics-15-00935-g003-550.jpg?1678779623) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00935/article_deploy/html/images/pharmaceutics-15-00935-g004-550.jpg?1678779627)

Open Access Article (/1999-4923/15/3/934/pdf?version=1678771754)

Effect of Inhalation Profile on Delivery of Treprostinil Palmitil Inhalation Powder (/1999-4923/15/3/934)

by **Helena Gauani (https://sciprofiles.com/profile/2833649)**, **Thomas Baker (https://sciprofiles.com/profile/author/WUVNR1FxMDFxVkxKRDZYWktJU2lFZStWYlp0cEtQc0JNVSt0eFhiWUxkMD0=)**,

Zhili Li (https://sciprofiles.com/profile/1419270), Vladimir S. Malinin (https://sciprofiles.com/profile/1364018), Walter R. Perkins (https://sciprofiles.com/profile/author/NEw3U3JzK1RZdjFlZFUrTTJ3bjgzRjRjUmlrYVNCL05lM3B4SDQ0WW0ydz0=), Eugene J. Sullivan (https://sciprofiles.com/profile/author/VUFsUndrNmxjRlcxc2hCNVMvWURBN0JOVFZOOG5jRENBQXcybEpwMDEzZz0=) and David Cipolla (https://sciprofiles.com/profile/118750)
Pharmaceutics **2023**, *15*(3), 934; https://doi.org/10.3390/pharmaceutics15030934 (https://doi.org/10.3390/pharmaceutics15030934) - 14 Mar 2023
Viewed by 1350

Abstract Treprostinil palmitil (TP), a prodrug of treprostinil, is being developed as an inhalation powder (TPIP) for the treatment of patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension due to interstitial lung disease (PH-ILD). In ongoing human clinical trials, TPIP is administered via **[...] Read more.**
(This article belongs to the Special Issue **Development and Evaluation of Inhalable Dry Powder Formulations (/journal/pharmaceutics/special_issues/Inhal_formula)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00934/article_deploy/html/images/pharmaceutics-15-00934-g001-550.jpg?1678771828) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00934/article_deploy/html/images/pharmaceutics-15-00934-g002-550.jpg?1678771818) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00934/article_deploy/html/images/pharmaceutics-15-00934-g003-550.jpg?1678771826) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00934/article_deploy/html/images/pharmaceutics-15-00934-g004-550.jpg?1678771824) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00934/article_deploy/html/images/pharmaceutics-15-00934-g005-550.jpg?1678771820)

Open Access Perspective (/1999-4923/15/3/933/pdf?version=1678764925)

Half a Century of Fragmented Research on Deviations from Advised Therapies: Is This a Good Time to Call for Multidisciplinary Medication Adherence Research Centres of Excellence? (/1999-4923/15/3/933)

by Przemysław Kardas (https://sciprofiles.com/profile/1339473), Tamás Ágh (https://sciprofiles.com/profile/2290348), Alexandra Dima (https://sciprofiles.com/profile/2022470), Catherine Goetzinger (https://sciprofiles.com/profile/author/Y1oxMDUwVDFBRHlnZmhtMFU4MC82TzJWSGlycCt6YmVZMUF6b2pqdzhqZz0=), Ines Potočnjak (https://sciprofiles.com/profile/520955), Björn Wettermark (https://sciprofiles.com/profile/author/K0pQZkpFNENDTmYrRGRLM2kyWVBFRWlxeFowdFAxZEJycnkvb0Z4clRuVT0=) and Job F. M. van Boven (https://sciprofiles.com/profile/author/U1lxS0JISUQwb3lwWlRWYURuZlVhNGszdDlyWURacW13TGRYcHh4WFpsVT0=)
Pharmaceutics **2023**, *15*(3), 933; https://doi.org/10.3390/pharmaceutics15030933 (https://doi.org/10.3390/pharmaceutics15030933) - 14 Mar 2023
Cited by 1 (/1999-4923/15/3/933#metrics) | Viewed by 1718

Abstract Medication adherence is a key precondition of the effectiveness of evidence-based therapies. However, in real-life settings, non-adherence to medication is still very common. This leads to profound health and economic consequences at both individual and public health levels. The problem of non-adherence has **[...] Read more.**
(This article belongs to the Topic **Drug Utilization and Medication Adherence: Strategies, Technologies and Practices (/topics/drug_utilization)**)
(This article belongs to the Section **Clinical Pharmaceutics (/journal/pharmaceutics/sections/Clinical_Pharmaceutics)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00933/article_deploy/html/images/pharmaceutics-15-00933-g001-550.jpg?1678764994) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00933/article_deploy/html/images/pharmaceutics-15-00933-g002-550.jpg?1678764996)

Open Access Article (/1999-4923/15/3/932/pdf?version=1678763400)

Paliperidone–Cation Exchange Resin Complexes of Different Particle Sizes for Controlled Release (/1999-4923/15/3/932)

by Jun-Pil Jee (https://sciprofiles.com/profile/309831), Young Hoon Kim (https://sciprofiles.com/profile/author/LzFoN1FUQ3VmSWZLcHVpSE9tMmhZeXVxNTBPbU9JTjFjSFdpUnREeGtpVT0=), Jun Hak Lee (https://sciprofiles.com/profile/2426488), Kyoung Ah Min (https://sciprofiles.com/profile/738731), Dong-Jin Jang (https://sciprofiles.com/profile/2811617), Sung Giu Jin (https://sciprofiles.com/profile/780468) and Kwan Hyung Cho (https://sciprofiles.com/profile/232530)
Pharmaceutics **2023**, *15*(3), 932; https://doi.org/10.3390/pharmaceutics15030932 (https://doi.org/10.3390/pharmaceutics15030932) - 13 Mar 2023
Viewed by 950

Abstract This study aimed to develop electrolyte complexes of paliperidone (PPD) with various particle sizes using cation-exchange resins (CERs) to enable controlled release (both immediate and sustained release). CERs of specific particle size ranges were obtained by sieving commercial products. PPD–CER complexes (PCCs) were **[...] Read more.**
(This article belongs to the Special Issue **Recent Advances in Oral Solid Dosages (/journal/pharmaceutics/special_issues/3W9NXR365N)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00932/article_deploy/html/images/pharmaceutics-15-00932-ag-550.jpg?1678787589) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00932/article_deploy/html/images/pharmaceutics-15-00932-g001-550.jpg?1678787573) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00932/article_deploy/html/images/pharmaceutics-15-00932-g002-550.jpg?1678787580) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00932/article_deploy/html/images/pharmaceutics-15-00932-g003-550.jpg?1678787568) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00932/article_deploy/html/images/pharmaceutics-15-00932-g004-550.jpg?1678787572) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00932/article_deploy/html/images/pharmaceutics-15-00932-g005-550.jpg?1678787570) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00932/article_deploy/html/images/pharmaceutics-15-00932-g006-550.jpg?1678787566) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00932/article_deploy/html/images/pharmaceutics-15-00932-g007-550.jpg?1678787581) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00932/article_deploy/html/images/pharmaceutics-15-00932-g008-550.jpg?1678787565) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00932/article_deploy/html/images/pharmaceutics-15-00932-g009-550.jpg?1678787567)

Open Access Review (/1999-4923/15/3/931/pdf?version=1678724651)

Utilization of Functionalized Metal–Organic Framework Nanoparticle as Targeted Drug Delivery System for Cancer Therapy (/1999-4923/15/3/931)

by Vy Anh Tran (https://sciprofiles.com/profile/963834), Van Thuan Le (https://sciprofiles.com/profile/2918333), Van Dat Doan (https://sciprofiles.com/profile/2696787) and Giang N. L. Vo (https://sciprofiles.com/profile/2696789)
Pharmaceutics **2023**, *15*(3), 931; https://doi.org/10.3390/pharmaceutics15030931 (https://doi.org/10.3390/pharmaceutics15030931) - 13 Mar 2023
Cited by 3 (/1999-4923/15/3/931#metrics) | Viewed by 2005

Abstract Cancer is a multifaceted disease that results from the complex interaction between genetic and environmental factors. Cancer is a mortal disease with the biggest clinical, societal, and economic burden. Research on better methods of the detection, diagnosis, and treatment of cancer is crucial. **[...] Read more.**
(This article belongs to the Special Issue **Targeted Drug Delivery to Improve Cancer Therapy (/journal/pharmaceutics/special_issues/target_cancer)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00931/article_deploy/html/images/pharmaceutics-15-00931-g001-550.jpg?1678724716) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00931/article_deploy/html/images/pharmaceutics-15-00931-g002-550.jpg?1678724719) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00931/article_deploy/html/images/pharmaceutics-15-00931-g003-550.jpg?1678724735) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00931/article_deploy/html/images/pharmaceutics-15-00931-g004-550.jpg?1678724734) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00931/article_deploy/html/images/pharmaceutics-15-00931-g005-550.jpg?1678724724) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00931/article_deploy/html/images/pharmaceutics-15-00931-g006-550.jpg?1678724732) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00931/article_deploy/html/images/pharmaceutics-15-00931-g007-550.jpg?1678724728) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00931/article_deploy/html/images/pharmaceutics-15-00931-g008-550.jpg?1678724723) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00931/article_deploy/html/images/pharmaceutics-15-00931-g009-550.jpg?1678724715) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00931/article_deploy/html/images/pharmaceutics-15-00931-g010-550.jpg?1678724737) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00931/article_deploy/html/images/pharmaceutics-15-00931-g011-550.jpg?1678724717) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00931/article_deploy/html/images/pharmaceutics-15-00931-g012-550.jpg?1678724730) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00931/article_deploy/html/images/pharmaceutics-15-00931-g013-550.jpg?1678724720) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00931/article_deploy/html/images/pharmaceutics-15-00931-g014-550.jpg?1678724726)

Open Access Article (/1999-4923/15/3/930/pdf?version=1678717206)

Real-Time Monitoring of Colorectal Cancer Location and Lymph Node Metastasis and Photodynamic Therapy Using Fucoidan-Based Therapeutic Nanogel and Near-Infrared Fluorescence Diagnostic–Therapy System (/1999-4923/15/3/930)

by Yoo-kyoung Shin (https://sciprofiles.com/profile/2727859), You-rim Park (https://sciprofiles.com/profile/author/ZHRrYnpjWW9rTFI1RDJUV3o5dGZFTnBsWUN6QXZEU0VWdDZKV3FKVFZOMD0=), Hyeri Lee (https://sciprofiles.com/profile/author/N1h6RWNaNk42SFZSY0RTSDVES3FrQT09), Yongdoo Choi (https://sciprofiles.com/profile/1103052) and Joo Beom Eom (https://sciprofiles.com/profile/120142)

Back to TopTop

Pharmaceutics **2023**, *15*(3), 930; **https://doi.org/10.3390/pharmaceutics15030930 (https://doi.org/10.3390/pharmaceutics15030930)** - 13 Mar 2023
Cited by 2 (/1999-4923/15/3/930#metrics) | Viewed by 920

Abstract We report real-time monitoring of colorectal cancer, lymph node metastasis of colorectal cancer cells, and tumor growth inhibition through photodynamic therapy (PDT) using a near-infrared fluorescence diagnostic–therapy system with a light source for PDT and a fucoidan-based theranostic nanogel (CFN-gel) with good accumulation **[...] Read more.**
(This article belongs to the Special Issue **Recent Advances in Anticancer Photodynamic Therapy (/journal/pharmaceutics/special_issues/I185LS4640)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00930/article_deploy/html/images/pharmaceutics-15-00930-g001-550.jpg?1678717274) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00930/article_deploy/html/images/pharmaceutics-15-00930-g002-550.jpg?1678717287) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00930/article_deploy/html/images/pharmaceutics-15-00930-g003-550.jpg?1678717286) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00930/article_deploy/html/images/pharmaceutics-15-00930-g004-550.jpg?1678717279) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00930/article_deploy/html/images/pharmaceutics-15-00930-g005-550.jpg?1678717277) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00930/article_deploy/html/images/pharmaceutics-15-00930-g006-550.jpg?1678717283) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00930/article_deploy/html/images/pharmaceutics-15-00930-g007-550.jpg?1678717281)

Open Access Article **(/1999-4923/15/3/929/pdf?version=1678772019)**

Lyophilization for Formulation Optimization of Drug-Loaded Thermoresponsive Polyelectrolyte Complex Nanogels from Functionalized Hyaluronic Acid (/1999-4923/15/3/929)

by **Huu Van Le (https://sciprofiles.com/profile/2818061)**, **Virginie Dulong (https://sciprofiles.com/profile/1703271)**, **Luc Picton (https://sciprofiles.com/profile/941791)** and **Didier Le Cerf (https://sciprofiles.com/profile/1663329)**
Pharmaceutics **2023**, *15*(3), 929; **https://doi.org/10.3390/pharmaceutics15030929 (https://doi.org/10.3390/pharmaceutics15030929)** - 13 Mar 2023
Viewed by 1282

Abstract The lyophilization of nanogels is practical not only for their long-term conservation but also for adjusting their concentration and dispersant type during reconstitution for different applications. However, lyophilization strategies must be adapted to each kind of nanoformulation in order to minimize aggregation after **[...] Read more.**
(This article belongs to the Special Issue **Major Contribution of Natural Polymers for Biological Applications in the Last 10 Years: Toward Tailor-Made Biotechnologies (/journal/pharmaceutics/special_issues/O0V9A68M7L)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00929/article_deploy/html/images/pharmaceutics-15-00929-g001-550.jpg?1678772089) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00929/article_deploy/html/images/pharmaceutics-15-00929-g002-550.jpg?1678772085) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00929/article_deploy/html/images/pharmaceutics-15-00929-g003-550.jpg?1678772086) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00929/article_deploy/html/images/pharmaceutics-15-00929-g004-550.jpg?1678772087) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00929/article_deploy/html/images/pharmaceutics-15-00929-g005-550.jpg?1678772091) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00929/article_deploy/html/images/pharmaceutics-15-00929-g006-550.jpg?1678772092) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00929/article_deploy/html/images/pharmaceutics-15-00929-g007-550.jpg?1678772093)

Open Access Review **(/1999-4923/15/3/928/pdf?version=1679384867)**

Highlighted Advances in Therapies for Difficult-To-Treat Brain Tumours Such as Glioblastoma (/1999-4923/15/3/928)

by **Nuno Cruz (https://sciprofiles.com/profile/1026159)**, **Manuel Herculano-Carvalho (https://sciprofiles.com/profile/author/UVdTR1ZyN2dNSUJYcGl6T2VyRzh2aEdQVjdpaXBEY1hPdC9EeWZwNlllVT0=)**, **Diogo Roque (https://sciprofiles.com/profile/2741512)**, **Cláudia C. Faria (https://sciprofiles.com/profile/2936610)**, **Rita Cascão (https://sciprofiles.com/profile/2832063)**, **Hugo Alexandre Ferreira (https://sciprofiles.com/profile/2355927)**, **Catarina Pinto Reis (https://sciprofiles.com/profile/381457)** and **Nuno Matela (https://sciprofiles.com/profile/984962)**
Pharmaceutics **2023**, *15*(3), 928; **https://doi.org/10.3390/pharmaceutics15030928 (https://doi.org/10.3390/pharmaceutics15030928)** - 13 Mar 2023
Cited by 1 (/1999-4923/15/3/928#metrics) | Viewed by 1646

Abstract Glioblastoma multiforme (GBM) remains a challenging disease, as it is the most common and deadly brain tumour in adults and has no curative solution and an overall short survival time. This incurability and short survival time means that, despite its rarity (average incidence **[...] Read more.**
(This article belongs to the Special Issue **Novel Anticancer Strategies (Volume III) (/journal/pharmaceutics/special_issues/YZVK72LQGZ)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00928/article_deploy/html/images/pharmaceutics-15-00928-ag-550.jpg?1679384949) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00928/article_deploy/html/images/pharmaceutics-15-00928-g001-550.jpg?1679384948) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00928/article_deploy/html/images/pharmaceutics-15-00928-g002-550.jpg?1679384949)

Open Access Review **(/1999-4923/15/3/927/pdf?version=1678694338)**

Biopolymer- and Lipid-Based Carriers for the Delivery of Plant-Based Ingredients (/1999-4923/15/3/927)

by **Lynda Gali (https://sciprofiles.com/profile/author/YlJPS2RYTnBvMkVteHRCM0tWaUYzWjVSN1pnSUxqSVFmd0ZiSzR4cURLOD0=)**, **Annachiara Pirozzi (https://sciprofiles.com/profile/1325030)** and **Francesco Donsì (https://sciprofiles.com/profile/1120108)**
Pharmaceutics **2023**, *15*(3), 927; **https://doi.org/10.3390/pharmaceutics15030927 (https://doi.org/10.3390/pharmaceutics15030927)** - 13 Mar 2023
Cited by 1 (/1999-4923/15/3/927#metrics) | Viewed by 1406

Abstract Natural ingredients are gaining increasing attention from manufacturers following consumers' concerns about the excessive use of synthetic ingredients. However, the use of natural extracts or molecules to achieve desirable qualities throughout the shelf life of foodstuff and, upon consumption, in the relevant biological **[...] Read more.**
(This article belongs to the Special Issue **Recent Advances in Nanodelivery Systems for Plant and Food Derivatives (/journal/pharmaceutics/special_issues/6S2S4QRAG0)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00927/article_deploy/html/images/pharmaceutics-15-00927-ag-550.jpg?1678700484) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00927/article_deploy/html/images/pharmaceutics-15-00927-g001-550.jpg?1678700371) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00927/article_deploy/html/images/pharmaceutics-15-00927-g002-550.jpg?1678700372) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00927/article_deploy/html/images/pharmaceutics-15-00927-g003-550.jpg?1678700373) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00927/article_deploy/html/images/pharmaceutics-15-00927-g004-550.jpg?1678700374) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00927/article_deploy/html/images/pharmaceutics-15-00927-g005-550.jpg?1678700373) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00927/article_deploy/html/images/pharmaceutics-15-00927-g006-550.jpg?1678700374) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00927/article_deploy/html/images/pharmaceutics-15-00927-g007-550.jpg?1678700372) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00927/article_deploy/html/images/pharmaceutics-15-00927-g008-550.jpg?1678700374)

Open Access Article **(/1999-4923/15/3/926/pdf?version=1678762992)**

Synergistic Antimicrobial Activity of Silver Nanoparticles with an Emergent Class of Azoimidazoles (/1999-4923/15/3/926)

by **Ana Isabel Ribeiro (https://sciprofiles.com/profile/1008690)**, **Bárbara Vieira (https://sciprofiles.com/profile/2765058)**, **Daniela Dantas (https://sciprofiles.com/profile/author/NmgzbjRNWU1oS0t4bWxhRTNsL3FWSjRiMHVQZndkS0JEcDhmaDNnaCtyZz0=)**, **Bárbara Silva (https://sciprofiles.com/profile/869069)**, **Eugénia Pinto (https://sciprofiles.com/profile/300350)**, **Fátima Cerqueira (https://sciprofiles.com/profile/812695)**, **Renata Silva (https://sciprofiles.com/profile/240662)**, **Fernando Remião (https://sciprofiles.com/profile/609800)**, **Jorge Padrão (https://sciprofiles.com/profile/955652)**, **Alice Maria Dias (https://sciprofiles.com/profile/author/a0JnMDdoeWdWWm40MGlsa0tHaTYvcHNkYm1kMGtjSUdhMVpacnA0VlVtVT0=)** and **Andrea Zille (https://sciprofiles.com/profile/563457)**
Pharmaceutics **2023**, *15*(3), 926; **https://doi.org/10.3390/pharmaceutics15030926 (https://doi.org/10.3390/pharmaceutics15030926)** - 13 Mar 2023
Cited by 3 (/1999-4923/15/3/926#metrics) | Viewed by 1635

Abstract The combination of two or more agents capable of acting in synergy has been reported as a valuable tool to fight against pathogens. Silver nanoparticles (AgNPs) present a strong antimicrobial action, although their cytotoxicity for healthy cells at active concentrations is a major **[...] Read more.**
(This article belongs to the Special Issue **Fighting Fungal Infections: Emerging Nanosystems Strategies (/journal/pharmaceutics/special_issues/nano_antifungal)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00926/article_deploy/html/images/pharmaceutics-15-00926-ag-550.jpg?1678763099) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00926/article_deploy/html/images/pharmaceutics-15-00926-g001-550.jpg?1678763075) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00926/article_deploy/html/images/pharmaceutics-15-00926-g002-550.jpg?1678763086) (https://pub.mdpi-res.com/pharmaceutics

Back to TopTop

/pharmaceutics-15-00926/article_deploy/html/images/pharmaceutics-15-00926-g003-550.jpg?1678763098) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00926/article_deploy/html/images/pharmaceutics-15-00926-g004-550.jpg?1678763073) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00926/article_deploy/html/images/pharmaceutics-15-00926-g005-550.jpg?1678763069) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00926/article_deploy/html/images/pharmaceutics-15-00926-g006-550.jpg?1678763080) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00926/article_deploy/html/images/pharmaceutics-15-00926-g007-550.jpg?1678763095) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00926/article_deploy/html/images/pharmaceutics-15-00926-g008-550.jpg?1678763091) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00926/article_deploy/html/images/pharmaceutics-15-00926-g009-550.jpg?1678763084)

Open Access Article (/1999-4923/15/3/925/pdf?version=1678702030)

Evaluation of In Vitro and In Vivo Antiviral Activities of Vitamin D for SARS-CoV-2 and Variants (/1999-4923/15/3/925)

by Chee-Keng Mok (https://sciprofiles.com/profile/728854),
Yan Ling Ng (https://sciprofiles.com/profile/author/d1hUbitlcGtuTDYwRTFlbmxUV1QvUXNSRmlROFdMYVcvcktCdFFNOGNSaz0=),
Bintou Ahmadou Ahidjo (https://sciprofiles.com/profile/author/SE9SSzhuSys4OFp3OU8rYnc0TEFJSEJzOUx6OExvNUpPaHM1eUZ1TFZiYz0=),
Zhen Qin Aw (https://sciprofiles.com/profile/author/VE9yYy9xaStKRzdYM1pENkYvR3FoUTZMb3gxQ0FuaFBnalR3SVQ5QXBkND0=),
Huixin Chen (https://sciprofiles.com/profile/author/RWh6dWw3c2hVYmhIVzExODhUbkIKdmg1MEp0VGJFRmR3Zm1NOHdreEhGaz0=),
Yi Hao Wong (https://sciprofiles.com/profile/author/ak8vNVo0Q0lrMFVSKzJuZVVWU0pMYkJwSDgrSWlMa05BQkNrRjFrNzE2dz0=),
Regina Ching Hua Lee (https://sciprofiles.com/profile/author/ZVRxWjlscE9qSklUSkxuc2RWVTF1NFNhekgydit6WEhvZnUvRURMY1VPUT0=),
Marcus Wing Choy Loe (https://sciprofiles.com/profile/author/VTdCMDBtcnAxbW1CUTRGdTUyNVBOdmlySjh2dEx5dng4MGFLOXN2U0taND0=),
Jing Liu (https://sciprofiles.com/profile/author/RFA5NkxBaDF3UEM4ZHJoU3pvRVVlK1RlR01KZDYzOFFrd0dmYSsxeUFUND0=),
Kai Sen Tan (https://sciprofiles.com/profile/author/TmZxdnJVRVU3Y2NlMFJKR2dUZDRwcklsS1l3Z2h2Vm45VlZrUnVRTStiST0=),
Parveen Kaur (https://sciprofiles.com/profile/author/TWwxaFFjYkxueXZxVkhHVHc3czUzbkl2UFpmenUrcGw4ZkROaWNRNFBFND0=),
De Yun Wang (https://sciprofiles.com/profile/769720), Erwei Hao (https://sciprofiles.com/profile/2332121), Xiaotao Hou (https://sciprofiles.com/profile/566995),
Yong Wah Tan (https://sciprofiles.com/profile/author/a1A0NEZLbzhZSlJ6Z0FnUmh5TlhSanN4SjZKbStLVHFqRlJnYXBGaGJXdz0=),
Jiagang Deng (https://sciprofiles.com/profile/623341) and Justin Jang Hann Chu (https://sciprofiles.com/profile/413716)
Pharmaceutics **2023**, *15*(3), 925; https://doi.org/10.3390/pharmaceutics15030925 (https://doi.org/10.3390/pharmaceutics15030925) - 12 Mar 2023
Viewed by 1667

Abstract The COVID-19 pandemic has brought about unprecedented medical and healthcare challenges worldwide. With the continual emergence and spread of new COVID-19 variants, four drug compound libraries were interrogated for their antiviral activities against SARS-CoV-2. Here, we show that the drug screen has resulted **[...] Read more.**

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00925/article_deploy/html/images/pharmaceutics-15-00925-g001-550.jpg?1678702107) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00925/article_deploy/html/images/pharmaceutics-15-00925-g002-550.jpg?1678702110) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00925/article_deploy/html/images/pharmaceutics-15-00925-g003-550.jpg?1678702099) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00925/article_deploy/html/images/pharmaceutics-15-00925-g004-550.jpg?1678702103) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00925/article_deploy/html/images/pharmaceutics-15-00925-g005-550.jpg?1678702113) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00925/article_deploy/html/images/pharmaceutics-15-00925-g006-550.jpg?1678702098)

Open Access Article (/1999-4923/15/3/924/pdf?version=1678613808)

Angiotensin II Receptor Blockers Reduce Tau/Aß42 Ratio: A Cerebrospinal Fluid Biomarkers' Case-Control Study (/1999-4923/15/3/924)

by Gemma García-Lluch (https://sciprofiles.com/profile/1817666), Carmen Peña-Bautista (https://sciprofiles.com/profile/1915966),
Lucrecia Moreno Royo (https://sciprofiles.com/profile/1117866),
Miguel Baquero (https://sciprofiles.com/profile/author/amdRV1VTUXZtL2FHRlFtTHB5Z2lFb3JnZTI5bU1aRW8yNTdTVTQrcUN6WT0=),
Antonio José Cañada-Martínez (https://sciprofiles.com/profile/author/d3RzUTBMcDh4bUY3QUJPTmVaYWdiYWwwdlcyOFMyeFVWS1hqL1N1NHBzZz0=) and
Consuelo Cháfer-Pericás (https://sciprofiles.com/profile/846125)
Pharmaceutics **2023**, *15*(3), 924; https://doi.org/10.3390/pharmaceutics15030924 (https://doi.org/10.3390/pharmaceutics15030924) - 12 Mar 2023
Cited by 1 (/1999-4923/15/3/924#metrics) | Viewed by 1173

Abstract (1) Background: The role of antihypertensives in Alzheimer's Disease (AD) prevention is controversial. This case-control study aims to assess whether antihypertensive medication has a protective role by studying its association with amyloid and tau abnormal levels. Furthermore, it suggests a holistic view of **[...] Read more.**
(This article belongs to the Special Issue **Emerging Strategies in Drug Development and Clinical Care in the Era of Personalized and Precision Medicine (/journal/pharmaceutics/special_issues/9WUD0G24J6)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00924/article_deploy/html/images/pharmaceutics-15-00924-ag-550.jpg?1678613882) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00924/article_deploy/html/images/pharmaceutics-15-00924-g001-550.jpg?1678613875) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00924/article_deploy/html/images/pharmaceutics-15-00924-g002-550.jpg?1678613878) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00924/article_deploy/html/images/pharmaceutics-15-00924-g003-550.jpg?1678613877) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00924/article_deploy/html/images/pharmaceutics-15-00924-g004-550.jpg?1678613881)

Open Access Article (/1999-4923/15/3/923/pdf?version=1678612366)

Development and Optimization of Sildenafil Orodispersible Mini-Tablets (ODMTs) for Treatment of Pediatric Pulmonary Hypertension Using Response Surface Methodology (/1999-4923/15/3/923)

by Ahmed Alalaiwe (https://sciprofiles.com/profile/1201933),
Mohammad A. Alsenaidy (https://sciprofiles.com/profile/author/aHlybG9taXl5L29udTEyMDRjQ3Noa1VtdEcwQXJkQ0RBQmVoYVhyMlIGcz0=),
Ziyad S. Almalki (https://sciprofiles.com/profile/2010554) and Mohamed H. Fayed (https://sciprofiles.com/profile/2254704)
Pharmaceutics **2023**, *15*(3), 923; https://doi.org/10.3390/pharmaceutics15030923 (https://doi.org/10.3390/pharmaceutics15030923) - 12 Mar 2023
Viewed by 952

Abstract The availability of age-appropriate oral dosage forms for pediatric patients has remained a challenge. Orodispersible mini-tablets (ODMTs) are a promising delivery system for pediatric patients. The purpose of this work was the development and optimization of sildenafil ODMTs as a new dosage form **[...] Read more.**
(This article belongs to the Special Issue **Understanding Pharmaceutical Quality by Design (/journal/pharmaceutics/special_issues/quality_design)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00923/article_deploy/html/images/pharmaceutics-15-00923-g001-550.jpg?1678612450) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00923/article_deploy/html/images/pharmaceutics-15-00923-g002-550.jpg?1678612444) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00923/article_deploy/html/images/pharmaceutics-15-00923-g003-550.jpg?1678612447) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00923/article_deploy/html/images/pharmaceutics-15-00923-g004-550.jpg?1678612443) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00923/article_deploy/html/images/pharmaceutics-15-00923-g005-550.jpg?1678612441)

Open Access Review (/1999-4923/15/3/922/pdf?version=1679015871)

Sustainable Nanomaterials for Biomedical Applications (/1999-4923/15/3/922)

by Yuhang Zhang (https://sciprofiles.com/profile/2647119),
Kingsley Poon (https://sciprofiles.com/profile/author/TW03MnZmNTZlOHk5aThuWkh5VWc5eTk1Q05YWWE0MTRLWm8zVms2VzVmYz0=),
Gweneth Sofia P. Masonsong (https://sciprofiles.com/profile/author/OVBrVENjd1VuclRGaDgxQmVDemE2eFlrWjJvOCtnUCtBWnNQNCtSeE42Yz0=),
Yogambha Ramaswamy (https://sciprofiles.com/profile/432346) and Gurvinder Singh (https://sciprofiles.com/profile/1312328)
Pharmaceutics **2023**, *15*(3), 922; https://doi.org/10.3390/pharmaceutics15030922 (https://doi.org/10.3390/pharmaceutics15030922) - 12 Mar 2023
Cited by 4 (/1999-4923/15/3/922#metrics) | Viewed by 1592

Abstract Significant progress in nanotechnology has enormously contributed to the design and development of innovative products that have transformed societal challenges related to energy, information technology, the environment, and health. A large portion of the nanomaterials developed for such applications is currently highly dependent **[...] Read more.**
(This article belongs to the Special Issue **Sustainable Materials and Technologies for Drug Delivery and Tissue Engineering (/journal/pharmaceutics/special_issues/Sustainable_Materials_Drug_Delivery_Tissue_Engineering)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00922/article_deploy/html/images/pharmaceutics-15-00922-g001-550.jpg?1679015948) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00922/article_deploy/html/images/pharmaceutics-15-00922-g002-550.jpg?1679015952) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00922/article_deploy/html/images/pharmaceutics-15-00922-g003-550.jpg?1679015950) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00922/article_deploy/html/images/pharmaceutics-15-00922-g004-550.jpg?1679015953)

Open Access Article (/1999-4923/15/3/921/pdf?version=1678685184)

Cataleptogenic Effect of Haloperidol Formulated in Water-Soluble Calixarene-Based Nanoparticles (/1999-4923/15/3/921)

by Nadezda E. Kashapova (https://sciprofiles.com/profile/2788287), Ruslan R. Kashapov (https://sciprofiles.com/profile/663823), Albina Y. Ziganshina (https://sciprofiles.com/profile/722006), Dmitry O. Nikitin (https://sciprofiles.com/profile/author/YIFqT2FzOVMrQzFxVGJxT09aeTJvZGJ2dmpMd1NsNEg0N0NFQXV2Q2Q2az0=), Irina I. Semina (https://sciprofiles.com/profile/author/MVILKzFkZk1VcnZteTBkZ0RVdTF3Zz09), Vadim V. Salnikov (https://sciprofiles.com/profile/author/QjJVVld2Q2N1V2FRb2FTbmdKSFJGdzQ5NFNSck0vVjZ0ZlhGci93RTJMZz0=), Vitaliy V. Khutoryanskiy (https://sciprofiles.com/profile/365743), Rouslan I. Moustafine (https://sciprofiles.com/profile/350561) and Lucia Y. Zakharova (https://sciprofiles.com/profile/916110)

Pharmaceutics **2023**, *15*(3), 921; https://doi.org/10.3390/pharmaceutics15030921 (https://doi.org/10.3390/pharmaceutics15030921) - 11 Mar 2023
Cited by 2 (/1999-4923/15/3/921#metrics) | Viewed by 1115

Abstract In this study, a water-soluble form of haloperidol was obtained by coaggregation with calix[4]resorcinol bearing viologen groups on the upper rim and decyl chains on the lower rim to form vesicular nanoparticles. The formation of nanoparticles is achieved by the spontaneous loading of **[...] Read more.**
(This article belongs to the Special Issue **Supramolecular Systems for Gene and Drug Delivery, 2nd Edition (/journal/pharmaceutics/special_issues/supra_gene_drug_volume_II)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00921/article_deploy/html/images/pharmaceutics-15-00921-ag-550.jpg?1678772171) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00921/article_deploy/html/images/pharmaceutics-15-00921-g001-550.jpg?1678685249) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00921/article_deploy/html/images/pharmaceutics-15-00921-g002-550.jpg?1678685250) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00921/article_deploy/html/images/pharmaceutics-15-00921-g003-550.jpg?1678685253) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00921/article_deploy/html/images/pharmaceutics-15-00921-g004-550.jpg?1678685251) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00921/article_deploy/html/images/pharmaceutics-15-00921-g005-550.jpg?1678685258) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00921/article_deploy/html/images/pharmaceutics-15-00921-g006-550.jpg?1678685258) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00921/article_deploy/html/images/pharmaceutics-15-00921-g007-550.jpg?1678685260) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00921/article_deploy/html/images/pharmaceutics-15-00921-g008-550.jpg?1678685261) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00921/article_deploy/html/images/pharmaceutics-15-00921-g009-550.jpg?1678685248)

Open Access Article (/1999-4923/15/3/920/pdf?version=1678665904)

Electrically Triggered Quercetin Release from Polycaprolactone/Bismuth Ferrite Microfibrous Scaffold for Skeletal Muscle Tissue (/1999-4923/15/3/920)

by Musa Ayran (https://sciprofiles.com/profile/2411854), Hatice Karabulut (https://sciprofiles.com/profile/2779512), Kudret Irem Deniz (https://sciprofiles.com/profile/author/dXBMSHdGRnpGR25lWGdBYVFkdHNXM0VibGlGUUZ6b2tSSFhJVk1RR2JPRT0=), Gamze Ceren Akcanli (https://sciprofiles.com/profile/2816381), Songul Ulag (https://sciprofiles.com/profile/2476455), Alexa-Maria Croitoru (https://sciprofiles.com/profile/2210950), Bianca-Maria Tihăuan (https://sciprofiles.com/profile/224312), Ali Sahin (https://sciprofiles.com/profile/1189132), Denisa Ficai (https://sciprofiles.com/profile/1166894), Oguzhan Gunduz (https://sciprofiles.com/profile/1065223) and Anton Ficai (https://sciprofiles.com/profile/206032)

Pharmaceutics **2023**, *15*(3), 920; https://doi.org/10.3390/pharmaceutics15030920 (https://doi.org/10.3390/pharmaceutics15030920) - 11 Mar 2023
Cited by 1 (/1999-4923/15/3/920#metrics) | Viewed by 1440

Abstract Skeletal muscle tissue engineering presents a promising avenue to address the limitations pertaining to the regenerative potential of stem cells in case of injury or damage. The objective of this research was to evaluate the effects of utilizing novel microfibrous scaffolds, containing the **[...] Read more.**
(This article belongs to the Special Issue **Nanomaterials-Based Drug Carriers Systems Approaches (/journal/pharmaceutics/special_issues/RF1DKC0568)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00920/article_deploy/html/images/pharmaceutics-15-00920-g001-550.jpg?1678666907) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00920/article_deploy/html/images/pharmaceutics-15-00920-g002-550.jpg?1678666925) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00920/article_deploy/html/images/pharmaceutics-15-00920-g003-550.jpg?1678666911) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00920/article_deploy/html/images/pharmaceutics-15-00920-g004-550.jpg?1678666908) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00920/article_deploy/html/images/pharmaceutics-15-00920-g005-550.jpg?1678666909) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00920/article_deploy/html/images/pharmaceutics-15-00920-g006-550.jpg?1678666920) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00920/article_deploy/html/images/pharmaceutics-15-00920-g007-550.jpg?1678666921) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00920/article_deploy/html/images/pharmaceutics-15-00920-g008-550.jpg?1678666926) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00920/article_deploy/html/images/pharmaceutics-15-00920-g009-550.jpg?1678666905) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00920/article_deploy/html/images/pharmaceutics-15-00920-g010-550.jpg?1678666918) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00920/article_deploy/html/images/pharmaceutics-15-00920-g011-550.jpg?1678666928) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00920/article_deploy/html/images/pharmaceutics-15-00920-g012-550.jpg?1678666903)

Open Access Article (/1999-4923/15/3/919/pdf?version=1678528914)

Identification of Blood Transport Proteins to Carry Temoporfin: A Domino Approach from Virtual Screening to Synthesis and In Vitro PDT Testing (/1999-4923/15/3/919)

by Alessia Marconi (https://sciprofiles.com/profile/2482553), Giulia Giugliano (https://sciprofiles.com/profile/2774986), Matteo Di Giosia (https://sciprofiles.com/profile/386432), Tainah Dorina Marforio (https://sciprofiles.com/profile/1854395), Michele Trivini (https://sciprofiles.com/profile/author/TnVlbnZBdUo4ZjR3QTUzSWFuSkhFNEo0OGpreTYwUzN3QVdvNTlSbGI0WT0=), Eleonora Turrini (https://sciprofiles.com/profile/163980), Carmela Fimognari (https://sciprofiles.com/profile/11442), Francesco Zerbetto (https://sciprofiles.com/profile/2109457), Edoardo Jun Mattioli (https://sciprofiles.com/profile/1878488) and Matteo Calvaresi (https://sciprofiles.com/profile/93798)

Pharmaceutics **2023**, *15*(3), 919; https://doi.org/10.3390/pharmaceutics15030919 (https://doi.org/10.3390/pharmaceutics15030919) - 11 Mar 2023
Cited by 1 (/1999-4923/15/3/919#metrics) | Viewed by 884

Abstract Temoporfin (mTHPC) is one of the most promising photosensitizers used in photodynamic therapy (PDT). Despite its clinical use, the lipophilic character of mTHPC still hampers the full exploitation of its potential. Low solubility in water, high tendency to aggregate, and low biocompatibility are **[...] Read more.**
(This article belongs to the Special Issue **Recent Advances in Anticancer Photodynamic Therapy (/journal/pharmaceutics/special_issues/I185LS4640)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00919/article_deploy/html/images/pharmaceutics-15-00919-g001-550.jpg?1678528987) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00919/article_deploy/html/images/pharmaceutics-15-00919-g002-550.jpg?1678528984) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00919/article_deploy/html/images/pharmaceutics-15-00919-g003-550.jpg?1678528980) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00919/article_deploy/html/images/pharmaceutics-15-00919-g004-550.jpg?1678528978) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00919/article_deploy/html/images/pharmaceutics-15-00919-g005-550.jpg?1678528990) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00919/article_deploy/html/images/pharmaceutics-15-00919-g006-550.jpg?1678528986) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00919/article_deploy/html/images/pharmaceutics-15-00919-g007-550.jpg?1678528990) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00919/article_deploy/html/images/pharmaceutics-15-00919-g008-550.jpg?1678528981) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00919/article_deploy/html/images/pharmaceutics-15-00919-g009-550.jpg?1678528982)

Open Access Review (/1999-4923/15/3/918/pdf?version=1679293592)

A Review of Quantitative Systems Pharmacology Models of the Coagulation Cascade: Opportunities for Improved Usability (/1999-4923/15/3/918)

by Douglas Chung (https://sciprofiles.com/profile/2426074), Suruchi Bakshi (https://sciprofiles.com/profile/author/b0d5L1IMNDBML0h4VzVDaVVQQTZFTkJtUVRnbkx4c3lYNTA3bkV1dkNFcz0=) and Piet H. van der Graaf (https://sciprofiles.com/profile/author/a2NVUDhGN01aOWVtKzRDTjNSOWtUMkRtdTBTMkRrdlJoZWhoeGphYWlIZz0=)

Pharmaceutics **2023**, *15*(3), 918; https://doi.org/10.3390/pharmaceutics15030918 (https://doi.org/10.3390/pharmaceutics15030918) - 11 Mar 2023
Cited by 1 (/1999-4923/15/3/918#metrics) | Viewed by 2276

Abstract Despite the numerous therapeutic options to treat bleeding or thrombosis, a comprehensive quantitative mechanistic understanding of the effects of these and potential novel therapies is lacking. Recently, the quality of quantitative systems pharmacology (QSP) models of the coagulation cascade has improved, simulating the **[...] Read more.**
(This article belongs to the Special Issue **The Role of Pharmacometrics in Drug Discovery and Development Process (Volume II) (/journal/pharmaceutics/special_issues/pharmacometrics_volume_II)**)

► Show Figures

Back to TopTop

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00918/article_deploy/html/images/pharmaceutics-15-00918-g001-550.jpg?1679293666) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00918/article_deploy/html/images/pharmaceutics-15-00918-g002-550.jpg?1679293668) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00918/article_deploy/html/images/pharmaceutics-15-00918-g003-550.jpg?1679293658) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00918/article_deploy/html/images/pharmaceutics-15-00918-g004-550.jpg?1679293660) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00918/article_deploy/html/images/pharmaceutics-15-00918-g005-550.jpg?1679293665) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00918/article_deploy/html/images/pharmaceutics-15-00918-g006-550.jpg?1679293669)

Open Access Review (/1999-4923/15/3/917/pdf?version=1678527132)

Immunomodulatory Activity of the Tyrosine Kinase Inhibitor Dasatinib to Elicit NK Cytotoxicity against Cancer, HIV Infection and Aging (/1999-4923/15/3/917)

by Andrea Rodríguez-Agustín (https://sciprofiles.com/profile/2829420),
Víctor Casanova (https://sciprofiles.com/profile/author/dHNzVEZIcDVqWW95ajk4am9aWEkvUjVnRmQ0SnlTUk9BNmJLSTEySUNjQT0=),
Judith Grau-Expósito (https://sciprofiles.com/profile/author/OFJrL0ZHWDlqa2xnTFROMWp5MHcrdFpEU2R2L1J6TnhFMk9VdUg4bmVkdz0=),
Sonsoles Sánchez-Palomino (https://sciprofiles.com/profile/author/WkdNejFXaC8rQnUvRlpraXNxVEZSOXkrYnRUcUJMbFdwMklxMXZNR214VT0=),
José Alcamí (https://sciprofiles.com/profile/819046) and Núria Climent (https://sciprofiles.com/profile/2780203)
Pharmaceutics **2023**, *15*(3), 917; https://doi.org/10.3390/pharmaceutics15030917 (https://doi.org/10.3390/pharmaceutics15030917) - 11 Mar 2023
Viewed by 2697

Abstract Tyrosine kinase inhibitors (TKIs) have been extensively used as a treatment for chronic myeloid leukemia (CML). Dasatinib is a broad-spectrum TKI with off-target effects that give it an immunomodulatory capacity resulting in increased innate immune responses against cancerous cells and viral infected cells. **[...] Read more.**
(This article belongs to the Special Issue **Kinase Inhibitor for Cancer Therapy (/journal/pharmaceutics/special_issues/Kinase_Inhibitor_Cancer)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00917/article_deploy/html/images/pharmaceutics-15-00917-g001-550.jpg?1678527200) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00917/article_deploy/html/images/pharmaceutics-15-00917-g002a-550.jpg?1678527202) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00917/article_deploy/html/images/pharmaceutics-15-00917-g002b-550.jpg?1678527204) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00917/article_deploy/html/images/pharmaceutics-15-00917-g003-550.jpg?1678527204)

Open Access Review (/1999-4923/15/3/916/pdf?version=1678689773)

Photobiomodulation in Alzheimer's Disease—A Complementary Method to State-of-the-Art Pharmaceutical Formulations and Nanomedicine? (/1999-4923/15/3/916)

by Laura Marinela Ailioaie (https://sciprofiles.com/profile/1213574),
Constantin Ailioaie (https://sciprofiles.com/profile/author/aCtORU1LbzZzaEtqdEFaUkk5ajNOZ1BvTnduaktTSmlxbU5tSVlSRzk0bz0=) and
Gerhard Litscher (https://sciprofiles.com/profile/78162)
Pharmaceutics **2023**, *15*(3), 916; https://doi.org/10.3390/pharmaceutics15030916 (https://doi.org/10.3390/pharmaceutics15030916) - 11 Mar 2023
Cited by 3 (/1999-4923/15/3/916#metrics) | Viewed by 3575

Abstract Alzheimer's disease (AD), as a neurodegenerative disorder, usually develops slowly but gradually worsens. It accounts for approximately 70% of dementia cases worldwide, and is recognized by WHO as a public health priority. Being a multifactorial disease, the origins of AD are not satisfactorily **[...] Read more.**
(This article belongs to the Special Issue **Novel Therapeutic Approaches for Neurodegenerative Diseases Treatment (/journal/pharmaceutics/special_issues/neuro_treat)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00916/article_deploy/html/images/pharmaceutics-15-00916-g001-550.jpg?1678689847) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00916/article_deploy/html/images/pharmaceutics-15-00916-g002-550.jpg?1678689849) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00916/article_deploy/html/images/pharmaceutics-15-00916-g003-550.jpg?1678689845)

Open Access Article (/1999-4923/15/3/915/pdf?version=1678694750)

DOPE/CHEMS-Based EGFR-Targeted Immunoliposomes for Docetaxel Delivery: Formulation Development, Physicochemical Characterization and Biological Evaluation on Prostate Cancer Cells (/1999-4923/15/3/915)

by Thais da Silva Moreira (https://sciprofiles.com/profile/author/QVZZRm9BT2Izc1B3alJyeGVOL3JZcEF1b2xMSTJ2QytSMHJQRnNFdUxMTT0=),
Alan Denis Olivindo Silva (https://sciprofiles.com/profile/author/OS9nUlNLYzB1QVRFelISUzVlL1hJTzJraU9Ua3Q4dDJ3Qlc4V1cxWXFjdz0=),
Bianca Rodrigues Farias Vasconcelos (https://sciprofiles.com/profile/author/ZER0YzkycE5GQ2hjblpvbUVFU3pJbnFLRnA3cWJuZ0haMC9keGRZazM5dlRHS3ZrbmFXdGYxKzNoOC
,
Elias da Silva Santos (https://sciprofiles.com/profile/author/K1gyNytEcWJ6UzhyeE9FYVVzMGdZcUJRWUsyK0Y1ckZpd1FJNXUrdWhwZz0=),
Ana Carolina Cruz de Sousa (https://sciprofiles.com/profile/author/NHBJb25VQTRvc1BGM215djlZNnlCdG50SExSUjZuYjN2c0c3ZDZmVy9qWT0=),
João Vito Barroso de Freitas (https://sciprofiles.com/profile/author/Zkc3MlQ3cEhqNXVTOEZ1eXZnV3pCVUU3LzlTYlBPMjc2QjJaTkk0T1lwUT0=),
Yara Santiago de Oliveira (https://sciprofiles.com/profile/author/eFY0WHRXNGtsV21LUTNWWFJQSzFQUjk2S0V5Yk55cnFUNTNQMXByZXVRbz0=),
Laura Maria Teodorio Vidal (https://sciprofiles.com/profile/2829589), Fábio de Oliveira Silva Ribeiro (https://sciprofiles.com/profile/1170351),
Alyne Rodrigues de Araújo (https://sciprofiles.com/profile/author/eUpNQmJ0N2l2RmpXbExieHJ1VWwxeUo5NlJBMTJ6Q3oxazhuQW8yd1NJWT0=),
José de Brito Vieira Neto (https://sciprofiles.com/profile/author/MDBqRmh2U24rWmVjQ2d4NmpKWDlFUnh2NGYzZ3pjTFNhdGp2WG43b2dUZz0=),
Cláudia do Ó Pessoa (https://sciprofiles.com/profile/714601),
Raquel Petrilli (https://sciprofiles.com/profile/author/UmhSQ1JWM0FWTjNVczUrbVFlM2dHUW5MUFZkb0lyTmZ0OGwzczkrRWdyOD0=) and
Josimar O. Eloy (https://sciprofiles.com/profile/2726885)
Pharmaceutics **2023**, *15*(3), 915; https://doi.org/10.3390/pharmaceutics15030915 (https://doi.org/10.3390/pharmaceutics15030915) - 11 Mar 2023
Viewed by 1495

Abstract Docetaxel (DTX) is a non-selective antineoplastic agent with low solubility and a series of side effects. The technology of pH-sensitive and anti-epidermal growth factor receptor (anti-EGFR) immunoliposomes aims to increase the selective delivery of the drug in the acidic tumor environment to cells **[...] Read more.**
(This article belongs to the Special Issue **Antibody Drug Conjugates: Unlocking the Future of Immunotherapies (/journal/pharmaceutics/special_issues/antibodies_drug)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00915/article_deploy/html/images/pharmaceutics-15-00915-g001-550.jpg?1678694843) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00915/article_deploy/html/images/pharmaceutics-15-00915-g002-550.jpg?1678694845) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00915/article_deploy/html/images/pharmaceutics-15-00915-g003-550.jpg?1678694835) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00915/article_deploy/html/images/pharmaceutics-15-00915-g004-550.jpg?1678694837) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00915/article_deploy/html/images/pharmaceutics-15-00915-g005-550.jpg?1678694841) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00915/article_deploy/html/images/pharmaceutics-15-00915-g006-550.jpg?1678694839) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00915/article_deploy/html/images/pharmaceutics-15-00915-g007-550.jpg?1678694850) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00915/article_deploy/html/images/pharmaceutics-15-00915-g008-550.jpg?1678694833) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00915/article_deploy/html/images/pharmaceutics-15-00915-g009-550.jpg?1678694847)

Open Access Article (/1999-4923/15/3/914/pdf?version=1678690038)

***Thymus vulgaris* Essential Oil in Beta-Cyclodextrin for Solid-State Pharmaceutical Applications (/1999-4923/15/3/914)**

by Aldo Arrais (https://sciprofiles.com/profile/1708599), Elisa Bona (https://sciprofiles.com/profile/1053419),
Valeria Todeschini (https://sciprofiles.com/profile/1139983), Alice Caramaschi (https://sciprofiles.com/profile/1723793),
Nadia Massa (https://sciprofiles.com/profile/1003377), Maddalena Roncoli (https://sciprofiles.com/profile/2340451),
Alessia Minervi (https://sciprofiles.com/profile/author/WE51RkpLMEROVGpDVGNLeTM2alJyb0ZUUWdoTzVlMGNuR1M0TmZZcWtqOD0=),
Elena Perin (https://sciprofiles.com/profile/2832404) and Valentina Gianotti (https://sciprofiles.com/profile/482183)
Pharmaceutics **2023**, *15*(3), 914; https://doi.org/10.3390/pharmaceutics15030914 (https://doi.org/10.3390/pharmaceutics15030914) - 11 Mar 2023
Cited by 2 (/1999-4923/15/3/914#metrics) | Viewed by 1069

Abstract Antimicrobial resistance related to the misuse of antibiotics is a well-known current topic. Their excessive use in several fields has led to enormous selective pressure on pathogenic and commensal bacteria, driving the evolution of antimicrobial resistance genes with severe impacts on human health. **[...] Read more.**
(This article belongs to the Special Issue **Cyclodextrins and Their Inclusion Complexes for Pharmaceutical Uses (/journal/pharmaceutics/special_issues/cyclodextrin_pharm)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00914/article_deploy/html/images/pharmaceutics-15-00914-g001-550.jpg?1678690120) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00914/article_deploy/html/images/pharmaceutics-15-00914-g002-550.jpg?1678690108) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00914/article_deploy/html/images/pharmaceutics-15-00914-g003-550.jpg?1678690106) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00914/article_deploy/html/images/pharmaceutics-15-00914-g004-550.jpg?1678690118) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-

15-00914/article_deploy/html/images/pharmaceutics-15-00914-g005-550.jpg?1678690115) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00914/article_deploy/html/images/pharmaceutics-15-00914-g006-550.jpg?1678690113) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00914/article_deploy/html/images/pharmaceutics-15-00914-g007-550.jpg?1678690105)

(/toggle_desktop_layout_cookie)

Open Access Review (/1999-4923/15/3/913/pdf?version=1678783282)

A Small Sugar Molecule with Huge Potential in Targeted Cancer Therapy (/1999-4923/15/3/913)

by Gabriela Pastuch-Gawołek (https://sciprofiles.com/profile/84991), Julia Szreder (https://sciprofiles.com/profile/2727492), Monika Domińska (https://sciprofiles.com/profile/866055), Mateusz Pielok (https://sciprofiles.com/profile/author/RFVXTG9GVDdMMGI3M3hOV0ROUldsak1pZDhpdlREMWVvYnI1TWVVSGhzVT0=), Piotr Cichy (https://sciprofiles.com/profile/2833505) and Mirosława Grymel (https://sciprofiles.com/profile/447522)

Pharmaceutics **2023**, *15*(3), 913; https://doi.org/10.3390/pharmaceutics15030913 (https://doi.org/10.3390/pharmaceutics15030913) - 11 Mar 2023

Abstract The number of cancer-related diseases is still growing. Despite the availability of a large number of anticancer drugs, the ideal drug is still being sought that would be effective, selective, and overcome the effect of multidrug resistance. Therefore, researchers are still looking for **[...] Read more.**

(This article belongs to the Special Issue **Recent Advances in Nanomedicine for Cancer Therapy (/journal/pharmaceutics/special_issues/O97F74UFO5)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00913/article_deploy/html/images/pharmaceutics-15-00913-ag-550.jpg?1678783405) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00913/article_deploy/html/images/pharmaceutics-15-00913-g001-550.jpg?1678783383) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00913/article_deploy/html/images/pharmaceutics-15-00913-g002-550.jpg?1678783386) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00913/article_deploy/html/images/pharmaceutics-15-00913-g003-550.jpg?1678783376) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00913/article_deploy/html/images/pharmaceutics-15-00913-g004-550.jpg?1678783392) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00913/article_deploy/html/images/pharmaceutics-15-00913-g005-550.jpg?1678783373) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00913/article_deploy/html/images/pharmaceutics-15-00913-g006-550.jpg?1678783371) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00913/article_deploy/html/images/pharmaceutics-15-00913-g007-550.jpg?1678783394) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00913/article_deploy/html/images/pharmaceutics-15-00913-g008-550.jpg?1678783379) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00913/article_deploy/html/images/pharmaceutics-15-00913-g009-550.jpg?1678783397) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00913/article_deploy/html/images/pharmaceutics-15-00913-g010-550.jpg?1678783394) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00913/article_deploy/html/images/pharmaceutics-15-00913-g011-550.jpg?1678783391) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00913/article_deploy/html/images/pharmaceutics-15-00913-g012-550.jpg?1678783370) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00913/article_deploy/html/images/pharmaceutics-15-00913-g013-550.jpg?1678783400) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00913/article_deploy/html/images/pharmaceutics-15-00913-g014-550.jpg?1678783387) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00913/article_deploy/html/images/pharmaceutics-15-00913-g015-550.jpg?1678783389) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00913/article_deploy/html/images/pharmaceutics-15-00913-sch001-550.jpg?1678783382) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00913/article_deploy/html/images/pharmaceutics-15-00913-sch002-550.jpg?1678783381)

Open Access Article (/1999-4923/15/3/912/pdf?version=1678696227)

Protective Efficacy of a Mucosal Influenza Vaccine Formulation Based on the Recombinant Nucleoprotein Co-Administered with a TLR2/6 Agonist BPPcysMPEG (/1999-4923/15/3/912)

by Maria Victoria Sanchez (https://sciprofiles.com/profile/2738005), Thomas Ebensen (https://sciprofiles.com/profile/1437684), Kai Schulze (https://sciprofiles.com/profile/1659402), Diego Esteban Cargnelutti (https://sciprofiles.com/profile/author/K1czN1FKakNnZnVVcjVLM2pKand3UUM1U1hTYmRVSDdJNnlWUCtzdXByQT0=), Eduardo A. Scodeller (https://sciprofiles.com/profile/author/Y256cThkM1NRRWtUZTJYb3k2UExtV1JwTElJblFmWHRzTXBMOTREUGp5UT0=) and Carlos A. Guzmán (https://sciprofiles.com/profile/1212529)

Pharmaceutics **2023**, *15*(3), 912; https://doi.org/10.3390/pharmaceutics15030912 (https://doi.org/10.3390/pharmaceutics15030912) - 10 Mar 2023

Abstract Current influenza vaccines target highly variable surface glycoproteins; thus, mismatches between vaccine strains and circulating strains often diminish vaccine protection. For this reason, there is still a critical need to develop effective influenza vaccines able to protect also against the drift and shift **[...] Read more.**

(This article belongs to the Special Issue **New Adjuvant Technologies for Next-Generation Vaccines (/journal/pharmaceutics/special_issues/124VPEE9A9)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00912/article_deploy/html/images/pharmaceutics-15-00912-g001-550.jpg?1678696299) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00912/article_deploy/html/images/pharmaceutics-15-00912-g002-550.jpg?1678696296) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00912/article_deploy/html/images/pharmaceutics-15-00912-g003-550.jpg?1678696303) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00912/article_deploy/html/images/pharmaceutics-15-00912-g004-550.jpg?1678696294) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00912/article_deploy/html/images/pharmaceutics-15-00912-g005-550.jpg?1678696301)

Open Access Article (/1999-4923/15/3/911/pdf?version=1678688822)

Quantitative Analysis of Photothermal Therapy of Tumor Tissue Using Various Gold Nanoparticle Injection Schemes (/1999-4923/15/3/911)

by Donghyuk Kim (https://sciprofiles.com/profile/1410670) and Hyunjung Kim (https://sciprofiles.com/profile/431745)

Pharmaceutics **2023**, *15*(3), 911; https://doi.org/10.3390/pharmaceutics15030911 (https://doi.org/10.3390/pharmaceutics15030911) - 10 Mar 2023

Abstract Photothermal therapy is a new chemotherapy technique using photothermal effects, a phenomenon in which light energy is converted into thermal energy. Since the treatment technique is performed without surgical incision, it does not cause bleeding and patients are expected to make rapid recoveries, **[...] Read more.**

(This article belongs to the Special Issue **Advances in Cancer Nanotechnology for Photodynamic and Photothermal Therapy (/journal/pharmaceutics/special_issues/XWXN8534AC)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00911/article_deploy/html/images/pharmaceutics-15-00911-g001-550.jpg?1678688896) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00911/article_deploy/html/images/pharmaceutics-15-00911-g002-550.jpg?1678688901) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00911/article_deploy/html/images/pharmaceutics-15-00911-g003-550.jpg?1678688893) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00911/article_deploy/html/images/pharmaceutics-15-00911-g004-550.jpg?1678688904) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00911/article_deploy/html/images/pharmaceutics-15-00911-g005-550.jpg?1678688890) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00911/article_deploy/html/images/pharmaceutics-15-00911-g006-550.jpg?1678688887) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00911/article_deploy/html/images/pharmaceutics-15-00911-g007-550.jpg?1678688892) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00911/article_deploy/html/images/pharmaceutics-15-00911-g008-550.jpg?1678688898) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00911/article_deploy/html/images/pharmaceutics-15-00911-g009-550.jpg?1678688895) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00911/article_deploy/html/images/pharmaceutics-15-00911-g010-550.jpg?1678688889) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00911/article_deploy/html/images/pharmaceutics-15-00911-g011-550.jpg?1678688903)

Open Access Article (/1999-4923/15/3/910/pdf?version=1678684164)

Preparation and Evaluation of a Dosage Form for Individualized Administration of Lyophilized Probiotics (/1999-4923/15/3/910)

by Nicole Fülöpová (https://sciprofiles.com/profile/2337980), Natália Chomová (https://sciprofiles.com/profile/2800302), Jan Elbl (https://sciprofiles.com/profile/1789850), Dagmar Mudroňová (https://sciprofiles.com/profile/1529883), Patrik Sivulič (https://sciprofiles.com/profile/author/ZTBDdFh0WXdnRFRQTStacjdqdnV3dz09), Sylvie Pavloková (https://sciprofiles.com/profile/1431067) and Aleš Franc (https://sciprofiles.com/profile/1724202)

Pharmaceutics **2023**, *15*(3), 910; https://doi.org/10.3390/pharmaceutics15030910 (https://doi.org/10.3390/pharmaceutics15030910) - 10 Mar 2023

Abstract Probiotics have been used in human and veterinary medicine to increase resistance to pathogens and provide protection against external impacts for many years. Pathogens are often transmitted to humans through animal product consumption. Therefore, it is assumed that probiotics protecting animals may also **[...] Read more.**

(This article belongs to the Special Issue **Advance in Development of Patient-Centric Dosage Form, 2nd Edition (/journal/pharmaceutics/special_issues/I6D9W3SIB4)**)

► Show Figures

Back to TopTop

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00910/article_deploy/html/images/pharmaceutics-15-00910-g001-550.jpg?1678684234) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00910/article_deploy/html/images/pharmaceutics-15-00910-g002-550.jpg?1678684232) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00910/article_deploy/html/images/pharmaceutics-15-00910-g003-550.jpg?1678684236) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00910/article_deploy/html/images/pharmaceutics-15-00910-g004-550.jpg?1678684245) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00910/article_deploy/html/images/pharmaceutics-15-00910-g005-550.jpg?1678684240)

Open Access Article (/1999-4923/15/3/909/pdf?version=1678679347)

The Effect of Particle Shape on the Compaction of Realistic Non-Spherical Particles—A Multi-Contact DEM Study (/1999-4923/15/3/909)

by Kostas Giannis (https://sciprofiles.com/profile/1906538), Arno Kwade (https://sciprofiles.com/profile/349084), Jan Henrik Finke (https://sciprofiles.com/profile/396986) and Carsten Schilde (https://sciprofiles.com/profile/1264143)

Pharmaceutics **2023**, *15*(3), 909; https://doi.org/10.3390/pharmaceutics15030909 (https://doi.org/10.3390/pharmaceutics15030909) - 10 Mar 2023

Cited by 1 (/1999-4923/15/3/909#metrics) | Viewed by 1739

Abstract The purpose of this study was to investigate the deformation behavior of non-spherical particles during high-load compaction using the multi-contact discrete element method (MC-DEM). To account for non-spherical particles, the bonded multi-sphere method (BMS), which incorporates intragranular bonds between particles, and the conventional **[...] Read more.**

(This article belongs to the Special Issue **Excipients for Direct Compaction (/journal/pharmaceutics/special_issues/M4B6BE4603)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00909/article_deploy/html/images/pharmaceutics-15-00909-g001-550.jpg?1678679422) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00909/article_deploy/html/images/pharmaceutics-15-00909-g002-550.jpg?1678679430) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00909/article_deploy/html/images/pharmaceutics-15-00909-g003-550.jpg?1678679426) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00909/article_deploy/html/images/pharmaceutics-15-00909-g004-550.jpg?1678679428) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00909/article_deploy/html/images/pharmaceutics-15-00909-g005-550.jpg?1678679418) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00909/article_deploy/html/images/pharmaceutics-15-00909-g006-550.jpg?1678679420) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00909/article_deploy/html/images/pharmaceutics-15-00909-g007-550.jpg?1678679428) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00909/article_deploy/html/images/pharmaceutics-15-00909-g008-550.jpg?1678679424)

Open Access Review (/1999-4923/15/3/908/pdf?version=1678677018)

Current Evidence on Bisphenol A Exposure and the Molecular Mechanism Involved in Related Pathological Conditions (/1999-4923/15/3/908)

by Ylenia Della Rocca (https://sciprofiles.com/profile/1918421), Enrico Matteo Traini (https://sciprofiles.com/profile/author/RitFV000V1k0d1VQUUp5TWtBOUkvZDRiZ0JNd3dDck5tak1EZlJzT2krUT0=), Francesca Diomede (https://sciprofiles.com/profile/370262), Luigia Fonticoli (https://sciprofiles.com/profile/1564399), Oriana Trubiani (https://sciprofiles.com/profile/466691), Alessia Paganelli (https://sciprofiles.com/profile/1743659), Jacopo Pizzicannella (https://sciprofiles.com/profile/624664) and Guya Diletta Marconi (https://sciprofiles.com/profile/1267395)

Pharmaceutics **2023**, *15*(3), 908; https://doi.org/10.3390/pharmaceutics15030908 (https://doi.org/10.3390/pharmaceutics15030908) - 10 Mar 2023

Cited by 3 (/1999-4923/15/3/908#metrics) | Viewed by 1532

Abstract Bisphenol A (BPA) is one of the so-called endocrine disrupting chemicals (EDCs) and is thought to be involved in the pathogenesis of different morbid conditions: immune-mediated disorders, type-2 diabetes mellitus, cardiovascular diseases, and cancer. The purpose of this review is to analyze the **[...] Read more.**

(This article belongs to the Special Issue **Stromal, Stem, Signaling Cells: The Multiple Roles and Applications of Mesenchymal Cells, 2nd Edition (/journal/pharmaceutics/special_issues/1S4BYOVRQ2)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00908/article_deploy/html/images/pharmaceutics-15-00908-ag-550.jpg?1678677087) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00908/article_deploy/html/images/pharmaceutics-15-00908-g001-550.jpg?1678677082) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00908/article_deploy/html/images/pharmaceutics-15-00908-g002-550.jpg?1678677084) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00908/article_deploy/html/images/pharmaceutics-15-00908-g003-550.jpg?1678677086)

Open Access Article (/1999-4923/15/3/907/pdf?version=1678851896)

Preparation of Apixaban Solid Dispersion for the Enhancement of Apixaban Solubility and Permeability (/1999-4923/15/3/907)

by Juseung Lee (https://sciprofiles.com/profile/2404138), Jong-Ju Lee (https://sciprofiles.com/profile/2778823), Seungyeol Lee (https://sciprofiles.com/profile/author/MIg2YXR1WlRUUDYzVnVqOGxSYk1GanBiSCtvb2NzQjgzSGljSzN1b25rdz0=), Linh Dinh (https://sciprofiles.com/profile/1680081), Hangyu Oh (https://sciprofiles.com/profile/author/ZHRGNExIdXpKNDhTdDhCTmFFa091SGVUc2RMZDRSN1VoR2UwSnBNQ0FpMD0=), Sharif Md Abuzar (https://sciprofiles.com/profile/573504), Jun-Hyun Ahn (https://sciprofiles.com/profile/author/MUtYRHdyTjhTMVlobDNTcDhVc2xkdWZEbHd4dUJuWGNWc2l4NWZzd2Z2ST0=) and Sung-Joo Hwang (https://sciprofiles.com/profile/613407)

Pharmaceutics **2023**, *15*(3), 907; https://doi.org/10.3390/pharmaceutics15030907 (https://doi.org/10.3390/pharmaceutics15030907) - 10 Mar 2023

Viewed by 1553

Abstract (1) Background: Solid dispersion (SD) can help increase the bioavailability of poorly water-soluble drugs. Meanwhile, apixaban (APX)—a new anticoagulation drug—has low water solubility (0.028 mg/mL) and low intestinal permeability (0.9×10^{-6} cm/s across Caco-2 colonic cells), thus resulting in a low **[...] Read more.**

(This article belongs to the Special Issue **Strategies for Enhancing the Bioavailability of Poorly Soluble Drugs (/journal/pharmaceutics/special_issues/solubilization_excipients)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00907/article_deploy/html/images/pharmaceutics-15-00907-g001-550.jpg?1678851974) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00907/article_deploy/html/images/pharmaceutics-15-00907-g002-550.jpg?1678851976) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00907/article_deploy/html/images/pharmaceutics-15-00907-g003-550.jpg?1678851971) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00907/article_deploy/html/images/pharmaceutics-15-00907-g004-550.jpg?1678851967) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00907/article_deploy/html/images/pharmaceutics-15-00907-g005-550.jpg?1678851973) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00907/article_deploy/html/images/pharmaceutics-15-00907-g006-550.jpg?1678851969) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00907/article_deploy/html/images/pharmaceutics-15-00907-g007-550.jpg?1678851966)

Open Access Article (/1999-4923/15/3/906/pdf?version=1678447394)

Myricetin Nanofibers Enhanced Water Solubility and Skin Penetration for Increasing Antioxidant and Photoprotective Activities (/1999-4923/15/3/906)

by Tzu-Ching Lin (https://sciprofiles.com/profile/1383531), Chun-Yin Yang (https://sciprofiles.com/profile/1796045), Tzu-Hui Wu (https://sciprofiles.com/profile/2211172), Chih-Hua Tseng (https://sciprofiles.com/profile/104246) and Feng-Lin Yen (https://sciprofiles.com/profile/25869)

Pharmaceutics **2023**, *15*(3), 906; https://doi.org/10.3390/pharmaceutics15030906 (https://doi.org/10.3390/pharmaceutics15030906) - 10 Mar 2023

Cited by 1 (/1999-4923/15/3/906#metrics) | Viewed by 1187

Abstract Excessive exposure to ultraviolet radiation (UV) can induce oxidative stress through the over-production of reactive oxygen species (ROS) on the skin. Myricetin (MYR), a natural flavonoid compound, significantly inhibited UV-induced keratinocyte damage; however, its bioavailability is limited by its poor water solubility and **[...] Read more.**

(This article belongs to the Special Issue **Nanotechnology-Enabled Strategies to Enhance Topical Bioavailability, 2nd Edition (/journal/pharmaceutics/special_issues/9IFWSF3149)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00906/article_deploy/html/images/pharmaceutics-15-00906-ag-550.jpg?1678447479) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00906/article_deploy/html/images/pharmaceutics-15-00906-g001-550.jpg?1678447472) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00906/article_deploy/html/images/pharmaceutics-15-00906-g002-550.jpg?1678447467) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00906/article_deploy/html/images/pharmaceutics-15-00906-g003-550.jpg?1678447474) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00906/article_deploy/html/images/pharmaceutics-15-00906-g004-550.jpg?1678447468) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00906/article_deploy/html/images/pharmaceutics-15-00906-g005-550.jpg?1678447461) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00906/article_deploy/html/images/pharmaceutics-15-00906-g006-550.jpg?1678447470) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00906/article_deploy/html/images/pharmaceutics-15-00906-g007-550.jpg?1678447472) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00906/article_deploy/html/images/pharmaceutics-15-00906-g008-550.jpg?1678447463) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00906/article_deploy/html/images/pharmaceutics-15-00906-

g009-550.jpg?1678447464)

Open Access Article (/1999-4923/15/3/905/pdf?version=1678449269)

Hospital Production of Sterile 2% Propofol Nanoemulsion: Proof of Concept (/1999-4923/15/3/905)

by Amélie Cèbe (https://sciprofiles.com/profile/2833207),
Bérangère Dessane (https://sciprofiles.com/profile/author/ZnRDb3BQcFRSOVIvdTJCMFN0S1FqbVRCaWU5MTcrU09zUUl0VDRqUjB6ND0=),
Pauline Gohier (https://sciprofiles.com/profile/2808668),
Jean-Marc Bernadou (https://sciprofiles.com/profile/author/Q083SGYvUDM4Mkhlam1rb3VVL0tqcjVsbmg0czFTdEo2bnpVT2drWXlhaGdndTU5empiTjhxUGRQdHlUNDhyTg==),
Arnaud Venet (https://sciprofiles.com/profile/author/UE1JK3ZleDZRNG5SZ3J0N3hXbDlOVExEOGFrK2lrd04rRWdxdHFVZkl5VT0=),
Fabien Xuereb (https://sciprofiles.com/profile/author/MzV6aFJLaExFQlBZR1lGL1diSUJFUnpMN0VhVW84dlNEd1VNVDJTckRwYz0=) and
Sylvie Crauste-Manciet (https://sciprofiles.com/profile/2717158)

Pharmaceutics **2023**, *15*(3), 905; https://doi.org/10.3390/pharmaceutics15030905 (https://doi.org/10.3390/pharmaceutics15030905) - 10 Mar 2023
Viewed by 971

Abstract In the context of essential drug shortages, this article reports a proof of concept for the hospital preparation of a 2% propofol injectable nanoemulsion. Two processes for propofol were assessed: mixing propofol with the commercial Intralipid® 20% emulsion and a “de novo” **[...] Read more.**
(This article belongs to the Special Issue **Stability and Formulation of Drug Substances and Pharmaceutical Products (/journal/pharmaceutics/special_issues/S30N03DT1W)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00905/article_deploy/html/images/pharmaceutics-15-00905-g001-550.jpg?1678449344) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00905/article_deploy/html/images/pharmaceutics-15-00905-g002-550.jpg?1678449342) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00905/article_deploy/html/images/pharmaceutics-15-00905-g003-550.jpg?1678449339) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00905/article_deploy/html/images/pharmaceutics-15-00905-g004-550.jpg?1678449337) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00905/article_deploy/html/images/pharmaceutics-15-00905-g005-550.jpg?1678449335) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00905/article_deploy/html/images/pharmaceutics-15-00905-g006-550.jpg?1678449341)

Open Access Article (/1999-4923/15/3/904/pdf?version=1678442165)

Emetic Tartar-Loaded Liposomes as a New Strategy for Leishmaniasis Treatment (/1999-4923/15/3/904)

by Larissa D. Coelho (https://sciprofiles.com/profile/author/QXBweEk5WDhkMmxLL0s5U1UzRFp4Q2tEQzNSMjdRYnhZOFd4VCtyMDJuaz0=),
Mirna M. D. Souza (https://sciprofiles.com/profile/author/bzh2cnpMNGpwRjg3QnRjUXppZ2xHZVVVaDg1QkF2YjMzKzZEYmU5d0RxQT0=),
Geovanni D. Cassali (https://sciprofiles.com/profile/2577549),
Raphaela A. Silva (https://sciprofiles.com/profile/author/bU1NZytKeFkyRDBENmc1T3dEbHcrY1FEd0ZMQjg4ZjJRZVZVWUN0Ylo0dz0=),
Maria J. N. Paiva (https://sciprofiles.com/profile/author/TGM4em5jRTI0RW1sTGhEQnY2WUthNzVjWlpCUXF6MWY0RTQ4K21ldTJYbz0=),
André L. B. Barros (https://sciprofiles.com/profile/893188),
Eliane M. Teixeira (https://sciprofiles.com/profile/author/azJxNzZwQmJoTUZiN2FUa3FBeFl0ak4xbitsRmpaODZSTjdnWGNkaWljST0=),
Josianne N. Silveira (https://sciprofiles.com/profile/author/NnRGV3ZCTDhwQmpWVHUvRUF0clMrbW4vOTdyWVJaZEtoMlAwbkszaHY5TT0=),
Paulo M. Z. Coelho (https://sciprofiles.com/profile/author/azUyVUI6R2QrQk9RYWQyMCs2dGNmaVZTOTZtaEpDV2s0OWg3b0RBTy9rdz0=),
Marta M. G. Aguiar (https://sciprofiles.com/profile/2687935) and Mônica C. Oliveira (https://sciprofiles.com/profile/2464397)

Pharmaceutics **2023**, *15*(3), 904; https://doi.org/10.3390/pharmaceutics15030904 (https://doi.org/10.3390/pharmaceutics15030904) - 10 Mar 2023
Cited by 1 (/1999-4923/15/3/904#metrics) | Viewed by 1151

Abstract Emetic tartar (ET), was used in the treatment of leishmaniasis but its use was discontinued due to its low therapeutic index. Liposomes have been shown to be a promising strategy for delivery of bioactive substances in the region of interest, in order to **[...] Read more.**
(This article belongs to the Special Issue **Advanced Liposomes for Drug Delivery (/journal/pharmaceutics/special_issues/YAZ3Y26O0Q)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00904/article_deploy/html/images/pharmaceutics-15-00904-ag-550.jpg?1678442256) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00904/article_deploy/html/images/pharmaceutics-15-00904-g001-550.jpg?1678442240) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00904/article_deploy/html/images/pharmaceutics-15-00904-g002-550.jpg?1678442256) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00904/article_deploy/html/images/pharmaceutics-15-00904-g003-550.jpg?1678442252) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00904/article_deploy/html/images/pharmaceutics-15-00904-g004-550.jpg?1678442254) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00904/article_deploy/html/images/pharmaceutics-15-00904-g005-550.jpg?1678442237) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00904/article_deploy/html/images/pharmaceutics-15-00904-g006a-550.jpg?1678442248) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00904/article_deploy/html/images/pharmaceutics-15-00904-g006b-550.jpg?1678442244) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00904/article_deploy/html/images/pharmaceutics-15-00904-g007-550.jpg?1678442251) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00904/article_deploy/html/images/pharmaceutics-15-00904-g008-550.jpg?1678442254) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00904/article_deploy/html/images/pharmaceutics-15-00904-g009-550.jpg?1678442253)

Open Access Article (/1999-4923/15/3/903/pdf?version=1678669884)

A Novel Trans-Tracheostomal Retrograde Inhalation Technique Increases Subglottic Drug Deposition Compared to Traditional Trans-Oral Inhalation (/1999-4923/15/3/903)

by Raviv Allon (https://sciprofiles.com/profile/2692640), Saurabh Bhardwaj (https://sciprofiles.com/profile/995245),
Josué Sznitman (https://sciprofiles.com/profile/979908),
Hagit Shoffel-Havakuk (https://sciprofiles.com/profile/author/NW5jRjVXMitYTzRxalBaK1JJbmxrdWtMS1ZWZEJNUkRkTWlyQ2JMWk9zcz0=),
Sapir Pinhas (https://sciprofiles.com/profile/author/M2dxK2JXaUZmb3VlY29aRkgyaGNaMU8rQnFnaUhQaW5JTlJPRThLbldtTT0=),
Elchanan Zloczower (https://sciprofiles.com/profile/author/K0xhU1RpcFdUMCt2b1pzZ1JsMGFDSStCSnU3R2VBM2JyMUhKSlQ5WDZzdz0=),
Yael Shapira-Galitz (https://sciprofiles.com/profile/author/ZFR3VlNLK05HaFV4VEE5RVZVdlhGWFNaNUNHU2U1dE5Ib3phVFd4RjhSYz0=) and
Yonatan Lahav (https://sciprofiles.com/profile/author/c1UrVmJpK3NCbmlzRENET3RTVUhYcXZwWVFlRms2WHdPcHRBRGV6OXdtZz0=)

Pharmaceutics **2023**, *15*(3), 903; https://doi.org/10.3390/pharmaceutics15030903 (https://doi.org/10.3390/pharmaceutics15030903) - 10 Mar 2023
Viewed by 854

Abstract Subglottic stenosis represents a challenging clinical condition in otolaryngology. Although patients often experience improvement following endoscopic surgery, recurrence rates remain high. Pursuing measures to maintain surgical results and prevent recurrence is thus necessary. Steroids therapy is considered effective in preventing restenosis. Currently, however, **[...] Read more.**
(This article belongs to the Special Issue **Personalized Pharmacotherapy and Individualized Delivering Strategies for ENT Applications (/journal/pharmaceutics/special_issues/Personalized_Pharm)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00903/article_deploy/html/images/pharmaceutics-15-00903-g001-550.jpg?1678669956) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00903/article_deploy/html/images/pharmaceutics-15-00903-g002-550.jpg?1678669967) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00903/article_deploy/html/images/pharmaceutics-15-00903-g003-550.jpg?1678669951) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00903/article_deploy/html/images/pharmaceutics-15-00903-g004-550.jpg?1678669964) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00903/article_deploy/html/images/pharmaceutics-15-00903-g005-550.jpg?1678669966) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00903/article_deploy/html/images/pharmaceutics-15-00903-g006-550.jpg?1678669970) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00903/article_deploy/html/images/pharmaceutics-15-00903-g007-550.jpg?1678669954) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00903/article_deploy/html/images/pharmaceutics-15-00903-g008-550.jpg?1678669961) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00903/article_deploy/html/images/pharmaceutics-15-00903-g009-550.jpg?1678669958)

Open Access Article (/1999-4923/15/3/902/pdf?version=1678438982)

Quatsomes Loaded with Squaraine Dye as an Effective Photosensitizer for Photodynamic Therapy (/1999-4923/15/3/902)

by Nicolò Bordignon (https://sciprofiles.com/profile/2604323), Mariana Köber (https://sciprofiles.com/profile/2026913),
Giorgia Chinigò (https://sciprofiles.com/profile/772340), Carlotta Pontremoli (https://sciprofiles.com/profile/1945098),
Ettore Sansone (https://sciprofiles.com/profile/author/aklGajBCZ1dSei9TZ3d5eml1a2pHWENEdFpsKzl2RWNRbHV6YS81QWNHVT0=),
Guillem Vargas-Nadal (https://sciprofiles.com/profile/author/bitsTTBnWGozNjEwMk00aVBYaGpsNy9KT0h2REh6MmxaYzYvQmJNRUl0UT0=),
Maria Jesus Moran Plata (https://sciprofiles.com/profile/author/MFhsbWQxYTFyMG5DOFk2N0hRT0tFb044Tm5pWTZKUGpKclNLektkNWUxTT0=),
Alessandra Fiorio Pla (https://sciprofiles.com/profile/750030), Nadia Barbero (https://sciprofiles.com/profile/168319),
Judit Morla-Folch (https://sciprofiles.com/profile/2015087) and Nora Ventosa (https://sciprofiles.com/profile/1766585)

Pharmaceutics **2023**, *15*(3), 902; **https://doi.org/10.3390/pharmaceutics15030902 (https://doi.org/10.3390/pharmaceutics15030902)** - 10 Mar 2023
Viewed by 1161

Abstract Photodynamic therapy is a non-invasive therapeutic strategy that combines external light with a photosensitizer (PS) to destroy abnormal cells. Despite the great progress in the development of new photosensitizers with improved efficacy, the PS's photosensitivity, high hydrophobicity, and tumor targeting activity still represent **[...] Read more.**
(This article belongs to the Special Issue **Fluorescent Organic Nanoparticles for Bioimaging and Theragnostics (/journal/pharmaceutics/special_issues /nanoparticles_theranostics)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00902/article_deploy/html/images/pharmaceutics-15-00902-g001-550.jpg?1678439046) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00902/article_deploy/html/images/pharmaceutics-15-00902-g002-550.jpg?1678439051) (https://pub.mdpi-res.com /pharmaceutics/pharmaceutics-15-00902/article_deploy/html/images/pharmaceutics-15-00902-g003-550.jpg?1678439057) (https://pub.mdpi-res.com/pharmaceutics /pharmaceutics-15-00902/article_deploy/html/images/pharmaceutics-15-00902-g004-550.jpg?1678439057) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00902/article_deploy/html/images/pharmaceutics-15-00902-g005-550.jpg?1678439048) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00902 /article_deploy/html/images/pharmaceutics-15-00902-g006-550.jpg?1678439051) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00902/article_deploy /html/images/pharmaceutics-15-00902-g007-550.jpg?1678439052) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00902/article_deploy/html/images /pharmaceutics-15-00902-g008-550.jpg?1678439054) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00902/article_deploy/html/images/pharmaceutics-15-00902-sch001-550.jpg?1678439048)

Open Access Article (/1999-4923/15/3/901/pdf?version=1678433518)

Topical Delivery of Diacetyl Boldine in a Microemulsion Formulation for Chemoprotection against Melanoma (/1999-4923/15/3/901)

by **Ahmed Al Saqr (https://sciprofiles.com/profile/2594419)**, **Manjusha Annaji (https://sciprofiles.com/profile/2593708)**, **Ishwor Poudel (https://sciprofiles.com/profile/2434898)**, **Mohammed F. Aldawsari (https://sciprofiles.com/profile/855201)**, **Hamad Alrbyawi (https://sciprofiles.com/profile/2373560)**, **Nur Mita (https://sciprofiles.com/profile/2110698)**, **Muralikrishnan Dhanasekaran (https://sciprofiles.com/profile/432199)**, **Sai H. S. Boddu (https://sciprofiles.com/profile/521759)**, **Rabin Neupane (https://sciprofiles.com/profile/942268)**, **Amit K. Tiwari (https://sciprofiles.com/profile/226661)** and **R. Jayachandra Babu (https://sciprofiles.com/profile/301090)**

Pharmaceutics **2023**, *15*(3), 901; **https://doi.org/10.3390/pharmaceutics15030901 (https://doi.org/10.3390/pharmaceutics15030901)** - 10 Mar 2023
Cited by 1 (/1999-4923/15/3/901#metrics) | Viewed by 1365

Abstract This study aimed to develop a microemulsion formulation for topical delivery of Diacetyl Boldine (DAB) and to evaluate its cytotoxicity against melanoma cell line (B16BL6) in vitro. Using a pseudo-ternary phase diagram, the optimal microemulsion formulation region was identified, and its particle size, **[...] Read more.**
(This article belongs to the Special Issue **Potential of Nano/Microemulsions for Drugs and Phytochemicals Delivery (/journal/pharmaceutics/special_issues /nanoemulsion_delivery)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00901/article_deploy/html/images/pharmaceutics-15-00901-g001-550.jpg?1678433585) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00901/article_deploy/html/images/pharmaceutics-15-00901-g002-550.jpg?1678433591) (https://pub.mdpi-res.com /pharmaceutics/pharmaceutics-15-00901/article_deploy/html/images/pharmaceutics-15-00901-g003-550.jpg?1678433587) (https://pub.mdpi-res.com/pharmaceutics /pharmaceutics-15-00901/article_deploy/html/images/pharmaceutics-15-00901-g004-550.jpg?1678433593) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00901/article_deploy/html/images/pharmaceutics-15-00901-g005-550.jpg?1678433590) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00901 /article_deploy/html/images/pharmaceutics-15-00901-g006-550.jpg?1678433588) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00901/article_deploy /html/images/pharmaceutics-15-00901-g007-550.jpg?1678433595)

Open Access Article (/1999-4923/15/3/900/pdf?version=1679475676)

Micro-Injection Moulding of PEO/PCL Blend–Based Matrices for Extended Oral Delivery of Fenbendazole (/1999-4923/15/3/900)

by **Gilberto S. N. Bezerra (https://sciprofiles.com/profile/author/bmN6TUFseEdPejEvMFJrZmFvL0dPenl0UGMyUW9WRmlsRzhqY2FPUHpnRT0=)**, **Gabriel G. De Lima (https://sciprofiles.com/profile/1257802)**, **Declan M. Colbert (https://sciprofiles.com/profile/2493752)**, **Elaine Halligan (https://sciprofiles.com/profile/2747607)**, **Joseph Geever (https://sciprofiles.com/profile/author/MmRad004NkJ1c2VUVlpva3B0OUo5UT09)** and **Luke Geever (https://sciprofiles.com/profile/414204)**

Pharmaceutics **2023**, *15*(3), 900; **https://doi.org/10.3390/pharmaceutics15030900 (https://doi.org/10.3390/pharmaceutics15030900)** - 10 Mar 2023
Viewed by 1224

Abstract Fenbendazole (FBZ) is a broad-spectrum anthelmintic administered orally to ruminants; nevertheless, its poor water solubility has been the main limitation to reaching satisfactory and sustained levels at the site of the target parasites. Hence, the exploitation of hot-melt extrusion (HME) and micro-injection moulding **[...] Read more.**
(This article belongs to the Special Issue **Functional Polymeric Materials for Drug Delivery and Sustained Drug Release (/journal/pharmaceutics/special_issues /functional_polymeric_materials_drug)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00900/article_deploy/html/images/pharmaceutics-15-00900-g001-550.jpg?1679475746) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00900/article_deploy/html/images/pharmaceutics-15-00900-g002-550.jpg?1679475759) (https://pub.mdpi-res.com /pharmaceutics/pharmaceutics-15-00900/article_deploy/html/images/pharmaceutics-15-00900-g003-550.jpg?1679475758) (https://pub.mdpi-res.com/pharmaceutics /pharmaceutics-15-00900/article_deploy/html/images/pharmaceutics-15-00900-g004-550.jpg?1679475749) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00900/article_deploy/html/images/pharmaceutics-15-00900-g005-550.jpg?1679475748) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00900 /article_deploy/html/images/pharmaceutics-15-00900-g006-550.jpg?1679475761) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00900/article_deploy /html/images/pharmaceutics-15-00900-g007-550.jpg?1679475757) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00900/article_deploy/html/images /pharmaceutics-15-00900-g008-550.jpg?1679475771) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00900/article_deploy/html/images/pharmaceutics-15-00900-g009-550.jpg?1679475752) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00900/article_deploy/html/images/pharmaceutics-15-00900-g010-550.jpg?1679475763) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00900/article_deploy/html/images/pharmaceutics-15-00900-g011-550.jpg?1679475750)

Open Access Article (/1999-4923/15/3/899/pdf?version=1678428307)

Natural Lipid Extracts as an Artificial Membrane for Drug Permeability Assay: In Vitro and In Silico Characterization (/1999-4923/15/3/899)

by **Anna Vincze (https://sciprofiles.com/profile/author/Uk5VS3hJWkhHRlhvNGlvRlF5dkhER0krVlF0UktRcGNQUURrSlkzMDhpYz0=)**, **Gergely Dékány (https://sciprofiles.com/profile/author/Zmd1NlNJekdzZHZpY0trWEltdWo3Nkc1VTJFUVRVanVQQjFGaFNLTlZ6cz0=)**, **Richárd Bicsak (https://sciprofiles.com/profile/author/dzUzZmZ4azNkd0RXWXFrYzRsYy9CSzNEZFFTQXMwNjBGOVAzRHM4OWN6ST0=)**, **András Formanek (https://sciprofiles.com/profile/author/SDgva1BmeXR4QlNTQW50SHdQTTI5SVJCOHlVd0djTkd3d0h6TUZpNVBoc1pzejV0T2k1VmI5UmpLUnViNkJwNw==)**, **Yves Moreau (https://sciprofiles.com/profile/author/bGhPaERET1VGVTdCQ29JbkFvSFV6Z081a0RJckF6RHdVek5jT21XeXZyRT0=)**, **Gábor Koplányi (https://sciprofiles.com/profile/2795145)**, **Gergely Takács (https://sciprofiles.com/profile/author/Nlo3NHU0aHZxOGRxUFg5NHZkemVOL2FzZEl0eDI3b0w3aVhxQlk5UnhQdz0=)**, **Gábor Katona (https://sciprofiles.com/profile/916549)**, **Diána Balogh-Weiser (https://sciprofiles.com/profile/822451)**, **Ádám Arany (https://sciprofiles.com/profile/author/ejNsR2NpRGpEV3dmSmlHcE9uaWQxbGsrZUk0ckhPdWlOYVBqNEdBOXNqUT0=)** and **György T. Balogh (https://sciprofiles.com/profile/1550726)**

Pharmaceutics **2023**, *15*(3), 899; **https://doi.org/10.3390/pharmaceutics15030899 (https://doi.org/10.3390/pharmaceutics15030899)** - 10 Mar 2023
Viewed by 1011

Abstract In vitro non-cellular permeability models such as the parallel artificial membrane permeability assay (PAMPA) are widely applied tools for early-phase drug candidate screening. In addition to the commonly used porcine brain polar lipid extract for modeling the blood–brain barrier's permeability, the total and **[...] Read more.**
(This article belongs to the Special Issue **Feature Papers in Physical Pharmacy and Formulation (/journal/pharmaceutics/special_issues/Formulation)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00899/article_deploy/html/images/pharmaceutics-15-00899-ag-550.jpg?1678428392) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00899/article_deploy/html/images/pharmaceutics-15-00899-g001-550.jpg?1678428376) (https://pub.mdpi-res.com /pharmaceutics/pharmaceutics-15-00899/article_deploy/html/images/pharmaceutics-15-00899-g002-550.jpg?1678428382) (https://pub.mdpi-res.com/pharmaceutics /pharmaceutics-15-00899/article_deploy/html/images/pharmaceutics-15-00899-g003-550.jpg?1678428384) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00899/article_deploy/html/images/pharmaceutics-15-00899-g004-550.jpg?1678428377) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00899 /article_deploy/html/images/pharmaceutics-15-00899-g005-550.jpg?1678428385) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00899/article_deploy /html/images/pharmaceutics-15-00899-g006-550.jpg?1678428385) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00899/article_deploy/html/images

Back to TopTop

(/pharmaceutics-15-00899-g007-550.jpg?1678428375) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00899/article_deploy/html/images/pharmaceutics-15-00899-g008-550.jpg?1678428381) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00899/article_deploy/html/images/pharmaceutics-15-00899-g009-550.jpg?1678428387) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00899/article_deploy/html/images/pharmaceutics-15-00899-g010-550.jpg?1678428380) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00899/article_deploy/html/images/pharmaceutics-15-00899-g011-550.jpg?1678428374) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00899/article_deploy/html/images/pharmaceutics-15-00899-g012-550.jpg?1678428388) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00899/article_deploy/html/images/pharmaceutics-15-00899-g013-550.jpg?1678428390) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00899/article_deploy/html/images/pharmaceutics-15-00899-g014-550.jpg?1678428378)

Open Access Review (/1999-4923/15/3/898/pdf?version=1678427611)

Dendrimers in Alzheimer's Disease: Recent Approaches in Multi-Targeting Strategies (/1999-4923/15/3/898)

by Cécile Arbez-Gindre (https://sciprofiles.com/profile/2069596), Barry R. Steele (https://sciprofiles.com/profile/1235667) and Maria Micha-Screttas (https://sciprofiles.com/profile/author/T3poY0NCeGh2VWZwL0tOYlRkcVhvQT09)

Pharmaceutics **2023**, *15*(3), 898; https://doi.org/10.3390/pharmaceutics15030898 (https://doi.org/10.3390/pharmaceutics15030898) - 10 Mar 2023

Cited by 2 (/1999-4923/15/3/898#metrics) | Viewed by 1329

Abstract Nanomaterials play an increasingly important role in current medicinal practice. As one of the most significant causes of human mortality, and one that is increasing year by year, Alzheimer's disease (AD) has been the subject of a very great body of research and [...] Read more.

(This article belongs to the Special Issue Dendrimers for Drug Delivery (/journal/pharmaceutics/special_issues/dendrimers_delivery))

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00898/article_deploy/html/images/pharmaceutics-15-00898-g001-550.jpg?1678427687) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00898/article_deploy/html/images/pharmaceutics-15-00898-g002-550.jpg?1678427685) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00898/article_deploy/html/images/pharmaceutics-15-00898-g003-550.jpg?1678427690) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00898/article_deploy/html/images/pharmaceutics-15-00898-g004-550.jpg?1678427701) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00898/article_deploy/html/images/pharmaceutics-15-00898-g005-550.jpg?1678427717) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00898/article_deploy/html/images/pharmaceutics-15-00898-g006-550.jpg?1678427716) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00898/article_deploy/html/images/pharmaceutics-15-00898-g007-550.jpg?1678427691) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00898/article_deploy/html/images/pharmaceutics-15-00898-g008-550.jpg?1678427693) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00898/article_deploy/html/images/pharmaceutics-15-00898-g009-550.jpg?1678427709) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00898/article_deploy/html/images/pharmaceutics-15-00898-g010-550.jpg?1678427713) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00898/article_deploy/html/images/pharmaceutics-15-00898-g011-550.jpg?1678427706) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00898/article_deploy/html/images/pharmaceutics-15-00898-g012-550.jpg?1678427710) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00898/article_deploy/html/images/pharmaceutics-15-00898-g013-550.jpg?1678427704) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00898/article_deploy/html/images/pharmaceutics-15-00898-g014-550.jpg?1678427699) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00898/article_deploy/html/images/pharmaceutics-15-00898-g015-550.jpg?1678427689) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00898/article_deploy/html/images/pharmaceutics-15-00898-g016-550.jpg?1678427686) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00898/article_deploy/html/images/pharmaceutics-15-00898-g017-550.jpg?1678427711) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00898/article_deploy/html/images/pharmaceutics-15-00898-g018-550.jpg?1678427696) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00898/article_deploy/html/images/pharmaceutics-15-00898-g019-550.jpg?1678427714) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00898/article_deploy/html/images/pharmaceutics-15-00898-g020-550.jpg?1678427698) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00898/article_deploy/html/images/pharmaceutics-15-00898-g021-550.jpg?1678427716)

Open Access Review (/1999-4923/15/3/897/pdf?version=1678418695)

Anti-Inflammatory Chilean Endemic Plants (/1999-4923/15/3/897)

by Carolina Otero (https://sciprofiles.com/profile/411233), Carolina Klagges (https://sciprofiles.com/profile/author/OTNoaEdvN0xZWWVUbEtUWXhQd1JTR2pBZ3NqSzFpa2wxVjZNVjdwWUpTaz0=), Bernardo Morales (https://sciprofiles.com/profile/2193320), Paula Sotomayor (https://sciprofiles.com/profile/2371693), Jorge Escobar (https://sciprofiles.com/profile/2586298), Juan A. Fuentes (https://sciprofiles.com/profile/1078498), Adrian A. Moreno (https://sciprofiles.com/profile/568429), Felipe M. Llancalahuen (https://sciprofiles.com/profile/1329836), Ramiro Arratia-Perez (https://sciprofiles.com/profile/author/ZUZFQ0VickNzR05DN1NwSlo5YmF6ak9XZjdCL1lxVEt1OENYWlYrcy82bz0=), Felipe Gordillo-Fuenzalida (https://sciprofiles.com/profile/751070), Michelle Herrera (https://sciprofiles.com/profile/author/YUVQVi9XQzVtSWF5N1JzNjg0UkZYQ0h4U2ZtdDVLUXh2bHlObGVaa0o4TT0=), Jose L. Martinez (https://sciprofiles.com/profile/324975) and Maité Rodriguez-Diaz (https://sciprofiles.com/profile/2586299)

Pharmaceutics **2023**, *15*(3), 897; https://doi.org/10.3390/pharmaceutics15030897 (https://doi.org/10.3390/pharmaceutics15030897) - 10 Mar 2023

Cited by 1 (/1999-4923/15/3/897#metrics) | Viewed by 2006

Abstract Medicinal plants have been used since prehistoric times and continue to treat several diseases as a fundamental part of the healing process. Inflammation is a condition characterized by redness, pain, and swelling. This process is a hard response by living tissue to any [...] Read more.

(This article belongs to the Special Issue Advances in Natural Products and Their Derivatives for Metabolic and Chronic Inflammatory Disease Therapy (/journal/pharmaceutics/special_issues/natural_Metabolic))

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00897/article_deploy/html/images/pharmaceutics-15-00897-ag-550.jpg?1678418784) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00897/article_deploy/html/images/pharmaceutics-15-00897-g001-550.jpg?1678418781) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00897/article_deploy/html/images/pharmaceutics-15-00897-g002-550.jpg?1678418772) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00897/article_deploy/html/images/pharmaceutics-15-00897-g003-550.jpg?1678418767) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00897/article_deploy/html/images/pharmaceutics-15-00897-g004-550.jpg?1678418769) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00897/article_deploy/html/images/pharmaceutics-15-00897-g005-550.jpg?1678418773) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00897/article_deploy/html/images/pharmaceutics-15-00897-g006-550.jpg?1678418777) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00897/article_deploy/html/images/pharmaceutics-15-00897-g007-550.jpg?1678418775) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00897/article_deploy/html/images/pharmaceutics-15-00897-g008-550.jpg?1678418764) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00897/article_deploy/html/images/pharmaceutics-15-00897-g009-550.jpg?1678418774) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00897/article_deploy/html/images/pharmaceutics-15-00897-g010-550.jpg?1678418765) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00897/article_deploy/html/images/pharmaceutics-15-00897-g011-550.jpg?1678418770) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00897/article_deploy/html/images/pharmaceutics-15-00897-g012-550.jpg?1678418783) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00897/article_deploy/html/images/pharmaceutics-15-00897-g013-550.jpg?1678418766) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00897/article_deploy/html/images/pharmaceutics-15-00897-g014-550.jpg?1678418778) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00897/article_deploy/html/images/pharmaceutics-15-00897-g015-550.jpg?1678418782)

Open Access Article (/1999-4923/15/3/896/pdf?version=1678429530)

Use of In Vivo Imaging and Physiologically-Based Kinetic Modelling to Predict Hepatic Transporter Mediated Drug–Drug Interactions in Rats (/1999-4923/15/3/896)

by Nicola Melillo (https://sciprofiles.com/profile/2709000), Daniel Scotcher (https://sciprofiles.com/profile/author/SnJsOE5NUTBNaUVocFk5MHJXVVV5WVFyN21nTFNpY2VHSno4b3dickZ3UE5GbG5mWk43N1FTaU10YVR4T1ZrYw==), J. Gerry Kenna (https://sciprofiles.com/profile/author/bS9WSXlVVW9iSU9qall4ZERnWVBiRlVyamZPd3lwcTN0a0F5WkhieDl0Zz0=), Claudia Green (https://sciprofiles.com/profile/author/eFRvYWhyR2d2d1R5eStxRzM1Y2FpQT09), Catherine D. G. Hines (https://sciprofiles.com/profile/author/aEhoZkQ0eU5mUmxDLzc3TmdnL1N1WnRZUW4rZC9LT0xYVFpKdFlFcUpvdz0=), Iina Laitinen (https://sciprofiles.com/profile/author/a1pUaXpFdDZLM0dVbDNBSzhHWnBxRElrcEtMdmtYaINBRjZwQU9sTHRQZ05DQ1Yzc0lkSlpzdjJXMGZlWXVhOQ==), Paul D. Hockings (https://sciprofiles.com/profile/2713065),

Kayode Ogungbenro (https://sciprofiles.com/profile/author/UzJicWdjL2Jqdkk3TUhyR0dlOUlPd1RPcHpxcWdxRS9xVXdVakJ6RXJDSDUrQ2IxdDJobXl4d05heVNjck90WQ==)
MDPI (/)
,
Ebony R. Gunwhy (https://sciprofiles.com/profile/author/UFhtY2NqYWJIR2RqMnU5bThIRUFNSkZZc2duV1E4bjV2Z3JPK25GMkN6bz0=),
Steven Sourbron (https://sciprofiles.com/profile/author/VHI2NXVzSGtjOEhIVkhCdGkvYzlhV3RkZTZLb2c3cjdMOEt3OG00OHBKaz0=), (/toggle_desktop_layout_cookie)
John C. Waterton (https://sciprofiles.com/profile/1411314),
Gunnar Schuetz (https://sciprofiles.com/profile/author/aHBmOXFHWU5obUVCOUU0M1o1N3NmWVF2RjJFbWx4MXhyTEZWZHRzNTJjcz0=) and
Aleksandra Galetin (https://sciprofiles.com/profile/2698795)
Pharmaceutics **2023**, *15*(3), 896; https://doi.org/10.3390/pharmaceutics15030896 (https://doi.org/10.3390/pharmaceutics15030896) - 10 Mar 2023
Viewed by 1912

Abstract Gadoxetate, a magnetic resonance imaging (MRI) contrast agent, is a substrate of organic-anion-transporting polypeptide 1B1 and multidrug resistance-associated protein 2. Six drugs, with varying degrees of transporter inhibition, were used to assess gadoxetate dynamic contrast enhanced MRI biomarkers for transporter inhibition in rats. [...] Read more.
(This article belongs to the Special Issue **Challenges and Perspectives of Drug Transporters: Where Do We Go from Here? (/journal/pharmaceutics/special_issues/challenges_perspectives_drug_transporters)**)

► Show Figures
(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00896/article_deploy/html/images/pharmaceutics-15-00896-g001-550.jpg?1678429616) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00896/article_deploy/html/images/pharmaceutics-15-00896-g002-550.jpg?1678429608) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00896/article_deploy/html/images/pharmaceutics-15-00896-g003-550.jpg?1678429610) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00896/article_deploy/html/images/pharmaceutics-15-00896-g004-550.jpg?1678429619) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00896/article_deploy/html/images/pharmaceutics-15-00896-g005-550.jpg?1678429614) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00896/article_deploy/html/images/pharmaceutics-15-00896-g006-550.jpg?1678429613) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00896/article_deploy/html/images/pharmaceutics-15-00896-g007-550.jpg?1678429605) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00896/article_deploy/html/images/pharmaceutics-15-00896-g008-550.jpg?1678429606)

Open Access Article (/1999-4923/15/3/895/pdf?version=1678421233)

An Adjuvanted Inactivated SARS-CoV-2 Microparticulate Vaccine Delivered Using Microneedles Induces a Robust Immune Response in Vaccinated Mice (/1999-4923/15/3/895)

by Sharon Vijayanand (https://sciprofiles.com/profile/1276208), Smital Patil (https://sciprofiles.com/profile/2851539),
Ipshita Menon (https://sciprofiles.com/profile/1548085), Keegan Braz Gomes (https://sciprofiles.com/profile/2423599),
Akanksha Kale (https://sciprofiles.com/profile/2491302), Priyal Bagwe (https://sciprofiles.com/profile/1371750),
Mohammad N. Uddin (https://sciprofiles.com/profile/1276190), Susu M. Zughaier (https://sciprofiles.com/profile/482198) and
Martin J. D'Souza (https://sciprofiles.com/profile/123090)
Pharmaceutics **2023**, *15*(3), 895; https://doi.org/10.3390/pharmaceutics15030895 (https://doi.org/10.3390/pharmaceutics15030895) - 09 Mar 2023
Cited by 2 (/1999-4923/15/3/895#metrics) | Viewed by 1775

Abstract SARS-CoV-2, the causal agent of COVID-19, is a contagious respiratory virus that frequently mutates, giving rise to variant strains and leading to reduced vaccine efficacy against the variants. Frequent vaccination against the emerging variants may be necessary; thus, an efficient vaccination system is [...] Read more.
(This article belongs to the Special Issue **Recent Advances in Microneedle-Mediated Drug Delivery (/journal/pharmaceutics/special_issues/recent_advances_in_mmdd)**)

► Show Figures
(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00895/article_deploy/html/images/pharmaceutics-15-00895-g001-550.jpg?1678421301) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00895/article_deploy/html/images/pharmaceutics-15-00895-g002-550.jpg?1678421305) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00895/article_deploy/html/images/pharmaceutics-15-00895-g003-550.jpg?1678421307) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00895/article_deploy/html/images/pharmaceutics-15-00895-g004-550.jpg?1678421307) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00895/article_deploy/html/images/pharmaceutics-15-00895-g005-550.jpg?1678421305) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00895/article_deploy/html/images/pharmaceutics-15-00895-g006-550.jpg?1678421308) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00895/article_deploy/html/images/pharmaceutics-15-00895-g007-550.jpg?1678421306) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00895/article_deploy/html/images/pharmaceutics-15-00895-g008-550.jpg?1678421310)

Open Access Article (/1999-4923/15/3/894/pdf?version=1678376093)

Building a Human Physiologically Based Pharmacokinetic Model for Aflatoxin B1 to Simulate Interactions with Drugs (/1999-4923/15/3/894)

by Orphélie Lootens (https://sciprofiles.com/profile/2590166), Marthe De Boevre (https://sciprofiles.com/profile/204192),
Jia Ning (https://sciprofiles.com/profile/author/YTE2MHUzTThONmRFZjVZNW1WTE1SNC9GVjg3LzBkUEtGZWdTTzNWZUVKRT0=),
Elke Gasthuys (https://sciprofiles.com/profile/1088906),
Jan Van Bocxlaer (https://sciprofiles.com/profile/author/TnY0M2srai9sdWI1ZERFMVlBajBlbDdZRHhKTDludnlFQ0F4bUJlaEErST0=),
Sarah De Saeger (https://sciprofiles.com/profile/169775) and
An Vermeulen (https://sciprofiles.com/profile/author/K1dFWFNQbkpvL01JT1FGQkc2QVk5K016WFNYcEJDOXk2TTExQldTeEZZcz0=)
Pharmaceutics **2023**, *15*(3), 894; https://doi.org/10.3390/pharmaceutics15030894 (https://doi.org/10.3390/pharmaceutics15030894) - 09 Mar 2023
Viewed by 1559

Abstract Mycotoxins such as aflatoxin B1 (AFB1) are secondary fungal metabolites present in food commodities and part of one's daily exposure, especially in certain regions, e.g., sub-Saharan Africa. AFB1 is mostly metabolised by cytochrome P450 (CYP) enzymes, namely, CYP1A2 and CYP3A4. As a consequence [...] Read more.
(This article belongs to the Special Issue **Advances in Pharmacokinetics, Pharmacodynamics and Drug Interactions (/journal/pharmaceutics/special_issues/pharmacokinetics_drug)**)

► Show Figures
(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00894/article_deploy/html/images/pharmaceutics-15-00894-g001-550.jpg?1678376169) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00894/article_deploy/html/images/pharmaceutics-15-00894-g002-550.jpg?1678376172) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00894/article_deploy/html/images/pharmaceutics-15-00894-g003-550.jpg?1678376174) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00894/article_deploy/html/images/pharmaceutics-15-00894-g004-550.jpg?1678376171)

Open Access Review (/1999-4923/15/3/893/pdf?version=1678439634)

Recent Preclinical and Clinical Progress in Liposomal Doxorubicin (/1999-4923/15/3/893)

by Kenan Aloss (https://sciprofiles.com/profile/2435351) and Peter Hamar (https://sciprofiles.com/profile/538719)
Pharmaceutics **2023**, *15*(3), 893; https://doi.org/10.3390/pharmaceutics15030893 (https://doi.org/10.3390/pharmaceutics15030893) - 09 Mar 2023
Cited by 6 (/1999-4923/15/3/893#metrics) | Viewed by 2166

Abstract Doxorubicin (DOX) is a potent anti-cancer agent that has garnered great interest in research due to its high efficacy despite dose-limiting toxicities. Several strategies have been exploited to enhance the efficacy and safety profile of DOX. Liposomes are the most established approach. Despite [...] Read more.

► Show Figures
(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00893/article_deploy/html/images/pharmaceutics-15-00893-g001-550.jpg?1678439708) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00893/article_deploy/html/images/pharmaceutics-15-00893-g002-550.jpg?1678439706) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00893/article_deploy/html/images/pharmaceutics-15-00893-g003-550.jpg?1678439706) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00893/article_deploy/html/images/pharmaceutics-15-00893-g004-550.jpg?1678439711) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00893/article_deploy/html/images/pharmaceutics-15-00893-g005-550.jpg?1678439710)

Open Access Review (/1999-4923/15/3/892/pdf?version=1678372939)

A Review of the Benefits 3D Printing Brings to Patients with Neurological Diseases (/1999-4923/15/3/892)

by Christine Gander (https://sciprofiles.com/profile/2825223), Kejing Shi (https://sciprofiles.com/profile/author/Umk2QlU3cjhJRGhCOXhJN2hEdnhkQT09),
Ali Nokhodchi (https://sciprofiles.com/profile/2686215) and
Matthew Lam (https://sciprofiles.com/profile/author/dTdDbk1yby80RUZ5N2dYSXo0S2JWR0c1UXBpTmpoSTg2eDM4QUdrVjkvRT0=)
Pharmaceutics **2023**, *15*(3), 892; https://doi.org/10.3390/pharmaceutics15030892 (https://doi.org/10.3390/pharmaceutics15030892) - 09 Mar 2023
Cited by 1 (/1999-4923/15/3/892#metrics) | Viewed by 1801

Abstract This interdisciplinary review focuses on how flexible three-dimensional printing (3DP) technology can aid patients with neurological diseases. It covers a wide variety of current and possible applications ranging from neurosurgery to customizable polypill along with a brief description of the various 3DP techniques. [...] Read more.
(This article belongs to the Special Issue **Additive Manufacturing Approaches to Produce Drug Delivery Systems Volume II (/journal/pharmaceutics/special_issues/additive_manufacturing_volume_II)**)

Back to TopTop

► Show Figures
(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00892/article_deploy/html/images/pharmaceutics-15-00892-g001-550.jpg?1678373025) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00892/article_deploy/html/images/pharmaceutics-15-00892-g002-550.jpg?1678373027) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00892/article_deploy/html/images/pharmaceutics-15-00892-g003-550.jpg?1678373017) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00892/article_deploy/html/images/pharmaceutics-15-00892-g004-550.jpg?1678373021) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00892/article_deploy/html/images/pharmaceutics-15-00892-g005-550.jpg?1678373022)

Open Access Review (/1999-4923/15/3/891/pdf?version=1679987248)

Extracellular Vesicles as Drug Delivery Systems in Organ Transplantation: The Next Frontier (/1999-4923/15/3/891)

by Harry V. M. Spiers (https://sciprofiles.com/profile/2330669), Lukas K. J. Stadler (https://sciprofiles.com/profile/author/SIRrNlpXQId2RzR4NDR2MmFBRnFxZz09), Hugo Smith (https://sciprofiles.com/profile/2830435) and Vasilis Kosmoliaptsis (https://sciprofiles.com/profile/2598909)

Pharmaceutics **2023**, *15*(3), 891; https://doi.org/10.3390/pharmaceutics15030891 (https://doi.org/10.3390/pharmaceutics15030891) - 09 Mar 2023

Cited by 3 (/1999-4923/15/3/891#metrics) | Viewed by 4580

Abstract Extracellular vesicles are lipid bilayer-delimited nanoparticles excreted into the extracellular space by all cells. They carry a cargo rich in proteins, lipids and DNA, as well as a full complement of RNA species, which they deliver to recipient cells to induce downstream signalling, **[...] Read more.**

(This article belongs to the Special Issue **Advances of Membrane Vesicles in Drug Delivery Systems (/journal/pharmaceutics/special_issues/Vesicles)**)

► Show Figures
(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00891/article_deploy/html/images/pharmaceutics-15-00891-g001-550.jpg?1679987335) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00891/article_deploy/html/images/pharmaceutics-15-00891-g002-550.jpg?1679987338) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00891/article_deploy/html/images/pharmaceutics-15-00891-g003-550.jpg?1679987332)

Open Access Article (/1999-4923/15/3/890/pdf?version=1678414676)

Feasibility of Child-Resistant and Senior-Friendly Press-Through Packages: Potential of Different Materials (/1999-4923/15/3/890)

by Kiyomi Sadamoto (https://sciprofiles.com/profile/2729990), Hiroyuki Ura (https://sciprofiles.com/profile/2681426), Mikio Murata (https://sciprofiles.com/profile/author/U3RhYm80Y0phNDBtdDVlVlVCQUVvR2JlVDRwR2prRmtGb1NRa3FFaTJHTT0=), Masaho Hayashi (https://sciprofiles.com/profile/author/enRhOCs0VGQwSkhkWGVMUG1hRzR0S1ZwVWhEUDVkZDZnbUp0UWlQUmtHOD0=) and Kiyoshi Kubota (https://sciprofiles.com/profile/author/ejBzVGZVN2EwUlhqL0V5UWtrRUlQNUVRUlVUdnBObks4blVpUkw1Q085az0=)

Pharmaceutics **2023**, *15*(3), 890; https://doi.org/10.3390/pharmaceutics15030890 (https://doi.org/10.3390/pharmaceutics15030890) - 09 Mar 2023

Viewed by 806

Abstract Press-through packaging (PTP) is the most common type of drug packaging in Japan, and a production procedure for PTP has been established at an acceptable cost. However, unknown problems and new needs with regard to safety among users of various age-groups still need **[...] Read more.**

(This article belongs to the Special Issue **Understanding Pharmaceutical Quality by Design (/journal/pharmaceutics/special_issues/quality_design)**)

► Show Figures
(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00890/article_deploy/html/images/pharmaceutics-15-00890-g001-550.jpg?1678414744) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00890/article_deploy/html/images/pharmaceutics-15-00890-g002-550.jpg?1678414750) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00890/article_deploy/html/images/pharmaceutics-15-00890-g003-550.jpg?1678414751) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00890/article_deploy/html/images/pharmaceutics-15-00890-g004-550.jpg?1678414748) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00890/article_deploy/html/images/pharmaceutics-15-00890-g005-550.jpg?1678414750)

Open Access Review (/1999-4923/15/3/889/pdf?version=1678937693)

Codelivery of Phytochemicals with Conventional Anticancer Drugs in Form of Nanocarriers (/1999-4923/15/3/889)

by Girish Kumar (https://sciprofiles.com/profile/2805727), Tarun Virmani (https://sciprofiles.com/profile/1918441), Ashwani Sharma (https://sciprofiles.com/profile/2756335) and Kamla Pathak (https://sciprofiles.com/profile/1357811)

Pharmaceutics **2023**, *15*(3), 889; https://doi.org/10.3390/pharmaceutics15030889 (https://doi.org/10.3390/pharmaceutics15030889) - 09 Mar 2023

Cited by 6 (/1999-4923/15/3/889#metrics) | Viewed by 1824

Abstract Anticancer drugs in monotherapy are ineffective to treat various kinds of cancer due to the heterogeneous nature of cancer. Moreover, available anticancer drugs possessed various hurdles, such as drug resistance, insensitivity of cancer cells to drugs, adverse effects and patient inconveniences. Hence, plant-based **[...] Read more.**

(This article belongs to the Special Issue **Advances in Nano Drug Design and Delivery (/journal/pharmaceutics/special_issues/3FWPU8XU2H)**)

► Show Figures
(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00889/article_deploy/html/images/pharmaceutics-15-00889-g001-550.jpg?1678937765) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00889/article_deploy/html/images/pharmaceutics-15-00889-g002-550.jpg?1678937767) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00889/article_deploy/html/images/pharmaceutics-15-00889-g003-550.jpg?1678937770) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00889/article_deploy/html/images/pharmaceutics-15-00889-g004-550.jpg?1678937769) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00889/article_deploy/html/images/pharmaceutics-15-00889-g005-550.jpg?1678937766) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00889/article_deploy/html/images/pharmaceutics-15-00889-g006-550.jpg?1678937772)

Open Access Article (/1999-4923/15/3/888/pdf?version=1678366714)

T Cell-Association of Carboxy-Terminal Dendrimers with Different Bound Numbers of Phenylalanine and Their Application to Drug Delivery (/1999-4923/15/3/888)

by Hiroya Shiba (https://sciprofiles.com/profile/author/WDlqdm9HeHhQRDVZbW1hamFWanBFZCtQejFZd083ajNsWlZjS1hhRUtVTT0=), Tomoka Hirose (https://sciprofiles.com/profile/author/Z3ZpYjhXTmZTWDBlbnZWeGpGYXV1anNQaTdYZ0JPYktpRzk5ZGJCMHQ2dz0=), Yunshen Fu (https://sciprofiles.com/profile/author/Z0pIV3lTWGd2dFI4cU4vMzdmUGZLOW9Fd2ZVRlJzVmpEQ2thcU5YZk50OD0=), Masataka Michigami (https://sciprofiles.com/profile/author/eW5kclNvcUJpMXpSOWlZWFhCdkxzRFU4SkpscVlpdzF6SHU5b0RkZ0R5ST0=), Ikuo Fujii (https://sciprofiles.com/profile/author/MVY3cFVCU3BLVGN1WUMwYkRLMGlXZz09), Ikuhiko Nakase (https://sciprofiles.com/profile/author/RVlRL3JTZmNlMUxYRHBvVDJLUnBZdkxKWS9aSEszcEtNWnNWNlhxRVdDVT0=), Akikazu Matsumoto (https://sciprofiles.com/profile/2528281) and Chie Kojima (https://sciprofiles.com/profile/2757751)

Pharmaceutics **2023**, *15*(3), 888; https://doi.org/10.3390/pharmaceutics15030888 (https://doi.org/10.3390/pharmaceutics15030888) - 09 Mar 2023

Cited by 1 (/1999-4923/15/3/888#metrics) | Viewed by 1115

Abstract T cells play important roles in various immune reactions, and their activation is necessary for cancer immunotherapy. Previously, we showed that polyamidoamine (PAMAM) dendrimers modified with 1,2-cyclohexanedicarboxylic acid (CHex) and phenylalanine (Phe) underwent effective uptake by various immune cells, including T cells and **[...] Read more.**

(This article belongs to the Special Issue **Dendrimers for Drug Delivery (/journal/pharmaceutics/special_issues/dendrimers_delivery)**)

► Show Figures
(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00888/article_deploy/html/images/pharmaceutics-15-00888-ag-550.jpg?1678366788) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00888/article_deploy/html/images/pharmaceutics-15-00888-g001-550.jpg?1678366784) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00888/article_deploy/html/images/pharmaceutics-15-00888-g002-550.jpg?1678366779) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00888/article_deploy/html/images/pharmaceutics-15-00888-g003-550.jpg?1678366787) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00888/article_deploy/html/images/pharmaceutics-15-00888-g004-550.jpg?1678366782) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00888/article_deploy/html/images/pharmaceutics-15-00888-g005-550.jpg?1678366784) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00888/article_deploy/html/images/pharmaceutics-15-00888-g006-550.jpg?1678366781) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00888/article_deploy/html/images/pharmaceutics-15-00888-g007-550.jpg?1678366788) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00888/article_deploy/html/images/pharmaceutics-15-00888-g008-550.jpg?1678366781)

Open Access Article (/1999-4923/15/3/887/pdf?version=1678370231)

Evaluation of Pharmacobezoar Formation from Suspensions of Spray-Dried Amorphous Solid Dispersions: An MRI Study in Rats (/1999-4923/15/3/887)

by Hannes Gierke (https://sciprofiles.com/profile/2547565), Susan Mouchantat (https://sciprofiles.com/profile/author/TVlxKy9hSExvb01xbzg3SDd2eWN0YjRPU0xMQ21lUWQrWW5NVG9ORXpGNVJtMEV2V2dXUlpqbENUVWlwRnpZbw==), Sabine Berg (https://sciprofiles.com/profile/2780751), Michael Grimm (https://sciprofiles.com/profile/1744175), Stefan Hadlich (https://sciprofiles.com/profile/author/Kzk5WGhGbU5DM0thRGd4Qk8vb0hhV0NwY0ttT3Y1ZlR6OWZrUERBY2dqTmkzUlZFU1JlZWpDbEhlQml0anNFTw==), Marie-Luise Kromrey (https://sciprofiles.com/profile/1915792),

Back to TopTop

Thomas Nolte (https://sciprofiles.com/profile/author/eUlPSFR0SUIwbElpbmp4N1FNME0ycVowV0ZUMnJtNmZ5amNvTGNHY09COXZKYWNTang2RERkalJkT0hWZTFkdA==),
Teresa Pfrommer (https://sciprofiles.com/profile/author/K3Y5Q2tac2JjdFFEOXFRbnlacjl0Z0EzdFhwYVc4ZHB5N3ZqenM5dWIxV1NRb2NPeFF5ODJDSGNxcmNmdW1kRA==),
Vincent Rönnpagel (https://sciprofiles.com/profile/author/MVdaZ2JRSkIld0x1Q2pVR1piTksyNTZsMy9qNG4zWWQ1eFJyaVc0RHFTaHgwSndJQlZhaHdrQS9oS1JjaFV5bA==),
Adrian Rump (https://sciprofiles.com/profile/1896268),
Kerstin Schaefer (https://sciprofiles.com/profile/author/ZmR5V0t1UVFncjNNQUpDak5SMlo0K2RqRE0rNy9jUTRJNWhRQ05GWXc4L1ROd01UNkxzeEUxK1BMUHlJejZidw==),
Ann-Cathrin Willmann (https://sciprofiles.com/profile/2556503) and Werner Weitschies (https://sciprofiles.com/profile/540846)

Pharmaceutics **2023**, *15*(3), 887; https://doi.org/10.3390/pharmaceutics15030887 (https://doi.org/10.3390/pharmaceutics15030887) - 09 Mar 2023
Viewed by 859

Abstract Spray-dried amorphous solid dispersions of new chemical entities and pH-dependent soluble polymer hydroxypropyl methylcellulose acetate succinate (HPMC-AS) were found to form solid agglomerates in the gastrointestinal tract of rodents after oral administration. These agglomerates, referring to descriptions of intra-gastrointestinal aggregated oral dosage forms **[...] Read more.**
(This article belongs to the Special Issue **Advanced Pharmaceutical Science and Technology in Germany** (/journal/pharmaceutics/special_issues/Pharm_Sci_Technol_Germany))

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00887/article_deploy/html/images/pharmaceutics-15-00887-g001-550.jpg?1678370314) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00887/article_deploy/html/images/pharmaceutics-15-00887-g002-550.jpg?1678370303) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00887/article_deploy/html/images/pharmaceutics-15-00887-g003-550.jpg?1678370310) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00887/article_deploy/html/images/pharmaceutics-15-00887-g004-550.jpg?1678370320) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00887/article_deploy/html/images/pharmaceutics-15-00887-g005-550.jpg?1678370316) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00887/article_deploy/html/images/pharmaceutics-15-00887-g006-550.jpg?1678370306) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00887/article_deploy/html/images/pharmaceutics-15-00887-g007-550.jpg?1678370321) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00887/article_deploy/html/images/pharmaceutics-15-00887-g008-550.jpg?1678370313) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00887/article_deploy/html/images/pharmaceutics-15-00887-g009-550.jpg?1678370309) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00887/article_deploy/html/images/pharmaceutics-15-00887-g010-550.jpg?1678370319)

Open Access Article (/1999-4923/15/3/886/pdf?version=1678366962)

Improving Properties of Podophyllic Aldehyde-Derived Cyclolignans: Design, Synthesis and Evaluation of Novel Lignohydroquinones, Dual-Selective Hybrids against Colorectal Cancer Cells (/1999-4923/15/3/886)

by Ángela-Patricia Hernández (https://sciprofiles.com/profile/1044278), Paula Díez (https://sciprofiles.com/profile/21307), Pablo A. García (https://sciprofiles.com/profile/491537), Martín Pérez-Andrés (https://sciprofiles.com/profile/2973097), Anzhela Veselinova (https://sciprofiles.com/profile/2821969), Pablo G. Jambrina (https://sciprofiles.com/profile/2785120), Arturo San Feliciano (https://sciprofiles.com/profile/10691), David Díez (https://sciprofiles.com/profile/107877), Manuel Fuentes (https://sciprofiles.com/profile/19500) and Mª Ángeles Castro (https://sciprofiles.com/profile/353195)

Pharmaceutics **2023**, *15*(3), 886; https://doi.org/10.3390/pharmaceutics15030886 (https://doi.org/10.3390/pharmaceutics15030886) - 09 Mar 2023
Viewed by 1051

Abstract New lignohydroquinone conjugates (L-HQs) were designed and synthesized using the hybridization strategy, and evaluated as cytotoxics against several cancer cell lines. The L-HQs were obtained from the natural product podophyllotoxin and some semisynthetic terpenylnaphthohydroquinones, prepared from natural terpenoids. Both entities of the conjugates **[...] Read more.**
(This article belongs to the Special Issue **Recent Advances in Natural Product Drugs** (/journal/pharmaceutics/special_issues/ra_npd))

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00886/article_deploy/html/images/pharmaceutics-15-00886-ag-550.jpg?1678779979) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00886/article_deploy/html/images/pharmaceutics-15-00886-g001-550.jpg?1678367055) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00886/article_deploy/html/images/pharmaceutics-15-00886-g002-550.jpg?1678367053) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00886/article_deploy/html/images/pharmaceutics-15-00886-g003-550.jpg?1678367048) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00886/article_deploy/html/images/pharmaceutics-15-00886-g004-550.jpg?1678367039) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00886/article_deploy/html/images/pharmaceutics-15-00886-g005-550.jpg?1678367040) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00886/article_deploy/html/images/pharmaceutics-15-00886-g006-550.jpg?1678367054) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00886/article_deploy/html/images/pharmaceutics-15-00886-g007-550.jpg?1678367041) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00886/article_deploy/html/images/pharmaceutics-15-00886-g008-550.jpg?1678367045) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00886/article_deploy/html/images/pharmaceutics-15-00886-sch001-550.jpg?1678367051)

Open Access Article (/1999-4923/15/3/885/pdf?version=1678361004)

Development of the ^{99m}Tc-Labelled SST$_2$ Antagonist TECANT-1 for a First-in-Man Multicentre Clinical Study (/1999-4923/15/3/885)

by Doroteja Novak (https://sciprofiles.com/profile/2819368), Barbara Janota (https://sciprofiles.com/profile/author/RWN6TmRZS0VVQ1J0eWEwYm4rOGlXczZhZ2xVckp6eHJWVWxtTmFvMW03dz0=), Anton Amadeus Hörmann (https://sciprofiles.com/profile/1353962), Agnieszka Sawicka (https://sciprofiles.com/profile/1897730), Marko Kroselj (https://sciprofiles.com/profile/1970921), Alicja Hubalewska-Dydejczyk (https://sciprofiles.com/profile/2141152), Melpomeni Fani (https://sciprofiles.com/profile/242705), Renata Mikolajczak (https://sciprofiles.com/profile/2045569), Petra Kolenc (https://sciprofiles.com/profile/63770), Clemens Decristoforo (https://sciprofiles.com/profile/470112) and Piotr Garnuszek (https://sciprofiles.com/profile/1479046)

Pharmaceutics **2023**, *15*(3), 885; https://doi.org/10.3390/pharmaceutics15030885 (https://doi.org/10.3390/pharmaceutics15030885) - 09 Mar 2023
Cited by 1 (/1999-4923/15/3/885#metrics) | Viewed by 897

Abstract Broad availability and cost-effectiveness of ^{99}Mo/^{99m}Tc generators worldwide support the use, and thus the development, of novel ^{99m}Tc-labelled radiopharmaceuticals. In recent years, preclinical and clinical developments for neuroendocrine neoplasms patient management focused on somatostatin receptor subtype 2 (SST$_2$ **[...] Read more.**
(This article belongs to the Special Issue **Radiopharmaceuticals for Cancer Imaging and Therapy** (/journal/pharmaceutics/special_issues/Radio_Therap))

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00885/article_deploy/html/images/pharmaceutics-15-00885-g001-550.jpg?1678361069) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00885/article_deploy/html/images/pharmaceutics-15-00885-g002-550.jpg?1678361071) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00885/article_deploy/html/images/pharmaceutics-15-00885-g003-550.jpg?1678361070)

Open Access Article (/1999-4923/15/3/884/pdf?version=1678349667)

Effect of Process Parameters, Protectants and Carrier Materials on the Survival of Yeast Cells during Fluidized Bed Granulation for Tableting (/1999-4923/15/3/884)

by Karl Vorländer (https://sciprofiles.com/profile/929402), Lukas Bahlmann (https://sciprofiles.com/profile/author/Zi9OVG9JRVdwL1kyYXgxVDhkMjhwV1NWbytrcjl0N0dna09lbEFla3NCa2c0RE13R3B5QVRvTmUwcFpLWUFlcA==), Arno Kwade (https://sciprofiles.com/profile/349084), Jan Henrik Finke (https://sciprofiles.com/profile/396986) and Ingo Kampen (https://sciprofiles.com/profile/author/c09VQ01weUplWlRFQVRhbzBoY0xyT0xhYXBELzdUZ1d1QkYyY295VnpEST0=)

Pharmaceutics **2023**, *15*(3), 884; https://doi.org/10.3390/pharmaceutics15030884 (https://doi.org/10.3390/pharmaceutics15030884) - 09 Mar 2023
Cited by 3 (/1999-4923/15/3/884#metrics) | Viewed by 1527

Abstract The administration of living microorganisms is of special interest, with regard to probiotic microorganisms providing health benefits to the patient. Effective dosage forms require the preservation of microbial viability until administration. Storage stability can be improved by drying, and the tablet is an **[...] Read more.**
(This article belongs to the Section **Pharmaceutical Technology, Manufacturing and Devices** (/journal/pharmaceutics/sections/Pharmaceutical_Technology_Manufacturing_Devices))

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00884/article_deploy/html/images/pharmaceutics-15-00884-ag-550.jpg?1678349775) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00884/article_deploy/html/images/pharmaceutics-15-00884-g001-550.jpg?1678349768) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00884/article_deploy/html/images/pharmaceutics-15-00884-g002-550.jpg?1678349759) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00884/article_deploy/html/images/pharmaceutics-15-00884-g003-550.jpg?1678349771) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00884/article_deploy/html/images/pharmaceutics-15-00884-g004-550.jpg?1678349766) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00884

Back to TopTop

/article_deploy/html/images/pharmaceutics-15-00884-g005-550.jpg?1678349764) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00884/article_deploy/html/images/pharmaceutics-15-00884-g006-550.jpg?1678349756) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00884/article_deploy/html/images/pharmaceutics-15-00884-g007-550.jpg?1678349774) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00884/article_deploy/html/images/pharmaceutics-15-00884-g008-550.jpg?1678349763) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00884/article_deploy/html/images/pharmaceutics-15-00884-g009-550.jpg?1678349754) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00884/article_deploy/html/images/pharmaceutics-15-00884-g010-550.jpg?1678349762) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00884/article_deploy/html/images/pharmaceutics-15-00884-g011-550.jpg?1678349770)

Open Access Article (/1999-4923/15/3/883/pdf?version=1678413015)

Modification of the Linker Amino Acid in the Cell-Penetrating Peptide NickFect55 Leads to Enhanced pDNA Transfection for In Vivo Applications (/1999-4923/15/3/883)

by Heleri H. Härk (https://sciprofiles.com/profile/2781959), Ly Porosk (https://sciprofiles.com/profile/2286496), Lucas R. de Mello (https://sciprofiles.com/profile/author/NWRqQ0tNZ1g0UDluQ1oxd0tUUW9KNkx3V2JaNHZybDlxNVZsZDFwa1Jidz0=), Piret Arukuusk (https://sciprofiles.com/profile/author/MHRpd3JXNEtmTG5FMnUyUlU1amptaWNlQTNzLyttWE12TmhHQ1hzcTRVQT0=), Emerson R. da Silva (https://sciprofiles.com/profile/602120) and Kaido Kurrikoff (https://sciprofiles.com/profile/470124)

Pharmaceutics **2023**, *15*(3), 883; https://doi.org/10.3390/pharmaceutics15030883 (https://doi.org/10.3390/pharmaceutics15030883) - 09 Mar 2023

Viewed by 837

Abstract Despite numerous efforts over the last three decades, nucleic acid-based therapeutics still lack delivery platforms in the clinical stage. Cell-penetrating peptides (CPPs) may offer solutions as potential delivery vectors. We have previously shown that designing a “kinked” structure in the peptide backbone resulted **[...] Read more.**

(This article belongs to the Section **Drug Delivery and Controlled Release (/journal/pharmaceutics/sections/Drug_Delivery_and_Control_Release)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00883/article_deploy/html/images/pharmaceutics-15-00883-g001-550.jpg?1678413084) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00883/article_deploy/html/images/pharmaceutics-15-00883-g002-550.jpg?1678413082) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00883/article_deploy/html/images/pharmaceutics-15-00883-g003-550.jpg?1678413081) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00883/article_deploy/html/images/pharmaceutics-15-00883-g004-550.jpg?1678413092) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00883/article_deploy/html/images/pharmaceutics-15-00883-g005-550.jpg?1678413086)

Open Access Article (/1999-4923/15/3/882/pdf?version=1678341153)

Use of In Vitro Dynamic Colon Model (DCM) to Inform a Physiologically Based Biopharmaceutic Model (PBBM) to Predict the In Vivo Performance of a Modified-Release Formulation of Theophylline (/1999-4923/15/3/882)

by Konstantinos Stamatopoulos (https://sciprofiles.com/profile/1104811), Connor O'Farrell (https://sciprofiles.com/profile/1166162), Mark J. H. Simmons (https://sciprofiles.com/profile/author/dzdmQ0RtR2FyOWJ5bUV4VGlVenB2a0xyYkpMcmVYVnRjNEpQSEVGQVFudz0=), Hannah K. Batchelor (https://sciprofiles.com/profile/1166156) and Nena Mistry (https://sciprofiles.com/profile/author/d1VueTd5cEJDMW5qeTl5VXZva3dCOUZVaktXckx3S2MxelAvNnR3bEd4UT0=)

Pharmaceutics **2023**, *15*(3), 882; https://doi.org/10.3390/pharmaceutics15030882 (https://doi.org/10.3390/pharmaceutics15030882) - 09 Mar 2023

Cited by 1 (/1999-4923/15/3/882#metrics) | Viewed by 1142

Abstract A physiologically based biopharmaceutic model (PBBM) of a modified-release formulation of theophylline (Uniphyllin Continus® 200 mg tablet) was developed and implemented to predict the pharmacokinetic (PK) data of healthy male volunteers by integrating dissolution profiles measured in a biorelevant in vitro model: **[...] Read more.**

(This article belongs to the Section **Biopharmaceutics (/journal/pharmaceutics/sections/Biopharmaceutics)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00882/article_deploy/html/images/pharmaceutics-15-00882-g001-550.jpg?1678341229) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00882/article_deploy/html/images/pharmaceutics-15-00882-g002-550.jpg?1678341233) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00882/article_deploy/html/images/pharmaceutics-15-00882-g003-550.jpg?1678341232) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00882/article_deploy/html/images/pharmaceutics-15-00882-g004-550.jpg?1678341220) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00882/article_deploy/html/images/pharmaceutics-15-00882-g005-550.jpg?1678341222) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00882/article_deploy/html/images/pharmaceutics-15-00882-g006-550.jpg?1678341228) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00882/article_deploy/html/images/pharmaceutics-15-00882-g007-550.jpg?1678341223)

Open Access Article (/1999-4923/15/3/881/pdf?version=1678354323)

Combined Dopamine and Grape Seed Extract-Loaded Solid Lipid Nanoparticles: Nasal Mucosa Permeation, and Uptake by Olfactory Ensheathing Cells and Neuronal SH-SY5Y Cells (/1999-4923/15/3/881)

by Adriana Trapani (https://sciprofiles.com/profile/1199509), Stefano Castellani (https://sciprofiles.com/profile/1458011), Lorenzo Guerra (https://sciprofiles.com/profile/1901553), Elvira De Giglio (https://sciprofiles.com/profile/441980), Giuseppe Facchiolla (https://sciprofiles.com/profile/1265939), Filomena Corbo (https://sciprofiles.com/profile/483638), Nicola Cioffi (https://sciprofiles.com/profile/170568), Giuseppe Passantino (https://sciprofiles.com/profile/301877), Maria Luana Poeta (https://sciprofiles.com/profile/author/UWlnbDloN1dmOEREbWdWMlFESVhrT05NaW4vZm5pd2hyeEoyVFJCZXdHUT0=), Pasqualina Montemurro (https://sciprofiles.com/profile/author/R3Q3MUt6RUlOTmZsTDduMUFKbVNWcVhSZzBJbmwzMkpmZEZHdDN5U2doQT0=), Rosanna Mallamaci (https://sciprofiles.com/profile/1222255), Rosa Angela Cardone (https://sciprofiles.com/profile/1190962) and Massimo Conese (https://sciprofiles.com/profile/205995)

Pharmaceutics **2023**, *15*(3), 881; https://doi.org/10.3390/pharmaceutics15030881 (https://doi.org/10.3390/pharmaceutics15030881) - 08 Mar 2023

Viewed by 868

Abstract We have already formulated solid lipid nanoparticles (SLNs) in which the combination of the neurotransmitter dopamine (DA) and the antioxidant grape-seed-derived proanthocyanidins (grape seed extract, GSE) was supposed to be favorable for Parkinson's disease (PD) treatment. In fact, GSE supply would reduce the **[...] Read more.**

(This article belongs to the Special Issue **Polymer- and Lipid-Based Nanostructured Drug Delivery Systems for the Treatment of CNS Diseases: Recent Advances towards Clinical Application (/journal/pharmaceutics/special_issues/CNS_diseases)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00881/article_deploy/html/images/pharmaceutics-15-00881-g001-550.jpg?1678354400) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00881/article_deploy/html/images/pharmaceutics-15-00881-g002-550.jpg?1678354394) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00881/article_deploy/html/images/pharmaceutics-15-00881-g003-550.jpg?1678354403) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00881/article_deploy/html/images/pharmaceutics-15-00881-g004-550.jpg?1678354397) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00881/article_deploy/html/images/pharmaceutics-15-00881-g005-550.jpg?1678354396) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00881/article_deploy/html/images/pharmaceutics-15-00881-g006-550.jpg?1678354398) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00881/article_deploy/html/images/pharmaceutics-15-00881-g007-550.jpg?1678354401) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00881/article_deploy/html/images/pharmaceutics-15-00881-g008-550.jpg?1678354395)

Open Access Article (/1999-4923/15/3/880/pdf?version=1678352244)

Collagen Functionalization of Polymeric Electrospun Scaffolds to Improve Integration into Full-Thickness Wounds (/1999-4923/15/3/880)

by Aswathy Ravindran Girija (https://sciprofiles.com/profile/2743903), Xanthe Strudwick (https://sciprofiles.com/profile/263062), Sivakumar Balasubramanian (https://sciprofiles.com/profile/author/ODNrYk41bnhzL2VOa1BSS2Fib291K2VUK29DbXFqZGt5RTJKc0g4RWoxRT0=), Vivekanandan Palaninathan (https://sciprofiles.com/profile/947440), Sakthikumar Dasappan Nair (https://sciprofiles.com/profile/283199) and Allison J. Cowin (https://sciprofiles.com/profile/270816)

Pharmaceutics **2023**, *15*(3), 880; https://doi.org/10.3390/pharmaceutics15030880 (https://doi.org/10.3390/pharmaceutics15030880) - 08 Mar 2023

Cited by 2 (/1999-4923/15/3/880#metrics) | Viewed by 906

Abstract Background: Electrospun fibers are widely studied in regenerative medicine for their ability to mimic the extracellular matrix (ECM) and provide mechanical support. In vitro studies indicated that cell adhesion and migration is superior on smooth poly(L-lactic acid) (PLLA) electrospun scaffolds and porous scaffolds **[...] Read more.**

(This article belongs to the Special Issue **Micro/Nanostructures and Micro/Nanodevices for Tissue Engineering and Biomedicine (/journal/pharmaceutics/special_issues/RA97131Y1L)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00880/article_deploy/html/images/pharmaceutics-15-00880-g001-550.jpg?1678352398) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00880/article_deploy/html/images/pharmaceutics-15-00880-g002-550.jpg?1678352392) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00880/article_deploy/html/images/pharmaceutics-15-00880-g003-550.jpg?1678352395) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00880/article_deploy/html/images/pharmaceutics-15-00880-g004-550.jpg?1678352400) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-

15-00880/article_deploy/html/images/pharmaceutics-15-00880-g005-550.jpg?1678352394) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00880/article_deploy/html/images/pharmaceutics-15-00880-g006-550.jpg?1678352402)

Open Access Review (/1999-4923/15/3/879/pdf?version=1678275337)

Chitosan-Based Nano-Smart Drug Delivery System in Breast Cancer Therapy (/1999-4923/15/3/879)

by Yedi Herdiana (https://sciprofiles.com/profile/1553639), Nasrul Wathoni (https://sciprofiles.com/profile/874210), Dolih Gozali (https://sciprofiles.com/profile/2180828), Shaharum Shamsuddin (https://sciprofiles.com/profile/1690341) and Muchtaridi Muchtaridi (https://sciprofiles.com/profile/615)

Pharmaceutics **2023**, *15*(3), 879; https://doi.org/10.3390/pharmaceutics15030879 (https://doi.org/10.3390/pharmaceutics15030879) - 08 Mar 2023

Cited by 4 (/1999-4923/15/3/879#metrics) | Viewed by 1691

Abstract Despite recent advances, cancer remains the primary killer on a global scale. Numerous forms of research have been conducted to discover novel and efficient anticancer medications. The complexity of breast cancer is a major challenge which is coupled with patient-to-patient variations and heterogeneity **[...] Read more.**

(This article belongs to the Special Issue Application of Nanoparticles in Cancer Therapy and Diagnosis (/journal/pharmaceutics/special_issues/211R24MFV4))

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00879/article_deploy/html/images/pharmaceutics-15-00879-g001-550.jpg?1678277599) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00879/article_deploy/html/images/pharmaceutics-15-00879-g002-550.jpg?1678277601) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00879/article_deploy/html/images/pharmaceutics-15-00879-g003-550.jpg?1678277605) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00879/article_deploy/html/images/pharmaceutics-15-00879-g004-550.jpg?1678277603) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00879/article_deploy/html/images/pharmaceutics-15-00879-g005-550.jpg?1678277605) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00879/article_deploy/html/images/pharmaceutics-15-00879-g006-550.jpg?1678277602)

Open Access Communication (/1999-4923/15/3/878/pdf?version=1678282917)

Supramolecular Organization in Salts of Riluzole with Dihydroxybenzoic Acids—The Key Role of the Mutual Arrangement of OH Groups (/1999-4923/15/3/878)

by Alexander P. Voronin (https://sciprofiles.com/profile/1987965), Artem O. Surov (https://sciprofiles.com/profile/author/Y3hhZ1pmTlVodDAxdmpWWDlBTTdJZz09), Andrei V. Churakov (https://sciprofiles.com/profile/1390586) and Mikhail V. Vener (https://sciprofiles.com/profile/1946530)

Pharmaceutics **2023**, *15*(3), 878; https://doi.org/10.3390/pharmaceutics15030878 (https://doi.org/10.3390/pharmaceutics15030878) - 08 Mar 2023

Cited by 2 (/1999-4923/15/3/878#metrics) | Viewed by 940

Abstract Intermolecular interactions, in particular hydrogen bonds, play a key role in crystal engineering. The ability to form hydrogen bonds of various types and strengths causes competition between supramolecular synthons in pharmaceutical multicomponent crystals. In this work, we investigate the influence of positional isomerism **[...] Read more.**

(This article belongs to the Special Issue New Properties of Supramolecular Complexes and Drug Nanoparticles (/journal/pharmaceutics/special_issues/Sup_drug))

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00878/article_deploy/html/images/pharmaceutics-15-00878-g001-550.jpg?1678282994) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00878/article_deploy/html/images/pharmaceutics-15-00878-g002-550.jpg?1678282996) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00878/article_deploy/html/images/pharmaceutics-15-00878-g003-550.jpg?1678282993) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00878/article_deploy/html/images/pharmaceutics-15-00878-sch001-550.jpg?1678282991)

Open Access Article (/1999-4923/15/3/877/pdf?version=1678271400)

Facile Preparation of Samarium Carbonate-Polymethacrylate Microspheres as a Neutron-Activatable Radioembolic Agent for Hepatic Radioembolization (/1999-4923/15/3/877)

by Yin How Wong (https://sciprofiles.com/profile/author/UzZaYTM4cFppajNqRjJXWVVOYVVodHJ6S2RTKzcwb2w3b1BQdGpzU3BSND0=), Azahari Kasbollah (https://sciprofiles.com/profile/author/NHVtOEpuY0dkdG5SdFY2ZDRCZGFDNHpLL09KK08vTHYxYTROQnRxN2ozTT0=), Basri Johan Jeet Abdullah (https://sciprofiles.com/profile/author/RWZJNkhCbEF0N1VPNjdLWTg2UFBHS1hTdFZmOGpPSVpiQnRadFVwOFc5OD0=) and Chai Hong Yeong (https://sciprofiles.com/profile/678557)

Pharmaceutics **2023**, *15*(3), 877; https://doi.org/10.3390/pharmaceutics15030877 (https://doi.org/10.3390/pharmaceutics15030877) - 08 Mar 2023

Viewed by 802

Abstract Radioembolization shows great potential as a treatment for intermediate- and advanced-stage liver cancer. However, the choices of radioembolic agents are currently limited, and hence the treatment is relatively costly compared to other approaches. In this study, a facile preparation method was developed to **[...] Read more.**

(This article belongs to the Special Issue Recent Advances in Radiopharmacy (/journal/pharmaceutics/special_issues/ra_radio))

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00877/article_deploy/html/images/pharmaceutics-15-00877-g001-550.jpg?1678271467) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00877/article_deploy/html/images/pharmaceutics-15-00877-g002-550.jpg?1678271472) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00877/article_deploy/html/images/pharmaceutics-15-00877-g003-550.jpg?1678271473) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00877/article_deploy/html/images/pharmaceutics-15-00877-g004-550.jpg?1678271474) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00877/article_deploy/html/images/pharmaceutics-15-00877-g005-550.jpg?1678271469) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00877/article_deploy/html/images/pharmaceutics-15-00877-g006-550.jpg?1678271476) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00877/article_deploy/html/images/pharmaceutics-15-00877-g007-550.jpg?1678271467) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00877/article_deploy/html/images/pharmaceutics-15-00877-g008-550.jpg?1678271477)

Open Access Article (/1999-4923/15/3/876/pdf?version=1678275023)

Electrochemical Nano-Imprinting of Trimetallic Dendritic Surface for Ultrasensitive Detection of Cephalexin in Pharmaceutical Formulations (/1999-4923/15/3/876)

by Rohini Kumari (https://sciprofiles.com/profile/2040559) and Pranjal Chandra (https://sciprofiles.com/profile/2294769)

Pharmaceutics **2023**, *15*(3), 876; https://doi.org/10.3390/pharmaceutics15030876 (https://doi.org/10.3390/pharmaceutics15030876) - 08 Mar 2023

Cited by 5 (/1999-4923/15/3/876#metrics) | Viewed by 1576

Abstract Cephalexin (CFX), a first-generation cephalosporin, is used to treat various infectious diseases. Although antibiotics have achieved considerable progress in the eradication of infectious diseases, their incorrect and excessive usage has contributed to various side effects, such as mouth soreness, pregnancy-related pruritus, and gastrointestinal **[...] Read more.**

(This article belongs to the Special Issue Pharmaceutical Additive Manufacturing (/journal/pharmaceutics/special_issues/390935742B))

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00876/article_deploy/html/images/pharmaceutics-15-00876-ag-550.jpg?1678275115) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00876/article_deploy/html/images/pharmaceutics-15-00876-g001-550.jpg?1678275102) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00876/article_deploy/html/images/pharmaceutics-15-00876-g002-550.jpg?1678275096) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00876/article_deploy/html/images/pharmaceutics-15-00876-g003-550.jpg?1678275104) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00876/article_deploy/html/images/pharmaceutics-15-00876-g004-550.jpg?1678275114) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00876/article_deploy/html/images/pharmaceutics-15-00876-g005-550.jpg?1678275112) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00876/article_deploy/html/images/pharmaceutics-15-00876-g006-550.jpg?1678275098) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00876/article_deploy/html/images/pharmaceutics-15-00876-g007-550.jpg?1678275093) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00876/article_deploy/html/images/pharmaceutics-15-00876-g008-550.jpg?1678275111) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00876/article_deploy/html/images/pharmaceutics-15-00876-g009-550.jpg?1678275108) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00876/article_deploy/html/images/pharmaceutics-15-00876-g010-550.jpg?1678275099) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00876/article_deploy/html/images/pharmaceutics-15-00876-sch001-550.jpg?1678275107)

Open Access Article (/1999-4923/15/3/875/pdf?version=1678262591)

Effect of Alkaline Conditions on Forming an Effective G4.0 PAMAM Complex with Doxorubicin (/1999-4923/15/3/875)

by Magdalena Szota (https://sciprofiles.com/profile/1801912) and Barbara Jachimska (https://sciprofiles.com/profile/1411299)

Pharmaceutics **2023**, *15*(3), 875; https://doi.org/10.3390/pharmaceutics15030875 (https://doi.org/10.3390/pharmaceutics15030875) - 08 Mar 2023

Viewed by 761

Abstract In this study, special attention was paid to the correlation between the degree of ionization of the components and the effective formation of the complex under alkaline conditions. Using UV-Vis, ^{1}H NMR, and CD, structural changes of the drug depending on the **[...] Read more.**

(This article belongs to the Special Issue Dendrimers for Drug Delivery (/journal/pharmaceutics/special_issues/dendrimers_delivery))

► Show Figures

Open Access Review (/1999-4923/15/3/874/pdf?version=1678262864)

Status and Future Scope of Soft Nanoparticles-Based Hydrogel in Wound Healing (/1999-4923/15/3/874)

by Marcel Henrique Marcondes Sari (https://sciprofiles.com/profile/2670822), Alexandre de Fátima Cobre (https://sciprofiles.com/profile/2821403), Roberto Pontarolo (https://sciprofiles.com/profile/99185) and Luana Mota Ferreira (https://sciprofiles.com/profile/2577219)

Pharmaceutics **2023**, *15*(3), 874; https://doi.org/10.3390/pharmaceutics15030874 (https://doi.org/10.3390/pharmaceutics15030874) - 08 Mar 2023

Cited by 5 (/1999-4923/15/3/874#metrics) | Viewed by 1522

Abstract Wounds are alterations in skin integrity resulting from any type of trauma. The healing process is complex, involving inflammation and reactive oxygen species formation. Therapeutic approaches for the wound healing process are diverse, associating dressings and topical pharmacological agents with antiseptics, anti-inflammatory, and **[...] Read more.**

(This article belongs to the Special Issue **Hydrogels for Biomedical Applications: Latest Advances and Prospects (/journal/pharmaceutics/special_issues/T9K8NHIVTY)**)

► Show Figures

Open Access Review (/1999-4923/15/3/873/pdf?version=1678259562)

Nucleotides Entrapped in Liposome Nanovesicles as Tools for Therapeutic and Diagnostic Use in Biomedical Applications (/1999-4923/15/3/873)

by Camila Magalhães Cardador (https://sciprofiles.com/profile/2810809), Luis Alexandre Muehlmann (https://sciprofiles.com/profile/1889034), Cíntia Marques Coelho (https://sciprofiles.com/profile/author/YVhvYi9JdTNjNmQ4QlNkR2VnV29RK1R6VkpuTmgxc0VtMFltRGJLQ093TT0=), Luciano Paulino Silva (https://sciprofiles.com/profile/1310894), Aisel Valle Garay (https://sciprofiles.com/profile/2757258), Alexandra Maria dos Santos Carvalho (https://sciprofiles.com/profile/2694012), Izabela Marques Dourado Bastos (https://sciprofiles.com/profile/1177842) and João Paulo Figueiró Longo (https://sciprofiles.com/profile/410110)

Pharmaceutics **2023**, *15*(3), 873; https://doi.org/10.3390/pharmaceutics15030873 (https://doi.org/10.3390/pharmaceutics15030873) - 08 Mar 2023

Viewed by 1211

Abstract The use of nucleotides for biomedical applications is an old desire in the scientific community. As we will present here, there are references published over the past 40 years with this intended use. The main problem is that, as unstable molecules, nucleotides require **[...] Read more.**

(This article belongs to the Special Issue **Advanced Liposomes for Drug Delivery (/journal/pharmaceutics/special_issues/YAZ3Y26O0Q)**)

► Show Figures

Open Access Article (/1999-4923/15/3/872/pdf?version=1678256477)

Functionalization of 3D-Printed Titanium Scaffolds with Elastin-like Recombinamers to Improve Cell Colonization and Osteoinduction (/1999-4923/15/3/872)

by Jordi Guillem-Marti (https://sciprofiles.com/profile/493116), Elia Vidal (https://sciprofiles.com/profile/author/UVEyOUxvcGITTTFwWDJOREFJbmp2T1BERkZNRjF2NCtOZ3RuTXlDeFNFdz0=), Alessandra Girotti (https://sciprofiles.com/profile/1304516), Aina Heras-Parets (https://sciprofiles.com/profile/2824702), Diego Torres (https://sciprofiles.com/profile/author/Q3g4U2s3VW02bGdNWFdiVHhNRHRvc3h4KzRHc2hTamlsWWxRdkl4cXJaRT0=), Francisco Javier Arias (https://sciprofiles.com/profile/276703), Maria-Pau Ginebra (https://sciprofiles.com/profile/412408), Jose Carlos Rodriguez-Cabello (https://sciprofiles.com/profile/2683327) and Jose Maria Manero (https://sciprofiles.com/profile/869181)

Pharmaceutics **2023**, *15*(3), 872; https://doi.org/10.3390/pharmaceutics15030872 (https://doi.org/10.3390/pharmaceutics15030872) - 08 Mar 2023

Cited by 1 (/1999-4923/15/3/872#metrics) | Viewed by 1040

Abstract The 3D printing of titanium (Ti) offers countless possibilities for the development of personalized implants with suitable mechanical properties for different medical applications. However, the poor bioactivity of Ti is still a challenge that needs to be addressed to promote scaffold osseointegration. The **[...] Read more.**

(This article belongs to the Special Issue **Bio-Organic Materials for Tissue Engineering and Regenerative Medicine (/journal/pharmaceutics/special_issues/Bioorganic_Materials)**)

► Show Figures

Open Access Article (/1999-4923/15/3/871/pdf?version=1678257218)

Prospects of Using Gum Arabic Silver Nanoparticles in Toothpaste to Prevent Dental Caries (/1999-4923/15/3/871)

by Omnia Abdelmoneim Khidir Ahmed (https://sciprofiles.com/profile/author/SVNTb1NTdVFvWWtFWDkxN1dleDRDUnBiUjd4WFZxQ21pK05PY21rK1VmVT0=), Nicole Remaliah Samantha Sibuyi (https://sciprofiles.com/profile/885815), Adewale Oluwaseun Fadaka (https://sciprofiles.com/profile/791549), Ernest Maboza (https://sciprofiles.com/profile/author/eElSdkdiQnVES0ttbEhmc2Fxb2FOdWhad09VcFlTTVBvYWxVQkEvb2JnZz0=), Annette Olivier (https://sciprofiles.com/profile/2719790), Abram Madimabe Madiehe (https://sciprofiles.com/profile/924985), Mervin Meyer (https://sciprofiles.com/profile/332731) and Greta Geerts (https://sciprofiles.com/profile/1967690)

Pharmaceutics **2023**, *15*(3), 871; https://doi.org/10.3390/pharmaceutics15030871 (https://doi.org/10.3390/pharmaceutics15030871) - 08 Mar 2023

Cited by 2 (/1999-4923/15/3/871#metrics) | Viewed by 1059

Abstract There is growing interest in the use of green synthesized silver nanoparticles (AgNPs) to control and prevent dental diseases. The incorporation of green synthesized AgNPs into dentifrices to reduce pathogenic oral microbes is motivated by their presumed biocompatibility and broad-spectrum antimicrobial activity. In **[...] Read more.**

(This article belongs to the Special Issue **Biomaterials and Agents: Pharmaceutical and Biomedical Applications in Dental Research (/journal/pharmaceutics/special_issues/Bio_dental)**)

Back to TopTop

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00871/article_deploy/html/images/pharmaceutics-15-00871-g001-550.jpg?1678257295) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00871/article_deploy/html/images/pharmaceutics-15-00871-g002-550.jpg?1678257296) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00871/article_deploy/html/images/pharmaceutics-15-00871-g003-550.jpg?1678257290) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00871/article_deploy/html/images/pharmaceutics-15-00871-g004-550.jpg?1678257293) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00871/article_deploy/html/images/pharmaceutics-15-00871-sch001-550.jpg?1678257292)

Open Access Article (/1999-4923/15/3/870/pdf?version=1678249903)

Digital Technologies Applied to Control the One-Step Process of Cannabis Olive Oil Preparations (/1999-4923/15/3/870)

by Paolo Bongiorno (https://sciprofiles.com/profile/2821735), Antonio Lopalco (https://sciprofiles.com/profile/399573), Antonella Casiraghi (https://sciprofiles.com/profile/928133), Antonio Spennacchio (https://sciprofiles.com/profile/author/dlI2UEZ3RTdFclJ2ZzJxd2dNZFVvaGhsMkxjeVhIRE9malZaME82ZFFFZz0=), Alessandro Pitruzzella (https://sciprofiles.com/profile/1840367), Angela Assunta Lopedota (https://sciprofiles.com/profile/651425), Paola Minghetti (https://sciprofiles.com/profile/699115) and Nunzio Denora (https://sciprofiles.com/profile/344219)

Pharmaceutics **2023**, *15*(3), 870; https://doi.org/10.3390/pharmaceutics15030870 (https://doi.org/10.3390/pharmaceutics15030870) - 08 Mar 2023

Viewed by 1385

Abstract The reproducibility of an extemporaneous preparation is an essential condition for guaranteeing the quality, efficacy, and safety of the medicinal product. This study aimed to develop a controlled one-step process for cannabis olive oil preparations by applying digital technologies. For this purpose, the **[...] Read more.**

(This article belongs to the Special Issue **New Perspectives for the Administration of Cannabis for Medical Use: From Traditional to Advanced Formulations. What Next? (/journal/pharmaceutics/special_issues/med_can_formulations)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00870/article_deploy/html/images/pharmaceutics-15-00870-g001-550.jpg?1678249976) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00870/article_deploy/html/images/pharmaceutics-15-00870-g002-550.jpg?1678249972) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00870/article_deploy/html/images/pharmaceutics-15-00870-g003-550.jpg?1678249969) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00870/article_deploy/html/images/pharmaceutics-15-00870-g004-550.jpg?1678249973)

Open Access Review (/1999-4923/15/3/869/pdf?version=1678242001)

The In Vitro, Ex Vivo, and In Vivo Effect of Edible Oils: A Review on Cell Interactions (/1999-4923/15/3/869)

by Ioannis Tsamesidis (https://sciprofiles.com/profile/1011549) and Eleni P. Kalogianni (https://sciprofiles.com/profile/1306821)

Pharmaceutics **2023**, *15*(3), 869; https://doi.org/10.3390/pharmaceutics15030869 (https://doi.org/10.3390/pharmaceutics15030869) - 08 Mar 2023

Cited by 1 (/1999-4923/15/3/869#metrics) | Viewed by 1475

Abstract Consumption of edible oils is a significant part of the dietary pattern in the developed and developing world. Marine and vegetable oils are assumed to be part of a healthy food pattern, especially if one takes into account their potential role in protecting **[...] Read more.**

(This article belongs to the Special Issue **Oxidative Stress and Inflammation: Novel Drug Formulation and Delivery Systems (/journal/pharmaceutics/special_issues/C39UN5XV49)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00869/article_deploy/html/images/pharmaceutics-15-00869-g001-550.jpg?1678242068)

Open Access Review (/1999-4923/15/3/868/pdf?version=1678247431)

A Review of Advanced Multifunctional Magnetic Nanostructures for Cancer Diagnosis and Therapy Integrated into an Artificial Intelligence Approach (/1999-4923/15/3/868)

by Bharath Govindan (https://sciprofiles.com/profile/2608054), Muhammad Ashraf Sabri (https://sciprofiles.com/profile/author/emxsOVRJVGVWc3hJUUJ0aXFrcldaMTFlWkpwVWEzSmdoWHBzMHNkb1oxMD0=), Abdul Hai (https://sciprofiles.com/profile/2920800), Fawzi Banat (https://sciprofiles.com/profile/565697) and Mohammad Abu Haija (https://sciprofiles.com/profile/1211702)

Pharmaceutics **2023**, *15*(3), 868; https://doi.org/10.3390/pharmaceutics15030868 (https://doi.org/10.3390/pharmaceutics15030868) - 07 Mar 2023

Cited by 5 (/1999-4923/15/3/868#metrics) | Viewed by 2543

Abstract The new era of nanomedicine offers significant opportunities for cancer diagnostics and treatment. Magnetic nanoplatforms could be highly effective tools for cancer diagnosis and treatment in the future. Due to their tunable morphologies and superior properties, multifunctional magnetic nanomaterials and their hybrid nanostructures **[...] Read more.**

(This article belongs to the Special Issue **Magnetic Nanomaterials – a Promising Approach in Cancer Therapy (/journal/pharmaceutics/special_issues/Magnetic_Cancer)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00868/article_deploy/html/images/pharmaceutics-15-00868-g001-550.jpg?1678247505) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00868/article_deploy/html/images/pharmaceutics-15-00868-g002-550.jpg?1678247516) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00868/article_deploy/html/images/pharmaceutics-15-00868-g003-550.jpg?1678247508) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00868/article_deploy/html/images/pharmaceutics-15-00868-g004-550.jpg?1678247514) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00868/article_deploy/html/images/pharmaceutics-15-00868-g005-550.jpg?1678247504) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00868/article_deploy/html/images/pharmaceutics-15-00868-g006-550.jpg?1678247502) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00868/article_deploy/html/images/pharmaceutics-15-00868-g007-550.jpg?1678247498) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00868/article_deploy/html/images/pharmaceutics-15-00868-g008-550.jpg?1678247512) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00868/article_deploy/html/images/pharmaceutics-15-00868-g009-550.jpg?1678247506) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00868/article_deploy/html/images/pharmaceutics-15-00868-g010-550.jpg?1678247510) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00868/article_deploy/html/images/pharmaceutics-15-00868-g011-550.jpg?1678247499) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00868/article_deploy/html/images/pharmaceutics-15-00868-g012-550.jpg?1678247496) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00868/article_deploy/html/images/pharmaceutics-15-00868-g013-550.jpg?1678247500)

Open Access Systematic Review (/1999-4923/15/3/867/pdf?version=1678243881)

Radiolabeled Dendrimer Coated Nanoparticles for Radionuclide Imaging and Therapy: A Systematic Review (/1999-4923/15/3/867)

by Miriam Conte (https://sciprofiles.com/profile/2595502), Maria Silvia De Feo (https://sciprofiles.com/profile/2883973), Marko Magdi Abdou Sidrak (https://sciprofiles.com/profile/author/VWJQR3pDQlVNYXMrMjRzSTBkRkRmSEtUTlQxMm44aExkVitGcUp1TW9BOD0=), Ferdinando Corica (https://sciprofiles.com/profile/author/ZkVndnJqbVlQY0M0OVB2bnBPK0pzWGpSMnQ3cHBMUnJLdWJFSzdQTEN4Zz0=), Joana Gorica (https://sciprofiles.com/profile/author/WXExaHpubVQ4STEycDBuNDJ1YitXayt2QlpjMXVhR2hzUzY0V1c2bjEyND0=), Luca Filippi (https://sciprofiles.com/profile/867101), Orazio Schillaci (https://sciprofiles.com/profile/827290), Giuseppe De Vincentis (https://sciprofiles.com/profile/1317857) and Viviana Frantellizzi (https://sciprofiles.com/profile/1207671)

Pharmaceutics **2023**, *15*(3), 867; https://doi.org/10.3390/pharmaceutics15030867 (https://doi.org/10.3390/pharmaceutics15030867) - 07 Mar 2023

Viewed by 802

Abstract Background: Dendrimers are nanoscale-size polymers with a globular structure. They are composed of an internal core and branching dendrons with surface active groups which can be functionalized for medical applications. Different complexes have been developed for imaging and therapeutic purposes. This systematic review **[...] Read more.**

(This article belongs to the Special Issue **Magnetic Nanomaterials – a Promising Approach in Cancer Therapy (/journal/pharmaceutics/special_issues/Magnetic_Cancer)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00867/article_deploy/html/images/pharmaceutics-15-00867-g001-550.jpg?1678243967) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00867/article_deploy/html/images/pharmaceutics-15-00867-g002-550.jpg?1678243969) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00867/article_deploy/html/images/pharmaceutics-15-00867-g003-550.jpg?1678243964) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00867/article_deploy/html/images/pharmaceutics-15-00867-g004-550.jpg?1678243965) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00867/article_deploy/html/images/pharmaceutics-15-00867-g005-550.jpg?1678243966) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00867/article_deploy/html/images/pharmaceutics-15-00867-g006-550.jpg?1678243962)

Open Access Article (/1999-4923/15/3/866/pdf?version=1678188659)

A Pilot Study Exploiting the Industrialization Potential of Solid Lipid Nanoparticle-Based Metered-Dose Inhalers (/1999-4923/15/3/866)

by Lei Shu (https://sciprofiles.com/profile/2298377), Wenhua Wang (https://sciprofiles.com/profile/author/dzROVjRkUWtBK0s5Zmk5cDVNZVR5RU1kMnVodEJSTmZSUmtmOGNsdmpWWT0=), Chon-iong Ng (https://sciprofiles.com/profile/author/dlEwS0RrQVdHS04wWmtQaXkwUXZOT3BNQStnVXdPZTVvOWRvRHZReVUwSmExckVRRkdhQVoxRnk1RjVOWDVMQw==), Xuejuan Zhang (https://sciprofiles.com/profile/2811611), Ying Huang (https://sciprofiles.com/profile/505426), Chuanbin Wu (https://sciprofiles.com/profile/3029681), Xin Pan (https://sciprofiles.com/profile/396949) and Zhengwei Huang (https://sciprofiles.com/profile/2053779)

Pharmaceutics **2023**, *15*(3), 866; https://doi.org/10.3390/pharmaceutics15030866 (https://doi.org/10.3390/pharmaceutics15030866) - 07 Mar 2023

Viewed by 882

Abstract Background: Delivery of inhalable nanoparticles through metered-dose inhalers (MDI) is a promising approach to treat lung disease such as asthma and chronic obstructive pulmonary disease. Nanocoating of the inhalable nanoparticles helps in stability and cellular uptake enhancement but complicates the production process. Thus, [...] Read more.

(This article belongs to the Special Issue Recent Advances in Polymeric Delivery Vehicles for Controlled and Sustained Drug Release (/journal/pharmaceutics/special_issues/0WK2RBQOWE))

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00866/article_deploy/html/images/pharmaceutics-15-00866-g001-550.jpg?1678188724) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00866/article_deploy/html/images/pharmaceutics-15-00866-g002-550.jpg?1678188725) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00866/article_deploy/html/images/pharmaceutics-15-00866-g003-550.jpg?1678188724) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00866/article_deploy/html/images/pharmaceutics-15-00866-g004-550.jpg?1678188726) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00866/article_deploy/html/images/pharmaceutics-15-00866-g005-550.jpg?1678188727)

Open Access Review (/1999-4923/15/3/865/pdf?version=1678187202)

Biomedical Applications of Lactoferrin on the Ocular Surface (/1999-4923/15/3/865)

by Uxía Regueiro (https://sciprofiles.com/profile/2048899), Maite López-López (https://sciprofiles.com/profile/2495888), Rubén Varela-Fernández (https://sciprofiles.com/profile/994891), Francisco Javier Otero-Espinar (https://sciprofiles.com/profile/420440) and Isabel Lema (https://sciprofiles.com/profile/1541494)

Pharmaceutics **2023**, *15*(3), 865; https://doi.org/10.3390/pharmaceutics15030865 (https://doi.org/10.3390/pharmaceutics15030865) - 07 Mar 2023

Cited by 2 (/1999-4923/15/3/865#metrics) | Viewed by 1875

Abstract Lactoferrin (LF) is a first-line defense protein with a pleiotropic functional pattern that includes anti-inflammatory, immunomodulatory, antiviral, antibacterial, and antitumoral properties. Remarkably, this iron-binding glycoprotein promotes iron retention, restricting free radical production and avoiding oxidative damage and inflammation. On the ocular surface, LF [...] Read more.

(This article belongs to the Special Issue Lactoferrin in Biomedical Applications (/journal/pharmaceutics/special_issues/Lactoferrin))

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00865/article_deploy/html/images/pharmaceutics-15-00865-g001-550.jpg?1678187281) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00865/article_deploy/html/images/pharmaceutics-15-00865-g002-550.jpg?1678187280) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00865/article_deploy/html/images/pharmaceutics-15-00865-g003-550.jpg?1678187272) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00865/article_deploy/html/images/pharmaceutics-15-00865-g004-550.jpg?1678187276) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00865/article_deploy/html/images/pharmaceutics-15-00865-g005-550.jpg?1678187279) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00865/article_deploy/html/images/pharmaceutics-15-00865-g006-550.jpg?1678187270)

Open Access Article (/1999-4923/15/3/864/pdf?version=1678181527)

Influence of Folate-Targeted Gold Nanoparticles on Subcellular Localization and Distribution into Lysosomes (/1999-4923/15/3/864)

by Raffaella Daniele (https://sciprofiles.com/profile/2822775), Chiara Brazzale (https://sciprofiles.com/profile/author/RzZHRmlyYlBtc2ZCWjlxZnNhVHVtd1JnOWtMVW8yTEhNWG9STGNNaGVXZz0=), Busra Arpac (https://sciprofiles.com/profile/2824685), Francesco Tognetti (https://sciprofiles.com/profile/2903755), Cristiano Pesce (https://sciprofiles.com/profile/2745799), Alessio Malfanti (https://sciprofiles.com/profile/1945994), Edward Sayers (https://sciprofiles.com/profile/665676), Francesca Mastrotto (https://sciprofiles.com/profile/1186056), Arwyn T. Jones (https://sciprofiles.com/profile/635022), Stefano Salmaso (https://sciprofiles.com/profile/973154) and Paolo Caliceti (https://sciprofiles.com/profile/1599568)

Pharmaceutics **2023**, *15*(3), 864; https://doi.org/10.3390/pharmaceutics15030864 (https://doi.org/10.3390/pharmaceutics15030864) - 07 Mar 2023

Cited by 3 (/1999-4923/15/3/864#metrics) | Viewed by 1131

Abstract The cell interaction, mechanism of cell entry and intracellular fate of surface decorated nanoparticles are known to be affected by the surface density of targeting agents. However, the correlation between nanoparticles multivalency and kinetics of the cell uptake process and disposition of intracellular [...] Read more.

(This article belongs to the Special Issue Special Issue in Honor of Professor Carla Caramella (/journal/pharmaceutics/special_issues/Carla_Caramella))

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00864/article_deploy/html/images/pharmaceutics-15-00864-ag-550.jpg?1678181618) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00864/article_deploy/html/images/pharmaceutics-15-00864-g001a-550.jpg?1678181604) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00864/article_deploy/html/images/pharmaceutics-15-00864-g001b-550.jpg?1678181593) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00864/article_deploy/html/images/pharmaceutics-15-00864-g002-550.jpg?1678181597) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00864/article_deploy/html/images/pharmaceutics-15-00864-g003-550.jpg?1678181594) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00864/article_deploy/html/images/pharmaceutics-15-00864-g004a-550.jpg?1678181603) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00864/article_deploy/html/images/pharmaceutics-15-00864-g004b-550.jpg?1678181607) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00864/article_deploy/html/images/pharmaceutics-15-00864-g005a-550.jpg?1678181614) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00864/article_deploy/html/images/pharmaceutics-15-00864-g005b-550.jpg?1678181611) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00864/article_deploy/html/images/pharmaceutics-15-00864-g006-550.jpg?1678181609) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00864/article_deploy/html/images/pharmaceutics-15-00864-g007-550.jpg?1678181610) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00864/article_deploy/html/images/pharmaceutics-15-00864-g008-550.jpg?1678181600) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00864/article_deploy/html/images/pharmaceutics-15-00864-sch001-550.jpg?1678181602)

Open Access Review (/1999-4923/15/3/863/pdf?version=1678178678)

Naringin: Nanotechnological Strategies for Potential Pharmaceutical Applications (/1999-4923/15/3/863)

by Soledad Ravetti (https://sciprofiles.com/profile/3091829), Ariel G. Garro (https://sciprofiles.com/profile/2736047), Agustina Gaitán (https://sciprofiles.com/profile/author/dFNJRFF3N0RyR2FBL0szYjhveFRlRXBFenVMbWh2YkxHbnpaZUdTWllxcz0=), Mariano Murature (https://sciprofiles.com/profile/author/YlICYmpaekRVeTBkZFZHNGVZZXp6ZXFnOTg3SlV6cHphNHRGTGdOZk02MD0=), Mariela Galiano (https://sciprofiles.com/profile/author/VlFnZzhQTFNOZDBSOGFKY2hyVExoTlFHY3FLd3Y1WEw1aWZOSzd6MjhrZz0=), Sofía G. Brignone (https://sciprofiles.com/profile/author/TmhqYXRSV0daYmRROE9rM3VidlRxWmYyY01VbUhHOWtGbHR3N0wycHM5Yz0=) and Santiago D. Palma (https://sciprofiles.com/profile/770118)

Pharmaceutics **2023**, *15*(3), 863; https://doi.org/10.3390/pharmaceutics15030863 (https://doi.org/10.3390/pharmaceutics15030863) - 07 Mar 2023

Cited by 3 (/1999-4923/15/3/863#metrics) | Viewed by 1727

Abstract Polyphenols comprise a number of natural substances, such as flavonoids, that show interesting biological effects. Among these substances is naringin, a naturally occurring flavanone glycoside found in citrus fruits and Chinese medicinal herbs. Several studies have shown that naringin has numerous biological properties, [...] Read more.

(This article belongs to the Special Issue Nanoformulation of Drug Delivery Systems for Natural Products (/journal/pharmaceutics/special_issues/Natural_Nanoformulation))

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00863/article_deploy/html/images/pharmaceutics-15-00863-g001-550.jpg?1678178748) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00863/article_deploy/html/images/pharmaceutics-15-00863-g002-550.jpg?1678178745) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00863/article_deploy/html/images/pharmaceutics-15-00863-g003-550.jpg?1678178743) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00863/article_deploy/html/images/pharmaceutics-15-00863-g004-550.jpg?1678178748) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00863/article_deploy/html/images/pharmaceutics-15-00863-g005-550.jpg?1678178750) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00863/article_deploy/html/images/pharmaceutics-15-00863-g006-550.jpg?1678178744)

Open Access Article (/1999-4923/15/3/862/pdf?version=1678181821)

Back to TopTop

The Role of Functionalization and Size of Gold Nanoparticles in the Response of MCF-7 Breast Cancer Cells to Ionizing Radiation Comparing 2D and 3D In Vitro Models (/1999-4923/15/3/862)
by Marika Musielak (https://sciprofiles.com/profile/1248488), Agnieszka Boś-Liedke (https://sciprofiles.com/profile/author/Zk96aDlSWiswaGNGb3FGSzFIQzZBcVpsTEZGNGp1UElrQ2QrYkU5cVRPQT0=), Oliwia Piwocka (https://sciprofiles.com/profile/2527010), Katarzyna Kowalska (https://sciprofiles.com/profile/author/WTM5UTloY1diUXN6TmtNWERQNDZCSjFMY0NSRlMrM0VrMGM5NzY1Z2lpbz0=), Roksana Markiewicz (https://sciprofiles.com/profile/1354023), Barbara Szymkowiak (https://sciprofiles.com/profile/2825028), Paweł Bakun (https://sciprofiles.com/profile/2197475) and Wiktoria M. Suchorska (https://sciprofiles.com/profile/384650)
Pharmaceutics **2023**, *15*(3), 862; https://doi.org/10.3390/pharmaceutics15030862 (https://doi.org/10.3390/pharmaceutics15030862) - 07 Mar 2023
Cited by 1 (/1999-4923/15/3/862#metrics) | Viewed by 1086

Abstract Gold nanoparticles (AuNPs), as an agent enhancing radiosensitivity, play a key role in the potential treatment of breast cancer (BC). Assessing and understanding the kinetics of modern drug delivery systems is a crucial element that allows the implementation of AuNPs in clinical treatment. [...] Read more.
(This article belongs to the Special Issue Metal Nanoparticles for Cancer Therapy (/journal/pharmaceutics/special_issues/metal_therapy))

► Show Figures
(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00862/article_deploy/html/images/pharmaceutics-15-00862-g001-550.jpg?1678181896) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00862/article_deploy/html/images/pharmaceutics-15-00862-g002-550.jpg?1678181894) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00862/article_deploy/html/images/pharmaceutics-15-00862-g003-550.jpg?1678181924) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00862/article_deploy/html/images/pharmaceutics-15-00862-g004-550.jpg?1678181907) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00862/article_deploy/html/images/pharmaceutics-15-00862-g005-550.jpg?1678181901) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00862/article_deploy/html/images/pharmaceutics-15-00862-g006-550.jpg?1678181921) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00862/article_deploy/html/images/pharmaceutics-15-00862-g007-550.jpg?1678181912) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00862/article_deploy/html/images/pharmaceutics-15-00862-g008-550.jpg?1678181891) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00862/article_deploy/html/images/pharmaceutics-15-00862-g009-550.jpg?1678181927) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00862/article_deploy/html/images/pharmaceutics-15-00862-g010-550.jpg?1678181903) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00862/article_deploy/html/images/pharmaceutics-15-00862-g011-550.jpg?1678181914) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00862/article_deploy/html/images/pharmaceutics-15-00862-g012-550.jpg?1678181916)

Open Access Article (/1999-4923/15/3/861/pdf?version=1678172587)

On the Use of Temperature Measurements as a Process Analytical Technology (PAT) for the Monitoring of a Pharmaceutical Freeze-Drying Process (/1999-4923/15/3/861)
by Alberto Vallan (https://sciprofiles.com/profile/92835), Davide Fissore (https://sciprofiles.com/profile/97373), Roberto Pisano (https://sciprofiles.com/profile/107357) and Antonello A. Barresi (https://sciprofiles.com/profile/497859)
Pharmaceutics **2023**, *15*(3), 861; https://doi.org/10.3390/pharmaceutics15030861 (https://doi.org/10.3390/pharmaceutics15030861) - 07 Mar 2023
Cited by 1 (/1999-4923/15/3/861#metrics) | Viewed by 844

Abstract The measurement of product temperature is one of the methods that can be adopted, especially in the pharmaceutical industry, to monitor the freeze-drying process and to obtain the values of the process parameters required by mathematical models useful for in-line (or off-line) optimization. [...] Read more.
(This article belongs to the Special Issue Advance in Pharmaceutical Engineering: PAT and Model-Based Approach for QbD and Continuous Processes (/journal/pharmaceutics/special_issues/pharmaceutical_PAT_QbD))

► Show Figures
(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00861/article_deploy/html/images/pharmaceutics-15-00861-g001-550.jpg?1678172663) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00861/article_deploy/html/images/pharmaceutics-15-00861-g002-550.jpg?1678172667) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00861/article_deploy/html/images/pharmaceutics-15-00861-g003-550.jpg?1678172663) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00861/article_deploy/html/images/pharmaceutics-15-00861-g004-550.jpg?1678172670) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00861/article_deploy/html/images/pharmaceutics-15-00861-g005-550.jpg?1678172668) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00861/article_deploy/html/images/pharmaceutics-15-00861-g006-550.jpg?1678172664)

Open Access Article (/1999-4923/15/3/860/pdf?version=1678344693)

Synthesis and Characterization of Linear Copolymers Based on Pharmaceutically Functionalized Monomeric Choline Ionic Liquid for Delivery of *p*-Aminosalicylate (/1999-4923/15/3/860)
by Shadi Keihankhadiv (https://sciprofiles.com/profile/2690034) and Dorota Neugebauer (https://sciprofiles.com/profile/562884)
Pharmaceutics **2023**, *15*(3), 860; https://doi.org/10.3390/pharmaceutics15030860 (https://doi.org/10.3390/pharmaceutics15030860) - 07 Mar 2023
Viewed by 949

Abstract Bioactive linear poly(ionic liquid)s (PIL) were designed as carriers in drug delivery systems (DDS). Their synthesis was based on a monomeric ionic liquid (MIL) with a relevant pharmaceutical anion to create therapeutically functionalized monomers, which further can be used in the controlled atom [...] Read more.
(This article belongs to the Special Issue Self-Assembled Amphiphilic Copolymers in Drug Delivery (/journal/pharmaceutics/special_issues/assembled_polymer))

► Show Figures
(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00860/article_deploy/html/images/pharmaceutics-15-00860-g001-550.jpg?1678344763) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00860/article_deploy/html/images/pharmaceutics-15-00860-g002-550.jpg?1678344770) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00860/article_deploy/html/images/pharmaceutics-15-00860-g003-550.jpg?1678344761) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00860/article_deploy/html/images/pharmaceutics-15-00860-g004-550.jpg?1678344774) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00860/article_deploy/html/images/pharmaceutics-15-00860-g005-550.jpg?1678344766) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00860/article_deploy/html/images/pharmaceutics-15-00860-g006-550.jpg?1678344765) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00860/article_deploy/html/images/pharmaceutics-15-00860-g007-550.jpg?1678344767) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00860/article_deploy/html/images/pharmaceutics-15-00860-g008-550.jpg?1678344768) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00860/article_deploy/html/images/pharmaceutics-15-00860-sch001-550.jpg?1678344775) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00860/article_deploy/html/images/pharmaceutics-15-00860-sch002-550.jpg?1678344764)

Open Access Article (/1999-4923/15/3/859/pdf?version=1678162309)

Chitosan-Coated Alginate Microcapsules of a Full-Spectrum Cannabis Extract: Characterization, Long-Term Stability and In Vitro Bioaccessibility (/1999-4923/15/3/859)
by Aitor Villate (https://sciprofiles.com/profile/2744551), Markel San Nicolas (https://sciprofiles.com/profile/author/Z1NqUmVrY1g3TlBBNEcwYS9Vc0hEQlYvZnBLdmY1K3R2MDhMdGM2YjdlWT0=), Maitane Olivares (https://sciprofiles.com/profile/author/MXlJM1c2T2UrdkJlejVTZ0dEKzhWOTlPb2p0N211UVlUKzlycDJhZTc3UT0=), Oier Aizpurua-Olaizola (https://sciprofiles.com/profile/author/N3FYMk1lNEFUSG9iRlBYSnNMSFAxSXpsdFJ1dTAxam9oNXdSWTl0QzJwYz0=) and Aresatz Usobiaga (https://sciprofiles.com/profile/author/VmlYU25wN2h0aGdFTkFLQ2lLdzhYSDRtZHJRQTE5dDE5UkpidlZtWmVjbz0=)
Pharmaceutics **2023**, *15*(3), 859; https://doi.org/10.3390/pharmaceutics15030859 (https://doi.org/10.3390/pharmaceutics15030859) - 07 Mar 2023
Cited by 1 (/1999-4923/15/3/859#metrics) | Viewed by 1252

Abstract Cannabinoids present in *Cannabis sativa* are increasingly used in medicine due to their therapeutic potential. Moreover, the synergistic interaction between different cannabinoids and other plant constituents has led to the development of full-spectrum formulations for therapeutic treatments. In this work, the microencapsulation of [...] Read more.
(This article belongs to the Special Issue Therapeutic Cannabinoid Formulation Development and Delivery Systems (/journal/pharmaceutics/special_issues/Cannabinoid_Delivery))

► Show Figures
(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00859/article_deploy/html/images/pharmaceutics-15-00859-g001-550.jpg?1678162396) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00859/article_deploy/html/images/pharmaceutics-15-00859-g002-550.jpg?1678162391) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00859/article_deploy/html/images/pharmaceutics-15-00859-g003-550.jpg?1678162404) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00859/article_deploy/html/images/pharmaceutics-15-00859-g004-550.jpg?1678162406)

Open Access Article (/1999-4923/15/3/858/pdf?version=1678108048)

Compaction Behavior of Co-Amorphous Systems (/1999-4923/15/3/858)
by Cecilie-Mathilde Sørensen (https://sciprofiles.com/profile/3029491), Jukka Rantanen (https://sciprofiles.com/profile/219247) and

Back to TopTop

Holder Grohganz (https://sciprofiles.com/profile/138436)
Pharmaceutics **2023**, *15*(3), 858; https://doi.org/10.3390/pharmaceutics15030858 (https://doi.org/10.3390/pharmaceutics15030858) - 06 Mar 2023
Cited by 1 (/1999-4923/15/3/858#metrics) | Viewed by 1265

Abstract Co-amorphous systems have been shown to be a promising strategy to address the poor water solubility of many drug candidates. However, little is known about the effect of downstream processing-induced stress on these systems. The aim of this study is to investigate the **[...] Read more.**
(This article belongs to the Special Issue **Amorphous Drug Formulations: Progress, Challenges and Perspectives (/journal/pharmaceutics/special_issues /amorphous_drug)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00858/article_deploy/html/images/pharmaceutics-15-00858-g001-550.jpg?1678108118) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00858/article_deploy/html/images/pharmaceutics-15-00858-g002-550.jpg?1678108123) (https://pub.mdpi-res.com /pharmaceutics/pharmaceutics-15-00858/article_deploy/html/images/pharmaceutics-15-00858-g003-550.jpg?1678108123) (https://pub.mdpi-res.com/pharmaceutics /pharmaceutics-15-00858/article_deploy/html/images/pharmaceutics-15-00858-g004-550.jpg?1678108120) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00858/article_deploy/html/images/pharmaceutics-15-00858-g005-550.jpg?1678108125) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00858 /article_deploy/html/images/pharmaceutics-15-00858-g006-550.jpg?1678108119)

Open Access Article (/1999-4923/15/3/857/pdf?version=1678111733)

H_2O_2-PLA-$(Alg)_2Ca$ Hydrogel Enriched in Matrigel® Promotes Diabetic Wound Healing (/1999-4923/15/3/857)

by Alexandra Cătălina Bîrcă (https://sciprofiles.com/profile/492045), Cristina Chircov (https://sciprofiles.com/profile/560848), Adelina Gabriela Niculescu (https://sciprofiles.com/profile/1576940), Herman Hildegard (https://sciprofiles.com/profile/author/TE01N0VoUklybGFRVng5bzhGa3VFSFdNYTM0U2FZbjY5cDVRQmNwS1VPRT0=), Cornel Baltă (https://sciprofiles.com/profile/227217), Marcel Roșu (https://sciprofiles.com/profile/author/TFUyUkI1bnFVY3BiYnVnSVcvYXRrSENReXNsTHJPOHh5bEFqR044VVRUYz0=), Bianca Mladin (https://sciprofiles.com/profile/author/bGdnRjBoWkxhMUJsM0NRelRKVzVVYy9xRXJjSFliQ1BzTnVKT3hMY0J3cz0=), Oana Gherasim (https://sciprofiles.com/profile/897518), Dan Eduard Mihaiescu (https://sciprofiles.com/profile/1865822), Bogdan Ștefan Vasile (https://sciprofiles.com/profile/73054), Alexandru Mihai Grumezescu (https://sciprofiles.com/profile/28219), Ecaterina Andronescu (https://sciprofiles.com/profile/474188) and Anca Oana Hermenean (https://sciprofiles.com/profile/26486)
Pharmaceutics **2023**, *15*(3), 857; https://doi.org/10.3390/pharmaceutics15030857 (https://doi.org/10.3390/pharmaceutics15030857) - 06 Mar 2023
Cited by 4 (/1999-4923/15/3/857#metrics) | Viewed by 1248

Abstract Hydrogel-based dressings exhibit suitable features for successful wound healing, including flexibility, high water-vapor permeability and moisture retention, and exudate absorption capacity. Moreover, enriching the hydrogel matrix with additional therapeutic components has the potential to generate synergistic results. Thus, the present study centered on **[...] Read more.**
(This article belongs to the Special Issue **Bio-Organic Materials for Tissue Engineering and Regenerative Medicine (/journal/pharmaceutics/special_issues /Bioorganic_Materials)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00857/article_deploy/html/images/pharmaceutics-15-00857-g001-550.jpg?1678111832) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00857/article_deploy/html/images/pharmaceutics-15-00857-g002-550.jpg?1678111825) (https://pub.mdpi-res.com /pharmaceutics/pharmaceutics-15-00857/article_deploy/html/images/pharmaceutics-15-00857-g003-550.jpg?1678111824) (https://pub.mdpi-res.com/pharmaceutics /pharmaceutics-15-00857/article_deploy/html/images/pharmaceutics-15-00857-g004-550.jpg?1678111840) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00857/article_deploy/html/images/pharmaceutics-15-00857-g005-550.jpg?1678111817) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00857 /article_deploy/html/images/pharmaceutics-15-00857-g006-550.jpg?1678111827) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00857/article_deploy /html/images/pharmaceutics-15-00857-g007-550.jpg?1678111813) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00857/article_deploy/html/images /pharmaceutics-15-00857-g008-550.jpg?1678111829) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00857/article_deploy/html/images/pharmaceutics-15-00857-g009-550.jpg?1678111835) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00857/article_deploy/html/images/pharmaceutics-15-00857-g010-550.jpg?1678111820) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00857/article_deploy/html/images/pharmaceutics-15-00857-g011-550.jpg?1678111833) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00857/article_deploy/html/images/pharmaceutics-15-00857-g012-550.jpg?1678111836) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00857/article_deploy/html/images/pharmaceutics-15-00857-g013-550.jpg?1678111818) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00857/article_deploy/html/images/pharmaceutics-15-00857-g014-550.jpg?1678111830) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00857/article_deploy/html/images/pharmaceutics-15-00857-g015-550.jpg?1678111826) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00857/article_deploy/html/images/pharmaceutics-15-00857-g016-550.jpg?1678111822)

Open Access Review (/1999-4923/15/3/856/pdf?version=1678097504)

Gene Therapy for Regenerative Medicine (/1999-4923/15/3/856)

by Hossein Hosseinkhani (https://sciprofiles.com/profile/1005000), Abraham J. Domb (https://sciprofiles.com/profile/11737), Ghorbanali Sharifzadeh (https://sciprofiles.com/profile/author/a1plRWYyZGhhRUEyaitkZlZlZHp2ZFNVTU1uYndqV29sQkd1eFRlUmJxZz0=) and Victoria Nahum (https://sciprofiles.com/profile/1389247)
Pharmaceutics **2023**, *15*(3), 856; https://doi.org/10.3390/pharmaceutics15030856 (https://doi.org/10.3390/pharmaceutics15030856) - 06 Mar 2023
Cited by 5 (/1999-4923/15/3/856#metrics) | Viewed by 2448

Abstract The development of biological methods over the past decade has stimulated great interest in the possibility to regenerate human tissues. Advances in stem cell research, gene therapy, and tissue engineering have accelerated the technology in tissue and organ regeneration. However, despite significant progress **[...] Read more.**
(This article belongs to the Section **Gene and Cell Therapy (/journal/pharmaceutics/sections/Gene_Cell_Therapy)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00856/article_deploy/html/images/pharmaceutics-15-00856-g001-550.jpg?1678097586) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00856/article_deploy/html/images/pharmaceutics-15-00856-g002-550.jpg?1678097593) (https://pub.mdpi-res.com /pharmaceutics/pharmaceutics-15-00856/article_deploy/html/images/pharmaceutics-15-00856-g003-550.jpg?1678097582) (https://pub.mdpi-res.com/pharmaceutics /pharmaceutics-15-00856/article_deploy/html/images/pharmaceutics-15-00856-g004-550.jpg?1678097602) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00856/article_deploy/html/images/pharmaceutics-15-00856-g005-550.jpg?1678097608) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00856 /article_deploy/html/images/pharmaceutics-15-00856-g006-550.jpg?1678097606) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00856/article_deploy /html/images/pharmaceutics-15-00856-g007-550.jpg?1678097595) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00856/article_deploy/html/images /pharmaceutics-15-00856-g008-550.jpg?1678097599)

Open Access Article (/1999-4923/15/3/855/pdf?version=1678096682)

Oligonucleotide Formulations Prepared by High-Speed Electrospinning: Maximizing Loading and Exploring Downstream Processability (/1999-4923/15/3/855)

by Edit Hirsch (https://sciprofiles.com/profile/736171), Márió Nacsa (https://sciprofiles.com/profile/author/Q0N3dXFGU21xVDI1RVBNUHRHNTIhdVZXRkEzcDNVVVBPQUFBbk9nWlI1MD0=), Eszter Pantea (https://sciprofiles.com/profile/author/a002WFBJbEFvSThEbDNEaTJvV3BKTmlGVFZlNTQvb2I6N1JNNnh6VU5tVT0=), Edina Szabó (https://sciprofiles.com/profile/2944003), Panna Vass (https://sciprofiles.com/profile/author/TkRMRm05SWlkck5hV25pVVdwdk9lTGMySW5vclVVNjEyK1k2QUhtUmNzTT0=), Júlia Domján (https://sciprofiles.com/profile/2763323), Attila Farkas (https://sciprofiles.com/profile/748812), Zoltán Nyíri (https://sciprofiles.com/profile/1255887), Zsuzsanna Eke (https://sciprofiles.com/profile/author/dUhKakVTL0lzOVAwMmFaZWYyelpjWHhzN3h4V1BYZHhXVUxhUmhQT0ZpZz0=), Tamás Vigh (https://sciprofiles.com/profile/author/a0dKYzdoOG5CMDdsQVZTT1ZjVDBROGQ1b2p6SHk3eGpiNzh0Q2FDZlJuaz0=), Sune Klint Andersen (https://sciprofiles.com/profile/748659), Geert Verreck (https://sciprofiles.com/profile/author/Y2FiZW90Y01MYVAvWjVvRTgwQWZ0RlBnSDRGVjdZVDdkeWlyK3ovWnROST0=), György János Marosi (https://sciprofiles.com/profile/author/OEZQemh4cVp0MExmQzlod0tGWjBhYmNDUENFSCs5R3pwbUdUTkpnLzBGUT0=) and Zsombor Kristóf Nagy (https://sciprofiles.com/profile/author/TGVucUJMQVAwMk01L3hUUGl0SjU5TmhKVzRkSzZ5U0VpR1hhTEdUNmo0RT0=)
Pharmaceutics **2023**, *15*(3), 855; https://doi.org/10.3390/pharmaceutics15030855 (https://doi.org/10.3390/pharmaceutics15030855) - 06 Mar 2023
Viewed by 1341

Abstract The aim of this study was to develop antisense oligonucleotide tablet formulations using high-speed electrospinning. Hydroxypropyl-beta-cyclodextrin (HPβCD) was used as a stabilizer and as an electrospinning matrix. In order to optimize the morphology of the fibers, electrospinning of various formulations was carried out **[...] Read more.**
(This article belongs to the Special Issue **Recent Development of Electrospinning for Drug Delivery, 3rd Edition (/journal/pharmaceutics/special_issues /electrospinning_drug_delivery_III)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00855/article_deploy/html/images/pharmaceutics-15-00855-ag-550.jpg?1678270830) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00855/article_deploy/html/images/pharmaceutics-15-00855-g001a-550.jpg?1678096750) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00855/article_deploy/html/images/pharmaceutics-15-00855-g001b-550.jpg?1678096761) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00855/article_deploy/html/images/pharmaceutics-15-00855-g002a-550.jpg?1678096763) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00855/article_deploy/html/images/pharmaceutics-15-00855-g002b-550.jpg?1678096748) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00855/article_deploy/html/images/pharmaceutics-15-00855-g003-550.jpg?1678096747) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00855/article_deploy/html/images/pharmaceutics-15-00855-g004-550.jpg?1678096750) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00855/article_deploy/html/images/pharmaceutics-15-00855-g005-550.jpg?1678096765) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00855/article_deploy/html/images/pharmaceutics-15-00855-g006-550.jpg?1678096753) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00855/article_deploy/html/images/pharmaceutics-15-00855-g007-550.jpg?1678096757) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00855/article_deploy/html/images/pharmaceutics-15-00855-g008-550.jpg?1678096756) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00855/article_deploy/html/images/pharmaceutics-15-00855-g0A1-550.jpg?1678096764)

Open Access Article (/1999-4923/15/3/854/pdf?version=1678095319)

Multifunctional Mesoporous Silica-Coated Gold Nanorods Mediate Mild Photothermal Heating-Enhanced Gene/Immunotherapy for Colorectal Cancer (/1999-4923/15/3/854)

by Meirong Li (https://sciprofiles.com/profile/1087708),
Jingyu Yang (https://sciprofiles.com/profile/author/aElTS2s4NW81Qk94a1J0WVd1aHRqcEZoTFZBSkxFMEdvSnpqSUxJT3Nubz0=),
Xinhuang Yao (https://sciprofiles.com/profile/author/c0pOdzhxSzZ0K3J1OG0rWmlIZFRHdz09),
Xiang Li (https://sciprofiles.com/profile/author/aWxkWHY4Q1QxZmpDcDhvUzNUeFVac2dxZWU3Wis4NzJTUFpPOXU1Q0RlYz0=),
Zhourui Xu (https://sciprofiles.com/profile/1731075),
Shiqi Tang (https://sciprofiles.com/profile/author/TDZneUdOYXFxQStnSlNFMHo1YzZZb1BmUnpXTXAzQVYrZlpHa1IMUlIsdz0=),
Bangxu Sun (https://sciprofiles.com/profile/author/bmZlTGFZc2pBR0o3Rm9hZTFjVngvZnB2a3ZuQVloVFE1eHlmY2tKYjVpQT0=),
Suxia Lin (https://sciprofiles.com/profile/author/WWdteEc0VzBjQUtCNXR1NTFVaVlrY3Brb0JqM0d5VmxadEM2YjFmT0x0WT0=),
Chengbin Yang (https://sciprofiles.com/profile/1707999) and Jia Liu (https://sciprofiles.com/profile/2764915)

Pharmaceutics **2023**, *15*(3), 854; https://doi.org/10.3390/pharmaceutics15030854 (https://doi.org/10.3390/pharmaceutics15030854) - 06 Mar 2023
Cited by 1 (/1999-4923/15/3/854#metrics) | Viewed by 1074

Abstract Colorectal cancer (CRC) is the third most common cancer worldwide and the second leading cause of cancer-related deaths in the world. It is urgent to search for safe and effective therapies to address the CRC crisis. The siRNA-based RNA interference targeted silencing of **[...] Read more.**
(This article belongs to the Special Issue **Advances in Cancer Nanotechnology for Photodynamic and Photothermal Therapy (/journal/pharmaceutics/special_issues/XWXN8534AC)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00854/article_deploy/html/images/pharmaceutics-15-00854-g001-550.jpg?1678095394) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00854/article_deploy/html/images/pharmaceutics-15-00854-g002-550.jpg?1678095395) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00854/article_deploy/html/images/pharmaceutics-15-00854-g003-550.jpg?1678095398) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00854/article_deploy/html/images/pharmaceutics-15-00854-g004-550.jpg?1678095387) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00854/article_deploy/html/images/pharmaceutics-15-00854-g005-550.jpg?1678095400) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00854/article_deploy/html/images/pharmaceutics-15-00854-g006-550.jpg?1678095391) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00854/article_deploy/html/images/pharmaceutics-15-00854-sch001-550.jpg?1678095402)

Open Access Article (/1999-4923/15/3/853/pdf?version=1678095070)

Pharmacokinetics of Orally Applied Cannabinoids and Medical Marijuana Extracts in Mouse Nervous Tissue and Plasma: Relevance for Pain Treatment (/1999-4923/15/3/853)

by Cristiana Dumbraveanu (https://sciprofiles.com/profile/2782369),
Katharina Strommer (https://sciprofiles.com/profile/author/ZXFlY1JDOGZ5ZWt0UkFQQUZ3YStEMWgzVFp6U0JISTlGVFRlTFV2eUNEOD0=),
Meinolf Wonnemann (https://sciprofiles.com/profile/author/dVpsbDRwWDJxMm1FY3B2YkZxZ2d6RGlyZml5Ymd2bmE1N1MwVVVtZ1UzWT0=),
Jeiny Luna Choconta (https://sciprofiles.com/profile/author/SDl4bEQwQ25QVnd2Y0lLVWVva2xlL0VJamZOV2ppd2R6NTZ3ZDV4dHhYRT0=),
Astrid Neumann (https://sciprofiles.com/profile/2774495), Michaela Kress (https://sciprofiles.com/profile/730333),
Theodora Kalpachidou (https://sciprofiles.com/profile/741617) and Kai K. Kummer (https://sciprofiles.com/profile/916243)

Pharmaceutics **2023**, *15*(3), 853; https://doi.org/10.3390/pharmaceutics15030853 (https://doi.org/10.3390/pharmaceutics15030853) - 06 Mar 2023
Cited by 3 (/1999-4923/15/3/853#metrics) | Viewed by 1420

Abstract Cannabis sativa plants contain a multitude of bioactive substances, which show broad variability between different plant strains. Of the more than a hundred naturally occurring phytocannabinoids, Δ9-Tetrahydrocannabinol (Δ9-THC) and cannabidiol (CBD) have been the most extensively studied, but whether and how the lesser **[...] Read more.**

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00853/article_deploy/html/images/pharmaceutics-15-00853-g001-550.jpg?1678095143) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00853/article_deploy/html/images/pharmaceutics-15-00853-g002-550.jpg?1678095147) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00853/article_deploy/html/images/pharmaceutics-15-00853-g003-550.jpg?1678095139) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00853/article_deploy/html/images/pharmaceutics-15-00853-g004-550.jpg?1678095140)

Open Access Article (/1999-4923/15/3/852/pdf?version=1678074757)

Kinin B_1 and B_2 Receptors Contribute to Cisplatin-Induced Painful Peripheral Neuropathy in Male Mice (/1999-4923/15/3/852)

by Gabriela Becker (https://sciprofiles.com/profile/author/c3ZkRWdJdnM4OGFlVXlwZWJVbjhYTVlEbnQyZTBheUNsbHFadHhlV1NMVT0=),
Maria Fernanda Pessano Fialho (https://sciprofiles.com/profile/author/QzJldy9BaXlIMkMvUnZNSmtJaGxFTGVpRCtwWGtDQ2Y2L3N1dDVpSkNYRT0=),
Indiara Brusco (https://sciprofiles.com/profile/author/dlord2xlZ2xHMFNFSi9OZmhvQ0JRZ2JtTVNTWE1jaGJpREpwRGVTaElBST0=) and
Sara Marchesan Oliveira (https://sciprofiles.com/profile/2709103)

Pharmaceutics **2023**, *15*(3), 852; https://doi.org/10.3390/pharmaceutics15030852 (https://doi.org/10.3390/pharmaceutics15030852) - 06 Mar 2023
Cited by 1 (/1999-4923/15/3/852#metrics) | Viewed by 1131

Abstract Cisplatin is the preferential chemotherapeutic drug for highly prevalent solid tumours. However, its clinical efficacy is frequently limited due to neurotoxic effects such as peripheral neuropathy. Chemotherapy-induced peripheral neuropathy is a dose-dependent adverse condition that negatively impacts quality of life, and it may **[...] Read more.**
(This article belongs to the Special Issue **Emerging Strategies in Drug Development and Clinical Care in the Era of Personalized and Precision Medicine (/journal/pharmaceutics/special_issues/9WUD0G24J6)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00852/article_deploy/html/images/pharmaceutics-15-00852-ag-550.jpg?1678074842) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00852/article_deploy/html/images/pharmaceutics-15-00852-g001-550.jpg?1678074836) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00852/article_deploy/html/images/pharmaceutics-15-00852-g002-550.jpg?1678074830) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00852/article_deploy/html/images/pharmaceutics-15-00852-g003-550.jpg?1678074832) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00852/article_deploy/html/images/pharmaceutics-15-00852-g004-550.jpg?1678074833) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00852/article_deploy/html/images/pharmaceutics-15-00852-g005-550.jpg?1678074839) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00852/article_deploy/html/images/pharmaceutics-15-00852-g006-550.jpg?1678074835) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00852/article_deploy/html/images/pharmaceutics-15-00852-g007-550.jpg?1678074838)

Open Access Article (/1999-4923/15/3/851/pdf?version=1678334318)

Self-Assembled Lecithin-Chitosan Nanoparticles Improved Rotigotine Nose-to-Brain Delivery and Brain Targeting Efficiency (/1999-4923/15/3/851)

by Paramita Saha (https://sciprofiles.com/profile/2816683),
Prabhjeet Singh (https://sciprofiles.com/profile/author/TXRCVFJLY1Q1a0kxZHA0NzJkM2MxOFJqVldJeVZwS3liSDlrTjdrRHhMST0=),
Himanshu Kathuria (https://sciprofiles.com/profile/131167),
Deepak Chitkara (https://sciprofiles.com/profile/author/MHlUSGFKTWpUcU9QVE9ibE5MWTVnanNnTnJzV3Jxb1ZjWkhZV04yVDM3LzRxcmg1VzMrL3lpRDM5NWhvSnlTRA==)
and
Murali Monohar Pandey (https://sciprofiles.com/profile/1596995)

Pharmaceutics **2023**, *15*(3), 851; https://doi.org/10.3390/pharmaceutics15030851 (https://doi.org/10.3390/pharmaceutics15030851) - 05 Mar 2023

Cited by 2 (/1999-4923/15/3/851#metrics) | Viewed by 1712

Abstract Rotigotine (RTG) is a non-ergoline dopamine agonist and an approved drug for treating Parkinson's disease. However, its clinical use is limited due to various problems, viz. poor oral bioavailability (<1%), low aqueous solubility, and extensive first-pass metabolism. In this study, rotigotine-loaded lecithin-chitosan nanoparticles **[...] Read more.**
(This article belongs to the Special Issue **Non-invasive Device-Mediated Brain Drug Delivery across the Blood-Brain Barrier (/journal/pharmaceutics/special_issues /6M57N69SSA)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00851/article_deploy/html/images/pharmaceutics-15-00851-ag-550.jpg?1678334410) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00851/article_deploy/html/images/pharmaceutics-15-00851-g001-550.jpg?1678334387) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00851/article_deploy/html/images/pharmaceutics-15-00851-g002-550.jpg?1678334404) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00851/article_deploy/html/images/pharmaceutics-15-00851-g003-550.jpg?1678334401) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00851/article_deploy/html/images/pharmaceutics-15-00851-g004-550.jpg?1678334398) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00851/article_deploy/html/images/pharmaceutics-15-00851-g005-550.jpg?1678334405) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00851/article_deploy/html/images/pharmaceutics-15-00851-g006-550.jpg?1678334402) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00851/article_deploy/html/images/pharmaceutics-15-00851-g007-550.jpg?1678334388) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00851/article_deploy/html/images/pharmaceutics-15-00851-g008-550.jpg?1678334392) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00851/article_deploy/html/images/pharmaceutics-15-00851-g009-550.jpg?1678334408)

Open Access Article (/1999-4923/15/3/850/pdf?version=1678005773)

Multimodal Radiobioconjugates of Magnetic Nanoparticles Labeled with ^{44}Sc and ^{47}Sc for Theranostic Application (/1999-4923/15/3/850)

by **Perihan Ünak (https://sciprofiles.com/profile/2717246)**, **Volkan Yasakçı (https://sciprofiles.com/profile/2790559)**, **Elif Tutun (https://sciprofiles.com/profile/author/VFVKaU5mZEVHMFd1NDliakRzR0NINS9yOXZnREInZ2gySFZnUlIaQzMrVT0=)**, **K. Buşra Karatay (https://sciprofiles.com/profile/2747873)**, **Rafał Walczak (https://sciprofiles.com/profile/author/K1Z5d2ZqRkt3S2g2cDlOUCsxaHBUNkhvRzgvV3dSUzBHMmVha0RDQng4TT0=)**, **Kamil Wawrowicz (https://sciprofiles.com/profile/1374315)**, **Kinga Żelechowska-Matysiak (https://sciprofiles.com/profile/2607141)**, **Agnieszka Majkowska-Pilip (https://sciprofiles.com/profile/515187)** and **Aleksander Bilewicz (https://sciprofiles.com/profile/377908)**

Pharmaceutics **2023**, *15*(3), 850; **https://doi.org/10.3390/pharmaceutics15030850 (https://doi.org/10.3390/pharmaceutics15030850)** - 05 Mar 2023

Cited by 2 (/1999-4923/15/3/850#metrics) | Viewed by 1235

Abstract This study was performed to synthesize multimodal radiopharmaceutical designed for the diagnosis and treatment of prostate cancer. To achieve this goal, superparamagnetic iron oxide (SPIO) nanoparticles were used as a platform for targeting molecule (PSMA-617) and for complexation of two scandium radionuclides, ^{44} **[...] Read more.**
(This article belongs to the Special Issue **Magnetic Nanomaterials for Hyperthermia-Based Therapy, Imaging, and Drug Delivery (/journal/pharmaceutics/special_issues /2123RIR422)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00850/article_deploy/html/images/pharmaceutics-15-00850-g001-550.jpg?1678005855) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00850/article_deploy/html/images/pharmaceutics-15-00850-g002-550.jpg?1678005849) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00850/article_deploy/html/images/pharmaceutics-15-00850-g003-550.jpg?1678005853) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00850/article_deploy/html/images/pharmaceutics-15-00850-g004-550.jpg?1678005850) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00850/article_deploy/html/images/pharmaceutics-15-00850-g005-550.jpg?1678005857) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00850/article_deploy/html/images/pharmaceutics-15-00850-g006-550.jpg?1678005858) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00850/article_deploy/html/images/pharmaceutics-15-00850-g007-550.jpg?1678005840) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00850/article_deploy/html/images/pharmaceutics-15-00850-g008-550.jpg?1678005846) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00850/article_deploy/html/images/pharmaceutics-15-00850-g009-550.jpg?1678005842) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00850/article_deploy/html/images/pharmaceutics-15-00850-g010-550.jpg?1678005844) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00850/article_deploy/html/images/pharmaceutics-15-00850-g011-550.jpg?1678005859)

Open Access Article (/1999-4923/15/3/849/pdf?version=1678007037)

Self-Assembled Nanodelivery System with Rapamycin and Curcumin for Combined Photo-Chemotherapy of Breast Cancer (/1999-4923/15/3/849)

by **Yanlong Yin (https://sciprofiles.com/profile/1013055)**, **Hong Jiang (https://sciprofiles.com/profile/2767261)**, **Yue Wang (https://sciprofiles.com/profile/author/SndjeVVGQUZWbWFRbTBvaHFmcktOenhLN3RNZDZjbDlxV2xlbXFNSjBSbz0=)**, **Longyao Zhang (https://sciprofiles.com/profile/author/RDNCbEhhcStqKytKR1Y5K0F2NXVOOUhWTENVSjRFeExMMlViNFl3VndYaz0=)**, **Chunyan Sun (https://sciprofiles.com/profile/author/S2ZiRjNlZEItNHBjckxyQVE3V1dyRjhZSWtTNGZUMlcyenpMekk3dG0zYz0=)**, **Pan Xie (https://sciprofiles.com/profile/2805138)**, **Kun Zheng (https://sciprofiles.com/profile/author/dlIkOXI2cWh6MUxTRlIsV2EvNkNDQ3k5RzBNMHFVdU1BK3ZYenZUc081RT0=)**, **Shaoqing Wang (https://sciprofiles.com/profile/2619483)** and **Qian Yang (https://sciprofiles.com/profile/2596600)**

Pharmaceutics **2023**, *15*(3), 849; **https://doi.org/10.3390/pharmaceutics15030849 (https://doi.org/10.3390/pharmaceutics15030849)** - 05 Mar 2023

Cited by 1 (/1999-4923/15/3/849#metrics) | Viewed by 1066

Abstract Nanodelivery systems combining photothermal therapy (PTT) and chemotherapy (CT), have been widely used to improve the efficacy and biosafety of chemotherapeutic agents in cancer. In this work, we constructed a self-assembled nanodelivery system, formed by the assembling of photosensitizer (IR820), rapamycin (RAPA), and **[...] Read more.**
(This article belongs to the Special Issue **Smart Nanoparticles for Tumor-Targeted Drug Delivery (/journal/pharmaceutics/special_issues/Nanoparticle_TTDD)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00849/article_deploy/html/images/pharmaceutics-15-00849-g001-550.jpg?1678007108) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00849/article_deploy/html/images/pharmaceutics-15-00849-g002-550.jpg?1678007108) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00849/article_deploy/html/images/pharmaceutics-15-00849-g003-550.jpg?1678007104) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00849/article_deploy/html/images/pharmaceutics-15-00849-g004-550.jpg?1678007107) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00849/article_deploy/html/images/pharmaceutics-15-00849-g005-550.jpg?1678007110) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00849/article_deploy/html/images/pharmaceutics-15-00849-g006-550.jpg?1678007102) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00849/article_deploy/html/images/pharmaceutics-15-00849-g007-550.jpg?1678007106) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00849/article_deploy/html/images/pharmaceutics-15-00849-g008-550.jpg?1678007106) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00849/article_deploy/html/images/pharmaceutics-15-00849-g009-550.jpg?1678007102) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00849/article_deploy/html/images/pharmaceutics-15-00849-g010-550.jpg?1678007110)

Open Access Article (/1999-4923/15/3/848/pdf?version=1678004592)

Screening Autoxidation Propensities of Drugs in the Solid-State Using PVP and in the Solution State Using *N*-Methyl Pyrrolidone (/1999-4923/15/3/848)

by **Jayant Iyer (https://sciprofiles.com/profile/2235888)**, **Anjali Karn (https://sciprofiles.com/profile/author/SkhuU1p4S1lRZUNQVjFlcGZvMndYc2lROHdVL2kvbmQxeHR4bU1hSk9QVT0=)**, **Michael Brunsteiner (https://sciprofiles.com/profile/author/OGVlNDFJbElXZER6NU5rR2c5ajJPRDhkQ2lTWkZrYnJPMTJIcy84UFZaWT0=)**, **Andrew Ray (https://sciprofiles.com/profile/author/M0dYQWF3NFI5T2ZvZ2ZHTjVMeUQ0UVJHSk92QjNaL0NRYkI2MSs4TVJubz0=)**, **Adrian Davis (https://sciprofiles.com/profile/author/SzFRRzR3clhWWUlUR0E5ZVczRzZSc2ZhS0wzVXBGcHdMZUw3c2p2d1ZWOD0=)**, **Isha Saraf (https://sciprofiles.com/profile/author/Z04rcjhLbmloaU1LLy9aR0Q0M0taNXhrVk9zZkhhclVaTmVTVFhrZHZLZz0=)** and **Amrit Paudel (https://sciprofiles.com/profile/453068)**

Pharmaceutics **2023**, *15*(3), 848; **https://doi.org/10.3390/pharmaceutics15030848 (https://doi.org/10.3390/pharmaceutics15030848)** - 05 Mar 2023

Viewed by 1234

Abstract Oxidative degradation of drugs is one of the major routes of drug substance and drug product instability. Among the diverse routes of oxidation, autoxidation is considered to be challenging to predict and control, potentially due to the multi-step mechanism involving free radicals. C–H **[...] Read more.**
(This article belongs to the Special Issue **Drug Stability: Factors and New Approaches to Overcome Drug Instability (/journal/pharmaceutics/special_issues /Drug_Instability)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00848/article_deploy/html/images/pharmaceutics-15-00848-ag-550.jpg?1680155956) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00848/article_deploy/html/images/pharmaceutics-15-00848-g001-550.jpg?1679624974) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00848/article_deploy/html/images/pharmaceutics-15-00848-g002-550.jpg?1679624970) (https://pub.mdpi-res.com/pharmaceutics

/pharmaceutics-15-00848/article_deploy/html/images/pharmaceutics-15-00848-g003-550.jpg?1679624976) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00848/article_deploy/html/images/pharmaceutics-15-00848-g004-550.jpg?1679624968) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00848/article_deploy/html/images/pharmaceutics-15-00848-g005-550.jpg?1679624964) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00848/article_deploy/html/images/pharmaceutics-15-00848-g006-550.jpg?1679624971)

Open Access Article (/1999-4923/15/3/847/pdf?version=1678156533)

pH-Responsive Water-Soluble Chitosan Amphiphilic Core–Shell Nanoparticles: Radiation-Assisted Green Synthesis and Drug-Controlled Release Studies (/1999-4923/15/3/847)

by Thananchai Piroonpan (https://sciprofiles.com/profile/author/ejduWFhXMHRES2RwQzh2aXZhZUJLd0l4R0VDN0JlWHU5NGY2SXY4U3FJWT0=), Pakjira Rimdusit (https://sciprofiles.com/profile/2823277), Saowaluk Taechutrakul (https://sciprofiles.com/profile/author/V2tlbWlONW5xdEdpeGhSdnNVOHFPM0tDeEoyaFNqR1VkTEZRVVhZYTAvbz0=) and Wanvimol Pasanphan (https://sciprofiles.com/profile/2669369)

Pharmaceutics **2023**, *15*(3), 847; https://doi.org/10.3390/pharmaceutics15030847 (https://doi.org/10.3390/pharmaceutics15030847) - 05 Mar 2023

Cited by 1 (/1999-4923/15/3/847#metrics) | Viewed by 989

Abstract This work aims to apply water radiolysis-mediated green synthesis of amphiphilic core–shell water-soluble chitosan nanoparticles (WCS NPs) via free radical graft copolymerization in an aqueous solution using irradiation. Robust grafting poly(ethylene glycol) monomethacrylate (PEGMA) comb-like brushes were established onto WCS NPs modified with **[...] Read more.**

(This article belongs to the Special Issue **Nanogels and Nanoparticles for Selective Drug Delivery (/journal/pharmaceutics/special_issues/nanogel_nanoparticle_selective_drug_delivery)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00847/article_deploy/html/images/pharmaceutics-15-00847-ag-550.jpg?1678156617) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00847/article_deploy/html/images/pharmaceutics-15-00847-g001-550.jpg?1678156614) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00847/article_deploy/html/images/pharmaceutics-15-00847-g002-550.jpg?1678156610) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00847/article_deploy/html/images/pharmaceutics-15-00847-g003-550.jpg?1678156602) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00847/article_deploy/html/images/pharmaceutics-15-00847-g004-550.jpg?1678156605) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00847/article_deploy/html/images/pharmaceutics-15-00847-g005-550.jpg?1678156600) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00847/article_deploy/html/images/pharmaceutics-15-00847-g006-550.jpg?1678156616) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00847/article_deploy/html/images/pharmaceutics-15-00847-g007-550.jpg?1678156611) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00847/article_deploy/html/images/pharmaceutics-15-00847-g008-550.jpg?1678156612) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00847/article_deploy/html/images/pharmaceutics-15-00847-sch001-550.jpg?1678156604)

Open Access Review (/1999-4923/15/3/846/pdf?version=1678071766)

Lentiviral Vectors as a Vaccine Platform against Infectious Diseases (/1999-4923/15/3/846)

by Kirill Nemirov (https://sciprofiles.com/profile/author/RVF4bFBDemtYQkppOHhCVHJubTdzeENBbjBsRWd0MTljRkY0L2N2eDNDVT0=), Maryline Bourgine (https://sciprofiles.com/profile/2559818), François Anna (https://sciprofiles.com/profile/author/eHIxV0N2d2VwZS9mcDNBbExReHdSMXA3UDhyaUYxZVFDa0RmdjU4S3BUbz0=), Yu Wei (https://sciprofiles.com/profile/author/MlJ4Q2ZXdlozQmM2c1JjWGU2T1BUbzZ4dnlPS0VFNnUzUVRLWGx0WEJSUT0=), Pierre Charneau (https://sciprofiles.com/profile/author/Z1ZWVjlubldlcTAwZ2VPaHF1TDRRUWtBdnh4L1FqK3NHTDBWVk14RlZrcz0=) and Laleh Majlessi (https://sciprofiles.com/profile/2764859)

Pharmaceutics **2023**, *15*(3), 846; https://doi.org/10.3390/pharmaceutics15030846 (https://doi.org/10.3390/pharmaceutics15030846) - 05 Mar 2023

Cited by 3 (/1999-4923/15/3/846#metrics) | Viewed by 1567

Abstract Lentiviral vectors are among the most effective viral vectors for vaccination. In clear contrast to the reference adenoviral vectors, lentiviral vectors have a high potential for transducing dendritic cells in vivo. Within these cells, which are the most efficient at activating naive T **[...] Read more.**

(This article belongs to the Special Issue **Dendritic Cell Vaccines Volume II (/journal/pharmaceutics/special_issues/dendritic_cell_vaccines_II)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00846/article_deploy/html/images/pharmaceutics-15-00846-g001-550.jpg?1678071839) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00846/article_deploy/html/images/pharmaceutics-15-00846-g002-550.jpg?1678071842) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00846/article_deploy/html/images/pharmaceutics-15-00846-g003-550.jpg?1678071841) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00846/article_deploy/html/images/pharmaceutics-15-00846-g004-550.jpg?1678071835) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00846/article_deploy/html/images/pharmaceutics-15-00846-g005-550.jpg?1678071837)

Open Access Article (/1999-4923/15/3/845/pdf?version=1678093812)

CD73-Positive Cell Spheroid Transplantation Attenuates Colonic Atrophy (/1999-4923/15/3/845)

by Daisuke Hisamatsu (https://sciprofiles.com/profile/2465894), Natsumi Itakura (https://sciprofiles.com/profile/author/YVJ4UjlqZlNoQkhKbVluM3BCZlU5TUN6ZldMWklZVUQ4RG9PUVpPa2F5WT0=), Yo Mabuchi (https://sciprofiles.com/profile/3037284), Rion Ozaki (https://sciprofiles.com/profile/author/RWdKaFBsMzFwcWRscS9LNkFrY0NlVmtnSEhmZmJiTmlNbG1HUWVaNTFhVT0=), Eriko Grace Suto (https://sciprofiles.com/profile/author/TlpXNkdtRHFReVZJTGhnL0ZhT2c1enNOYkZlNEZkMFlUNUVJV0xPZXpSYz0=), Yuna Naraoka (https://sciprofiles.com/profile/1745476), Akari Ikeda (https://sciprofiles.com/profile/author/clg1aWM0SUluOVVhZkhYdWdscHdiUDFxdlIxQzMyc1FlZ3pBZWVmT3MyMD0=), Lisa Ito (https://sciprofiles.com/profile/author/cDI1YWpMMCtEOXFPNHFBUEQydUlCZmF4VTJveGZpWnVlSkhWcllLNTFZVT0=) and Chihiro Akazawa (https://sciprofiles.com/profile/1749418)

Pharmaceutics **2023**, *15*(3), 845; https://doi.org/10.3390/pharmaceutics15030845 (https://doi.org/10.3390/pharmaceutics15030845) - 04 Mar 2023

Viewed by 959

Abstract The incidence of inflammatory bowel diseases (IBD) is increasing worldwide. Mesenchymal stem/stromal cells (MSCs) have immunomodulatory functions and are a promising source for cell transplantation therapy for IBD. However, owing to their heterogeneous nature, their therapeutic efficacy in colitis is controversial and depends **[...] Read more.**

(This article belongs to the Special Issue **Stromal, Stem, Signaling Cells: The Multiple Roles and Applications of Mesenchymal Cells, 2nd Edition (/journal/pharmaceutics/special_issues/1S4BYOVRQ2)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00845/article_deploy/html/images/pharmaceutics-15-00845-g001-550.jpg?1678093899) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00845/article_deploy/html/images/pharmaceutics-15-00845-g002-550.jpg?1678093883) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00845/article_deploy/html/images/pharmaceutics-15-00845-g003-550.jpg?1678093887) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00845/article_deploy/html/images/pharmaceutics-15-00845-g004-550.jpg?1678093890) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00845/article_deploy/html/images/pharmaceutics-15-00845-g005-550.jpg?1678093901) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00845/article_deploy/html/images/pharmaceutics-15-00845-g006-550.jpg?1678093879) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00845/article_deploy/html/images/pharmaceutics-15-00845-g007-550.jpg?1678093894)

Open Access Article (/1999-4923/15/3/844/pdf?version=1677927749)

Dexamethasone and Dexamethasone Phosphate: Effect on DMPC Membrane Models (/1999-4923/15/3/844)

by Candelaria Ines Cámara (https://sciprofiles.com/profile/2620437), Matías Ariel Crosio (https://sciprofiles.com/profile/author/VG5mbWFveU0rZ1BmK29zbnhnTUV2S1NNbzlXQ2s4L1VrcDd6OXhLYkp3QT0=), Ana Valeria Juarez (https://sciprofiles.com/profile/author/K0pRSU0zdTNwQU9HWkdZeHV3NkFicHY2UDF0TUNkSTRYL2RXcXc3aWl0ST0=) and Natalia Wilke (https://sciprofiles.com/profile/841149)

Pharmaceutics **2023**, *15*(3), 844; https://doi.org/10.3390/pharmaceutics15030844 (https://doi.org/10.3390/pharmaceutics15030844) - 04 Mar 2023

Viewed by 988

Abstract Dexamethasone (Dex) and Dexamethasone phosphate (Dex-P) are synthetic glucocorticoids with high anti-inflammatory and immunosuppressive actions that gained visibility because they reduce the mortality in critical patients with COVID-19 connected to assisted breathing. They have been widely used for the treatment of several diseases **[...] Read more.**

(This article belongs to the Special Issue **Sustainable Materials and Technologies for Drug Delivery and Tissue Engineering (/journal/pharmaceutics/special_issues/Sustainable_Materials_Drug_Delivery_Tissue_Engineering)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00844/article_deploy/html/images/pharmaceutics-15-00844-g001-550.jpg?1677927829) (https://pub.mdpi-

Back to TopTop

res.com/pharmaceutics/pharmaceutics-15-00844/article_deploy/html/images/pharmaceutics-15-00844-g002a-550.jpg?1677927825) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00844/article_deploy/html/images/pharmaceutics-15-00844-g002b-550.jpg?1677927820) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00844/article_deploy/html/images/pharmaceutics-15-00844-g003-550.jpg?1677927823) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00844/article_deploy/html/images/pharmaceutics-15-00844-g004-550.jpg?1677927832) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00844/article_deploy/html/images/pharmaceutics-15-00844-g005-550.jpg?1677927828) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00844/article_deploy/html/images/pharmaceutics-15-00844-g006-550.jpg?1677927826) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00844/article_deploy/html/images/pharmaceutics-15-00844-g007-550.jpg?1677927834) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00844/article_deploy/html/images/pharmaceutics-15-00844-sch001-550.jpg?1677927826) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00844/article_deploy/html/images/pharmaceutics-15-00844-sch002-550.jpg?1677927819)

Open Access Article (/1999-4923/15/3/843/pdf?version=1678082492)

Radiolabeled Risperidone microSPECT/CT Imaging for Intranasal Implant Studies Development (/1999-4923/15/3/843)

by Jon Ander Simón (https://sciprofiles.com/profile/2765616), Emilia Utomo (https://sciprofiles.com/profile/author/NDNlU1JSYTFUN1NxejRzd2l4U0VlRTAyNlVHb2daeExaOFByaHAwazlzST0=), Félix Pareja (https://sciprofiles.com/profile/author/QWdFUjFqMnFndHNGN25Ubm1QQjNEK3plaEQvYysxSWxUS3ZtV21UcjZMZz0=), María Collantes (https://sciprofiles.com/profile/2753758), Gemma Quincoces (https://sciprofiles.com/profile/author/QVFCOWFBSEV5VzVaRE5yU3g3eW4reEpqM3VSY0ZEbStsTzlzVWhPc1Bscz0=), Aarón Otero (https://sciprofiles.com/profile/2818350), Margarita Ecay (https://sciprofiles.com/profile/1313017), Juan Domínguez-Robles (https://sciprofiles.com/profile/681312), Eneko Larrañeta (https://sciprofiles.com/profile/366590) and Iván Peñuelas (https://sciprofiles.com/profile/636711)

Pharmaceutics **2023**, *15*(3), 843; https://doi.org/10.3390/pharmaceutics15030843 (https://doi.org/10.3390/pharmaceutics15030843) - 04 Mar 2023

Cited by 3 (/1999-4923/15/3/843#metrics) | Viewed by 1012

Abstract The use of intranasal implantable drug delivery systems has many potential advantages for the treatment of different diseases, as they can provide sustained drug delivery, improving patient compliance. We describe a novel proof-of-concept methodological study using intranasal implants with radiolabeled risperidone (RISP) as **[...] Read more.**

(This article belongs to the Special Issue **New Trends in the Controlled Release Systems of Medicinal Substances Used in the Treatment of Diseases of the Central Nervous System (/journal/pharmaceutics/special_issues/7RD5STD199)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00843/article_deploy/html/images/pharmaceutics-15-00843-g001-550.jpg?1678082564) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00843/article_deploy/html/images/pharmaceutics-15-00843-g002-550.jpg?1678082569) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00843/article_deploy/html/images/pharmaceutics-15-00843-g003-550.jpg?1678082565) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00843/article_deploy/html/images/pharmaceutics-15-00843-g004-550.jpg?1678082567) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00843/article_deploy/html/images/pharmaceutics-15-00843-g005-550.jpg?1678082566) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00843/article_deploy/html/images/pharmaceutics-15-00843-g006-550.jpg?1678082563) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00843/article_deploy/html/images/pharmaceutics-15-00843-g007-550.jpg?1678082570)

Open Access Article (/1999-4923/15/3/842/pdf?version=1677921872)

Hydrophilic High Drug-Loaded 3D Printed Gastroretentive System with Robust Release Kinetics (/1999-4923/15/3/842)

by Gloria Mora-Castaño (https://sciprofiles.com/profile/1081736), Mónica Millán-Jiménez (https://sciprofiles.com/profile/1063303) and Isidoro Caraballo (https://sciprofiles.com/profile/658523)

Pharmaceutics **2023**, *15*(3), 842; https://doi.org/10.3390/pharmaceutics15030842 (https://doi.org/10.3390/pharmaceutics15030842) - 04 Mar 2023

Cited by 2 (/1999-4923/15/3/842#metrics) | Viewed by 1003

Abstract Three-dimensional printing (3DP) technology enables an important improvement in the design of new drug delivery systems, such as gastroretentive floating tablets. These systems show a better temporal and spatial control of the drug release and can be customized based on individual therapeutic needs. **[...] Read more.**

(This article belongs to the Special Issue **Sustainable Materials and Technologies for Drug Delivery and Tissue Engineering (/journal/pharmaceutics/special_issues/Sustainable_Materials_Drug_Delivery_Tissue_Engineering)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00842/article_deploy/html/images/pharmaceutics-15-00842-g001-550.jpg?1677921943) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00842/article_deploy/html/images/pharmaceutics-15-00842-g002-550.jpg?1677921944) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00842/article_deploy/html/images/pharmaceutics-15-00842-g003-550.jpg?1677921946) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00842/article_deploy/html/images/pharmaceutics-15-00842-g004-550.jpg?1677921942) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00842/article_deploy/html/images/pharmaceutics-15-00842-g005-550.jpg?1677921936) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00842/article_deploy/html/images/pharmaceutics-15-00842-g006a-550.jpg?1677921950) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00842/article_deploy/html/images/pharmaceutics-15-00842-g006b-550.jpg?1677921941) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00842/article_deploy/html/images/pharmaceutics-15-00842-g007-550.jpg?1677921948) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00842/article_deploy/html/images/pharmaceutics-15-00842-g008a-550.jpg?1677921939) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00842/article_deploy/html/images/pharmaceutics-15-00842-g008b-550.jpg?1677921938)

Open Access Article (/1999-4923/15/3/841/pdf?version=1677899098)

Terbinafine Nanohybrid: Proposing a Hydrogel Carrying Nanoparticles for Topical Release (/1999-4923/15/3/841)

by Louise Lacalendola Tundisi (https://sciprofiles.com/profile/980218), Janaína Artem Ataide (https://sciprofiles.com/profile/792705), Jéssica Heline Lopes da Fonseca (https://sciprofiles.com/profile/2454142), Luiza Aparecida Luna Silvério (https://sciprofiles.com/profile/2776208), Marcelo Lancellotti (https://sciprofiles.com/profile/2708279), Ana Cláudia Paiva-Santos (https://sciprofiles.com/profile/713309), Marcos Akira d'Ávila (https://sciprofiles.com/profile/2472609), Daniel S. Kohane (https://sciprofiles.com/profile/author/UVczcVl6SUZDKzBHUTFrcXUwZUVoYmtHK0RUU0VtQTJvaDlhYXJxSjB5R2Q4RXY0aE50TG9OYW42dzZDZmozdQ==) and Priscila Gava Mazzola (https://sciprofiles.com/profile/803558)

Pharmaceutics **2023**, *15*(3), 841; https://doi.org/10.3390/pharmaceutics15030841 (https://doi.org/10.3390/pharmaceutics15030841) - 04 Mar 2023

Cited by 1 (/1999-4923/15/3/841#metrics) | Viewed by 1195

Abstract A poloxamer 407 (P407)—Casein hydrogel was chosen to carry polycaprolactone nanoparticles carrying terbinafine (PCL-TBH-NP). In this study, terbinafine hydrochloride (TBH) was encapsulated into polycaprolactone (PCL) nanoparticles, which were further incorporated into a poloxamer-casein hydrogel in a different addition order to evaluate the effect **[...] Read more.**

(This article belongs to the Special Issue **Novel Strategies to Enhance the Encapsulation of Bioactive Molecules (/journal/pharmaceutics/special_issues/Encapsulation_Bioactive_Molecules)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00841/article_deploy/html/images/pharmaceutics-15-00841-ag-550.jpg?1677899198) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00841/article_deploy/html/images/pharmaceutics-15-00841-g001-550.jpg?1677899181) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00841/article_deploy/html/images/pharmaceutics-15-00841-g002-550.jpg?1677899189) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00841/article_deploy/html/images/pharmaceutics-15-00841-g003-550.jpg?1677899197) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00841/article_deploy/html/images/pharmaceutics-15-00841-g004-550.jpg?1677899182) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00841/article_deploy/html/images/pharmaceutics-15-00841-g005-550.jpg?1677899192) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00841/article_deploy/html/images/pharmaceutics-15-00841-g006-550.jpg?1677899196) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00841/article_deploy/html/images/pharmaceutics-15-00841-g007-550.jpg?1677899194) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00841/article_deploy/html/images/pharmaceutics-15-00841-g008-550.jpg?1677899183) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00841/article_deploy/html/images/pharmaceutics-15-00841-g009-550.jpg?1677899184)

Open Access Review (/1999-4923/15/3/840/pdf?version=1677896176)

Prevalence, Risk, and Challenges of Extemporaneous Preparation for Pediatric Patients in Developing Nations: A Review (/1999-4923/15/3/840)

by Sri Hartati Yuliani (https://sciprofiles.com/profile/2431230), Dina Christin Ayuning Putri (https://sciprofiles.com/profile/author/QXVMcUNMQkF1eGh1VHF5MytoM3hROXFRTFp2ZDlxeXFvSTI5UGtHdzVxaz0=),

Back to TopTop

Dita Maria Virginia (https://sciprofiles.com/profile/author/ajlCcnVuMlVNbmFLbEoxT3JPOUMrWmM3WG9YYkowY2JvbXhyZEpyOGpLOD0=), Michael Raharja Gani (https://sciprofiles.com/profile/author/Y085WXR1NGM1dld0MDQwK0VMcVlsUTlaUlB5ZUdacWpMK0JPSzd3eEZqND0=) and Florentinus Dika Octa Riswanto (https://sciprofiles.com/profile/315062)

Pharmaceutics **2023**, *15*(3), 840; https://doi.org/10.3390/pharmaceutics15030840 (https://doi.org/10.3390/pharmaceutics15030840) - 07 Mar 2023
Cited by 1 (/1999-4923/15/3/840#metrics) | Viewed by 2023

Abstract Extemporaneous preparations are still widely prescribed for pediatric patients with special treatments of certain doses and/or combinations of drugs. Several problems related to extemporaneous preparations have been linked to the incidence of adverse events or a lack of therapeutic effectiveness. Developing nations are **[...] Read more.**
(This article belongs to the Special Issue **Pharmacy Compounding of Personalized Preparation for Specific Patients: Challenges and Advantages (/journal/pharmaceutics/special_issues/0LMCZPN945)**)

Open Access Review (/1999-4923/15/3/839/pdf?version=1677866065)

Development of Small Molecules Targeting α-Synuclein Aggregation: A Promising Strategy to Treat Parkinson's Disease (/1999-4923/15/3/839)

by Samuel Peña-Díaz (https://sciprofiles.com/profile/2748938), Javier García-Pardo (https://sciprofiles.com/profile/374515) and Salvador Ventura (https://sciprofiles.com/profile/469960)

Pharmaceutics **2023**, *15*(3), 839; https://doi.org/10.3390/pharmaceutics15030839 (https://doi.org/10.3390/pharmaceutics15030839) - 03 Mar 2023
Cited by 4 (/1999-4923/15/3/839#metrics) | Viewed by 2598

Abstract Parkinson's disease, the second most common neurodegenerative disorder worldwide, is characterized by the accumulation of protein deposits in the dopaminergic neurons. These deposits are primarily composed of aggregated forms of α-Synuclein (α-Syn). Despite the extensive research on this disease, only symptomatic treatments are **[...] Read more.**
(This article belongs to the Special Issue **Novel Therapeutic Approaches for Neurodegenerative Diseases Treatment (/journal/pharmaceutics/special_issues/neuro_treat)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00839/article_deploy/html/images/pharmaceutics-15-00839-g001-550.jpg?1677861228) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00839/article_deploy/html/images/pharmaceutics-15-00839-g002-550.jpg?1677861231) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00839/article_deploy/html/images/pharmaceutics-15-00839-g003-550.jpg?1677861229) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00839/article_deploy/html/images/pharmaceutics-15-00839-g004-550.jpg?1677861229) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00839/article_deploy/html/images/pharmaceutics-15-00839-g005-550.jpg?1677861227) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00839/article_deploy/html/images/pharmaceutics-15-00839-g006-550.jpg?1677861230) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00839/article_deploy/html/images/pharmaceutics-15-00839-g007-550.jpg?1677861227)

Open Access Article (/1999-4923/15/3/838/pdf?version=1678156491)

Application of Minimal Physiologically-Based Pharmacokinetic Model to Simulate Lung and Trachea Exposure of Pyronaridine and Artesunate in Hamsters (/1999-4923/15/3/838)

by Dong Wook Kang (https://sciprofiles.com/profile/author/VXlwTTZFZGdhQytCOXdDMDFXMnBmUDNyWSt2MnEvRjF4aFcwQ1hBZmttcz0=), Kyung Min Kim (https://sciprofiles.com/profile/author/bVdUZ0RoMG1SV2pad3ZDWis4RGJySUh4UmU2WXBleWFMMWROOGZpaElOND0=), Ju Hee Kim (https://sciprofiles.com/profile/author/ZUI4Z1ZmQ09pbTduNXF1ZzJwdXdqWVl4aDdpTnBMWThpVVF1VTFYMmpWVT0=) and Hea-Young Cho (https://sciprofiles.com/profile/395998)

Pharmaceutics **2023**, *15*(3), 838; https://doi.org/10.3390/pharmaceutics15030838 (https://doi.org/10.3390/pharmaceutics15030838) - 03 Mar 2023
Viewed by 1987

Abstract A fixed-dose combination of pyronaridine and artesunate, one of the artemisinin-based combination therapies, has been used as a potent antimalarial treatment regimen. Recently, several studies have reported the antiviral effects of both drugs against severe acute respiratory syndrome coronavirus two (SARS-CoV-2). However, there **[...] Read more.**
(This article belongs to the Special Issue **Approaches to Individualized Drug Therapy Based on Population Pharmacometrics (/journal/pharmaceutics/special_issues/3BWA61U074)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00838/article_deploy/html/images/pharmaceutics-15-00838-g001-550.jpg?1678156566) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00838/article_deploy/html/images/pharmaceutics-15-00838-g002-550.jpg?1678156562) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00838/article_deploy/html/images/pharmaceutics-15-00838-g003-550.jpg?1678156567) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00838/article_deploy/html/images/pharmaceutics-15-00838-g004-550.jpg?1678156570) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00838/article_deploy/html/images/pharmaceutics-15-00838-g005-550.jpg?1678156561) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00838/article_deploy/html/images/pharmaceutics-15-00838-g006-550.jpg?1678156563) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00838/article_deploy/html/images/pharmaceutics-15-00838-g007-550.jpg?1678156569)

Open Access Review (/1999-4923/15/3/837/pdf?version=1677858546)

Nanocarriers for the Delivery of Neuroprotective Agents in the Treatment of Ocular Neurodegenerative Diseases (/1999-4923/15/3/837)

by Chirag Patel (https://sciprofiles.com/profile/2457841), Sonal Pande (https://sciprofiles.com/profile/1704725), Vrunda Sagathia (https://sciprofiles.com/profile/author/MjJiTHUzcGFaYnlEOUlxUzlxVUswdXQyd3A2SG5pK3RkWVorTE1QZ0UyTT0=), Ketan Ranch (https://sciprofiles.com/profile/1748842), Jayesh Beladiya (https://sciprofiles.com/profile/author/Vk5BWThza0NYWE5kSUdUSnN1ZXp6ZUVQM1pNMTVyaUgvSTZBUjBNT0dWQT0=), Sai H. S. Boddu (https://sciprofiles.com/profile/521759), Shery Jacob (https://sciprofiles.com/profile/2037042), Moawia M. Al-Tabakha (https://sciprofiles.com/profile/1473215), Nageeb Hassan (https://sciprofiles.com/profile/2907942) and Moyad Shahwan (https://sciprofiles.com/profile/author/Z25Cc091bU9pOUd4WlhrZVlySEZyb1lXSEF6OEs5NjNiZ3FvUjQ3d0Vpcz0=)

Pharmaceutics **2023**, *15*(3), 837; https://doi.org/10.3390/pharmaceutics15030837 (https://doi.org/10.3390/pharmaceutics15030837) - 03 Mar 2023
Viewed by 1765

Abstract Retinal neurodegeneration is considered an early event in the pathogenesis of several ocular diseases, such as diabetic retinopathy, age-related macular degeneration, and glaucoma. At present, there is no definitive treatment to prevent the progression or reversal of vision loss caused by photoreceptor degeneration **[...] Read more.**
(This article belongs to the Special Issue **Novel Ophthalmic Nanomedicine-Based Delivery (/journal/pharmaceutics/special_issues/4CO725IN34)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00837/article_deploy/html/images/pharmaceutics-15-00837-ag-550.jpg?1678245626) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00837/article_deploy/html/images/pharmaceutics-15-00837-g001-550.jpg?1677858615) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00837/article_deploy/html/images/pharmaceutics-15-00837-g002-550.jpg?1677858621) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00837/article_deploy/html/images/pharmaceutics-15-00837-g003-550.jpg?1677858623) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00837/article_deploy/html/images/pharmaceutics-15-00837-g004-550.jpg?1677858625) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00837/article_deploy/html/images/pharmaceutics-15-00837-g005-550.jpg?1677858616) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00837/article_deploy/html/images/pharmaceutics-15-00837-g006-550.jpg?1677858627) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00837/article_deploy/html/images/pharmaceutics-15-00837-g007-550.jpg?1677858618)

Open Access Article (/1999-4923/15/3/836/pdf?version=1677851791)

Virtual Screening, Structural Analysis, and Formation Thermodynamics of Carbamazepine Cocrystals (/1999-4923/15/3/836)

by Artem O. Surov (https://sciprofiles.com/profile/author/Y3hhZ1pmTlVodDAxdmpWWDlBTTdJZz09), Anna G. Ramazanova (https://sciprofiles.com/profile/2792553), Alexander P. Voronin (https://sciprofiles.com/profile/1987965), Ksenia V. Drozd (https://sciprofiles.com/profile/1599995), Andrei V. Churakov (https://sciprofiles.com/profile/1390586) and German L. Perlovich (https://sciprofiles.com/profile/1598173)

Pharmaceutics **2023**, *15*(3), 836; https://doi.org/10.3390/pharmaceutics15030836 (https://doi.org/10.3390/pharmaceutics15030836) - 03 Mar 2023
Cited by 3 (/1999-4923/15/3/836#metrics) | Viewed by 1189

Abstract In this study, the existing set of carbamazepine (CBZ) cocrystals was extended through the successful combination of the drug with the positional isomers of acetamidobenzoic acid. The structural and energetic features of the CBZ cocrystals with 3- and 4-acetamidobenzoic acids were elucidated via **[...] Read more.**
(This article belongs to the Special Issue **Drug Polymorphism and Dosage Form Design (Volume II) (/journal/pharmaceutics/special_issues/8C878W2OJH)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00836/article_deploy/html/images/pharmaceutics-15-00836-g001-550.jpg?1677851861) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00836/article_deploy/html/images/pharmaceutics-15-00836-g002-550.jpg?1677851862) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00836/article_deploy/html/images/pharmaceutics-15-00836-g003-550.jpg?1677851868) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00836/article_deploy/html/images/pharmaceutics-15-00836-g004-550.jpg?1677851867) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-

15-00836/article_deploy/html/images/pharmaceutics-15-00836-g005-550.jpg?1677851863)

Open Access Article (/1999-4923/15/3/835/pdf?version=1678244123)

Cannabimimetic *N*-Stearoylethanolamine as "Double-Edged Sword" in Anticancer Chemotherapy: Proapoptotic Effect on Tumor Cells and Suppression of Tumor Growth versus Its Bio-Protective Actions in Complex with Polymeric Carrier on General Toxicity of Doxorubicin In Vivo (/1999-4923/15/3/835)

by Rostyslav Panchuk (https://sciprofiles.com/profile/1008698),
Nadiya Skorokhyd (https://sciprofiles.com/profile/author/TUZPUHlVbWYxbXRzb244ekxzMUszUDdKNzlHSWhoTzZLWkV1d0FSSkVpbz0=),
Vira Chumak (https://sciprofiles.com/profile/author/R2tFRVFuKzZPRk1ibVRoUWdNdm0zTlNpYTg1ZE91b21yWnhUT0lwaGRiUT0=),
Liiya Lehka (https://sciprofiles.com/profile/author/SDZuckloWU9mUnhtZHlpa2tkSmczeUxYMk9CNEFGdVo0anBzcEVEc0I2UT0=),
Halyna Kosiakova (https://sciprofiles.com/profile/author/blZ5c3ViMlZaYWFmWEVlczNqb1BWMXVXaURPZmpFZUtEZ3dXUFkvSHp4Yz0=),
Tetyana Horid'ko (https://sciprofiles.com/profile/author/cm1TQlJVL0dQeXZ5MDE1Q1V2WEZSdz09),
Iehor Hudz (https://sciprofiles.com/profile/author/NHIlbjk1bW0vVjkrUWsyazgrY0M2c2FJVW5jaUVKOXcrM0wxSERKK0hKTT0=),
Nadiya Hula (https://sciprofiles.com/profile/author/M2lVQWFEaDA0ZHlFdFpzek9XSUYwcElIVDZCZnNWMk14Kzg5L3hmQlN2WT0=),
Anna Riabtseva (https://sciprofiles.com/profile/author/RnFkVHQ1YmRlcVZ4VFV5QjJoMS9wNG5mcFhOYUhkTlNoVE9Td2psdHhaVT0=),
Nataliya Mitina (https://sciprofiles.com/profile/1533241), Alexander Zaichenko (https://sciprofiles.com/profile/956882),
Petra Heffeter (https://sciprofiles.com/profile/2015945), Walter Berger (https://sciprofiles.com/profile/267698) and
Rostyslav Stoika (https://sciprofiles.com/profile/1949844)

Pharmaceutics **2023**, *15*(3), 835; https://doi.org/10.3390/pharmaceutics15030835 (https://doi.org/10.3390/pharmaceutics15030835) - 03 Mar 2023
Viewed by 870

Abstract This study reports a dose-dependent pro-apoptotic action of synthetic cannabimimetic *N*-stearoylethanolamine (NSE) on diverse cancer cell lines, including multidrug-resistant models. No antioxidant or cytoprotective effects of NSE were found when it was applied together with doxorubicin. A complex of NSE with the **[...] Read more.**
(This article belongs to the Special Issue **Polymeric Nanoparticles for Cancer Therapy and Biomedical-Related Application (/journal/pharmaceutics/special_issues/biomedical_cancer)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00835/article_deploy/html/images/pharmaceutics-15-00835-g001-550.jpg?1678244212) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00835/article_deploy/html/images/pharmaceutics-15-00835-g002-550.jpg?1678244201) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00835/article_deploy/html/images/pharmaceutics-15-00835-g003-550.jpg?1678244216) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00835/article_deploy/html/images/pharmaceutics-15-00835-g004-550.jpg?1678244202) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00835/article_deploy/html/images/pharmaceutics-15-00835-g005-550.jpg?1678244217) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00835/article_deploy/html/images/pharmaceutics-15-00835-g006-550.jpg?1678244207) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00835/article_deploy/html/images/pharmaceutics-15-00835-g007-550.jpg?1678244214) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00835/article_deploy/html/images/pharmaceutics-15-00835-g008-550.jpg?1678244213) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00835/article_deploy/html/images/pharmaceutics-15-00835-g009-550.jpg?1678244200) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00835/article_deploy/html/images/pharmaceutics-15-00835-g010-550.jpg?1678244208) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00835/article_deploy/html/images/pharmaceutics-15-00835-g011-550.jpg?1678244211) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00835/article_deploy/html/images/pharmaceutics-15-00835-g012-550.jpg?1678244204)

Open Access Article (/1999-4923/15/3/834/pdf?version=1677839724)

Anionic and Ampholytic High-Amylose Starch Derivatives as Excipients for Pharmaceutical and Biopharmaceutical Applications: Structure-Properties Correlations (/1999-4923/15/3/834)

by Marc-André Labelle (https://sciprofiles.com/profile/2675488), Pompilia Ispas-Szabo (https://sciprofiles.com/profile/697165),
Salma Tajer (https://sciprofiles.com/profile/2778954),
Yong Xiao (https://sciprofiles.com/profile/author/SmJNWmlSRjVoRHdseXRZZktvV0lLd0NXT3lOSFpRK1d3SlI3bkF3bkMwYz0=),
Benoît Barbeau (https://sciprofiles.com/profile/8808) and Mircea Alexandru Mateescu (https://sciprofiles.com/profile/693045)

Pharmaceutics **2023**, *15*(3), 834; https://doi.org/10.3390/pharmaceutics15030834 (https://doi.org/10.3390/pharmaceutics15030834) - 03 Mar 2023
Cited by 1 (/1999-4923/15/3/834#metrics) | Viewed by 848

Abstract Many chemical modifications of starch are realized in organic (mostly methanol) phase, allowing high degrees of substitution (DS). Some of these materials are used as disintegrants. To expand the usage of starch derivative biopolymers as drug delivery system, various starch derivatives obtained in **[...] Read more.**
(This article belongs to the Special Issue **Major Contribution of Natural Polymers for Biological Applications in the Last 10 Years: Toward Tailor-Made Biotechnologies (/journal/pharmaceutics/special_issues/O0V9A68M7L)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00834/article_deploy/html/images/pharmaceutics-15-00834-ag-550.jpg?1677839809) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00834/article_deploy/html/images/pharmaceutics-15-00834-g001-550.jpg?1677839792) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00834/article_deploy/html/images/pharmaceutics-15-00834-g002-550.jpg?1677839803) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00834/article_deploy/html/images/pharmaceutics-15-00834-g003-550.jpg?1677839805) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00834/article_deploy/html/images/pharmaceutics-15-00834-g004-550.jpg?1677839797) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00834/article_deploy/html/images/pharmaceutics-15-00834-g005-550.jpg?1677839801) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00834/article_deploy/html/images/pharmaceutics-15-00834-g006-550.jpg?1677839807) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00834/article_deploy/html/images/pharmaceutics-15-00834-g007-550.jpg?1677839801)

Open Access Article (/1999-4923/15/3/833/pdf?version=1677838995)

Targeted Two-Step Delivery of Oncotheranostic Nano-PLGA for HER2-Positive Tumor Imaging and Therapy In Vivo: Improved Effectiveness Compared to One-Step Strategy (/1999-4923/15/3/833)

by Victoria O. Shipunova (https://sciprofiles.com/profile/1048196),
Elena N. Komedchikova (https://sciprofiles.com/profile/author/VEphRmNTWnhlMDVrekxDL0lOdytZSTE4L2JkUjF1eTBHTndjMEIDNnZHRT0=),
Polina A. Kotelnikova (https://sciprofiles.com/profile/1831674), Maxim P. Nikitin (https://sciprofiles.com/profile/2514121) and
Sergey M. Deyev (https://sciprofiles.com/profile/1070920)

Pharmaceutics **2023**, *15*(3), 833; https://doi.org/10.3390/pharmaceutics15030833 (https://doi.org/10.3390/pharmaceutics15030833) - 03 Mar 2023
Cited by 3 (/1999-4923/15/3/833#metrics) | Viewed by 1185

Abstract Therapy for aggressive metastatic breast cancer remains a great challenge for modern biomedicine. Biocompatible polymer nanoparticles have been successfully used in clinic and are seen as a potential solution. Specifically, researchers are exploring the development of chemotherapeutic nanoagents targeting the membrane-associated receptors of **[...] Read more.**
(This article belongs to the Special Issue **PLGA Nanoparticles for Drug Delivery (/journal/pharmaceutics/special_issues/9884LKGU9O)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00833/article_deploy/html/images/pharmaceutics-15-00833-g001-550.jpg?1677839068) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00833/article_deploy/html/images/pharmaceutics-15-00833-g002-550.jpg?1677839066) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00833/article_deploy/html/images/pharmaceutics-15-00833-g003-550.jpg?1677839072) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00833/article_deploy/html/images/pharmaceutics-15-00833-g004-550.jpg?1677839064) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00833/article_deploy/html/images/pharmaceutics-15-00833-g005-550.jpg?1677839070) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00833/article_deploy/html/images/pharmaceutics-15-00833-g006-550.jpg?1677839072) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00833/article_deploy/html/images/pharmaceutics-15-00833-g007-550.jpg?1677839060) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00833/article_deploy/html/images/pharmaceutics-15-00833-g008-550.jpg?1677839061)

Open Access Article (/1999-4923/15/3/832/pdf?version=1677837913)

Layer-by-Layer Hollow Mesoporous Silica Nanoparticles with Tunable Degradation Profile (/1999-4923/15/3/832)

by Jason William Grunberger (https://sciprofiles.com/profile/2097017) and Hamidreza Ghandehari (https://sciprofiles.com/profile/1384437)

Pharmaceutics **2023**, *15*(3), 832; https://doi.org/10.3390/pharmaceutics15030832 (https://doi.org/10.3390/pharmaceutics15030832) - 03 Mar 2023
Cited by 2 (/1999-4923/15/3/832#metrics) | Viewed by 1066

Abstract Silica nanoparticles (SNPs) have shown promise in biomedical applications such as drug delivery and imaging due to their versatile synthetic methods, tunable physicochemical properties, and ability to load both hydrophilic and hydrophobic cargo with high efficiency. To improve the utility of these nanostructures, **[...] Read more.**
(This article belongs to the Special Issue **Mesoporous Silica Nanoparticles: Smart Delivery Platform (/journal/pharmaceutics/special_issues/silica_delivery)**)

► Show Figures

Back to TopTop

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00832/article_deploy/html/images/pharmaceutics-15-00832-ag-550.jpg?1677838000) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00832/article_deploy/html/images/pharmaceutics-15-00832-g001-550.jpg?1677837984) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00832/article_deploy/html/images/pharmaceutics-15-00832-g002-550.jpg?1677837986) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00832/article_deploy/html/images/pharmaceutics-15-00832-g003-550.jpg?1677837995) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00832/article_deploy/html/images/pharmaceutics-15-00832-g004-550.jpg?1677837988) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00832/article_deploy/html/images/pharmaceutics-15-00832-g005-550.jpg?1677837991) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00832/article_deploy/html/images/pharmaceutics-15-00832-g006-550.jpg?1677838000) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00832/article_deploy/html/images/pharmaceutics-15-00832-sch001-550.jpg?1677837994) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00832/article_deploy/html/images/pharmaceutics-15-00832-sch002-550.jpg?1677837990)

Open Access Review (/1999-4923/15/3/831/pdf?version=1677836921)

Solid Lipid Nanoparticles: Multitasking Nano-Carriers for Cancer Treatment (/1999-4923/15/3/831)

by Júlia German-Cortés (https://sciprofiles.com/profile/2812980), Mireia Vilar-Hernández (https://sciprofiles.com/profile/2816527), Diana Rafael (https://sciprofiles.com/profile/980062), Ibane Abasolo (https://sciprofiles.com/profile/980585) and Fernanda Andrade (https://sciprofiles.com/profile/2751140)

Pharmaceutics **2023**, *15*(3), 831; https://doi.org/10.3390/pharmaceutics15030831 (https://doi.org/10.3390/pharmaceutics15030831) - 03 Mar 2023

Cited by 3 (/1999-4923/15/3/831#metrics) | Viewed by 1762

Abstract Despite all the advances seen in recent years, the severe adverse effects and low specificity of conventional chemotherapy are still challenging problems regarding cancer treatment. Nanotechnology has helped to address these questions, making important contributions in the oncological field. The use of nanoparticles **[...] Read more.**

(This article belongs to the Special Issue **Nanoparticles and Hydrogels as Drug Delivery Systems for the Treatment of Challenging Diseases (/journal/pharmaceutics/special_issues/nanoparticles_hydrogels_delivery)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00831/article_deploy/html/images/pharmaceutics-15-00831-g001-550.jpg?1677836995) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00831/article_deploy/html/images/pharmaceutics-15-00831-g002-550.jpg?1677836993) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00831/article_deploy/html/images/pharmaceutics-15-00831-g003-550.jpg?1677836991) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00831/article_deploy/html/images/pharmaceutics-15-00831-g004-550.jpg?1677836990)

Open Access Review (/1999-4923/15/3/830/pdf?version=1677834163)

Polymeric Gel Systems Cytotoxicity and Drug Release as Key Features for their Effective Application in Various Fields of Addressed Pharmaceuticals Delivery (/1999-4923/15/3/830)

by Veronika Smagina (https://sciprofiles.com/profile/author/d04zeEpZVlZEUzJYSFV2TWVmdXFNRTNud0ZlV2wyazFkM2pNUE9abjdsRT0=), Pavel Yudaev (https://sciprofiles.com/profile/2076701), Andrey Kuskov (https://sciprofiles.com/profile/1007217) and Evgeniy Chistyakov (https://sciprofiles.com/profile/733829)

Pharmaceutics **2023**, *15*(3), 830; https://doi.org/10.3390/pharmaceutics15030830 (https://doi.org/10.3390/pharmaceutics15030830) - 03 Mar 2023

Cited by 3 (/1999-4923/15/3/830#metrics) | Viewed by 1799

Abstract Modified polymeric gels, including nanogels, which play not only the role of a bioinert matrix, but also perform regulatory, catalytic, and transport functions due to the active fragments introduced into them, can significantly advance the solution to the problem of targeted drug delivery **[...] Read more.**

(This article belongs to the Special Issue **Nanotechnology-Based Drug Delivery Systems (/journal/pharmaceutics/special_issues/nano_drug_deliv)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00830/article_deploy/html/images/pharmaceutics-15-00830-ag-550.jpg?1677834241) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00830/article_deploy/html/images/pharmaceutics-15-00830-g001-550.jpg?1677834228) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00830/article_deploy/html/images/pharmaceutics-15-00830-g002-550.jpg?1677834230) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00830/article_deploy/html/images/pharmaceutics-15-00830-g003-550.jpg?1677834231) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00830/article_deploy/html/images/pharmaceutics-15-00830-g004-550.jpg?1677834227) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00830/article_deploy/html/images/pharmaceutics-15-00830-g005-550.jpg?1677834229)

Open Access Article (/1999-4923/15/3/829/pdf?version=1677829901)

Chitosan-Based Nanoparticles for Targeted Nasal Galantamine Delivery as a Promising Tool in Alzheimer's Disease Therapy (/1999-4923/15/3/829)

by Dilyana Georgieva (https://sciprofiles.com/profile/2754620), Denitsa Nikolova (https://sciprofiles.com/profile/2670812), Elena Vassileva (https://sciprofiles.com/profile/2169634) and Bistra Kostova (https://sciprofiles.com/profile/2752943)

Pharmaceutics **2023**, *15*(3), 829; https://doi.org/10.3390/pharmaceutics15030829 (https://doi.org/10.3390/pharmaceutics15030829) - 03 Mar 2023

Cited by 1 (/1999-4923/15/3/829#metrics) | Viewed by 1125

Abstract Natural alkaloid galantamine is widely used for the treatment of mild to moderate Alzheimer's dementia. Galantamine hydrobromide (GH) is available as fast-release tablets, extended-release capsules, and oral solutions. However, its oral delivery can cause some unwanted side effects, such as gastrointestinal disturbances, nausea, **[...] Read more.**

(This article belongs to the Special Issue **Advances and Challenges in Nasal Formulation Developments (/journal/pharmaceutics/special_issues/nasal_formulation)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00829/article_deploy/html/images/pharmaceutics-15-00829-g001-550.jpg?1677829967) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00829/article_deploy/html/images/pharmaceutics-15-00829-g002-550.jpg?1677829971) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00829/article_deploy/html/images/pharmaceutics-15-00829-g003-550.jpg?1677829969) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00829/article_deploy/html/images/pharmaceutics-15-00829-g004-550.jpg?1677829970) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00829/article_deploy/html/images/pharmaceutics-15-00829-g005-550.jpg?1677829972)

Open Access Article (/1999-4923/15/3/828/pdf?version=1677832374)

Bioluminescence Imaging and ICP-MS Associated with SPION as a Tool for Hematopoietic Stem and Progenitor Cells Homing and Engraftment Evaluation (/1999-4923/15/3/828)

by Murilo M. Garrigós (https://sciprofiles.com/profile/2708068), Fernando A. Oliveira (https://sciprofiles.com/profile/1040708), Mariana P. Nucci (https://sciprofiles.com/profile/1212897), Javier B. Mamani (https://sciprofiles.com/profile/2465671), Olivia F. M. Dias (https://sciprofiles.com/profile/author/dGZBaWNncGNscUFldEg5TWdSVXdNRnlweWY5MXR6YjBFMWMyYmQ4WUhKbz0=), Gabriel N. A. Rego (https://sciprofiles.com/profile/author/MWlybDVKRTNSK1NrM0Z6UkExTzkyR01hRGY1Q0RNQndCTll5TDJRUVY1bz0=), Mara S. Junqueira (https://sciprofiles.com/profile/author/V2lTaXc2UUlGQzVwVk1tcm9lem9BZ3VPTi9wRzVSUDV5T0xMT0F2YnJmZz0=), Cícero J. S. Costa (https://sciprofiles.com/profile/author/S3NZYnlyWlEvaHZsWHZoYmtMdEIjeWYvN2tyQmlXUFB5bTBmRnlpN2Q5ST0=), Lucas R. R. Silva (https://sciprofiles.com/profile/author/Zy9uaWFLSnhsSS9XL0JqdmRLbDBCTDdBWmJzdE0rb3hvRm1DMGVMbmZWMD0=), Arielly H. Alves (https://sciprofiles.com/profile/1224095), Nicole M. E. Valle (https://sciprofiles.com/profile/2044928), Luciana Marti (https://sciprofiles.com/profile/952913) and Lionel F. Gamarra (https://sciprofiles.com/profile/656445)

Pharmaceutics **2023**, *15*(3), 828; https://doi.org/10.3390/pharmaceutics15030828 (https://doi.org/10.3390/pharmaceutics15030828) - 03 Mar 2023

Viewed by 1056

Abstract Bone marrow transplantation is a treatment for a variety of hematological and non-hematological diseases. For the transplant success, it is mandatory to have a thriving engraftment of transplanted cells, which directly depends on their homing. The present study proposes an alternative method to **[...] Read more.**

(This article belongs to the Special Issue **Nanotechnological Strategies for Biomedical and Pharmaceutical Applications (/journal/pharmaceutics/special_issues/Y63VTPC387)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00828/article_deploy/html/images/pharmaceutics-15-00828-g001-550.jpg?1677832452) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00828/article_deploy/html/images/pharmaceutics-15-00828-g002-550.jpg?1677832442) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00828/article_deploy/html/images/pharmaceutics-15-00828-g003-550.jpg?1677832441) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00828/article_deploy/html/images/pharmaceutics-15-00828-g004-550.jpg?1677832449) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00828/article_deploy/html/images/pharmaceutics-15-00828-g005-550.jpg?1677832446)

Open Access Editorial (/1999-4923/15/3/827/pdf?version=1677823394)

Chemically Enhanced Peptide and Protein Therapeutics (/1999-4923/15/3/827)

by Cristina Díaz-Perlas (https://sciprofiles.com/profile/2780314) and Benjamí Oller-Salvia (https://sciprofiles.com/profile/1551093)

Pharmaceutics **2023**, *15*(3), 827; https://doi.org/10.3390/pharmaceutics15030827 (https://doi.org/10.3390/pharmaceutics15030827) - 03 Mar 2023

Back to TopTop

Open Access Article (/1999-4923/15/3/826/pdf?version=1677823235)

Development of the First ^{18}F-Labeled Radiohybrid-Based Minigastrin Derivative with High Target Affinity and Tumor Accumulation by Substitution of the Chelating Moiety (/1999-4923/15/3/826)

by Thomas Günther (https://sciprofiles.com/profile/2360466), Nadine Holzleitner (https://sciprofiles.com/profile/2569498), Daniel Di Carlo (https://sciprofiles.com/profile/author/MkRRZGF5WHJvYUJrd2U0dzVWbmFweEdKVXBUWkZDMVNVb2tmSkx0QVRoTT0=), Nicole Urtz-Urban (https://sciprofiles.com/profile/author/MHI1b091T2cxUi9EY2hZa0JOS21zRHBvK050MWRFbDVveGZQSVE2bnp5UT0=), Constantin Lapa (https://sciprofiles.com/profile/501191) and Hans-Jürgen Wester (https://sciprofiles.com/profile/author/MDJlVzlQbHB5WEtKU2tZYkJjWk5ybFRuUEpTK3krOG1sbTFPN3FROEMxYz0=)
Pharmaceutics **2023**, *15*(3), 826; https://doi.org/10.3390/pharmaceutics15030826 (https://doi.org/10.3390/pharmaceutics15030826) - 03 Mar 2023
Cited by 1 (/1999-4923/15/3/826#metrics) | Viewed by 905

Abstract In order to optimize elevated kidney retention of previously reported minigastrin derivatives, we substituted (*R*)-DOTAGA by DOTA in (*R*)-DOTAGA-rhCCK-16/-18. CCK-2R-mediated internalization and affinity of the new compounds were determined using AR42J cells. Biodistribution and *μ*SPECT/CT imaging studies at **[...] Read more.**

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00826/article_deploy/html/images/pharmaceutics-15-00826-g001-550.jpg?1677823307) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00826/article_deploy/html/images/pharmaceutics-15-00826-g002-550.jpg?1677823304) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00826/article_deploy/html/images/pharmaceutics-15-00826-g003-550.jpg?1677823303) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00826/article_deploy/html/images/pharmaceutics-15-00826-g004-550.jpg?1677823305) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00826/article_deploy/html/images/pharmaceutics-15-00826-g005-550.jpg?1677823309)

Open Access Article (/1999-4923/15/3/825/pdf?version=1677770242)

CuMV VLPs Containing the RBM from SARS-CoV-2 Spike Protein Drive Dendritic Cell Activation and Th1 Polarization (/1999-4923/15/3/825)

by Ana Isabel Sebastião (https://sciprofiles.com/profile/2759604), Daniela Mateus (https://sciprofiles.com/profile/2760591), Mylène A. Carrascal (https://sciprofiles.com/profile/658547), Cátia Sousa (https://sciprofiles.com/profile/author/QlUvREpHMUhSUGoyQUVKa1VvUzZxaVZNVlhmOGdGQjN4anovZHo0Qll1VT0=), Luísa Cortes (https://sciprofiles.com/profile/940531), Martin F. Bachmann (https://sciprofiles.com/profile/712849), Anália do Carmo (https://sciprofiles.com/profile/author/a1JJSXphMnU4VHhOTHAzQ2hoenNxWENuemxYV24yd2huK041WXUzS0Jtcz0=), Ana Miguel Matos (https://sciprofiles.com/profile/585722), Maria Goreti F. Sales (https://sciprofiles.com/profile/826970) and Maria Teresa Cruz (https://sciprofiles.com/profile/658545)
Pharmaceutics **2023**, *15*(3), 825; https://doi.org/10.3390/pharmaceutics15030825 (https://doi.org/10.3390/pharmaceutics15030825) - 02 Mar 2023
Viewed by 984

Abstract Dendritic cells (DCs) are the most specialized and proficient antigen-presenting cells. They bridge innate and adaptive immunity and display a powerful capacity to prime antigen-specific T cells. The interaction of DCs with the receptor-binding domain of the spike (S) protein from the severe **[...] Read more.**
(This article belongs to the Section Biopharmaceutics (/journal/pharmaceutics/sections/Biopharmaceutics))

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00825/article_deploy/html/images/pharmaceutics-15-00825-g001-550.jpg?1677770325) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00825/article_deploy/html/images/pharmaceutics-15-00825-g002a-550.jpg?1677770329) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00825/article_deploy/html/images/pharmaceutics-15-00825-g002b-550.jpg?1677770319) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00825/article_deploy/html/images/pharmaceutics-15-00825-g003-550.jpg?1677770332) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00825/article_deploy/html/images/pharmaceutics-15-00825-g004a-550.jpg?1677770327) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00825/article_deploy/html/images/pharmaceutics-15-00825-g004b-550.jpg?1677770321) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00825/article_deploy/html/images/pharmaceutics-15-00825-g005-550.jpg?1677770331) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00825/article_deploy/html/images/pharmaceutics-15-00825-g006-550.jpg?1677770313)

Open Access Article (/1999-4923/15/3/824/pdf?version=1677804050)

A Validated Chiral LC–MS/MS Method for the Enantioselective Determination of (S)-(+)- and (R)-(-)-Ibuprofen in Dog Plasma: Its Application to a Pharmacokinetic Study (/1999-4923/15/3/824)

by Sanghee Choi (https://sciprofiles.com/profile/1828775), Wang-Seob Shim (https://sciprofiles.com/profile/1533167), Jiyoung Yoon (https://sciprofiles.com/profile/1828772), Doowon Choi (https://sciprofiles.com/profile/2807473), Jinseong Lee (https://sciprofiles.com/profile/author/MjRkaGU5MEVBMUlFaTQ2TFQ5QjZYeWxxdUtxRXRka3hzUmFlNlA0aEd4VT0=), Soo-Heui Paik (https://sciprofiles.com/profile/2742650), Eun-Kyoung Chung (https://sciprofiles.com/profile/862742) and Kyung-Tae Lee (https://sciprofiles.com/profile/406486)
Pharmaceutics **2023**, *15*(3), 824; https://doi.org/10.3390/pharmaceutics15030824 (https://doi.org/10.3390/pharmaceutics15030824) - 02 Mar 2023
Viewed by 2851

Abstract The purpose of this study was to develop a method for simultaneously separating ibuprofen enantiomers using electrospray ionization (ESI) liquid chromatography with tandem mass spectrometry (LC–MS/MS). LC–MS/MS was operated with negative ionization and multiple reaction monitoring modes; transitions were monitored at *m/* **[...] Read more.**
(This article belongs to the Section Pharmaceutical Technology, Manufacturing and Devices (/journal/pharmaceutics/sections/Pharmaceutical_Technology_Manufacturing_Devices))

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00824/article_deploy/html/images/pharmaceutics-15-00824-g001-550.jpg?1677804125) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00824/article_deploy/html/images/pharmaceutics-15-00824-g002-550.jpg?1677804131) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00824/article_deploy/html/images/pharmaceutics-15-00824-g003-550.jpg?1677804124) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00824/article_deploy/html/images/pharmaceutics-15-00824-g004-550.jpg?1677804128)

Open Access Review (/1999-4923/15/3/823/pdf?version=1677811748)

Immunotherapy Resumption/Rechallenge in Melanoma Patients after Toxicity: Do We Have Another Chance? (/1999-4923/15/3/823)

by Sofia España Fernandez (https://sciprofiles.com/profile/2632292), Chen Sun (https://sciprofiles.com/profile/2942615), Carme Solé-Blanch (https://sciprofiles.com/profile/author/U042cVYyWkRobDJHSmdUZzU2aUVBLyt6bFBtUXgrZlpQT2JKaG5WMXZRUT0=), Aram Boada (https://sciprofiles.com/profile/2069019), Anna Martínez-Cardús (https://sciprofiles.com/profile/1073069) and José Luis Manzano (https://sciprofiles.com/profile/1805752)
Pharmaceutics **2023**, *15*(3), 823; https://doi.org/10.3390/pharmaceutics15030823 (https://doi.org/10.3390/pharmaceutics15030823) - 02 Mar 2023
Viewed by 1166

Abstract Introduction: Immune checkpoint inhibitors (ICIs) have radically changed the prognosis of several neoplasias, among them metastatic melanoma. In the past decade, some of these new drugs have appeared together with a new toxicity spectrum previously unknown to clinicians, until now. A common situation **[...] Read more.**
(This article belongs to the Special Issue Drug Repurposing and Delivery Systems for Immunotherapy (/journal/pharmaceutics/special_issues/Delivery_Immunotherapy))

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00823/article_deploy/html/images/pharmaceutics-15-00823-g001-550.jpg?1677811811)

Open Access Article (/1999-4923/15/3/822/pdf?version=1677832617)

Polydopamine-Coated Cu-BTC Nanowires for Effective Magnetic Resonance Imaging and Photothermal Therapy (/1999-4923/15/3/822)

by Senthilkumar Thirumurugan (https://sciprofiles.com/profile/2621393), Kayalvizhi Samuvel Muthiah (https://sciprofiles.com/profile/author/M0tEV1U3aVpyTEhlb1AvaEM1S3Z5dHVnQmQ3VWNJblBrdVRpRlVndGxRQT0=), Rajalakshmi Sakthivel (https://sciprofiles.com/profile/1216239), Mei-Yi Liao (https://sciprofiles.com/profile/1086360), Hitoshi Kasai (https://sciprofiles.com/profile/2525185) and Ren-Jei Chung (https://sciprofiles.com/profile/62323)
Pharmaceutics **2023**, *15*(3), 822; https://doi.org/10.3390/pharmaceutics15030822 (https://doi.org/10.3390/pharmaceutics15030822) - 02 Mar 2023
Cited by 2 (/1999-4923/15/3/822#metrics) | Viewed by 997

Abstract Herein, we present a one-pot hydrothermal approach for synthesizing metal–organic framework-derived copper (II) benzene-1,3,5-tricarboxylate (Cu-BTC) nanowires (NWs) using dopamine as the reducing agent and precursor for a polydopamine (PDA) surface coating formation. In addition, PDA can act as a PTT agent and enhance **[...] Read more.**
(This article belongs to the Special Issue Nanoparticles for Imaging and Drug Delivery (/journal/pharmaceutics/special_issues/Nanoparticles_Imaging_Drug))

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00822/article_deploy/html/images/pharmaceutics-15-00822-g001-550.jpg?1677832701) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00822/article_deploy/html/images/pharmaceutics-15-00822-g002-550.jpg?1677832710) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00822/article_deploy/html/images/pharmaceutics-15-00822-g003-550.jpg?1677832696) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00822/article_deploy/html/images/pharmaceutics-15-00822-g004-550.jpg?1677832704) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00822/article_deploy/html/images/pharmaceutics-15-00822-g005-550.jpg?1677832708) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00822/article_deploy/html/images/pharmaceutics-15-00822-g006-550.jpg?1677832711) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00822/article_deploy/html/images/pharmaceutics-15-00822-g007-550.jpg?1677832693) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00822/article_deploy/html/images/pharmaceutics-15-00822-g008-550.jpg?1677832690) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00822/article_deploy/html/images/pharmaceutics-15-00822-sch001-550.jpg?1677832692)

Open Access Article (/1999-4923/15/3/821/pdf?version=1677835602)

Selenized Polymer-Lipid Hybrid Nanoparticles for Oral Delivery of Tripterine with Ameliorative Oral Anti-Enteritis Activity and Bioavailability (/1999-4923/15/3/821)

by Yuehong Ren (https://sciprofiles.com/profile/2725920), Chunli Qi (https://sciprofiles.com/profile/author/TGJkZWFQcFE1c3orcXA5eW9RdEM0K0Jtbmw2a2lwQXkwdmNNbjJDYkg3Yz0=), Shuxian Ruan (https://sciprofiles.com/profile/author/a0FrRGxqbjhPd0lmZFVKUFVGTnMzK1cxeHh6aThlK1dMckFreVlQZ3hQOD0=), Guangshang Cao (https://sciprofiles.com/profile/author/c0taY2ZVN3BRUXU4b3FMaUFBM2d5TFhhZ01FMW5LT1JoMXoyaVU1cEJOdz0=), Zhiguo Ma (https://sciprofiles.com/profile/author/MGliQzlzWHYvQ0l5N091SFdQRHN5UT09) and Xingwang Zhang (https://sciprofiles.com/profile/447326)

Pharmaceutics **2023**, *15*(3), 821; https://doi.org/10.3390/pharmaceutics15030821 (https://doi.org/10.3390/pharmaceutics15030821) - 02 Mar 2023

Cited by 1 (/1999-4923/15/3/821#metrics) | Viewed by 905

Abstract The oral delivery of insoluble and enterotoxic drugs has been largely plagued by gastrointestinal irritation, side effects, and limited bioavailability. Tripterine (Tri) ranks as the hotspot of anti-inflammatory research other than inferior water-solubility and biocompatibility. This study was intended to develop selenized polymer-lipid **[...] Read more.**

(This article belongs to the Special Issue **Novel Drug Delivery Systems of Phytomedicines** (/journal/pharmaceutics/special_issues/S0Z47J7Y1W))

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00821/article_deploy/html/images/pharmaceutics-15-00821-ag-550.jpg?1677835691) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00821/article_deploy/html/images/pharmaceutics-15-00821-g001-550.jpg?1677835691) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00821/article_deploy/html/images/pharmaceutics-15-00821-g002-550.jpg?1677835674) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00821/article_deploy/html/images/pharmaceutics-15-00821-g003-550.jpg?1677835682) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00821/article_deploy/html/images/pharmaceutics-15-00821-g004-550.jpg?1677835681) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00821/article_deploy/html/images/pharmaceutics-15-00821-g005-550.jpg?1677835685) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00821/article_deploy/html/images/pharmaceutics-15-00821-g006-550.jpg?1677835684) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00821/article_deploy/html/images/pharmaceutics-15-00821-g007-550.jpg?1677835679) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00821/article_deploy/html/images/pharmaceutics-15-00821-g008-550.jpg?1677835676) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00821/article_deploy/html/images/pharmaceutics-15-00821-g009-550.jpg?1677835689) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00821/article_deploy/html/images/pharmaceutics-15-00821-g010-550.jpg?1677835673) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00821/article_deploy/html/images/pharmaceutics-15-00821-g011-550.jpg?1677835688)

Open Access Article (/1999-4923/15/3/820/pdf?version=1677760678)

pH-Responsive and Mucoadhesive Nanoparticles for Enhanced Oral Insulin Delivery: The Effect of Hyaluronic Acid with Different Molecular Weights (/1999-4923/15/3/820)

by Shuangqing Wang (https://sciprofiles.com/profile/author/OEpaNjlza3JzSUNiUWRMS09rM2dPbDBTaWdBV2dZUnJXWndlait6OVJGbz0=), Saige Meng (https://sciprofiles.com/profile/author/VVpTMXlVQXkzUHhPQk9GS1hKUFVzYVFaZHFmTDZLdmlPdzNmdFhqTStlQT0=), Xinlei Zhou (https://sciprofiles.com/profile/author/N1JjYkhKN3RiVWlud21iUmxYWTUyMDhtTXhpZzYvQzh3bmNDS1gvdnRaRT0=), Zhonggao Gao (https://sciprofiles.com/profile/87936) and Ming Guan Piao (https://sciprofiles.com/profile/2794237)

Pharmaceutics **2023**, *15*(3), 820; https://doi.org/10.3390/pharmaceutics15030820 (https://doi.org/10.3390/pharmaceutics15030820) - 02 Mar 2023

Cited by 5 (/1999-4923/15/3/820#metrics) | Viewed by 1044

Abstract Drug degradation at low pH and rapid clearance from intestinal absorption sites are the main factors limiting the development of oral macromolecular delivery systems. Based on the pH responsiveness and mucosal adhesion of hyaluronic acid (HA) and poly[2-(dimethylamino)ethyl methacrylate] (PDM), we prepared three **[...] Read more.**

(This article belongs to the Special Issue **Polymer-Based Nanoparticles for Oral Delivery of Drugs, Bioactives and Vaccines** (/journal/pharmaceutics/special_issues/P23SQLYCPM))

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00820/article_deploy/html/images/pharmaceutics-15-00820-ag-550.jpg?1677760774) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00820/article_deploy/html/images/pharmaceutics-15-00820-g001-550.jpg?1677760766) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00820/article_deploy/html/images/pharmaceutics-15-00820-g002-550.jpg?1677760763) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00820/article_deploy/html/images/pharmaceutics-15-00820-g003-550.jpg?1677760767) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00820/article_deploy/html/images/pharmaceutics-15-00820-g004-550.jpg?1677760764) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00820/article_deploy/html/images/pharmaceutics-15-00820-g005-550.jpg?1677760761) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00820/article_deploy/html/images/pharmaceutics-15-00820-g006-550.jpg?1677760770) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00820/article_deploy/html/images/pharmaceutics-15-00820-g007-550.jpg?1677760772) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00820/article_deploy/html/images/pharmaceutics-15-00820-g008-550.jpg?1677760760) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00820/article_deploy/html/images/pharmaceutics-15-00820-g009-550.jpg?1677760774)

Open Access Article (/1999-4923/15/3/819/pdf?version=1678361407)

Composite PLGA–Nanobioceramic Coating on Moxifloxacin-Loaded Akermanite 3D Porous Scaffolds for Bone Tissue Regeneration (/1999-4923/15/3/819)

by Georgia K. Pouroutzidou (https://sciprofiles.com/profile/1741518), Lambrini Papadopoulou (https://sciprofiles.com/profile/970323), Maria Lazaridou (https://sciprofiles.com/profile/991060), Konstantinos Tsachouridis (https://sciprofiles.com/profile/2627873), Chrysanthi Papoulia (https://sciprofiles.com/profile/1755219), Dimitra Patsiaoura (https://sciprofiles.com/profile/author/cStUUkxjTDNyNlZweWc5YUczRVYxN3g4T1R1UzVQanFBWW8rVVhEUGhjaz0=), Ioannis Tsamesidis (https://sciprofiles.com/profile/1011549), Konstantinos Chrissafis (https://sciprofiles.com/profile/687599), George Vourlias (https://sciprofiles.com/profile/1168787), Konstantinos M. Paraskevopoulos (https://sciprofiles.com/profile/author/WGNhbEpFQndPVlVCajNZK2RvQ0RrQT09), Antonios D. Anastasiou (https://sciprofiles.com/profile/480920), Dimitrios N. Bikiaris (https://sciprofiles.com/profile/8950) and Eleana Kontonasaki (https://sciprofiles.com/profile/468294)

Pharmaceutics **2023**, *15*(3), 819; https://doi.org/10.3390/pharmaceutics15030819 (https://doi.org/10.3390/pharmaceutics15030819) - 02 Mar 2023

Cited by 3 (/1999-4923/15/3/819#metrics) | Viewed by 1335

Abstract Silica-based ceramics doped with calcium and magnesium have been proposed as suitable materials for scaffold fabrication. Akermanite ($Ca_2MgSi_2O_7$) has attracted interest for bone regeneration due to its controllable biodegradation rate, improved mechanical properties, and high apatite-forming ability. **[...] Read more.**

(This article belongs to the Special Issue **Sustainable Materials and Technologies for Drug Delivery and Tissue Engineering** (/journal/pharmaceutics/special_issues/Sustainable_Materials_Drug_Delivery_Tissue_Engineering))

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00819/article_deploy/html/images/pharmaceutics-15-00819-g001-550.jpg?1678361479) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00819/article_deploy/html/images/pharmaceutics-15-00819-g002-550.jpg?1678361504) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00819/article_deploy/html/images/pharmaceutics-15-00819-g003-550.jpg?1678361509) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00819/article_deploy/html/images/pharmaceutics-15-00819-g004-550.jpg?1678361498) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00819/article_deploy/html/images/pharmaceutics-15-00819-g005-550.jpg?1678361514) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00819/article_deploy/html/images/pharmaceutics-15-00819-g006-550.jpg?1678361488) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00819/article_deploy/html/images/pharmaceutics-15-00819-g007-550.jpg?1678361501) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00819/article_deploy/html/images/pharmaceutics-15-00819-g008-550.jpg?1678361488) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00819/article_deploy/html/images/pharmaceutics-15-00819-g009-550.jpg?1678361519) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00819/article_deploy/html/images/pharmaceutics-15-00819-

g010-550.jpg?1678361492) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00819/article_deploy/html/images/pharmaceutics-15-00819-g011-550.jpg?1678361499) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00819/article_deploy/html/images/pharmaceutics-15-00819-g012-550.jpg?1678361512) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00819/article_deploy/html/images/pharmaceutics-15-00819-g013-550.jpg?1678361487) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00819/article_deploy/html/images/pharmaceutics-15-00819-g014-550.jpg?1678361511) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00819/article_deploy/html/images/pharmaceutics-15-00819-g015-550.jpg?1678361503) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00819/article_deploy/html/images/pharmaceutics-15-00819-g016-550.jpg?1678361483) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00819/article_deploy/html/images/pharmaceutics-15-00819-g017-550.jpg?1678361495) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00819/article_deploy/html/images/pharmaceutics-15-00819-g018-550.jpg?1678361483) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00819/article_deploy/html/images/pharmaceutics-15-00819-g019-550.jpg?1678361481) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00819/article_deploy/html/images/pharmaceutics-15-00819-g020-550.jpg?1678361518) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00819/article_deploy/html/images/pharmaceutics-15-00819-g021-550.jpg?1678361491) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00819/article_deploy/html/images/pharmaceutics-15-00819-g022-550.jpg?1678361492) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00819/article_deploy/html/images/pharmaceutics-15-00819-g023-550.jpg?1678361505)

Open Access Article (/1999-4923/15/3/818/pdf?version=1677754553)

Paclitaxel-Loaded Lipid-Coated Magnetic Nanoparticles for Dual Chemo-Magnetic Hyperthermia Therapy of Melanoma (/1999-4923/15/3/818)

by Relton R. Oliveira (https://sciprofiles.com/profile/2806361), Emílio R. Cintra (https://sciprofiles.com/profile/author/UnY0NTlxUExkdithdllwMmtHNTMrM1hqTmVCMkVMREtMejczWmhFY0cyTT0=), Ailton A. Sousa-Junior (https://sciprofiles.com/profile/1750250), Larissa C. Moreira (https://sciprofiles.com/profile/author/dFBndFZKc3lDVVNxckQ2ZjB2b2FMS3NkV3J4SU1GSXM0bm9Uekt0Z3pjMD0=), Artur C. G. da Silva (https://sciprofiles.com/profile/author/WitVdkVHUFc2TSt6bFhVTmF0RjR1MCtjcmJwdlF6QTA3ZXErdmpNR0E3VT0=), Ana Luiza R. de Souza (https://sciprofiles.com/profile/author/NmVSRGRQa1UySkZDZUJXeCtvWXExeklreU9JYXRtYzlxRE53T2x5M3RmST0=), Marize C. Valadares (https://sciprofiles.com/profile/2641329), Marcus S. Carrião (https://sciprofiles.com/profile/2720683), Andris F. Bakuzis (https://sciprofiles.com/profile/2521761) and Eliana M. Lima (https://sciprofiles.com/profile/1626632)

Pharmaceutics **2023**, *15*(3), 818; https://doi.org/10.3390/pharmaceutics15030818 (https://doi.org/10.3390/pharmaceutics15030818) - 02 Mar 2023

Cited by 3 (/1999-4923/15/3/818#metrics) | Viewed by 1267

Abstract Melanoma is the most aggressive and metastasis-prone form of skin cancer. Conventional therapies include chemotherapeutic agents, either as small molecules or carried by FDA-approved nanostructures. However, systemic toxicity and side effects still remain as major drawbacks. With the advancement of nanomedicine, new delivery **[...] Read more.**

(This article belongs to the Special Issue **Magnetic Nanomaterials for Hyperthermia-Based Therapy, Imaging, and Drug Delivery (/journal/pharmaceutics/special_issues/2123RIR422)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00818/article_deploy/html/images/pharmaceutics-15-00818-g001-550.jpg?1677754627) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00818/article_deploy/html/images/pharmaceutics-15-00818-g002-550.jpg?1677754624) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00818/article_deploy/html/images/pharmaceutics-15-00818-g003-550.jpg?1677754620) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00818/article_deploy/html/images/pharmaceutics-15-00818-g004-550.jpg?1677754628) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00818/article_deploy/html/images/pharmaceutics-15-00818-g005-550.jpg?1677754625)

Open Access Article (/1999-4923/15/3/817/pdf?version=1677750243)

Radioimmune Imaging of $\alpha_4\beta_7$ Integrin and TNFα for Diagnostic and Therapeutic Applications in Inflammatory Bowel Disease (/1999-4923/15/3/817)

by Alberto Signore (https://sciprofiles.com/profile/616732), Rita Bonfiglio (https://sciprofiles.com/profile/1339652), Michela Varani (https://sciprofiles.com/profile/673346), Filippo Galli (https://sciprofiles.com/profile/654268), Giuseppe Campagna (https://sciprofiles.com/profile/1196027), Manuel Desco (https://sciprofiles.com/profile/1090277), Lorena Cussó (https://sciprofiles.com/profile/1257700), Maurizio Mattei (https://sciprofiles.com/profile/2572243), Andreas Wunder (https://sciprofiles.com/profile/author/bFV1RW1kVUxTTi9CN0VxM2dRSG9LRWRrRlk2NjlPT0QrbFVsak9wVEVrVDZLZ2QzTjBqVmxuM2VrMVB3MjhJVw==), Filippo Borri (https://sciprofiles.com/profile/1426378), Maria T. Lupo (https://sciprofiles.com/profile/2816558) and Elena Bonanno (https://sciprofiles.com/profile/851803)

Pharmaceutics **2023**, *15*(3), 817; https://doi.org/10.3390/pharmaceutics15030817 (https://doi.org/10.3390/pharmaceutics15030817) - 02 Mar 2023

Viewed by 932

Abstract Imaging using radiolabelled monoclonal antibodies can provide, non-invasively, molecular information which allows for the planning of the best treatment and for monitoring the therapeutic response in cancer, as well as in chronic inflammatory diseases. In the present study, our main goal was to **[...] Read more.**

(This article belongs to the Special Issue **Recent Advances in Radiopharmacy (/journal/pharmaceutics/special_issues/ra_radio)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00817/article_deploy/html/images/pharmaceutics-15-00817-g001-550.jpg?1677750317) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00817/article_deploy/html/images/pharmaceutics-15-00817-g002-550.jpg?1677750325) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00817/article_deploy/html/images/pharmaceutics-15-00817-g003-550.jpg?1677750321) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00817/article_deploy/html/images/pharmaceutics-15-00817-g004-550.jpg?1677750318) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00817/article_deploy/html/images/pharmaceutics-15-00817-g005-550.jpg?1677750323) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00817/article_deploy/html/images/pharmaceutics-15-00817-g006-550.jpg?1677750320) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00817/article_deploy/html/images/pharmaceutics-15-00817-g007-550.jpg?1677750324)

Open Access Article (/1999-4923/15/3/816/pdf?version=1677749384)

pH-Responsive Super-Porous Hybrid Hydrogels for Gastroretentive Controlled-Release Drug Delivery (/1999-4923/15/3/816)

by Ajkia Zaman Juthi (https://sciprofiles.com/profile/author/YXJiQkxpLzl2V1BvL2FoZlV4UEUxVVkyOElsUXUrbnkvekQrcnBzbHc0cz0=), Fenfen Li (https://sciprofiles.com/profile/894944), Bo Wang (https://sciprofiles.com/profile/2140998), Md Mofasserul Alam (https://sciprofiles.com/profile/2085919), Md Eman Talukder (https://sciprofiles.com/profile/author/MkZob0VBL0Q0K0VwTHIzUlNOTi9aM2tSdnZMWEE2Mi9KU3F6V2l1WFY5Zz0=) and Bensheng Qiu (https://sciprofiles.com/profile/1485691)

Pharmaceutics **2023**, *15*(3), 816; https://doi.org/10.3390/pharmaceutics15030816 (https://doi.org/10.3390/pharmaceutics15030816) - 02 Mar 2023

Viewed by 1153

Abstract Super-porous hydrogels are considered a potential drug delivery network for the sedation of gastric mechanisms with retention windows in the abdomen and upper part of the gastrointestinal tract (GIT). In this study, a novel pH-responsive super-porous hybrid hydrogels (SPHHs) was synthesized from pectin, **[...] Read more.**

(This article belongs to the Special Issue **Hydrogels in Drug Delivery: Progress and Challenges (/journal/pharmaceutics/special_issues/Hydrogel_DD)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00816/article_deploy/html/images/pharmaceutics-15-00816-ag-550.jpg?1677749464) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00816/article_deploy/html/images/pharmaceutics-15-00816-g001-550.jpg?1677749459) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00816/article_deploy/html/images/pharmaceutics-15-00816-g002-550.jpg?1677749454) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00816/article_deploy/html/images/pharmaceutics-15-00816-g003-550.jpg?1677749463) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00816/article_deploy/html/images/pharmaceutics-15-00816-g004-550.jpg?1677749462) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00816/article_deploy/html/images/pharmaceutics-15-00816-g005-550.jpg?1677749457) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00816/article_deploy/html/images/pharmaceutics-15-00816-g006-550.jpg?1677749452)

Open Access Article (/1999-4923/15/3/815/pdf?version=1677748681)

A Computational Model for the Release of Bioactive Molecules by the Hydrolytic Degradation of a Functionalized Polyester-Based Scaffold (/1999-4923/15/3/815)

by Elisa Batoni (https://sciprofiles.com/profile/2657384), Amedeo Franco Bonatti (https://sciprofiles.com/profile/1431617), Carmelo De Maria (https://sciprofiles.com/profile/594586), Kenneth Dalgarno (https://sciprofiles.com/profile/909352), Raasti Naseem (https://sciprofiles.com/profile/1401558), Umberto Dianzani (https://sciprofiles.com/profile/572852), Casimiro Luca Gigliotti (https://sciprofiles.com/profile/691301), Elena Boggio (https://sciprofiles.com/profile/363687) and Giovanni Vozzi (https://sciprofiles.com/profile/59864)

Pharmaceutics **2023**, *15*(3), 815; **https://doi.org/10.3390/pharmaceutics15030815 (https://doi.org/10.3390/pharmaceutics15030815)** - 02 Mar 2023
Cited by 1 (/1999-4923/15/3/815#metrics) | Viewed by 687

Abstract This work presents a computational model to study the degradation behavior of polyester-based three-dimensional (3D) functionalized scaffolds for bone regeneration. As a case study, we investigated the behavior of a 3D-printed scaffold presenting a functionalized surface with ICOS-Fc, a bioactive protein able to **[...] Read more.**
(This article belongs to the Special Issue **Additive Manufacturing Approaches to Produce Drug Delivery Systems Volume II (/journal/pharmaceutics/special_issues/additive_manufacturing_volume_II)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00815/article_deploy/html/images/pharmaceutics-15-00815-g001-550.jpg?1677748755) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00815/article_deploy/html/images/pharmaceutics-15-00815-g002-550.jpg?1677748750) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00815/article_deploy/html/images/pharmaceutics-15-00815-g003-550.jpg?1677748753) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00815/article_deploy/html/images/pharmaceutics-15-00815-g004-550.jpg?1677748757)

Open Access Review (/1999-4923/15/3/814/pdf?version=1677746538)

Plausible Role of Stem Cell Types for Treating and Understanding the Pathophysiology of Depression (/1999-4923/15/3/814)

by **Punya Sachdeva (https://sciprofiles.com/profile/2125066)**, **Seongmin Ji (https://sciprofiles.com/profile/1852595)**, **Shampa Ghosh (https://sciprofiles.com/profile/author/azI5U2tUeWhuZ2kvaHdWZmhpcWpGcHN5UTdLZnh4VUh1NkJZY0lwbjM0dz0=)**, **Soumya Ghosh (https://sciprofiles.com/profile/author/MlFoM1FEanJKUFRLaXpmV2licXdXMERqdlIrajdpU1k5eEl1RHZOK2tSVT0=)**, **Manchala Raghunath (https://sciprofiles.com/profile/author/VjF5KzNuRVc5b3pydUtpU3g5SUszMHI5S0NTRkp1K09uTUlwLzdvcWxFbz0=)**, **Hyunjin Kim (https://sciprofiles.com/profile/author/T1Jnanptbkx6MFc5dTdkdWdianBGQT09)**, **Rakesh Bhaskar (https://sciprofiles.com/profile/1797765)**, **Jitendra Kumar Sinha (https://sciprofiles.com/profile/293737)** and **Sung Soo Han (https://sciprofiles.com/profile/22042)**

Pharmaceutics **2023**, *15*(3), 814; **https://doi.org/10.3390/pharmaceutics15030814 (https://doi.org/10.3390/pharmaceutics15030814)** - 02 Mar 2023
Cited by 2 (/1999-4923/15/3/814#metrics) | Viewed by 2369

Abstract Major Depressive Disorder (MDD), colloquially known as depression, is a debilitating condition affecting an estimated 3.8% of the population globally, of which 5.0% are adults and 5.7% are above the age of 60. MDD is differentiated from common mood changes and short-lived emotional **[...] Read more.**
(This article belongs to the Special Issue **Stromal, Stem, Signaling Cells: The Multiple Roles and Applications of Mesenchymal Cells, 2nd Edition (/journal/pharmaceutics/special_issues/1S4BYOVRQ2)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00814/article_deploy/html/images/pharmaceutics-15-00814-g001-550.jpg?1677746605) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00814/article_deploy/html/images/pharmaceutics-15-00814-g002-550.jpg?1677746607) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00814/article_deploy/html/images/pharmaceutics-15-00814-g003-550.jpg?1677746608)

Open Access Article (/1999-4923/15/3/813/pdf?version=1677756258)

Derivatives of L-Ascorbic Acid in Emulgel: Development and Comprehensive Evaluation of the Topical Delivery System (/1999-4923/15/3/813)

by **Aleksandra Stolić Jovanović (https://sciprofiles.com/profile/2658107)**, **Milica Martinović (https://sciprofiles.com/profile/1522041)**, **Ana Žugić (https://sciprofiles.com/profile/4460)**, **Ivana Nešić (https://sciprofiles.com/profile/2948847)**, **Tomislav Tosti (https://sciprofiles.com/profile/854846)**, **Stevan Blagojević (https://sciprofiles.com/profile/author/emtyam5KN09lWGxodWJ3RWM2QTJLbHBkb3hsWUdxT0J4NmZzWHVxcGhVVT0=)** and **Vanja M. Tadić (https://sciprofiles.com/profile/5233)**

Pharmaceutics **2023**, *15*(3), 813; **https://doi.org/10.3390/pharmaceutics15030813 (https://doi.org/10.3390/pharmaceutics15030813)** - 02 Mar 2023
Cited by 1 (/1999-4923/15/3/813#metrics) | Viewed by 1056

Abstract The dual controlled release of emulgels makes them efficient drug delivery systems of increasing interest. The framework of this study was to incorporate selected L-ascorbic acid derivatives into emulgels. From the formulated emulgels, the release profiles of actives were evaluated considering their different **[...] Read more.**
(This article belongs to the Special Issue **Advances in Topical and Transdermal Drug Delivery, 2nd Edition (/journal/pharmaceutics/special_issues/CE65EL3JR0)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00813/article_deploy/html/images/pharmaceutics-15-00813-ag-550.jpg?1677756351) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00813/article_deploy/html/images/pharmaceutics-15-00813-g001-550.jpg?1677756323) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00813/article_deploy/html/images/pharmaceutics-15-00813-g002-550.jpg?1677756326) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00813/article_deploy/html/images/pharmaceutics-15-00813-g003-550.jpg?1677756333) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00813/article_deploy/html/images/pharmaceutics-15-00813-g004-550.jpg?1677756329) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00813/article_deploy/html/images/pharmaceutics-15-00813-g005-550.jpg?1677756326) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00813/article_deploy/html/images/pharmaceutics-15-00813-g006-550.jpg?1677756323) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00813/article_deploy/html/images/pharmaceutics-15-00813-g007-550.jpg?1677756331) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00813/article_deploy/html/images/pharmaceutics-15-00813-g008-550.jpg?1677756328)

Open Access Review (/1999-4923/15/3/812/pdf?version=1677741926)

Cereblon-Recruiting PROTACs: Will New Drugs Have to Face Old Challenges? (/1999-4923/15/3/812)

by **Marcin Cieślak (https://sciprofiles.com/profile/680511)** and **Marta Słowianek (https://sciprofiles.com/profile/579049)**

Pharmaceutics **2023**, *15*(3), 812; **https://doi.org/10.3390/pharmaceutics15030812 (https://doi.org/10.3390/pharmaceutics15030812)** - 02 Mar 2023
Cited by 2 (/1999-4923/15/3/812#metrics) | Viewed by 2474

Abstract The classical low-molecular-weight drugs are designed to bind with high affinity to the biological targets endowed with receptor or enzymatic activity, and inhibit their function. However, there are many non-receptor or non-enzymatic disease proteins that seem undruggable using the traditional drug approach. This **[...] Read more.**
(This article belongs to the Special Issue **Advances in Anticancer Agent (/journal/pharmaceutics/special_issues/cancer_agent)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00812/article_deploy/html/images/pharmaceutics-15-00812-g001-550.jpg?1677742008) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00812/article_deploy/html/images/pharmaceutics-15-00812-g002-550.jpg?1677741993) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00812/article_deploy/html/images/pharmaceutics-15-00812-g003-550.jpg?1677742001)

Open Access Article (/1999-4923/15/3/811/pdf?version=1677741703)

The ClC-2 Chloride Channel Activator, Lubiprostone, Improves Intestinal Barrier Function in Biopsies from Crohn's Disease but Not Ulcerative Colitis Patients (/1999-4923/15/3/811)

by **Young Su Park (https://sciprofiles.com/profile/author/ZjlvdUFGYm1PNWtwNVd6M3NDRVBYZz09)**, **Sang Bum Kang (https://sciprofiles.com/profile/770101)**, **Ronald R. Marchelletta (https://sciprofiles.com/profile/author/Y0xsdTVWK25PM0VqVDEwNEJrU2V5M2NwYlJ6WEhjcjlhMStKRXZxS3FGOTlxNmR4dnp4cHdKTUlLVHVOTG5LcA==)**, **Harrison M. Penrose (https://sciprofiles.com/profile/author/bGhKbkVUZVlXOG9vME9PdGVkZGthR3ZOSnFXSmtUQmhPZG5Rc0l0LzNnQD0=)**, **Roos Ruiter-Visser (https://sciprofiles.com/profile/author/L1dFQ3B0RHA2cThyNGcxQ2JLUXF1eFJ5dXU5V1gyQXFzY0NPbGlJUithRT0=)**, **Barbara Jung (https://sciprofiles.com/profile/2884425)**, **Michael J. Docherty (https://sciprofiles.com/profile/author/eXJ6ZkVpV0hkWXRrczlpa1U4Zmdqd1RHNnc1ay91YThnQkdTNjdWUkl6WT0=)**, **Brigid S. Boland (https://sciprofiles.com/profile/author/WjgwMkhjTWpRQ0RKTldYV2ZDSjd5a0VSVlZCaVJlckJhcEN5TndnVFFhOD0=)**, **William J. Sandborn (https://sciprofiles.com/profile/author/bzN3cURlZGQ5V0RWVThVdlBKd3lWaXJ5dWQxNXlPekV2M2hOZUNNMytTRT0=)** and **Declan F. McCole (https://sciprofiles.com/profile/763558)**

Pharmaceutics **2023**, *15*(3), 811; **https://doi.org/10.3390/pharmaceutics15030811 (https://doi.org/10.3390/pharmaceutics15030811)** - 02 Mar 2023
Viewed by 923

Abstract The prostone analog, lubiprostone, is approved to manage constipation-predominant irritable bowel syndrome. Lubiprostone also protects intestinal mucosal barrier function in animal models of colitis. The aim of this study was to determine if lubiprostone improves barrier properties in isolated colonic biopsies from Crohn's **[...] Read more.**
(This article belongs to the Special Issue **Targeting Cell Junctions for Therapy and Delivery (/journal/pharmaceutics/special_issues/Target_Junctions)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00811/article_deploy/html/images/pharmaceutics-15-00811-g001-550.jpg?1677741775) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00811/article_deploy/html/images/pharmaceutics-15-00811-g002-550.jpg?1677741774) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00811/article_deploy/html/images/pharmaceutics-15-00811-g003-550.jpg?1677741769) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00811/article_deploy/html/images/pharmaceutics-15-00811-g004-550.jpg?1677741781) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00811/article_deploy/html/images/pharmaceutics-15-00811-g005-550.jpg?1677741778) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00811/article_deploy/html/images/pharmaceutics-15-00811-g006-550.jpg?1677741779) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00811/article_deploy/html/images/pharmaceutics-15-00811-g007-550.jpg?1677741771)

Open Access Article (/1999-4923/15/3/810/pdf?version=1677736323)

System Analysis Based on Lipid-Metabolism-Related Genes Identifies AGT as a Novel Therapy Target for Gastric Cancer with Neoadjuvant Chemotherapy (/1999-4923/15/3/810)

by Le Zhu (https://sciprofiles.com/profile/author/UEp4bzFseXdYelpwdVJGeU0zODdyZkxobytuOWFXVllyOHorOHBxM0tjQT0=), Ming Ma (https://sciprofiles.com/profile/author/d0hiR21UenhUUTJzMG1XNUtFdVpGZHRZWkt2WXFCTUlybiswTmZnT01UVT0=), Lumin Zhang (https://sciprofiles.com/profile/author/T3Z3WENjeVVmY2Nzc25TZE81K1JkbUFzWkY3Y0dtY2xTRnBuVTYzVjNjdz0=), Shun Wang (https://sciprofiles.com/profile/2539222), Yu Guo (https://sciprofiles.com/profile/author/RGZra2cxZktob3NLMVczb3NGQTJDbHNZS1VRK0xSdnc5QmxJbEhYQ1ZBdz0=), Xinxin Ling (https://sciprofiles.com/profile/author/cTVGZWNEV2FXQ1kveE1WcTNUR3ZhakNRMEZZM0pGUkhuc1ZmRDJlYXFaVT0=), Hanchao Lin (https://sciprofiles.com/profile/2457220), Nannan Lai (https://sciprofiles.com/profile/author/bWRzbDRZV0FpRjdZOTdXNzNseTg2c1Imdi9QUFpWRy90T0RtcVBBdm4wWT0=), Shengli Lin (https://sciprofiles.com/profile/2389387), Ling Du (https://sciprofiles.com/profile/2546097) and Qiongzhu Dong (https://sciprofiles.com/profile/595048)

Pharmaceutics **2023**, *15*(3), 810; https://doi.org/10.3390/pharmaceutics15030810 (https://doi.org/10.3390/pharmaceutics15030810) - 02 Mar 2023

Viewed by 1073

Abstract Gastric cancer (GC) is one of the most common causes of cancer-related deaths worldwide, and chemotherapy is still a standard strategy for treating patients with advanced GC. Lipid metabolism has been reported to play an important role in the carcinogenesis and development of **[...] Read more.**

(This article belongs to the Special Issue **Novel Anticancer Strategies (Volume III)** (/journal/pharmaceutics/special_issues/YZVK72LQGZ))

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00810/article_deploy/html/images/pharmaceutics-15-00810-g001-550.jpg?1677736397) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00810/article_deploy/html/images/pharmaceutics-15-00810-g002-550.jpg?1677736395) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00810/article_deploy/html/images/pharmaceutics-15-00810-g003-550.jpg?1677736423) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00810/article_deploy/html/images/pharmaceutics-15-00810-g004-550.jpg?1677736411) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00810/article_deploy/html/images/pharmaceutics-15-00810-g005-550.jpg?1677736405) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00810/article_deploy/html/images/pharmaceutics-15-00810-g006-550.jpg?1677736401) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00810/article_deploy/html/images/pharmaceutics-15-00810-g007-550.jpg?1677736416) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00810/article_deploy/html/images/pharmaceutics-15-00810-g008-550.jpg?1677736420) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00810/article_deploy/html/images/pharmaceutics-15-00810-g009-550.jpg?1677736409) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00810/article_deploy/html/images/pharmaceutics-15-00810-g010-550.jpg?1677736403)

Open Access Article (/1999-4923/15/3/809/pdf?version=1677739265)

Hybrid Materials with Antimicrobial Properties Based on Hyperbranched Polyaminopropylalkoxysiloxanes Embedded with Ag Nanoparticles (/1999-4923/15/3/809)

by Alexander Vasil'kov (https://sciprofiles.com/profile/1050035), Dmitry Migulin (https://sciprofiles.com/profile/author/dnBTWUIaa3J2QTdkQ1NBeXR2NGFXRHJCYWo0T3BrZk5zRm53UTgxU29KQT0=), Alexander Naumkin (https://sciprofiles.com/profile/485144), Ilya Volkov (https://sciprofiles.com/profile/author/Y0lnaIB3VlkvUmhaOTdHek56cjVFZ2VvZTdRa0JseHJ3bUxnZGFtaVBPdz0=), Ivan Butenko (https://sciprofiles.com/profile/2780407), Alexandre Golub (https://sciprofiles.com/profile/1357899), Vera Sadykova (https://sciprofiles.com/profile/542365) and Aziz Muzafarov (https://sciprofiles.com/profile/313036)

Pharmaceutics **2023**, *15*(3), 809; https://doi.org/10.3390/pharmaceutics15030809 (https://doi.org/10.3390/pharmaceutics15030809) - 02 Mar 2023

Cited by 2 (/1999-4923/15/3/809#metrics) | Viewed by 937

Abstract New hybrid materials based on Ag nanoparticles stabilized by a polyaminopropylalkoxysiloxane hyperbranched polymer matrix were prepared. The Ag nanoparticles were synthesized in 2-propanol by metal vapor synthesis (MVS) and incorporated into the polymer matrix using metal-containing organosol. MVS is based on the interaction **[...] Read more.**

(This article belongs to the Special Issue **Pharmaceutical Formulations with Antimicrobial Properties, 2nd Edition** (/journal/pharmaceutics/special_issues/1629OZQV6L))

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00809/article_deploy/html/images/pharmaceutics-15-00809-g001-550.jpg?1677739355) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00809/article_deploy/html/images/pharmaceutics-15-00809-g002-550.jpg?1677739335) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00809/article_deploy/html/images/pharmaceutics-15-00809-g003-550.jpg?1677739344) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00809/article_deploy/html/images/pharmaceutics-15-00809-g004-550.jpg?1677739343) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00809/article_deploy/html/images/pharmaceutics-15-00809-g005-550.jpg?1677739350) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00809/article_deploy/html/images/pharmaceutics-15-00809-g006-550.jpg?1677739352) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00809/article_deploy/html/images/pharmaceutics-15-00809-g007a-550.jpg?1677739341) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00809/article_deploy/html/images/pharmaceutics-15-00809-g007b-550.jpg?1677739357) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00809/article_deploy/html/images/pharmaceutics-15-00809-g008-550.jpg?1677739356) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00809/article_deploy/html/images/pharmaceutics-15-00809-g009-550.jpg?1677739336) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00809/article_deploy/html/images/pharmaceutics-15-00809-g010-550.jpg?1677739352) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00809/article_deploy/html/images/pharmaceutics-15-00809-g011-550.jpg?1677739348) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00809/article_deploy/html/images/pharmaceutics-15-00809-g012-550.jpg?1677739333) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00809/article_deploy/html/images/pharmaceutics-15-00809-g013-550.jpg?1677739347) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00809/article_deploy/html/images/pharmaceutics-15-00809-g014a-550.jpg?1677739354) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00809/article_deploy/html/images/pharmaceutics-15-00809-g014b-550.jpg?1677739334) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00809/article_deploy/html/images/pharmaceutics-15-00809-g015-550.jpg?1677739339)

Open Access Review (/1999-4923/15/3/808/pdf?version=1677739844)

Relevance of the Extraction Stage on the Anti-Inflammatory Action of Fucoidans (/1999-4923/15/3/808)

by Noelia Flórez-Fernández (https://sciprofiles.com/profile/685365), Carlos Vaamonde-García (https://sciprofiles.com/profile/1150142), María Dolores Torres (https://sciprofiles.com/profile/2900021), Manuela Buján (https://sciprofiles.com/profile/2373458), Alexandra Muíños (https://sciprofiles.com/profile/author/VHJlVU1vd3l3YTRGL1ZmVFkzSjh4TjRMNkRvS0hZcE1GY0g5ZllsSnJVZz0=), Antonio Muíños (https://sciprofiles.com/profile/author/TG43bElNbVlFUFdTTHd3M0VSc0lLQVVRdWgzeGVKN2ltTVkvTDYvTGh2Yz0=), María J. Lamas-Vázquez (https://sciprofiles.com/profile/author/eGluZ0VYR25Ta3JyQ281Tkc1Uk8wcU5wR1Z2eUVVR09oMk5lajBpNUJjVT0=), Rosa Meijide-Failde (https://sciprofiles.com/profile/1177065), Francisco J. Blanco (https://sciprofiles.com/profile/1226777) and Herminia Domínguez (https://sciprofiles.com/profile/2831965)

Pharmaceutics **2023**, *15*(3), 808; https://doi.org/10.3390/pharmaceutics15030808 (https://doi.org/10.3390/pharmaceutics15030808) - 01 Mar 2023

Viewed by 1226

Abstract The anti-inflammatory action of fucoidans is well known, based on both in vitro and some in vivo studies. The other biological properties of these compounds, their lack of toxicity, and the possibility of obtaining them from a widely distributed and renewable source, makes **[...] Read more.**

(This article belongs to the Special Issue **Advances in Natural Products and Their Derivatives for Metabolic and Chronic Inflammatory Disease Therapy** (/journal/pharmaceutics/special_issues/natural_Metabolic))

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00808/article_deploy/html/images/pharmaceutics-15-00808-g001-550.jpg?1677739913) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00808/article_deploy/html/images/pharmaceutics-15-00808-g002-550.jpg?1677739914) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00808/article_deploy/html/images/pharmaceutics-15-00808-g003-550.jpg?1677739915)

Open Access Review (/1999-4923/15/3/807/pdf?version=1677738969)

Chitosan-Based Biomaterials for Tissue Regeneration (/1999-4923/15/3/807)

by Yevgeniy Kim (https://sciprofiles.com/profile/1900540), Zharylkasyn Zharkinbekov (https://sciprofiles.com/profile/1361708), Kamila Raziyeva (https://sciprofiles.com/profile/1263222), Laura Tabyldiyeva (https://sciprofiles.com/profile/2739011), Kamila Berikova (https://sciprofiles.com/profile/author/b2ovaTROZUI3Q0RNTXd3MkJOK1gzeFdDV1BEYTkvcEZXVldKUmlXWFJNND0=), Dias Zhumagul (https://sciprofiles.com/profile/author/RnUrWENYT3dTeTZobk12OFR1alIhTVM4U2N2NUM5bU1OcS94eTduV2ttbz0=), Kamila Temirkhanova (https://sciprofiles.com/profile/2366265) and Arman Saparov (https://sciprofiles.com/profile/50496)

Pharmaceutics **2023**, *15*(3), 807; https://doi.org/10.3390/pharmaceutics15030807 (https://doi.org/10.3390/pharmaceutics15030807) - 01 Mar 2023

Back to TopTop

Cited by 11 (/1999-4923/15/3/807#metrics) | Viewed by 2661

Abstract Chitosan is a chitin-derived biopolymer that has shown great potential for tissue regeneration and controlled drug delivery. It has numerous qualities that make it attractive for biomedical applications such as biocompatibility, low toxicity, broad-spectrum antimicrobial activity, and many others. Importantly, chitosan can be [...] Read more.
(This article belongs to the Special Issue Recent Advances in Pharmaceutical Applications of Functionalized Polysaccharides and Their Derivatives (/journal/pharmaceutics/special_issues/ra_pa_fptd))

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00807/article_deploy/html/images/pharmaceutics-15-00807-ag-550.jpg?1678074229) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00807/article_deploy/html/images/pharmaceutics-15-00807-g001-550.jpg?1677739048) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00807/article_deploy/html/images/pharmaceutics-15-00807-g002-550.jpg?1677739044)

Open Access Review (/1999-4923/15/3/806/pdf?version=1677679934)

Tumor Spheroids as Model to Design Acoustically Mediated Drug Therapies: A Review (/1999-4923/15/3/806)

by Marie Roy (https://sciprofiles.com/profile/author/L1YycU5VWDNUbEswL0NZUHE1Y0htNXpqZHJwS3E2aTM2Q1FFOUlVNUw1MD0=), Corentin Alix (https://sciprofiles.com/profile/author/RlBlczNkald4TTdDckxkbFluOENKK0g2cmp1U3JHYm4xc0Y2VEU3bXpSbz0=), Ayache Bouakaz (https://sciprofiles.com/profile/author/VWI4RkRCTkN5WFF5NExYMkYwaDdzSEtOUjNETU9JYW5idTRSY0I1WWNpaz0=), Sophie Serrière (https://sciprofiles.com/profile/2745301) and Jean-Michel Escoffre (https://sciprofiles.com/profile/1208843)
Pharmaceutics **2023**, *15*(3), 806; https://doi.org/10.3390/pharmaceutics15030806 (https://doi.org/10.3390/pharmaceutics15030806) - 01 Mar 2023
Cited by 2 (/1999-4923/15/3/806#metrics) | Viewed by 2143

Abstract Tumor spheroids as well as multicellular tumor spheroids (MCTSs) are promising 3D in vitro tumor models for drug screening, drug design, drug targeting, drug toxicity, and validation of drug delivery methods. These models partly reflect the tridimensional architecture of tumors, their heterogeneity and [...] Read more.
(This article belongs to the Special Issue Ultrasound-Mediated Drug Delivery (/journal/pharmaceutics/special_issues/ultrasound_delivery))

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00806/article_deploy/html/images/pharmaceutics-15-00806-ag-550.jpg?1677680021) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00806/article_deploy/html/images/pharmaceutics-15-00806-g001-550.jpg?1677680010) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00806/article_deploy/html/images/pharmaceutics-15-00806-g002-550.jpg?1677680017) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00806/article_deploy/html/images/pharmaceutics-15-00806-g003-550.jpg?1677680008) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00806/article_deploy/html/images/pharmaceutics-15-00806-g004-550.jpg?1677680020) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00806/article_deploy/html/images/pharmaceutics-15-00806-g005-550.jpg?1677680013) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00806/article_deploy/html/images/pharmaceutics-15-00806-g006-550.jpg?1677680015)

Open Access Article (/1999-4923/15/3/805/pdf?version=1677664556)

Polylactic Acid/Poly(vinylpyrrolidone) Co-Electrospun Fibrous Membrane as a Tunable Quercetin Delivery Platform for Diabetic Wounds (/1999-4923/15/3/805)

by Francesca Di Cristo (https://sciprofiles.com/profile/author/ck1jR2dWZXFyM3hFSDRLcURyMWVlMEo2SW1ORFJjV0RDbVplbWY1OGN3MXg5bGNjVVV2MWdhM0lLb0MrSitPSw==), Anna Valentino (https://sciprofiles.com/profile/2133366), Ilenia De Luca (https://sciprofiles.com/profile/1454043), Gianfranco Peluso (https://sciprofiles.com/profile/author/QXA5cWVxTkQvOGk0d3B6NnRlNFlxS2JsajFKdU05SUpaOXlCTnBzYXBMN0xtdEUwVmtHZDhZOXh2QU93dVhjdg==), Irene Bonadies (https://sciprofiles.com/profile/2067803), Anna Di Salle (https://sciprofiles.com/profile/622339) and Anna Calarco (https://sciprofiles.com/profile/296577)
Pharmaceutics **2023**, *15*(3), 805; https://doi.org/10.3390/pharmaceutics15030805 (https://doi.org/10.3390/pharmaceutics15030805) - 01 Mar 2023
Cited by 5 (/1999-4923/15/3/805#metrics) | Viewed by 1338

Abstract Diabetic wound infections (DWI) represent one of the most costly and disruptive complications in diabetic mellitus. The hyperglycemic state induces a persistent inflammation with immunological and biochemical impairments that promotes delayed wound healing processes and wound infection that often results in extended hospitalization [...] Read more.
(This article belongs to the Special Issue Biodegradable Nanomaterials for Targeted Drug Delivery (/journal/pharmaceutics/special_issues/biodegradable_nanomaterial))

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00805/article_deploy/html/images/pharmaceutics-15-00805-ag-550.jpg?1677664653) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00805/article_deploy/html/images/pharmaceutics-15-00805-g001-550.jpg?1677664638) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00805/article_deploy/html/images/pharmaceutics-15-00805-g002-550.jpg?1677664647) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00805/article_deploy/html/images/pharmaceutics-15-00805-g003-550.jpg?1677664652) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00805/article_deploy/html/images/pharmaceutics-15-00805-g004-550.jpg?1677664643) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00805/article_deploy/html/images/pharmaceutics-15-00805-g005-550.jpg?1677664640) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00805/article_deploy/html/images/pharmaceutics-15-00805-g006-550.jpg?1677664649)

Open Access Review (/1999-4923/15/3/804/pdf?version=1677659161)

Overview of Side-Effects of Antibacterial Fluoroquinolones: New Drugs versus Old Drugs, a Step Forward in the Safety Profile? (/1999-4923/15/3/804)

by Aura Rusu (https://sciprofiles.com/profile/635260), Alexandra-Cristina Munteanu (https://sciprofiles.com/profile/1308271), Eliza-Mihaela Arbănași (https://sciprofiles.com/profile/2000162) and Valentina Uivarosi (https://sciprofiles.com/profile/48963)
Pharmaceutics **2023**, *15*(3), 804; https://doi.org/10.3390/pharmaceutics15030804 (https://doi.org/10.3390/pharmaceutics15030804) - 01 Mar 2023
Cited by 7 (/1999-4923/15/3/804#metrics) | Viewed by 3809

Abstract Antibacterial fluoroquinolones (FQs) are frequently used in treating infections. However, the value of FQs is debatable due to their association with severe adverse effects (AEs). The Food and Drug Administration (FDA) issued safety warnings concerning their side-effects in 2008, followed by the European [...] Read more.
(This article belongs to the Special Issue Therapeutic Drug Monitoring (/journal/pharmaceutics/special_issues/G40VC161N4))

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00804/article_deploy/html/images/pharmaceutics-15-00804-g001-550.jpg?1677659229) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00804/article_deploy/html/images/pharmaceutics-15-00804-g002-550.jpg?1677659232) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00804/article_deploy/html/images/pharmaceutics-15-00804-g003-550.jpg?1677659227)

Open Access Article (/1999-4923/15/3/803/pdf?version=1678342842)

The Importance of Epigallocatechin as a Scaffold for Drug Development against Flaviviruses (/1999-4923/15/3/803)

by Mónika A. Coronado (https://sciprofiles.com/profile/1470301), Ian Gering (https://sciprofiles.com/profile/1619068), Marc Sevenich (https://sciprofiles.com/profile/author/akJ4eHhqL1IyNjN1cDN6SHM5VzYvTHgxT1FMcmlZeWJHLzBnQVhpcTlNUT0=), Danilo S. Olivier (https://sciprofiles.com/profile/2791491), Mohammadamin Mastalipour (https://sciprofiles.com/profile/2808652), Marcos S. Amaral (https://sciprofiles.com/profile/1011206), Dieter Willbold (https://sciprofiles.com/profile/311797) and Raphael J. Eberle (https://sciprofiles.com/profile/1468464)
Pharmaceutics **2023**, *15*(3), 803; https://doi.org/10.3390/pharmaceutics15030803 (https://doi.org/10.3390/pharmaceutics15030803) - 01 Mar 2023
Viewed by 1171

Abstract Arboviruses such as Dengue, yellow fever, West Nile, and Zika are flaviviruses vector-borne RNA viruses transmitted biologically among vertebrate hosts by blood-taking vectors. Many flaviviruses are associated with neurological, viscerotropic, and hemorrhagic diseases, posing significant health and socioeconomic concerns as they adapt to [...] Read more.
(This article belongs to the Special Issue Bioactive Molecules from Plants: Discovery and Pharmaceutical Applications (Volume II) (/journal/pharmaceutics/special_issues/bioactive_molecules_pharmaceutical_applications_volume_II))

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00803/article_deploy/html/images/pharmaceutics-15-00803-g001-550.jpg?1678342921) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00803/article_deploy/html/images/pharmaceutics-15-00803-g002-550.jpg?1678342916) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00803/article_deploy/html/images/pharmaceutics-15-00803-g003-550.jpg?1678342918) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00803/article_deploy/html/images/pharmaceutics-15-00803-g004-550.jpg?1678342919)

Open Access Article (/1999-4923/15/3/802/pdf?version=1677656357)

Development of Robust Tablet Formulations with Enhanced Drug Dissolution Profiles from Centrifugally-Spun Micro-Fibrous Solid Dispersions of Itraconazole, a BCS Class II Drug (/1999-4923/15/3/802)

MDPI (/) (/toggle_desktop_layout_cookie)

by Stefania Marano (https://sciprofiles.com/profile/1277268),
Manish Ghimire (https://sciprofiles.com/profile/author/d096OVpXeCtEcTc1WG1tc01WK1lHWXlhZm9tQlJXNU5WZDZwSTdEV3NaOD0=),
Shahrzad Missaghi (https://sciprofiles.com/profile/author/SFlPTXAzSld0Lzk3ZzlwWXB0ajh4R3NzcjlQTEhHbHUwUlBodE1qaXhQRT0=),
Ali Rajabi-Siahboomi (https://sciprofiles.com/profile/author/dUN0YlN6ZmY3KzhwSUg4T1pCcmxYUFFkTVRqSlVPNGZHbk5aYz[illegible]),
Duncan Q. M. Craig (https://sciprofiles.com/profile/762257) and Susan A. Barker (https://sciprofiles.com/profile/1205475)
Pharmaceutics **2023**, *15*(3), 802; https://doi.org/10.3390/pharmaceutics15030802 (https://doi.org/10.3390/pharmaceutics15030802) - 01 Mar 2023

Abstract Fibre-based oral drug delivery systems are an attractive approach to addressing low drug solubility, although clear strategies for incorporating such systems into viable dosage forms have not yet been demonstrated. The present study extends our previous work on drug-loaded sucrose microfibres produced by [...] Read more.
(This article belongs to the Special Issue Dosage Form Formulation Technologies for Improving Bioavailability (/journal/pharmaceutics/special_issues/4IEDR453W2))

► Show Figures
(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00802/article_deploy/html/images/pharmaceutics-15-00802-g001-550.jpg?1677656448) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00802/article_deploy/html/images/pharmaceutics-15-00802-g002-550.jpg?1677656425) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00802/article_deploy/html/images/pharmaceutics-15-00802-g003-550.jpg?1677656429) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00802/article_deploy/html/images/pharmaceutics-15-00802-g004-550.jpg?1677656452) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00802/article_deploy/html/images/pharmaceutics-15-00802-g005-550.jpg?1677656423) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00802/article_deploy/html/images/pharmaceutics-15-00802-g006-550.jpg?1677656440) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00802/article_deploy/html/images/pharmaceutics-15-00802-g007-550.jpg?1677656434) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00802/article_deploy/html/images/pharmaceutics-15-00802-g008-550.jpg?1677656427) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00802/article_deploy/html/images/pharmaceutics-15-00802-g009-550.jpg?1677656438) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00802/article_deploy/html/images/pharmaceutics-15-00802-g010-550.jpg?1677656443) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00802/article_deploy/html/images/pharmaceutics-15-00802-g011-550.jpg?1677656432) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00802/article_deploy/html/images/pharmaceutics-15-00802-g012-550.jpg?1677656449)

Open Access Review (/1999-4923/15/3/801/pdf?version=1677650739)

Dendrimer-Mediated Delivery of Anticancer Drugs for Colon Cancer Treatment (/1999-4923/15/3/801)

by Divya Bharti Rai (https://sciprofiles.com/profile/author/RzRGMEtHRkNHTjBVSTZLOU1XSGtJVWx3UEM5OEltVDhLMkwvV29DUTltOD0=),
Kanakaraju Medicherla (https://sciprofiles.com/profile/author/YjFMMzNtVnlicGlIZmxpdXNuazliSStJNGplbVcyaTFQZmdxQk81RE5qMD0=),
Deep Pooja (https://sciprofiles.com/profile/586304) and Hitesh Kulhari (https://sciprofiles.com/profile/2552582)
Pharmaceutics **2023**, *15*(3), 801; https://doi.org/10.3390/pharmaceutics15030801 (https://doi.org/10.3390/pharmaceutics15030801) - 01 Mar 2023

Abstract The third most common cancer worldwide is colon cancer (CC). Every year, there more cases are reported, yet there are not enough effective treatments. This emphasizes the need for new drug delivery strategies to increase the success rate and reduce side effects. Recently, [...] Read more.
(This article belongs to the Special Issue Smart Nanocarriers for Drug Delivery in Colon Cancer (/journal/pharmaceutics/special_issues/colon_nano))

► Show Figures
(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00801/article_deploy/html/images/pharmaceutics-15-00801-g001-550.jpg?1677650812) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00801/article_deploy/html/images/pharmaceutics-15-00801-g002-550.jpg?1677650814) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00801/article_deploy/html/images/pharmaceutics-15-00801-g003-550.jpg?1677650816) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00801/article_deploy/html/images/pharmaceutics-15-00801-g004-550.jpg?1677650813) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00801/article_deploy/html/images/pharmaceutics-15-00801-g005-550.jpg?1677650818)

Open Access Review (/1999-4923/15/3/800/pdf?version=1677642725)

An Adequate Pharmaceutical Quality System for Personalized Preparation (/1999-4923/15/3/800)

by Marta Uriel (https://sciprofiles.com/profile/2494147),
Diego Marro (https://sciprofiles.com/profile/author/WHp0MHc2b2YwcFpmanRqdVhjcUVEcmFEUHhWdjdBZGx6VnJCL25WRXRVRT0=) and
Carlota Gómez Rincón (https://sciprofiles.com/profile/559215)
Pharmaceutics **2023**, *15*(3), 800; https://doi.org/10.3390/pharmaceutics15030800 (https://doi.org/10.3390/pharmaceutics15030800) - 01 Mar 2023

Abstract The pharmacy compounding of personalized preparations has evolved a great deal, and with it, the way of working and the legal requirements have also evolved. An adequate pharmaceutical quality system for personalized preparations presents fundamental differences with respect to the system designed for [...] Read more.
(This article belongs to the Special Issue Pharmacy Compounding of Personalized Preparation for Specific Patients: Challenges and Advantages (/journal/pharmaceutics/special_issues/0LMCZPN945))

► Show Figures
(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00800/article_deploy/html/images/pharmaceutics-15-00800-g001-550.jpg?1677642798) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00800/article_deploy/html/images/pharmaceutics-15-00800-g002-550.jpg?1677642795)

Open Access Article (/1999-4923/15/3/799/pdf?version=1677665667)

Hot Melt Extruded Posaconazole-Based Amorphous Solid Dispersions—The Effect of Different Types of Polymers (/1999-4923/15/3/799)

by Daniel Kramarczyk (https://sciprofiles.com/profile/1448983), Justyna Knapik-Kowalczuk (https://sciprofiles.com/profile/658930),
Mateusz Kurek (https://sciprofiles.com/profile/449406), Witold Jamróz (https://sciprofiles.com/profile/1287213),
Renata Jachowicz (https://sciprofiles.com/profile/author/ZGdPRWh2UEZoQ0FBY0J5dDhTQnBuZnAvRTV5b0Y0OVBRUGhQRE9pcG0vaz0=) and
Marian Paluch (https://sciprofiles.com/profile/1224897)
Pharmaceutics **2023**, *15*(3), 799; https://doi.org/10.3390/pharmaceutics15030799 (https://doi.org/10.3390/pharmaceutics15030799) - 28 Feb 2023

Abstract Four model polymers, representing (i) amorphous homopolymers (Kollidon K30, K30), (ii) amorphous heteropolymers (Kollidon VA64, KVA), (iii) semi-crystalline homopolymers (Parteck MXP, PXP), and (iv) semi-crystalline heteropolymers (Kollicoat IR, KIR), were examined for their effectiveness in creating posaconazole-based amorphous solid dispersions (ASDs). Posaconazole (POS) [...] Read more.
(This article belongs to the Special Issue Recent Advances in Amorphous Drug (/journal/pharmaceutics/special_issues/ra_ad))

► Show Figures
(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00799/article_deploy/html/images/pharmaceutics-15-00799-g001-550.jpg?1677665735) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00799/article_deploy/html/images/pharmaceutics-15-00799-g002-550.jpg?1677665738) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00799/article_deploy/html/images/pharmaceutics-15-00799-g003-550.jpg?1677665745) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00799/article_deploy/html/images/pharmaceutics-15-00799-g004-550.jpg?1677665740) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00799/article_deploy/html/images/pharmaceutics-15-00799-g005-550.jpg?1677665736) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00799/article_deploy/html/images/pharmaceutics-15-00799-g006-550.jpg?1677665734) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00799/article_deploy/html/images/pharmaceutics-15-00799-g007-550.jpg?1677665742) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00799/article_deploy/html/images/pharmaceutics-15-00799-g008-550.jpg?1677665744) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00799/article_deploy/html/images/pharmaceutics-15-00799-g009-550.jpg?1677665739)

Open Access Article (/1999-4923/15/3/798/pdf?version=1677591237)

Enhanced Skin Penetration of Cannabidiol Using Organosilane Particles as Transdermal Delivery Vehicles (/1999-4923/15/3/798)

by Zahra Khabir (https://sciprofiles.com/profile/1464763),
Connie Partalis (https://sciprofiles.com/profile/author/YVF1UUtFelNVYk93cjNoNjhKRDVKMkdJalVTaFp4NWFqM0R0U3p3ZFZLcEd5VkZmbTFmQzliVndRRHoyZDFuag==)
,
Jimit Vijay Panchal (https://sciprofiles.com/profile/author/RDNvalFzNmF0RGdNQVZLYnRRb2ZBalhXL21OYTNhcGdUUVZGdGJOVXBPWjFleEp0Nzg1QkxHblpoTFlmUkVwdQ==)
,
Anand Deva (https://sciprofiles.com/profile/1266389),
Aparajita Khatri (https://sciprofiles.com/profile/author/VWMwekJUQVpRSnBRbm81dnhCYUw5NG5zRmhjdkl3Wnd5QVdaTG04ZmpERT0=) and
Alfonso Garcia-Bennett (https://sciprofiles.com/profile/1000129)
Pharmaceutics **2023**, *15*(3), 798; https://doi.org/10.3390/pharmaceutics15030798 (https://doi.org/10.3390/pharmaceutics15030798) - 28 Feb 2023

Abstract There is potential for cannabidiol to act as an analgesic, anxiolytic and antipsychotic active ingredient; however, there is a need to find alternate administration routes to

Back to TopTop

overcome its low oral bioavailability. In this work, we propose a new delivery vehicle based on encapsulation **[...] Read more.**

► **Show Figures**

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00798/article_deploy/html/images/pharmaceutics-15-00798-ag-550.jpg?1677591315) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00798/article_deploy/html/images/pharmaceutics-15-00798-g001-550.jpg?1677591309) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00798/article_deploy/html/images/pharmaceutics-15-00798-g002-550.jpg?1677591307) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00798/article_deploy/html/images/pharmaceutics-15-00798-g003-550.jpg?1677591305) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00798/article_deploy/html/images/pharmaceutics-15-00798-g004-550.jpg?1677591311) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00798/article_deploy/html/images/pharmaceutics-15-00798-g005-550.jpg?1677591310) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00798/article_deploy/html/images/pharmaceutics-15-00798-g006-550.jpg?1677591314) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00798/article_deploy/html/images/pharmaceutics-15-00798-sch001-550.jpg?1677591303)

Open Access Article (/1999-4923/15/3/797/pdf?version=1677583269)

In Silico Study of Different Thrombolytic Agents for Fibrinolysis in Acute Ischemic Stroke (/1999-4923/15/3/797)

by Yilin Yang (https://sciprofiles.com/profile/author/dlVDVFNLZnU3K2lIWG53VVRaQmt3NkpZcUp5RzVrMnJDVVFTbWxZU0xSQT0=), Boram Gu (https://sciprofiles.com/profile/2746337) and Xiao Yun Xu (https://sciprofiles.com/profile/634313)

Pharmaceutics **2023**, *15*(3), 797; https://doi.org/10.3390/pharmaceutics15030797 (https://doi.org/10.3390/pharmaceutics15030797) - 28 Feb 2023

Viewed by 1155

Abstract Alteplase is the only FDA-approved drug for thrombolysis in acute ischemic stroke (AIS). Meanwhile, several thrombolytic drugs are deemed to be promising candidates to substitute alteplase. This paper evaluates the efficacy and safety of urokinase, ateplase, tenecteplase, and reteplase for intravenous AIS therapy **[...] Read more.**

(This article belongs to the Section **Pharmacokinetics and Pharmacodynamics (/journal/pharmaceutics/sections/Pharmacokinetics_and_Pharmacodynamics)**)

► **Show Figures**

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00797/article_deploy/html/images/pharmaceutics-15-00797-g001-550.jpg?1677583342) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00797/article_deploy/html/images/pharmaceutics-15-00797-g002-550.jpg?1677583346) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00797/article_deploy/html/images/pharmaceutics-15-00797-g003-550.jpg?1677583343) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00797/article_deploy/html/images/pharmaceutics-15-00797-g004-550.jpg?1677583341) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00797/article_deploy/html/images/pharmaceutics-15-00797-g005-550.jpg?1677583343) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00797/article_deploy/html/images/pharmaceutics-15-00797-g006-550.jpg?1677583347) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00797/article_deploy/html/images/pharmaceutics-15-00797-g007-550.jpg?1677583344) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00797/article_deploy/html/images/pharmaceutics-15-00797-g008-550.jpg?1677583340) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00797/article_deploy/html/images/pharmaceutics-15-00797-g009-550.jpg?1677583349) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00797/article_deploy/html/images/pharmaceutics-15-00797-g0A1-550.jpg?1677583347) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00797/article_deploy/html/images/pharmaceutics-15-00797-g0A2-550.jpg?1677583345) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00797/article_deploy/html/images/pharmaceutics-15-00797-g0A3-550.jpg?1677583348)

Open Access Article (/1999-4923/15/3/796/pdf?version=1677579226)

Effect of *N*-Terminal Peptide Modifications on In Vitro and In Vivo Properties of ^{177}Lu-Labeled Peptide Analogs Targeting CCK2R (/1999-4923/15/3/796)

by Anton Amadeus Hörmann (https://sciprofiles.com/profile/1353962), Maximilian Klingler (https://sciprofiles.com/profile/author/VEdlUzVnTHV5dG9BQ2lCMDBSaUlzS0JGM3RlZ0hQclJnSHRNNEowam1KRT0=), Christine Rangger (https://sciprofiles.com/profile/592526), Christian Mair (https://sciprofiles.com/profile/2693959), Lieke Joosten (https://sciprofiles.com/profile/2250584), Gerben M. Franssen (https://sciprofiles.com/profile/author/MnJSTXk2dzNidnRvc3dOR2UvNVpyN3BrLytBV1lsKy9rY1JLZWhXNG5Jbz0=), Peter Laverman (https://sciprofiles.com/profile/1559449) and Elisabeth von Guggenberg (https://sciprofiles.com/profile/576468)

Pharmaceutics **2023**, *15*(3), 796; https://doi.org/10.3390/pharmaceutics15030796 (https://doi.org/10.3390/pharmaceutics15030796) - 28 Feb 2023

Cited by 2 (/1999-4923/15/3/796#metrics) | Viewed by 816

Abstract The therapeutic potential of minigastrin (MG) analogs for the treatment of cholecystokinin-2 receptor (CCK2R)-expressing cancers is limited by poor in vivo stability or unfavorable accumulation in non-target tissues. Increased stability against metabolic degradation was achieved by modifying the C-terminal receptor-specific region. This modification **[...] Read more.**

(This article belongs to the Special Issue **Radiopharmaceuticals for Cancer Imaging and Therapy (/journal/pharmaceutics/special_issues/Radio_Therap)**)

► **Show Figures**

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00796/article_deploy/html/images/pharmaceutics-15-00796-g001-550.jpg?1677579302) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00796/article_deploy/html/images/pharmaceutics-15-00796-g002-550.jpg?1677579295) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00796/article_deploy/html/images/pharmaceutics-15-00796-g003-550.jpg?1677579309) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00796/article_deploy/html/images/pharmaceutics-15-00796-g004-550.jpg?1677579293) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00796/article_deploy/html/images/pharmaceutics-15-00796-g005-550.jpg?1677579308) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00796/article_deploy/html/images/pharmaceutics-15-00796-g006-550.jpg?1677579299) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00796/article_deploy/html/images/pharmaceutics-15-00796-g007-550.jpg?1677579304)

Open Access Article (/1999-4923/15/3/795/pdf?version=1677579155)

Thermosensitive Polymer-Modified Mesoporous Silica for pH and Temperature-Responsive Drug Delivery (/1999-4923/15/3/795)

by Kokila Thirupathi (https://sciprofiles.com/profile/author/SkFVSm81RURVZ0xaRXRTbXdmSmp6MWU2bWJMRHE5NG8zMDhiaGRZRkU1QT0=), Madhappan Santhamoorthy (https://sciprofiles.com/profile/2424655), Sivaprakasam Radhakrishnan (https://sciprofiles.com/profile/346146), Selvakumari Ulagesan (https://sciprofiles.com/profile/896401), Taek-Jeong Nam (https://sciprofiles.com/profile/291911), Thi Tuong Vy Phan (https://sciprofiles.com/profile/600357) and Seong-Cheol Kim (https://sciprofiles.com/profile/2740114)

Pharmaceutics **2023**, *15*(3), 795; https://doi.org/10.3390/pharmaceutics15030795 (https://doi.org/10.3390/pharmaceutics15030795) - 28 Feb 2023

Cited by 4 (/1999-4923/15/3/795#metrics) | Viewed by 912

Abstract A mesoporous silica-based drug delivery system (MS@PNIPAm-PAAm NPs) was synthesized by conjugating the PNIPAm-PAAm copolymer onto the mesoporous silica (MS) surface as a gatekeeper that responds to temperature and pH changes. The drug delivery studies are carried out in vitro at different pH **[...] Read more.**

(This article belongs to the Special Issue **Metal Nanoparticles for Cancer Therapy (/journal/pharmaceutics/special_issues/metal_therapy)**)

► **Show Figures**

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00795/article_deploy/html/images/pharmaceutics-15-00795-g001-550.jpg?1677579232) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00795/article_deploy/html/images/pharmaceutics-15-00795-g002-550.jpg?1677579234) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00795/article_deploy/html/images/pharmaceutics-15-00795-g003-550.jpg?1677579223) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00795/article_deploy/html/images/pharmaceutics-15-00795-g004-550.jpg?1677579226) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00795/article_deploy/html/images/pharmaceutics-15-00795-g005-550.jpg?1677579227) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00795/article_deploy/html/images/pharmaceutics-15-00795-g006-550.jpg?1677579220) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00795/article_deploy/html/images/pharmaceutics-15-00795-g007-550.jpg?1677579236) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00795/article_deploy/html/images/pharmaceutics-15-00795-g008-550.jpg?1677579224) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00795/article_deploy/html/images/pharmaceutics-15-00795-sch001-550.jpg?1677579229)

Open Access Review (/1999-4923/15/3/794/pdf?version=1677582863)

Modulation of Macrophage Function by Bioactive Wound Dressings with an Emphasis on Extracellular Matrix-Based Scaffolds and Nanofibrous Composites (/1999-4923/15/3/794)

by Tao He (https://sciprofiles.com/profile/author/L3ZiVE15UXUyTEg1Q0h3L1dVVHRGZnhFa2psRTYrdFJxWGpRYy9mRjdXZz0=), Yuzhen Xiao (https://sciprofiles.com/profile/author/bkttNXdJZENUVzF4VDNIVjU5cHMyMk9Qd1Q0MGpiZW0wdUhyYlp1MGtSMD0=), Zhijun Guo (https://sciprofiles.com/profile/1126793), Yifeng Shi (https://sciprofiles.com/profile/author/Mk1mMW44MWJwWTZTV3RFcytTaGN0aXVjV05uQ2ZKUURvL0FOREd3M0NOUT0=), Qiuwen Tan (https://sciprofiles.com/profile/2689748), Yizhou Huang (https://sciprofiles.com/profile/2410280) and Huiqi Xie (https://sciprofiles.com/profile/1809372)

Pharmaceutics **2023**, *15*(3), 794; https://doi.org/10.3390/pharmaceutics15030794 (https://doi.org/10.3390/pharmaceutics15030794) - 28 Feb 2023

Cited by 1 (/1999-4923/15/3/794#metrics) | Viewed by 1122

Abstract Bioactive wound dressings that are capable of regulating the local wound microenvironment have attracted a very large interest in the field of regenerative medicine. Macrophages have many critical roles in normal wound healing, and the dysfunction of macrophages significantly contributes to impaired or **[...] Read more.**
(This article belongs to the Special Issue **Nanofibrous Scaffolds: Promising Wound Dressing Materials (/journal/pharmaceutics/special_issues/nano_wound)**)

► **Show Figures**

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00794/article_deploy/html/images/pharmaceutics-15-00794-ag-550.jpg?1681349846)

Open Access Article **(/1999-4923/15/3/793/pdf?version=1677577939)**

Computational Modeling on Drugs Effects for Left Ventricle in Cardiomyopathy Disease (/1999-4923/15/3/793)

by **Smiljana Tomasevic (https://sciprofiles.com/profile/421986)**, **Miljan Milosevic (https://sciprofiles.com/profile/540748)**, **Bogdan Milicevic (https://sciprofiles.com/profile/author/d3pmSEFYWEFrdW50RzBnZnhlRnZCN0xkbmNyTXY3UDlCZEhCMmhDZ25JTT0=)**, **Vladimir Simic (https://sciprofiles.com/profile/2868093)**, **Momcilo Prodanovic (https://sciprofiles.com/profile/author/MDJWU3FESWk5VWNlZkU2R21LVGpRU0xvS2JIcFRyMWVWV3dtSVNwY2Z6ND0=)**, **Srboljub M. Mijailovich (https://sciprofiles.com/profile/813192)** and **Nenad Filipovic (https://sciprofiles.com/profile/262612)**
Pharmaceutics **2023**, *15*(3), 793; **https://doi.org/10.3390/pharmaceutics15030793 (https://doi.org/10.3390/pharmaceutics15030793)** - 28 Feb 2023
Viewed by 1038

Abstract Cardiomyopathy is associated with structural and functional abnormalities of the ventricular myocardium and can be classified in two major groups: hypertrophic (HCM) and dilated (DCM) cardiomyopathy. Computational modeling and drug design approaches can speed up the drug discovery and significantly reduce expenses aiming **[...] Read more.**
(This article belongs to the Special Issue **In Silico Drug Testing and Optimization, Coupling Physical-Based Modeling and Machine Learning (/journal/pharmaceutics/special_issues/drug_modeling)**)

► **Show Figures**

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00793/article_deploy/html/images/pharmaceutics-15-00793-ag-550.jpg?1677578031) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00793/article_deploy/html/images/pharmaceutics-15-00793-g001-550.jpg?1677578018) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00793/article_deploy/html/images/pharmaceutics-15-00793-g002-550.jpg?1677578023) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00793/article_deploy/html/images/pharmaceutics-15-00793-g003-550.jpg?1677578024) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00793/article_deploy/html/images/pharmaceutics-15-00793-g004-550.jpg?1677578025) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00793/article_deploy/html/images/pharmaceutics-15-00793-g005-550.jpg?1677578012) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00793/article_deploy/html/images/pharmaceutics-15-00793-g006-550.jpg?1677578018) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00793/article_deploy/html/images/pharmaceutics-15-00793-g007-550.jpg?1677578012) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00793/article_deploy/html/images/pharmaceutics-15-00793-g008-550.jpg?1677578020) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00793/article_deploy/html/images/pharmaceutics-15-00793-g009-550.jpg?1677578013) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00793/article_deploy/html/images/pharmaceutics-15-00793-g010-550.jpg?1677578027) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00793/article_deploy/html/images/pharmaceutics-15-00793-g011-550.jpg?1677578017) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00793/article_deploy/html/images/pharmaceutics-15-00793-g012-550.jpg?1677578011) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00793/article_deploy/html/images/pharmaceutics-15-00793-g013-550.jpg?1677578022) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00793/article_deploy/html/images/pharmaceutics-15-00793-g014-550.jpg?1677578027) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00793/article_deploy/html/images/pharmaceutics-15-00793-g015-550.jpg?1677578019) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00793/article_deploy/html/images/pharmaceutics-15-00793-g016-550.jpg?1677578022) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00793/article_deploy/html/images/pharmaceutics-15-00793-g017-550.jpg?1677578015)

Open Access Systematic Review **(/1999-4923/15/3/792/pdf?version=1677569751)**

Microneedles in Advanced Microfluidic Systems: A Systematic Review throughout Lab and Organ-on-a-Chip Applications (/1999-4923/15/3/792)

by **Renata Maia (https://sciprofiles.com/profile/author/ZGZ0alU1MUcrRXRHWXEvZjJ2Y1ZtSUpxMWJoa0w0RU1GYWM2QUxNbGJhND0=)**, **Violeta Carvalho (https://sciprofiles.com/profile/author/WDdlL09zSXpPWDJZOWQyS0VRaWVWazM3ZFNRM2FOeXlhWVhVL1dnNERlND0=)**, **Rui Lima (https://sciprofiles.com/profile/92024)**, **Graça Minas (https://sciprofiles.com/profile/85911)** and **Raquel O. Rodrigues (https://sciprofiles.com/profile/519503)**
Pharmaceutics **2023**, *15*(3), 792; **https://doi.org/10.3390/pharmaceutics15030792 (https://doi.org/10.3390/pharmaceutics15030792)** - 28 Feb 2023
Cited by 4 (/1999-4923/15/3/792#metrics) | Viewed by 1908

Abstract Microneedles (MNs) have been widely used in biomedical applications for drug delivery and biomarker detection purposes. Furthermore, MNs can also be used as a stand-alone tool to be combined with microfluidic devices. For that purpose, lab- or organ-on-a-chip are being developed. This systematic **[...] Read more.**
(This article belongs to the Special Issue **Recent Advances in Microneedle-Mediated Drug Delivery (/journal/pharmaceutics/special_issues/recent_advances_in_mmdd)**)

► **Show Figures**

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00792/article_deploy/html/images/pharmaceutics-15-00792-ag-550.jpg?1677836066) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00792/article_deploy/html/images/pharmaceutics-15-00792-g001-550.jpg?1677569832) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00792/article_deploy/html/images/pharmaceutics-15-00792-g002-550.jpg?1677569825) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00792/article_deploy/html/images/pharmaceutics-15-00792-g003-550.jpg?1677569826) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00792/article_deploy/html/images/pharmaceutics-15-00792-g004-550.jpg?1677569831) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00792/article_deploy/html/images/pharmaceutics-15-00792-g005-550.jpg?1677569828)

Open Access Article **(/1999-4923/15/3/791/pdf?version=1677653101)**

Micellar Form of a Ferrocene-Containing Camphor Sulfonamide with Improved Aqueous Solubility and Tumor Curing Potential (/1999-4923/15/3/791)

by **Maria Schröder (https://sciprofiles.com/profile/2293590)**, **Maria Petrova (https://sciprofiles.com/profile/1774359)**, **Georgi M. Dobrikov (https://sciprofiles.com/profile/2360902)**, **Georgy Grancharov (https://sciprofiles.com/profile/1850229)**, **Denitsa Momekova (https://sciprofiles.com/profile/1871109)**, **Petar D. Petrov (https://sciprofiles.com/profile/1064652)** and **Iva Ugrinova (https://sciprofiles.com/profile/624772)**
Pharmaceutics **2023**, *15*(3), 791; **https://doi.org/10.3390/pharmaceutics15030791 (https://doi.org/10.3390/pharmaceutics15030791)** - 27 Feb 2023
Cited by 1 (/1999-4923/15/3/791#metrics) | Viewed by 1012

Abstract The discovery of new anticancer drugs with a higher, more specific activity and diminished side effects than the conventional chemotherapeutic agents is a tremendous challenge to contemporary medical research and development. To achieve a pronounced efficacy, the design of antitumor agents can combine **[...] Read more.**
(This article belongs to the Special Issue **Application of Polymeric Micelles for Drug and Gene Delivery (/journal/pharmaceutics/special_issues/PQNR45I30D)**)

► **Show Figures**

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00791/article_deploy/html/images/pharmaceutics-15-00791-g001-550.jpg?1677653191) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00791/article_deploy/html/images/pharmaceutics-15-00791-g002-550.jpg?1677653187) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00791/article_deploy/html/images/pharmaceutics-15-00791-g003-550.jpg?1677653182) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00791/article_deploy/html/images/pharmaceutics-15-00791-g004-550.jpg?1677653190) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00791/article_deploy/html/images/pharmaceutics-15-00791-g005a-550.jpg?1677653185) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00791/article_deploy/html/images/pharmaceutics-15-00791-g005b-550.jpg?1677653183) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00791/article_deploy/html/images/pharmaceutics-15-00791-g006-550.jpg?1677653189) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00791/article_deploy/html/images/pharmaceutics-15-00791-g007-550.jpg?1677653180) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00791/article_deploy/html/images/pharmaceutics-15-00791-g008-550.jpg?1677653186)

Open Access Article **(/1999-4923/15/3/790/pdf?version=1677508556)**

Influence of the Topology of Poly(L-Cysteine) on the Self-Assembly, Encapsulation and Release Profile of Doxorubicin on Dual-Responsive Hybrid Polypeptides (/1999-4923/15/3/790)

by **Dimitra Stavroulaki (https://sciprofiles.com/profile/author/azhCaVRqcTJrZXMwODR3VUt6TEM0OEpublFhK1UrSDZnS1BYd29taCtBOD0=)**, **Iro Kyroglou (https://sciprofiles.com/profile/author/YXYvRk0yYlJGNHFHY3JBbmNxMG5nN0RaazBPa2dFYkF2anp1VnlwYXAwVT0=)**, **Dimitrios Skourtis (https://sciprofiles.com/profile/1352837)**, **Varvara Athanasiou (https://sciprofiles.com/profile/author/Q3ZMTkl1cW9yOGxuUm5pTVRVWDRGRGxtUkRVZHlzY3lwK3NDWnQ4cEZlcz0=)**, **Pandora Thimi (https://sciprofiles.com/profile/author/TUt4Qnd0d0taSTVNWUpKWTFRTmpoYWhXbVk2amdvczdyRzd2a0RQN0JGYz0=)**, **Sosanna Sofianopoulou (https://sciprofiles.com/profile/author/Wi9lUFZlVVlURStXQkZNT0s1L0htT1REVHVwWTRhWis4K2J1cko3ZUUvcz0=)**,

Diana Kazaryan (https://sciprofiles.com/profile/author/Y2pqUTNnbVh0c2o2ZndNcVRwbHRCcmgyaEVrbER2ZUpldkFESkw4alFxRT0=),
Panagiota G. Fragouli (https://sciprofiles.com/profile/author/VXZjK3RXQmhEYUZxdGNENTU2V1AySWFJV2ttYThGcIRCYmVXZW9kVXZHYz0=),
Andromahi Labrianidou (https://sciprofiles.com/profile/654032), Konstantinos Dimas (https://sciprofiles.com/profile/1367193),
Georgios Patias (https://sciprofiles.com/profile/author/SFZzN1RPNnlxRzNTcTZaQmVpa1RZY0JJUndJQTMydUNjQ3pjZGlxZWY%3D),
David M. Haddleton (https://sciprofiles.com/profile/author/NkJuT0R5NHNiYlpPNDA1d0g4K3hucFY1N3ErVSs3SHRqUUo2dHRUZ2d2MD0=) and
Hermis Iatrou (https://sciprofiles.com/profile/266301)

Pharmaceutics **2023**, *15*(3), 790; https://doi.org/10.3390/pharmaceutics15030790 - 27 Feb 2023
Viewed by 1109

Abstract The synthesis of a series of novel hybrid block copolypeptides based on poly(ethylene oxide) (PEO), poly(L-histidine) (PHis) and poly(L-cysteine) (PCys) is presented. The synthesis of the terpolymers was achieved through a ring-opening polymerization (ROP) of the corresponding protected *N* **[...] Read more.**
(This article belongs to the Special Issue **Polymers Enhancing Bioavailability in Drug Delivery, 2nd Edition** (/journal/pharmaceutics/special_issues/0JC3F78273))

► **Show Figures**

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00790/article_deploy/html/images/pharmaceutics-15-00790-g001-550.jpg?1677508628) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00790/article_deploy/html/images/pharmaceutics-15-00790-g002-550.jpg?1677508623) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00790/article_deploy/html/images/pharmaceutics-15-00790-g003-550.jpg?1677508627) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00790/article_deploy/html/images/pharmaceutics-15-00790-g004-550.jpg?1677508632) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00790/article_deploy/html/images/pharmaceutics-15-00790-g005-550.jpg?1677508624) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00790/article_deploy/html/images/pharmaceutics-15-00790-sch001-550.jpg?1677508626) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00790/article_deploy/html/images/pharmaceutics-15-00790-sch002-550.jpg?1677508621)

Open Access Review (/1999-4923/15/3/789/pdf?version=1677504670)

Antimicrobial Peptides: Avant-Garde Antifungal Agents to Fight against Medically Important *Candida* Species (/1999-4923/15/3/789)

by Gina P. Rodríguez-Castaño (https://sciprofiles.com/profile/author/UW5vK2hlN2Y5Q0M2bXNDdjF5TXZZSzl2OGU3dnFpMkFJdWtmZFFFamgyTT0=),
Frank Rosenau (https://sciprofiles.com/profile/1104302), Ludger Ständker (https://sciprofiles.com/profile/1237147) and
Carolina Firacative (https://sciprofiles.com/profile/377983)

Pharmaceutics **2023**, *15*(3), 789; https://doi.org/10.3390/pharmaceutics15030789 - 27 Feb 2023
Cited by 2 (/1999-4923/15/3/789#metrics) | Viewed by 995

Abstract Expanding the antifungal drug arsenal for treating *Candida* infections is crucial in this era of the rising life expectancy of patients with immunosuppression and comorbidities. Infections caused by *Candida* species are on the rise, including those caused by multidrug-resistant strains or species, and **[...] Read more.**

► **Show Figures**

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00789/article_deploy/html/images/pharmaceutics-15-00789-g001-550.jpg?1677504732)

Open Access Article (/1999-4923/15/3/788/pdf?version=1677663272)

Hyaluronidase Promote Transdermal Diffusion of Small Sized Curcumin Nanocrystal by Dissolving Microneedles Delivery (/1999-4923/15/3/788)

by Xiaoqing Miao (https://sciprofiles.com/profile/1989870),
Jingru Zhao (https://sciprofiles.com/profile/author/VG9nNFRUZFFLVHMyTkllT0VFZXg1Y2NlcHN0dWFPc2sxSUhTQ3ZHN3hRND0=),
Hong Xiang (https://sciprofiles.com/profile/2054004) and
Xiaoxi Shi (https://sciprofiles.com/profile/author/c1Fjbkd5NGxpdXo3bW1rcUp3RngweHNheVFQUzJoaC9kMEd4QnZTK1lQOD0=)

Pharmaceutics **2023**, *15*(3), 788; https://doi.org/10.3390/pharmaceutics15030788 - 27 Feb 2023
Viewed by 1147

Abstract Hyaluronidase is clinically used in treating many skin diseases due to its good permeability-promoting effect, which may motivate the diffusion and absorption of drugs. To verify the penetration osmotic effect of hyaluronidase in microneedles, 55 nm-size curcumin nanocrystals were fabricated and loaded into **[...] Read more.**
(This article belongs to the Special Issue **The Latest Development of Multifunctional Nanopharmaceutical Formulations and Its Application** (/journal/pharmaceutics/special_issues/D311QVP59L))

► **Show Figures**

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00788/article_deploy/html/images/pharmaceutics-15-00788-g001-550.jpg?1677663342) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00788/article_deploy/html/images/pharmaceutics-15-00788-g002-550.jpg?1677663339) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00788/article_deploy/html/images/pharmaceutics-15-00788-g003-550.jpg?1677663345) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00788/article_deploy/html/images/pharmaceutics-15-00788-g004-550.jpg?1677663340) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00788/article_deploy/html/images/pharmaceutics-15-00788-g005-550.jpg?1677663337) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00788/article_deploy/html/images/pharmaceutics-15-00788-g006-550.jpg?1677663344)

Open Access Article (/1999-4923/15/3/787/pdf?version=1677748182)

Discovery of New 1,4,6-Trisubstituted-1*H*-pyrazolo[3,4-*b*]pyridines with Anti-Tumor Efficacy in Mouse Model of Breast Cancer (/1999-4923/15/3/787)

by Maria Georgiou (https://sciprofiles.com/profile/2747747), Nikolaos Lougiakis (https://sciprofiles.com/profile/1167667),
Roxane Tenta (https://sciprofiles.com/profile/367348),
Katerina Gioti (https://sciprofiles.com/profile/author/RGdPL1BJY0lySmw4MGFCYk03VFdWNUdCMGNJMlpiUjh5RE5kcWFwMFlwRT0=),
Stavroula Baritaki (https://sciprofiles.com/profile/809459), Lydia-Evangelia Gkaralea (https://sciprofiles.com/profile/2897640),
Elisavet Deligianni (https://sciprofiles.com/profile/2764584), Panagiotis Marakos (https://sciprofiles.com/profile/1137495),
Nicole Pouli (https://sciprofiles.com/profile/385071) and Dimitris Stellas (https://sciprofiles.com/profile/989474)

Pharmaceutics **2023**, *15*(3), 787; https://doi.org/10.3390/pharmaceutics15030787 - 27 Feb 2023
Cited by 2 (/1999-4923/15/3/787#metrics) | Viewed by 1031

Abstract Purine analogues are important therapeutic tools due to their affinity to enzymes or receptors that are involved in critical biological processes. In this study, new 1,4,6-trisubstituted pyrazolo[3,4-*b*]pyridines were designed and synthesized, and their cytotoxic potential was been studied. The new derivatives **[...] Read more.**
(This article belongs to the Special Issue **Advances in Anticancer Agent** (/journal/pharmaceutics/special_issues/cancer_agent))

► **Show Figures**

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00787/article_deploy/html/images/pharmaceutics-15-00787-g001-550.jpg?1677748265) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00787/article_deploy/html/images/pharmaceutics-15-00787-g002-550.jpg?1677748255) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00787/article_deploy/html/images/pharmaceutics-15-00787-g003-550.jpg?1677748250) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00787/article_deploy/html/images/pharmaceutics-15-00787-g004-550.jpg?1677748267) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00787/article_deploy/html/images/pharmaceutics-15-00787-g005-550.jpg?1677748252) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00787/article_deploy/html/images/pharmaceutics-15-00787-sch001-550.jpg?1677748261)

Open Access Article (/1999-4923/15/3/786/pdf?version=1677499706)

Ex Vivo Visualization of Distribution of Intravitreal Injections in the Porcine Vitreous and Hydrogels Simulating the Vitreous (/1999-4923/15/3/786)

by Tobias Auel (https://sciprofiles.com/profile/1743868),
Lara Paula Scherke (https://sciprofiles.com/profile/author/bjJaeVNKNHEvdktEK3dSbm9uMHNsZU5zNUN4WEpKR0FoK05NcFVrdnp3bz0=),
Stefan Hadlich (https://sciprofiles.com/profile/author/aFFZaExiV2VjbTVlOGtKcytRRlF6SVhlSjQ0NG1kMGxlbno1MFRua3ZxM215UHVuNzFVL0tkT2NJRndxZFpTeg==),
Susan Mouchantat (https://sciprofiles.com/profile/author/TVlxKy9hSExvb01xbzg3SDd2eWN0YjRPU0xMQ21lUWQrWW5NVG9ORXpGNVJtMEV2V2dXUlpqbENUVWlwRnpZbw==),
Michael Grimm (https://sciprofiles.com/profile/1744175), Werner Weitschies (https://sciprofiles.com/profile/540846) and
Anne Seidlitz (https://sciprofiles.com/profile/1654191)

Pharmaceutics **2023**, *15*(3), 786; https://doi.org/10.3390/pharmaceutics15030786 - 27 Feb 2023
Cited by 1 (/1999-4923/15/3/786#metrics) | Viewed by 763

Abstract The characterization of intravitreal dosage forms with regard to their behavior in vivo is usually explored in preclinical development through animal studies. In vitro vitreous substitutes (VS) to simulate the vitreous body for preclinical investigations have so far been insufficiently studied. To determine **[...] Read more.**
(This article belongs to the Special Issue **Ophthalmic Drug Delivery, 3rd Edition** (/journal/pharmaceutics/special_issues/NMABJ908RR))

► **Show Figures**

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00786/article_deploy/html/images/pharmaceutics-15-00786-g001-550.jpg?1677499780) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00786/article_deploy/html/images/pharmaceutics-15-00786-g002-550.jpg?1677499778) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00786/article_deploy/html/images/pharmaceutics-15-00786-g003-550.jpg?1677499781) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00786/article_deploy/html/images/pharmaceutics-15-00786-g004-550.jpg?1677499776) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-

Back to TopTop

15-00786/article_deploy/html/images/pharmaceutics-15-00786-g005-550.jpg?1677499786) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00786/article_deploy/html/images/pharmaceutics-15-00786-g006-550.jpg?1677499777)

Open Access Review (/1999-4923/15/3/785/pdf?version=1677579932)

Potential Roles of Melatonin in Doxorubicin-Induced Cardiotoxicity: From Cellular Mechanisms to Clinical Application (/1999-4923/15/3/785)

by Tanawat Attachaipanich (https://sciprofiles.com/profile/author/cXBMUTNxa2VCQ1pGNUV3UFlCRkZOcS90L3hWdTdsamg2YmRwTEdaeXlxUT0=), Siriporn C. Chattipakorn (https://sciprofiles.com/profile/1767731) and Nipon Chattipakorn (https://sciprofiles.com/profile/1141276)

Pharmaceutics **2023**, *15*(3), 785; https://doi.org/10.3390/pharmaceutics15030785 (https://doi.org/10.3390/pharmaceutics15030785) - 27 Feb 2023

Viewed by 836

Abstract Doxorubicin is a potent chemotherapeutic drug; however, its clinical application has been limited due to its cardiotoxicity. One of the major mechanisms of doxorubicin-induced cardiotoxicity is the induction of oxidative stress. Evidence from in vitro and in vivo studies demonstrates that melatonin attenuated **[...] Read more.**

(This article belongs to the Special Issue **Recent Advances in Melatonin for Cancer Therapy** (/journal/pharmaceutics/special_issues/24W46F8FT2))

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00785/article_deploy/html/images/pharmaceutics-15-00785-g001-550.jpg?1677576005)

Open Access Article (/1999-4923/15/3/784/pdf?version=1677490785)

Reduction-Hypersensitive Podophyllotoxin Prodrug Self-Assembled Nanoparticles for Cancer Treatment (/1999-4923/15/3/784)

by Xinhui Wang (https://sciprofiles.com/profile/author/M2RGdnppK2s1bmdkeStLQ3owN2JEZjk1WTU2b25NUkZQaHBlVC85ek1SQmtOYVRlNExRbTVFN3cyTzJFcE1rSA==), Yuequan Wang (https://sciprofiles.com/profile/2650840), Jiaxin Yu (https://sciprofiles.com/profile/author/dUNTRDIpdEk5NjB3WjJibU9ETFhaeUl6L3RCSW9BaFI5WUVRUlVxQURRUT0=), Qian Qiu (https://sciprofiles.com/profile/author/QTNHbU5mNUZwL3R0VEtHZzFSWTlKQT09), Rui Liao (https://sciprofiles.com/profile/author/SW1GbWN6Z0RSdU9zMkd6aURTdXdSbVFOR21DcmhFRm1mcHpVM1l5UG1SST0=), Shenwu Zhang (https://sciprofiles.com/profile/author/TzBqcDNScTl4UEpZSjFWMTZWTXE1QzdRZWdld25URUtLcEtZblRLK1dnMD0=) and Cong Luo (https://sciprofiles.com/profile/2502310)

Pharmaceutics **2023**, *15*(3), 784; https://doi.org/10.3390/pharmaceutics15030784 (https://doi.org/10.3390/pharmaceutics15030784) - 27 Feb 2023

Viewed by 1188

Abstract Podophyllotoxin (PPT) has shown strong antitumor effects on various types of cancers. However, the non-specific toxicity and poor solubility severely limits its clinical transformation. In order to overcome the adverse properties of PPT and explore its clinical potential, three novel PTT−fluorene methanol prodrugs **[...] Read more.**

(This article belongs to the Special Issue **Functional Nanomaterials for Drug Delivery and Pharmaceutical Applications** (/journal/pharmaceutics/special_issues/KQE93AS3VO))

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00784/article_deploy/html/images/pharmaceutics-15-00784-g001-550.jpg?1677490856) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00784/article_deploy/html/images/pharmaceutics-15-00784-g002-550.jpg?1677490872) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00784/article_deploy/html/images/pharmaceutics-15-00784-g003-550.jpg?1677490857) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00784/article_deploy/html/images/pharmaceutics-15-00784-g004-550.jpg?1677490863) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00784/article_deploy/html/images/pharmaceutics-15-00784-g005-550.jpg?1677490871) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00784/article_deploy/html/images/pharmaceutics-15-00784-g006-550.jpg?1677490865) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00784/article_deploy/html/images/pharmaceutics-15-00784-g007-550.jpg?1677490859) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00784/article_deploy/html/images/pharmaceutics-15-00784-g008-550.jpg?1677490876) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00784/article_deploy/html/images/pharmaceutics-15-00784-ch001-550.jpg?1677490870) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00784/article_deploy/html/images/pharmaceutics-15-00784-sch001-550.jpg?1677490868)

Open Access Article (/1999-4923/15/3/783/pdf?version=1677483546)

Novel Approach for the Approximation of Vitamin D_3 Pharmacokinetics from In Vivo Absorption Studies (/1999-4923/15/3/783)

by Grzegorz Żurek (https://sciprofiles.com/profile/author/bXpBdFo3N3VSb1BlSGVBMFduQlNrelJMa2RtVDYyWmdCRlNHNG1taVgvaz0=), Magdalena Przybyło (https://sciprofiles.com/profile/author/dG5hY0lFZ3ZaMTh4SHN6U3VXcy9sQUYvK05DSG9hNWprc0pWcE9sT1lVZz0=), Wojciech Witkiewicz (https://sciprofiles.com/profile/author/YW5VellJdzZLbXJFVWZWanZVS1laaStyM09lOStqTzRHazdHd0pEL01YND0=) and Marek Langner (https://sciprofiles.com/profile/2618709)

Pharmaceutics **2023**, *15*(3), 783; https://doi.org/10.3390/pharmaceutics15030783 (https://doi.org/10.3390/pharmaceutics15030783) - 27 Feb 2023

Viewed by 1004

Abstract The changing environment and modified lifestyles have meant that many vitamins and minerals are deficient in a significant portion of the human population. Therefore, supplementation is a viable nutritional approach, which helps to maintain health and well-being. The supplementation efficiency of a highly **[...] Read more.**

(This article belongs to the Section **Pharmacokinetics and Pharmacodynamics** (/journal/pharmaceutics/sections/Pharmacokinetics_and_Pharmacodynamics))

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00783/article_deploy/html/images/pharmaceutics-15-00783-g001-550.jpg?1677483610) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00783/article_deploy/html/images/pharmaceutics-15-00783-g002-550.jpg?1677483612)

Open Access Article (/1999-4923/15/3/782/pdf?version=1677473507)

Virus-like Particle Vaccine Expressing the Respiratory Syncytial Virus Pre-Fusion and G Proteins Confers Protection against RSV Challenge Infection (/1999-4923/15/3/782)

by Su-Hwa Lee (https://sciprofiles.com/profile/author/dlMvb2t1c3hpUnJWZUxVYy9rQWVrTHdaRmEwV3NUOTgvTjYvTWZOc0w5MD0=), Ki-Back Chu (https://sciprofiles.com/profile/author/c2FCTHhycWhHbi9rMDRPN1hZcllzdz09), Min-Ju Kim (https://sciprofiles.com/profile/author/WHgyTkhvMkM3ODNGZ3VXVXYyTWplZFdlV1UxekNMYzlQamU4Y0xPZU1Pdz0=), Jie Mao (https://sciprofiles.com/profile/author/dFk0ZU1sS1dlVDE2aFhrN0YvSViY2JZQmlNaHkzVm43SGVQRzVNS3g2Yz0=), Gi-Deok Eom (https://sciprofiles.com/profile/author/d1paUFBhdUZndnJNbi9nQmgxK0VJeFg2YUJuMHNCTFR3cWJGcDZWSURKaz0=), Keon-Woong Yoon (https://sciprofiles.com/profile/author/ekpjSXhoTkl2NXFaK0ZlODdrVHlmUFNWb1dWUXZXd2NOMW1DbVM2OUhMQT0=), Md Atique Ahmed (https://sciprofiles.com/profile/922966) and Fu-Shi Quan (https://sciprofiles.com/profile/532339)

Pharmaceutics **2023**, *15*(3), 782; https://doi.org/10.3390/pharmaceutics15030782 (https://doi.org/10.3390/pharmaceutics15030782) - 27 Feb 2023

Cited by 1 (/1999-4923/15/3/782#metrics) | Viewed by 1517

Abstract Respiratory syncytial virus (RSV) causes severe lower respiratory tract disease in children and the elderly. However, there are no effective antiviral drugs or licensed vaccines available for RSV infection. Here, RSV virus-like particle (VLP) vaccines expressing Pre-F, G, or Pre-F and G proteins **[...] Read more.**

(This article belongs to the Special Issue **Non-invasive Biopharmaceutical/Vaccine Delivery Systems and Formulation Strategies** (/journal/pharmaceutics/special_issues/85QHMU1517))

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00782/article_deploy/html/images/pharmaceutics-15-00782-g001-550.jpg?1677473587) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00782/article_deploy/html/images/pharmaceutics-15-00782-g002-550.jpg?1677473583) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00782/article_deploy/html/images/pharmaceutics-15-00782-g003-550.jpg?1677473591) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00782/article_deploy/html/images/pharmaceutics-15-00782-g004-550.jpg?1677473592) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00782/article_deploy/html/images/pharmaceutics-15-00782-g005-550.jpg?1677473596) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00782/article_deploy/html/images/pharmaceutics-15-00782-g006-550.jpg?1677473594) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00782/article_deploy/html/images/pharmaceutics-15-00782-g007-550.jpg?1677473581)

Open Access Article (/1999-4923/15/3/781/pdf?version=1677472198)

A Multifunctional Trypsin Protease Inhibitor from Yellow Bell Pepper Seeds: Uncovering Its Dual Antifungal and Hypoglycemic Properties (/1999-4923/15/3/781)

by Juliana Cotabarren (https://sciprofiles.com/profile/1500692), Brenda Ozón (https://sciprofiles.com/profile/1740196), Santiago Claver (https://sciprofiles.com/profile/author/elpVbkZsRHVTNWhYaTZ0QloxUkNyck5vM0ZPRjZxbCtvTHRzaTdER0dzZz0=), Florencia Geier (https://sciprofiles.com/profile/author/dmkza1NZUWtGcnR1T0xzV2l4K1ZlWFlOUER5S1pleiswRDNXWkZFU0FDVT0=), Martina Rossotti (https://sciprofiles.com/profile/2796544), Javier Garcia-Pardo (https://sciprofiles.com/profile/374515) and Walter David Obregón (https://sciprofiles.com/profile/353572)

Pharmaceutics **2023**, *15*(3), 781; https://doi.org/10.3390/pharmaceutics15030781 (https://doi.org/10.3390/pharmaceutics15030781) - 27 Feb 2023

Viewed by 1214

Abstract Fungal infections are a growing public health concern worldwide and the emergence of antifungal resistance has limited the number of therapeutic options. Therefore,

developing novel strategies for identifying and developing new antifungal compounds is an active area of research in the pharmaceutical industry. **[...] Read more.**
(This article belongs to the Special Issue **Bioactive Molecules from Plants: Discovery and Pharmaceutical Applications (Volume II) (/journal/pharmaceutics /special_issues/bioactive_molecules_pharmaceutical_applications_volume_II)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00781/article_deploy/html/images/pharmaceutics-15-00781-g001-550.jpg?1677472266) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00781/article_deploy/html/images/pharmaceutics-15-00781-g002-550.jpg?1677472270) (https://pub.mdpi-res.com /pharmaceutics/pharmaceutics-15-00781/article_deploy/html/images/pharmaceutics-15-00781-g003-550.jpg?1677472265) (https://pub.mdpi-res.com/pharmaceutics /pharmaceutics-15-00781/article_deploy/html/images/pharmaceutics-15-00781-g004-550.jpg?1677472269) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00781/article_deploy/html/images/pharmaceutics-15-00781-g005-550.jpg?1677472268) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00781 /article_deploy/html/images/pharmaceutics-15-00781-g006-550.jpg?1677472267)

Open Access Article (/1999-4923/15/3/780/pdf?version=1677415411)

2-Styrylchromones Prevent IL-1β-Induced Pro-Inflammatory Activation of Fibroblast-like Synoviocytes while Increasing COX-2 Expression (/1999-4923/15/3/780)

by **Ana Teresa Rufino (https://sciprofiles.com/profile/270539)**, **Mariana Lucas (https://sciprofiles.com/profile/2451640)**, **Artur M. S. Silva (https://sciprofiles.com/profile/77309)**, **Daniela Ribeiro (https://sciprofiles.com/profile/530873)** and **Eduarda Fernandes (https://sciprofiles.com/profile/384861)**

Pharmaceutics **2023**, *15*(3), 780; **https://doi.org/10.3390/pharmaceutics15030780 (https://doi.org/10.3390/pharmaceutics15030780)** - 26 Feb 2023
Viewed by 1244

Abstract Rheumatoid arthritis (RA) is characterized by systemic immune and chronic inflammatory features, leading to the destruction of the joints. Presently, there are no effective drugs able to control synovitis and catabolism in the process of RA. 2-Styrylchromones (2-SC) are a small group of **[...] Read more.**
(This article belongs to the Special Issue **Advances in Natural Products and Their Derivatives for Metabolic and Chronic Inflammatory Disease Therapy (/journal /pharmaceutics/special_issues/natural_Metabolic)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00780/article_deploy/html/images/pharmaceutics-15-00780-ag-550.jpg?1677415491) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00780/article_deploy/html/images/pharmaceutics-15-00780-g001-550.jpg?1677415489) (https://pub.mdpi-res.com /pharmaceutics/pharmaceutics-15-00780/article_deploy/html/images/pharmaceutics-15-00780-g002-550.jpg?1677415486) (https://pub.mdpi-res.com/pharmaceutics /pharmaceutics-15-00780/article_deploy/html/images/pharmaceutics-15-00780-g003-550.jpg?1677415483) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00780/article_deploy/html/images/pharmaceutics-15-00780-g004-550.jpg?1677415490) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00780 /article_deploy/html/images/pharmaceutics-15-00780-g005-550.jpg?1677415487)

Open Access Article (/1999-4923/15/3/779/pdf?version=1677413281)

Synthesis of Schiff Bases Containing Phenol Rings and Investigation of Their Antioxidant Capacity, Anticholinesterase, Butyrylcholinesterase, and Carbonic Anhydrase Inhibition Properties (/1999-4923/15/3/779)

by **Sertan Aytac (https://sciprofiles.com/profile/author/amMwS08rWkRxTzZXdWltYVV0Zk56YXg1RGlyLzJNV2c1RHNQVmtvYVpXMD0=)**, **Ozlem Gundogdu (https://sciprofiles.com/profile/2562018)**, **Zeynebe Bingol (https://sciprofiles.com/profile/author/Q1B3SGRNOVM5ZXZ5TjdCSU1OTXJIZGI0ck9HMkszKzBxOVlhMFl2OFVvND0=)** and **İlhami Gulcin (https://sciprofiles.com/profile/76706)**

Pharmaceutics **2023**, *15*(3), 779; **https://doi.org/10.3390/pharmaceutics15030779 (https://doi.org/10.3390/pharmaceutics15030779)** - 26 Feb 2023
Cited by 12 (/1999-4923/15/3/779#metrics) | Viewed by 1852

Abstract The widespread usage of Schiff bases in chemistry, industry, medicine, and pharmacy has increased interest in these compounds. Schiff bases and derivative compounds have important bioactive properties. Heterocyclic compounds containing phenol derivative groups in their structure have the potential to capture free radicals **[...] Read more.**
(This article belongs to the Special Issue **New Insights on Drug Design, Delivery and Targeting in Neurodegeneration (/journal/pharmaceutics/special_issues /drug_neurodegeneration)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00779/article_deploy/html/images/pharmaceutics-15-00779-g001-550.jpg?1677413344) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00779/article_deploy/html/images/pharmaceutics-15-00779-sch001-550.jpg?1677413345) (https://pub.mdpi-res.com /pharmaceutics/pharmaceutics-15-00779/article_deploy/html/images/pharmaceutics-15-00779-sch002-550.jpg?1677413347)

Open Access Review (/1999-4923/15/3/778/pdf?version=1677407741)

Recent Trends in Antisense Therapies for Duchenne Muscular Dystrophy (/1999-4923/15/3/778)

by **Harry Wilton-Clark (https://sciprofiles.com/profile/2016682)** and **Toshifumi Yokota (https://sciprofiles.com/profile/49477)**

Pharmaceutics **2023**, *15*(3), 778; **https://doi.org/10.3390/pharmaceutics15030778 (https://doi.org/10.3390/pharmaceutics15030778)** - 26 Feb 2023
Cited by 4 (/1999-4923/15/3/778#metrics) | Viewed by 2020

Abstract Duchenne muscular dystrophy (DMD) is a debilitating and fatal genetic disease affecting 1/5000 boys globally, characterized by progressive muscle breakdown and eventual death, with an average lifespan in the mid–late twenties. While no cure yet exists for DMD, gene and antisense therapies have **[...] Read more.**
(This article belongs to the Special Issue **Recent Trends in Oligonucleotide Based Therapies (/journal/pharmaceutics/special_issues/rt_olibt)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00778/article_deploy/html/images/pharmaceutics-15-00778-g001-550.jpg?1677407804)

Open Access Review (/1999-4923/15/3/777/pdf?version=1677406170)

Future Pharmacotherapy for Sensorineural Hearing Loss by Protection and Regeneration of Auditory Hair Cells (/1999-4923/15/3/777)

by **Mami Matsunaga (https://sciprofiles.com/profile/author/N1JOOGlpcFd4bUxTQjM3ZzE2S1cxSVMwbURibWlROStGN1YxbCtOYlc5WWt2QW1HTGtyVkczeFlFMWhCQm9VYg==)** and **Takayuki Nakagawa (https://sciprofiles.com/profile/1913541)**

Pharmaceutics **2023**, *15*(3), 777; **https://doi.org/10.3390/pharmaceutics15030777 (https://doi.org/10.3390/pharmaceutics15030777)** - 26 Feb 2023
Cited by 3 (/1999-4923/15/3/777#metrics) | Viewed by 1816

Abstract Sensorineural hearing loss has been a global burden of diseases for decades. However, according to recent progress in experimental studies on hair cell regeneration and protection, clinical trials of pharmacotherapy for sensorineural hearing loss have rapidly progressed. In this review, we focus on **[...] Read more.**
(This article belongs to the Special Issue **Personalized Pharmacotherapy and Individualized Delivering Strategies for ENT Applications (/journal/pharmaceutics /special_issues/Personalized_Pharm)**)

Open Access Article (/1999-4923/15/3/776/pdf?version=1677491761)

[^{111}In]In/[^{177}Lu]Lu-AAZTA^{5}-LM4 SST$_2$R-Antagonists in Cancer Theranostics: From Preclinical Testing to First Patient Results (/1999-4923/15/3/776)

by **Berthold A. Nock (https://sciprofiles.com/profile/334623)**, **Panagiotis Kanellopoulos (https://sciprofiles.com/profile/1270141)**, **Euy Sung Moon (https://sciprofiles.com/profile/author/L01OMWVCb1JOSGV3Zk1YK3VUNjZFaXZFajRxcFNpaVVSRG5VOTVwSFFFOD0=)**, **Maritina Rouchota (https://sciprofiles.com/profile/2806842)**, **George Loudos (https://sciprofiles.com/profile/author/dWpCU1ZKaVVMdGp5elVhdjY3QzhzRU5rZ0J3SG8wVHdOeHI0YzVPNUw0UT0=)**, **Sanjana Ballal (https://sciprofiles.com/profile/author/S1hQL1hUWFVsb3o1OHJnWjhYL09VWXBSdlcwbWNPMmxOMkFDeExySkRFYz0=)**, **Madhav P. Yadav (https://sciprofiles.com/profile/author/WFF1elVzUW1yV3o0QjE5TkFFR012QzFjbjBJdThsRDJHZlFrc0pOMEgvTT0=)**, **Chandrasekhar Bal (https://sciprofiles.com/profile/1874555)**, **Prashant Mishra (https://sciprofiles.com/profile/2814966)**, **Parvind Sheokand (https://sciprofiles.com/profile/2803873)**, **Frank Roesch (https://sciprofiles.com/profile/author/akcrbVR5dXlzbFQ5K3lISHlhNFRENWhWOU9McFh5WUZHa2srNGh1MlFjZz0=)** and **Theodosia Maina (https://sciprofiles.com/profile/630954)**

Pharmaceutics **2023**, *15*(3), 776; **https://doi.org/10.3390/pharmaceutics15030776 (https://doi.org/10.3390/pharmaceutics15030776)** - 26 Feb 2023
Cited by 2 (/1999-4923/15/3/776#metrics) | Viewed by 1276

Abstract Aiming to expand the application of the SST$_2$R-antagonist LM4 (DPhe-c[DCys-4Pal-DAph(Cbm)-Lys-Thr-Cys]-DTyr-NH$_2$) beyond [^{68}Ga]Ga-DATA^{5m}-LM4 PET/CT (DATA^{5m}, (6-pentanoic acid)-6-(amino)methy-1,4-diazepinetriacetate), we now introduce AAZTA^{5}-LM4 (AAZTA^{5}, 1,4-bis(carboxymethyl)-6-[bis(carboxymethyl)]amino-6-[pentanoic-acid]perhydro-1,4-diazepine), allowing for the convenient coordination of trivalent **[...] Read more.**
(This article belongs to the Special Issue **Recent Advances in Radiopharmaceutics, 2nd Edition (/journal/pharmaceutics/special_issues/L409Z0F619)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00776/article_deploy/html/images/pharmaceutics-15-00776-g001-550.jpg?1677491844) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00776/article_deploy/html/images/pharmaceutics-15-00776-g002-550.jpg?1677491856) (https://pub.mdpi-res.com /pharmaceutics/pharmaceutics-15-00776/article_deploy/html/images/pharmaceutics-15-00776-g003-550.jpg?1677491843) (https://pub.mdpi-res.com/pharmaceutics

Back to TopTop

/pharmaceutics-15-00776/article_deploy/html/images/pharmaceutics-15-00776-g004-550.jpg?1677491850) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00776/article_deploy/html/images/pharmaceutics-15-00776-g005-550.jpg?1677491855) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00776/article_deploy/html/images/pharmaceutics-15-00776-g006-550.jpg?1677491854)

(/toggle_desktop_layout_cookie)

Open Access Review (/1999-4923/15/3/775/pdf?version=1677649764)

Smart Polymeric Nanoparticles in Cancer Immunotherapy (/1999-4923/15/3/775)

by Zhecheng Yu (https://sciprofiles.com/profile/2797157), Xingyue Shen (https://sciprofiles.com/profile/2797156), Han Yu (https://sciprofiles.com/profile/2097955), Haohong Tu (https://sciprofiles.com/profile/2512711), Chuda Chittasupho (https://sciprofiles.com/profile/1308444) and Yunqi Zhao (https://sciprofiles.com/profile/2054388)

Pharmaceutics **2023**, *15*(3), 775; https://doi.org/10.3390/pharmaceutics15030775 (https://doi.org/10.3390/pharmaceutics15030775) - 26 Feb 2023

Cited by 3 (/1999-4923/15/3/775#metrics) | Viewed by 1755

Abstract Cancer develops with unexpected mutations and causes death in many patients. Among the different cancer treatment strategies, immunotherapy is promising with the benefits of high specificity and accuracy, as well as modulating immune responses. Nanomaterials can be used to formulate drug delivery carriers **[...] Read more.**

(This article belongs to the Special Issue **Advances in Polymeric Drug Delivery Systems (/journal/pharmaceutics/special_issues/polymeric_drug)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00775/article_deploy/html/images/pharmaceutics-15-00775-g001-550.jpg?1677649832) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00775/article_deploy/html/images/pharmaceutics-15-00775-g002-550.jpg?1677649837) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00775/article_deploy/html/images/pharmaceutics-15-00775-g003-550.jpg?1677649839) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00775/article_deploy/html/images/pharmaceutics-15-00775-g004-550.jpg?1677649834)

Open Access Review (/1999-4923/15/3/774/pdf?version=1677718909)

Approved Nanomedicine against Diseases (/1999-4923/15/3/774)

by Yuanchao Jia (https://sciprofiles.com/profile/author/L0lZUWF2NG0yYmhaL1FYY3Q5N2tRUnh0MXpVZUdxakhPVU5SRzBHOUU3cz0=), Yuxin Jiang (https://sciprofiles.com/profile/author/MlE3dENqUXRwaWNLbWtYbzlTMHVwNnZOOUFNYXZuZ2tqdks2SGdRazFWTT0=), Yonglong He (https://sciprofiles.com/profile/author/anFNb2Q3Y3d0UEtsM09CN1YrNlQ2RUM3T2VqdG5LNXk3WTlWMS9NRlVSVT0=), Wanting Zhang (https://sciprofiles.com/profile/author/MTk1cFp2YjFTSTlBVllzVnhaT2pZdFAxM211SXRNQkNSNkJ3RkxBN053RT0=), Jiahui Zou (https://sciprofiles.com/profile/author/OXA1RnJHWHVnT0JRTUJURXcydXBHOUZjUFZSc3VtUXY4emp4cytORG9UMD0=), Kosheli Thapa Magar (https://sciprofiles.com/profile/2517465), Hamza Boucetta (https://sciprofiles.com/profile/2789655), Chao Teng (https://sciprofiles.com/profile/author/b0hPNWRTVXBkSkhEelRCSmtXeFRYYVVaczVDWXUwOGUxRWJacHZ6TnlwUT0=) and Wei He (https://sciprofiles.com/profile/453927)

Pharmaceutics **2023**, *15*(3), 774; https://doi.org/10.3390/pharmaceutics15030774 (https://doi.org/10.3390/pharmaceutics15030774) - 26 Feb 2023

Cited by 3 (/1999-4923/15/3/774#metrics) | Viewed by 1943

Abstract Nanomedicine is a branch of medicine using nanotechnology to prevent and treat diseases. Nanotechnology represents one of the most effective approaches in elevating a drug's treatment efficacy and reducing toxicity by improving drug solubility, altering biodistribution, and controlling the release. The development of **[...] Read more.**

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00774/article_deploy/html/images/pharmaceutics-15-00774-g001-550.jpg?1677718978) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00774/article_deploy/html/images/pharmaceutics-15-00774-g002-550.jpg?1677718976) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00774/article_deploy/html/images/pharmaceutics-15-00774-g003-550.jpg?1677718977)

Open Access Article (/1999-4923/15/3/773/pdf?version=1677651737)

Product Validation and Stability Testing of Pharmacy Compounded Cholic Acid Capsules for Dutch Patients with Rare Bile Acid Synthesis Defects (/1999-4923/15/3/773)

by Yasmin Polak (https://sciprofiles.com/profile/2624951), Bart A. W. Jacobs (https://sciprofiles.com/profile/author/WlhkSS8zeDVaMFF0YzhtZHQ4dkNvdz09), Natalja Bouwhuis (https://sciprofiles.com/profile/author/MkRoZGJ3VjZTOVhLL24vVnBmbEQ1VmV6RjhzQ05EVEx3RHZtYXdJU2U5QT0=), Carla E. M. Hollak (https://sciprofiles.com/profile/3083825), Maurice A. G. M. Kroon (https://sciprofiles.com/profile/3056830) and Elles Marleen Kemper (https://sciprofiles.com/profile/author/c1ZMcjFTRjA3MU5razZqaXFNdTd5blM4dFB6S3BSazlHR2M3cVpzMFEyUT0=)

Pharmaceutics **2023**, *15*(3), 773; https://doi.org/10.3390/pharmaceutics15030773 (https://doi.org/10.3390/pharmaceutics15030773) - 26 Feb 2023

Viewed by 912

Abstract Bile acid synthesis defects (BASDs) comprise a group of rare diseases that can be severely disabling. Bile acid supplementation with 5 to 15 mg/kg cholic acid (CA) has been hypothesized to decrease endogenous bile acid production, stimulate bile secretion, and improve bile flow **[...] Read more.**

(This article belongs to the Special Issue **Pharmacy Compounding of Personalized Preparation for Specific Patients: Challenges and Advantages (/journal/pharmaceutics/special_issues/0LMCZPN945)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00773/article_deploy/html/images/pharmaceutics-15-00773-g001-550.jpg?1677651805)

Open Access Review (/1999-4923/15/3/772/pdf?version=1677657465)

Recent Progress of Lipid Nanoparticles-Based Lipophilic Drug Delivery: Focus on Surface Modifications (/1999-4923/15/3/772)

by Yoseph Seo (https://sciprofiles.com/profile/author/M3E3bzVPWGxrSlA5MVYrMnd6emV1OEZjYWRuMXZLOW13aml0TE5EYjJ6RT0=), Hayeon Lim (https://sciprofiles.com/profile/author/ZU5xWmovZHNrQ0JWWDdMZVl2NHdQMWRZQnF3NUhhdHBhbXBHc1ZLWjgxMD0=), Hyunjun Park (https://sciprofiles.com/profile/2791778), Jiyun Yu (https://sciprofiles.com/profile/author/dmlyeHNkMUk0bytBc3R0NjNPdmN2azM3d25ER1RlWi85UmM1UXFpeVpNdz0=), Jeongyun An (https://sciprofiles.com/profile/author/S3FWdUphSnFkcFZ6QlFJZjZZa2cyNHVsZmxrVHRHN3B0Z0RucWxkSURRTT0=), Hah Young Yoo (https://sciprofiles.com/profile/751928) and Taek Lee (https://sciprofiles.com/profile/510414)

Pharmaceutics **2023**, *15*(3), 772; https://doi.org/10.3390/pharmaceutics15030772 (https://doi.org/10.3390/pharmaceutics15030772) - 26 Feb 2023

Cited by 1 (/1999-4923/15/3/772#metrics) | Viewed by 3249

Abstract Numerous drugs have emerged to treat various diseases, such as COVID-19, cancer, and protect human health. Approximately 40% of them are lipophilic and are used for treating diseases through various delivery routes, including skin absorption, oral administration, and injection. However, as lipophilic drugs **[...] Read more.**

(This article belongs to the Special Issue **Lipid-Based Drug Delivery Systems: The Key Ingredient for Future Medicine (/journal/pharmaceutics/special_issues/lipid_drug)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00772/article_deploy/html/images/pharmaceutics-15-00772-g001-550.jpg?1677657547) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00772/article_deploy/html/images/pharmaceutics-15-00772-g002-550.jpg?1677657539) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00772/article_deploy/html/images/pharmaceutics-15-00772-g003-550.jpg?1677657531) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00772/article_deploy/html/images/pharmaceutics-15-00772-g004-550.jpg?1677657532) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00772/article_deploy/html/images/pharmaceutics-15-00772-g005-550.jpg?1677657545) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00772/article_deploy/html/images/pharmaceutics-15-00772-g006-550.jpg?1677657537) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00772/article_deploy/html/images/pharmaceutics-15-00772-g007-550.jpg?1677657542)

Open Access Article (/1999-4923/15/3/771/pdf?version=1677653055)

pH-Responsible Doxorubicin-Loaded Fe_3O_4@$CaCO_3$ Nanocomposites for Cancer Treatment (/1999-4923/15/3/771)

by Victoriya Popova (https://sciprofiles.com/profile/author/b3J1dHlTQlBZcFZFYzNwQmVjTklLcFE0bGtPT05xMWpoL3BMMC92VVU4WT0=), Yuliya Poletaeva (https://sciprofiles.com/profile/author/RzVudGViRjczYTY5cjFNN2FNdzJ2QXJ0NmpIN1F2d29jTnAzeTNVSXZEaz0=), Alexey Chubarov (https://sciprofiles.com/profile/1308465) and Elena Dmitrienko (https://sciprofiles.com/profile/1308465)

Pharmaceutics **2023**, *15*(3), 771; https://doi.org/10.3390/pharmaceutics15030771 (https://doi.org/10.3390/pharmaceutics15030771) - 26 Feb 2023

Cited by 5 (/1999-4923/15/3/771#metrics) | Viewed by 1847

Abstract A magnetic nanocomposite (MNC) is an integrated nanoplatform that combines a set of functions of two types of materials. A successful combination can give rise to a completely new material with unique physical, chemical, and biological properties. The magnetic core of MNC provides **[...] Read more.**

(This article belongs to the Special Issue **New Properties of Supramolecular Complexes and Drug Nanoparticles (/journal/pharmaceutics/special_issues/Sup_drug)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00771/article_deploy/html/images/pharmaceutics-15-00771-ag-550.jpg?1677728055) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00771/article_deploy/html/images/pharmaceutics-15-00771-g001-550.jpg?1677727907) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00771/article_deploy/html/images/pharmaceutics-15-00771-g002-550.jpg?1677727908) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00771/article_deploy/html/images/pharmaceutics-15-00771-g003-550.jpg?1677727904) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00771/article_deploy/html/images/pharmaceutics-15-00771-g004-550.jpg?1677727905) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00771

/article_deploy/html/images/pharmaceutics-15-00771-g005-550.jpg?1677727906) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00771/article_deploy/html/images/pharmaceutics-15-00771-g006-550.jpg?1677727907) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00771/article_deploy/html/images/pharmaceutics-15-00771-g007-550.jpg?1677727905) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00771/article_deploy/html/images/pharmaceutics-15-00771-g008-550.jpg?1677727904) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00771/article_deploy/html/images/pharmaceutics-15-00771-g009-550.jpg?1677727906) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00771/article_deploy/html/images/pharmaceutics-15-00771-g010-550.jpg?1677727904) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00771/article_deploy/html/images/pharmaceutics-15-00771-g011-550.jpg?1677727909)

Open Access Review (/1999-4923/15/3/770/pdf?version=1677329833)

Current Treatments and New, Tentative Therapies for Parkinson's Disease (/1999-4923/15/3/770)

by Teresa Pardo-Moreno (https://sciprofiles.com/profile/author/VmVUQTZYREZRYmtCMStWZk1LbTcvQ2VjT05LZy9yR3ZhTWVNR0R3WVpxQT0=), Victoria García-Morales (https://sciprofiles.com/profile/1960822), Sami Suleiman-Martos (https://sciprofiles.com/profile/2798247), Antonio Rivas-Domínguez (https://sciprofiles.com/profile/1734476), Himan Mohamed-Mohamed (https://sciprofiles.com/profile/author/V3RsZlpuMWRCczFRTW5yVExkVmFQRDVyd1hnZjhwOUVtYXdTbzE5UFdBbz0=), Juan José Ramos-Rodríguez (https://sciprofiles.com/profile/1648551), Lucía Melguizo-Rodríguez (https://sciprofiles.com/profile/786760) and Anabel González-Acedo (https://sciprofiles.com/profile/2825015)

Pharmaceutics **2023**, *15*(3), 770; https://doi.org/10.3390/pharmaceutics15030770 (https://doi.org/10.3390/pharmaceutics15030770) - 25 Feb 2023

Cited by 2 (/1999-4923/15/3/770#metrics) | Viewed by 2349

Abstract Parkinson's disease (PD) is a neurodegenerative pathology, the origin of which is associated with the death of neuronal cells involved in the production of dopamine. The prevalence of PD has increased exponentially. The aim of this review was to describe the novel treatments **[...] Read more.**

(This article belongs to the Special Issue **Advances in Drug Targeting for Central Nervous System Disease (/journal/pharmaceutics/special_issues/V5N20K0YZ0)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00770/article_deploy/html/images/pharmaceutics-15-00770-g001-550.jpg?1677329896) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00770/article_deploy/html/images/pharmaceutics-15-00770-g002-550.jpg?1677329897)

Open Access Article (/1999-4923/15/3/769/pdf?version=1677320271)

Dual-Labelled Nanoparticles Inform on the Stability of Fluorescent Labels In Vivo (/1999-4923/15/3/769)

by Sabrina Roussel (https://sciprofiles.com/profile/2783312), Philippe Grenier (https://sciprofiles.com/profile/author/TU1nV3RNbmtFbldidlg5cTVtU3d0ajhqQVBoRUVTQnFXRldwN2Z5Tmppdz0=), Valérie Chénard (https://sciprofiles.com/profile/2801328) and Nicolas Bertrand (https://sciprofiles.com/profile/2662851)

Pharmaceutics **2023**, *15*(3), 769; https://doi.org/10.3390/pharmaceutics15030769 (https://doi.org/10.3390/pharmaceutics15030769) - 25 Feb 2023

Cited by 1 (/1999-4923/15/3/769#metrics) | Viewed by 1177

Abstract Fluorescent labelling is commonly used to monitor the biodistribution of nanomedicines. However, meaningful interpretation of the results requires that the fluorescent label remains attached to the nanomedicine. In this work, we explore the stability of three fluorophores (BODIPY650, Cyanine 5 and AZ647) attached **[...] Read more.**

(This article belongs to the Special Issue **Feature Papers in Nanomedicine and Nanotechnology (/journal/pharmaceutics/special_issues/fp_nanomedicine)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00769/article_deploy/html/images/pharmaceutics-15-00769-g001-550.jpg?1677320350) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00769/article_deploy/html/images/pharmaceutics-15-00769-g002-550.jpg?1677320347) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00769/article_deploy/html/images/pharmaceutics-15-00769-g003-550.jpg?1677320343) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00769/article_deploy/html/images/pharmaceutics-15-00769-g004-550.jpg?1677320352) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00769/article_deploy/html/images/pharmaceutics-15-00769-g005-550.jpg?1677320345)

Open Access Review (/1999-4923/15/3/768/pdf?version=1677316515)

Intrathecal Pseudodelivery of Drugs in the Therapy of Neurodegenerative Diseases: Rationale, Basis and Potential Applications (/1999-4923/15/3/768)

by Menéndez-González Manuel (https://sciprofiles.com/profile/395551), Bogdan-Ionel Tamba (https://sciprofiles.com/profile/865051), Maxime Leclere (https://sciprofiles.com/profile/2747587), Mostafa Mabrouk (https://sciprofiles.com/profile/409868), Thomas-Gabriel Schreiner (https://sciprofiles.com/profile/1620106), Romeo Ciobanu (https://sciprofiles.com/profile/1895219) and Tomás-Zapico Cristina (https://sciprofiles.com/profile/846964)

Pharmaceutics **2023**, *15*(3), 768; https://doi.org/10.3390/pharmaceutics15030768 (https://doi.org/10.3390/pharmaceutics15030768) - 25 Feb 2023

Cited by 1 (/1999-4923/15/3/768#metrics) | Viewed by 1142

Abstract Intrathecal pseudodelivery of drugs is a novel route to administer medications to treat neurodegenerative diseases based on the CSF-sink therapeutic strategy by means of implantable devices. While the development of this therapy is still in the preclinical stage, it offers promising advantages over **[...] Read more.**

(This article belongs to the Special Issue **Novel Therapeutic Approaches for Neurodegenerative Diseases Treatment (/journal/pharmaceutics/special_issues/neuro_treat)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00768/article_deploy/html/images/pharmaceutics-15-00768-g001-550.jpg?1677316582) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00768/article_deploy/html/images/pharmaceutics-15-00768-g002-550.jpg?1677316584) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00768/article_deploy/html/images/pharmaceutics-15-00768-g003-550.jpg?1677316586) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00768/article_deploy/html/images/pharmaceutics-15-00768-g004-550.jpg?1677316583)

Open Access Article (/1999-4923/15/3/767/pdf?version=1677313450)

Preclinical PET Imaging and Toxicity Study of a ^{68}Ga-Functionalized Polymeric Cardiac Blood Pool Agent (/1999-4923/15/3/767)

by Katayoun Saatchi (https://sciprofiles.com/profile/2604573), François Bénard (https://sciprofiles.com/profile/2217163), Navjit Hundal (https://sciprofiles.com/profile/author/eHBpcWFxVjVMZzlxN1BMd2lFVFQ5cmJHM3hDVnU5ZTQySGtWbW80ZHBhTT0=), Joshua Grimes (https://sciprofiles.com/profile/author/cS9RMmJ3ai9FZWs5NmVwd0FLZDFXU2RDYVJmR2R6VDRDc2RkNWV0dUp3Yz0=), Sergey Shcherbinin (https://sciprofiles.com/profile/author/SVF2SmY1OTFJUnR1UU5zZFRLNGFLMzROVUV6R255TGFFYUY0MlNENHgyQT0=), Maral Pourghiasian (https://sciprofiles.com/profile/author/N0JsQXpnanRVR1pmTTRKTkFYR1k1RlQ1SjBESG9KM2pHUXlTK3FtS2hiVT0=), Donald E. Brooks (https://sciprofiles.com/profile/426147), Anna Celler (https://sciprofiles.com/profile/author/RXdFM204dDJTdW1PUkpmYVRnc0wxb3Q0N3o4SG16ZW9iYmgrV3NEYjdCND0=) and Urs O. Häfeli (https://sciprofiles.com/profile/2575393)

Pharmaceutics **2023**, *15*(3), 767; https://doi.org/10.3390/pharmaceutics15030767 (https://doi.org/10.3390/pharmaceutics15030767) - 25 Feb 2023

Viewed by 869

Abstract Cardiac blood pool imaging is currently performed almost exclusively with ^{99m}Tc-based compounds and SPECT/CT imaging. Using a generator-based PET radioisotope has a few advantages, including not needing nuclear reactors to produce it, obtaining better resolution in humans, and potentially reducing the radiation **[...] Read more.**

(This article belongs to the Special Issue **Multifunctional Nanoparticles for Cancer Therapy and Imaging (/journal/pharmaceutics/special_issues/30Z9ZI9L02)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00767/article_deploy/html/images/pharmaceutics-15-00767-ag-550.jpg?1677728890) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00767/article_deploy/html/images/pharmaceutics-15-00767-g001-550.jpg?1677728766) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00767/article_deploy/html/images/pharmaceutics-15-00767-g002-550.jpg?1677728769) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00767/article_deploy/html/images/pharmaceutics-15-00767-g003-550.jpg?1677728760) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00767/article_deploy/html/images/pharmaceutics-15-00767-g004-550.jpg?1677728767) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00767/article_deploy/html/images/pharmaceutics-15-00767-g005-550.jpg?1677728764)

Open Access Review (/1999-4923/15/3/766/pdf?version=1678323195)

Perspectives of Therapeutic Drug Monitoring of Biological Agents in Non-Infectious Uveitis Treatment: A Review (/1999-4923/15/3/766)

by Manuel Busto-Iglesias (https://sciprofiles.com/profile/2297710), Lorena Rodríguez-Martínez (https://sciprofiles.com/profile/2761770), Carmen Antía Rodríguez-Fernández (https://sciprofiles.com/profile/1497069), Jaime González-López (https://sciprofiles.com/profile/1612533), Miguel González-Barcia (https://sciprofiles.com/profile/author/bEpacE1GdlhlMlR6RnhRM1R5Y04wU0N3Z0RKM0xNUTByOUxiSTFFUDU5MVMzMHY2NGEzTTNyRmMrV1RWMUxrR0, Begoña de Domingo (https://sciprofiles.com/profile/2291801), Luis Rodríguez-Rodríguez (https://sciprofiles.com/profile/726197), Anxo Fernández-Ferreiro (https://sciprofiles.com/profile/338637) and Cristina Mondelo-García (https://sciprofiles.com/profile/1164200)

Pharmaceutics **2023**, *15*(3), 766; https://doi.org/10.3390/pharmaceutics15030766 (https://doi.org/10.3390/pharmaceutics15030766) - 25 Feb 2023

Viewed by 1858

Abstract Biological drugs, especially those targeting anti-tumour necrosis factor α (TNFα) molecule, have revolutionized the treatment of patients with non-infectious uveitis (NIU), a sight-threatening condition characterized by ocular inflammation that can lead to severe vision threatening and blindness. Adalimumab (ADA) and infliximab (IFX), the **[...] Read more.**

(This article belongs to the Special Issue **Therapeutic Drug Monitoring and Pharmacokinetics-Based Individualization of Drug Therapy** (/journal/pharmaceutics/special_issues/drug_monitoring_pharmacokinetics))

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00766/article_deploy/html/images/pharmaceutics-15-00766-g001-550.jpg?1678323278) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00766/article_deploy/html/images/pharmaceutics-15-00766-g002-550.jpg?1678323276)

Open Access Review (/1999-4923/15/3/765/pdf?version=1677483163)

Current Status of Oligonucleotide-Based Protein Degraders (/1999-4923/15/3/765)

by **Po-Chang Shih (https://sciprofiles.com/profile/795231)**, **Miyako Naganuma (https://sciprofiles.com/profile/author/YUc5a05qOGs4QzBaaGpjTGlya2N1QjVzOGc2V3JFVVFjKzBtRm5LRGhpUT0=)**, **Yosuke Demizu (https://sciprofiles.com/profile/106079)** and **Mikihiko Naito (https://sciprofiles.com/profile/366330)**

Pharmaceutics **2023**, *15*(3), 765; **https://doi.org/10.3390/pharmaceutics15030765 (https://doi.org/10.3390/pharmaceutics15030765)** - 24 Feb 2023

Viewed by 1502

Abstract Transcription factors (TFs) and RNA-binding proteins (RBPs) have long been considered undruggable, mainly because they lack ligand-binding sites and are equipped with flat and narrow protein surfaces. Protein-specific oligonucleotides have been harnessed to target these proteins with some satisfactory preclinical results. The emerging **[...] Read more.**

(This article belongs to the Special Issue **State of Art in Protein Degraders and Autophagy Modulators in the Cancer Treatment** (/journal/pharmaceutics/special_issues/281CHG0WE6))

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00765/article_deploy/html/images/pharmaceutics-15-00765-ag-550.jpg?1677483242) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00765/article_deploy/html/images/pharmaceutics-15-00765-g001-550.jpg?1677483238) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00765/article_deploy/html/images/pharmaceutics-15-00765-g002-550.jpg?1677483242) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00765/article_deploy/html/images/pharmaceutics-15-00765-g003-550.jpg?1677483240) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00765/article_deploy/html/images/pharmaceutics-15-00765-g004-550.jpg?1677483237)

Open Access Article (/1999-4923/15/3/764/pdf?version=1677242715)

Amorphous Solid Dispersions Layered onto Pellets—An Alternative to Spray Drying? (/1999-4923/15/3/764)

by **Marius Neuwirth (https://sciprofiles.com/profile/author/YWR1akNvYzVTM2VnNjFTNng4M3BVRDJ4azNkczJod3NlZDVrVHJ3UTBMdz0=)**, **Sebastian K. Kappes (https://sciprofiles.com/profile/author/U3NhQkI0YlR1cXI1WHlsZndNK2NHSEJEelQxTVNUWUlpMEoyeVJ3N2g2TT0=)**, **Michael U. Hartig (https://sciprofiles.com/profile/author/OE9xZS9QK0w2dFBxY0o4K2lkOHd4NW14Lzc0cWVXRU90UkFrdXU5d0Vvdz0=)** and **Karl G. Wagner (https://sciprofiles.com/profile/748604)**

Pharmaceutics **2023**, *15*(3), 764; **https://doi.org/10.3390/pharmaceutics15030764 (https://doi.org/10.3390/pharmaceutics15030764)** - 24 Feb 2023

Viewed by 1467

Abstract Spray drying is one of the most frequently used solvent-based processes for manufacturing amorphous solid dispersions (ASDs). However, the resulting fine powders usually require further downstream processing when intended for solid oral dosage forms. In this study, we compare properties and performance of **[...] Read more.**

(This article belongs to the Special Issue **Recent Advances in Oral Solid Dosages** (/journal/pharmaceutics/special_issues/3W9NXR365N))

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00764/article_deploy/html/images/pharmaceutics-15-00764-g001-550.jpg?1677242806) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00764/article_deploy/html/images/pharmaceutics-15-00764-g002-550.jpg?1677242794) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00764/article_deploy/html/images/pharmaceutics-15-00764-g003-550.jpg?1677242800) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00764/article_deploy/html/images/pharmaceutics-15-00764-g004-550.jpg?1677242785) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00764/article_deploy/html/images/pharmaceutics-15-00764-g005-550.jpg?1677242804) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00764/article_deploy/html/images/pharmaceutics-15-00764-g006-550.jpg?1677242808) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00764/article_deploy/html/images/pharmaceutics-15-00764-g007-550.jpg?1677242802)

Open Access Article (/1999-4923/15/3/763/pdf?version=1677239622)

3D-Printing of Silk Nanofibrils Reinforced Alginate for Soft Tissue Engineering (/1999-4923/15/3/763)

by **Zahra Mohammadpour (https://sciprofiles.com/profile/author/Ky9DVXoyN1Fza0xXeE5sYlg1N1NXL0xZV3BqQyt6eUhmWC85L0ZxdGQ1Yz0=)**, **Mahshid Kharaziha (https://sciprofiles.com/profile/1613204)** and **Ali Zarrabi (https://sciprofiles.com/profile/959071)**

Pharmaceutics **2023**, *15*(3), 763; **https://doi.org/10.3390/pharmaceutics15030763 (https://doi.org/10.3390/pharmaceutics15030763)** - 24 Feb 2023

Cited by 5 (/1999-4923/15/3/763#metrics) | Viewed by 1207

Abstract The main challenge of extrusion 3D bioprinting is the development of bioinks with the desired rheological and mechanical performance and biocompatibility to create complex and patient-specific scaffolds in a repeatable and accurate manner. This study aims to introduce non-synthetic bioinks based on alginate **[...] Read more.**

(This article belongs to the Special Issue **Sustainable Materials and Technologies for Drug Delivery and Tissue Engineering** (/journal/pharmaceutics/special_issues/Sustainable_Materials_Drug_Delivery_Tissue_Engineering))

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00763/article_deploy/html/images/pharmaceutics-15-00763-g001-550.jpg?1677239687) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00763/article_deploy/html/images/pharmaceutics-15-00763-g002-550.jpg?1677239696) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00763/article_deploy/html/images/pharmaceutics-15-00763-g003-550.jpg?1677239698) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00763/article_deploy/html/images/pharmaceutics-15-00763-g004-550.jpg?1677239699) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00763/article_deploy/html/images/pharmaceutics-15-00763-g005-550.jpg?1677239702) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00763/article_deploy/html/images/pharmaceutics-15-00763-g006-550.jpg?1677239694) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00763/article_deploy/html/images/pharmaceutics-15-00763-g007-550.jpg?1677239690)

Open Access Review (/1999-4923/15/3/762/pdf?version=1679559321)

New Technological Approaches for Dental Caries Treatment: From Liquid Crystalline Systems to Nanocarriers (/1999-4923/15/3/762)

by **Marcela Tavares Luiz (https://sciprofiles.com/profile/author/a1o1bGdEZnRaaVA5cXB3RGNNdzBSOFJUc2dmT01wSFNFTC9ITDY2WDdxND0=)**, **Leonardo Delello di Filippo (https://sciprofiles.com/profile/2251339)**, **Jessyca Aparecida Paes Dutra (https://sciprofiles.com/profile/2156497)**, **Juliana Santos Rosa Viegas (https://sciprofiles.com/profile/2706618)**, **Amanda Leticia Polli Silvestre (https://sciprofiles.com/profile/author/YWNsdktmbkVXdlNXQmNqUDBNOHliZkhuOHBRYmlQRW5abVhSODBjRHZsST0=)**, **Caroline Anselmi (https://sciprofiles.com/profile/2982590)**, **Jonatas Lobato Duarte (https://sciprofiles.com/profile/2819153)**, **Giovana Maria Fioramonti Calixto (https://sciprofiles.com/profile/143778)** and **Marlus Chorilli (https://sciprofiles.com/profile/1205991)**

Pharmaceutics **2023**, *15*(3), 762; **https://doi.org/10.3390/pharmaceutics15030762 (https://doi.org/10.3390/pharmaceutics15030762)** - 24 Feb 2023

Cited by 3 (/1999-4923/15/3/762#metrics) | Viewed by 1968

Abstract Dental caries is the most common oral disease, with high prevalence rates in adolescents and low-income and lower-middle-income countries. This disease originates from acid production by bacteria, leading to demineralization of the dental enamel and the formation of cavities. The treatment of caries **[...] Read more.**

(This article belongs to the Special Issue **Liquid Crystalline Drug Delivery Systems Applicable in Different Routes of Administration** (/journal/pharmaceutics/special_issues/15C5A0M1BC))

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00762/article_deploy/html/images/pharmaceutics-15-00762-g001-550.jpg?1679559384) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00762/article_deploy/html/images/pharmaceutics-15-00762-g002-550.jpg?1679559385)

Open Access Article (/1999-4923/15/3/761/pdf?version=1677241627)

The Mechanism of Action of SAAP-148 Antimicrobial Peptide as Studied with NMR and Molecular Dynamics Simulations (/1999-4923/15/3/761)

by **Morgane Adélaïde (https://sciprofiles.com/profile/2796384)**, **Evgeniy Salnikov (https://sciprofiles.com/profile/author/djBrMzk3Qm14UU5qbHh4eVZGc25uYWZ2dTBuYmxkUHlSNmZMSW8vTTdaOD0=)**, **Francisco Ramos-Martín (https://sciprofiles.com/profile/1348364)**, **Christopher Aisenbrey (https://sciprofiles.com/profile/author/LzZUaVFVUVh4T1hEdkRlQ0c5bmhZektNZ3FXK1RyYW53M2dpQ21xck5OOD0=)**, **Catherine Sarazin (https://sciprofiles.com/profile/124345)**, **Burkhard Bechinger (https://sciprofiles.com/profile/414116)** and **Nicola D'Amelio (https://sciprofiles.com/profile/1345863)**

Back to TopTop

Pharmaceutics **2023**, *15*(3), 761; **https://doi.org/10.3390/pharmaceutics15030761 (https://doi.org/10.3390/pharmaceutics15030761)** - 24 Feb 2023
Cited by 1 (/1999-4923/15/3/761#metrics) | Viewed by 1261

Abstract Background: SAAP-148 is an antimicrobial peptide derived from LL-37. It exhibits excellent activity against drug-resistant bacteria and biofilms while resisting degradation in physiological conditions. Despite its optimal pharmacological properties, its mechanism of action at the molecular level has not been explored. Methods: The **[...] Read more.**
(This article belongs to the Special Issue **State of the Art of Membrane Active Peptides (/journal/pharmaceutics/special_issues/Active_Peptide)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00761/article_deploy/html/images/pharmaceutics-15-00761-g001-550.jpg?1677287496) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00761/article_deploy/html/images/pharmaceutics-15-00761-g002-550.jpg?1677287489) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00761/article_deploy/html/images/pharmaceutics-15-00761-g003-550.jpg?1677287499) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00761/article_deploy/html/images/pharmaceutics-15-00761-g004-550.jpg?1677287492) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00761/article_deploy/html/images/pharmaceutics-15-00761-g005-550.jpg?1677287501)

Open Access Review .(/1999-4923/15/3/760/pdf?version=1677232559)

Recent Advances of Photoactive Near-Infrared Carbon Dots in Cancer Photodynamic Therapy (/1999-4923/15/3/760)

by **Jinxing Song (https://sciprofiles.com/profile/author/N1FlbHZSUVkwL210eDlsYlUrd1RiaVpSRW1uN3RwVHplcGlHVzRoVjBPRT0=)**, **Xiaobo Gao (https://sciprofiles.com/profile/2799578)**, **Mei Yang (https://sciprofiles.com/profile/author/eXowaEZyaHVkUGFYZnVOdnRHM0pWbTdEQ3JtRm5wQk85dGU1dGg2dFJwZz0=)**, **Weiju Hao (https://sciprofiles.com/profile/1685524)** and **Ding-Kun Ji (https://sciprofiles.com/profile/2729005)**

Pharmaceutics **2023**, *15*(3), 760; **https://doi.org/10.3390/pharmaceutics15030760 (https://doi.org/10.3390/pharmaceutics15030760)** - 24 Feb 2023
Cited by 2 (/1999-4923/15/3/760#metrics) | Viewed by 1093

Abstract Photodynamic therapy (PDT) is a treatment that employs exogenously produced reactive oxygen species (ROS) to kill cancer cells. ROS are generated from the interaction of excited-state photosensitizers (PSs) or photosensitizing agents with molecular oxygen. Novel PSs with high ROS generation efficiency is essential **[...] Read more.**
(This article belongs to the Special Issue **Recent Advances in Anticancer Photodynamic Therapy (/journal/pharmaceutics/special_issues/I185LS4640)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00760/article_deploy/html/images/pharmaceutics-15-00760-g001-550.jpg?1677232633) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00760/article_deploy/html/images/pharmaceutics-15-00760-g002-550.jpg?1677232639) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00760/article_deploy/html/images/pharmaceutics-15-00760-g003-550.jpg?1677232630) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00760/article_deploy/html/images/pharmaceutics-15-00760-g004-550.jpg?1677232645) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00760/article_deploy/html/images/pharmaceutics-15-00760-g005-550.jpg?1677232643) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00760/article_deploy/html/images/pharmaceutics-15-00760-g006-550.jpg?1677232633) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00760/article_deploy/html/images/pharmaceutics-15-00760-g007-550.jpg?1677232641) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00760/article_deploy/html/images/pharmaceutics-15-00760-g008-550.jpg?1677232636)

Open Access Review .(/1999-4923/15/3/759/pdf?version=1677232325)

Natural Gums in Drug-Loaded Micro- and Nanogels (/1999-4923/15/3/759)

by **Anna Froelich (https://sciprofiles.com/profile/449483)**, **Emilia Jakubowska (https://sciprofiles.com/profile/1850849)**, **Barbara Jadach (https://sciprofiles.com/profile/1435482)**, **Piotr Gadziński (https://sciprofiles.com/profile/1632708)** and **Tomasz Osmałek (https://sciprofiles.com/profile/46919)**

Pharmaceutics **2023**, *15*(3), 759; **https://doi.org/10.3390/pharmaceutics15030759 (https://doi.org/10.3390/pharmaceutics15030759)** - 24 Feb 2023
Cited by 5 (/1999-4923/15/3/759#metrics) | Viewed by 1585

Abstract Gums are polysaccharide compounds obtained from natural sources, such as plants, algae and bacteria. Because of their excellent biocompatibility and biodegradability, as well as their ability to swell and their sensitivity to degradation by the colon microbiome, they are regarded as interesting potential **[...] Read more.**
(This article belongs to the Special Issue **Biopolymer Micro/Nanogel Particles as Smart Drug Delivery and Theranostic Systems (/journal/pharmaceutics/special_issues/biopolymer_particles_drug_delivery_theranostic)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00759/article_deploy/html/images/pharmaceutics-15-00759-ag-550.jpg?1677232458) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00759/article_deploy/html/images/pharmaceutics-15-00759-g001-550.jpg?1677232436) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00759/article_deploy/html/images/pharmaceutics-15-00759-g002-550.jpg?1677232410) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00759/article_deploy/html/images/pharmaceutics-15-00759-g003-550.jpg?1677232451) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00759/article_deploy/html/images/pharmaceutics-15-00759-g004-550.jpg?1677232434) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00759/article_deploy/html/images/pharmaceutics-15-00759-g005-550.jpg?1677232446) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00759/article_deploy/html/images/pharmaceutics-15-00759-g006-550.jpg?1677232441) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00759/article_deploy/html/images/pharmaceutics-15-00759-g007-550.jpg?1677232419) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00759/article_deploy/html/images/pharmaceutics-15-00759-g008-550.jpg?1677232422) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00759/article_deploy/html/images/pharmaceutics-15-00759-g009-550.jpg?1677232455) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00759/article_deploy/html/images/pharmaceutics-15-00759-g010-550.jpg?1677232453) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00759/article_deploy/html/images/pharmaceutics-15-00759-g011-550.jpg?1677232412) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00759/article_deploy/html/images/pharmaceutics-15-00759-g012-550.jpg?1677232448) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00759/article_deploy/html/images/pharmaceutics-15-00759-g013-550.jpg?1677232458) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00759/article_deploy/html/images/pharmaceutics-15-00759-g014-550.jpg?1677232443) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00759/article_deploy/html/images/pharmaceutics-15-00759-g015-550.jpg?1677232426) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00759/article_deploy/html/images/pharmaceutics-15-00759-g016-550.jpg?1677232424) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00759/article_deploy/html/images/pharmaceutics-15-00759-g017-550.jpg?1677232414) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00759/article_deploy/html/images/pharmaceutics-15-00759-g018-550.jpg?1677232432) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00759/article_deploy/html/images/pharmaceutics-15-00759-g019-550.jpg?1677232449) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00759/article_deploy/html/images/pharmaceutics-15-00759-g020-550.jpg?1677232439) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00759/article_deploy/html/images/pharmaceutics-15-00759-g021-550.jpg?1677232456)

Open Access Article .(/1999-4923/15/3/758/pdf?version=1677226097)

Three-Dimensional-Printed Oral Films Based on LCD: Influence Factors of the Film Printability and Received Qualities (/1999-4923/15/3/758)

by **Tingfeng Xu (https://sciprofiles.com/profile/author/RXNURVZ0RHR3Yk5QN2tKWUxwRis3eTh5a0NTQlJHbHFqWlFhQ040eVFlZz0=)**, **Huijie Li (https://sciprofiles.com/profile/author/Uk5uK2YwMFREejE1TzFmMldVT1VEbTFsY1NNWDhMK3o2ZmovNEhMUy9lMD0=)**, **Yi Xia (https://sciprofiles.com/profile/2798650)**, **Sheng Ding (https://sciprofiles.com/profile/author/bHpvZ0JSZklrYjA0MzJTRkFJR0JRZGIzN1REMmdHTXlIVG4yTUhKTGpvST0=)**, **Qingliang Yang (https://sciprofiles.com/profile/790284)** and **Gensheng Yang (https://sciprofiles.com/profile/783511)**

Pharmaceutics **2023**, *15*(3), 758; **https://doi.org/10.3390/pharmaceutics15030758 (https://doi.org/10.3390/pharmaceutics15030758)** - 24 Feb 2023
Cited by 1 (/1999-4923/15/3/758#metrics) | Viewed by 1013

Abstract As an oral mucosal drug delivery system, oral films have been of wide concern in recent years because of their advantages such as rapid absorption, being easy to swallow and avoiding the first-pass effect common for mucoadhesive oral films. However, the currently utilized **[...] Read more.**
(This article belongs to the Special Issue **Excipients Used in Pharmaceutical Dosage Forms (/journal/pharmaceutics/special_issues/Excipients_Pharmaceutical)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00758/article_deploy/html/images/pharmaceutics-15-00758-g001-550.jpg?1677226177) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00758/article_deploy/html/images/pharmaceutics-15-00758-g002-550.jpg?1677226178) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00758/article_deploy/html/images/pharmaceutics-15-00758-g003-550.jpg?1677226169) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00758/article_deploy/html/images/pharmaceutics-15-00758-g004-550.jpg?1677226167) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00758/article_deploy/html/images/pharmaceutics-15-00758-g005-550.jpg?1677226172) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00758/article_deploy/html/images/pharmaceutics-15-00758-g006-550.jpg?1677226165) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00758/article_deploy

/html/images/pharmaceutics-15-00758-g007-550.jpg?1677226178) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00758/article_deploy/html/images/pharmaceutics-15-00758-g008-550.jpg?1677226175) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00758/article_deploy/html/images/pharmaceutics-15-00758-g009-550.jpg?1677226177) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00758/article_deploy/html/images/pharmaceutics-15-00758-g010-550.jpg?1677226173) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00758/article_deploy/html/images/pharmaceutics-15-00758-g011-550.jpg?1677226171) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00758/article_deploy/html/images/pharmaceutics-15-00758-g012-550.jpg?1677226174) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00758/article_deploy/html/images/pharmaceutics-15-00758-g013-550.jpg?1677226163)

Open Access Article (/1999-4923/15/3/757/pdf?version=1677225501)

Insights into the Safety and Versatility of 4D Printed Intravesical Drug Delivery Systems (/1999-4923/15/3/757)

by Marco Uboldi (https://sciprofiles.com/profile/2516642), Cristiana Perrotta (https://sciprofiles.com/profile/981692), Claudia Moscheni (https://sciprofiles.com/profile/484147), Silvia Zecchini (https://sciprofiles.com/profile/2774585), Alessandra Napoli (https://sciprofiles.com/profile/1001873), Chiara Castiglioni (https://sciprofiles.com/profile/2530875), Andrea Gazzaniga (https://sciprofiles.com/profile/2216210), Alice Melocchi (https://sciprofiles.com/profile/1781638) and Lucia Zema (https://sciprofiles.com/profile/640545)

Pharmaceutics **2023**, *15*(3), 757; https://doi.org/10.3390/pharmaceutics15030757 (https://doi.org/10.3390/pharmaceutics15030757) - 24 Feb 2023

Cited by 3 (/1999-4923/15/3/757#metrics) | Viewed by 1028

Abstract This paper focuses on recent advancements in the development of 4D printed drug delivery systems (DDSs) for the intravesical administration of drugs. By coupling the effectiveness of local treatments with major compliance and long-lasting performance, they would represent a promising innovation for the [...] Read more.

(This article belongs to the Special Issue Local Drug Delivery System (/journal/pharmaceutics/special_issues/Local_Drug_Delivery))

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00757/article_deploy/html/images/pharmaceutics-15-00757-ag-550.jpg?1677225594) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00757/article_deploy/html/images/pharmaceutics-15-00757-g001-550.jpg?1677225581) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00757/article_deploy/html/images/pharmaceutics-15-00757-g002-550.jpg?1677225591) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00757/article_deploy/html/images/pharmaceutics-15-00757-g003-550.jpg?1677225571) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00757/article_deploy/html/images/pharmaceutics-15-00757-g004-550.jpg?1677225578) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00757/article_deploy/html/images/pharmaceutics-15-00757-g005-550.jpg?1677225588) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00757/article_deploy/html/images/pharmaceutics-15-00757-g006-550.jpg?1677225575) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00757/article_deploy/html/images/pharmaceutics-15-00757-g007-550.jpg?1677225574) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00757/article_deploy/html/images/pharmaceutics-15-00757-g008-550.jpg?1677225585) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00757/article_deploy/html/images/pharmaceutics-15-00757-g009-550.jpg?1677225583) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00757/article_deploy/html/images/pharmaceutics-15-00757-g010-550.jpg?1677225593)

Open Access Article (/1999-4923/15/3/756/pdf?version=1677224358)

Implementation of Systematic Bioanalysis of Antibody–Drug Conjugates for Preclinical Pharmacokinetic Study of Ado-Trastuzumab Emtansine (T-DM1) in Rats (/1999-4923/15/3/756)

by Eun-Jeong Jeon (https://sciprofiles.com/profile/2684072), Ju-Hee Han (https://sciprofiles.com/profile/2743422), Youjin Seo (https://sciprofiles.com/profile/author/bGErWHZLN2JKRXJMTnJSQ29pL05BRWVyYk9meEZqTmtmYUdxb3pDemgwST0=), Eun Mi Koh (https://sciprofiles.com/profile/2743427), Kang-Hyun Han (https://sciprofiles.com/profile/author/ODgxT1AzVUFDaFkwc1J6UkZwbzJRemxIL25rZ2RUeHBuUGswbDF3cWlKVT0=), Kyunghwa Hwang (https://sciprofiles.com/profile/author/cjNPbDZGa2MxU3RPbUVCSkZ2MnB0ckxIUU9xWDkzZDl3SmhmT244VlpzVT0=) and Kyung Jin Jung (https://sciprofiles.com/profile/17399)

Pharmaceutics **2023**, *15*(3), 756; https://doi.org/10.3390/pharmaceutics15030756 (https://doi.org/10.3390/pharmaceutics15030756) - 24 Feb 2023

Cited by 1 (/1999-4923/15/3/756#metrics) | Viewed by 1522

Abstract Antibody–drug conjugates (ADCs) are composed of monoclonal antibodies covalently bound to cytotoxic drugs by a linker. They are designed to selectively bind target antigens and present a promising cancer treatment without the debilitating side effects of conventional chemotherapies. Ado-trastuzumab emtansine (T-DM1) is an [...] Read more.

(This article belongs to the Special Issue Antibody Drug Conjugates: Unlocking the Future of Immunotherapies (/journal/pharmaceutics/special_issues/antibodies_drug))

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00756/article_deploy/html/images/pharmaceutics-15-00756-g001-550.jpg?1677224429) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00756/article_deploy/html/images/pharmaceutics-15-00756-g002-550.jpg?1677224426) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00756/article_deploy/html/images/pharmaceutics-15-00756-g003-550.jpg?1677224428)

Open Access Article (/1999-4923/15/3/755/pdf?version=1677222729)

Development and Stability of a New Formulation of Pentobarbital Suppositories for Paediatric Procedural Sedation (/1999-4923/15/3/755)

by Matthieu Lebrat (https://sciprofiles.com/profile/author/Y05hd3FPREV3NFBiYm8rVU1FRzJZS1lGTnBlZ3ZPMEhvUS9FQ2F2TUxPaz0=), Yassine Bouattour (https://sciprofiles.com/profile/1143143), Coralie Gaudet (https://sciprofiles.com/profile/author/b1FjVk9leXpZU1FRWTZ2S0gvS0U5ZFh4QzR6TzM5SmlpaEdwOThlVTYzRT0=), Mouloud Yessaad (https://sciprofiles.com/profile/1200433), Mireille Jouannet (https://sciprofiles.com/profile/1185762), Mathieu Wasiak (https://sciprofiles.com/profile/author/QVQwN3VpclhWOHA0Yi9DcEdiQVg0T3FkZGtSZDY0aEx1N1RvRGNrVjZ0OD0=), Imen Dhifallah (https://sciprofiles.com/profile/2466156), Eric Beyssac (https://sciprofiles.com/profile/author/emxUZno0SHVhQ25tVkdJYUtrL2M3cnFQRTYwVlA0eGl0aWlVU0tlUUdKbz0=), Ghislain Garrait (https://sciprofiles.com/profile/author/ZTdycTNyeE5Qa3dNMHB0YWZHa2ZpN1ZDQUE0VjBEN0QxTGw1UjZMM29QND0=), Philip Chennell (https://sciprofiles.com/profile/1133295) and Valérie Sautou (https://sciprofiles.com/profile/2045116)

Pharmaceutics **2023**, *15*(3), 755; https://doi.org/10.3390/pharmaceutics15030755 (https://doi.org/10.3390/pharmaceutics15030755) - 24 Feb 2023

Viewed by 1383

Abstract Pentobarbital is a drug of choice to limit motion in children during paediatric procedural sedations (PPSs). However, despite the rectal route being preferred for infants and children, no pentobarbital suppositories are marketed, and therefore they must be prepared by compounding pharmacies. In this [...] Read more.

(This article belongs to the Section Physical Pharmacy and Formulation (/journal/pharmaceutics/sections/Physical_Pharmacy_Formulation))

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00755/article_deploy/html/images/pharmaceutics-15-00755-g001-550.jpg?1677222809) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00755/article_deploy/html/images/pharmaceutics-15-00755-g002-550.jpg?1677222811) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00755/article_deploy/html/images/pharmaceutics-15-00755-g003-550.jpg?1677222806) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00755/article_deploy/html/images/pharmaceutics-15-00755-g004-550.jpg?1677222817) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00755/article_deploy/html/images/pharmaceutics-15-00755-g005-550.jpg?1677222814)

Open Access Article (/1999-4923/15/3/754/pdf?version=1677224799)

Exploring Synthetic Dihydrobenzofuran and Benzofuran Neolignans as Antiprotozoal Agents against *Trypanosoma cruzi* (/1999-4923/15/3/754)

by Mariana C. Pagotti (https://sciprofiles.com/profile/author/ZlFEd3ZvN3VnVW41TjdxOVUxbDQxcEVYYlNGQnpVVXpoeGpLVEgrOFFQdz0=), Herbert J. Dias (https://sciprofiles.com/profile/30256), Ana Carolina B. B. Candido (https://sciprofiles.com/profile/author/cnBKS2R2T3doMTcreU1uZDY1dVQ4OXBwVWVOOFY3U21OdzB0SDVSV1FkTT0=), Thaís A. S. Oliveira (https://sciprofiles.com/profile/author/Z0xBZWZKMzZPSHFSa3ZGV0hUSnVNQTdRblVxQUVKOWRRWlRiZ0RzT2pPdz0=), Alexandre Borges (https://sciprofiles.com/profile/2088954), Nicoli D. Oliveira (https://sciprofiles.com/profile/author/azF1NU9zaXNMcnpCMnFGc2ViQ213QWV2NngvOUw2YU9oQ25TQ2lJZnQrUT0=), Carla D. Lopes (https://sciprofiles.com/profile/author/NndlTFRncUw1aHFQN3R1NHlqTi8wZUdLRS91amsxelJzWG1sVW5ONFpLZz0=), Renato P. Orenha (https://sciprofiles.com/profile/2765145), Renato L. T. Parreira (https://sciprofiles.com/profile/2798565), Antônio E. M. Crotti (https://sciprofiles.com/profile/3305) and Lizandra G. Magalhães (https://sciprofiles.com/profile/1080942)

Pharmaceutics **2023**, *15*(3), 754; https://doi.org/10.3390/pharmaceutics15030754 (https://doi.org/10.3390/pharmaceutics15030754) - 24 Feb 2023

Viewed by 1135

Abstract Chagas disease is a neglected tropical disease that affects more than 8 million people. Although there are therapies against this disease, the search for new drugs is important because the current treatments show limited effectiveness and high toxicity. In this work, eighteen dihydrobenzofuran-type [...] Read more.

(This article belongs to the Special Issue Development of Novel Pharmaceuticals for the Treatment of Parasitic Diseases (/journal/pharmaceutics/special_issues/Parasitic_Disease))

Back to TopTop

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00754/article_deploy/html/images/pharmaceutics-15-00754-ag-550.jpg?1677224881) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00754/article_deploy/html/images/pharmaceutics-15-00754-g001-550.jpg?1677224880) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00754/article_deploy/html/images/pharmaceutics-15-00754-sch001-550.jpg?1677224877)

Open Access Article (/1999-4923/15/3/753/pdf?version=1677212537)

Multi-Compartmental Dissolution Method, an Efficient Tool for the Development of Enhanced Bioavailability Formulations Containing Poorly Soluble Acidic Drugs (/1999-4923/15/3/753)

by Miklós Tamás Katona (https://sciprofiles.com/profile/1470017), Lili Nagy-Katona (https://sciprofiles.com/profile/author/cktvekwzM25pT05qRHJPQTJUeGllbmdGMEk3blY2N2xidGVMakYycnJSYz0=), Réka Szabó (https://sciprofiles.com/profile/author/eVBvWS9ocTh0OHdyNkpKanZMcDNlYnhNak9wbmtZUUliQmorOHBybjZNWT0=), Enikő Borbás (https://sciprofiles.com/profile/1992169), Péter Tonka-Nagy (https://sciprofiles.com/profile/author/N20xaHNXTzVqMlphRDM2c2dlRlFoK043MytyUzRyMlhKVXptUm05QkZzND0=) and Krisztina Takács-Novák (https://sciprofiles.com/profile/1678613)

Pharmaceutics **2023**, *15*(3), 753; https://doi.org/10.3390/pharmaceutics15030753 (https://doi.org/10.3390/pharmaceutics15030753) - 24 Feb 2023

Viewed by 1338

Abstract The purpose of this study was to investigate the applicability of the Gastrointestinal Simulator (GIS), a multi-compartmental dissolution model, to predict the in vivo performance of Biopharmaceutics Classification System (BCS) Class IIa compounds. As the bioavailability enhancement of poorly soluble drugs requires a **[...] Read more.**

(This article belongs to the Special Issue **Strategies for Enhancing the Bioavailability of Poorly Soluble Drugs (/journal/pharmaceutics/special_issues/solubilization_excipients)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00753/article_deploy/html/images/pharmaceutics-15-00753-g001-550.jpg?1677212602) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00753/article_deploy/html/images/pharmaceutics-15-00753-g002-550.jpg?1677212603) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00753/article_deploy/html/images/pharmaceutics-15-00753-g003-550.jpg?1677212605) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00753/article_deploy/html/images/pharmaceutics-15-00753-g004-550.jpg?1677212609) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00753/article_deploy/html/images/pharmaceutics-15-00753-g005-550.jpg?1677212612) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00753/article_deploy/html/images/pharmaceutics-15-00753-g006-550.jpg?1677212604) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00753/article_deploy/html/images/pharmaceutics-15-00753-g007-550.jpg?1677212611) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00753/article_deploy/html/images/pharmaceutics-15-00753-g008-550.jpg?1677212608) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00753/article_deploy/html/images/pharmaceutics-15-00753-g009-550.jpg?1677212606) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00753/article_deploy/html/images/pharmaceutics-15-00753-g010-550.jpg?1677212605) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00753/article_deploy/html/images/pharmaceutics-15-00753-g011-550.jpg?1677212607) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00753/article_deploy/html/images/pharmaceutics-15-00753-g012-550.jpg?1677212610)

Open Access Article (/1999-4923/15/3/752/pdf?version=1677563245)

Influence of Physicochemical Properties of Budesonide Micro-Suspensions on Their Expected Lung Delivery Using a Vibrating Mesh Nebulizer (/1999-4923/15/3/752)

by Katarzyna Dobrowolska (https://sciprofiles.com/profile/2606233), Andrzej Emeryk (https://sciprofiles.com/profile/author/R09uSnFMeFQwY0JOZkRyM2MvSGd1Qm1CV3ZrNjNpdjRORXJjaDBBOE1Nbz0=), Kamil Janeczek (https://sciprofiles.com/profile/1923334), Radosław Krzosa (https://sciprofiles.com/profile/author/NVZpSHA1ZFZ4N2g2MFFqNklwNW1icHRocm9scnVrK3UzS1EwaXFKZWhpdz0=), Michał Pirożyński (https://sciprofiles.com/profile/author/ZlYzTk9yZWNCVTJQMXpPUHg3eWFEdWp1em0yTFFtOUFLTVcwZlpvU04wQT0=) and Tomasz R. Sosnowski (https://sciprofiles.com/profile/1781330)

Pharmaceutics **2023**, *15*(3), 752; https://doi.org/10.3390/pharmaceutics15030752 (https://doi.org/10.3390/pharmaceutics15030752) - 23 Feb 2023

Viewed by 1227

Abstract The efficiency of lung drug delivery of nebulized drugs is governed by aerosol quality, which depends both on the aerosolization process itself but also on the properties of aerosol precursors. This paper determines physicochemical properties of four analogous micro-suspensions of a micronized steroid **[...] Read more.**

(This article belongs to the Collection **Feature Papers in Pharmaceutical Technology (/journal/pharmaceutics/topical_collections/pharm_technol)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00752/article_deploy/html/images/pharmaceutics-15-00752-ag-550.jpg?1677563325) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00752/article_deploy/html/images/pharmaceutics-15-00752-g001-550.jpg?1677563320) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00752/article_deploy/html/images/pharmaceutics-15-00752-g002-550.jpg?1677563310) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00752/article_deploy/html/images/pharmaceutics-15-00752-g003-550.jpg?1677563311) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00752/article_deploy/html/images/pharmaceutics-15-00752-g004-550.jpg?1677563316) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00752/article_deploy/html/images/pharmaceutics-15-00752-g005-550.jpg?1677563308) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00752/article_deploy/html/images/pharmaceutics-15-00752-g006-550.jpg?1677563325) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00752/article_deploy/html/images/pharmaceutics-15-00752-g007-550.jpg?1677563313) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00752/article_deploy/html/images/pharmaceutics-15-00752-g008-550.jpg?1677563315) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00752/article_deploy/html/images/pharmaceutics-15-00752-g009-550.jpg?1677563322) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00752/article_deploy/html/images/pharmaceutics-15-00752-g010-550.jpg?1677563319) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00752/article_deploy/html/images/pharmaceutics-15-00752-g011-550.jpg?1677563322)

Open Access Review (/1999-4923/15/3/751/pdf?version=1677579459)

Hybrid Magnetic Lipid-Based Nanoparticles for Cancer Therapy (/1999-4923/15/3/751)

by Marcela Tavares Luiz (https://sciprofiles.com/profile/author/a1o1bGdEZnRaaVA5cXB3RGNNdzBSOFJUc2dmT01wSFNFTC9ITDY2WDdxND0=), Jessyca Aparecida Paes Dutra (https://sciprofiles.com/profile/2156497), Juliana Santos Rosa Viegas (https://sciprofiles.com/profile/2706618), Jennifer Thayanne Cavalcante de Araújo (https://sciprofiles.com/profile/author/TlczWGZQSTcrNjcyVE5pdWNEZWhyZkx6Rk50dXRubHdGSGpja0tZNnlycz0=), Alberto Gomes Tavares Junior (https://sciprofiles.com/profile/2793917) and Marlus Chorilli (https://sciprofiles.com/profile/1205991)

Pharmaceutics **2023**, *15*(3), 751; https://doi.org/10.3390/pharmaceutics15030751 (https://doi.org/10.3390/pharmaceutics15030751) - 23 Feb 2023

Cited by 2 (/1999-4923/15/3/751#metrics) | Viewed by 1201

Abstract Cancer is one of the major public health problems worldwide. Despite the advances in cancer therapy, it remains a challenge due to the low specificity of treatment and the development of multidrug resistance mechanisms. To overcome these drawbacks, several drug delivery nanosystems have **[...] Read more.**

(This article belongs to the Special Issue **Advanced Liposomes for Drug Delivery (/journal/pharmaceutics/special_issues/YAZ3Y26O0Q)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00751/article_deploy/html/images/pharmaceutics-15-00751-g001-550.jpg?1677579529) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00751/article_deploy/html/images/pharmaceutics-15-00751-g002-550.jpg?1677579528) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00751/article_deploy/html/images/pharmaceutics-15-00751-g003-550.jpg?1677579526) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00751/article_deploy/html/images/pharmaceutics-15-00751-g004-550.jpg?1677579525)

Open Access Review (/1999-4923/15/3/750/pdf?version=1677158635)

Can Essential Oils/Botanical Agents Smart-Nanoformulations Be the Winning Cards against Psoriasis? (/1999-4923/15/3/750)

by Mohamed Ashraf (https://sciprofiles.com/profile/2753573), Hossam S. El-Sawy (https://sciprofiles.com/profile/2692070), Ghada M. El Zaafarany (https://sciprofiles.com/profile/545984) and Mona M. A. Abdel-Mottaleb (https://sciprofiles.com/profile/1751526)

Pharmaceutics **2023**, *15*(3), 750; https://doi.org/10.3390/pharmaceutics15030750 (https://doi.org/10.3390/pharmaceutics15030750) - 23 Feb 2023

Cited by 1 (/1999-4923/15/3/750#metrics) | Viewed by 2004

Abstract Although psoriasis remains one of the most devastating inflammatory disorders due to its huge negative impact on patients' quality of life, new "green" treatment approaches still need to be fully explored. The purpose of this review article is to focus on the utilization **[...] Read more.**

(This article belongs to the Special Issue **Nanotechnology-Enabled Strategies to Enhance Topical Bioavailability, 2nd Edition (/journal/pharmaceutics/special_issues/9IFWSF3I49)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00750/article_deploy/html/images/pharmaceutics-15-00750-ag-550.jpg?1677158712) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00750/article_deploy/html/images/pharmaceutics-15-00750-g001-550.jpg?1677158710) (https://pub.mdpi-res.com

Back to TopTop

/pharmaceutics/pharmaceutics-15-00750/article_deploy/html/images/pharmaceutics-15-00750-g002-550.jpg?1677158709) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00750/article_deploy/html/images/pharmaceutics-15-00750-g003-550.jpg?1677158708)

Open Access Review (/1999-4923/15/3/749/pdf?version=1677235560)

Plant-Derived Bioactive Compounds in the Management of Neurodegenerative Disorders: Challenges, Future Directions and Molecular Mechanisms Involved in Neuroprotection (/1999-4923/15/3/749)

by Shoaib Shoaib (https://sciprofiles.com/profile/2554787), Mohammad Azam Ansari (https://sciprofiles.com/profile/471276), Adel Al Fatease (https://sciprofiles.com/profile/1675971), Awaji Y. Safhi (https://sciprofiles.com/profile/1905521), Umme Hani (https://sciprofiles.com/profile/2213643), Roshan Jahan (https://sciprofiles.com/profile/author/WVUxeFBNYksyV2VrQ3MyN01ZNHk4Q1BXKzVMblBhc1ZXZjNkUzN3SVBmTT0=), Mohammad N. Alomary (https://sciprofiles.com/profile/741018), Mohd Nazam Ansari (https://sciprofiles.com/profile/599300), Nabeel Ahmed (https://sciprofiles.com/profile/2799739), Shadma Wahab (https://sciprofiles.com/profile/1234874), Wasim Ahmad (https://sciprofiles.com/profile/1589022), Nabiha Yusuf (https://sciprofiles.com/profile/1765224) and Najmul Islam (https://sciprofiles.com/profile/2534769)

Pharmaceutics **2023**, *15*(3), 749; https://doi.org/10.3390/pharmaceutics15030749 (https://doi.org/10.3390/pharmaceutics15030749) - 23 Feb 2023

Cited by 5 (/1999-4923/15/3/749#metrics) | Viewed by 1891

Abstract Neurodegenerative disorders encompass a wide range of pathological conditions caused by progressive damage to the neuronal cells and nervous-system connections, which primarily target neuronal dysfunction and result in problems with mobility, cognition, coordination, sensation, and strength. Molecular insights have revealed that stress-related biochemical **[...] Read more.**

(This article belongs to the Special Issue **Novel Therapeutic Approaches for Neurodegenerative Diseases Treatment (/journal/pharmaceutics/special_issues/neuro_treat)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00749/article_deploy/html/images/pharmaceutics-15-00749-ag-550.jpg?1677235640) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00749/article_deploy/html/images/pharmaceutics-15-00749-g001-550.jpg?1677235638) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00749/article_deploy/html/images/pharmaceutics-15-00749-g002-550.jpg?1677235634)

Open Access Review (/1999-4923/15/3/748/pdf?version=1677148389)

Application of Amniotic Membrane in Skin Regeneration (/1999-4923/15/3/748)

by Nurul Fitriani (https://sciprofiles.com/profile/author/QWZDMm5SRyt5RmUyU2ILNnd0eEFqWFBEWnY0VGVpZmFRZGxzdjVJRmdFND0=), Gofarana Wilar (https://sciprofiles.com/profile/1298039), Angga Cipta Narsa (https://sciprofiles.com/profile/author/T0R1ZnVzblZ0aTJ0UkVjS3FmRkR0OXBOWUhPY2Z1TkVjRGwzNlZhTjlzVT0=), Ahmed F. A. Mohammed (https://sciprofiles.com/profile/1250518) and Nasrul Wathoni (https://sciprofiles.com/profile/874210)

Pharmaceutics **2023**, *15*(3), 748; https://doi.org/10.3390/pharmaceutics15030748 (https://doi.org/10.3390/pharmaceutics15030748) - 23 Feb 2023

Viewed by 1377

Abstract Amniotic membrane (AM) is an avascular structure composed of three different layers, which contain collagen, extracellular matrix, and biologically active cells (stem cells). Collagen, a naturally occurring matrix polymer, provides the structural matrix/strength of the amniotic membrane. Tissue remodeling is regulated by growth **[...] Read more.**

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00748/article_deploy/html/images/pharmaceutics-15-00748-ag-550.jpg?1677148472) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00748/article_deploy/html/images/pharmaceutics-15-00748-g001-550.jpg?1677148469) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00748/article_deploy/html/images/pharmaceutics-15-00748-g002-550.jpg?1677148468) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00748/article_deploy/html/images/pharmaceutics-15-00748-g003-550.jpg?1677148467) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00748/article_deploy/html/images/pharmaceutics-15-00748-g004-550.jpg?1677148466)

Open Access Article (/1999-4923/15/3/747/pdf?version=1677148701)

Electrospun Naringin-Loaded Fibers for Preventing Scar Formation during Wound Healing (/1999-4923/15/3/747)

by Erika M. Tottoli (https://sciprofiles.com/profile/1197199), Laura Benedetti (https://sciprofiles.com/profile/author/MS9JTmQwcUxDZGp5NHRKZEd3ckZsTUFaeEVPRkRVb3MvVkpmVGFqZ2c2Yz0=), Enrica Chiesa (https://sciprofiles.com/profile/558656), Silvia Pisani (https://sciprofiles.com/profile/1057412), Giovanna Bruni (https://sciprofiles.com/profile/158252), Ida Genta (https://sciprofiles.com/profile/336052), Bice Conti (https://sciprofiles.com/profile/276007), Gabriele Ceccarelli (https://sciprofiles.com/profile/325090) and Rossella Dorati (https://sciprofiles.com/profile/534532)

Pharmaceutics **2023**, *15*(3), 747; https://doi.org/10.3390/pharmaceutics15030747 (https://doi.org/10.3390/pharmaceutics15030747) - 23 Feb 2023

Cited by 1 (/1999-4923/15/3/747#metrics) | Viewed by 982

Abstract Hypertrophic scars (HTSs) are aberrant structures that develop where skin is injured complexly and represent the result of a chronic inflammation as a healing response. To date, there is no satisfactory prevention option for HTSs, which is due to the complexity of multiple **[...] Read more.**

(This article belongs to the Special Issue **Electrospun Fibers: Advancement in Drug Delivery, Controlled Release, and Tissue Regeneration (/journal/pharmaceutics/special_issues/electrospun_fibers_drug_delivery)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00747/article_deploy/html/images/pharmaceutics-15-00747-ag-550.jpg?1677148806) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00747/article_deploy/html/images/pharmaceutics-15-00747-g001-550.jpg?1677148784) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00747/article_deploy/html/images/pharmaceutics-15-00747-g002-550.jpg?1677148800) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00747/article_deploy/html/images/pharmaceutics-15-00747-g003-550.jpg?1677148804) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00747/article_deploy/html/images/pharmaceutics-15-00747-g004-550.jpg?1677148794) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00747/article_deploy/html/images/pharmaceutics-15-00747-g005-550.jpg?1677148805) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00747/article_deploy/html/images/pharmaceutics-15-00747-g006-550.jpg?1677148786) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00747/article_deploy/html/images/pharmaceutics-15-00747-g007-550.jpg?1677148803) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00747/article_deploy/html/images/pharmaceutics-15-00747-g008-550.jpg?1677148789) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00747/article_deploy/html/images/pharmaceutics-15-00747-g009-550.jpg?1677148795) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00747/article_deploy/html/images/pharmaceutics-15-00747-g010-550.jpg?1677148802) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00747/article_deploy/html/images/pharmaceutics-15-00747-g011-550.jpg?1677148799) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00747/article_deploy/html/images/pharmaceutics-15-00747-g012-550.jpg?1677148788) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00747/article_deploy/html/images/pharmaceutics-15-00747-g013-550.jpg?1677148796)

Open Access Review (/1999-4923/15/3/746/pdf?version=1677146486)

Intranasal Polymeric and Lipid-Based Nanocarriers for CNS Drug Delivery (/1999-4923/15/3/746)

by Rebecca Maher (https://sciprofiles.com/profile/2782804), Almudena Moreno-Borrallo (https://sciprofiles.com/profile/author/VFdSMGRWR1VpOFpJVW04TUdJelpJdz09), Dhruvi Jindal (https://sciprofiles.com/profile/author/TjA4dC82YU9JcElERGxEUnhGcXhlQT09), Binh T. Mai (https://sciprofiles.com/profile/author/UFJHMjB6WElaYzVpdnN2QnVqTTc1QT09), Eduardo Ruiz-Hernandez (https://sciprofiles.com/profile/420094) and Andrew Harkin (https://sciprofiles.com/profile/2739332)

Pharmaceutics **2023**, *15*(3), 746; https://doi.org/10.3390/pharmaceutics15030746 (https://doi.org/10.3390/pharmaceutics15030746) - 23 Feb 2023

Cited by 4 (/1999-4923/15/3/746#metrics) | Viewed by 2687

Abstract Nanomedicine is currently focused on the design and development of nanocarriers that enhance drug delivery to the brain to address unmet clinical needs for treating neuropsychiatric disorders and neurological diseases. Polymer and lipid-based drug carriers are advantageous for delivery to the central nervous **[...] Read more.**

(This article belongs to the Special Issue **Polymer- and Lipid-Based Nanostructured Drug Delivery Systems for the Treatment of CNS Diseases: Recent Advances towards Clinical Application (/journal/pharmaceutics/special_issues/CNS_diseases)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00746/article_deploy/html/images/pharmaceutics-15-00746-g001-550.jpg?1677146559) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00746/article_deploy/html/images/pharmaceutics-15-00746-g002-550.jpg?1677146560) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00746/article_deploy/html/images/pharmaceutics-15-00746-g003-550.jpg?1677146557) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00746/article_deploy/html/images/pharmaceutics-15-00746-g004-550.jpg?1677146561)

Open Access Article (/1999-4923/15/3/745/pdf?version=1677139544)

Intraocular siRNA Delivery Mediated by Penetratin Derivative to Silence Orthotopic Retinoblastoma Gene (/1999-4923/15/3/745)

Back to TopTop

by Xin Gao (https://sciprofiles.com/profile/author/Z2pyT3U2TnhBbWJ6VzZ6Z090ejZjMWJhdHpvSVNDYVR5bll2VVM3a0R4RT0=), Xingyan Fan (https://sciprofiles.com/profile/2530963), Kuan Jiang (https://sciprofiles.com/profile/author/Y0xleC9RUXprUDJWWEl0dE1EcVkxcXVKd0tQVXdQVWs5cDhWbXBiVE5TYz0=), Yang Hu (https://sciprofiles.com/profile/author/Z3JDRVVuOFA1SUxvSUpMVzlwZTVTWlpPc0MyakQ4Q0ZvQ0llVjZTTThFcz0=), Yu Liu (https://sciprofiles.com/profile/937040), Weiyue Lu (https://sciprofiles.com/profile/2060039) and Gang Wei (https://sciprofiles.com/profile/1760654)
Pharmaceutics **2023**, *15*(3), 745; https://doi.org/10.3390/pharmaceutics15030745 (https://doi.org/10.3390/pharmaceutics15030745) - 23 Feb 2023
Viewed by 955

Abstract Gene therapy brings a ray of hope for inherited ocular diseases that may cause severe vision loss and even blindness. However, due to the dynamic and static absorption barriers, it is challenging to deliver genes to the posterior segment of the eye by **[...] Read more.**
(This article belongs to the Special Issue **Local Drug Delivery System (/journal/pharmaceutics/special_issues/Local_Drug_Delivery)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00745/article_deploy/html/images/pharmaceutics-15-00745-ag-550.jpg?1677642803) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00745/article_deploy/html/images/pharmaceutics-15-00745-g001-550.jpg?1677139618) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00745/article_deploy/html/images/pharmaceutics-15-00745-g002-550.jpg?1677139624) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00745/article_deploy/html/images/pharmaceutics-15-00745-g003-550.jpg?1677139631) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00745/article_deploy/html/images/pharmaceutics-15-00745-g004-550.jpg?1677139629) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00745/article_deploy/html/images/pharmaceutics-15-00745-g005-550.jpg?1677139622) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00745/article_deploy/html/images/pharmaceutics-15-00745-g006-550.jpg?1677139615) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00745/article_deploy/html/images/pharmaceutics-15-00745-g007-550.jpg?1677139620) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00745/article_deploy/html/images/pharmaceutics-15-00745-g008-550.jpg?1677139627)

Open Access Review (/1999-4923/15/3/744/pdf?version=1677140954)

Microneedles for Efficient and Precise Drug Delivery in Cancer Therapy (/1999-4923/15/3/744)

by Keisheni Ganeson (https://sciprofiles.com/profile/1316182), Ain Hafizah Alias (https://sciprofiles.com/profile/author/QnU0eUYxVW9IcUdqdU0vRjFMcDdqcGo2aFlkTHlZSm5BR0NCQzVsK3hMTT0=), Vikneswaran Murugaiyah (https://sciprofiles.com/profile/1401244), Al-Ashraf Abdullah Amirul (https://sciprofiles.com/profile/1155407), Seeram Ramakrishna (https://sciprofiles.com/profile/148492) and Sevakumaran Vigneswari (https://sciprofiles.com/profile/753736)
Pharmaceutics **2023**, *15*(3), 744; https://doi.org/10.3390/pharmaceutics15030744 (https://doi.org/10.3390/pharmaceutics15030744) - 23 Feb 2023
Cited by 3 (/1999-4923/15/3/744#metrics) | Viewed by 1709

Abstract Cancer is the leading cause of death, acting as a global burden, severely impacting the patients' quality of life and affecting the world economy despite the expansion of cumulative advances in oncology. The current conventional therapies for cancer which involve long treatment duration **[...] Read more.**
(This article belongs to the Special Issue **Responsive Polymer Nanostructured Assemblies: Activity in Cancer Therapy (/journal/pharmaceutics/special_issues/W324J4O863)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00744/article_deploy/html/images/pharmaceutics-15-00744-g001-550.jpg?1677141034) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00744/article_deploy/html/images/pharmaceutics-15-00744-g002-550.jpg?1677141037) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00744/article_deploy/html/images/pharmaceutics-15-00744-g003-550.jpg?1677141039) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00744/article_deploy/html/images/pharmaceutics-15-00744-g004-550.jpg?1677141041)

Open Access Article (/1999-4923/15/3/743/pdf?version=1677136341)

The Pharmaceutical Formulation Plays a Pivotal Role in Hydroxytyrosol Pharmacokinetics (/1999-4923/15/3/743)

by Laura Di Renzo (https://sciprofiles.com/profile/135305), Antonella Smeriglio (https://sciprofiles.com/profile/198499), Mariarosaria Ingegneri (https://sciprofiles.com/profile/author/QkV5UFloVk56TElBOEQ0Vkk2a3VYdXFjaThxQTRlOUZmeDJSN3dNcURxQT0=), Paola Gualtieri (https://sciprofiles.com/profile/736162) and Domenico Trombetta (https://sciprofiles.com/profile/195221)
Pharmaceutics **2023**, *15*(3), 743; https://doi.org/10.3390/pharmaceutics15030743 (https://doi.org/10.3390/pharmaceutics15030743) - 23 Feb 2023
Viewed by 765

Abstract Current evidence supports the use of extra virgin olive oil (EVOO) and its minor components such as hydroxytyrosol or 3,4-dihydroxyphenyl ethanol (DOPET), to improve cardiovascular and metabolic health. Nevertheless, more intervention studies in humans are needed because some gaps remain in its bioavailability **[...] Read more.**
(This article belongs to the Special Issue **Dosage Form Formulation Technologies for Improving Bioavailability (/journal/pharmaceutics/special_issues/4IEDR453W2)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00743/article_deploy/html/images/pharmaceutics-15-00743-ag-550.jpg?1677642478) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00743/article_deploy/html/images/pharmaceutics-15-00743-g001-550.jpg?1677136658) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00743/article_deploy/html/images/pharmaceutics-15-00743-g002-550.jpg?1677136659) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00743/article_deploy/html/images/pharmaceutics-15-00743-g003-550.jpg?1677136656) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00743/article_deploy/html/images/pharmaceutics-15-00743-g004-550.jpg?1677136656) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00743/article_deploy/html/images/pharmaceutics-15-00743-g005-550.jpg?1677136654)

Open Access Article (/1999-4923/15/3/742/pdf?version=1677135558)

Exploring *RAB11A* Pathway to Hinder Chronic Myeloid Leukemia-Induced Angiogenesis In Vivo (/1999-4923/15/3/742)

by Catarina Roma-Rodrigues (https://sciprofiles.com/profile/638410), Alexandra R. Fernandes (https://sciprofiles.com/profile/121514) and Pedro V. Baptista (https://sciprofiles.com/profile/20129)
Pharmaceutics **2023**, *15*(3), 742; https://doi.org/10.3390/pharmaceutics15030742 (https://doi.org/10.3390/pharmaceutics15030742) - 23 Feb 2023
Cited by 2 (/1999-4923/15/3/742#metrics) | Viewed by 1105

Abstract Neoangiogenesis is generally correlated with poor prognosis, due to the promotion of cancer cell growth, invasion and metastasis. The progression of chronic myeloid leukemia (CML) is frequently associated with an increased vascular density in bone marrow. From a molecular point of view, the **[...] Read more.**
(This article belongs to the Special Issue **Nanocarriers for Cancer Therapy and Diagnosis, 2nd Edition (/journal/pharmaceutics/special_issues/MP30XG0Y93)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00742/article_deploy/html/images/pharmaceutics-15-00742-ag-550.jpg?1677135637) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00742/article_deploy/html/images/pharmaceutics-15-00742-g001-550.jpg?1677135632) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00742/article_deploy/html/images/pharmaceutics-15-00742-g002-550.jpg?1677135631) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00742/article_deploy/html/images/pharmaceutics-15-00742-g003-550.jpg?1677135635) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00742/article_deploy/html/images/pharmaceutics-15-00742-g004-550.jpg?1677135628)

Open Access Article (/1999-4923/15/3/741/pdf?version=1677134790)

Application of Machine-Learning Algorithms for Better Understanding the Properties of Liquisolid Systems Prepared with Three Mesoporous Silica Based Carriers (/1999-4923/15/3/741)

by Teodora Glišić (https://sciprofiles.com/profile/1911216), Jelena Djuriš (https://sciprofiles.com/profile/177827), Ivana Vasiljević (https://sciprofiles.com/profile/author/TlhXV3EzQzd2OHYrd3ZtVTBSRHNGZXFReGxBblNnVmFNV3pYbkZleTVGbzZBYm92djZod1FoRlh5OE1wNVpxeA==), Jelena Parojčić (https://sciprofiles.com/profile/177882) and Ivana Aleksić (https://sciprofiles.com/profile/1614459)
Pharmaceutics **2023**, *15*(3), 741; https://doi.org/10.3390/pharmaceutics15030741 (https://doi.org/10.3390/pharmaceutics15030741) - 23 Feb 2023
Viewed by 907

Abstract The processing of liquisolid systems (LSS), which are considered a promising approach to improving the oral bioavailability of poorly soluble drugs, has proven challenging due to the relatively high amount of liquid phase incorporated within them. The objective of this study was to **[...] Read more.**
(This article belongs to the Special Issue **Recent Advances in Solid Dosage Form (/journal/pharmaceutics/special_issues/solid_dosage_form)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00741/article_deploy/html/images/pharmaceutics-15-00741-g001-550.jpg?1677134870) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00741/article_deploy/html/images/pharmaceutics-15-00741-g002-550.jpg?1677134872) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00741/article_deploy/html/images/pharmaceutics-15-00741-g003-550.jpg?1677134864) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00741/article_deploy/html/images/pharmaceutics-15-00741-g004-550.jpg?1677134858) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00741/article_deploy/html/images/pharmaceutics-15-00741-g005-550.jpg?1677134857) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00741

/article_deploy/html/images/pharmaceutics-15-00741-g006-550.jpg?1677134861) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00741/article_deploy/html/images/pharmaceutics-15-00741-g007-550.jpg?1677134867) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00741/article_deploy/html/images/pharmaceutics-15-00741-g008-550.jpg?1677134865) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00741/article_deploy/html/images/pharmaceutics-15-00741-g009-550.jpg?1677134860)

Open Access Article (/1999-4923/15/3/740/pdf?version=1677133687)

Synthesis and Characterization of Supermagnetic Nanocomposites Coated with Pluronic F127 as a Contrast Agent for Biomedical Applications (/1999-4923/15/3/740)

by Maria Janina Carrera Espinoza (https://sciprofiles.com/profile/author/bGtFZkFjTDdzOCtXb3pIMnk0R3pCOGR5cjRKdDJSVHVKQmJ5L2lWZ0hpTT0=), Kuen-Song Lin (https://sciprofiles.com/profile/1700), Meng-Tzu Weng (https://sciprofiles.com/profile/529535), Sikhumbuzo Charles Kunene (https://sciprofiles.com/profile/author/Zm8xVDFxY21yK3dtektpTXRTZytlaExCNmhjdzFQZG5oaU1MTDBCY3BOND0=), You-Sheng Lin (https://sciprofiles.com/profile/author/dUE5NE9SVytxTmRwcThUeUx2bE9OUVEydEk5YzhWMURoUitHY2Rjdm5zND0=) and Chun-Ming Wu (https://sciprofiles.com/profile/author/RHBzelg1dVpPRHFwbGJhMzRUckVDZ1JGQWZ5ZHdQckNLcTRyK0Z3dE1Haz0=)

Pharmaceutics **2023**, *15*(3), 740; https://doi.org/10.3390/pharmaceutics15030740 (https://doi.org/10.3390/pharmaceutics15030740) - 23 Feb 2023

Cited by 1 (/1999-4923/15/3/740#metrics) | Viewed by 1147

Abstract Nanomedicine has garnered significant interest owing to advances in drug delivery, effectively demonstrated in the treatment of certain diseases. Here, smart supermagnetic nanocomposites based on iron oxide nanoparticles (MNPs) coated with Pluronic F127 (F127) were developed for the delivery of doxorubicin (DOX) to **[...] Read more.**

(This article belongs to the Special Issue **Nanocarriers for Cancer Therapy and Diagnosis, 2nd Edition** (/journal/pharmaceutics/special_issues/MP30XG0Y93))

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00740/article_deploy/html/images/pharmaceutics-15-00740-ag-550.jpg?1677133800) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00740/article_deploy/html/images/pharmaceutics-15-00740-g001-550.jpg?1677133772) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00740/article_deploy/html/images/pharmaceutics-15-00740-g002-550.jpg?1677133799) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00740/article_deploy/html/images/pharmaceutics-15-00740-g003-550.jpg?1677133781) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00740/article_deploy/html/images/pharmaceutics-15-00740-g004-550.jpg?1677133789) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00740/article_deploy/html/images/pharmaceutics-15-00740-g005-550.jpg?1677133775) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00740/article_deploy/html/images/pharmaceutics-15-00740-g006-550.jpg?1677133793) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00740/article_deploy/html/images/pharmaceutics-15-00740-g007-550.jpg?1677133796) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00740/article_deploy/html/images/pharmaceutics-15-00740-g008-550.jpg?1677133767) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00740/article_deploy/html/images/pharmaceutics-15-00740-g009-550.jpg?1677133784) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00740/article_deploy/html/images/pharmaceutics-15-00740-sch001-550.jpg?1677133763) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00740/article_deploy/html/images/pharmaceutics-15-00740-sch002-550.jpg?1677133776)

Open Access Article (/1999-4923/15/3/739/pdf?version=1677144573)

CDR3 Variants of the TXB2 Shuttle with Increased TfR1 Association Rate and Enhanced Brain Penetration (/1999-4923/15/3/739)

by Pawel Stocki (https://sciprofiles.com/profile/2246849), Jaroslaw Szary (https://sciprofiles.com/profile/author/OElRQTRaNmRVL3ByVXRqY04zMklwTXdyODJNa3hGYnI2aHI6QURVeFBFYz0=), Mykhaylo Demydchuk (https://sciprofiles.com/profile/author/cTZVUWJUTE5XckZoU2wvWUtlejlwdVRZT1pEckR3SExrVE5nQXpiV25iaz0=), Leandra Northall (https://sciprofiles.com/profile/author/WU9Vc2ZzUGNCYldtdVFqQ2t4NUNmUkYwQWFFRGFiMHp0eTR1NkUvZm16UT0=), Charlotte L. M. Rasmussen (https://sciprofiles.com/profile/2707682), Diana Bahu Logan (https://sciprofiles.com/profile/author/cFVwUXJDMHM4NGxLUWhCMzA3OHVDZVhwVU9JRFF3YSs4Zm9UQXJGcTRwQT0=), Aziz Gauhar (https://sciprofiles.com/profile/2280561), Laura Thei (https://sciprofiles.com/profile/author/d0RaY2p4dEx4aXVTUHp2VFZuZXlMYldONzQ4RWtFeGhZb2lsVDU3bWNwOD0=), Shu-Fen Coker (https://sciprofiles.com/profile/author/M0V4Y1V2OHA4RnVlZVlrMHRlS2F0WE03aXpaK2s0VFV2cnpiQXNPUGFQRT0=), Torben Moos (https://sciprofiles.com/profile/37049), Frank S. Walsh (https://sciprofiles.com/profile/author/WjZEUlZRbFRKaXlMSTRzUG1scTlyU1B2UjhwM3QwSlZUMThETkVlVUhtYz0=) and J. Lynn Rutkowski (https://sciprofiles.com/profile/2178000)

Pharmaceutics **2023**, *15*(3), 739; https://doi.org/10.3390/pharmaceutics15030739 (https://doi.org/10.3390/pharmaceutics15030739) - 23 Feb 2023

Cited by 3 (/1999-4923/15/3/739#metrics) | Viewed by 1211

Abstract Since the delivery of biologic drugs to the brain is greatly hampered by the existence of the blood–brain barrier (BBB), brain shuttles are being developed to enhance therapeutic efficacy. As we have previously shown, efficient and selective brain delivery was achieved with TXB2, **[...] Read more.**

(This article belongs to the Special Issue **Blood–Brain Barrier Drug Targeting: The Future of Brain Drug Development, 2nd Edition** (/journal/pharmaceutics/special_issues/77MC148KOB))

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00739/article_deploy/html/images/pharmaceutics-15-00739-g001-550.jpg?1677144653) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00739/article_deploy/html/images/pharmaceutics-15-00739-g002-550.jpg?1677144648) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00739/article_deploy/html/images/pharmaceutics-15-00739-g003-550.jpg?1677144644) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00739/article_deploy/html/images/pharmaceutics-15-00739-g004-550.jpg?1677144661) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00739/article_deploy/html/images/pharmaceutics-15-00739-g005-550.jpg?1677144658) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00739/article_deploy/html/images/pharmaceutics-15-00739-g006-550.jpg?1677144664)

Open Access Article (/1999-4923/15/3/738/pdf?version=1677132470)

Transcriptional Regulation of Liver-Type OATP1B3 (Lt-OATP1B3) and Cancer-Type OATP1B3 (Ct-OATP1B3) Studied in Hepatocyte-Derived and Colon Cancer-Derived Cell Lines (/1999-4923/15/3/738)

by Bastian Haberkorn (https://sciprofiles.com/profile/2118151), Dennis Löwen (https://sciprofiles.com/profile/author/dG1sdXpNcms1T090NHp0VWZSTDRzL0hUNjl2NmJ6UjhnMXd2VGh1dDVLdz0=), Lukas Meier (https://sciprofiles.com/profile/2792418), Martin F. Fromm (https://sciprofiles.com/profile/author/YU9ORjVpZk5qTnA4Rlg2NlJiNjEyN2FSZGNLRGJkOUxlOEhSMmhhT21rcz0=) and Jörg König (https://sciprofiles.com/profile/804277)

Pharmaceutics **2023**, *15*(3), 738; https://doi.org/10.3390/pharmaceutics15030738 (https://doi.org/10.3390/pharmaceutics15030738) - 23 Feb 2023

Viewed by 892

Abstract Due to alternative splicing, the *SLCO1B3* gene encodes two protein variants; the hepatic uptake transporter liver-type OATP1B3 (Lt-OATP1B3) and the cancer-type OATP1B3 (Ct-OATP1B3) expressed in several cancerous tissues. There is limited information about the cell type-specific transcriptional regulation of both variants and about **[...] Read more.**

(This article belongs to the Special Issue **Challenges and Perspectives of Drug Transporters: Where Do We Go from Here?** (/journal/pharmaceutics/special_issues/challenges_perspectives_drug_transporters))

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00738/article_deploy/html/images/pharmaceutics-15-00738-g001-550.jpg?1677132552) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00738/article_deploy/html/images/pharmaceutics-15-00738-g002-550.jpg?1677132545) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00738/article_deploy/html/images/pharmaceutics-15-00738-g003-550.jpg?1677132555) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00738/article_deploy/html/images/pharmaceutics-15-00738-g004-550.jpg?1677132548)

Open Access Article (/1999-4923/15/3/737/pdf?version=1677569454)

A Novel Approach for the Fabrication of 3D-Printed Dental Membrane Scaffolds including Antimicrobial Pomegranate Extract (/1999-4923/15/3/737)

by Hatice Karabulut (https://sciprofiles.com/profile/2779512), Songul Ulag (https://sciprofiles.com/profile/2476455), Basak Dalbayrak (https://sciprofiles.com/profile/2780383), Elif Damla Arisan (https://sciprofiles.com/profile/342737), Turgut Taskin (https://sciprofiles.com/profile/2808742), Mehmet Mucahit Guncu (https://sciprofiles.com/profile/author/RWpNWnhLZEISN2lpcXd1Z2JqY1VRS2EyM1pRMFJWK1QzY2VzV2ZWMjYrOD0=), Burak Aksu (https://sciprofiles.com/profile/author/ZHJibXZMQ3RQRTg1MjJsSnM2MWtqQ3NRemlMUHJ4QmdOYko3eUNTL3NCUT0=), Alireza Valanezhad (https://sciprofiles.com/profile/1809146) and Oguzhan Gunduz (https://sciprofiles.com/profile/730128)

Pharmaceutics **2023**, *15*(3), 737; https://doi.org/10.3390/pharmaceutics15030737 (https://doi.org/10.3390/pharmaceutics15030737) - 22 Feb 2023

Cited by 1 (/1999-4923/15/3/737#metrics) | Viewed by 1006

Abstract In this study, a dental membrane scaffold was fabricated using a 3D printing technique, and the antimicrobial effect of pomegranate seed and peel extract were investigated. For the production of the dental membrane scaffold, a combination of polyvinyl alcohol, starch, and pomegranate seed **[...] Read more.**

(This article belongs to the Special Issue **Advances in Biopolymer-Based Drug Delivery System** (/journal/pharmaceutics/special_issues/90L45W1N1N))

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00737/article_deploy/html/images/pharmaceutics-15-00737-g001-550.jpg?1677569534) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00737/article_deploy/html/images/pharmaceutics-15-00737-g002-550.jpg?1677569549) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00737/article_deploy/html/images/pharmaceutics-15-00737-g003-550.jpg?1677569543) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00737/article_deploy/html/images/pharmaceutics-15-00737-g004-550.jpg?1677569550) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00737/article_deploy/html/images/pharmaceutics-15-00737-g005-550.jpg?1677569546) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00737/article_deploy/html/images/pharmaceutics-15-00737-g006-550.jpg?1677569551) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00737/article_deploy/html/images/pharmaceutics-15-00737-g007-550.jpg?1677569545) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00737/article_deploy/html/images/pharmaceutics-15-00737-g008-550.jpg?1677569542) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00737/article_deploy/html/images/pharmaceutics-15-00737-g009-550.jpg?1677569535) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00737/article_deploy/html/images/pharmaceutics-15-00737-g010-550.jpg?1677569540) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00737/article_deploy/html/images/pharmaceutics-15-00737-g011-550.jpg?1677569532)

Open Access Article (/1999-4923/15/3/736/pdf?version=1677203235)

Dasatinib-Loaded Topical Nano-Emulgel for Rheumatoid Arthritis: Formulation Design and Optimization by QbD, In Vitro, Ex Vivo, and In Vivo Evaluation (/1999-4923/15/3/736)

by
Mahipal Reddy Donthi (https://sciprofiles.com/profile/author/WVg0ekN2ZC8xSVprUlRnNlBDVkgyNVlqamdxN0puNk1WbVJDZmFNWjJnMzhYaWVpajl1Zkd2VHgwUUk2WEVGQg==)
,
Ranendra Narayan Saha (https://sciprofiles.com/profile/2678001), Gautam Singhvi (https://sciprofiles.com/profile/1221336) and
Sunil Kumar Dubey (https://sciprofiles.com/profile/2563917)
Pharmaceutics **2023**, *15*(3), 736; https://doi.org/10.3390/pharmaceutics15030736 (https://doi.org/10.3390/pharmaceutics15030736) - 22 Feb 2023
Cited by 3 (/1999-4923/15/3/736#metrics) | Viewed by 1714

Abstract The current study aimed to develop a topical emulgel of dasatinib (DTB) for rheumatoid arthritis (RA) treatment to reduce systemic side effects. The quality by design (QbD) approach was employed to optimize DTB-loaded nano-emulgel using a central composite design (CCD). Emulgel was prepared **[...] Read more.**
(This article belongs to the Section **Drug Delivery and Controlled Release (/journal/pharmaceutics/sections/Drug_Delivery_and_Control_Release)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00736/article_deploy/html/images/pharmaceutics-15-00736-g001-550.jpg?1677203313) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00736/article_deploy/html/images/pharmaceutics-15-00736-g002-550.jpg?1677203307) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00736/article_deploy/html/images/pharmaceutics-15-00736-g003-550.jpg?1677203308) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00736/article_deploy/html/images/pharmaceutics-15-00736-g004-550.jpg?1677203301) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00736/article_deploy/html/images/pharmaceutics-15-00736-g005-550.jpg?1677203305) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00736/article_deploy/html/images/pharmaceutics-15-00736-g006-550.jpg?1677203312) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00736/article_deploy/html/images/pharmaceutics-15-00736-g007-550.jpg?1677203317) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00736/article_deploy/html/images/pharmaceutics-15-00736-g008-550.jpg?1677203321) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00736/article_deploy/html/images/pharmaceutics-15-00736-g009-550.jpg?1677203309) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00736/article_deploy/html/images/pharmaceutics-15-00736-g010-550.jpg?1677203310) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00736/article_deploy/html/images/pharmaceutics-15-00736-g011-550.jpg?1677203325) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00736/article_deploy/html/images/pharmaceutics-15-00736-g012-550.jpg?1677203319) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00736/article_deploy/html/images/pharmaceutics-15-00736-g013-550.jpg?1677203302) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00736/article_deploy/html/images/pharmaceutics-15-00736-g014-550.jpg?1677203315)

Open Access Review (/1999-4923/15/3/735/pdf?version=1677161920)

Recent Advances in Polymer-Based Nanomaterials for Non-Invasive Photothermal Therapy of Arthritis (/1999-4923/15/3/735)

by Muktika Tekade (https://sciprofiles.com/profile/author/cGpjaGtjUEswT1MrRUdGK08zWG5zTmRtd1hsK3NpZ2JvWFpYSDlYUHU0QT0=),
Prashant Pingale (https://sciprofiles.com/profile/1418564), Rachna Gupta (https://sciprofiles.com/profile/2763794),
Bhakti Pawar (https://sciprofiles.com/profile/author/Wm5ldEtmOTlIOFgrTFdXdSszUXFwV3RuNTJkMktDbXBhTm16QU5wWU1Udz0=),
Rakesh Kumar Tekade (https://sciprofiles.com/profile/1741739) and Mukesh Chandra Sharma (https://sciprofiles.com/profile/2766173)
Pharmaceutics **2023**, *15*(3), 735; https://doi.org/10.3390/pharmaceutics15030735 (https://doi.org/10.3390/pharmaceutics15030735) - 22 Feb 2023
Cited by 1 (/1999-4923/15/3/735#metrics) | Viewed by 1116

Abstract To date, nanomaterials have been widely used for the treatment and diagnosis of rheumatoid arthritis. Amongst various nanomaterials, polymer-based nanomaterials are becoming increasingly popular in nanomedicine due to their functionalised fabrication and easy synthesis, making them biocompatible, cost-effective, biodegradable, and efficient nanocarriers for **[...] Read more.**
(This article belongs to the Special Issue **Metal Nanoparticles for Cancer Therapy (/journal/pharmaceutics/special_issues/metal_therapy)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00735/article_deploy/html/images/pharmaceutics-15-00735-g001-550.jpg?1677162000) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00735/article_deploy/html/images/pharmaceutics-15-00735-g002-550.jpg?1677161998) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00735/article_deploy/html/images/pharmaceutics-15-00735-g003-550.jpg?1677161995) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00735/article_deploy/html/images/pharmaceutics-15-00735-g004-550.jpg?1677161989) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00735/article_deploy/html/images/pharmaceutics-15-00735-g005-550.jpg?1677161990) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00735/article_deploy/html/images/pharmaceutics-15-00735-g006-550.jpg?1677161987) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00735/article_deploy/html/images/pharmaceutics-15-00735-g007-550.jpg?1677161984) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00735/article_deploy/html/images/pharmaceutics-15-00735-g008-550.jpg?1677161985) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00735/article_deploy/html/images/pharmaceutics-15-00735-g009-550.jpg?1677161993)

Open Access Review (/1999-4923/15/3/734/pdf?version=1677240249)

Updates on Biodegradable Formulations for Ocular Drug Delivery (/1999-4923/15/3/734)

by Ta-Hsin Tsung (https://sciprofiles.com/profile/2667957),
Yi-Hao Chen (https://sciprofiles.com/profile/author/N0xnWDRyYUR0MFA0VjJMUFRaWG0xTURoT0FnMzhOcjJCYkZYeVorRFpDZz0=) and
Da-Wen Lu (https://sciprofiles.com/profile/760002)
Pharmaceutics **2023**, *15*(3), 734; https://doi.org/10.3390/pharmaceutics15030734 (https://doi.org/10.3390/pharmaceutics15030734) - 22 Feb 2023
Cited by 3 (/1999-4923/15/3/734#metrics) | Viewed by 1595

Abstract The complex nature of the ocular drug delivery barrier presents a significant challenge to the effective administration of drugs, resulting in poor therapeutic outcomes. To address this issue, it is essential to investigate new drugs and alternative delivery routes and vehicles. One promising **[...] Read more.**
(This article belongs to the Special Issue **Biodegradable Formulations for Ocular Drug Delivery (/journal/pharmaceutics/special_issues/biodegradable_odd)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00734/article_deploy/html/images/pharmaceutics-15-00734-g001-550.jpg?1677240319)

Open Access Article (/1999-4923/15/3/733/pdf?version=1677505428)

HER2-Specific Peptide (LTVSPWY) and Antibody (Herceptin) Targeted Core Cross-Linked Micelles for Breast Cancer: A Comparative Study (/1999-4923/15/3/733)

by Nazende Nur Bayram (https://sciprofiles.com/profile/author/TUZXdUJ0cmNpMUhLV2FoOHUyNEVBL2JWdThLWlZxQ09xemcybkhOa0dVST0=),
Gizem Tuğçe Ulu (https://sciprofiles.com/profile/703351), Nusaibah Abdulsalam Abdulhadi (https://sciprofiles.com/profile/2785155),
Seda Gürdap (https://sciprofiles.com/profile/author/V1UrUE9WZjJTS1ZYeGFSMVVPK2RpalgxdW4WVhSRUN0Vmo5ZStkTmVDZz0=),
İsmail Alper İşoğlu (https://sciprofiles.com/profile/author/dWlyNnExV1hTcjlMTldoZjBOa3JxTitsdkwxREJQZ3c5c2ZQekJsZWtRTT0=),
Yusuf Baran (https://sciprofiles.com/profile/706971) and Sevil Dinçer İşoğlu (https://sciprofiles.com/profile/2601938)
Pharmaceutics **2023**, *15*(3), 733; https://doi.org/10.3390/pharmaceutics15030733 (https://doi.org/10.3390/pharmaceutics15030733) - 22 Feb 2023
Viewed by 1364

Abstract This study aims to prepare a novel breast cancer-targeted micelle-based nanocarrier, which is stable in circulation, allowing intracellular drug release, and to investigate its cytotoxicity, apoptosis, and cytostatic effects, in vitro. The shell part of the micelle is composed of zwitterionic sulfobetaine ((N-3-sulfopropyl-N,N-dimethylamonium)ethyl **[...] Read more.**
(This article belongs to the Special Issue **Sustainable Materials and Technologies for Drug Delivery and Tissue Engineering (/journal/pharmaceutics/special_issues**

/Sustainable_Materials_Drug_Delivery_Tissue_Engineering_))

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00733/article_deploy/html/images/pharmaceutics-15-00733-ag-550.jpg?1677505517) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00733/article_deploy/html/images/pharmaceutics-15-00733-g001-550.jpg?1677505507) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00733/article_deploy/html/images/pharmaceutics-15-00733-g002-550.jpg?1677505509) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00733/article_deploy/html/images/pharmaceutics-15-00733-g003-550.jpg?1677505512) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00733/article_deploy/html/images/pharmaceutics-15-00733-g004-550.jpg?1677505497) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00733/article_deploy/html/images/pharmaceutics-15-00733-g005-550.jpg?1677505516) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00733/article_deploy/html/images/pharmaceutics-15-00733-g006-550.jpg?1677505495) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00733/article_deploy/html/images/pharmaceutics-15-00733-g007-550.jpg?1677505501) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00733/article_deploy/html/images/pharmaceutics-15-00733-g008-550.jpg?1677505505) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00733/article_deploy/html/images/pharmaceutics-15-00733-g009-550.jpg?1677505514) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00733/article_deploy/html/images/pharmaceutics-15-00733-g010-550.jpg?1677505493) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00733/article_deploy/html/images/pharmaceutics-15-00733-sch001-550.jpg?1677505491)

Open Access Feature Paper Article (/(1999-4923/15/3/732/pdf?version=1677061992)

Synthesis of Magnetic Iron Oxide-Incorporated Cellulose Composite Particles: An Investigation on Antioxidant Properties and Drug Delivery Applications (/1999-4923/15/3/732)

by Arifa Naznin (https://sciprofiles.com/profile/author/MXJvd2NkaXdUbnZ1SnN0Ujg1RUJ4QnRERUZGSDMvbEJyVVovM2tEbmtLYz0=), Palash Kumar Dhar (https://sciprofiles.com/profile/2580881), Sagar Kumar Dutta (https://sciprofiles.com/profile/author/Qnpna29XaGlDOTV6STFRYUlyU0tjZzh4aHpoalpQU213WExTTGJud1ZRbz0=), Sumon Chakrabarty (https://sciprofiles.com/profile/author/VmZtMG9selBXNUg0eXluYjRTYTFQK3lWL1dQSm9BT1lrT0pOT3dkcXphbz0=), Utpal Kumar Karmakar (https://sciprofiles.com/profile/author/UFNVWTc3b1ZNRGxFMk9VeEl3dWhFWVA0eFRZYW90Tmc0N0prbU1STEZ4Zz0=), Pritam Kundu (https://sciprofiles.com/profile/author/MHV1MDFNQytCWkNZcTY4RDkvY1JUZmJqeHkyL05rSk5yVVRpQzRaZkQ1cz0=), Muhammad Sarwar Hossain (https://sciprofiles.com/profile/1055982), Hasi Rani Barai (https://sciprofiles.com/profile/354645) and Md. Rezaul Haque (https://sciprofiles.com/profile/2580882)

Pharmaceutics **2023**, *15*(3), 732; https://doi.org/10.3390/pharmaceutics15030732 (https://doi.org/10.3390/pharmaceutics15030732) - 22 Feb 2023

Cited by 1 (/(1999-4923/15/3/732#metrics)) | Viewed by 1230

Abstract In recent years, polymer-supported magnetic iron oxide nanoparticles (MIO-NPs) have gained a lot of attention in biomedical and healthcare applications due to their unique magnetic properties, low toxicity, cost-effectiveness, biocompatibility, and biodegradability. In this study, waste tissue papers (WTP) and sugarcane bagasse (SCB) **[...] Read more.**

(This article belongs to the Special Issue **Sustainable Materials and Technologies for Drug Delivery and Tissue Engineering** (/journal/pharmaceutics/special_issues/Sustainable_Materials_Drug_Delivery_Tissue_Engineering_))

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00732/article_deploy/html/images/pharmaceutics-15-00732-g001-550.jpg?1677062070) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00732/article_deploy/html/images/pharmaceutics-15-00732-g002-550.jpg?1677062075) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00732/article_deploy/html/images/pharmaceutics-15-00732-g003-550.jpg?1677062066) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00732/article_deploy/html/images/pharmaceutics-15-00732-g004-550.jpg?1677062068) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00732/article_deploy/html/images/pharmaceutics-15-00732-g005-550.jpg?1677062074) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00732/article_deploy/html/images/pharmaceutics-15-00732-g006-550.jpg?1677062084) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00732/article_deploy/html/images/pharmaceutics-15-00732-g007-550.jpg?1677062072) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00732/article_deploy/html/images/pharmaceutics-15-00732-g008-550.jpg?1677062080) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00732/article_deploy/html/images/pharmaceutics-15-00732-g009-550.jpg?1677062082) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00732/article_deploy/html/images/pharmaceutics-15-00732-g010-550.jpg?1677062069) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00732/article_deploy/html/images/pharmaceutics-15-00732-g011-550.jpg?1677062077) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00732/article_deploy/html/images/pharmaceutics-15-00732-g012-550.jpg?1677062079)

Open Access Article (/(1999-4923/15/3/731/pdf?version=1677060934)

High Stability and Low Irritation of Retinol Propionate and Hydroxypinacolone Retinoate Supramolecular Nanoparticles with Effective Anti-Wrinkle Efficacy (/1999-4923/15/3/731)

by De Bai (https://sciprofiles.com/profile/author/dWZkNzBOWWdrUWR1TDNPalpxVmNNTEdEb1poVFB6ZWhjYU1DcmFNOUJtaz0=), Fan Hu (https://sciprofiles.com/profile/author/ckFwd01LUm0rV1BWZkFZRzNJOUF1TEl0ck1XSHpZbit2ZVNPa2dHcDY2UT0=), Huixian Xu (https://sciprofiles.com/profile/author/TVJsUlBwUUE5aU1CeEgzamZRNHpTcklmUFZ5U1ladnJKUnFlVWtyNTNoST0=), Jiahong Huang (https://sciprofiles.com/profile/author/L051cHM4SmtzMnpkQ1lPZ1Jjbk8vdzBFeWduanNLUXdvRWVTNjlqQkdTbz0=), Chengyu Wu (https://sciprofiles.com/profile/2686329), Jiaheng Zhang (https://sciprofiles.com/profile/2403257) and Rui Ye (https://sciprofiles.com/profile/2686330)

Pharmaceutics **2023**, *15*(3), 731; https://doi.org/10.3390/pharmaceutics15030731 (https://doi.org/10.3390/pharmaceutics15030731) - 22 Feb 2023

Viewed by 1769

Abstract Gravi-A nanoparticles, composed of retinyl propionate (RP) and hydroxypinacolone retinoate (HPR), were prepared by encapsulating the two using the high-pressure homogenization technique. The nanoparticles are effective in anti-wrinkle treatment with high stability and low irritation. We evaluated the effect of different process parameters **[...] Read more.**

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00731/article_deploy/html/images/pharmaceutics-15-00731-g001-550.jpg?1677061015) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00731/article_deploy/html/images/pharmaceutics-15-00731-g002-550.jpg?1677061014) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00731/article_deploy/html/images/pharmaceutics-15-00731-g003-550.jpg?1677061016) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00731/article_deploy/html/images/pharmaceutics-15-00731-g004-550.jpg?1677061014) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00731/article_deploy/html/images/pharmaceutics-15-00731-g005-550.jpg?1677061017) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00731/article_deploy/html/images/pharmaceutics-15-00731-g006-550.jpg?1677061012) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00731/article_deploy/html/images/pharmaceutics-15-00731-g007-550.jpg?1677061010)

Open Access Article (/(1999-4923/15/3/730/pdf?version=1677057484)

Formation of Hydrophilic Nanofibers from Nanostructural Design in the Co-Encapsulation of Celecoxib through Electrospinning (/1999-4923/15/3/730)

by Kedi Chu (https://sciprofiles.com/profile/author/eVBoaG5QOXpKUjZ3aXgweXZFK2gwZz09), Yi Zhu (https://sciprofiles.com/profile/author/SjQwKyt5Um9KTVJNbDBPVzF0b29idUdqSXFwNTZtdnpBQy9QNkhOUEhaST0=), Geng Lu (https://sciprofiles.com/profile/2741676), Sa Huang (https://sciprofiles.com/profile/author/UUJrTXVhM3FLNGpmdE9WZmVqZ1ZPbWcydEdSQkxLZDRFZVpvUUY5VjNydz0=), Chuangzan Yang (https://sciprofiles.com/profile/author/WlJWcVVhVlBpOElUS3MwN2FBU0wwUllNUDJaVk5BR2IxcWl2Mk4zT2VQbz0=), Juying Zheng (https://sciprofiles.com/profile/author/TzVTSFM3OEpMV1IzU3dRbVFXVDEwWitFb0MzbWVXWHlOYTNqeStpTWwyMD0=), Junming Chen (https://sciprofiles.com/profile/author/SjRpVUxrbDlFZXpvbnJsOGlqdU5zdz09), Junfeng Ban (https://sciprofiles.com/profile/2313687), Huanhuan Jia (https://sciprofiles.com/profile/author/N0dxZzdtREVDTUtmMkVyNVVBUHV5UT09) and Zhufen Lu (https://sciprofiles.com/profile/1972475)

Pharmaceutics **2023**, *15*(3), 730; https://doi.org/10.3390/pharmaceutics15030730 (https://doi.org/10.3390/pharmaceutics15030730) - 22 Feb 2023

Viewed by 1108

Abstract This study presents a method for a one-step co-encapsulation of PLGA nanoparticles in hydrophilic nanofibers. The aim is to effectively deliver the drug to the lesion site and achieve a longer release time. The celecoxib nanofiber membrane (Cel-NPs-NFs) was prepared by emulsion solvent **[...] Read more.**

(This article belongs to the Section **Nanomedicine and Nanotechnology** (/journal/pharmaceutics/sections/Nanomedicine_and_Nanotechnology))

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00730/article_deploy/html/images/pharmaceutics-15-00730-ag-550.jpg?1677057577) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00730/article_deploy/html/images/pharmaceutics-15-00730-g001-550.jpg?1677057570) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00730/article_deploy/html/images/pharmaceutics-15-00730-g002-550.jpg?1677057564) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00730/article_deploy/html/images/pharmaceutics-15-00730-g003-550.jpg?1677057567) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00730/article_deploy/html/images/pharmaceutics-15-00730-g004-550.jpg?1677057574) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00730

/article_deploy/html/images/pharmaceutics-15-00730-g005-550.jpg?1677057565) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00730/article_deploy/html/images/pharmaceutics-15-00730-g006-550.jpg?1677057573) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00730/article_deploy/html/images/pharmaceutics-15-00730-g007-550.jpg?1677057569)

(/toggle_desktop_layout_cookie)

Open Access Article (/1999-4923/15/3/729/pdf?version=1677055119)

Ultrasonic Microbubble Cavitation Deliver Gal-3 shRNA to Inhibit Myocardial Fibrosis after Myocardial Infarction (/1999-4923/15/3/729)

by Wenqu Li (https://sciprofiles.com/profile/2690899), Qiaofeng Jin (https://sciprofiles.com/profile/2602120), Li Zhang (https://sciprofiles.com/profile/2140929), Shukun He (https://sciprofiles.com/profile/author/V3EyU2dDTkdzVEFiUTJidXdubzVOeEhOQ3UyN1lYN3lrVTRiNmhaUG00RT0=), Yishu Song (https://sciprofiles.com/profile/author/eU1oTVluM2dRU0tPMGdPTUpWNnZkWTlnMm1relc2TGdOcjdqRk8rQmNSRT0=), Lingling Xu (https://sciprofiles.com/profile/author/M0FuQ29pT1kxSnJ5UTFEczFXMlo2S0hCUkVFWTlGR1UwWDZCQkVldG02ND0=), Cheng Deng (https://sciprofiles.com/profile/author/VFp3WnhGQ0lMVG0zS1YxUkc1WDdWRDlla2tlNndrTmlqV3dtSEg2U2JJbz0=), Lufang Wang (https://sciprofiles.com/profile/2696169), Xiaojuan Qin (https://sciprofiles.com/profile/2696056) and Mingxing Xie (https://sciprofiles.com/profile/1897022)

Pharmaceutics **2023**, *15*(3), 729; https://doi.org/10.3390/pharmaceutics15030729 (https://doi.org/10.3390/pharmaceutics15030729) - 22 Feb 2023

Viewed by 873

Abstract Galectin-3 (Gal-3) participates in myocardial fibrosis (MF) in a variety of ways. Inhibiting the expression of Gal-3 can effectively interfere with MF. This study aimed to explore the value of Gal-3 short hairpin RNA (shRNA) transfection mediated by ultrasound-targeted microbubble destruction (UTMD) in **[...] Read more.**

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00729/article_deploy/html/images/pharmaceutics-15-00729-g001-550.jpg?1677055195) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00729/article_deploy/html/images/pharmaceutics-15-00729-g002-550.jpg?1677055213) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00729/article_deploy/html/images/pharmaceutics-15-00729-g003-550.jpg?1677055202) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00729/article_deploy/html/images/pharmaceutics-15-00729-g004-550.jpg?1677055198) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00729/article_deploy/html/images/pharmaceutics-15-00729-g005-550.jpg?1677055205) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00729/article_deploy/html/images/pharmaceutics-15-00729-g006-550.jpg?1677055209)

Open Access Review (/1999-4923/15/3/728/pdf?version=1677741685)

Recent Progress in Multiple Sclerosis Treatment Using Immune Cells as Targets (/1999-4923/15/3/728)

by Xiaohong Ma (https://sciprofiles.com/profile/3034735), Rong Ma (https://sciprofiles.com/profile/author/UXAzOXdSVDRWL1pla2Zuc1c4NHBlK0hhb0RFaDNLYjcwemdlR2Y0Q3JxTT0=), Mengzhe Zhang (https://sciprofiles.com/profile/author/b1BKZ0Ilb0hacjZqZmsxSm9pYVJ3N3hMY3JSMFNPcFdRNGdkbTF3Vm1KST0=), Baicheng Qian (https://sciprofiles.com/profile/author/Vkx5S2pNVDB0TXh1WlZFaThiWTE0ZlRGc1h0NTN6VXloMWowckdYOEk4RT0=), Baoliang Wang (https://sciprofiles.com/profile/2644939) and Weijing Yang (https://sciprofiles.com/profile/2342535)

Pharmaceutics **2023**, *15*(3), 728; https://doi.org/10.3390/pharmaceutics15030728 (https://doi.org/10.3390/pharmaceutics15030728) - 22 Feb 2023

Cited by 1 (/1999-4923/15/3/728#metrics) | Viewed by 1875

Abstract Multiple sclerosis (MS) is an autoimmune-mediated demyelinating disease of the central nervous system. The main pathological features are inflammatory reaction, demyelination, axonal disintegration, reactive gliosis, etc. The etiology and pathogenesis of the disease have not been clarified. The initial studies believed that T **[...] Read more.**

(This article belongs to the Special Issue **Drug Repurposing and Delivery Systems for Immunotherapy (/journal/pharmaceutics/special_issues/Delivery_Immunotherapy)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00728/article_deploy/html/images/pharmaceutics-15-00728-g001-550.jpg?1677741750)

Open Access Article (/1999-4923/15/3/727/pdf?version=1677055548)

T22-PE24-H6 Nanotoxin Selectively Kills CXCR4-High Expressing AML Patient Cells In Vitro and Potently Blocks Dissemination In Vivo (/1999-4923/15/3/727)

by Yáiza Núñez (https://sciprofiles.com/profile/2790022), Annabel Garcia-León (https://sciprofiles.com/profile/author/Z21ZbFY0YmhVNmlKK3A4d001d0pudHlTV1N1L3N4SmVJWHFqUXdpQXdOTT0=), Aïda Falgàs (https://sciprofiles.com/profile/author/TkFyVElCTndxUzlvendKWlJXQTg0QWVmZ0U0VVJPajlZaHh5MDJWNEVNUT0=), Naroa Serna (https://sciprofiles.com/profile/author/Z3VJRHdLMWN5WTdnOEV2L3hzVUZMVi9JVkNsTGR6U09HR2w3QlEva3ZOUT0=), Laura Sánchez-García (https://sciprofiles.com/profile/author/SnVrV0xjbkdxSitnRHlURXAzeS9GK2hOWkQ0NDhKSEFaUlppSE1pZStNYz0=), Ana Garrido (https://sciprofiles.com/profile/author/Q0tHdzFBbVh3d2FTUkpnNGdsbFgwdHk1dnBlSUwzdHBHYm00a2lvNU1rST0=), Jorge Sierra (https://sciprofiles.com/profile/539929), Alberto Gallardo (https://sciprofiles.com/profile/2632174), Ugutz Unzueta (https://sciprofiles.com/profile/1270251), Esther Vázquez (https://sciprofiles.com/profile/861122), Antonio Villaverde (https://sciprofiles.com/profile/861123), Ramon Mangues (https://sciprofiles.com/profile/539930) and Isolda Casanova (https://sciprofiles.com/profile/1628381)

Pharmaceutics **2023**, *15*(3), 727; https://doi.org/10.3390/pharmaceutics15030727 (https://doi.org/10.3390/pharmaceutics15030727) - 22 Feb 2023

Cited by 3 (/1999-4923/15/3/727#metrics) | Viewed by 1127

Abstract Despite advances in the development of targeted therapies for acute myeloid leukemia (AML), most patients relapse. For that reason, it is still necessary to develop novel therapies that improve treatment effectiveness and overcome drug resistance. We developed T22-PE24-H6, a protein nanoparticle that contains **[...] Read more.**

(This article belongs to the Special Issue **Recent Advances in Nanomedicine for Cancer Therapy (/journal/pharmaceutics/special_issues/O97F74UFO5)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00727/article_deploy/html/images/pharmaceutics-15-00727-ag-550.jpg?1677055639) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00727/article_deploy/html/images/pharmaceutics-15-00727-g001-550.jpg?1677055636) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00727/article_deploy/html/images/pharmaceutics-15-00727-g002-550.jpg?1677055639) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00727/article_deploy/html/images/pharmaceutics-15-00727-g003-550.jpg?1677055633) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00727/article_deploy/html/images/pharmaceutics-15-00727-g004-550.jpg?1677055631) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00727/article_deploy/html/images/pharmaceutics-15-00727-g005-550.jpg?1677055629)

Open Access Article (/1999-4923/15/3/726/pdf?version=1677053876)

Dual Drug Delivery in Cochlear Implants: In Vivo Study of Dexamethasone Combined with Diclofenac or Immunophilin Inhibitor MM284 in Guinea Pigs (/1999-4923/15/3/726)

by Wiebke Behrends (https://sciprofiles.com/profile/author/L254c1RPVWdGMUdXRG1PT2wvd3pnb3VScWdRQk9QUFdka0twTXBod1psUT0=), Katharina Wulf (https://sciprofiles.com/profile/995092), Stefan Raggl (https://sciprofiles.com/profile/author/ZWRxVVZhWUNzdCtkdnR0eThxcG1ETnNnN2U1WmhnUVBOMk8rZk1GYnZudz0=), Max Fröhlich (https://sciprofiles.com/profile/1557083), Thomas Eickner (https://sciprofiles.com/profile/author/NnhjdFRxOERvanp6WkpiUHY2QzhRdkhpeWxZQ0wzSndYemY3TW1Kb1dkOD0=), Dana Dohr (https://sciprofiles.com/profile/1605089), Karl-Heinz Esser (https://sciprofiles.com/profile/author/N0ZDSDVmMVZCTWZMK054Y05ZdHpRSmtxalVlZE1CMCtHWFNyQitaOU5rST0=), Thomas Lenarz (https://sciprofiles.com/profile/1328400), Verena Scheper (https://sciprofiles.com/profile/210298) and Gerrit Paasche (https://sciprofiles.com/profile/1177442)

Pharmaceutics **2023**, *15*(3), 726; https://doi.org/10.3390/pharmaceutics15030726 (https://doi.org/10.3390/pharmaceutics15030726) - 22 Feb 2023

Viewed by 1002

Abstract Cochlear implants are well established to treat severe hearing impairments. Despite many different approaches to reduce the formation of connective tissue after electrode insertion and to keep electrical impedances low, results are not yet satisfying. Therefore, the aim of the current study was **[...] Read more.**

(This article belongs to the Special Issue **Personalized Pharmacotherapy and Individualized Delivering Strategies for ENT Applications (/journal/pharmaceutics/special_issues/Personalized_Pharm)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00726/article_deploy/html/images/pharmaceutics-15-00726-g001-550.jpg?1677053949) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00726/article_deploy/html/images/pharmaceutics-15-00726-g002-550.jpg?1677053951) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00726/article_deploy/html/images/pharmaceutics-15-00726-g003-550.jpg?1677053952) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00726/article_deploy/html/images/pharmaceutics-15-00726-g004-550.jpg?1677053961) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00726/article_deploy/html/images/pharmaceutics-15-00726-g005-550.jpg?1677053959) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00726/article_deploy/html/images/pharmaceutics-15-00726-g006-550.jpg?1677053957) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00726/article_deploy/html/images/pharmaceutics-15-00726-g007-550.jpg?1677053947) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00726/article_deploy/html/images/pharmaceutics-15-00726-g008-550.jpg?1677053956) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00726/article_deploy/html/images/pharmaceutics-15-00726-g009-550.jpg?1677053948)

Back to TopTop

Open Access Review (/1999-4923/15/3/725/pdf?version=1677060712)

New Frontiers in Three-Dimensional Culture Platforms to Improve Diabetes Research (/1999-4923/15/3/725)

by Sundhar Mohandas (https://sciprofiles.com/profile/author/bWRnSzdibEtqQ2FpLzhNa2ZSUDhwWVlmbWxMNnhsYnd1S3Bvcz...), Vijaya Gayatri (https://sciprofiles.com/profile/2784505), Kriya Kumaran (https://sciprofiles.com/profile/2788224), Vipin Gopinath (https://sciprofiles.com/profile/author/MmRZMHZnaXowTWFKblhEVWd1bTZpVVlPdHovWndmQjVDM24zVFdVKzM0MD0=), Ramasamy Paulmurugan (https://sciprofiles.com/profile/1673375) and Kunka Mohanram Ramkumar (https://sciprofiles.com/profile/1149076)

Pharmaceutics **2023**, *15*(3), 725; https://doi.org/10.3390/pharmaceutics15030725 (https://doi.org/10.3390/pharmaceutics15030725) - 22 Feb 2023
Viewed by 1745

Abstract Diabetes mellitus is associated with defects in islet β-cell functioning and consequent hyperglycemia resulting in multi-organ damage. Physiologically relevant models that mimic human diabetic progression are urgently needed to identify new drug targets. Three-dimensional (3D) cell-culture systems are gaining a considerable interest in **[...] Read more.**

(This article belongs to the Special Issue **Micro/Nanostructures and Micro/Nanodevices for Tissue Engineering and Biomedicine (/journal/pharmaceutics/special_issues/RA97131Y1L)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00725/article_deploy/html/images/pharmaceutics-15-00725-g001-550.jpg?1677060784) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00725/article_deploy/html/images/pharmaceutics-15-00725-g002-550.jpg?1677060781) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00725/article_deploy/html/images/pharmaceutics-15-00725-g003-550.jpg?1677060786) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00725/article_deploy/html/images/pharmaceutics-15-00725-g004-550.jpg?1677060788) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00725/article_deploy/html/images/pharmaceutics-15-00725-g005-550.jpg?1677060783) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00725/article_deploy/html/images/pharmaceutics-15-00725-g006-550.jpg?1677060790)

Open Access Article (/1999-4923/15/3/724/pdf?version=1677053053)

Intracellular Delivery of Itaconate by Metal–Organic Framework-Anchored Hydrogel Microspheres for Osteoarthritis Therapy (/1999-4923/15/3/724)

by Han Yu (https://sciprofiles.com/profile/2519416), Peng Ren (https://sciprofiles.com/profile/author/T2ZDcENSNDAvelZkdmdIMFJOUE05Skptb3hYNmJQei9meVlvQzlTUTBhST0=), Xuekang Pan (https://sciprofiles.com/profile/2958321), Xinyu Zhang (https://sciprofiles.com/profile/author/UzFFSWxjUnJCRGxYL2dYMFhPWEM5WXY4TFlsaisyV1VVaU8wcHBLWnQzcz0=), Jun Ma (https://sciprofiles.com/profile/author/b3lML2JxeTlUQ2lMdno5a2hzZmhlUT09), Jiayi Chen (https://sciprofiles.com/profile/author/eEVJTlV6NWgyTlhoOVRXSkl3bEdSWTZXODRmdHduSjBHd3E4TVNEd2poOD0=), Jian Sheng (https://sciprofiles.com/profile/author/bFYrY2U0b09jMThVcUtmSEVCMmVFWndMNkovMkc5VGhRbkdwdStaRm1CST0=), Huanhuan Luo (https://sciprofiles.com/profile/2476144), Huigen Lu (https://sciprofiles.com/profile/2646081) and Gang Chen (https://sciprofiles.com/profile/2646082)

Pharmaceutics **2023**, *15*(3), 724; https://doi.org/10.3390/pharmaceutics15030724 (https://doi.org/10.3390/pharmaceutics15030724) - 22 Feb 2023
Cited by 1 (/1999-4923/15/3/724#metrics) | Viewed by 1152

Abstract Treatment of osteoarthritis (OA) remains a significant clinical challenge. Itaconate (IA), an emerging regulator of intracellular inflammation and oxidative stress, may potentially be harnessed to treat OA. However, the short joint residence time, inefficient drug delivery, and cell-impermeable property of IA can seriously **[...] Read more.**

(This article belongs to the Special Issue **Sustainable Materials and Technologies for Drug Delivery and Tissue Engineering (/journal/pharmaceutics/special_issues/Sustainable_Materials_Drug_Delivery_Tissue_Engineering)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00724/article_deploy/html/images/pharmaceutics-15-00724-g001-550.jpg?1677053139) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00724/article_deploy/html/images/pharmaceutics-15-00724-g002-550.jpg?1677053130) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00724/article_deploy/html/images/pharmaceutics-15-00724-g003-550.jpg?1677053136) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00724/article_deploy/html/images/pharmaceutics-15-00724-g004-550.jpg?1677053135) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00724/article_deploy/html/images/pharmaceutics-15-00724-g005-550.jpg?1677053142) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00724/article_deploy/html/images/pharmaceutics-15-00724-sch001-550.jpg?1677053133)

Open Access Article (/1999-4923/15/3/723/pdf?version=1677052725)

Micro-Scale Vacuum Compression Molding as a Predictive Screening Tool of Protein Integrity for Potential Hot-Melt Extrusion Processes (/1999-4923/15/3/723)

by Katharina Dauer (https://sciprofiles.com/profile/1450218) and Karl G. Wagner (https://sciprofiles.com/profile/748604)

Pharmaceutics **2023**, *15*(3), 723; https://doi.org/10.3390/pharmaceutics15030723 (https://doi.org/10.3390/pharmaceutics15030723) - 22 Feb 2023
Viewed by 1522

Abstract Hot-melt extrusion (HME) is used for the production of solid protein formulations mainly for two reasons: increased protein stability in solid state and/or long-term release systems (e.g., protein-loaded implants). However, HME requires considerable amounts of material even at small-scale (>2 g batch size). **[...] Read more.**

(This article belongs to the Special Issue **Developing Peptide and Protein Drug Formulations (/journal/pharmaceutics/special_issues/peptide_protein_formulation)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00723/article_deploy/html/images/pharmaceutics-15-00723-ag-550.jpg?1677052800) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00723/article_deploy/html/images/pharmaceutics-15-00723-g001-550.jpg?1677052799) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00723/article_deploy/html/images/pharmaceutics-15-00723-g002-550.jpg?1677052795) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00723/article_deploy/html/images/pharmaceutics-15-00723-g003-550.jpg?1677052797)

Open Access Review (/1999-4923/15/3/722/pdf?version=1677233205)

Vitamin E TPGS-Based Nanomedicine, Nanotheranostics, and Targeted Drug Delivery: Past, Present, and Future (/1999-4923/15/3/722)

by Abhishesh Kumar Mehata (https://sciprofiles.com/profile/2103038), Aseem Setia (https://sciprofiles.com/profile/1896086), Vikas (https://sciprofiles.com/profile/2527821), Ankit Kumar Malik (https://sciprofiles.com/profile/author/dnhNeGNOcCtuc0tGU0NRcDRCSW1YYW5PZFN1NlJBcWJFK1BzWSt6QlY5cU5lQUV2YS8wVDlrNm1HN0RKN0MxSA==), Rym Hassani (https://sciprofiles.com/profile/author/VXRNTFNJbytGOU5oVGh1VnNuNWsxelhsQVEwcStjWC9jeFh0RUVkYjF0Yz0=), Hamad Ghaleb Dailah (https://sciprofiles.com/profile/2174326), Hassan A. Alhazmi (https://sciprofiles.com/profile/author/Uk1LOEJXZ25mMVloMTBFYmJLSnlONHZZNXJYV2cvbXM0Wk53d2ZlK1pzYz0=), Ahmed A. Albarraq (https://sciprofiles.com/profile/author/VW4yektNckdlVlZ6c0RkVTQyRlZsbE0vQUJseVoySEpLaUVTOUd3WlVMWT0=), Syam Mohan (https://sciprofiles.com/profile/24876) and Madaswamy S. Muthu (https://sciprofiles.com/profile/2103172)

Pharmaceutics **2023**, *15*(3), 722; https://doi.org/10.3390/pharmaceutics15030722 (https://doi.org/10.3390/pharmaceutics15030722) - 21 Feb 2023
Cited by 3 (/1999-4923/15/3/722#metrics) | Viewed by 2030

Abstract It has been seventy years since a water-soluble version of vitamin E called tocophersolan (also known as TPGS) was produced; it was approved by USFDA in 1998 as an inactive ingredient. Drug formulation developers were initially intrigued by its surfactant qualities, and gradually **[...] Read more.**

(This article belongs to the Special Issue **Nanotechnology: A Promising Approach for Drug Delivery (/journal/pharmaceutics/special_issues/VSB8VF7V40)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00722/article_deploy/html/images/pharmaceutics-15-00722-g001-550.jpg?1677233317) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00722/article_deploy/html/images/pharmaceutics-15-00722-g002-550.jpg?1677233287) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00722/article_deploy/html/images/pharmaceutics-15-00722-g003-550.jpg?1677233321) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00722/article_deploy/html/images/pharmaceutics-15-00722-g004-550.jpg?1677233302) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00722/article_deploy/html/images/pharmaceutics-15-00722-g005-550.jpg?1677233320) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00722/article_deploy/html/images/pharmaceutics-15-00722-g006-550.jpg?1677233300) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00722/article_deploy/html/images/pharmaceutics-15-00722-g007-550.jpg?1677233315) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00722/article_deploy/html/images/pharmaceutics-15-00722-g008-550.jpg?1677233311) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00722/article_deploy/html/images/pharmaceutics-15-00722-g009-550.jpg?1677233278) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00722/article_deploy/html/images/pharmaceutics-15-00722-g010-550.jpg?1677233296) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00722/article_deploy/html/images/pharmaceutics-15-00722-g011-550.jpg?1677233307) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00722/article_deploy/html/images/pharmaceutics-15-00722-g012-550.jpg?1677233292) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00722/article_deploy/html/images/pharmaceutics-15-00722-g013-550.jpg?1677233313)

Open Access Article (/1999-4923/15/3/721/pdf?version=1676975755)

Back to TopTop

A 3D Model of Human Buccal Mucosa for Compatibility Testing of Mouth Rinsing Solutions (/1999-4923/15/3/721)

by Paula Zwicker (https://sciprofiles.com/profile/1761063), Maxi Zumpe (https://sciprofiles.com/profile/1083007), Axel Kramer (https://sciprofiles.com/profile/2126754) and Gerald Müller (https://sciprofiles.com/profile/1791178)

Pharmaceutics **2023**, *15*(3), 721; https://doi.org/10.3390/pharmaceutics15030721 (https://doi.org/10.3390/pharmaceutics15030721) - 1 Feb 2023

Viewed by 1352

Abstract Oral mucositis is the most common and severe non-hematological complication associated with cancer radiotherapy, chemotherapy, or their combination. Treatment of oral mucositis focuses on pain management and the use of natural anti-inflammatory, sometimes weakly antiseptic mouth rinses in combination with optimal oral cavity **[...] Read more.**

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00721/article_deploy/html/images/pharmaceutics-15-00721-g001-550.jpg?1677038603) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00721/article_deploy/html/images/pharmaceutics-15-00721-g002-550.jpg?1677038604) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00721/article_deploy/html/images/pharmaceutics-15-00721-g003-550.jpg?1677038602) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00721/article_deploy/html/images/pharmaceutics-15-00721-g004-550.jpg?1677038606) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00721/article_deploy/html/images/pharmaceutics-15-00721-g005-550.jpg?1677038605) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00721/article_deploy/html/images/pharmaceutics-15-00721-g006-550.jpg?1677038603)

Open Access Article (/1999-4923/15/3/720/pdf?version=1677031222)

Drug Combination of Ciprofloxacin and Polymyxin B for the Treatment of Multidrug–Resistant *Acinetobacter baumannii* Infections: A Drug Pair Limiting the Development of Resistance (/1999-4923/15/3/720)

by Junwei Wang (https://sciprofiles.com/profile/2670850), Marc Stegger (https://sciprofiles.com/profile/1367042), Arshnee Moodley (https://sciprofiles.com/profile/2696504) and Mingshi Yang (https://sciprofiles.com/profile/2665350)

Pharmaceutics **2023**, *15*(3), 720; https://doi.org/10.3390/pharmaceutics15030720 (https://doi.org/10.3390/pharmaceutics15030720) - 21 Feb 2023

Cited by 3 (/1999-4923/15/3/720#metrics) | Viewed by 1280

Abstract Polymyxins are considered as last–resort antibiotics to treat infections caused by *Acinetobacter baumannii*. However, there are increasing reports of resistance in *A. baumannii* to polymyxins. In this study, inhalable combinational dry powders consisting of ciprofloxacin (CIP) and polymyxin B (PMB) were prepared **[...] Read more.**

(This article belongs to the Special Issue **Inhaled Treatment of Respiratory Infections (/journal/pharmaceutics/special_issues/inhaled_treatment)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00720/article_deploy/html/images/pharmaceutics-15-00720-g001-550.jpg?1677031309) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00720/article_deploy/html/images/pharmaceutics-15-00720-g002-550.jpg?1677031297) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00720/article_deploy/html/images/pharmaceutics-15-00720-g003-550.jpg?1677031303) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00720/article_deploy/html/images/pharmaceutics-15-00720-g004-550.jpg?1677031311) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00720/article_deploy/html/images/pharmaceutics-15-00720-g005-550.jpg?1677031308) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00720/article_deploy/html/images/pharmaceutics-15-00720-g006-550.jpg?1677031292) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00720/article_deploy/html/images/pharmaceutics-15-00720-g007a-550.jpg?1677031302) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00720/article_deploy/html/images/pharmaceutics-15-00720-g007b-550.jpg?1677031305) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00720/article_deploy/html/images/pharmaceutics-15-00720-g008-550.jpg?1677031300) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00720/article_deploy/html/images/pharmaceutics-15-00720-g009-550.jpg?1677031294)

Open Access Article (/1999-4923/15/3/719/pdf?version=1676975582)

"Click-to-Clear": A Strategy to Minimize Radioactivity from the Blood Pool Utilizing Staudinger Ligation (/1999-4923/15/3/719)

by Nisarg Soni (https://sciprofiles.com/profile/1436471), Swarbhanu Sarkar (https://sciprofiles.com/profile/3037109), Abhinav Bhise (https://sciprofiles.com/profile/2194317), Yeong Su Ha (https://sciprofiles.com/profile/2331839), Wonchoul Park (https://sciprofiles.com/profile/author/Yk9yZFZDT0RoZ09UOTRsaTV3dWplc1VLWklORUJFdjU0dTE2ck1nS0E0ST0=), A-Ram Yu (https://sciprofiles.com/profile/author/VXZMam9JNlRYODAzOEcvN0R0dlBudz09), Virendra Kumar (https://sciprofiles.com/profile/author/aWVMcUVocXkrb1V5OGNYTHdOcVI5WnJreUlyY1MwTHlmRmpqYi9aQlNsQT0=), Jeong Eun Lim (https://sciprofiles.com/profile/author/eExBWEVuYnpoNmNsNjZVc2dSQ0ZSZWFmUTNVRmc4U3UyVVhRWkFzSmlSaz0=), Young-Ran Yoon (https://sciprofiles.com/profile/450882) and Jeongsoo Yoo (https://sciprofiles.com/profile/2196567)

Pharmaceutics **2023**, *15*(3), 719; https://doi.org/10.3390/pharmaceutics15030719 (https://doi.org/10.3390/pharmaceutics15030719) - 21 Feb 2023

Viewed by 1119

Abstract The availability of several bioorthogonal reactions that can proceed selectively and efficiently under physiologically relevant conditions has garnered the interest of biochemists and organic chemists alike. Bioorthogonal cleavage reactions represent the latest innovation in click chemistry. Here, we employed the Staudinger ligation reaction **[...] Read more.**

(This article belongs to the Special Issue **Advances in the Development and Application of Targeted Radiopharmaceuticals for Cancer Management (/journal/pharmaceutics/special_issues/radiopharmaceuticals_cancer_management)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00719/article_deploy/html/images/pharmaceutics-15-00719-ag-550.jpg?1676975790) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00719/article_deploy/html/images/pharmaceutics-15-00719-g001-550.jpg?1676975779) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00719/article_deploy/html/images/pharmaceutics-15-00719-g002-550.jpg?1676975779) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00719/article_deploy/html/images/pharmaceutics-15-00719-g003-550.jpg?1676975776) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00719/article_deploy/html/images/pharmaceutics-15-00719-g004-550.jpg?1676975781) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00719/article_deploy/html/images/pharmaceutics-15-00719-g005-550.jpg?1676975780) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00719/article_deploy/html/images/pharmaceutics-15-00719-g006-550.jpg?1676975775) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00719/article_deploy/html/images/pharmaceutics-15-00719-g007-550.jpg?1676975789) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00719/article_deploy/html/images/pharmaceutics-15-00719-g008-550.jpg?1676975785) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00719/article_deploy/html/images/pharmaceutics-15-00719-sch001-550.jpg?1676975784)

Open Access Article (/1999-4923/15/3/718/pdf?version=1676968886)

Doxorubicin Loading into Milk and Mesenchymal Stem Cells' Extracellular Vesicles as Drug Delivery Vehicles (/1999-4923/15/3/718)

by Anindya Mukhopadhya (https://sciprofiles.com/profile/943857), Dimitrios Tsiapalis (https://sciprofiles.com/profile/1041656), Niamh McNamee (https://sciprofiles.com/profile/1708545), Brian Talbot (https://sciprofiles.com/profile/author/LzBjSnFRYTBRNnZEdk9KZGd6RDN4Zz09) and Lorraine O'Driscoll (https://sciprofiles.com/profile/869025)

Pharmaceutics **2023**, *15*(3), 718; https://doi.org/10.3390/pharmaceutics15030718 (https://doi.org/10.3390/pharmaceutics15030718) - 21 Feb 2023

Cited by 5 (/1999-4923/15/3/718#metrics) | Viewed by 1537

Abstract Extracellular vesicles (EVs) have great potential as drug delivery vehicles. While mesenchymal/stromal stem cell (MSC) conditioned medium (CM) and milk are potentially safe and scalable sources of EVs for this purpose, the suitability of MSC EVs and milk EVs as drug delivery vehicles **[...] Read more.**

(This article belongs to the Special Issue **Advances of Membrane Vesicles in Drug Delivery Systems (/journal/pharmaceutics/special_issues/Vesicles)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00718/article_deploy/html/images/pharmaceutics-15-00718-g001-550.jpg?1676968963) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00718/article_deploy/html/images/pharmaceutics-15-00718-g002a-550.jpg?1676968967) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00718/article_deploy/html/images/pharmaceutics-15-00718-g002b-550.jpg?1676968973) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00718/article_deploy/html/images/pharmaceutics-15-00718-g002c-550.jpg?1676968977) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00718/article_deploy/html/images/pharmaceutics-15-00718-g003-550.jpg?1676968960) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00718/article_deploy/html/images/pharmaceutics-15-00718-g004-550.jpg?1676968966) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00718/article_deploy/html/images/pharmaceutics-15-00718-g005-550.jpg?1676968983)

Open Access Article (/1999-4923/15/3/717/pdf?version=1677058683)

Compounding of Liquid and Solid Dose Adjustable Formulations with Pantoprazole: Comparison of Stability, Applicability and Suitability (/1999-4923/15/3/717)

by Nemanja Todorović (https://sciprofiles.com/profile/2414022), Jelena Čanji Panić (https://sciprofiles.com/profile/2496235), Mina Zavišić (https://sciprofiles.com/profile/author/eXgvWGNXZGJva2RwTUM4N1F5Qjl0NG5NSFRyRHNuNDBtZXVXTlBTRE9lTT0=), Jelena Krtolica (https://sciprofiles.com/profile/author/M3o1cFlzY09xazlzUUpLS1hZaHpsb3dUdWZEblFRUDNTQTRHbStZTEFMaz0=), Radomir Ratajac (https://sciprofiles.com/profile/author/VE5QVUYwd013akZTQ2JhVmxYVWhPci80cGJjdXQyYVc5Mjl1dVc3bjRZND0=),

Jelena Petrović (https://sciprofiles.com/profile/928752), Dušica Bosiljčić (https://sciprofiles.com/profile/author/MFFLQnVJcHNkQWlZMTlPOG5CakNWeVZDZjN1bzNHTi95MDNCOHZ5OHRBVT0=), Nebojša Kladar (https://sciprofiles.com/profile/1332127), Nataša Milošević (https://sciprofiles.com/profile/758234) and Mladena Lalić-Popović (https://sciprofiles.com/profile/1356239)

Pharmaceutics **2023**, *15*(3), 717; https://doi.org/10.3390/pharmaceutics15030717 (https://doi.org/10.3390/pharmaceutics15030717) - 21 Feb 2023

Viewed by 1326

Abstract Pantoprazole is a model substance that requires dosage form adjustments to meet the needs of all patients. Pediatric pantoprazole formulations in Serbia are mostly compounded as capsules (divided powders), while in Western Europe liquid formulations are more common. The aim of this work **[...] Read more.**

(This article belongs to the Special Issue **Pharmacy Compounding of Personalized Preparation for Specific Patients: Challenges and Advantages (/journal/pharmaceutics/special_issues/0LMCZPN945)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00717/article_deploy/html/images/pharmaceutics-15-00717-g001-550.jpg?1677058772) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00717/article_deploy/html/images/pharmaceutics-15-00717-g002-550.jpg?1677058765) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00717/article_deploy/html/images/pharmaceutics-15-00717-g003a-550.jpg?1677058772) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00717/article_deploy/html/images/pharmaceutics-15-00717-g003b-550.jpg?1677058765) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00717/article_deploy/html/images/pharmaceutics-15-00717-g004a-550.jpg?1677058778) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00717/article_deploy/html/images/pharmaceutics-15-00717-g004b-550.jpg?1677058769)

Open Access Review (/1999-4923/15/3/716/pdf?version=1676968321)

Oral Administration as a Potential Alternative for the Delivery of Small Extracellular Vesicles (/1999-4923/15/3/716)

by Darío Donoso-Meneses (https://sciprofiles.com/profile/author/R0hha1d6NkhyczVVL01DMTBydDJRZz09), Aliosha I. Figueroa-Valdés (https://sciprofiles.com/profile/2837031), Maroun Khoury (https://sciprofiles.com/profile/121196) and Francisca Alcayaga-Miranda (https://sciprofiles.com/profile/author/TWdFT2tibTQyMEFLcFA5bUdWKzU5VkFPVnFGTEhDTEFyN05NNkJJZndvWT0=)

Pharmaceutics **2023**, *15*(3), 716; https://doi.org/10.3390/pharmaceutics15030716 (https://doi.org/10.3390/pharmaceutics15030716) - 21 Feb 2023

Cited by 2 (/1999-4923/15/3/716#metrics) | Viewed by 1169

Abstract Small extracellular vesicles (sEVs) have burst into biomedicine as a natural therapeutic alternative for different diseases. Considered nanocarriers of biological origin, various studies have demonstrated the feasibility of their systemic administration, even with repeated doses. However, despite being the preferred route of physicians **[...] Read more.**

(This article belongs to the Special Issue **Advances of Membrane Vesicles in Drug Delivery Systems (/journal/pharmaceutics/special_issues/Vesicles)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00716/article_deploy/html/images/pharmaceutics-15-00716-g001-550.jpg?1676968396) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00716/article_deploy/html/images/pharmaceutics-15-00716-g002-550.jpg?1676968397) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00716/article_deploy/html/images/pharmaceutics-15-00716-g003-550.jpg?1676968398) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00716/article_deploy/html/images/pharmaceutics-15-00716-g004-550.jpg?1676968394)

Open Access Review (/1999-4923/15/3/715/pdf?version=1676963588)

Silver Nanoparticles and Their Therapeutic Applications in Endodontics: A Narrative Review (/1999-4923/15/3/715)

by Farzaneh Afkhami (https://sciprofiles.com/profile/2704086), Parisa Forghan (https://sciprofiles.com/profile/2763986), James L. Gutmann (https://sciprofiles.com/profile/504602) and Anil Kishen (https://sciprofiles.com/profile/2649022)

Pharmaceutics **2023**, *15*(3), 715; https://doi.org/10.3390/pharmaceutics15030715 (https://doi.org/10.3390/pharmaceutics15030715) - 21 Feb 2023

Cited by 6 (/1999-4923/15/3/715#metrics) | Viewed by 2122

Abstract The efficient elimination of microorganisms and their byproducts from infected root canals is compromised by the limitations in conventional root canal disinfection strategies and antimicrobials. Silver nanoparticles (AgNPs) are advantageous for root canal disinfection, mainly due to their wide-spectrum anti-microbial activity. Compared to **[...] Read more.**

(This article belongs to the Special Issue **Feature Papers in Nanomedicine and Nanotechnology (/journal/pharmaceutics/special_issues/fp_nanomedicine)**)

► Show Figures

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00715/article_deploy/html/images/pharmaceutics-15-00715-g001-550.jpg?1676963651) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-15-00715/article_deploy/html/images/pharmaceutics-15-00715-g002-550.jpg?1676963653)

Show export options

Displaying articles 1-316

Previous Issue
Volume 15, February (/1999-4923/15/2)

Next Issue
Volume 15, April (/1999-4923/15/4)

***Pharmaceutics* (/journal/pharmaceutics)**, EISSN 1999-4923, Published by MDPI

RSS (/rss/journal/pharmaceutics) **Content Alert (/journal/pharmaceutics/toc-alert)**

Back to TopTop

Pharmaceutics

COUNTRY	SUBJECT AREA AND CATEGORY	PUBLISHER	H-INDEX
Switzerland Universities and research institutions in Switzerland Media Ranking in Switzerland	Pharmacology, Toxicology and Pharmaceutics Pharmaceutical Science	Multidisciplinary Digital Publishing Institute (MDPI)	85

PUBLICATION TYPE	ISSN	COVERAGE	INFORMATION
Journals	19994923	2009-2022	Homepage How to publish in this journal yvonne.perrie@strath.ac.uk

SCOPE

Pharmaceutics (ISSN 1999-4923) is an open access journal which provides an advanced forum for the science and technology of pharmaceutics and biopharmaceutics. It publishes reviews, regular research papers, communications, opinions, commentaries, and short notes. Covered topics include pharmaceutical formulation, process development, drug delivery, pharmacokinetics, biopharmaceutics, pharmacogenetics, and interdisciplinary research involving, but not limited to, engineering, biomedical sciences, and cell biology. Our aim is to encourage scientists to publish their experimental results and theoretical assumptions in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. In addition, this journal presents the following unique features: Manuscripts regarding research proposals and research ideas will be particularly welcomed Computed data or files regarding the full details of the experimental procedures can be deposited as supplementary material if it is not possible to published them in the Material and Methods section, as usual We also accept manuscripts addressed to a broader audience, regarding research projects financed by public funds.

Join the conversation about this journal

Quartiles

FIND SIMILAR JOURNALS options

1	2	3	4	5
Drug Delivery and Translational Research	**Current Drug Delivery**	**Journal of Drug Delivery Science and Technology**	**Therapeutic Delivery**	**Expert Opinion on Drug Delivery**
USA	ARE	FRA	GBR	GBR
93% similarity	92% similarity	89% similarity	89% similarity	88% similarity

















← Show this widget in your own website

Just copy the code below and paste within your html code:

<a href="https://www.scim

SCImago Graphica

Explore, visually communicate and make sense of data with our new data visualization tool.

Metrics based on Scopus® data as of April 2023

N **nita** 3 years ago

hello,
how much percent plagiarism is accepted?

reply

SCImago Team

Melanie Ortiz 3 years ago

Dear Nita,
thank you for contacting us.
We are sorry to tell you that SCImago Journal & Country Rank is not a journal. SJR is a portal with scientometric indicators of journals indexed in Elsevier/Scopus.
Unfortunately, we cannot help you with your request, we suggest you visit the journal's homepage or contact the journal's editorial staff , so they could inform you more deeply.
Best Regards, SCImago Team

F **forouzan** 4 years ago

Im pharmacy student

reply

SCImago Team

Melanie Ortiz 4 years ago

Dear user, thanks for your participation! Best Regards, SCImago Team

Leave a comment

Name

Email
(will not be published)

Submit

The users of Scimago Journal & Country Rank have the possibility to dialogue through comments linked to a specific journal. The purpose is to have a forum in which general doubts about the processes of publication in the journal, experiences and other issues derived from the publication of papers are resolved. For topics on particular articles, maintain the dialogue through the usual channels with your editor.

Source details

Pharmaceutics

Open Access

Scopus coverage years: from 2009 to Present

Publisher: Multidisciplinary Digital Publishing Institute (MDPI)

ISSN: 1999-4923

Subject area: Pharmacology, Toxicology and Pharmaceutics: Pharmaceutical Science

Source type: Journal

CiteScore 2022
6.9

SJR 2022
0.795

SNIP 2022
1.150

View all documents > | Set document alert | Save to source list

CiteScore | CiteScore rank & trend | Scopus content coverage

CiteScore 2022

$$6.9 = \frac{47{,}131 \text{ Citations } 2019 - 2022}{6{,}861 \text{ Documents } 2019 - 2022}$$

Calculated on 05 May, 2023

CiteScoreTracker 2023

$$7.1 = \frac{59{,}954 \text{ Citations to date}}{8{,}488 \text{ Documents to date}}$$

Last updated on 05 October, 2023 • Updated monthly

CiteScore rank 2022

Category	Rank	Percentile
Pharmacology, Toxicology and Pharmaceutics └ Pharmaceutical Science	#41/171	76th

View CiteScore methodology > | CiteScore FAQ > | Add CiteScore to your site

About Scopus

What is Scopus

Content coverage

Scopus blog

Scopus API

Privacy matters

Language

日本語版を表示する

查看简体中文版本

查看繁體中文版本

Просмотр версии на русском языке

Customer Service

Help

Tutorials

Contact us